



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 139521

TO: Dave Nguyen
Location: REM/2D31/2C18
Art Unit: 1632
Monday, December 13, 2004

Case Serial Number: 10/068160

From: Noble Jarrell
Location: Biotech-Chem Library
Rem 1B71
Phone: 272-2556

Noble.jarrell@uspto.gov

Search Notes

STIC-Biotech/ChemLib

134521

CRFE

From: Nguyen, Dave
Sent: Friday, December 03, 2004 3:50 PM
To: STIC-Biotech/ChemLib
Subject: formula search 10/068160

Please search the following claim:

A substantially pure or isolated oligodeoxynucleotide of between 18 and 30 nucleotides in length comprising a sequence represented by the following formula:

5' X₁X₂X₃Pu₁Py₂CpG Pu₃ Py₄X₄X₅X₆(W)_M(G)_N-3'

wherein the central CpG motif is unmethylated, Pu is a purine nucleotide, Py is a pyrimidine nucleotide, X and W are any nucleotide, M is any integer from 0 to 10, and N is any integer from 4 to 10, and

wherein X₁X₂X₃Pu₁Py₂ and Pu₃ Py₄X₄X₅X₆ are complementary

MailBox:2c18
Dave Trong Nguyen
Primary Examiner
Remsen 2D31
571-272-0731

RECEIVED
DEC - 3 2005
STIC-Biotech/ChemLib
(STIC)

STAFF USE ONLY

Searcher: Noble
Searcher Phone: 2-
Date Searcher Picked up: 12/13/04
Date Completed: 12/13/04
Searcher Prep/Rev. Time: 10
Online Time: 20

Type of Search

NA Sequence: #
AA Sequence: #
Structure: # 1
Bibliographic: ☒
Litigation: ☐
Patent Family: ☐
Other: ☐

Vendors and cost where applicable

STN: 283
DIALOG: ☐
QUESTEL/ORBIT: ☐
LEXIS/NEXIS: ☐
SEQUENCE SYSTEM: ☐
WWW/Internet: ☐
Other(Specify): ☐

=> d his

(FILE 'HOME' ENTERED AT 08:46:58 ON 13 DEC 2004)

FILE 'HCAPLUS' ENTERED AT 08:47:03 ON 13 DEC 2004

L1 1 US20030060440/PN
E WO2000-US9839/AP, PRN
L2 1 WO2000-US9839/AP, PRN
E US1999-128898/AP, PRN
L3 2 US1999-128898P/AP, PRN
L4 2 L1-3

FILE 'REGISTRY' ENTERED AT 08:49:20 ON 13 DEC 2004

FILE 'HCAPLUS' ENTERED AT 08:49:22 ON 13 DEC 2004

L5 TRA L4 1- RN : 251 TERMS

FILE 'REGISTRY' ENTERED AT 08:49:23 ON 13 DEC 2004

L6 251 SEA L5

FILE 'WPLX' ENTERED AT 08:49:27 ON 13 DEC 2004

L7 1 US20030060440/PN
E WO2000-US9839/AP, PRN
L8 1 WO2000-US9839/AP, PRN
E US1999-128898/AP, PRN
L9 1 US1999-128898P/AP, PRN
L10 1 L7-9

FILE 'HCAPLUS' ENTERED AT 08:50:45 ON 13 DEC 2004

=> b hcap

FILE 'HCAPLUS' ENTERED AT 08:51:05 ON 13 DEC 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Dec 2004 VOL 141 ISS 25
FILE LAST UPDATED: 12 Dec 2004 (20041212/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all 14 tot

L4 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:241991 HCAPLUS
DN 138:270283
ED Entered STN: 28 Mar 2003
TI Oligodeoxynucleotide and its use to induce an immune response
IN Klinman, Dennis; Verthelyi, Daniela; Ishii, Ken; Mond, James J.; Gursel, Mayda
PA USA
SO U.S. Pat. Appl. Publ., 52 pp., Cont.-in-part of U.S. Ser. No. 958,713.
CODEN: USXXCO
DT Patent
LA English
IC A61K048-00; C07H021-04
NCL 514044000; 536023100
CC 15-2 (Immunochimistry)
Section cross-reference(s): 1
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003060440	A1	20030327	US 2002-068200	20020206 <--

PRAI ~~US 1999-128898E~~
US 2001-958713

~~P 19990412~~
A2 ~~20011011~~

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003060440	IC	A61K048-00IC C07H021-04
	NCL	514044000; 536023100
US 2003060440	ECLA	A61K031/7088; A61K031/7088+M; A61K039/39+M <--
AB	D type CpG oligodeoxynucleotides are provided herein that include a sequence represented by the following formula: 5'-X1X2X3Pu1Py2CpGPu3Py4X4X5X6(W)M(G)N-3' wherein the central CpG motif is unmethylated, Pu is a purine nucleotide, Py is a pyrimidine nucleotide, X and W are any nucleotide, M is any integer from 0 to 10, and N is any integer from 4 to 10. The oligodeoxynucleotides can activate immune cells, such as antigen-presenting cells or natural killer cell, and/or can stimulate production of cytokines. Methods of using these oligodeoxynucleotides to induce an immune response are provided. The oligodeoxynucleotides can be used in treatment or amelioration of cancer, allergy, autoimmune disease, immunodeficiency, or infection. They can also be used to enhance the efficacy of vaccines.	
ST	CpG oligodeoxynucleotide immunotherapy immunostimulation	
IT	Allergy Allergy inhibitors Anti-infective agents Antibiotics Antitumor agents Antiviral agents Asthma Autoimmune disease Cell activation Chemotherapy Dendritic cell Fungicides Human Immunodeficiency Immunostimulation Immunotherapy Leishmania major Monocyte Mycosis Neoplasm Radiotherapy Vaccines (CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)	
IT	Allergens RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)	
IT	Cytokines RL: BSU (Biological study, unclassified); BIOL (Biological study) (CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)	
IT	Interleukin 10 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)	
IT	Oligodeoxyribonucleotides RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (CpG-containing; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)	
IT	Immunostimulants (adjuvants; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)	
IT	Infection (bacterial; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)	
IT	Immunity (cell-mediated; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)	
IT	Lipids, biological studies RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (delivery complex; CpG oligodeoxynucleotides for immunostimulation and	

immunotherapy of various diseases)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(interferon .gamma.-inducible protein-10; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT Drug delivery systems
(liposomes; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT Lymphocyte
(natural killer cell; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT Neoplasm
(solid; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT Infection
(viral; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT Drug delivery systems
(viroosomes; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT Interferons
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT Interferons
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.gamma.; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT 503572-62-1 503572-63-2 503572-64-3 503572-65-4 503572-66-5
503572-67-6 503572-68-7 503572-69-8 503572-70-1 503572-71-2
503572-72-3 503572-73-4 503572-74-5 503572-75-6 503572-76-7
503572-77-8 503572-78-9
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT 503540-93-0 503540-94-1
RL: PRP (Properties)
(Unclaimed; oligodeoxynucleotide and its use to induce an immune response)

IT 57-88-5, Cholesterol, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(delivery complex; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT 503575-68-6 503575-69-7 503575-70-0 503575-71-1 503575-72-2
503575-73-3 503575-74-4 503575-75-5 503575-76-6 503575-77-7
503575-78-8 503575-79-9 503575-80-2 503575-81-3 503575-82-4
503575-83-5 503575-84-6 503575-85-7 503575-86-8 503575-87-9
503575-88-0 503575-89-1 503575-90-4 503575-91-5 503575-92-6
503575-93-7 503575-94-8 503575-95-9 503575-96-0 503575-97-1
503575-98-2 503575-99-3 503576-00-9 503576-01-0 503576-02-1
503576-03-2 503576-04-3 503576-05-4 503576-06-5 503576-07-6
503576-08-7 503576-09-8 503576-10-1 503576-11-2 503576-12-3
503576-13-4 503576-14-5 503576-15-6 503576-16-7 503576-17-8
503576-18-9 503576-19-0 503576-20-3 503576-21-4 503576-22-5
503576-23-6 503576-24-7 503576-25-8 503576-26-9 503576-27-0
503576-28-1 503576-29-2 503576-30-5 503576-31-6 503576-32-7
503576-33-8 503576-34-9 503576-35-0 503576-36-1 503576-37-2
503576-38-3 503576-39-4 503576-40-7 503576-41-8 503576-42-9
503576-43-0 503576-44-1 503576-45-2 503576-46-3 503576-47-4
503576-48-5 503576-49-6 503576-50-9 503576-51-0 503576-52-1
503576-53-2 503576-54-3 503576-55-4 503576-56-5 503576-57-6
503576-58-7 503576-59-8
RL: PRP (Properties)
(unclaimed nucleotide sequence; oligodeoxynucleotide and its use to induce an immune response)

IT 503576-60-1 503576-61-2 503576-62-3 503576-63-4 503576-64-5
503576-65-6 503576-66-7
RL: PRP (Properties)
(unclaimed sequence; oligodeoxynucleotide and its use to induce an immune response)

DN 133:320986
 ED Entered STN: 20 Oct 2000
 TI Oligodeoxynucleotide and its use to induce an immune response
 IN Klinman, Dennis; Ishii, Ken; Verthelyi, Daniela
 PA United States Dept. of Health and Human Services, USA
 SO PCT Int. Appl., 46 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 IC ICM A61K031-70
 ICS A61K039-39; C07H021-00
 CC 15-2 (Immunochimistry)
 Section cross-reference(s): 3, 63

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061151	A2	20001019	WO 2000-US9839	20000412 <--
WO 2000061151	A3	20010426		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG EP 1176956 A2 20020206 EP 2000-922283 20000412 <--				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI US 1999-128898P	P	19990412 <--		
WO 2000-US9839	W	20000412 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 2000061151	ICM	A61K031-70
	ICS	A61K039-39; C07H021-00

AB The present invention provides a substantially pure or isolated oligodeoxynucleotide of at least about 10 nucleotides comprising a sequence represented by either the formula: 5' N1N2N3T-CpG-WN4N5N6 3' wherein the central CpG motif is unmethylated, W is A or T, and N1, N2, N3, N4, N5, and N6 are any nucleotides, or the formula: 5' RY-CpG-RY 3' wherein the central CpG motif is unmethylated, R is A or G, and Y is C or T, as well as an oligodeoxynucleotide delivery complex and a pharmacol. composition comprising the present inventive oligodeoxynucleotide, and a method of inducing an immune response by administering the present inventive oligodeoxynucleotide to a host. The oligodeoxynucleotides with phosphate or phosphorothioate backbone modification are useful for inducing cell-mediated and humoral immune response and are therefore useful for treatment of allergy, asthma, cancer, autoimmune disease, immunol. disease, infection, and immune deficiency.

ST oligodeoxynucleotide adjuvant vaccine allergy cancer infection; autoimmune disease asthma oligodeoxynucleotide adjuvant vaccine

IT Cell activation
 (B cell; oligodeoxynucleotide for use to induce immune response)

IT B cell (lymphocyte)
 Lymphocyte
 (activation; oligodeoxynucleotide for use to induce immune response)

IT Infection
 (anti-; oligodeoxynucleotide for use to induce immune response)

IT Chemical warfare agents
 (bio-; oligodeoxynucleotide for use to induce immune response)

IT Diagnosis
 (cancer; oligodeoxynucleotide for use to induce immune response)

IT Drug delivery systems
 (carriers; oligodeoxynucleotide for use to induce immune response)

IT Immunity
 (cell-mediated; oligodeoxynucleotide for use to induce immune response)

IT Neoplasm
 (diagnosis; oligodeoxynucleotide for use to induce immune response)

IT Immunity
 (disorder; oligodeoxynucleotide for use to induce immune response)

IT Immunity
 (humoral; oligodeoxynucleotide for use to induce immune response)

IT Drug delivery systems
 (liposomes; oligodeoxynucleotide for use to induce immune response)

IT Cell activation
(lymphocyte; oligodeoxynucleotide for use to induce immune response)

IT Animal cell
(non-B; oligodeoxynucleotide for use to induce immune response)

IT Allergy
Allergy inhibitors
Antitumor agents
Asthma
Autoimmune disease
B cell (lymphocyte)
Drug targeting
Immunodeficiency
Immunostimulants
Neoplasm
Vaccines
(oligodeoxynucleotide for use to induce immune response)

IT Antibodies
Cytokines
Interleukin 6
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); USES (Uses)
(oligodeoxynucleotide for use to induce immune response)

IT Lipids, biological studies
Oligodeoxyribonucleotides
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligodeoxynucleotide for use to induce immune response)

IT Neoplasm
(solid; oligodeoxynucleotide for use to induce immune response)

IT Antisense oligonucleotides
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); USES (Uses)
(therapy; oligodeoxynucleotide for use to induce immune response)

IT Liposomes
(virosomes; oligodeoxynucleotide for use to induce immune response)

IT Interferons
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); USES (Uses)
(.gamma.; oligodeoxynucleotide for use to induce immune response)

IT 199810-73-6D, phosphate or phosphorothioate derivs. 250141-69-6D, phosphate or phosphorothioate derivs. 301939-29-7D, phosphate or phosphorothioate derivs. 301939-30-0D, phosphate or phosphorothioate derivs. 301939-31-1D, phosphate or phosphorothioate derivs. 301939-32-2D, phosphate or phosphorothioate derivs. 301939-33-3D, phosphate or phosphorothioate derivs. 301939-34-4D, phosphate or phosphorothioate derivs. 301939-35-5D, phosphate or phosphorothioate derivs. 301939-36-6D, phosphate or phosphorothioate derivs. 301939-37-7D, phosphate or phosphorothioate derivs. 301939-38-8D, phosphate or phosphorothioate derivs. 301939-39-9D, phosphate or phosphorothioate derivs. 301939-40-2D, phosphate or phosphorothioate derivs. 301939-41-3D, phosphate or phosphorothioate derivs. 301939-42-4D, phosphate or phosphorothioate derivs. 301939-43-5D, phosphate or phosphorothioate derivs. 301939-44-6D, phosphate or phosphorothioate derivs. 301939-45-7D, phosphate or phosphorothioate derivs. 301939-46-8D, phosphate or phosphorothioate derivs. 301939-47-9D, phosphate or phosphorothioate derivs. 301939-48-0D, phosphate or phosphorothioate derivs. 301939-49-1D, phosphate or phosphorothioate derivs. 301939-50-4D, phosphate or phosphorothioate derivs. 301939-51-5D, phosphate or phosphorothioate derivs. 301939-52-6D, phosphate or phosphorothioate derivs. 301939-53-7D, phosphate or phosphorothioate derivs. 301939-54-8D, phosphate or phosphorothioate derivs. 301939-55-9D, phosphate or phosphorothioate derivs. 301939-56-0D, phosphate or phosphorothioate derivs. 301939-57-1D, phosphate or phosphorothioate derivs. 301939-58-2D, phosphate or phosphorothioate derivs. 301939-59-3D, phosphate or phosphorothioate derivs. 301939-60-6D, phosphate or phosphorothioate derivs. 301939-61-7D, phosphate or phosphorothioate derivs. 301939-62-8D, phosphate or phosphorothioate derivs. 301939-63-9D, phosphate or phosphorothioate derivs. 301939-64-0D, phosphate or phosphorothioate derivs. 301939-65-1D, phosphate or phosphorothioate derivs. 301939-66-2D, phosphate or phosphorothioate derivs. 301939-67-3D, phosphate or phosphorothioate derivs. 301939-68-4D, phosphate or phosphorothioate derivs. 301939-69-5D, phosphate or

phosphorothioate derivs. 301939-70-8D, phosphate or phosphorothioate derivs. 301939-71-9D, phosphate or phosphorothioate derivs. 301939-72-0D, phosphate or phosphorothioate derivs. 301939-73-1D, phosphate or phosphorothioate derivs. 301939-74-2D, phosphate or phosphorothioate derivs. 301939-75-3D, phosphate or phosphorothioate derivs. 301939-76-4D, phosphate or phosphorothioate derivs. 301939-77-5D, phosphate or phosphorothioate derivs. 301939-78-6D, phosphate or phosphorothioate derivs. 301939-79-7D, phosphate or phosphorothioate derivs. 301939-80-0D, phosphate or phosphorothioate derivs. 301939-81-1D, phosphate or phosphorothioate derivs. 301939-82-2D, phosphate or phosphorothioate derivs. 301939-83-3D, phosphate or phosphorothioate derivs. 301939-84-4D, phosphate or phosphorothioate derivs. 301939-85-5D, phosphate or phosphorothioate derivs. 301939-86-6D, phosphate or phosphorothioate derivs. 301939-87-7D, phosphate or phosphorothioate derivs. 301939-88-8D, phosphate or phosphorothioate derivs. 301939-89-9D, phosphate or phosphorothioate derivs. 301939-90-2D, phosphate or phosphorothioate derivs. 301939-91-3D, phosphate or phosphorothioate derivs. 301939-92-4D, phosphate or phosphorothioate derivs. 301939-93-5D, phosphate or phosphorothioate derivs. 301939-94-6D, phosphate or phosphorothioate derivs. 301939-95-7D, phosphate or phosphorothioate derivs. 301939-96-8D, phosphate or phosphorothioate derivs. 301939-97-9D, phosphate or phosphorothioate derivs. 301939-98-0D, phosphate or phosphorothioate derivs. 301939-99-1D, phosphate or phosphorothioate derivs. 301940-00-1D, phosphate or phosphorothioate derivs. 301940-01-2D, phosphate or phosphorothioate derivs. 301940-02-3D, phosphate or phosphorothioate derivs. 301940-03-4D, phosphate or phosphorothioate derivs. 301940-04-5D, phosphate or phosphorothioate derivs. 301940-05-6D, phosphate or phosphorothioate derivs. 301940-06-7D, phosphate or phosphorothioate derivs. 301940-07-8D, phosphate or phosphorothioate derivs. 301940-08-9D, phosphate or phosphorothioate derivs. 301940-09-0D, phosphate or phosphorothioate derivs. 301940-10-3D, phosphate or phosphorothioate derivs. 301940-11-4D, phosphate or phosphorothioate derivs. 301940-12-5D, phosphate or phosphorothioate derivs. 301940-13-6D, phosphate or phosphorothioate derivs. 301940-14-7D, phosphate or phosphorothioate derivs. 301940-15-8D, phosphate or phosphorothioate derivs. 301940-16-9D, phosphate or phosphorothioate derivs. 302865-50-5D, phosphate or phosphorothioate derivs. 302865-51-6D, phosphate or phosphorothioate derivs. 302865-52-7D, phosphate or phosphorothioate derivs. 302865-53-8D, phosphate or phosphorothioate derivs. 302865-54-9D, phosphate or phosphorothioate derivs. 302865-55-0D, phosphate or phosphorothioate derivs. 302865-56-1D, phosphate or phosphorothioate derivs. 302865-57-2D, phosphate or phosphorothioate derivs. 302865-58-3D, phosphate or phosphorothioate derivs. 302865-59-4D, phosphate or phosphorothioate derivs. 302865-60-7D, phosphate or phosphorothioate derivs. 302865-61-8D, phosphate or phosphorothioate derivs. 302865-62-9D, phosphate or phosphorothioate derivs. 302865-63-0D, phosphate or phosphorothioate derivs. 302865-64-1D, phosphate or phosphorothioate derivs. 302865-65-2D, phosphate or phosphorothioate derivs. 302865-66-3D, phosphate or phosphorothioate derivs. 302865-67-4D, phosphate or phosphorothioate derivs. 302865-68-5D, phosphate or phosphorothioate derivs. 302865-69-6D, phosphate or phosphorothioate derivs. 302865-70-9D, phosphate or phosphorothioate derivs. 302865-71-0D, phosphate or phosphorothioate derivs. 302865-72-1D, phosphate or phosphorothioate derivs. 302865-73-2D, phosphate or phosphorothioate derivs. 302865-74-3D, phosphate or phosphorothioate derivs. 302865-75-4D, phosphate or phosphorothioate derivs. 302865-76-5D, phosphate or phosphorothioate derivs. 302865-77-6D, phosphate or phosphorothioate derivs. 302865-78-7D, phosphate or phosphorothioate derivs. 302865-79-8D, phosphate or phosphorothioate derivs. 302865-80-1D, phosphate or phosphorothioate derivs. 302865-81-2D, phosphate or phosphorothioate derivs. 302865-82-3D, phosphate or phosphorothioate derivs. 302865-83-4D, phosphate or phosphorothioate derivs. 302865-84-5D, phosphate or phosphorothioate derivs. 302865-85-6D, phosphate or phosphorothioate derivs. 302865-86-7D, phosphate or phosphorothioate derivs. 302865-87-8D, phosphate or phosphorothioate derivs. 302865-88-9D, phosphate or phosphorothioate derivs. 302865-89-0D, phosphate or phosphorothioate derivs. 302865-90-3D, phosphate or phosphorothioate derivs. 302865-91-4D, phosphate or phosphorothioate derivs.

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (oligodeoxynucleotide for use to induce immune response)

IT 57-88-5, Cholesterol, biological studies

Search done by Noble Jarrell

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(oligodeoxynucleotide for use to induce immune response)

=> b wpiX

FILE WPIX ENTERED AT 08:51:14 ON 13 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE LAST UPDATED: 8 DEC 2004 <20041208/UP>
MOST RECENT DERWENT UPDATE: 200479 <200479/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> NEW DISPLAY FORMAT HITSTR ADDED ALLOWING DISPLAY OF
HIT STRUCTURES WITHIN THE BIBLIOGRAPHIC DOCUMENT <<<

>>> SMILES and ISOSMILES strings are no longer available as
Derwent Chemistry Resource display fields <<<

=> d all 110 tot

L10 ANSWER 1 OF 1 WPIX COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2001-006880 [01] WPIX
DNC C2001-001559
TI Novel oligonucleotides useful for the prevention and treatment of
allergies, cancer, and autoimmune disorders and for ameliorating symptoms
resulting from exposure to a bio-warfare agent.
DC B04 D16
IN ISHII, K; KLINMAN, D; VERTHELYI, D; GURSEL, M; MOND, J J
PA (USSH) US DEPT HEALTH & HUMAN SERVICES; (GURS-I) GURSEL M; (ISHI-I) ISHII
K; (KLIN-I) KLINMAN D; (MOND-I) MOND J J; (VERT-I) VERTHELYI D
CYC 93
PI WO 2000061151 A2 20001019 (200101)* EN 46 A61K031-70
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ
EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK
LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI
SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU 2000043437 A 20001114 (200108) A61K031-70
EP 1176966 A2 20020206 (200218) EN A61K031-70
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI
US 2003060440 A1 20030327 (200325) A61K048-00 <--
ADT WO 2000061151 A2 WO 2000-059839 20000412; AU 2000043437 A AU
2000-43437 20000412; EP 1176966 A2 EP 2000-923283 20000412; WO
2000-059839 20000412; US 2003060440 A1 Provisional US
1999-128898P 19990412, CIP of US 2001-958713 20011010, US 2002-68160
20020206
FDT AU 2000043437 A Based on WO 2000061151; EP 1176966 A2 Based on WO
2000061151
PRAI US 1999-128898P 19990412; US 2001-958713
20011010; US 2002-68160 20020206
IC ICM A61K031-70; A61K048-00
ICS A61K039-39; C07H021-00; C07H021-04
AB WO 2000061151 A UPAB: 20001230
NOVELTY - A pure or isolated oligonucleotide (I) of at least 10
nucleotides, comprising a specific sequence, is new.
DETAILED DESCRIPTION - A pure or isolated oligonucleotide (I) of at
least 10 nucleotides, comprising a specific sequence, is new. (I)

comprises the sequence: 5'-N1N2N3T-CpG-WN4N5N6-3' or 5'-RY-CpG-RY-3'.

W = A or T;

N1-6 = any nucleotides;

R = A or G; and

Y = C or T.

The central CpG motif is unmethylated.

INDEPENDENT CLAIMS are also included for the following:

(1) an oligonucleotide delivery complex (II), comprising (I) and a targeting agent; and

(2) a pharmacological composition comprising (I).

ACTIVITY - Cytostatic; Immunosuppressive; Antiarthritic; Antimicrobial; Antiallergic; Anti-HIV (human immunodeficiency virus); Protozoacide; Tuberculostatic; Antiasthmatic; Dermatological; Neuroprotective. No biological data is given.

MECHANISM OF ACTION - Inducer of cell or humoral mediated immune response. Vaccine. Oligodeoxynucleotides (ODNs) ATCGACTCTCGAGCGTTCT and ATCGACTAGCGTTCTTCTC were synthesized on a DNA synthesizer and the induction of immune response by the ODNs was tested. The normal DNA backbone phosphodiesterase linkages were replaced with phosphorothioate linkages. Human peripheral blood mononuclear cells were incubated for 72 hours with the ODNs. Interleukin (IL-6) and tumor necrosis factor gamma (TNF- gamma) levels were determined by enzyme linked immunosorbent assay (ELISA) using anti-IL-6 and anti-TNF- gamma antibodies. Cell proliferation was determined by (3H) thymidine incorporation. The results showed that the sequence containing 5'-N1N2N3T-CpG-WN4N5N6 3' was desirable to induce a humoral immune response. In addition, maximum induction was observed for ODNs that contained a phosphorothioate backbone. The sequence containing 5'RY-CpG-RY 3', was desirable to induce a cell-mediated immune response. The IL-6 levels and cell proliferation obtained with ATCGACTCTCGAGCGTTCT was 85 and 44 and the IL-6 level obtained with ATCGACTAGCGTTCTTCTC was 55.

USE - (I) is useful for inducing cell-mediated immune response in humans by activating non-B cells or inducing humoral-mediated immune response by activating B cells in the human. (I) induces cytokine e.g. interleukin (IL)-6, or antibody production in the host. The induction of immune response is useful for treating, preventing or ameliorating an allergic reaction, preferably asthma or an infection, where (I) is administered either alone or in combination with an anti-allergenic agent or anti-infectious agent, autoimmune disorder, a disease associated with immune system deficiency and symptoms resulting from exposure to a bio-warfare agent. (I) alone or in combination with an anti-cancer agent is useful for treating solid tumor cancer. The induction of immune response is used in antisense therapy and to improve the efficacy of a vaccine. (I) is preferably administered to lymphocytes ex vivo, producing activated lymphocytes which are then administered to the host (claimed). Allergic conditions include eczema, allergic rhinitis, food allergies and other atopic conditions, immune system deficiencies e.g. lupus erythematosus and autoimmune diseases include rheumatoid arthritis and multiple sclerosis and infections include viral, bacterial and fungi infections such as tuberculosis, acquired immunodeficiency syndrome (AIDS), leishmania and schistosomiasis.

ADVANTAGE - The oligodeoxynucleotides are more resistant to degradation.

Dwg.0/0

FS

CPI

FA

AB; DCN

MC

CPI: B01-D02; B04-E02F; B04-E06; B14-A01; B14-A02; B14-A02B1; B14-A04; B14-C06; B14-C09B; B14-G01B; B14-G02A; B14-G02D; B14-H01; B14-H01B; B14-K01A; B14-N17C; B14-S01; B14-S03; B14-S11; D05-H07; D05-H12B2

=> b home

FILE 'HOME' ENTERED AT 08:51:29 ON 13 DEC 2004

=>

=> d his

(FILE 'HOME' ENTERED AT 08:46:58 ON 13 DEC 2004)

FILE 'HCAPLUS' ENTERED AT 08:47:03 ON 13 DEC 2004

L1 1 US20030060440/PN
E WO2000-US9839/AP, PRN
L2 1 WO2000-US9839/AP, PRN
E US1999-128898/AP, PRN
L3 2 US1999-128898P/AP, PRN
L4 2 L1-3

FILE 'REGISTRY' ENTERED AT 08:49:20 ON 13 DEC 2004

FILE 'HCAPLUS' ENTERED AT 08:49:22 ON 13 DEC 2004

L5 TRA L4 1- RN : 251 TERMS

FILE 'REGISTRY' ENTERED AT 08:49:23 ON 13 DEC 2004

L6 251 SEA L5

FILE 'WPIX' ENTERED AT 08:49:27 ON 13 DEC 2004

L7 1 US20030060440/PN
E WO2000-US9839/AP, PRN
L8 1 WO2000-US9839/AP, PRN
E US1999-128898/AP, PRN
L9 1 US1999-128898P/AP, PRN
L10 1 L7-9

FILE 'REGISTRY' ENTERED AT 09:25:16 ON 13 DEC 2004

L11 QUE ...RYCGRY.{3-13}G{4-10}/SQSN

L12 1340 L11 AND SQL<=30

FILE 'HCAPLUS' ENTERED AT 09:30:27 ON 13 DEC 2004

L13 260 L12
E KLINMAN D/AU
L14 180 E3-8
E VERTHELTI D/AU
L15 40 E4-7
E ISHII K/AU
L16 937 E3-5
E ISHII KEN/AU
L17 63 E3-6
E MOND J/AU
L18 150 E3-6
E GURSEL M/AU
L19 34 E3-4
L20 3572 (HHS OR HEALTH (1A) HUMAN (1A) SERV?)/CS, PA
L21 21 L13 AND L14-20
L22 259 L13 NOT L21
L23 QUE PY<=1999 OR AY<=1999 OR PRY<=1999 OR PRD<19990412 OR PD<199
L24 72 L22 AND L23
L25 61 L24 AND P/DT
L26 47 L25 AND US/PC
L27 25 L25 AND US/PC-E

=> b hcap

FILE 'HCAPLUS' ENTERED AT 09:41:22 ON 13 DEC 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Dec 2004 VOL 141 ISS 25

FILE LAST UPDATED: 12 Dec 2004 (20041212/ED)

This file contains CAS Registry Numbers for easy and accurate

Search done by Noble Jarrell

substance identification.

=> d all Chitstr 121 tot

L21 ANSWER 1 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:995900 HCAPLUS
 ED Entered STN: 19 Nov 2004
 TI Method of preventing infections from bioterrorism agents with
 immunostimulatory CPG oligonucleotides
 IN **Kliman, Dennis M.; Ivins, Bruce; Verthelyi, Daniela**
 PA The Government of the United States of America as Represented by the
 Secretary of the Department of **Health and Human**
 Services, USA
 SO PCT Int. Appl., 142 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 3

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004098491	A2	20041118	WO 2003-US34523	20031031
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2002-422964P P 20021101

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 2004098491	ICM	A61K
AB	The present disclosure relates to a method of preventing or treating an infection caused by a bioterrorism agent, specifically to a method of increasing an immune response to a bioterrorism agent using an oligodeoxynucleotide including a CpG motif, and a method of enhancing the immunogenicity of a vaccine against a bioterrorism agent using an oligodeoxynucleotide including a CpG motif.	
ST	infection bioterrorism immunostimulatory CPG oligonucleotide	
IT	G proteins (guanine nucleotide-binding proteins) RL: BSU (Biological study, unclassified); BIOL (Biological study) (Rac; method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)	
IT	Bacillus anthracis (anthrax from; method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)	
IT	Infection (bacterial; method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)	
IT	Terrorism (bioterrorism; method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)	
IT	Staphylococcus (enterotoxin B; method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)	
IT	Oligodeoxyribonucleotides RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (immunostimulatory; method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)	
IT	Drug delivery systems (inhalants; method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)	
IT	Drug delivery systems (injections, i.m.; method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)	
IT	Drug delivery systems (injections, i.v.; method of preventing infections from bioterrorism	

Search done by Noble Jarrell

agents with immunostimulatory CPG oligonucleotides)

IT Drug delivery systems
(injections, s.c.; method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)

IT Anti-infective agents
Antibiotics
Antiviral agents
Bacillus anthracis
Combination chemotherapy
Drug bioavailability
Ebola virus
Encephalitis
Escherichia coli
Fungicides
Haemophilus influenzae
Histoplasma capsulatum
Immunostimulants
Salmonella
Shellfish
Shigella dysenteriae
Shigella flexneri
Tick-borne encephalitis virus
Vaccines
Variola major virus
Venoms
Yersinia pestis
(method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)

IT Aflatoxins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)

IT Antibodies and Immunoglobulins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)

IT Ricins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ricin toxin; method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)

IT Encephalitis
(tick-borne; method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)

IT Mycotoxins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(trichothecene; method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)

IT Infection
(variola; method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)

IT Infection
(viral; method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)

IT 35523-89-8, Saxitoxin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)

IT 84216-59-1 94855-01-3 97802-24-9 132952-72-8 698365-81-0
698365-82-1 794235-01-1 794235-02-2
794235-03-3 794235-04-4 794235-05-5
794235-06-6 794235-07-7 794235-08-8
794235-09-9 794235-10-2 794235-11-3 794235-12-4
794235-13-5 794235-14-6 794235-15-7 794235-16-8
794235-17-9 794235-18-0 794235-19-1 794235-20-4 794235-21-5
794235-22-6 794235-23-7 794235-24-8 794235-25-9 794235-26-0
794235-27-1 794235-28-2 794235-29-3 794235-30-6 794235-31-7
794235-32-8 794235-33-9 794235-34-0
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of preventing infections from bioterrorism agents with immunostimulatory CPG oligonucleotides)

IT 794237-43-7 794237-44-8 794237-45-9 794237-46-0
794237-47-1 794237-48-2 794237-49-3
794237-50-6 794237-51-7 794237-52-8

794237-53-9 794237-54-0 794237-55-1
 794237-56-2 794237-57-3 794237-58-4
 794237-59-5 794237-60-8 794237-61-9
 794237-62-0 794237-63-1 794237-64-2
 794237-65-3 794237-66-4 794237-67-5
 794237-68-6 794237-69-7 794237-70-0
 794237-71-1 794237-72-2 794237-73-3
 794237-74-4 794237-75-5 794237-76-6
 794237-77-7 794237-78-8 794237-79-9
 794237-80-2 794237-81-3 794237-82-4
 794237-83-5 794237-84-6 794237-85-7
 794237-86-8 794237-87-9 794237-88-0
 794237-89-1 794237-90-4 794237-91-5
 794237-92-6 794237-93-7 794237-94-8
 794237-95-9 794237-96-0 794237-97-1
 794237-98-2 794237-99-3 794238-00-9
 794238-01-0 794238-02-1 794238-03-2
 794238-04-3 794238-05-4 794238-06-5
 794238-07-6 794238-08-7 794238-09-8
 794238-10-1 794238-11-2 794238-12-3
 794238-13-4 794238-14-5 794238-15-6
 794238-16-7 794238-17-8 794238-18-9
 794238-19-0 794238-20-3 794238-21-4 794238-22-5
 794238-23-6 794238-24-7 794238-25-8
 794238-26-9 794238-27-0 794238-28-1
 794238-29-2 794238-30-5 794238-31-6
 794238-32-7 794238-33-8 794238-34-9
 794238-35-0 794238-36-1 794238-37-2
 794238-38-3 794238-39-4 794238-40-7
 794238-41-8 794238-42-9 794238-43-0
 794238-44-1 794238-45-2 794238-46-3
 794238-47-4 794238-48-5 794238-49-6
 794238-50-9 794238-51-0 794238-52-1
 794238-53-2 794238-54-3 794238-55-4
 794238-56-5 794238-57-6 794238-58-7
 794238-59-8 794238-60-1 794238-61-2
 794238-62-3 794238-63-4 794238-64-5
 794238-65-6 794238-66-7 794238-67-8
 794238-68-9 794238-69-0 794238-70-3
 794238-71-4 794238-72-5 794238-73-6
 794238-74-7 794238-75-8 794238-76-9
 794238-77-0 794238-78-1 794238-79-2 794238-80-5
 794238-81-6 794238-82-7 794238-83-8
 794238-84-9 794238-85-0 794238-86-1
 794238-87-2 794238-88-3 794238-89-4 794238-90-7
 794238-91-8 794238-92-9 794238-93-0
 794238-94-1 794238-95-2 794238-96-3
 794238-97-4 794238-98-5 794238-99-6 794239-00-2

RL: PRP (Properties)
 (unclaimed nucleotide sequence; method of preventing infections from
 bioterrorism agents with immunostimulatory CPG oligonucleotides)

IT 794235-01-1
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (method of preventing infections from bioterrorism agents with
 immunostimulatory CPG oligonucleotides)

RN 794235-01-1 HCAPLUS

CN DNA, d(N-N-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 2 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:496197 HCAPLUS

DN 141:275892

ED Entered STN: 20 Jun 2004

TI CpG oligodeoxynucleotides improve the response to hepatitis B immunization
 in healthy and SIV-infected rhesus macaques

AU Verthelyi, Daniela; Wang, Vivian W.; Lifson, Jeffrey D.;
 Klinman, Dennis M.

CS Division of Therapeutic Proteins, Center for Biologics Evaluation and
 Research, Food and Drug Administration, Bethesda, USA

SO AIDS (London, United Kingdom) (2004), 18(7), 1003-1008

CODEN: AIDSET; ISSN: 0269-9370

PB Lippincott Williams & Wilkins

DT Journal

LA English
 CC 15-2 (Immunochemistry)
 AB Objective: The development of an immunogenic vaccine against hepatitis B virus (HBV) is particularly important for HIV-infected patients since shared epidemiol. risks result in HIV-infected subjects having a high incidence of HBV, and coinfection with HBV increases the occurrence of hepatotoxicity with antiretroviral therapy. Although HBV vaccination is recommended to all HIV-pos. patients, its efficacy in these patients is reduced. Methods: Healthy (n = 15) and SIV-infected (n = 17) rhesus macaques were immunized with Engerix B alone or combined with type D or type K CpG ODN. SIV plasma RNA levels were determined by a real time reverse transcriptase polymerase chain reaction and antibody titers to HBV surface antigen (HbsAg) were measured by ELISA every 2 wk. Results: In healthy macaques, adding D or K ODN to Engerix B accelerated and boosted the titer of the anti-HbsAg response. In SIV-infected macaques, Engerix B alone elicited no detectable antibody response but a significant response was seen when it was combined with K or D ODN. The antibody titer induced by vaccinating HIV-infected macaques was inversely correlated with their initial viral load, with animals having >107 copies/mL being unable to mount a significant response. No adverse events or changes in SIV viral load were evident during the study. Conclusions: These findings support the development of clin. studies to assess the use of CpG ODN as an adjuvant for HBV vaccination in healthy and immunocompromised HIV-infected subjects.

ST hepatitis B virus vaccine CpG oligodeoxynucleotide SIV infection macaque
 IT Vaccines
 (AIDS; CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques)

IT AIDS (disease)
 Hepatitis B virus
 Human immunodeficiency virus
 Macaca mulatta
 Simian immunodeficiency virus
 Vaccines
 (CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques)

IT Antibodies and Immunoglobulins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques)

IT Oligodeoxyribonucleotides
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques)

IT Immunostimulants
 (adjuvants; CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques)

IT Antigens
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (hepatitis B surface; CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques)

IT Immunization
 (vaccination; CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques)

IT Anti-AIDS agents
 (vaccines; CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques)

IT Infection
 (viral; CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques)

IT 351186-51-1, Engerix B 756902-34-8 756902-35-9
 756902-36-0 757252-01-0 757252-02-1 757252-03-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques)

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Azzoni, L; J Immunol 2002, V168, P5764 HCAPLUS
 (2) Chehimi, J; J Exp Med 1994, V179, P1361 HCAPLUS
 (3) Chehimi, J; J Immunol 2002, V168, P4796 HCAPLUS
 (4) Choudhury, S; Pediatr Infect Dis J 1995, V14, P65 MEDLINE
 (5) Cooley, L; J Clin Virol 2003, V26, P185
 (6) Davis, H; Vaccine 2000, V19, P413

(7) Dianmant, E; Pediatr Infect Dis J 1993, V12, P877
 (8) Donaghy, H; Blood 2001, V98, P2574 HCAPLUS
 (9) Feldman, S; Clin Immunol 2001, V101, P201 HCAPLUS
 (10) Gursel, M; Eur J Immunol 2002, V32, P2617 HCAPLUS
 (11) Hartmann, G; J Immunol 2000, V164, P1617 HCAPLUS
 (12) Hemmi, H; Nature 2000, V408, P740 HCAPLUS
 (13) Homann, C; J Acquir Immune Defic Syndr 1991, V4, P416 MEDLINE
 (14) Horowitz, M; Ann Intern Med 1988, V108, P185 MEDLINE
 (15) Jones, T; Vaccine 1999, V17, P3065 HCAPLUS
 (16) Kadowaki, N; J Exp Med 2001, V194, P863 HCAPLUS
 (17) Klinman, D; Microb Infect 2002, V4, P897 HCAPLUS
 (18) Krieg, A; Annu Rev Immunol 2002, V20, P709 HCAPLUS
 (19) Krug, A; Eur J Immunol 2001, V31, P2154 HCAPLUS
 (20) Leifer, C; J Immunother 2003, V26, P313 HCAPLUS
 (21) Lemon, S; N Engl J Med 1997, V336, P196 HCAPLUS
 (22) Lifson, J; J Virol 2001, V75, P10187 HCAPLUS
 (23) Newell, A; Br J Clin Pract 2003, V49, P247
 (24) Pacanowski, J; Blood 2001, V98, P3016 HCAPLUS
 (25) Puoti, M; AIDS Rev 2002, V4, P27
 (26) Rey, D; Vaccine 2000, V18, P1161 HCAPLUS
 (27) Rustgi, V; Ann Intern Med 1984, V101, P795 MEDLINE
 (28) Takeshita, F; J Immunol 2001, V167, P3555 HCAPLUS
 (29) Verthelyi, D; J Immunol 2001, V166, P2372 HCAPLUS
 (30) Verthelyi, D; J Immunol 2002, V168, P1659 HCAPLUS
 (31) Verthelyi, D; J Immunol 2003, V170, P4717 HCAPLUS
 (32) Verthelyi, D; Trends Immunol 2003, V24, P519 HCAPLUS
 (33) Wong, E; Int J STD AIDS 1996, V7, P490 MEDLINE
 IT 756902-34-8
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (CpG oligodeoxynucleotides improve the response to hepatitis B
 immunization in healthy and SIV-infected rhesus macaques)
 RN 756902-34-8 HCAPLUS
 CN DNA, d(G-sp-G-sp-T-G-C-A-T-C-G-A-T-G-C-A-G-G-sp-G-sp-G-sp-G) (9CI)
 (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 3 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:451477 HCAPLUS
 DN 141:33759
 ED Entered STN: 04 Jun 2004
 TI Method of treating and preventing infections in immunocompromised subjects
 with immunostimulatory CpG oligonucleotides
 IN Klinman, Dennis M.; Verthelyi, Daniela
 PA The Government of the USA as Represented by the Secretary of the Dept. of
 Health & Human Services, USA
 SO U.S. Pat. Appl. Publ., 64 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K031-70
 ICS A01N043-04; A61K039-395; A61K039-12; C12N005-06; C12N005-16
 NCL 424204100; 424130100; 435345000
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 15

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004105872	A1	20040603	US 2003-666022	20030917
PRAI US 2002-411944P	P	20020918		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004105872	ICM	A61K031-70
	ICS	A01N043-04; A61K039-395; A61K039-12; C12N005-06; C12N005-16
	NCL	424204100; 424130100; 435345000
US 2004105872	ECLA	A61K031/7115; A61K031/7125; A61K039/39

AB A method is disclosed herein for increasing an immune response to an
 opportunistic infection in an immunocompromised subject. In one
 embodiment, the subject is infected with a lentivirus. The method
 includes increasing an immune response to a pathogen using D
 oligodeoxynucleotides including a CpG motif. Addition of K or D CpG
 oligodeoxynucleotides boosted the immunogenicity of the Engerix B
 hepatitis B virus vaccine to render refractory SIV-infected macaques

responsive to vaccination.

ST opportunistic infection immunocompromised immunostimulatory CpG oligonucleotide; lentivirus infection treatment immunostimulatory CpG oligonucleotide; hepatitis B virus vaccine immunostimulatory oligodeoxynucleotide SIV

IT Hepatitis
(B, opportunistic infection; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Oligodeoxyribonucleotides
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(D or K, having CpG motif; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Sarcoma
(Kaposi's, opportunistic; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Vaccines
(adjuvants for; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Immunostimulants
(adjuvants; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Mycosis
(as opportunistic infection; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Aspergillus
(aspergillosis from; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Infection
(bacillary angiomatosis, opportunistic; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Infection
(bacterial, as opportunistic infection; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Candida
(candidiasis from, opportunistic; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Nervous system, neoplasm
(central, primary lymphoma, opportunistic; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Granulomatous disease
(chronic, PBMC from humans with, response to CpG oligodeoxynucleotides; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Mycosis
(coccidioidomycosis, opportunistic; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Immunity
(disorder, immunocompromised; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Interleukin 6
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(enhancement of production of; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Cell proliferation
(enhancement of; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Mouth, disease
(hairy leukoplakia, opportunistic; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Vaccines
(hepatitis B, adjuvants for; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Antiviral agents
(highly active antiretroviral therapy (HAART) combination; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Human immunodeficiency virus
Human immunodeficiency virus 1

Human immunodeficiency virus 2
 Simian immunodeficiency virus
 (immunocompromisation from infection with; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Immune system
 (immunoprotective CpG oligodeoxynucleotides; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT AIDS (disease)
 Human
 Immunity
 Immunostimulants
 Infection
 Leishmania amazonensis
 Leishmania major
 Tuberculosis
 (immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Phosphorothioate oligodeoxyribonucleotides
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (immunostimulatory oligodeoxynucleotides containing; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Pathogen
 (increasing immune response to; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Dendritic cell
 Monocyte
 (induction of maturation of; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Lentivirus
 (infection; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Syphilis
 (neurosyphilis, opportunistic infection with; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Lymphoma
 (non-Hodgkin's, systemic, opportunistic; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Antigens
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (of immunodeficiency virus, in treatment of immunodeficiency virus infection; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Meningitis
 (opportunistic cryptococcal; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Cryptosporidium
 (opportunistic cryptosporidiosis infection from; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Pneumonia
 (opportunistic infection with Pneumocystis carinii; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Cytomegalovirus
 Human herpesvirus
 Human herpesvirus 3
 Human papillomavirus
 Leishmania
 Molluscum contagiosum virus
 Mycobacterium
 Syphilis
 (opportunistic infection with; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Hepatitis
 Histoplasma capsulatum
 (opportunistic infection; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Isospora
 (opportunistic isosporiasis infection from; immunostimulatory CpG

oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Microsporidia
(opportunistic microsporidiosis infection from; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Cryptococcus (fungus)
(opportunistic; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Functional groups
(phosphodiester; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Pneumocystis carinii
(pneumonia from; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Brain, disease
(progressive multifocal leukoencephalopathy, opportunistic; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Infection
(protozoal, as opportunistic infection; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Mononuclear cell (leukocyte)
(response to CpG oligodeoxynucleotides; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Salmonella
(salmonellosis from; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Toxoplasma gondii
(toxoplasmosis from, opportunistic infection; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Neoplasm
Prion diseases
(treatment of; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(vaccinated animals development of protective levels of; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Immunization
(vaccination; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Infection
(viral, as opportunistic infection; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Interferons
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha., triggering secretion of; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT Interferons
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.gamma., triggering secretion of; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT 30516-87-1, AZT
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT 2382-65-2
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunostimulatory oligonucleotides containing; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT 697319-80-5 697319-81-6 697319-82-7 700878-94-0
700878-95-1 700878-96-2
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(nucleotide sequence, immunocompromised macaques response to HBV vaccine improvement with; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT 84216-59-1 94855-01-3 97802-24-9 132952-72-8 698365-81-0
 698365-82-1 698400-46-3 698400-47-4
 698400-48-5 698400-49-6 698400-50-9
 698400-51-0 698400-52-1 698400-53-2
 698400-54-3 698400-55-4 698400-56-5
 698400-57-6 698400-58-7 698400-59-8
 698400-60-1 698400-61-2 698400-62-3
 698400-63-4 698400-64-5 698400-65-6
 698400-66-7 698400-67-8 698400-68-9
 698400-69-0 698400-70-3 698400-71-4
 698400-72-5 698400-73-6 698400-74-7
 698400-75-8 698400-76-9 698400-77-0
 698400-78-1 698400-79-2 698400-80-5
 698400-81-6 698400-82-7 698400-83-8
 698400-84-9 698400-85-0 698400-86-1
 698400-87-2 698400-88-3 698400-89-4
 698400-90-7 698400-91-8 698400-92-9
 698400-93-0 698400-94-1 698400-95-2
 698400-96-3 698400-97-4 698400-98-5
 698400-99-6 698401-00-2 698401-01-3
 698401-02-4 698401-03-5 698401-04-6
 698401-05-7 698401-06-8 698401-07-9
 698401-08-0 698401-09-1 698401-10-4
 698401-11-5 698401-12-6 698401-13-7
 698401-14-8 698401-15-9 698401-16-0
 698401-17-1 698401-18-2 698401-19-3
 698401-20-6 698401-21-7 698401-22-8
 698401-23-9 698401-24-0 698401-25-1
 698401-26-2 698401-27-3 698401-28-4
 698401-29-5 698401-30-8 698401-31-9 698401-32-0
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(nucleotide sequence; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT 698753-95-6 698753-96-7 698753-97-8 698753-98-9
 698753-99-0 698754-00-6 698754-01-7
 698754-02-8 698754-03-9 698754-04-0
 698754-05-1 698754-06-2 698754-07-3
 698754-08-4 698754-09-5 698754-10-8
 698754-11-9 698754-12-0 698754-13-1
 698754-14-2 698754-15-3 698754-16-4
 698754-17-5 698754-18-6 698754-19-7
 698754-20-0 698754-21-1 698754-22-2
 698754-23-3 698754-24-4 698754-25-5
 698754-26-6 698754-27-7 698754-28-8
 698754-29-9 698754-30-2 698754-31-3
 698754-32-4 698754-33-5 698754-34-6
 698754-35-7 698754-36-8 698754-37-9
 698754-38-0 698754-39-1 698754-40-4
 698754-41-5 698754-42-6 698754-43-7
 698754-44-8 698754-45-9 698754-46-0
 698754-47-1 698754-48-2 698754-49-3
 698754-50-6 698754-51-7 698754-52-8 698754-53-9
 698754-54-0 698754-55-1 698754-56-2
 698754-57-3 698754-58-4 698754-59-5
 698754-60-8 698754-61-9 698754-62-0 698754-63-1
 698754-64-2 698754-65-3 698754-66-4
 698754-67-5 698754-68-6 698754-69-7
 698754-70-0 698754-71-1 698754-72-2 698754-73-3
 698754-74-4 698754-75-5 698754-76-6 698754-77-7
 698754-85-7 698754-86-8 698754-87-9

RL: PRP (Properties)

(unclaimed nucleotide sequence; method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides)

IT 700878-94-0

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(nucleotide sequence, immunocompromised macaques response to HBV vaccine improvement with; immunostimulatory CpG oligonucleotides for

treating and preventing infections in immunocompromised subjects)
 RN 700878-94-0 HCAPLUS
 CN DNA, d(G-sp-G-sp-T-G-C-A-T-C-G-A-T-G-C-A-G-sp-G-sp-G-sp-G-sp-G) (9CI)
 (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 4 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:120676 HCAPLUS
 DN 140:175130
 ED Entered STN: 13 Feb 2004
 TI Treating inflammatory arthropathies with oligodeoxynucleotide suppressors
 of CpG-containing oligonucleotides
 IN Klinman, Dennis M.; Zeuner, Rainald; Verthelyi, Daniela
 ; Gursel, Ihsan; Gursel, Mayda
 PA The Government of the United States of America as Represented by the
 Secretary of the Department of Health and Human
 Services, USA
 SO PCT Int. Appl., 119 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K
 CC 1-7 (Pharmacology)
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004012669	A2	20040212	WO 2003-US24205	20030731
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI US 2002-400826P	P	20020801		
US 2002-401631P	P	20020806		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004012669	ICM	A61K

AB The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. The oligodeoxynucleotides comprise .gtoreq.8 nucleotides in length, form a G-quadruplex (G tetrad), have a CD value of >2.9, has at least two guanosines, and suppresses an immune response. Optionally, the suppressive oligodeoxynucleotide has multiple guanosine-rich sequences, and in some examples, has one or more TTAGGG motifs; it may also be modified (e.g., with phosphorothioate linkages) to prevent degradation or is part of an oligodeoxynucleotide delivery complex that includes a targeting moiety. The suppressive oligodeoxynucleotides suppress CpG-DNA-induced immune activation, are highly specific, and are neither toxic nor non-specifically immunosuppressive. Suppression is mediated by the two-dimensional structure of the motifs, as shown by replacing individual guanosines by 7-deazaguanosine analogs to reduce G tetrad formation.

ST inflammatory arthropathy immunosuppression oligodeoxynucleotide; arthritis immunosuppression oligodeoxynucleotide

IT DNA
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (CpG-containing, suppression of arthritis induced by; treating inflammatory arthropathies with oligodeoxynucleotide suppressors of CpG-containing oligonucleotides)

IT Steroids, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (co-treatment with; treating inflammatory arthropathies with oligodeoxynucleotide suppressors of CpG-containing oligonucleotides)

IT Joint, anatomical
 (disease; treating inflammatory arthropathies with oligodeoxynucleotide suppressors of CpG-containing oligonucleotides)

IT Drug delivery systems
 (liposomes; treating inflammatory arthropathies with

oligodeoxynucleotide suppressors of CpG-containing oligonucleotides)

IT Anti-inflammatory agents
(nonsteroidal, co-treatment with; treating inflammatory arthropathies with oligodeoxynucleotide suppressors of CpG-containing oligonucleotides)

IT Collagens, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(suppression of arthritis induced by; treating inflammatory arthropathies with oligodeoxynucleotide suppressors of CpG-containing oligonucleotides)

IT Lipids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(targeting moiety; treating inflammatory arthropathies with oligodeoxynucleotide suppressors of CpG-containing oligonucleotides)

IT Anti-inflammatory agents
Antiarthritics
Antirheumatic agents
Arthritis
Human
Immunosuppressants
Rheumatoid arthritis
(treating inflammatory arthropathies with oligodeoxynucleotide suppressors of CpG-containing oligonucleotides)

IT Oligodeoxyribonucleotides
Phosphorothioate oligodeoxyribonucleotides
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating inflammatory arthropathies with oligodeoxynucleotide suppressors of CpG-containing oligonucleotides)

IT Drug delivery systems
(virosomes, targeting moiety; treating inflammatory arthropathies with oligodeoxynucleotide suppressors of CpG-containing oligonucleotides)

IT 329900-75-6, Cyclooxygenase 2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors, co-treatment with; treating inflammatory arthropathies with oligodeoxynucleotide suppressors of CpG-containing oligonucleotides)

IT 2382-65-2D, DNA containing
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(suppression of arthritis induced by; treating inflammatory arthropathies with oligodeoxynucleotide suppressors of CpG-containing oligonucleotides)

IT 57-88-5, Cholesterol, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(targeting moiety; treating inflammatory arthropathies with oligodeoxynucleotide suppressors of CpG-containing oligonucleotides)

IT 157961-44-9 657710-63-9 657710-64-0 657710-65-1 657710-66-2
657710-67-3 657710-68-4 657710-69-5 657710-70-8 657710-71-9
657710-72-0 657710-73-1 657710-74-2 657710-75-3 657710-76-4
657710-77-5 657710-78-6 657710-79-7 657710-80-0 657710-81-1
657710-82-2 657710-83-3 657710-84-4 657710-85-5 657710-86-6
657710-87-7
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating inflammatory arthropathies with oligodeoxynucleotide suppressors of CpG-containing oligonucleotides)

IT 657710-88-8 657710-89-9 657710-90-2 657710-91-3 657710-92-4
657710-93-5 657710-94-6 657710-95-7 657710-96-8 657710-97-9
657710-98-0 657710-99-1 657711-00-7
657711-01-8 657711-02-9 657711-03-0
657711-04-1 657711-05-2 657711-06-3
657711-07-4 657711-08-5 657711-09-6
657711-10-9 657711-11-0 657711-12-1
657711-13-2 657711-14-3 657711-15-4
657711-16-5 657711-17-6 657711-18-7
657711-19-8 657711-20-1 657711-21-2
657711-22-3 657711-23-4 657711-24-5
657711-25-6 657711-26-7 657711-27-8
657711-28-9 657711-29-0 657711-30-3
657711-31-4 657711-32-5 657711-33-6
657711-34-7 657711-35-8 657711-36-9
657711-37-0 657711-38-1 657711-39-2
657711-40-5 657711-41-6 657711-42-7
657711-43-8 657711-44-9 657711-45-0
657711-46-1 657711-47-2 657711-48-3
657711-49-4 657711-50-7 657711-51-8
657711-52-9 657711-53-0 657711-54-1
657711-55-2 657711-56-3 657711-57-4

657711-58-5 657711-59-6 657711-60-9
657711-61-0 657711-62-1 657711-63-2
657711-64-3 657711-65-4 657711-66-5
657711-67-6 657711-68-7 657711-69-8
657711-70-1 657711-71-2 657711-72-3 657711-73-4

RL: PRP (Properties)

(unclaimed nucleotide sequence; treating inflammatory arthropathies
with oligodeoxynucleotide suppressors of CpG-containing oligonucleotides)

IT 657710-97-9

RL: PRP (Properties)

(unclaimed nucleotide sequence; treating inflammatory arthropathies
with oligodeoxynucleotide suppressors of CpG-containing oligonucleotides)

RN 657710-97-9 HCAPLUS

CN DNA, d(N-N-N-R-Y-C-G-R-Y-N-N-N-G-G-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 5 OF 21 HCAPLUS COPYRIGHT 2004 ACS.on STN

AN 2003:590824 HCAPLUS

DN 139:154891

ED Entered STN: 01 Aug 2003

TI Multiple CpG oligodeoxynucleotides and their use to induce an immune
response

IN Klinman, Dennis; Ishii, Ken; Verthelyi,
Daniela

PA The Government of the U.S.A., the Secretary of the Department of
Health and Human Services, USA

SO U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of Appl. No. PCT/US01/01122.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K048-00

ICS A61K031-70; C07H021-04

NCL 514044000; 536023200

CC 63-6 (Pharmaceuticals)

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003144229	A1	20030731	US 2002-194035	20020712
WO 2001051500	A1	20010719	WO 2001-US1122	20010112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI US 2000-176115P	P	20000114		
WO 2001-US1122	A2	20010112		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

US 2003144229	ICM	A61K048-00
	ICS	A61K031-70; C07H021-04
	NCL	514044000; 536023200

OS MARPAT 139:154891

AB Compns. including multiple oligodeoxynucleotides with a CpG motif are
disclosed herein. The compns. can include either D or K type
oligodeoxynucleotides. These compns. are of use in inducing an immune
response in a large percentage of the individuals in a population.

ST CpG oligodeoxyribonucleotide sequence vaccine immunostimulant

IT Antibodies and Immunoglobulins

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
BIOL (Biological study); PREP (Preparation)

(IgM, production of; multiple CpG oligodeoxynucleotides and their use to
induce an immune response)

IT Immunostimulants

(adjuvants; multiple CpG oligodeoxynucleotides and their use to induce
an immune response)

IT Infection

(bacterial; multiple CpG oligodeoxynucleotides and their use to induce
an immune response)

IT Drug delivery systems

(carriers; multiple CpG oligodeoxynucleotides and their use to induce

an immune response)

IT Drug delivery systems
(liposomes, targeting moiety; multiple CpG oligodeoxynucleotides and their use to induce an immune response)

IT Antibiotics
Antiviral agents
Fungicides
Human
Immunostimulants
Immunotherapy
Mycosis
Neoplasm
Vaccines
Viral vectors
(multiple CpG oligodeoxynucleotides and their use to induce an immune response)

IT Oligodeoxyribonucleotides
Phosphorothioate oligonucleotides
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multiple CpG oligodeoxynucleotides and their use to induce an immune response)

IT Interleukin 6
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); BIOL (Biological study); PREP (Preparation)
(production of; multiple CpG oligodeoxynucleotides and their use to induce an immune response)

IT Mononuclear cell (leukocyte)
(proliferation of; multiple CpG oligodeoxynucleotides and their use to induce an immune response)

IT Drug delivery systems
(targeted; multiple CpG oligodeoxynucleotides and their use to induce an immune response)

IT Lipids, biological studies
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(targeting moiety; multiple CpG oligodeoxynucleotides and their use to induce an immune response)

IT Vaccines
(tumor; multiple CpG oligodeoxynucleotides and their use to induce an immune response)

IT Antitumor agents
(vaccines; multiple CpG oligodeoxynucleotides and their use to induce an immune response)

IT Infection
(viral; multiple CpG oligodeoxynucleotides and their use to induce an immune response)

IT 2382-65-2D, oligonucleotides 569386-89-6 569386-90-9 569386-91-0
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multiple CpG oligodeoxynucleotides and their use to induce an immune response)

IT 57-88-5, Cholesterol, biological studies
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(targeting moiety; multiple CpG oligodeoxynucleotides and their use to induce an immune response)

IT 569430-82-6 569430-83-7 569430-84-8 569430-85-9 569430-86-0
569430-87-1 569430-88-2 569430-89-3 569430-90-6 569430-91-7
569430-92-8 569430-93-9 569430-94-0 569430-95-1 569430-96-2
569430-97-3 569430-98-4 569430-99-5 569431-00-1
569431-01-2 569431-02-3 569431-03-4 569431-04-5 569431-05-6
569431-06-7 569431-07-8 569431-08-9 569431-09-0 569431-10-3
569431-11-4 569431-12-5 569431-13-6 569431-14-7
569431-15-8 569431-16-9 569431-17-0 569431-18-1
569431-19-2 569431-20-5 569431-21-6 569431-22-7 569431-23-8
569431-24-9 569431-25-0 569431-26-1 569431-27-2
569431-28-3 569431-29-4 569431-30-7 569431-31-8 569431-32-9
569431-33-0 569431-34-1 569431-35-2 569431-36-3 569431-37-4
569431-38-5 569431-39-6 569431-40-9 569431-41-0 569431-42-1
569431-43-2 569431-44-3 569431-45-4 569431-46-5 569431-47-6
569431-48-7 569431-49-8 569431-50-1 569431-51-2
569431-52-3 569431-53-4 569431-54-5 569431-55-6
569431-56-7 569431-57-8 569431-58-9 569431-59-0

569431-60-3 569431-61-4 569431-62-5 569431-63-6 569431-64-7
 569431-65-8 569431-66-9 569431-67-0 569431-68-1
 569431-69-2 569431-70-5 569431-71-6 569431-72-7
 569431-73-8 569431-74-9 569431-75-0 569431-76-1
 569431-77-2 569431-78-3 569431-79-4 569431-80-7 569431-81-8
 569431-82-9 569431-83-0 569431-84-1 569431-85-2 569431-86-3
 569431-87-4

RL: PRP (Properties)

(unclaimed nucleotide sequence; multiple CpG oligodeoxynucleotides and their use to induce an immune response)

IT 569431-00-1

RL: PRP (Properties)

(unclaimed nucleotide sequence; multiple CpG oligodeoxynucleotides and their use to induce an immune response)

RN 569431-00-1 HCAPLUS

CN DNA, d(G-G-T-G-C-A-C-C-G-A-T-G-C-A-G-G-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 6 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:511473 HCAPLUS

DN 139:79147

ED Entered STN: 04 Jul 2003

TI Use of CpG oligodeoxynucleotides to induce angiogenesis

IN Klinman, Dennis M.; Zheng, Mei; Rouse, Barry T.

PA The Government of the United States of America as Represented by the

Secretary of the Department of Health and Human

Services, USA; The University of Tennessee Research Corporation

SO PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C12N

CC 1-8 (Pharmacology)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003054161	A2	20030703	WO 2002-US40955	20021219
WO 2003054161	A3	20031030		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2001-343457P

P

20011220

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003054161	ICM	C12N

OS MARPAT 139:79147

AB This disclosure provides a method of inducing production of vascular endothelial growth factor by a cell. The method includes contacting the cell with a CpG oligonucleotide, thereby inducing the production of vascular endothelial growth factor by the cell. The disclosure further provides a method inducing neovascularization in a tissue. This method includes comprising introducing a CpG oligodeoxynucleotide into an area of the tissue wherein the formation of new blood vessels is desired, thereby inducing neovascularization in the area of the tissue.

ST CpG oligodeoxynucleotide angiogenesis induction

IT Immune system

(cells; use of CpG oligodeoxynucleotides to induce angiogenesis by stimulating production of vascular endothelial growth factor in cells in relation to screening for antiangiogenic agents)

IT Scalp

Transplant and Transplantation

(neovascularization in; use of CpG oligodeoxynucleotides to induce angiogenesis by stimulating production of vascular endothelial growth factor in cells in relation to screening for antiangiogenic agents)

IT Angiogenesis

(neovascularization; use of CpG oligodeoxynucleotides to induce angiogenesis by stimulating production of vascular endothelial growth

factor in cells in relation to screening for antiangiogenic agents)

IT Human herpesvirus
Human herpesvirus 1
Virus
(oligodeoxynucleotides from; use of CpG oligodeoxynucleotides to induce angiogenesis by stimulating production of vascular endothelial growth factor in cells in relation to screening for antiangiogenic agents)

IT Blood vessel, disease
(peripheral, treatment; use of CpG oligodeoxynucleotides to induce angiogenesis by stimulating production of vascular endothelial growth factor in cells in relation to screening for antiangiogenic agents)

IT Transplant and Transplantation
(skin, neovascularization in; use of CpG oligodeoxynucleotides to induce angiogenesis by stimulating production of vascular endothelial growth factor in cells in relation to screening for antiangiogenic agents)

IT Skin
(transplant, neovascularization in; use of CpG oligodeoxynucleotides to induce angiogenesis by stimulating production of vascular endothelial growth factor in cells in relation to screening for antiangiogenic agents)

IT Angiogenesis inhibitors
Animal cell
Blood vessel
Drug screening
Human
Macrophage
(use of CpG oligodeoxynucleotides to induce angiogenesis by stimulating production of vascular endothelial growth factor in cells in relation to screening for antiangiogenic agents)

IT Oligodeoxyribonucleotides
RL: BUU (Biological use, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of CpG oligodeoxynucleotides to induce angiogenesis by stimulating production of vascular endothelial growth factor in cells in relation to screening for antiangiogenic agents)

IT DNA
Viral DNA
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of CpG oligodeoxynucleotides to induce angiogenesis by stimulating production of vascular endothelial growth factor in cells in relation to screening for antiangiogenic agents)

IT Nucleic acids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(viral; use of CpG oligodeoxynucleotides to induce angiogenesis by stimulating production of vascular endothelial growth factor in cells in relation to screening for antiangiogenic agents)

IT 2382-65-2
RL: BUU (Biological use, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligodeoxynucleotides containing; use of CpG oligodeoxynucleotides to induce angiogenesis by stimulating production of vascular endothelial growth factor in cells in relation to screening for antiangiogenic agents)

IT 552439-42-6 552439-43-7 552439-44-8 552439-45-9 552439-46-0
552439-47-1 552439-48-2 552439-49-3 552439-50-6
552439-51-7 552439-52-8 552439-53-9
552439-54-0 552439-55-1 552439-56-2
552439-57-3 552439-58-4 552439-59-5
552439-60-8 552439-61-9 552439-62-0
552439-63-1 552439-64-2 552439-65-3 552439-66-4
552439-67-5 552439-68-6 552439-69-7 552439-70-0
552439-71-1 552439-72-2 552439-73-3 552439-74-4 552439-75-5
552439-76-6 552439-77-7 552439-78-8 552439-79-9 552439-80-2
552439-81-3 552439-82-4 552439-83-5 552439-84-6
552439-85-7 552439-86-8 552439-87-9 552439-88-0 552439-89-1
552439-90-4 552439-91-5 552439-92-6 552439-93-7 552439-94-8
552439-95-9 552439-96-0 552439-97-1 552439-98-2 552439-99-3
552440-00-3 552440-01-4 552440-02-5 552440-03-6 552440-04-7
552440-05-8 552440-06-9 552440-07-0 552440-08-1 552440-09-2
552440-10-5 552440-11-6 552440-12-7 552440-13-8 552440-14-9
552440-15-0 552440-16-1 552440-17-2 552440-18-3 552440-19-4
552440-20-7 552440-21-8 552440-22-9 552440-23-0 552440-24-1
552440-25-2 552440-26-3 552440-27-4 552440-28-5 552440-29-6

552440-30-9 552440-31-0 552440-32-1 552440-33-2 552440-34-3
552440-35-4 552440-36-5 552440-37-6 552440-38-7 552440-39-8
552440-40-1 552440-41-2 552440-42-3

RL: PRP (Properties)
(unclaimed nucleotide sequence; use of CpG oligodeoxynucleotides to induce angiogenesis)

IT 503540-93-0 503540-94-1

RL: PRP (Properties)
(unclaimed sequence; use of CpG oligodeoxynucleotides to induce angiogenesis)

IT 127464-60-2, Vascular endothelial growth factor

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(use of CpG oligodeoxynucleotides to induce angiogenesis by stimulating production of vascular endothelial growth factor in cells in relation to screening for antiangiogenic agents)

IT 550394-91-7 550394-92-8

RL: BUU (Biological use, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of CpG oligodeoxynucleotides to induce angiogenesis by stimulating production of vascular endothelial growth factor in cells in relation to screening for antiangiogenic agents)

IT 552439-49-3

RL: PRP (Properties)
(unclaimed nucleotide sequence; use of CpG oligodeoxynucleotides to induce angiogenesis)

RN 552439-49-3 HCAPLUS

CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 7 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:377001 HCAPLUS

DN 138:390866

ED Entered STN: 16 May 2003

TI Use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo

IN Klinman, Dennis M.; Gursel, Ihsan; Ishii, Ken J.; Kawakami, Koji; Joshi, Bharat H.; Puri, Raj K.

PA Department of Health and Human Services, USA

SO PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C12N

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 8

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040308	A2	20030515	WO 2002-US24235	20020729
WO 2003040308	A3	20031120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI US 2001-308283P	P	20010727		
US 2002-206407	A	20020725		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003040308	ICM	C12N

OS MARPAT 138:390866

AB Sterically stabilized cationic liposomes (SSCL) encapsulating a K type oligodeoxynucleotide (ODN) including a CpG motif are disclosed. These SSCL encapsulating a K type ODN can be used to effectively deliver the ODN to a cell. A novel method is also disclosed for producing the SSCL encapsulating the K type ODN. Administration of the SSCL encapsulating a K type ODN and a chemotherapeutic agent, such as a chimeric mol. comprising a targeting mol. selected from the group consisting of an IL-13, and an anti-IL-13 receptor antibody; and an effector mol. selected

from the group consisting of a Pseudomonas exotoxin, a Diphtheria toxin, and a radionuclide, can be used to dramatically reduce the growth of solid tumors.

- ST antitumor oligonucleotide CpG delivery liposome IL13 IL13R antibody
- IT Infection
 - (bacterial; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)
- IT Drug delivery systems
 - (carriers; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)
- IT Toxins
 - RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 - (diphtheria; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)
- IT Pseudomonas
 - (exotoxin; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)
- IT Toxins
 - RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 - (exotoxins, of Pseudomonas; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)
- IT Cytokines
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (induction of; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)
- IT Drug delivery systems
 - (injections, i.v.; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)
- IT Drug delivery systems
 - (injections; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)
- IT Interleukin receptors
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (interleukin 13, antibodies to; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)
- IT Drug delivery systems
 - (liposomes; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)
- IT Encapsulation
 - (microencapsulation; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)
- IT Neck, anatomical
 - (neoplasm; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)
- IT Neoplasm
 - (solid; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)
- IT Drug delivery systems
 - (targeted; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)
- IT Antibodies and Immunoglobulins
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (to IL13 receptor; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)
- IT Antimicrobial agents
 - Antitumor agents
 - Fungicides
 - Head, neoplasm
 - Human
 - Immunostimulants
 - Lymphocyte
 - Mycosis
 - Particle size distribution
 - Stabilizing agents
 - Vaccines
 - (use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)
- IT Interleukin 13
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)
- IT Polyoxyalkylenes, biological studies

RL: MOA (Modifier or additive use); PEP (Physical, engineering or chemical process); POF (Polymer in formulation); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)

IT Aminoplasts

Oligodeoxyribonucleotides

Phosphatidylethanolamines, biological studies

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)

IT Antigens

Polysaccharides, biological studies

Proteins

Radionuclides, biological studies

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)

IT Fusion proteins (chimeric proteins)

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)

IT Infection

(viral; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)

IT Interferons

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(,gamma., induction of; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)

IT 524985-31-7 524985-32-8 524985-33-9 524985-34-0 524985-35-1

524985-36-2 524985-37-3 524985-38-4 524985-39-5 524985-40-8

524985-41-9 524985-42-0 524985-43-1 524985-44-2 524985-45-3

524985-46-4 524985-47-5 524985-48-6 524985-49-7 524985-50-0

524985-51-1 524985-52-2 524985-53-3 524985-54-4 524985-55-5

524985-56-6 524985-57-7 524985-58-8 524985-59-9 524985-60-2

524985-61-3 524985-62-4 524985-63-5 524985-64-6 524985-65-7

524985-66-8 524985-67-9 524985-68-0 524985-69-1 524985-70-4

524985-71-5 524985-72-6 524985-73-7 524985-74-8 524985-75-9

524985-76-0 524985-77-1 524985-78-2 524985-79-3 524985-80-6

524985-81-7 524985-82-8 524985-83-9 524985-84-0 524985-85-1

524985-86-2 524985-87-3 524985-88-4 524985-89-5

524985-90-8 524985-91-9 524985-92-0

524985-93-1 524985-94-2 524985-95-3

524985-96-4 524985-97-5 524985-98-6 524985-99-7

524986-00-3 524986-01-4 524986-02-5 524986-03-6 524986-04-7

524986-05-8 524986-06-9 524986-07-0 524986-08-1 524986-09-2

524986-10-5 524986-11-6 524986-12-7 524986-13-8

524986-14-9 524986-15-0 524986-16-1 524986-17-2 524986-18-3

RL: PRP (Properties)

(unclaimed nucleotide sequence; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)

IT 25322-68-3, Polyethylene glycol

RL: MOA (Modifier or additive use); PEP (Physical, engineering or chemical process); POF (Polymer in formulation); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)

IT 57-88-5, Cholesterol, biological studies 598-56-1 4004-05-1, Dioleoyl

phosphatidyl ethanolamine 9011-05-6, Carbamol 524974-46-7

524974-47-8

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)

IT 2382-65-2D, oligonucleotides

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(use of sterically stabilized cationic liposomes to efficiently deliver

CpG oligonucleotides in vivo)
IT 524985-88-4
RL: PRP (Properties)
(unclaimed nucleotide sequence; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)
RN 524985-88-4 HCAPLUS
CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
L21 ANSWER 8 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:306455 HCAPLUS
DN 139:159661
ED Entered STN: 22 Apr 2003
TI CpG Oligodeoxynucleotides Protect Normal and SIV-Infected Macaques from Leishmania Infection
AU Verthelyi, Daniela; Gursel, Mayda; Kenney, Richard T.; Lifson, Jeffrey D.; Liu, Shuying; Mican, Joan; Klinman, Dennis M.
CS Center for Biologics Evaluation and Research, Section of Retroviral Immunology, Food and Drug Administration, Bethesda, MD, 20892, USA
SO Journal of Immunology (2003), 170(9), 4717-4723
CODEN: JOIMA3; ISSN: 0022-1767
PB American Association of Immunologists
DT Journal
LA English
CC 1-7 (Pharmacology)
AB Oligodeoxynucleotides containing CpG motifs (CpG ODNs) mimic microbial DNA and activate effectors of the innate immune response, which limits the spread of pathogens and promotes an adaptive immune response. CpG ODNs have been shown to protect mice from infection with intracellular pathogens. Unfortunately, CpG motifs that optimally stimulate humans are only weakly active in mice, mandating the use of nonhuman primates to monitor the activity and safety of "human" CpG ODNs in vivo. This study demonstrates that CpG ODN treatment of rhesus macaques significantly reduces the severity of the lesions caused by a challenge with Leishmania: Leishmania superinfection is common in immunocompromised hosts, particularly those infected with HIV. This study shows that PBMCs from HIV-infected subjects respond to stimulation with CpG ODNs. To determine whether CpG ODNs can protect retrovirus-infected primates, SIV-infected macaques were treated with CpG ODNs and then challenged with Leishmania: Both lesion size and parasite load were significantly reduced in the CpG-treated animals. These findings support the clin. development of CpG ODNs as immunoprotective agents in normal and HIV-infected patients.
ST CpG oligodeoxynucleotide immunoprotection SIV Leishmania infection
IT Human
Immunostimulants
Simian immunodeficiency virus
(CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection)
IT Oligodeoxyribonucleotides
Phosphorothioate oligodeoxyribonucleotides
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection)
IT Human immunodeficiency virus
(CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection in relation to immunoprotection in HIV-infected patients)
IT Leishmania
(leishmaniasis from; CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection)
IT 572925-91-8 572925-92-9 572925-93-0 573722-80-2
573722-82-4 573722-83-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection)
RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Amaral, V; Exp Parasitol 1996, V82, P34 MEDLINE
(2) Azzoni, L; J Immunol 2002, V168, P5764 HCAPLUS
(3) Bauer, M; Immunology 1999, V97, P699 HCAPLUS
(4) Campos-Neto, A; Infect Immun 2001, V69, P4103 HCAPLUS
(5) Chehimi, J; J Exp Med 1994, V179, P1361 HCAPLUS
(6) Chehimi, J; J Immunol 2002, V168, P4796 HCAPLUS

- (7) Choi, C; Am J Clin Dermatol 2002, V3, P91
- (8) Corbett, E; Lancet 2002, V359, P2177
- (9) Davis, H; Vaccine 2000, V19, P413
- (10) Donaghy, H; Blood 2001, V98, P2574 HCAPLUS
- (11) Elkins, K; J Immunol 1999, V162, P2291 HCAPLUS
- (12) Feldman, S; Clin Immunol 2001, V101, P201 HCAPLUS
- (13) Gursel, M; Eur J Immunol 2002, V32, P2617 HCAPLUS
- (14) Gursel, M; J Leukocyte Biol 2002, V71, P813 HCAPLUS
- (15) Gurunathan, S; Annu Rev Immunol 2000, V18, P927 HCAPLUS
- (16) Hartmann, G; J Immunol 2000, V164, P1617 HCAPLUS
- (17) Hartmann, G; J Immunol 2000, V164, P944 HCAPLUS
- (18) Hemmi, H; Nature 2000, V408, P740 HCAPLUS
- (19) Howell, D; Clin Immunol Immunopathol 1994, V71, P223 MEDLINE
- (20) Jones, T; Vaccine 1999, V17, P3065 HCAPLUS
- (21) Kadowaki, N; J Exp Med 2001, V194, P863 HCAPLUS
- (22) Kenney, R; J Immunol 1999, V163, P4481 HCAPLUS
- (23) Klinman, D; Microbes Infect 2002, V4, P897 HCAPLUS
- (24) Krieg, A; Annu Rev Immunol 2002, V20, P709 HCAPLUS
- (25) Krieg, A; J Immunol 1998, V161, P2428 HCAPLUS
- (26) Krieg, A; Nature 1995, V374, P546 HCAPLUS
- (27) Krug, A; Eur J Immunol 2001, V31, P2154 HCAPLUS
- (28) Krug, A; Eur J Immunol 2001, V31, P3026 HCAPLUS
- (29) Leifer, C; J Immunother. In press
- (30) Lifson, J; J Med Primatol 2002, V31, P205 HCAPLUS
- (31) Lifson, J; J Virol 2001, V75, P10187 HCAPLUS
- (32) Medzhitov, R; Curr Opin Immunol 1997, V9, P4 HCAPLUS
- (33) Morales, M; J Infect Dis 2002, V185, P1533
- (34) Murphy, M; Eur J Immunol 2001, V31, P2848 HCAPLUS
- (35) Pacanowski, J; Blood 2001, V98, P3016 HCAPLUS
- (36) Takeshita, F; J Immunol 2001, V167, P3555 HCAPLUS
- (37) UNAIDS; AIDS epidemic update 2002
- (38) Verthelyi, D; J Immunol 2001, V166, P2372 HCAPLUS
- (39) Verthelyi, D; J Immunol 2002, V168, P1659 HCAPLUS
- (40) Walker, P; Proc Natl Acad Sci USA 1999, V96, P6970 HCAPLUS
- (41) Walker, P; Proc Natl Acad Sci USA 1999, V96, P6970 HCAPLUS
- (42) Wolday, D; Parasitol Today 1999, V15, P182 HCAPLUS
- (43) Wolday, D; Scand J Infect Dis 1998, V30, P29 MEDLINE
- (44) World Health Organization; Fact Sheet 116: Leishmania/HIV Co-infection in Southwestern Europe, 1990-1998 2000
- (45) Zhao, Q; Antisense Nucleic Acid Drug Dev 1997, V7, P495 HCAPLUS
- (46) Zimmermann, S; J Immunol 1998, V160, P3627 HCAPLUS

IT 573722-80-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection)

RN 573722-80-2 HCAPLUS

CN DNA, d(G-sp-G-sp-T-G-C-A-T-G-C-A-T-G-C-A-G-G-sp-G-sp-G-sp-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 9 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:241991 HCAPLUS

DN 138:270283

ED Entered STN: 28 Mar 2003

TI Oligodeoxynucleotide and its use to induce an immune response

IN Klinman, Dennis; Verthelyi, Daniela; Ishii,

Ken; Mond, James J.; Gursel, Mayda

PA USA

SO U.S. Pat. Appl. Publ., 52 pp., Cont.-in-part of U.S. Ser. No. 958,713.

CODEN: USXXCO

DT Patent

LA English

IC A61K048-00; C07H021-04

NCL 514044000; 536023100

CC 15-2 (Immunochemistry)

Section cross-reference(s): 1

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003060440	A1	20030327	US 2002-68160	20020206
PRAI	US 1999-128898P	P	19990412		
	US 2001-958713	A2	20011011		

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

Search done by Noble Jarrell

```

-----
US 2003060440 IC A61K048-00IC C07H021-04
NCL 514044000; 536023100
US 2003060440 ECLA A61K031/7088; A61K031/7088+M; A61K039/39+M
AB D type CpG oligodeoxynucleotides are provided herein that include a
sequence represented by the following formula: 5'-
X1X2X3Pu1Py2CpGPu3Py4X4X5X6(W)M(G)N-3' wherein the central CpG motif is
unmethylated, Pu is a purine nucleotide, Py is a pyrimidine nucleotide, X
and W are any nucleotide, M is any integer from 0 to 10, and N is any
integer from 4 to 10. The oligodeoxynucleotides can activate immune
cells, such as antigen-presenting cells or natural killer cell, and/or can
stimulate production of cytokines. Methods of using these
oligodeoxynucleotides to induce an immune response are provided. The
oligodeoxynucleotides can be used in treatment or amelioration of cancer,
allergy, autoimmune disease, immunodeficiency, or infection. They can
also be used to enhance the efficacy of vaccines.
ST CpG oligodeoxynucleotide immunotherapy immunostimulation
IT Allergy
Allergy inhibitors
Anti-infective agents
Antibiotics
Antitumor agents
Antiviral agents
Asthma
Autoimmune disease
Cell activation
Chemotherapy
Dendritic cell
Fungicides
Human
Immunodeficiency
Immunostimulation
Immunotherapy
Leishmania major
Monocyte
Mycosis
Neoplasm
Radiotherapy
Vaccines
(CpG oligodeoxynucleotides for immunostimulation and immunotherapy of
various diseases)
IT Allergens
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(CpG oligodeoxynucleotides for immunostimulation and immunotherapy of
various diseases)
IT Cytokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CpG oligodeoxynucleotides for immunostimulation and immunotherapy of
various diseases)
IT Interleukin 10
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CpG oligodeoxynucleotides for immunostimulation and immunotherapy of
various diseases)
IT Oligodeoxyribonucleotides
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(CpG-containing; CpG oligodeoxynucleotides for immunostimulation and
immunotherapy of various diseases)
IT Immunostimulants
(adjuvants; CpG oligodeoxynucleotides for immunostimulation and
immunotherapy of various diseases)
IT Infection
(bacterial; CpG oligodeoxynucleotides for immunostimulation and
immunotherapy of various diseases)
IT Immunity
(cell-mediated; CpG oligodeoxynucleotides for immunostimulation and
immunotherapy of various diseases)
IT Lipids, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(delivery complex; CpG oligodeoxynucleotides for immunostimulation and
immunotherapy of various diseases)
IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(interferon .gamma.-inducible protein-10; CpG oligodeoxynucleotides for

```

immunostimulation and immunotherapy of various diseases)

IT Drug delivery systems
(liposomes; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT Lymphocyte
(natural killer cell; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT Neoplasm
(solid; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT Infection
(viral; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT Drug delivery systems
(viroosomes; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT Interferons
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT Interferons
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.gamma.; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT 503572-62-1 503572-63-2 503572-64-3
503572-65-4 503572-66-5 503572-67-6
503572-68-7 503572-69-8 503572-70-1
503572-71-2 503572-72-3 503572-73-4
503572-74-5 503572-75-6 503572-76-7 503572-77-8
503572-78-9
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT 503540-93-0 503540-94-1
RL: PRP (Properties)
(Unclaimed; oligodeoxynucleotide and its use to induce an immune response)

IT 57-88-5, Cholesterol, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(delivery complex; CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

IT 503575-68-6 503575-69-7 503575-70-0 503575-71-1 503575-72-2
503575-73-3 503575-74-4 503575-75-5 503575-76-6
503575-77-7 503575-78-8 503575-79-9 503575-80-2 503575-81-3
503575-82-4 503575-83-5 503575-84-6 503575-85-7
503575-86-8 503575-87-9 503575-88-0 503575-89-1
503575-90-4 503575-91-5 503575-92-6
503575-93-7 503575-94-8 503575-95-9
503575-96-0 503575-97-1 503575-98-2 503575-99-3
503576-00-9 503576-01-0 503576-02-1 503576-03-2
503576-04-3 503576-05-4 503576-06-5 503576-07-6 503576-08-7
503576-09-8 503576-10-1 503576-11-2 503576-12-3 503576-13-4
503576-14-5 503576-15-6 503576-16-7 503576-17-8 503576-18-9
503576-19-0 503576-20-3 503576-21-4 503576-22-5 503576-23-6
503576-24-7 503576-25-8 503576-26-9 503576-27-0 503576-28-1
503576-29-2 503576-30-5 503576-31-6 503576-32-7 503576-33-8
503576-34-9 503576-35-0 503576-36-1 503576-37-2 503576-38-3
503576-39-4 503576-40-7 503576-41-8 503576-42-9 503576-43-0
503576-44-1 503576-45-2 503576-46-3 503576-47-4 503576-48-5
503576-49-6 503576-50-9 503576-51-0 503576-52-1 503576-53-2
503576-54-3 503576-55-4 503576-56-5 503576-57-6 503576-58-7
503576-59-8
RL: PRP (Properties)
(unclaimed nucleotide sequence; oligodeoxynucleotide and its use to induce an immune response)

IT 503576-60-1 503576-61-2 503576-62-3 503576-63-4
503576-64-5 503576-65-6 503576-66-7
RL: PRP (Properties)
(unclaimed sequence; oligodeoxynucleotide and its use to induce an immune response)

IT 503572-62-1
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(CpG oligodeoxynucleotides for immunostimulation and immunotherapy of various diseases)

RN 503572-62-1 HCAPLUS

CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 10 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:229621 HCAPLUS

DN 139:20882

ED Entered STN: 25 Mar 2003

TI Response of peripheral blood mononuclear cells from lupus patients to stimulation by CpG oligodeoxynucleotides

AU Zeuner, R. A.; Klinman, D. M.; Illei, G.; Yarboro, C.;

Ishii, K. J.; Gursel, M.; Verthelyi, D.

CS Center for Biologics Evaluation and Research/Food and Drug Administration, Bethesda, MD, 20892, USA

SO Rheumatology (Oxford, United Kingdom) (2003), 42(4), 563-569

CODEN: RUMAFK; ISSN: 1462-0324

PB Oxford University Press

DT Journal

LA English

CC 15-8 (Immunochemistry)

AB Objectives: Increased levels of hypomethylated CpG-containing DNA in sera from patients with systemic lupus erythematosus (SLE) may contribute to the initiation and/or perpetuation of the disease. This study characterizes the in vitro response of peripheral blood mononuclear cells (PBMC) from SLE patients to CpG DNA. Methods: Secretion of cytokines and IgM, cell proliferation and up-regulation of co-stimulatory mols. were evaluated in PBMC from SLE patients and normal controls after stimulation with synthetic oligodeoxynucleotides (ODN) containing CpG motifs. Results: Up-regulation of co-stimulatory mols. and the secretion of interferon-.alpha. and interleukin-6 (IL-6) in response to CpG ODN was significantly reduced in monocytes and dendritic cells from SLE patients. Secretion of interferon-.gamma. by natural killer (NK) cells was also reduced. In contrast, the IgM and IL-10 response of B cells to CpG ODN was normal. Conclusion: Monocytes, dendritic cells and NK cells from SLE patients respond abnormally to CpG ODN stimulation, which may contribute to the cytokine imbalance observed in SLE.

ST monocyte dendritic cell NK lupus CpG oligodeoxynucleotide cytokine

IT Phosphorothioate oligodeoxyribonucleotides

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CpG; monocytes, dendritic cells and NK cells from lupus patients respond to CpG oligodeoxynucleotides stimulation and contribute to the cytokine imbalance)

IT Histocompatibility antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HLA-DR; monocytes, dendritic cells and NK cells from lupus patients respond to CpG oligodeoxynucleotides stimulation and contribute to the cytokine imbalance)

IT Dendritic cell

Monocyte
(monocytes, dendritic cells and NK cells from lupus patients respond to CpG oligodeoxynucleotides stimulation and contribute to the cytokine imbalance)

IT CD40 (antigen)

Interleukin 6
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(monocytes, dendritic cells and NK cells from lupus patients respond to CpG oligodeoxynucleotides stimulation and contribute to the cytokine imbalance)

IT Human

(monocytes, dendritic cells and NK cells from lupus patients respond to CpG oligodeoxynucleotides stimulation which may contribute to the cytokine imbalance)

IT Lymphocyte

(natural killer cell; monocytes, dendritic cells and NK cells from lupus patients respond to CpG oligodeoxynucleotides stimulation and contribute to the cytokine imbalance)

IT Lupus erythematosus

(systemic; monocytes, dendritic cells and NK cells from lupus patients respond to CpG oligodeoxynucleotides stimulation and contribute to the cytokine imbalance)

IT Interferons

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(.alpha.; monocytes, dendritic cells and NK cells from lupus patients respond to CpG oligodeoxynucleotides stimulation and contribute to the cytokine imbalance)

IT Interferons
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (.gamma.; monocytes, dendritic cells and NK cells from lupus patients respond to CpG oligodeoxynucleotides stimulation and contribute to the cytokine imbalance)

IT 537058-58-5 537058-59-6 537075-81-3
 537732-32-4 537732-33-5 537732-34-6
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (monocytes, dendritic cells and NK cells from lupus patients respond to CpG oligodeoxynucleotides stimulation and contribute to the cytokine imbalance)

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD

- RE
- (1) Blanco, P; Science 2001, V294, P1540 HCAPLUS
 - (2) de la Fuente, H; Immunol Lett 2001, V77, P175 HCAPLUS
 - (3) Decker, T; Blood 2000, V95, P999 HCAPLUS
 - (4) Erkeller-Yuksel, F; Lupus 1997, V6, P708 MEDLINE
 - (5) Gilkeson, G; J Immunol 1989, V142, P1482 HCAPLUS
 - (6) Hagiwara, E; Arthritis Rheum 1996, V39, P379 HCAPLUS
 - (7) Hagiwara, E; Cytokine 1995, V7, P815 HCAPLUS
 - (8) Hochberg, M; Arthritis Rheum 1997, V40, P1725 MEDLINE
 - (9) Hornung, V; J Immunol 2002, V168, P4531 HCAPLUS
 - (10) Krieg, A; Trends Microbiol 2001, V9, P249 HCAPLUS
 - (11) Krug, A; Eur J Immunol 2001, V31, P2154 HCAPLUS
 - (12) Napierei, M; Nat Genet 2000, V25, P177 HCAPLUS
 - (13) Piccioli, D; J Exp Med 2002, V195, P335 HCAPLUS
 - (14) Pisetsky, D; Clin Immunol 2001, V100, P157 HCAPLUS
 - (15) Pisetsky, D; J Rheumatol 1999, V26, P1934 HCAPLUS
 - (16) Riccieri, V; Lupus 2000, V9, P333 MEDLINE
 - (17) Richardson, B; Arthritis Rheum 1990, V33, P1665 HCAPLUS
 - (18) Sato, Y; J Rheumatol 1999, V26, P294 HCAPLUS
 - (19) Scheinecker, C; Arthritis Rheum 2001, V44, P856 HCAPLUS
 - (20) Steinbach, F; Ann Rheum Dis 2000, V59, P283 MEDLINE
 - (21) Stohl, W; Arthritis Rheum 1996, V39, P1840 MEDLINE
 - (22) Tan, E; Arthritis Rheum 1982, V25, P1271 MEDLINE
 - (23) Vallin, H; J Immunol 1999, V163, P6306 HCAPLUS
 - (24) Verthelyi, D; Immunology 2000, V100, P384 HCAPLUS
 - (25) Verthelyi, D; J Immunol 2001, V166, P2372 HCAPLUS
 - (26) Verthelyi, D; Lupus 2001, V10, P352 HCAPLUS
 - (27) Walport, M; Nat Genet 2000, V25, P135 HCAPLUS
 - (28) Yabuhara, A; J Rheumatol 1996, V23, P171 MEDLINE
 - (29) Yung, R; Lupus 1994, V3, P487 HCAPLUS

IT 537058-58-5
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (monocytes, dendritic cells and NK cells from lupus patients respond to CpG oligodeoxynucleotides stimulation and contribute to the cytokine imbalance)

RN 537058-58-5 HCAPLUS

CN DNA, d(G-sp-G-sp-T-G-C-A-C-C-G-G-T-G-C-A-G-G-sp-G-sp-G-sp-G-sp-G) (9CI)
 (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 11 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:202770 HCAPLUS
 DN 138:236936
 ED Entered STN: 14 Mar 2003
 TI Differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides
 IN Klinman, Dennis M.; Gursel, Mayda; Verthelyi, Daniela
 PA The Government of the United States of America as Represented by the Secretary of Health and Human Services, USA
 SO PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C12N
 CC 15-10 (Immunochemistry)
 Section cross-reference(s): 3, 9

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI WO 2003020884 A2 20030313 WO 2002-US25732 20020813
 WO 2003020884 A3 20040916
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
 RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG
 US 2004241841 A1 20041202 US 2004-486755 20040212
 PRAI US 2001-312190P P 20010814
 WO 2002-US25732 W 20020813

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

WO 2003020884 ICM C12N

AB This disclosure relates to dendritic cells, specifically to the methods of generating mature dendritic cells using D type oligodeoxynucleotides including a CpG motif. The methods include contacting a dendritic cell precursor with a D ODN to generate a mature dendritic cell. In one specific, non-limiting example, the method includes contacting the dendritic cell with an antigen. In another specific, non-limiting example, the method is a single step method wherein the D ODN is administered without other cytokines, such as GM-CSF and/or IL-4. These methods are of use both in vitro and in vivo. The findings disclosed herein document that mature DC can be rapidly and reproducibly generated by culturing PBMC or elutriated monocytes with D ODN in serum-free or conventional medium. These DC efficiently present antigen to autologous T cells in vitro and in vivo, and support the induction of Th1 biased immune responses. Without being bound by theory, the effect of D ODN on DC differentiation is dependent upon IFN.alpha. -secreting pDC being present during culture. Current results indicate that IFN.alpha. is necessary but not sufficient by itself to induce the differentiation of human monocytes into functionally active DC (Fig 2C). It is likely that functional differences between D and K type CpG ODN reflects differences in their recognition, uptake and/or processing by immune cells. These differences in uptake and activity have a structural basis. Whereas the immunostimulatory motif of a conventional ODN consists of a phosphorothioate TCGTT/A, the relevant motif in a D ODN consists of a phosphodiester purine/pyrimidine/CG/purine/pyrimidine hexamer (Verthelyi et al., JImmunol. 166: 2372-2377, 2001, which is incorporated herein by reference). In addition, the hexamer of a D ODN is flanked by complementary bases that form a hairpin loop with the CpG dinucleotide at its apex - secondary structure that is absent from conventional CpG ODN. Finally, D but not K ODN are capped at the 3' end with a poly-G tail. This poly-G tail may interact with scavenger receptors on immune cells. D ODN reproducibly stimulated approx. 60 % of monocytes to differentiate into DC, as determined phenotypically, histol. and functionally. The production of IFN.alpha. by pDC present in culture contributed to this maturation (Fig 1A and 2B). The DC generated by D ODN are functionally active, as they promote antigen-specific immune responses in vitro and in vivo (Fig 3, 4, 5 and 6).

ST monocyte differentiation dendritic cell CpG oligonucleotide

IT T cell (lymphocyte)
 (activated, generating; differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides)

IT Immunity
 (cell-mediated, producing; differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides)

IT Cell
 (contacting a dendritic cell precursor with; differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides)

IT Antigens
 Cytokines
 DNA
 Interleukin 4
 Peptides, biological studies
 Polysaccharides, biological studies
 Proteins
 RNA

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES

(Uses)
 (contacting a dendritic cell precursor with; differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides)

IT Cell differentiation
 DNA sequences
 Dendritic cell
 Human
 Monocyte
 (differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides)

IT Oligodeoxyribonucleotides
 Phosphorothioate oligodeoxyribonucleotides
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
 (differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides)

IT Oligonucleotides
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (dinucleotides, CpG; differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides)

IT Conformation
 (hairpin loop, oligodeoxynucleotides forming; differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides)

IT Immunity
 (humoral, producing; differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides)

IT Conformation
 (loop, nucleic acid, oligodeoxynucleotides forming; differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides)

IT Immunity
 (producing; differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides)

IT Interferons
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (.alpha., secretion of; differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides)

IT 501729-67-5 501729-68-6
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
 (ODN nucleotide sequence; differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides)

IT 83869-56-1, GM-CSF
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (contacting a dendritic cell precursor with; differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides)

IT 501834-11-3 501834-12-4 501834-13-5
 501834-14-6 501834-15-7 501834-16-8
 501834-17-9 501834-18-0 501834-19-1
 501834-20-4 501834-21-5 501834-22-6 501834-23-7
 501834-24-8 501834-25-9 501834-26-0
 501834-27-1 501834-28-2 501834-29-3
 501834-30-6 501834-31-7 501834-32-8 501834-33-9 501834-34-0
 501834-35-1 501834-36-2 501834-37-3 501834-38-4 501834-39-5
 501834-40-8 501834-41-9 501834-42-0 501834-43-1
 501834-44-2 501834-45-3 501834-46-4 501834-47-5
 501834-48-6 501834-49-7 501834-50-0
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides)

IT 501729-67-5
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
 (ODN nucleotide sequence; differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides)

RN 501729-67-5 HCAPLUS
 CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 12 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:737476 HCAPLUS

Search done by Noble Jarrell

DN 137:231323
ED Entered STN: 29 Sep 2002
TI CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells
AU Gursel, Mayda; Verthelyi, Daniela; Klinman, Dennis M.
CS Section of Retroviral Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, 20892, USA
SO European Journal of Immunology (2002), 32(9), 2617-2622
CODEN: EJIMAF; ISSN: 0014-2980
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
CC 15-10 (Immunochemistry)
AB Dendritic cells (DC) excel at presenting antigen to T cells and thus make a key contribution to the induction of primary and secondary immune responses. DC matured in vitro and pulsed with antigen show promise for the immunotherapy of cancer and infectious diseases. Synthetic oligonucleotides (ODN) expressing immunomodulatory "CpG motifs" were found to boost APC function in mice. Current results demonstrate that the recently identified "D" type of CpG ODN stimulate human peripheral blood monocytes to mature into functionally active DC over 2-4 days. The transition from monocyte to DC is characterized by the upregulation of CD83, CD86, CD80, CD40 and the down-regulation of CD14. These DC support antigen-specific humoral and cellular responses in vitro and in vivo. The differentiation of these monocytes is mediated by plasmacytoid DC, which respond to D type ODN by secreting IFN-.alpha.. Since D type CpG motifs are present in bacterial and viral DNA, the maturation of monocytes into functional DC may reflect a physiol. response that can be harnessed therapeutically through the use of CpG ODN.
ST monocyte differentiation dendritic cell CpG oligonucleotide
IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CpG island; CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells)
IT Antigen presentation
Cell differentiation
Dendritic cell
Human
Monocyte
(CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells)
IT Oligodeoxyribonucleotides
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells)
IT T cell (lymphocyte)
(activation; CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells)
IT Interferons
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.; CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells)
IT 459471-16-0 459471-17-1 459471-18-2
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells)
RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Ban, E; Int Immunol 2000, V12, P737 HCAPLUS
(2) Banchereau, J; Ann Rev Immunol 2000, V18, P767 HCAPLUS
(3) Banchereau, J; Nature 1998, V392, P245 HCAPLUS
(4) Bauer, M; J Immunol 2001, V166, P5000 HCAPLUS
(5) Behboudi, S; Immunology 2000, V99, P361 HCAPLUS
(6) Bender, A; J Immunol Methods 1996, V196, P121 HCAPLUS
(7) Blanco, P; Science 2001, V294, P1540 HCAPLUS
(8) Caetano, R; Immunity 2001, V14, P495
(9) Fields, R; Proc Natl Acad Sci 1998, V95, P9482 HCAPLUS
(10) Gursel, M; J Leuko Biol 2002, V71, P813 HCAPLUS
(11) Hartmann, G; Gene Ther 1999, V6, P893 HCAPLUS
(12) Hartmann, G; Proc Natl Acad Sci 1999, V96, P9305 HCAPLUS
(13) Hemmi, H; Nature 2000, V408, P740 HCAPLUS
(14) Kadowaki, N; J Immunol 2001, V166, P2291 HCAPLUS
(15) Kaisho, T; Trends Immunol 2001, V22, P78 HCAPLUS

- (16) Kiertscher, S; J Leukoc Biol 1996, V59, P208 HCAPLUS
- (17) Klinman, D; Proc Natl Acad Sci 1996, V93, P2879 HCAPLUS
- (18) Klinman, D; Vaccine 1999, V17, P19 HCAPLUS
- (19) Krieg, A; Nature 1995, V374, P546 HCAPLUS
- (20) Krug, A; Eur J Immunol 2001, V31, P2154 HCAPLUS
- (21) Krug, A; Eur J Immunol 2001, V31, P3026 HCAPLUS
- (22) McRae, B; Blood 2000, V96, P210 HCAPLUS
- (23) Paquette, R; J Leukoc Biol 1998, V64, P358 HCAPLUS
- (24) Romani, N; J Immunol Methods 1996, V196, P137 HCAPLUS
- (25) Sallusto, F; J Exp Med 1994, V179, P1109 HCAPLUS
- (26) Santini, S; J Exp Med 2000, V191, P1777 HCAPLUS
- (27) Shattenberg, D; Eur J Immunol 2000, V30, P2824
- (28) Sparwasser, T; Eur J Immunol 1998, V28, P2045 HCAPLUS
- (29) Su, H; J Exp Med 1998, V188, P809 HCAPLUS
- (30) Verthelyi, D; J Immunol 2001, V166, P2372 HCAPLUS
- (31) Verthelyi, D; J Immunol 2002, V168, P1659 HCAPLUS
- (32) Wagner, H; Adv Immunol 1999, V73, P329 HCAPLUS
- (33) Weiner, G; Proc Natl Acad Sci 1997, V94, P10833 HCAPLUS
- (34) Yi, A; J Immunol 1996, V157, P5394 HCAPLUS
- (35) Zhou, L; Proc Natl Acad Sci 1996, V93, P2588 HCAPLUS
- (36) Zou, W; Eur J Immunol 2001, V31, P3833 HCAPLUS

IT 459471-16-0

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)
(CpG oligodeoxynucleotides induce human monocytes to mature into
functional dendritic cells)

RN 459471-16-0 HCAPLUS

CN DNA, d(G-sp-G-sp-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-sp-G-sp-G) (9CI) (CA
INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 13 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:369804 HCAPLUS

DN 137:19096

ED Entered STN: 19 May 2002

TI Differential and competitive activation of human immune cells by distinct
classes of CpG oligodeoxynucleotide

AU Gursel, Mayda; Verthelyi, Daniela; Gursel, Ihsan;
Ishii, Ken J.; Klinman, Dennis M.

CS Section of Retroviral Research, Center for Biologics Evaluation and
Research, Food and Drug Administration, Bethesda, MD, 20892, USA

SO Journal of Leukocyte Biology (2002), 71(5), 813-820
CODEN: JLBIE7; ISSN: 0741-5400

PB Federation of American Societies for Experimental Biology

DT Journal

LA English

CC 15-5 (Immunochemistry)

AB Synthetic oligodeoxynucleotides (ODN) expressing "CpG motifs" show promise
as immune adjuvants, antiallergens, anticancer, and immunoprotective
agents. Two structurally distinct classes of CpG ODN have been identified
that stimulate human PBMC. This work establishes that both types of ODN
bind to and are internalized by the same individual B cells, NK cells, and
monocytes. However, the intracellular localization of "D" and "K" ODN
differs, as does their functional activity: "K" type ODN trigger monocytes
and B cells to proliferate and secrete IL-6 and IgM, whereas "D" type ODN
induce NK cells to produce IFN- γ and monocytes to differentiate into
CD83+/CD86+ dendritic cells. In monocytes, these two types of ODN (which
differ in backbone composition and CpG motif) cross-inhibit one another's
activity. Thus, different types of CpG ODN have distinct and in some
cases incompatible effects on the same cells, a finding with important
implications for the therapeutic use of these agents.

ST oligodeoxynucleotide activation immune cell

IT Oligodeoxyribonucleotides

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CpG-containing; differential and competitive activation of human immune
cells by distinct classes of CpG oligodeoxynucleotide)

IT Antibodies and Immunoglobulins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgM; differential and competitive activation of human immune cells by
distinct classes of CpG oligodeoxynucleotide and formation of)

IT B cell (lymphocyte)

Dendritic cell

Human

(differential and competitive activation of human immune cells by
distinct classes of CpG oligodeoxynucleotide)

IT Interleukin 6
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (differential and competitive activation of human immune cells by
 distinct classes of CpG oligodeoxynucleotide and formation of)
 IT Monocyte
 (differential and competitive activation of human
 immune cells by distinct classes of CpG oligodeoxynucleotide)
 IT Lymphocyte
 (natural killer cell; differential and competitive activation of human
 immune cells by distinct classes of CpG oligodeoxynucleotide)
 IT Interferons
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (.gamma.; differential and competitive activation of human immune cells
 by distinct classes of CpG oligodeoxynucleotide and formation of)
 IT 434529-76-7 434529-77-8
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (differential and competitive activation of human immune cells by
 distinct classes of CpG oligodeoxynucleotide)

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE
 (1) Ballas, Z; J Immunol 1996, V157, P1840 HCAPLUS
 (2) Ballas, Z; J Immunol 2001, V167, P4878 HCAPLUS
 (3) Bauer, M; Immunology 1999, V97, P699 HCAPLUS
 (4) Bauer, S; Proc Natl Acad Sci 2001, V98, P9237 HCAPLUS
 (5) Behboudi, S; Immunology 2000, V99, P361 HCAPLUS
 (6) Bohle, B; Eur J Immunol 1999, V29, P2344 HCAPLUS
 (7) Bohle, B; J Immunol 2001, V166, P3743 HCAPLUS
 (8) Britigan, B; J Immunol 2001, V167, P2921 HCAPLUS
 (9) Chomarat, P; Nat Immunol 2000, V1, P510 HCAPLUS
 (10) Elkins, K; J Immunol 1999, V162, P2291 HCAPLUS
 (11) Hacker, H; EMBO J 1998, V17, P6230 HCAPLUS
 (12) Hartmann, G; J Immunol 2000, V164, P944 HCAPLUS
 (13) Hasbold, J; Immunol Cell Biol 1999, V77, P516 HCAPLUS
 (14) Kline, J; J Immunol 1998, V160, P2555 HCAPLUS
 (15) Klinman, D; Proc Natl Acad Sci 1996, V93, P2879 HCAPLUS
 (16) Klinman, D; Vaccine 1999, V17, P19 HCAPLUS
 (17) Krieg, A; Nature 1995, V374, P546 HCAPLUS
 (18) Krug, A; Eur J Immunol 2001, V31, P2154 HCAPLUS
 (19) Lee, S; J Immunol 2000, V165, P3631 HCAPLUS
 (20) Liang, H; J Immunol 2000, V165, P1438 MEDLINE
 (21) Lipford, G; Eur J Immunol 1997, V27, P2340 HCAPLUS
 (22) Liu, H; Blood 1998, V92, P3730 HCAPLUS
 (23) Mitani, H; Br J Haematol 2000, V109, P288 HCAPLUS
 (24) Palucka, K; J Leukoc Biol 1999, V65, P232 HCAPLUS
 (25) Roman, M; Nat Med 1997, V3, P849 HCAPLUS
 (26) Sato, Y; Science 1996, V273, P352 HCAPLUS
 (27) Sparwasser, T; Eur J Immunol 1997, V27, P1671 HCAPLUS
 (28) Sparwasser, T; Eur J Immunol 1998, V28, P2045 HCAPLUS
 (29) Stacey, K; J Immunol 1996, V157, P2116 HCAPLUS
 (30) Sur, S; J Immunol 1999, V162, P6284 HCAPLUS
 (31) Takeshita, F; J Immunol 2001, V167, P3555 HCAPLUS
 (32) Tascon, R; Immunology 2000, V99, P1 HCAPLUS
 (33) Vabulas, R; J Immunol 2000, V164, P2372 HCAPLUS
 (34) Verthelyi, D; J Immunol 2001, V166, P2372 HCAPLUS
 (35) Warren, T; J Immunol 2000, V165, P6244 HCAPLUS
 (36) Weiner, G; Proc Natl Acad Sci 1997, V94, P10833 HCAPLUS
 (37) Yamamoto, S; J Immunol 1992, V148, P4072 HCAPLUS
 (38) Yamamoto, S; Microbiol Immunol 1992, V36, P983 HCAPLUS
 (39) Yi, A; J Immunol 1996, V157, P5394 HCAPLUS
 (40) Yi, A; J Immunol 1998, V161, P4493 HCAPLUS

IT 434529-77-8
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (differential and competitive activation of human immune cells by
 distinct classes of CpG oligodeoxynucleotide)

RN 434529-77-8 HCAPLUS

CN DNA, d(G-sp-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-sp-G) (9CI) (CA INDEX
 NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 14 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:124395 HCAPLUS
 DN 136:293135
 ED Entered STN: 17 Feb 2002
 TI CpG oligodeoxynucleotides as vaccine adjuvants in primates
 AU Verthelyi, Daniela; Kenney, Richard T.; Seder, Robert A.; Gam,

Search done by Noble Jarrell

Albert A.; Friedag, Brenda; Klinman, Dennis M.
 CS Division of Viral Products, Center for Biologics Evaluation and
 Research/Food and Drug Administration, Bethesda, MD, 20892, USA
 SO Journal of Immunology (2002), 168(4), 1659-1663
 CODEN: JOIMA3; ISSN: 0022-1767
 PB American Association of Immunologists
 DT Journal
 LA English
 CC 15-2 (Immunochemistry)
 AB Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs act
 as immune adjuvants in mice, boosting the humoral and cellular response to
 coadministered Ags. CpG ODN that stimulate human PBMC are only weakly
 active in mice. Thus, alternative animal models are needed to monitor the
 activity and safety of "human" CpG ODN in vivo. This work demonstrates
 that rhesus macaques recognize and respond to the same CpG motifs that
 trigger human immune cells. Coadministering CpG ODN with heat-killed
 Leishmania vaccine provided significantly increased protection of macaques
 against cutaneous Leishmania infection. These findings indicate that
 rhesus macaques provide a useful model for studying the in vivo activity
 of human CpG motifs, and that ODN expressing these motifs act as strong
 immune adjuvants.
 ST vaccine adjuvant CpG oligodeoxynucleotide Macaca Leishmania
 IT Human
 Leishmania major
 Macaca mulatta
 Vaccines
 (CpG oligodeoxynucleotides as vaccine adjuvants in primates)
 IT Interleukin 6
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CpG oligodeoxynucleotides as vaccine adjuvants in primates)
 IT Oligodeoxyribonucleotides
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)
 (CpG oligodeoxynucleotides as vaccine adjuvants in primates)
 IT Antibodies and Immunoglobulins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IgG; CpG oligodeoxynucleotides as vaccine adjuvants in primates)
 IT Immunostimulants
 (adjuvants; CpG oligodeoxynucleotides as vaccine adjuvants in primates)
 IT T cell (lymphocyte)
 (proliferation; CpG oligodeoxynucleotides as vaccine adjuvants in
 primates)
 IT Interferons
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (.gamma.; CpG oligodeoxynucleotides as vaccine adjuvants in primates)
 IT 406966-34-5 406966-35-6 406966-36-7 406966-37-8
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)
 (CpG oligodeoxynucleotides as vaccine adjuvants in primates)
 RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Amaral, V; Exp Parasitol 1996, V82, P34 MEDLINE
 (2) Bauer, M; Immunology 1999, V97, P699 HCAPLUS
 (3) Bauer, S; Proc Natl Acad Sci 2001, V98, P9237 HCAPLUS
 (4) Davis, H; Curr Top Microbiol Immunol 2000, V247, P171 HCAPLUS
 (5) Davis, H; J Immunol 1998, V160, P870 HCAPLUS
 (6) Davis, H; Vaccine 2000, V19, P413
 (7) Deml, L; Clin Chem Lab Med 1999, V37, P199 HCAPLUS
 (8) Freidag, B; Infect Immun 2000, V68, P2948 HCAPLUS
 (9) Hagiwara, E; Cytokine 1995, V7, P815 HCAPLUS
 (10) Handman, E; Clin Microbiol Rev 2001, V14, P229 HCAPLUS
 (11) Hartmann, G; J Immunol 2000, V164, P1617 HCAPLUS
 (12) Hartmann, G; J Immunol 2000, V164, P944 HCAPLUS
 (13) Hemmi, H; Nature 2000, V408, P740 HCAPLUS
 (14) Jones, T; Vaccine 1999, V17, P3065 HCAPLUS
 (15) Kadowaki, N; J Exp Med 2001, V194, P863 HCAPLUS
 (16) Kadowaki, N; J Immunol 2001, V166, P2291 HCAPLUS
 (17) Kenney, R; J Immunol 1999, V163, P4481 HCAPLUS
 (18) Klinman, D; Antisense Nucleic Acid Drug Dev 1998, V8, P181 HCAPLUS
 (19) Klinman, D; Proc Natl Acad Sci 1996, V93, P2879 HCAPLUS
 (20) Klinman, D; Springer Semin Immunopathol 2000, V22, P173 HCAPLUS
 (21) Klinman, D; Vaccine 1999, V17, P19 HCAPLUS
 (22) Krieg, A; Antisense Nucleic Acid Drug Dev 2001, V11, P181 HCAPLUS
 (23) Krieg, A; Curr Opin Mol Ther 2001, V3, P15 HCAPLUS
 (24) Krieg, A; Nature 1995, V374, P546 HCAPLUS
 (25) Krug, A; Eur J Immunol 2001, V31, P2154 HCAPLUS

(26) Leifer, C; Keystone Symposia 2001
 (27) Lipford, G; Eur J Immunol 1997, V27, P2340 HCAPLUS
 (28) Messina, J; J Immunol 1991, V147, P1759 HCAPLUS
 (29) Moldoveanu, Z; Vaccine 1998, V16, P1216 HCAPLUS
 (30) Roman, M; Nat Med 1997, V3, P849 HCAPLUS
 (31) Sparwasser, T; Eur J Immunol 1998, V28, P2045 HCAPLUS
 (32) Stacey, K; Infect Immun 1999, V67, P3719 HCAPLUS
 (33) Takeshita, F; J Immunol 2001, V167, P3555 HCAPLUS
 (34) Verthelyi, D; J Immunol 2001, V166, P2372 HCAPLUS
 (35) von Stebut, E; Eur J Immunol 2000, V30, P3498 HCAPLUS
 (36) Wagner, H; Adv Immunol 1999, V73, P329 HCAPLUS
 (37) Weeratna, R; Vaccine 2000, V6, P1755
 (38) Yamamoto, S; Microbiol Immunol 1992, V36, P983 HCAPLUS
 IT 406966-34-5
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CpG oligodeoxynucleotides as vaccine adjuvants in primates)
 RN 406966-34-5 HCAPLUS
 CN DNA, d(G-sp-G-sp-T-G-C-A-C-G-G-T-G-C-A-G-G-sp-G-sp-G-sp-G) (9CI)
 (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 15 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:122818 HCAPLUS
 DN 136:182447
 ED Entered STN: 15 Feb 2002
 TI Vaccine against respiratory syncytial virus (RSV)
 IN Mond, James J.; Prince, Gregory; Klinman, Dennis M.
 PA Henry M. Jackson Foundation for the Advancement of Military Medicine, USA
 SO PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K039-39
 CC 15-2 (Immunochemistry)
 Section cross-reference(s): 3, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002011761	A2	20020214	WO 2001-US41633	20010809
	WO 2002011761	A3	20030123		
	W: AU, CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	AU 2001085421	A5	20020218	AU 2001-85421	20010809
PRAI	US 2000-224011P	P	20000810		
	US 2000-229307P	P	20000901		
	WO 2001-US41633	W	20010809		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 2002011761	ICM	A61K039-39
---------------	-----	------------

AB The present invention relates to a vaccine comprising adjuvanting oligodeoxynucleotides (ODNs), containing at least one CpG dinucleotide and an antigen comprising a peptide sequence bearing at least one epitope of a Paramyxoviridae F protein. In one embodiment, the ODN is admixed or conjugated to an F protein from a respiratory syncytial virus (RSV). The vaccine of the invention may be administered directly to mucosal tissues of the respiratory tract by inhalation or intranasal administration.

ST vaccine Pneumovirus Paramyxoviridae F protein CpG; immunostimulatory oligonucleotide respiratory syncytial virus vaccine

IT Oligonucleotides

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CpG-containing immunostimulatory; vaccine compns. comprising Paramyxoviridae F protein epitopes and immunostimulatory oligonucleotides against respiratory syncytial virus)

IT Proteins

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (F; vaccine compns. comprising Paramyxoviridae F protein epitopes and immunostimulatory oligonucleotides against respiratory syncytial virus)

IT Immunostimulants

(adjuvants; vaccine compns. comprising Paramyxoviridae F protein

epitopes and immunostimulatory oligonucleotides against respiratory syncytial virus)

IT Respiratory tract
(administration; vaccine compns. comprising Paramyxoviridae F protein epitopes and immunostimulatory oligonucleotides against respiratory syncytial virus)

IT Proteins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(conjugates, G/F proteins; vaccine compns. comprising Paramyxoviridae F protein epitopes and immunostimulatory oligonucleotides against respiratory syncytial virus)

IT Drug delivery systems
(inhalants; vaccine compns. comprising Paramyxoviridae F protein epitopes and immunostimulatory oligonucleotides against respiratory syncytial virus)

IT Drug delivery systems
(injections, i.m.; vaccine compns. comprising Paramyxoviridae F protein epitopes and immunostimulatory oligonucleotides against respiratory syncytial virus)

IT Drug delivery systems
(mucosal; vaccine compns. comprising Paramyxoviridae F protein epitopes and immunostimulatory oligonucleotides against respiratory syncytial virus)

IT Drug delivery systems
(nasal, intra-; vaccine compns. comprising Paramyxoviridae F protein epitopes and immunostimulatory oligonucleotides against respiratory syncytial virus)

IT Drug delivery systems
(respiratory tract; vaccine compns. comprising Paramyxoviridae F protein epitopes and immunostimulatory oligonucleotides against respiratory syncytial virus)

IT Drug delivery systems
(solns., nasal; vaccine compns. comprising Paramyxoviridae F protein epitopes and immunostimulatory oligonucleotides against respiratory syncytial virus)

IT DNA sequences
Epitopes
Paramyxoviridae
Pneumovirus
Respiratory syncytial virus
Vaccines
(vaccine compns. comprising Paramyxoviridae F protein epitopes and immunostimulatory oligonucleotides against respiratory syncytial virus)

IT Fusion proteins (chimeric proteins)
G proteins (guanine nucleotide-binding proteins)
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(vaccine compns. comprising Paramyxoviridae F protein epitopes and immunostimulatory oligonucleotides against respiratory syncytial virus)

IT Antigens
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vaccine compns. comprising Paramyxoviridae F protein epitopes and immunostimulatory oligonucleotides against respiratory syncytial virus)

IT 2382-65-2D, oligonucleotide derivs. 185810-20-2 207496-24-0
207496-25-1 207496-26-2 207496-27-3 400185-99-1 400186-00-7
400186-01-8 400186-02-9 400186-03-0 400186-04-1 400186-05-2
400186-06-3 400186-07-4 400186-08-5 400186-09-6 400186-10-9
400186-11-0 400186-12-1 400186-13-2 400186-14-3 400186-15-4
400186-16-5 400186-17-6 400186-18-7 400186-19-8 400186-20-1
400186-21-2 400186-22-3 400186-23-4 400186-24-5 400186-25-6
400186-26-7 400186-27-8 400186-28-9 400186-29-0 400186-30-3
400186-31-4 400186-32-5 400186-33-6 400186-34-7
400186-35-8 400186-36-9 400186-37-0 400186-38-1 400186-39-2
400186-40-5 400186-41-6 400186-42-7 400186-43-8
400186-44-9 400186-45-0 400186-46-1 400186-47-2
400186-48-3 400186-49-4 400186-50-7 400186-51-8
400186-52-9 400186-53-0 400186-54-1 400186-55-2 400186-56-3
400186-57-4 400186-58-5 400186-59-6 400186-60-9
400186-61-0 400186-62-1 400186-63-2 400186-64-3 400186-65-4
400186-66-5 400186-67-6 400186-68-7 400186-69-8 400186-70-1
400186-71-2 400186-72-3 400186-73-4 400186-74-5 400186-75-6
400186-76-7 400186-77-8 400186-78-9 400186-79-0 400186-80-3

400186-81-4 400186-82-5 400186-83-6 400186-84-7
400186-85-8 400186-86-9 400186-87-0 400186-88-1
400186-89-2 400186-90-5 400186-91-6 400186-92-7
400186-93-8 400186-94-9 400186-95-0 400186-96-1 400186-97-2
400186-98-3 400186-99-4 400187-00-0

RL: BSU (Biological study, unclassified); PRP (Properties); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)

(vaccine compns. comprising Paramyxoviridae F protein epitopes and
immunostimulatory oligonucleotides against respiratory syncytial virus)

IT 400186-33-6

RL: BSU (Biological study, unclassified); PRP (Properties); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)

(vaccine compns. comprising Paramyxoviridae F protein epitopes and
immunostimulatory oligonucleotides against respiratory syncytial virus)

RN 400186-33-6 HCAPLUS

CN DNA, d(G-G-T-G-C-A-C-C-G-A-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 16 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:903912 HCAPLUS

DN 136:52708

ED Entered STN: 14 Dec 2001

TI Immunostimulatory RNA/DNA hybrid molecules

IN Mond, James J.; Flora, Michael; Klinman, Dennis M.

PA Biosynexus Incorporated, USA

SO PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K039-00

CC 15-2 (Immunochemistry)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001093902	A2	20011213	WO 2001-US18276	20010607
	WO 2001093902	A3	20020418		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2412026	AA	20011213	CA 2001-2412026	20010607
	EP 1292331	A2	20030319	EP 2001-941989	20010607
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	US 2004052763	A1	20040318	US 2001-874991	20010607
	JP 2004530629	T2	20041007	JP 2002-501473	20010607
PRAI	US 2000-209797P	P	20000607		
	WO 2001-US18276	W	20010607		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001093902	ICM	A61K039-00
JP 2004530629	FTERM	4B024/AA01; 4B024/CA01; 4B024/CA11; 4B024/DA02; 4B024/GA11; 4B024/HA17; 4C084/AA13; 4C084/BA35; 4C084/CA18; 4C084/NA14; 4C084/ZB09; 4C085/AA03; 4C085/BB23; 4C085/CC03; 4C085/EE03; 4C085/EE06; 4C085/FF30; 4C086/AA01; 4C086/AA02; 4C086/EA16; 4C086/MA03; 4C086/MA04; 4C086/NA14; 4C086/ZB09

AB The present invention provides immunol. compns. and methods relating to immunostimulatory intra-strand DNA/RNA hybrid oligonucleotides (HDRs), optimally encoding one or more CpG motif, which may be an unmethylated CpG motif. Administration of these compds., alone or in the context of one or more target antigens, promotes innate and antigen specific immunities.

ST vaccine adjuvant immunostimulatory RNA DNA hybrid antigen cytokine Ig

IT Genetic element

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CpG island; immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT Oligonucleotides

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)
 (CpG-containing; immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT Recombination, genetic
 (Ig class switching; immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT Antibodies and Immunoglobulins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IgA; immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT Antibodies and Immunoglobulins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IgG1; immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT Antibodies and Immunoglobulins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IgG2; immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT Antibodies and Immunoglobulins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IgG2a; immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT Antibodies and Immunoglobulins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IgM; immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT Immunostimulants
 (adjuvants; immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT Immunity
 (cell-mediated; immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT T cell (lymphocyte)
 (helper cell/inducer, TH1; immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT T cell (lymphocyte)
 (helper cell/inducer, TH2; immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT Immunity
 (humoral; immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT Immunostimulants
 Vaccines
 (immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT Antibodies and Immunoglobulins
 DNA
 Interleukin 10
 Interleukin 12
 Interleukin 6
 RNA
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT Antigens
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT Lymphocyte
 (natural killer cell; immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT B cell (lymphocyte)
 T cell (lymphocyte)
 (proliferation; immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT Interferons
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (.gamma.; immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT 380690-93-7
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT 380690-91-5
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT 380535-25-1 380690-92-6 380690-94-8 380690-95-9 380690-96-0
 380690-97-1 380690-98-2 380991-84-4
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (immunostimulatory RNA/DNA hybrid mols. for use in vaccines)

IT 381254-85-9 381256-61-7 381256-62-8 381256-63-9 381256-64-0
 381256-65-1 381256-66-2 381256-67-3 381256-68-4 381256-69-5
 381256-70-8 381256-71-9 381256-72-0 381256-73-1 381256-74-2
 381256-75-3 381256-76-4 381256-77-5 381256-78-6 381256-79-7
 381256-80-0 381256-81-1 381256-82-2 381256-83-3 381256-84-4

381256-85-5	381256-86-6	381256-87-7	381256-88-8	381256-89-9
381256-90-2	381256-91-3	381256-92-4	381256-93-5	381256-94-6
381256-95-7	381256-96-8	381256-97-9	381256-98-0	381256-99-1
381257-00-7	381257-01-8	381257-02-9	381257-03-0	381257-04-1
381257-05-2	381257-06-3	381257-07-4	381257-08-5	381257-09-6
381257-10-9	381257-11-0	381257-12-1	381257-13-2	381257-14-3
381257-15-4	381257-16-5	381257-17-6	381257-18-7	381257-19-8
381257-20-1	381257-21-2	381257-22-3	381257-23-4	381257-24-5
381257-25-6	381257-26-7	381257-27-8	381257-28-9	381257-29-0
381257-30-3	381257-31-4	381257-32-5	381257-33-6	381257-34-7
381257-35-8	381257-36-9	381257-37-0	381257-38-1	381257-39-2
381257-40-5	381257-41-6	381257-42-7	381257-43-8	381257-44-9
381257-45-0	381257-46-1	381257-47-2	381257-48-3	381257-49-4
381257-50-7	381257-51-8	381257-52-9	381257-53-0	381257-54-1
381257-55-2	381257-56-3	381257-57-4	381257-58-5	381257-59-6
381257-60-9	381257-61-0	381257-62-1	381257-63-2	381257-64-3
381257-65-4	381257-66-5	381257-67-6	381257-68-7	381257-69-8
381257-70-1	381257-71-2	381257-72-3	381257-73-4	381257-74-5
381257-75-6	381257-76-7	381257-77-8	381257-78-9	381257-79-0
381257-80-3	381257-81-4	381257-82-5	381257-83-6	381257-84-7
381257-85-8	381257-86-9	381257-87-0	381257-88-1	381257-89-2
381257-90-5	381257-91-6	381257-92-7	381257-93-8	381257-94-9
381257-95-0	381257-96-1	381257-97-2	381257-98-3	381257-99-4
381258-00-0	381258-01-1	381258-02-2	381258-03-3	381258-04-4
381258-05-5	381258-06-6	381258-07-7	381258-08-8	381258-09-9
381258-10-2	381258-11-3	381258-12-4	381258-13-5	381258-14-6
381258-15-7	381258-16-8	381258-17-9	381258-18-0	381258-19-1
381258-20-4	381258-21-5	381258-22-6	381258-23-7	381258-24-8
381258-25-9	381258-26-0	381258-27-1	381258-28-2	381258-29-3
381258-30-6	381258-31-7	381258-32-8	381258-33-9	381258-34-0
381258-35-1	381258-36-2	381258-37-3	381258-38-4	381258-39-5
381258-40-8	381258-41-9	381258-42-0	381258-43-1	381258-44-2
381258-45-3	381258-46-4	381258-47-5	381258-48-6	381258-49-7
381258-50-0	381258-51-1	381258-52-2	381258-53-3	381258-54-4
381258-55-5	381258-56-6	381258-57-7	381258-58-8	381258-59-9
381258-60-2	381258-61-3	381258-62-4	381258-63-5	381258-64-6
381258-65-7	381258-66-8	381258-67-9	381258-68-0	381258-69-1
381258-70-4	381258-71-5	381258-72-6	381258-73-7	381258-74-8
381258-75-9	381258-76-0	381258-77-1	381258-78-2	381258-79-3
381258-80-6	381258-81-7	381258-82-8	381258-83-9	381258-84-0
381258-85-1	381258-86-2	381258-87-3	381258-88-4	381258-89-5
381258-90-8	381258-91-9	381258-92-0	381258-93-1	381258-94-2
381258-95-3	381258-96-4	381258-97-5	381258-98-6	381258-99-7

RL: PRP (Properties)

(unclaimed nucleotide sequence; immunostimulatory RNA/DNA hybrid mols.)

IT	381259-00-3	381259-01-4	381259-02-5	381259-03-6	381259-04-7
	381259-05-8	381259-06-9	381259-07-0	381259-08-1	381259-09-2
	381259-10-5	381259-11-6	381259-12-7	381259-13-8	381259-14-9
	381259-15-0	381259-16-1	381259-17-2	381259-18-3	381259-19-4
	381259-20-7	381259-21-8	381259-22-9	381259-23-0	381259-24-1
	381259-25-2	381259-26-3	381259-27-4	381259-28-5	381259-29-6
	381259-30-9	381259-31-0	381259-32-1	381259-33-2	381259-34-3
	381259-35-4	381259-36-5	381259-37-6	381259-38-7	381259-39-8
	381259-40-1	381259-41-2	381259-42-3	381259-43-4	381259-44-5
	381259-45-6	381259-46-7	381259-47-8	381259-48-9	381259-49-0
	381259-50-3	381259-51-4	381259-52-5	381259-53-6	381259-54-7
	381259-55-8	381259-56-9	381259-57-0	381259-58-1	381259-59-2
	381259-60-5	381259-61-6	381259-62-7	381259-63-8	381259-64-9
	381259-65-0	381259-66-1	381259-67-2	381259-68-3	381259-69-4
	381259-70-7	381259-71-8	381259-72-9	381259-73-0	381259-74-1
	381259-75-2	381259-76-3	381259-77-4	381259-78-5	381259-79-6
	381259-80-9	381259-81-0	381259-82-1	381259-83-2	381259-84-3
	381259-85-4	381259-86-5	381259-87-6	381259-88-7	381259-89-8
	381259-90-1	381259-91-2	381259-92-3	381259-93-4	381259-94-5
	381259-95-6	381259-96-7	381259-97-8	381259-98-9	381259-99-0
	381260-00-0	381260-01-1	381260-02-2	381260-03-3	381260-04-4
	381260-05-5	381260-06-6	381260-07-7	381260-08-8	381260-09-9
	381260-10-2	381260-11-3	381260-12-4	381260-13-5	381260-14-6
	381260-15-7	381260-16-8	381260-17-9	381260-18-0	381260-19-1
	381260-20-4	381260-21-5	381260-22-6	381260-23-7	381260-24-8
	381260-25-9	381260-26-0	381260-27-1	381260-28-2	381260-29-3
	381260-30-6	381260-31-7	381260-32-8	381260-33-9	381260-34-0
	381260-35-1	381260-36-2	381260-37-3	381260-38-4	381260-39-5
	381260-40-8	381260-41-9	381260-42-0	381260-43-1	381260-44-2
	381260-45-3	381260-46-4	381260-47-5	381260-48-6	381260-49-7
	381260-50-0	381260-51-1	381260-52-2	381260-53-3	381260-54-4

381260-55-5 381260-56-6 381260-57-7 381260-58-8 381260-59-9
 381260-60-2 381260-61-3 381260-62-4 381260-63-5 381260-64-6
 381260-65-7 381260-66-8 381260-67-9 381260-68-0 381260-69-1
 381260-70-4 381260-71-5 381260-72-6 381260-73-7
 381260-74-8 381260-75-9 381260-76-0
 381260-77-1 381260-78-2 381260-79-3
 381260-80-6 381260-81-7 381260-82-8
 381260-83-9 381260-84-0 381260-85-1
 381260-86-2 381260-87-3 381260-88-4
 381260-89-5 381260-90-8 381260-91-9
 381260-92-0 381260-93-1 381260-94-2
 381260-95-3 381260-96-4 381260-97-5
 381260-98-6 381260-99-7 381261-00-3
 381261-01-4 381261-02-5 381261-03-6
 381261-04-7 381261-05-8 381261-06-9
 381261-07-0 381261-08-1 381261-09-2
 381261-10-5 381261-11-6 381261-12-7
 381261-13-8 381261-14-9 381261-15-0
 381261-16-1 381261-17-2 381261-18-3 381261-19-4
 381261-20-7 381261-21-8 381261-22-9 381261-23-0 381261-24-1
 381261-25-2 381261-26-3 381261-27-4 381261-28-5 381261-29-6
 381261-30-9 381261-31-0 381261-32-1 381261-33-2 381261-34-3
 381261-35-4 381261-36-5 381261-37-6 381261-38-7 381261-39-8

RL: PRP (Properties)

(unclaimed nucleotide sequence; immunostimulatory RNA/DNA hybrid mols.)

IT 381261-40-1 381261-41-2 381261-42-3 381261-43-4 381261-44-5
 381261-45-6 381261-46-7 381261-47-8 381261-48-9 381261-49-0
 381261-50-3 381261-51-4 381261-52-5 381261-53-6 381261-54-7
 381261-55-8 381261-56-9 381261-57-0 381261-58-1 381261-59-2
 381261-60-5 381261-61-6 381261-62-7 381261-63-8 381261-64-9
 381261-65-0 381261-66-1 381261-67-2 381261-68-3 381261-69-4
 381261-70-7 381261-71-8 381261-72-9 381261-73-0 381261-74-1
 381261-75-2 381261-76-3 381261-77-4 381261-78-5 381261-79-6
 381261-80-9 381261-81-0 381261-82-1

RL: PRP (Properties)

(unclaimed nucleotide sequence; immunostimulatory RNA/DNA hybrid mols.)

IT 207496-41-1 207496-43-3 381164-30-3 381164-31-4 381164-32-5
 381164-33-6 381164-34-7 381164-35-8 381164-36-9 381164-37-0
 381164-38-1

RL: PRP (Properties)

(unclaimed sequence; immunostimulatory RNA/DNA hybrid mols.)

IT 381260-71-5

RL: PRP (Properties)

(unclaimed nucleotide sequence; immunostimulatory RNA/DNA hybrid mols.)

RN 381260-71-5 HCAPLUS

CN RNA, (G-G-U-G-C-A-U-C-G-A-U-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 17 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:526086 HCAPLUS

DN 135:102560

ED Entered STN: 20 Jul 2001

TI Oligodeoxynucleotide and its use to induce an immune response

IN Klinman, Dennis; Ishii, Ken; Verthelyi, Daniela

PA United States Dept. of Health and Human Services, USA

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07H021-00

ICS A61K031-70; A61K039-39; C12N015-11

CC 1-7 (Pharmacology)

Section cross-reference(s): 15, 63

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051500	A1	20010719	WO 2001-US1122	20010112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001027889 A5 20010724 AU 2001-27889 20010112

EP 1322655 A1 20030702 EP 2001-902045 20010112

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, CY, TR

US 2003144229 A1 20030731 US 2002-194035 20020712

PRAI US 2000-176115P P 20000114

WO 2001-US1122 W 20010112

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

WO 2001051500 ICM C07H021-00
ICS A61K031-70; A61K039-39; C12N015-11

AB The present invention provides a substantially pure or isolated
oligodeoxynucleotide (ODN) of at least about 10 nucleotides comprising
different CpG sequences, as well as an oligodeoxynucleotide delivery
complex and a pharmacol. composition comprising an ODN or ODNs, and a method of
inducing an immune response by administering such an ODN or ODNs to a
host.

ST phosphorothioate oligodeoxynucleotide immunostimulant antitumor sequence

IT Genetic element

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic
use); BIOL (Biological study); PROC (Process); USES (Uses)
(CpG island; oligodeoxynucleotide and its use to induce an immune
response)

IT B cell (lymphocyte)
(activation; oligodeoxynucleotide and its use to induce an immune
response)

IT Immunostimulants
(adjuvants; oligodeoxynucleotide and its use to induce an immune
response)

IT Chemical warfare agents
(biowarfare agents; oligodeoxynucleotide and its use to induce an
immune response)

IT Immunity
(cell-mediated; oligodeoxynucleotide and its use to induce an immune
response)

IT Lipids, biological studies
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic
use); BIOL (Biological study); PROC (Process); USES (Uses)
(drug targeting with; oligodeoxynucleotide and its use to induce an
immune response)

IT Immunity
(humoral; oligodeoxynucleotide and its use to induce an immune
response)

IT Drug delivery systems
(liposomes, drug targeting with; oligodeoxynucleotide and its use to
induce an immune response)

IT Allergy inhibitors

Antiasthmatics

Antibiotics

Antitumor agents

Drug targeting

Immunodeficiency

Immunostimulants

Vaccines

(oligodeoxynucleotide and its use to induce an immune response)

IT Oligodeoxyribonucleotides

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PEP (Physical, engineering or chemical process); PRP
(Properties); THU (Therapeutic use); BIOL (Biological study); PROC
(Process); USES (Uses)

(oligodeoxynucleotide and its use to induce an immune response)

IT Antibodies

Cytokines

Interleukin 6

RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL
(Biological study); FORM (Formation, nonpreparative)

(oligodeoxynucleotide and its use to induce an immune response)

IT Phosphorothioate oligodeoxyribonucleotides

RL: PEP (Physical, engineering or chemical process); THU (Therapeutic
use); BIOL (Biological study); PROC (Process); USES (Uses)

(oligodeoxynucleotide and its use to induce an immune response)

IT Neoplasm

(solid, inhibitors; oligodeoxynucleotide and its use to induce an immune response)

IT Drug delivery systems
(viroosomes, drug targeting with; oligodeoxynucleotide and its use to induce an immune response)

IT Interferons
RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(.gamma.; oligodeoxynucleotide and its use to induce an immune response)

IT 57-88-5, Cholesterol, biological studies
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(drug targeting with; oligodeoxynucleotide and its use to induce an immune response)

IT 350270-71-2 350270-72-3 350270-73-4 350270-74-5 350270-75-6
350270-76-7 350270-77-8 350270-78-9 350270-79-0 350270-80-3
350270-81-4 350270-82-5 350270-83-6 350270-84-7 350270-85-8
350270-86-9 350270-87-0 350270-88-1 350270-89-2 350270-90-5
350270-91-6 350270-92-7 350270-93-8 350270-94-9
350270-95-0 350270-96-1 350270-97-2 350270-98-3 350270-99-4
350271-00-0 350271-01-1 350271-02-2 350271-03-3
350271-04-4 350271-05-5 350271-06-6
350271-07-7 350271-08-8 350271-09-9 350271-10-2
350271-11-3 350271-12-4 350271-13-5 350271-14-6 350271-15-7
350271-16-8 350271-17-9 350271-18-0 350271-19-1
350271-20-4 350271-21-5 350271-22-6 350271-23-7 350271-24-8
350271-25-9 350271-26-0 350271-27-1 350271-28-2 350271-29-3
350271-30-6 350271-31-7 350271-32-8 350271-33-9 350271-34-0
350271-35-1 350271-36-2 350271-37-3 350271-38-4 350271-39-5
350271-40-8 350271-41-9 350271-42-0 350271-43-1
350271-44-2 350271-45-3 350271-46-4 350271-47-5
350271-48-6 350271-49-7 350271-50-0 350271-51-1 350271-52-2
350271-53-3 350271-54-4 350271-55-5 350271-56-6 350271-57-7
350271-58-8 350271-59-9 350271-60-2
350271-61-3 350271-62-4 350271-63-5 350271-64-6
350271-65-7 350271-66-8 350271-67-9 350271-68-0
350271-69-1 350271-70-4 350271-71-5 350560-85-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligodeoxynucleotide and its use to induce an immune response)

IT 2382-65-2
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(oligodeoxynucleotide and its use to induce an immune response)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Cpg Immunopharmaceuticals GmbH; WO 9958118 A 1999 HCAPLUS
(2) Davis, H; WO 9840100 A 1998 HCAPLUS
(3) Dynavax Technologies Corp; WO 9855495 A 1998 HCAPLUS
(4) Hybridon Inc; WO 9849288 A 1998 HCAPLUS
(5) Ottawa Civic Loeb Res Inst; WO 9956755 A 1999 HCAPLUS
(6) Univ Iowa Res Found; WO 9818810 A 1998 HCAPLUS
(7) Univ Iowa Res Found; WO 9951259 A 1999 HCAPLUS
(8) Wu, T; WO 9852581 A 1998 HCAPLUS

IT 350270-92-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligodeoxynucleotide and its use to induce an immune response)

RN 350270-92-7 HCAPLUS

CN DNA, d(G-sp-G-T-G-C-A-C-C-G-A-T-G-C-A-G-G-G-sp-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 18 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:129322 HCAPLUS
DN 135:302807
ED Entered STN: 21 Feb 2001
TI Response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides
AU Kamstrup, S.; Verthelyi, D.; Klinman, D. M.
CS Department for Pathobiology and Diagnostics, Danish Veterinary Institute for Virus Research, Kalvehave, Lindholm, DK-4771, Den.
SO Veterinary Microbiology (2001), 78(4), 353-362

CODEN: VMICDQ; ISSN: 0378-1135

PB Elsevier Science B.V.

DT Journal

LA English

CC 15-10 (Immunochemistry)

AB Exposure to bacterial DNA generates a "danger signal" that stimulates cellular elements of the mammalian immune system to proliferate and/or secrete cytokines. Stimulation is critically dependent on hexameric motifs that contain an unmethylated CpG dinucleotide: these are commonly found in bacterial but not vertebrate DNA. Different motifs are optimally stimulatory in different species. This work examines whether oligodeoxynucleotides (ODNs) containing CpG motifs stimulate peripheral blood mononuclear cells from pigs. Results show that pigs respond to CpG ODN by proliferating and secreting IL-6, IL-12 and TNF- α . By screening a large panel (>100) of ODNs, the palindromic hexamer 'ATCGAT' was identified as being optimally active in all animals examined (N=10). These findings are the first to establish the immunostimulatory activity of CpG ODN in pigs, and suggest that the therapeutic uses envisioned for these ODNs (as vaccine adjuvants and immunoprotective agents) may be applicable to husbandry animals.

ST CpG oligodeoxynucleotide adjuvant leukocyte proliferation cytokine swine

IT Genetic element

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CpG island; response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides)

IT Oligodeoxyribonucleotides

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CpG-containing; response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides)

IT Immunostimulants

(adjuvants; response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides)

IT Cell proliferation

Mononuclear cell (leukocyte)

Swine

Vaccines

(response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides)

IT Interleukin 12

Interleukin 6

Tumor necrosis factors

RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)

(response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides)

IT 84216-59-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(CpG oligodeoxynucleotides containing; response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides)

IT 366065-16-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides)

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Ballas, Z; J Immunol 1996, V157, P1840 HCAPLUS
- (2) Bauer, M; Immunology 1999, V97(4), P699 HCAPLUS
- (3) Brown, W; Infect Immunol 1998, V66(11), P5423 HCAPLUS
- (4) Carpentier, A; Cancer Res 1999, V59(21), P5429 HCAPLUS
- (5) Deml, L; Clin Chem Lab Med 1999, V37(3), P199 HCAPLUS
- (6) Eder, P; Antisense Res Dev 1991, V1(2), P141 HCAPLUS
- (7) Elkins, K; J Immunol 1999, V162(4), P2291 HCAPLUS
- (8) Hacker, H; EMBO J 1998, V17(21), P6230 HCAPLUS
- (9) Halpern, M; Cell Immunol 1996, V167(1), P72 HCAPLUS
- (10) Hartmann, G; J Immunol 2000, V164(3), P1617 HCAPLUS
- (11) Hartmann, G; J Immunol 2000, V164, P944 HCAPLUS
- (12) Klinman, D; Antisense Nucleic Acid Drug Dev 1998, V8(2), P181 HCAPLUS
- (13) Klinman, D; Infect Immun 1999, V67(11), P5658 HCAPLUS
- (14) Klinman, D; J Immunol 1997, V158(8), P3635 HCAPLUS
- (15) Klinman, D; Proc Natl Acad Sci USA 1996, V93(7), P2879 HCAPLUS
- (16) Klinman, D; Vaccine 1999, V17(1), P19 HCAPLUS

Search done by Noble Jarrell

- (17) Krieg, A; Antisense Nucleic Acid Drug Dev 1996, V6, P133 HCAPLUS
- (18) Krieg, A; Nature 1995, V374(6522), P546 HCAPLUS
- (19) Liang, H; J Clin Invest 1996, V98(5), P1119 HCAPLUS
- (20) McCluskie, M; J Immunol 1998, V161(9), P4463 HCAPLUS
- (21) McCluskie, M; Vaccine 1999, V18(3-4), P231 HCAPLUS
- (22) Moss, R; Vaccine 2000, V18(11-12), P1081 MEDLINE
- (23) Oxenius, A; J Virol 1999, V73(5), P4120 HCAPLUS
- (24) Pisetky, D; Immunopharmacology 1998, V40(3), P199 HCAPLUS
- (25) Stacey, K; Infect Immun 1999, V67, P3719
- (26) Walker, P; Proc Natl Acad Sci USA 1999, V96(12), P6970 HCAPLUS
- (27) Weiner, G; Proc Natl Acad Sci USA 1997, V94(20), P10833
- (28) Wloch, M; Human Gene Therapy 1998, V9, P1439 MEDLINE
- (29) Yamamoto, T; Jpn J Cancer Res 1994, V85, P775 HCAPLUS
- (30) Yi, A; J Immunol 1996, V157(12), P5394 HCAPLUS
- (31) Yi, A; J Immunol 1998, V161(9), P4493 HCAPLUS
- (32) Zimmermann, S; J Immunol 1998, V160(8), P3627

IT 366065-16-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides)

RN 366065-16-9 HCAPLUS

CN DNA, d(G-sp-G-sp-T-G-C-A-T-C-G-A-T-G-C-A-G-sp-G-sp-G-sp-G-sp-G) (9CI)
(CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 19 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:125171 HCAPLUS

DN 134:294478

ED Entered STN: 21 Feb 2001

TI Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs

AU Verthelyi, Daniela; Ishii, Ken J.; Gursel, Mayda; Takeshita, Fumihiko; Klinman, Dennis M.

CS Section of Retroviral Research, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, 20892, USA

SO Journal of Immunology (2001), 166(4), 2372-2377
CODEN: JOIMA3; ISSN: 0022-1767

PB American Association of Immunologists

DT Journal

LA English

CC 15-10 (Immunochemistry)

AB Oligodeoxynucleotides (ODN) that contain unmethylated CpG dinucleotides trigger a strong innate immune response in vertebrates. CpG ODN show promise as vaccine adjuvants, anti-allergens, and immunoprotective agents in animal models. Their transition to clin. use requires the identification of motifs that are optimally stimulatory in humans. Anal. of hundreds of novel ODN resulted in the identification and characterization of two structurally distinct "clusters" of immunostimulatory CpG ODN. One cluster ("D") preferentially stimulates IFN-gamma production by NK cells, whereas the other ("K") stimulates cell proliferation and the production of IL-6 and IgM by monocytes and B cells. The distinct immunostimulatory properties of K and D ODN can improve the design of CpG-based products to achieve specific therapeutic goals.

ST CpG motif vaccine monocyte lymphocyte cytokine IgM

IT Genetic element

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(CpG island; two distinct CpG motifs in stimulation of human peripheral blood cells)

IT Immunoglobulins

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(M; two distinct CpG motifs in stimulation of human peripheral blood cells)

IT Immunostimulants

(adjuvants; two distinct CpG motifs in stimulation of human peripheral blood cells)

IT Lymphocyte

(natural killer cell; two distinct CpG motifs in stimulation of human peripheral blood cells)

IT Allergy

B cell (lymphocyte)
Cell proliferation

Monocyte

Vaccines

(two distinct CpG motifs in stimulation of human peripheral blood cells)

IT Oligodeoxyribonucleotides

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(two distinct CpG motifs in stimulation of human peripheral blood cells)

IT Interleukin 6

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)

(two distinct CpG motifs in stimulation of human peripheral blood cells)

IT Interferons

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)

(.gamma.; two distinct CpG motifs in stimulation of human peripheral blood cells)

IT 246163-61-1 334074-91-8 334074-92-9 334581-75-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(two distinct CpG motifs in stimulation of human peripheral blood cells)

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Ballas, Z; J Immunol 1996, V157, P1840 HCAPLUS
- (2) Bauer, M; Immunology 1999, V97, P699 HCAPLUS
- (3) Bohle, B; Eur J Immunol 1999, V29, P2344 HCAPLUS
- (4) Broide, D; J Immunol 1998, V161, P7054 HCAPLUS
- (5) Hagiwara, E; Cytokine 1995, V7, P815 HCAPLUS
- (6) Hartmann, G; J Immunol 2000, V164, P1617 HCAPLUS
- (7) Hartmann, G; J Immunol 2000, V164, P944 HCAPLUS
- (8) Hartmann, G; Proc Natl Acad Sci USA 2000, V96, P9305
- (9) Iho, S; J Immunol 1999, V163, P3642 HCAPLUS
- (10) Kanellos, T; Immunology 1999, V96, P507 HCAPLUS
- (11) Kline, J; J Immunol 1998, V160, P2555 HCAPLUS
- (12) Klinman, D; Proc Natl Acad Sci USA 1996, V93, P2879 HCAPLUS
- (13) Klinman, D; Vaccine 1999, V17, P19 HCAPLUS
- (14) Krieg, A; Nature 1995, V374, P546 HCAPLUS
- (15) Liang, H; J Clin Invest 1996, V98, P1119 HCAPLUS
- (16) Lipford, G; Eur J Immunol 1997, V27, P2340 HCAPLUS
- (17) Medzhitov, R; Curr Opin Immunol 1997, V9, P4 HCAPLUS
- (18) Moss, R; Vaccine 2000, V18, P1081 MEDLINE
- (19) Pisetsky, D; Immunol Res 1999, V19, P35 HCAPLUS
- (20) Roman, M; Nat Med 1997, V3, P849 HCAPLUS
- (21) Sato, Y; Science 1996, V273, P352 HCAPLUS
- (22) Sparwasser, T; Eur J Immunol 1997, V27, P1671 HCAPLUS
- (23) Sparwasser, T; Eur J Immunol 1998, V28, P2045 HCAPLUS
- (24) Stacey, K; J Immunol 1996, V157, P2116 HCAPLUS
- (25) Tighe, H; Eur J Immunol 2000, V30, P1939 HCAPLUS
- (26) Verthelyi, D; Endocrinology 1994, V135, P2615 HCAPLUS
- (27) Yamamoto, S; J Immunol 1992, V148, P4072 HCAPLUS
- (28) Yamamoto, T; Jpn J Cancer Res 1994, V85, P775 HCAPLUS

IT 334074-91-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(two distinct CpG motifs in stimulation of human peripheral blood cells)

RN 334074-91-8 HCAPLUS

CN DNA, d(G-sp-G-sp-T-G-C-A-T-C-G-A-T-G-C-A-G-G-sp-G-sp-G-sp-G) (9CI)
(CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 20 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:31630 HCAPLUS

DN 134:96243

ED Entered STN: 12 Jan 2001

TI DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression

IN Bell, Adam C.; West, Adam G.; Felsenfeld, Gary

PA United States Dept. of Health and Human Services, USA

SO PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DT Patent
LA English
IC ICM C12N015-00
CC 3-2 (Biochemical Genetics)
Section cross-reference(s): 12, 13

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002553	A2	20010111	WO 2000-US10509	20000419
	WO 2001002553	A3	20010503		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2377929	AA	20010111	CA 2000-2377929	20000419
	AU 2000046475	A5	20010122	AU 2000-46475	20000419
	AU 776752	B2	20040923		
	EP 1196612	A2	20020417	EP 2000-928209	20000419
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	JP 2003504016	T2	20030204	JP 2001-508326	20000419
PRAI	US 1999-141728P	P	19990630		
	WO 2000-US10509	W	20000419		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 2001002553	ICM	C12N015-00
AB	An insulator element shown to be both necessary and sufficient for the enhancer-blocking activity in human cells is described. The insulator element of the invention is a 42-bp DNA mol. having specific enhancer blocking activity for regulation of gene expression and found in the chicken .beta.-globin gene cluster. The insulator element has also been shown to be the core binding site for CTCF, a DNA binding protein that is highly conserved in vertebrates. In addition, an insulator element containing CTCF binding sites has been identified in the region of the mouse, rat, and human insulin-like growth factor 2 Igf2 locus which is methylated exclusively on the paternal allele. Methylation of the insulator sequence abolishes the ability of CTCF to bind to the insulator and results in loss of enhancer-blocking activity.		
ST	enhancer blocking insulator element gene expression; CTCF DNA binding protein insulator element; globin gene insulator element enhancer blocking; Igf2 gene insulator element enhancer blocking		
IT	Antibiotic resistance Drugs Molecular cloning (DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)		
IT	Enzymes, preparation Hormones, animal, preparation Proteins, general, preparation RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation) (DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)		
IT	Enhancer (genetic element) RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)		
IT	Proteins, specific or class RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses) (DNA-binding, CTCF; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)		
IT	Transcription factors RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses) (GAL4; DNA-binding protein CTCF and insulators sequences having		

- specific enhancer-blocking activity for regulation of gene expression)
- IT Genetic element
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (ICR (imprinted control region); DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
- IT Methylation
 (biol., insulator element inhibition by; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
- IT Gene
 (expression; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
- IT Transcription factors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
 (gene lexA; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
- IT Mouse
 Rat
 (insulator element from Igf2 locus of; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
- IT Hemoglobins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (insulator element from .beta.-globin locus for; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
- IT Chicken (Gallus domesticus)
 (insulator element from .beta.-globin locus of; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
- IT Genetic element
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (insulator element; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
- IT 9037-42-7, DNA methyltransferase
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (3; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
- IT 319023-08-0
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (insulator element consensus from Igf2-H19 locus; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
- IT 319022-93-0 319023-09-1
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (insulator element from chicken .beta.-globin locus; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
- IT 67763-97-7, Insulin-like growth factor 2
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (insulator element from gene for; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
- IT 319023-02-4 319023-03-5 319023-04-6 319023-05-7 319023-06-8 319023-07-9
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (insulator element from human Igf2-H19 locus; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
- IT 319022-94-1 319022-95-2 319022-96-3 319022-97-4
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (insulator element from mouse Igf2-H19 locus; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
 IT 319022-98-5 319022-99-6 319023-00-2 319023-01-3
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (insulator element from rat Igf2-H19 locus; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
 IT 1404-04-2, Neomycin 6379-56-2, Hygromycin
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (resistance to; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
 IT 318409-01-7 318409-02-8 318409-03-9 318409-04-0 318409-07-3
 318409-08-4 318409-09-5 318409-10-8 318409-11-9 318409-12-0
 318409-29-9 318409-30-2 318409-31-3 318409-32-4 318409-34-6
 318409-35-7 319025-05-3, 2: PN: WO0102553 SEQID: 2 unclaimed DNA
 319025-06-4, 3: PN: WO0102553 SEQID: 3 unclaimed DNA 319025-07-5, 4: PN: WO0102553 SEQID: 5 unclaimed DNA 319025-08-6, 5: PN: WO0102553 SEQID: 6 unclaimed DNA 319025-09-7, 6: PN: WO0102553 SEQID: 7 unclaimed DNA
 319025-10-0, 7: PN: WO0102553 SEQID: 8 unclaimed DNA 319025-11-1, 8: PN: WO0102553 SEQID: 9 unclaimed DNA 319025-12-2, 9: PN: WO0102553 SEQID: 10 unclaimed DNA
 319025-13-3 319025-14-4 319025-15-5 319025-16-6
 319025-17-7 319025-18-8 319025-19-9 319025-20-2 319025-21-3
 319025-22-4 319025-23-5 319025-24-6 319025-25-7 319025-26-8
 319025-27-9 319025-28-0 319025-29-1 319025-30-4 319025-31-5
 319025-32-6 319025-33-7 319025-34-8 319025-35-9
 319025-36-0 319025-37-1 319025-38-2 319025-39-3 319025-40-6
 319025-41-7 319025-42-8 319025-43-9 319025-44-0 319025-45-1
 319025-46-2 319025-47-3 319025-48-4 319025-49-5 319025-50-8
 319025-51-9 319025-52-0 319025-53-1 319025-54-2 319025-55-3
 319025-56-4 319025-57-5 319025-58-6 319025-59-7 319025-60-0
 319025-61-1 319025-62-2 319025-63-3 319025-64-4
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
 IT 318968-16-0 318968-17-1
 RL: PRP (Properties)
 (unclaimed sequence; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
 IT 319025-35-9
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; DNA-binding protein CTCF and insulators sequences having specific enhancer-blocking activity for regulation of gene expression)
 RN 319025-35-9 HCAPLUS
 CN 35: PN: WO0102553 SEQID: 36 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L21 ANSWER 21 OF 21 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:741930 HCAPLUS
 DN 133:320986
 ED Entered STN: 20 Oct 2000
 TI Oligodeoxynucleotide and its use to induce an immune response
 IN Klinman, Dennis; Ishii, Ken; Verthelyi, Daniela
 PA United States Dept. of Health and Human Services, USA
 SO PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-70
 ICS A61K039-39; C07H021-00
 CC 15-2 (Immunochemistry)
 Section cross-reference(s): 3, 63
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

Search done by Noble Jarrell

PI WO 2000061151 A2 20001019 WO 2000-US9839 20000412
 WO 2000061151 A3 20010426
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
 CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
 ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
 SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
 ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1176966 A2 20020206 EP 2000-923283 20000412
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 PRAI US 1999-128898P P 19990412
 WO 2000-US9839 W 20000412

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

WO 2000061151 ICM A61K031-70
 ICS A61K039-39; C07H021-00

AB The present invention provides a substantially pure or isolated oligodeoxynucleotide of at least about 10 nucleotides comprising a sequence represented by either the formula: 5' N1N2N3T-CpG-WN4N5N6 3' wherein the central CpG motif is unmethylated, W is A or T, and N1, N2, N3, N4, N5, and N6 are any nucleotides, or the formula: 5' RY-CpG-RY 3' wherein the central CpG motif is unmethylated, R is A or G, and Y is C or T, as well as an oligodeoxynucleotide delivery complex and a pharmacol. composition comprising the present inventive oligodeoxynucleotide, and a method of inducing an immune response by administering the present inventive oligodeoxynucleotide to a host. The oligodeoxynucleotides with phosphate or phosphorothioate backbone modification are useful for inducing cell-mediated and humoral immune response and are therefore useful for treatment of allergy, asthma, cancer, autoimmune disease, immunol. disease, infection, and immune deficiency.

ST oligodeoxynucleotide adjuvant vaccine allergy cancer infection; autoimmune disease asthma oligodeoxynucleotide adjuvant vaccine

IT Cell activation
 (B cell; oligodeoxynucleotide for use to induce immune response)

IT B cell (lymphocyte)
 Lymphocyte
 (activation; oligodeoxynucleotide for use to induce immune response)

IT Infection
 (anti-; oligodeoxynucleotide for use to induce immune response)

IT Chemical warfare agents
 (bio-; oligodeoxynucleotide for use to induce immune response)

IT Diagnosis
 (cancer; oligodeoxynucleotide for use to induce immune response)

IT Drug delivery systems
 (carriers; oligodeoxynucleotide for use to induce immune response)

IT Immunity
 (cell-mediated; oligodeoxynucleotide for use to induce immune response)

IT Neoplasm
 (diagnosis; oligodeoxynucleotide for use to induce immune response)

IT Immunity
 (disorder; oligodeoxynucleotide for use to induce immune response)

IT Immunity
 (humoral; oligodeoxynucleotide for use to induce immune response)

IT Drug delivery systems
 (liposomes; oligodeoxynucleotide for use to induce immune response)

IT Cell activation
 (lymphocyte; oligodeoxynucleotide for use to induce immune response)

IT Animal cell
 (non-B; oligodeoxynucleotide for use to induce immune response)

IT Allergy
 Allergy inhibitors
 Antitumor agents
 Asthma
 Autoimmune disease
 B cell (lymphocyte)
 Drug targeting
 Immunodeficiency
 Immunostimulants
 Neoplasm
 Vaccines

(oligodeoxynucleotide for use to induce immune response)

IT Antibodies
Cytokines
Interleukin 6
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); USES (Uses)
(oligodeoxynucleotide for use to induce immune response)

IT Lipids, biological studies
Oligodeoxyribonucleotides
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligodeoxynucleotide for use to induce immune response)

IT Neoplasm
(solid; oligodeoxynucleotide for use to induce immune response)

IT Antisense oligonucleotides
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); USES (Uses)
(therapy; oligodeoxynucleotide for use to induce immune response)

IT Liposomes
(virosomes; oligodeoxynucleotide for use to induce immune response)

IT Interferons
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); USES (Uses)
(gamma.; oligodeoxynucleotide for use to induce immune response)

IT 199810-73-6D, phosphate or phosphorothioate derivs. 250141-69-6D, phosphate or phosphorothioate derivs. 301939-29-7D, phosphate or phosphorothioate derivs. 301939-30-0D, phosphate or phosphorothioate derivs. 301939-31-1D, phosphate or phosphorothioate derivs. 301939-32-2D, phosphate or phosphorothioate derivs. 301939-33-3D, phosphate or phosphorothioate derivs. 301939-34-4D, phosphate or phosphorothioate derivs. 301939-35-5D, phosphate or phosphorothioate derivs. 301939-36-6D, phosphate or phosphorothioate derivs. 301939-37-7D, phosphate or phosphorothioate derivs. 301939-38-8D, phosphate or phosphorothioate derivs. 301939-39-9D, phosphate or phosphorothioate derivs. 301939-40-2D, phosphate or phosphorothioate derivs. 301939-41-3D, phosphate or phosphorothioate derivs. 301939-42-4D, phosphate or phosphorothioate derivs. 301939-43-5D, phosphate or phosphorothioate derivs. 301939-44-6D, phosphate or phosphorothioate derivs. 301939-45-7D, phosphate or phosphorothioate derivs. 301939-46-8D, phosphate or phosphorothioate derivs. 301939-47-9D, phosphate or phosphorothioate derivs. 301939-48-0D, phosphate or phosphorothioate derivs. 301939-49-1D, phosphate or phosphorothioate derivs. 301939-50-4D, phosphate or phosphorothioate derivs. 301939-51-5D, phosphate or phosphorothioate derivs. 301939-52-6D, phosphate or phosphorothioate derivs. 301939-53-7D, phosphate or phosphorothioate derivs. 301939-54-8D, phosphate or phosphorothioate derivs. 301939-55-9D, phosphate or phosphorothioate derivs. 301939-56-0D, phosphate or phosphorothioate derivs. 301939-57-1D, phosphate or phosphorothioate derivs. 301939-58-2D, phosphate or phosphorothioate derivs. 301939-59-3D, phosphate or phosphorothioate derivs. 301939-60-6D, phosphate or phosphorothioate derivs. 301939-61-7D, phosphate or phosphorothioate derivs. 301939-62-8D, phosphate or phosphorothioate derivs. 301939-63-9D, phosphate or phosphorothioate derivs. 301939-64-0D, phosphate or phosphorothioate derivs. 301939-65-1D, phosphate or phosphorothioate derivs. 301939-66-2D, phosphate or phosphorothioate derivs. 301939-67-3D, phosphate or phosphorothioate derivs. 301939-68-4D, phosphate or phosphorothioate derivs. 301939-69-5D, phosphate or phosphorothioate derivs. 301939-70-8D, phosphate or phosphorothioate derivs. 301939-71-9D, phosphate or phosphorothioate derivs. 301939-72-0D, phosphate or phosphorothioate derivs. 301939-73-1D, phosphate or phosphorothioate derivs. 301939-74-2D, phosphate or phosphorothioate derivs. 301939-75-3D, phosphate or phosphorothioate derivs. 301939-76-4D, phosphate or phosphorothioate derivs. 301939-77-5D, phosphate or phosphorothioate derivs. 301939-78-6D, phosphate or phosphorothioate derivs. 301939-79-7D, phosphate or phosphorothioate derivs. 301939-80-0D, phosphate or phosphorothioate derivs. 301939-81-1D, phosphate or phosphorothioate derivs. 301939-82-2D, phosphate or phosphorothioate derivs. 301939-83-3D, phosphate or phosphorothioate derivs. 301939-84-4D, phosphate or phosphorothioate derivs. 301939-85-5D, phosphate or phosphorothioate derivs. 301939-86-6D, phosphate or phosphorothioate derivs. 301939-87-7D,

phosphate or phosphorothioate derivs. 301939-88-8D, phosphate or phosphorothioate derivs. 301939-89-9D, phosphate or phosphorothioate derivs. 301939-90-2D, phosphate or phosphorothioate derivs. 301939-91-3D, phosphate or phosphorothioate derivs. 301939-92-4D, phosphate or phosphorothioate derivs. 301939-93-5D, phosphate or phosphorothioate derivs. 301939-94-6D, phosphate or phosphorothioate derivs. 301939-95-7D, phosphate or phosphorothioate derivs. 301939-96-8D, phosphate or phosphorothioate derivs. 301939-97-9D, phosphate or phosphorothioate derivs. 301939-98-0D, phosphate or phosphorothioate derivs. 301939-99-1D, phosphate or phosphorothioate derivs. 301940-00-1D, phosphate or phosphorothioate derivs. 301940-01-2D, phosphate or phosphorothioate derivs. 301940-02-3D, phosphate or phosphorothioate derivs. 301940-03-4D, phosphate or phosphorothioate derivs. 301940-04-5D, phosphate or phosphorothioate derivs. 301940-05-6D, phosphate or phosphorothioate derivs. 301940-06-7D, phosphate or phosphorothioate derivs. 301940-07-8D, phosphate or phosphorothioate derivs. 301940-08-9D, phosphate or phosphorothioate derivs. 301940-09-0D, phosphate or phosphorothioate derivs. 301940-10-3D, phosphate or phosphorothioate derivs. 301940-11-4D, phosphate or phosphorothioate derivs. 301940-12-5D, phosphate or phosphorothioate derivs. 301940-13-6D, phosphate or phosphorothioate derivs. 301940-14-7D, phosphate or phosphorothioate derivs. 301940-15-8D, phosphate or phosphorothioate derivs. 301940-16-9D, phosphate or phosphorothioate derivs. 302865-50-5D, phosphate or phosphorothioate derivs. 302865-51-6D, phosphate or phosphorothioate derivs. 302865-52-7D, phosphate or phosphorothioate derivs. 302865-53-8D, phosphate or phosphorothioate derivs. 302865-54-9D, phosphate or phosphorothioate derivs. 302865-55-0D, phosphate or phosphorothioate derivs. 302865-56-1D, phosphate or phosphorothioate derivs. 302865-57-2D, phosphate or phosphorothioate derivs. 302865-58-3D, phosphate or phosphorothioate derivs. 302865-59-4D, phosphate or phosphorothioate derivs. 302865-60-7D, phosphate or phosphorothioate derivs. 302865-61-8D, phosphate or phosphorothioate derivs. 302865-62-9D, phosphate or phosphorothioate derivs. 302865-63-0D, phosphate or phosphorothioate derivs. 302865-64-1D, phosphate or phosphorothioate derivs. 302865-65-2D, phosphate or phosphorothioate derivs. 302865-66-3D, phosphate or phosphorothioate derivs. 302865-67-4D, phosphate or phosphorothioate derivs. 302865-68-5D, phosphate or phosphorothioate derivs. 302865-69-6D, phosphate or phosphorothioate derivs. 302865-70-9D, phosphate or phosphorothioate derivs. 302865-71-0D, phosphate or phosphorothioate derivs. 302865-72-1D, phosphate or phosphorothioate derivs. 302865-73-2D, phosphate or phosphorothioate derivs. 302865-74-3D, phosphate or phosphorothioate derivs. 302865-75-4D, phosphate or phosphorothioate derivs. 302865-76-5D, phosphate or phosphorothioate derivs. 302865-77-6D, phosphate or phosphorothioate derivs. 302865-78-7D, phosphate or phosphorothioate derivs. 302865-79-8D, phosphate or phosphorothioate derivs. 302865-80-1D, phosphate or phosphorothioate derivs. 302865-81-2D, phosphate or phosphorothioate derivs. 302865-82-3D, phosphate or phosphorothioate derivs. 302865-83-4D, phosphate or phosphorothioate derivs. 302865-84-5D, phosphate or phosphorothioate derivs. 302865-85-6D, phosphate or phosphorothioate derivs. 302865-86-7D, phosphate or phosphorothioate derivs. 302865-87-8D, phosphate or phosphorothioate derivs. 302865-88-9D, phosphate or phosphorothioate derivs. 302865-89-0D, phosphate or phosphorothioate derivs. 302865-90-3D, phosphate or phosphorothioate derivs. 302865-91-4D, phosphate or phosphorothioate derivs.

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligodeoxynucleotide for use to induce immune response)

IT 57-88-5, Cholesterol, biological studies

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligodeoxynucleotide for use to induce immune response)

IT 301939-49-1D, phosphate or phosphorothioate derivs.

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligodeoxynucleotide for use to induce immune response)

RN 301939-49-1 HCAPLUS

CN DNA, d(G-G-T-G-C-A-C-C-G-A-T-G-C-A-G-G-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*** 427 ***

L27 ANSWER 1 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:1022690 HCAPLUS
 ED Entered STN: 29 Nov 2004
 TI Oligonucleotide probes in nucleic acid arrays for genetic analysis of mouse
 IN Mittman, Michael; Mack, David J.; Lockhart, David J.
 PA Affymetrix, Inc., USA
 SO U.S., 183 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 IC C12Q001-68; C07H021-02; C07H021-04; G01N015-06; G01N033-00
 NCL 435006000; 422068100; 536023100; 536024300; 536024310
 CC 3-1 (Biochemical Genetics)
 Section cross-reference(s): 13

FAN.CNT 26

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6821724	B1	20041123	US 1999-396196	19990915 <--
	US 6821724	B1	20041123	US 1999-396196	19990915 <--
PRAI	US 1998-100678P	P	19980917	<--	
	US 1999-396196	A	19990915	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6821724	IC	C12Q001-68IC C07H021-02IC C07H021-04IC G01N015-06IC G01N033-00
	NCL	435006000; 422068100; 536023100; 536024300; 536024310

AB This invention provides 127,806 unique oligonucleotide sequences which are complementary to .apprx.6500 specific known murine genes. The invention provides the sequences in such a way as to make them available for gene expression monitoring by hybridization to high d. oligonucleotide arrays, or for use as primers for PCR and other amplification protocols. As such, the invention related to diverse fields impacted by the nature of mol. interaction, including chemical, biol., medicine, and medical diagnostics. [This abstract record is one of 26 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

ST oligonucleotide probe microarray genetic analysis mouse; gene expression mouse oligonucleotide probe hybridization

IT DNA microarray technology
 DNA sequences
 Gene expression profiles, animal
 Genetic methods
 Mus musculus
 Nucleic acid amplification (method)
 Nucleic acid hybridization
 PCR (polymerase chain reaction)
 (oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT Primers (nucleic acid)
 Probes (nucleic acid)
 RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
 (oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795660-73-0	795660-76-3	795660-77-4	795660-78-5	795660-79-6
	795660-80-9	795660-81-0	795660-84-3	795660-85-4	795660-86-5
	795660-87-6	795660-88-7	795660-89-8	795660-91-2	795660-93-4
	795660-94-5	795660-95-6	795660-96-7	795660-97-8	795660-98-9
	795661-01-7	795661-02-8	795661-03-9	795661-04-0	795661-05-1
	795661-06-2	795661-07-3	795661-10-8	795661-11-9	795661-12-0
	795661-13-1	795661-14-2	795661-15-3	795661-18-6	795661-19-7
	795661-20-0	795661-21-1	795661-22-2	795661-23-3	795661-24-4
	795661-27-7	795661-28-8	795661-29-9	795661-30-2	795661-31-3
	795661-33-5	795661-34-6	795661-35-7	795661-37-9	795661-38-0
	795661-39-1	795661-40-4	795661-41-5	795661-42-6	795661-44-8
	795661-45-9	795661-46-0	795661-47-1	795661-48-2	795661-49-3
	795661-50-6	795661-52-8	795661-53-9	795661-54-0	795661-56-2
	795661-58-4	795661-59-5	795661-60-8	795661-61-9	795661-62-0
	795661-65-3	795661-66-4	795661-67-5	795661-69-7	795661-70-0
	795661-72-2	795661-73-3	795661-76-6	795661-77-7	795661-78-8
	795661-80-2	795661-81-3	795661-82-4	795661-83-5	795661-84-6
	795661-86-8	795661-87-9	795661-88-0	795661-89-1	795661-90-4

795661-97-1	795661-98-2	795661-99-3	795662-00-9	795662-02-1
795662-03-2	795662-04-3	795662-06-5	795662-07-6	795662-08-7
795662-10-1	795662-11-2	795662-12-3	795662-14-5	795662-38-3
795662-39-4	795662-40-7	795662-42-9	795662-43-0	795662-44-1
795662-46-3	795662-47-4	795662-48-5	795662-50-9	795662-51-0
795662-52-1	795662-54-3	795662-55-4	795662-56-5	795662-58-7
795662-59-8	795662-60-1	795662-62-3	795662-63-4	795662-64-5
795662-65-6	795662-67-8	795662-68-9	795662-69-0	795662-71-4
795662-72-5	795662-73-6	795662-75-8	795662-76-9	795662-77-0
795662-79-2	795662-80-5	795662-82-7	795662-83-8	795662-84-9
795662-86-1	795662-87-2	795662-88-3	795662-90-7	795662-91-8
795662-92-9	795662-94-1	795662-95-2	795662-96-3	795662-98-5
795663-00-2	795663-04-6	795663-07-9	795663-11-5	795663-13-7
795663-14-8	795663-15-9	795663-17-1	795663-18-2	795663-19-3
795663-20-6	795663-22-8	795663-23-9	795663-24-0	795663-26-2
795663-27-3	795663-28-4	795663-29-5	795663-31-9	795663-32-0
795663-34-2	795663-35-3	795663-36-4	795663-37-5	795663-38-6
795663-39-7	795663-41-1	795663-43-3	795663-44-4	795663-45-5
795663-46-6	795663-47-7	795663-49-9	795663-51-3	795663-52-4
795663-53-5	795663-55-7	795663-57-9	795663-58-0	795663-59-1
795663-60-4	795663-61-5	795663-62-6	795663-64-8	795663-66-0
795663-67-1	795663-68-2	795663-69-3	795663-70-6	795663-72-8
795663-73-9	795663-75-1	795663-76-2	795663-77-3	795663-78-4
795663-79-5	795663-81-9	795663-83-1	795663-84-2	795663-85-3
795663-86-4	795663-87-5	795663-88-6	795663-91-1	795663-92-2
795663-93-3	795663-94-4	795663-95-5	795663-96-6	795663-97-7
795664-00-5	795664-01-6	795664-02-7	795664-03-8	795664-04-9
795664-05-0	795664-08-3	795664-09-4	795664-10-7	795664-11-8
795664-12-9	795664-13-0	795664-15-2	795664-17-4	795664-18-5
795664-19-6	795664-20-9			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795664-21-0	795664-22-1	795664-25-4	795664-26-5	795664-27-6
	795664-28-7	795664-29-8	795664-30-1	795664-33-4	795664-34-5
	795664-35-6	795664-36-7	795664-37-8	795664-38-9	795664-41-4
	795664-42-5	795664-43-6	795664-44-7	795664-45-8	795664-46-9
	795664-47-0	795664-49-2	795664-50-5	795664-52-7	795664-53-8
	795664-54-9	795664-56-1	795664-57-2	795664-58-3	795664-59-4
	795664-60-7	795664-61-8	795664-63-0	795664-64-1	795664-65-2
	795664-66-3	795664-67-4	795664-68-5	795664-70-9	795664-71-0
	795664-72-1	795664-73-2	795664-74-3	795664-75-4	795664-77-6
	795664-79-8	795664-80-1	795664-81-2	795664-82-3	795664-83-4
	795664-85-6	795664-87-8	795664-88-9	795664-89-0	795664-90-3
	795664-91-4	795664-92-5	795664-95-8	795664-96-9	795664-97-0
	795664-98-1	795664-99-2	795665-00-8	795665-02-0	795665-04-2
	795665-05-3	795665-06-4	795665-07-5	795665-08-6	795665-10-0
	795665-12-2	795665-13-3	795665-14-4	795665-15-5	795665-16-6
	795665-18-8	795665-20-2	795665-21-3	795665-22-4	795665-23-5
	795665-24-6	795665-26-8	795665-28-0	795665-29-1	795665-30-4
	795665-31-5	795665-32-6	795665-34-8	795665-36-0	795665-37-1
	795665-38-2	795665-39-3	795665-40-6	795665-42-8	795665-44-0
	795665-45-1	795665-46-2	795665-47-3	795665-48-4	795665-50-8
	795665-51-9	795665-53-1	795665-54-2	795665-55-3	795665-56-4
	795665-58-6	795665-59-7	795665-61-1	795665-62-2	795665-63-3
	795665-64-4	795665-65-5	795665-67-7	795665-69-9	795665-70-2
	795665-71-3	795665-72-4	795665-74-6	795665-75-7	795665-77-9
	795665-78-0	795665-79-1	795665-80-4	795665-82-6	795665-83-7
	795665-85-9	795665-86-0	795665-87-1	795665-88-2	795665-90-6
	795665-91-7	795665-93-9	795665-94-0	795665-95-1	795665-96-2
	795665-98-4	795665-99-5	795666-01-2	795666-02-3	795666-03-4
	795666-04-5	795666-06-7	795666-07-8	795666-08-9	795666-10-3
	795666-11-4	795666-12-5	795666-14-7	795666-15-8	795666-16-9
	795666-18-1	795666-19-2	795666-20-5	795666-22-7	795666-23-8
	795666-24-9	795666-26-1	795666-27-2	795666-28-3	795666-29-4
	795666-31-8	795666-32-9	795666-34-1	795666-35-2	795666-36-3
	795666-38-5	795666-39-6	795666-41-0	795666-42-1	795666-43-2
	795666-44-3	795666-46-5	795666-47-6	795666-49-8	795666-50-1
	795666-51-2	795666-52-3	795666-54-5	795666-55-6	795666-57-8
	795666-58-9	795666-59-0	795666-60-3	795666-62-5	795666-63-6
	795666-65-8	795666-66-9	795666-67-0	795666-68-1	795666-70-5
	795666-71-6	795666-73-8	795666-74-9	795666-76-1	795666-77-2
	795666-78-3	795666-80-7	795666-81-8	795666-83-0	795666-84-1
	795666-85-2	795666-87-4	795666-88-5	795666-89-6	795666-91-0
	795666-92-1	795666-93-2	795666-94-3	795666-96-5	795666-97-6

795666-99-8	795667-00-4	795667-01-5	795667-02-6	795667-03-7
795667-04-8	795667-06-0	795667-07-1	795667-09-3	795667-10-6
795667-11-7	795667-12-8	795667-13-9	795667-14-0	795667-16-2
795667-18-4	795667-19-5	795667-20-8	795667-21-9	795667-22-0
795667-24-2	795667-26-4	795667-27-5	795667-28-6	795667-29-7
795667-30-0	795667-32-2			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795667-33-3	795667-34-4	795667-35-5	795667-36-6	795667-37-7
	795667-40-2	795667-41-3	795667-42-4	795667-43-5	795667-44-6
	795667-45-7	795667-48-0	795667-49-1	795667-50-4	795667-51-5
	795667-52-6	795667-54-8	795667-56-0	795667-57-1	795667-58-2
	795667-59-3	795667-60-6	795667-62-8	795667-64-0	795667-65-1
	795667-66-2	795667-67-3	795667-68-4	795667-70-8	795667-72-0
	795667-73-1	795667-74-2	795667-75-3	795667-76-4	795667-79-7
	795667-80-0	795667-81-1	795667-82-2	795667-84-4	795667-86-6
	795667-87-7	795667-88-8	795667-89-9	795667-90-2	795667-92-4
	795667-94-6	795667-95-7	795667-96-8	795667-97-9	795667-99-1
	795668-01-8	795668-02-9	795668-03-0	795668-04-1	795668-05-2
	795668-08-5	795668-09-6	795668-10-9	795668-11-0	795668-13-2
	795668-14-3	795668-16-5	795668-17-6	795668-18-7	795668-20-1
	795668-22-3	795668-23-4	795668-24-5	795668-25-6	795668-27-8
	795668-29-0	795668-30-3	795668-31-4	795668-32-5	795668-34-7
	795668-36-9	795668-37-0	795668-38-1	795668-39-2	795668-41-6
	795668-42-7	795668-44-9	795668-45-0	795668-46-1	795668-47-2
	795668-49-4	795668-50-7	795668-52-9	795668-53-0	795668-54-1
	795668-55-2	795668-57-4	795668-59-6	795668-60-9	795668-61-0
	795668-62-1	795668-64-3	795668-65-4	795668-67-6	795668-68-7
	795668-69-8	795668-70-1	795668-72-3	795668-73-4	795668-75-6
	795668-76-7	795668-77-8	795668-79-0	795668-80-3	795668-82-5
	795668-83-6	795668-84-7	795668-85-8	795668-87-0	795668-89-2
	795668-90-5	795668-91-6	795668-92-7	795668-94-9	795668-95-0
	795668-97-2	795668-98-3	795668-99-4	795669-00-0	795669-02-2
	795669-03-3	795669-05-5	795669-06-6	795669-07-7	795669-09-9
	795669-10-2	795669-12-4	795669-13-5	795669-14-6	795669-15-7
	795669-17-9	795669-18-0	795669-20-4	795669-21-5	795669-22-6
	795669-23-7	795669-25-9	795669-27-1	795669-28-2	795669-29-3
	795669-30-6	795669-32-8	795669-34-0	795669-35-1	795669-36-2
	795669-37-3	795669-39-5	795669-40-8	795669-42-0	795669-43-1
	795669-44-2	795669-46-4	795669-47-5	795669-49-7	795669-50-0
	795669-51-1	795669-53-3	795669-54-4	795669-55-5	795669-57-7
	795669-58-8	795669-60-2	795669-61-3	795669-62-4	795669-64-6
	795669-65-7	795669-66-8	795669-68-0	795669-69-1	795669-70-4
	795669-72-6	795669-73-7	795669-74-8	795669-75-9	795669-77-1
	795669-79-3	795669-80-6	795669-81-7	795669-82-8	795669-84-0
	795669-86-2	795669-87-3	795669-88-4	795669-89-5	795669-90-8
	795669-92-0	795669-93-1	795669-94-2	795669-95-3	795669-96-4
	795669-98-6	795670-00-7	795670-01-8	795670-02-9	795670-03-0
	795670-04-1	795670-07-4	795670-08-5	795670-09-6	795670-10-9
	795670-11-0	795670-14-3	795670-15-4	795670-16-5	795670-17-6
	795670-18-7	795670-20-1	795670-22-3	795670-23-4	795670-24-5
	795670-25-6	795670-26-7	795670-29-0	795670-30-3	795670-31-4
	795670-32-5	795670-33-6	795670-36-9	795670-37-0	795670-38-1
	795670-39-2	795670-40-5	795670-43-8	795670-44-9	795670-45-0
	795670-46-1	795670-47-2	795670-49-4	795670-51-8	795670-52-9
	795670-53-0	795670-54-1			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795670-55-2	795670-58-5	795670-59-6	795670-60-9	795670-61-0
	795670-62-1	795670-64-3	795670-66-5	795670-67-6	795670-68-7
	795670-69-8	795670-70-1	795670-73-4	795670-74-5	795670-75-6
	795670-76-7	795670-77-8	795670-80-3	795670-81-4	795670-82-5
	795670-83-6	795670-84-7	795670-87-0	795670-88-1	795670-89-2
	795670-90-5	795670-91-6	795670-94-9	795670-95-0	795670-96-1
	795670-97-2	795670-98-3	795671-00-0	795671-02-2	795671-03-3
	795671-04-4	795671-05-5	795671-07-7	795671-09-9	795671-10-2
	795671-11-3	795671-12-4	795671-14-6	795671-15-7	795671-17-9
	795671-18-0	795671-19-1	795671-21-5	795671-22-6	795671-23-7
	795671-25-9	795671-26-0	795671-27-1	795671-29-3	795671-30-6
	795671-32-8	795671-34-0	795671-35-1	795671-36-2	795671-38-4
	795671-39-5	795671-41-9	795671-42-0	795671-43-1	795671-45-3
	795671-46-4	795671-47-5	795671-49-7	795671-50-0	795671-52-2

795671-53-3	795671-54-4	795671-56-6	795671-57-7	795671-59-9
795671-60-2	795671-61-3	795671-63-5	795671-64-6	795671-65-7
795671-67-9	795671-68-0	795671-70-4	795671-71-5	795671-72-6
795671-74-8	795671-75-9	795671-77-1	795671-78-2	795671-79-3
795671-81-7	795671-82-8	795671-83-9	795671-85-1	795671-86-2
795671-87-3	795671-89-5	795671-90-8	795671-92-0	795671-93-1
795671-94-2	795671-96-4	795671-97-5	795671-99-7	795672-00-3
795672-01-4	795672-03-6	795672-04-7	795672-06-9	795672-07-0
795672-08-1	795672-10-5	795672-11-6	795672-13-8	795672-14-9
795672-15-0	795672-17-2	795672-18-3	795672-20-7	795672-21-8
795672-22-9	795672-23-0	795672-24-1	795672-27-4	795672-28-5
795672-29-6	795672-30-9	795672-32-1	795672-34-3	795672-35-4
795672-36-5	795672-37-6	795672-38-7	795672-41-2	795672-42-3
795672-43-4	795672-44-5	795672-45-6	795672-48-9	795672-49-0
795672-50-3	795672-51-4	795672-52-5	795672-54-7	795672-55-8
795672-57-0	795672-58-1	795672-59-2	795672-61-6	795672-62-7
795672-63-8	795672-64-9	795672-65-0	795672-66-1	795672-67-2
795672-70-7	795672-71-8	795672-72-9	795672-73-0	795672-74-1
795672-77-4	795672-80-9	795672-83-2	795672-84-3	795672-86-5
795672-87-6	795672-89-8	795672-90-1	795672-91-2	795672-93-4
795672-94-5	795672-96-7	795672-97-8	795672-98-9	795673-00-6
795673-02-8	795673-03-9	795673-04-0	795673-05-1	795673-07-3
795673-09-5	795673-10-8	795673-11-9	795673-12-0	795673-14-2
795673-16-4	795673-17-5	795673-18-6	795673-19-7	795673-21-1
795673-22-2	795673-24-4	795673-25-5	795673-27-7	795673-28-8
795673-29-9	795673-31-3	795673-32-4	795673-34-6	795673-35-7
795673-36-8	795673-38-0	795673-39-1	795673-41-5	795673-42-6
795673-43-7	795673-44-8	795673-46-0	795673-48-2	795673-49-3
795673-50-6	795673-52-8	795673-53-9	795673-55-1	795673-56-2
795673-57-3	795673-58-4	795673-60-8	795673-62-0	795673-63-1
795673-64-2	795673-65-3	795673-67-5	795673-69-7	795673-70-0
795673-71-1	795673-73-3	795673-75-5	795673-76-6	795673-77-7
795673-78-8	795673-80-2	795673-82-4	795673-83-5	795673-84-6
795673-85-7	795673-87-9			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795673-89-1	795673-90-4	795673-91-5	795673-92-6	795673-94-8
	795673-96-0	795673-97-1	795673-98-2	795673-99-3	795674-01-0
	795674-03-2	795674-04-3	795674-05-4	795674-06-5	795674-09-8
	795674-10-1	795674-11-2	795674-12-3	795674-13-4	795674-16-7
	795674-17-8	795674-18-9	795674-19-0	795674-21-4	795674-23-6
	795674-24-7	795674-25-8	795674-26-9	795674-29-2	795674-30-5
	795674-31-6	795674-32-7	795674-35-0	795674-36-1	795674-37-2
	795674-38-3	795674-40-7	795674-42-9	795674-43-0	795674-44-1
	795674-45-2	795674-47-4	795674-49-6	795674-50-9	795674-51-0
	795674-53-2	795674-55-4	795674-56-5	795674-57-6	795674-59-8
	795674-61-2	795674-62-3	795674-63-4	795674-64-5	795674-66-7
	795674-67-8	795674-69-0	795674-70-3	795674-72-5	795674-73-6
	795674-74-7	795674-76-9	795674-77-0	795674-79-2	795674-80-5
	795674-82-7	795674-83-8	795674-85-0	795674-86-1	795674-87-2
	795674-88-3	795674-89-4	795674-91-8	795674-92-9	795674-93-0
	795674-94-1	795674-95-2	795674-97-4	795674-99-6	795675-00-2
	795675-01-3	795675-03-5	795675-04-6	795675-06-8	795675-07-9
	795675-08-0	795675-10-4	795675-11-5	795675-13-7	795675-14-8
	795675-15-9	795675-17-1	795675-18-2	795675-20-6	795675-21-7
	795675-23-9	795675-24-0	795675-26-2	795675-27-3	795675-28-4
	795675-30-8	795675-31-9	795675-33-1	795675-34-2	795675-36-4
	795675-37-5	795675-38-6	795675-40-0	795675-41-1	795675-43-3
	795675-44-4	795675-45-5	795675-47-7	795675-48-8	795675-50-2
	795675-51-3	795675-52-4	795675-54-6	795675-56-8	795675-57-9
	795675-58-0	795675-59-1	795675-60-4	795675-62-6	795675-63-7
	795675-64-8	795675-65-9	795675-66-0	795675-68-2	795675-70-6
	795675-71-7	795675-72-8	795675-74-0	795675-75-1	795675-77-3
	795675-78-4	795675-80-8	795675-81-9	795675-83-1	795675-84-2
	795675-86-4	795675-87-5	795675-89-7	795675-90-0	795675-91-1
	795675-93-3	795675-94-4	795675-96-6	795675-97-7	795675-99-9
	795676-00-5	795676-02-7	795676-03-8	795676-04-9	795676-06-1
	795676-07-2	795676-09-4	795676-10-7	795676-11-8	795676-12-9
	795676-13-0	795676-15-2	795676-16-3	795676-17-4	795676-18-5
	795676-20-9	795676-22-1	795676-23-2	795676-24-3	795676-25-4
	795676-28-7	795676-29-8	795676-30-1	795676-31-2	795676-33-4
	795676-35-6	795676-36-7	795676-37-8	795676-38-9	795676-41-4
	795676-42-5	795676-43-6	795676-44-7	795676-46-9	795676-48-1
	795676-49-2	795676-50-5	795676-51-6	795676-53-8	795676-55-0

795676-56-1	795676-57-2	795676-59-4	795676-61-8	795676-62-9
795676-63-0	795676-64-1	795676-67-4	795676-68-5	795676-69-6
795676-70-9	795676-72-1	795676-74-3	795676-75-4	795676-76-5
795676-77-6	795676-79-8	795676-81-2	795676-82-3	795676-83-4
795676-85-6	795676-87-8	795676-88-9	795676-89-0	795676-90-3
795676-92-5	795676-93-6	795676-94-7	795676-96-9	795676-97-0
795676-99-2	795677-00-8	795677-01-9	795677-03-1	795677-05-3
795677-06-4	795677-07-5	795677-08-6	795677-10-0	795677-12-2
795677-13-3	795677-14-4	795677-15-5	795677-17-7	795677-18-8
795677-19-9	795677-21-3			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795677-22-4	795677-24-6	795677-25-7	795677-27-9	795677-28-0
	795677-30-4	795677-31-5	795677-33-7	795677-34-8	795677-36-0
	795677-37-1	795677-38-2	795677-40-6	795677-41-7	795677-43-9
	795677-44-0	795677-46-2	795677-47-3	795677-49-5	795677-50-8
	795677-51-9	795677-53-1	795677-54-2	795677-56-4	795677-57-5
	795677-59-7	795677-60-0	795677-62-2	795677-63-3	795677-64-4
	795677-66-6	795677-67-7	795677-69-9	795677-70-2	795677-72-4
	795677-73-5	795677-75-7	795677-76-8	795677-77-9	795677-79-1
	795677-81-5	795677-82-6	795677-83-7	795677-85-9	795677-86-0
	795677-87-1	795677-88-2	795677-90-6	795677-91-7	795677-92-8
	795677-93-9	795677-95-1	795677-96-2	795677-97-3	795677-98-4
	795677-99-5	795678-01-2	795678-02-3	795678-03-4	795678-04-5
	795678-06-7	795678-07-8	795678-08-9	795678-09-0	795678-11-4
	795678-12-5	795678-13-6	795678-15-8	795678-17-0	795678-18-1
	795678-19-2	795678-21-6	795678-22-7	795678-24-9	795678-25-0
	795678-26-1	795678-28-3	795678-29-4	795678-31-8	795678-32-9
	795678-34-1	795678-35-2	795678-37-4	795678-38-5	795678-40-9
	795678-41-0	795678-43-2	795678-44-3	795678-46-5	795678-47-6
	795678-49-8	795678-50-1	795678-52-3	795678-53-4	795678-54-5
	795678-56-7	795678-58-9	795678-59-0	795678-60-3	795678-62-5
	795678-64-7	795678-65-8	795678-66-9	795678-68-1	795678-70-5
	795678-71-6	795678-72-7	795678-73-8	795678-75-0	795678-77-2
	795678-78-3	795678-79-4	795678-81-8	795678-83-0	795678-84-1
	795678-85-2	795678-86-3	795678-88-5	795678-89-6	795678-90-9
	795678-92-1	795678-94-3	795678-95-4	795678-96-5	795678-98-7
	795678-99-8	795679-01-5	795679-02-6	795679-04-8	795679-05-9
	795679-07-1	795679-08-2	795679-09-3	795679-11-7	795679-13-9
	795679-14-0	795679-15-1	795679-17-3	795679-19-5	795679-20-8
	795679-21-9	795679-22-0	795679-25-3	795679-26-4	795679-27-5
	795679-28-6	795679-30-0	795679-32-2	795679-33-3	795679-34-4
	795679-36-6	795679-37-7	795679-38-8	795679-39-9	795679-41-3
	795679-42-4	795679-44-6	795679-45-7	795679-47-9	795679-48-0
	795679-50-4	795679-51-5	795679-53-7	795679-54-8	795679-56-0
	795679-57-1	795679-58-2	795679-60-6	795679-62-8	795679-63-9
	795679-64-0	795679-66-2	795679-67-3	795679-69-5	795679-70-8
	795679-71-9	795679-72-0	795679-75-3	795679-76-4	795679-77-5
	795679-79-7	795679-81-1	795679-82-2	795679-83-3	795679-85-5
	795679-87-7	795679-88-8	795679-89-9	795679-91-3	795679-93-5
	795679-94-6	795679-95-7	795679-96-8	795679-99-1	795680-00-1
	795680-01-2	795680-02-3	795680-04-5	795680-06-7	795680-07-8
	795680-08-9	795680-09-0	795680-12-5	795680-13-6	795680-14-7
	795680-15-8	795680-18-1	795680-19-2	795680-20-5	795680-21-6
	795680-24-9	795680-25-0	795680-26-1	795680-27-2	795680-30-7
	795680-31-8	795680-32-9	795680-33-0	795680-36-3	795680-37-4
	795680-38-5	795680-40-9	795680-42-1	795680-43-2	795680-44-3
	795680-46-5	795680-48-7	795680-49-8	795680-50-1	795680-52-3
	795680-54-5	795680-55-6	795680-57-8	795680-59-0	795680-60-3
	795680-62-5	795680-64-7			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795680-65-8	795680-66-9	795680-67-0	795680-68-1	795680-71-6
	795680-72-7	795680-73-8	795680-74-9	795680-77-2	795680-78-3
	795680-79-4	795680-81-8	795680-83-0	795680-84-1	795680-85-2
	795680-86-3	795680-89-6	795680-90-9	795680-91-0	795680-92-1
	795680-94-3	795680-95-4	795680-97-6	795680-98-7	795681-00-4
	795681-01-5	795681-03-7	795681-04-8	795681-06-0	795681-07-1
	795681-09-3	795681-10-6	795681-12-8	795681-13-9	795681-15-1
	795681-16-2	795681-19-5	795681-21-9	795681-22-0	795681-23-1
	795681-25-3	795681-27-5	795681-28-6	795681-29-7	795681-31-1
	795681-33-3	795681-34-4	795681-35-5	795681-37-7	795681-39-9

795681-40-2	795681-41-3	795681-43-5	795681-45-7	795681-46-8
795681-47-9	795681-49-1	795681-51-5	795681-52-6	795681-53-7
795681-55-9	795681-56-0	795681-58-2	795681-59-3	795681-61-7
795681-62-8	795681-64-0	795681-65-1	795681-67-3	795681-68-4
795681-70-8	795681-71-9	795681-73-1	795681-74-2	795681-75-3
795681-76-4	795681-78-6	795681-79-7	795681-80-0	795681-83-3
795681-84-4	795681-85-5	795681-86-6	795681-89-9	795681-90-2
795681-91-3	795681-92-4	795681-95-7	795681-96-8	795681-97-9
795681-98-0	795682-01-8	795682-02-9	795682-03-0	795682-04-1
795682-07-4	795682-08-5	795682-09-6	795682-11-0	795682-13-2
795682-14-3	795682-15-4	795682-17-6	795682-19-8	795682-20-1
795682-21-2	795682-22-3	795682-25-6	795682-26-7	795682-27-8
795682-29-0	795682-31-4	795682-32-5	795682-33-6	795682-36-9
795682-37-0	795682-38-1	795682-39-2	795682-42-7	795682-43-8
795682-44-9	795682-45-0	795682-48-3	795682-49-4	795682-50-7
795682-51-8	795682-54-1	795682-55-2	795682-56-3	795682-58-5
795682-60-9	795682-61-0	795682-62-1	795682-64-3	795682-66-5
795682-67-6	795682-68-7	795682-70-1	795682-72-3	795682-73-4
795682-74-5	795682-77-8	795682-78-9	795682-79-0	795682-81-4
795682-83-6	795682-84-7	795682-85-8	795682-87-0	795682-89-2
795682-90-5	795682-91-6	795682-93-8	795682-95-0	795682-96-1
795682-97-2	795682-99-4	795683-00-0	795683-01-1	795683-02-2
795683-04-4	795683-06-6	795683-07-7	795683-08-8	795683-10-2
795683-12-4	795683-13-5	795683-14-6	795683-17-9	795683-18-0
795683-19-1	795683-20-4	795683-23-7	795683-24-8	795683-25-9
795683-26-0	795683-28-2	795683-29-3	795683-31-7	795683-32-8
795683-34-0	795683-35-1	795683-37-3	795683-38-4	795683-39-5
795683-40-8	795683-43-1	795683-44-2	795683-45-3	795683-48-6
795683-49-7	795683-50-0	795683-51-1	795683-54-4	795683-55-5
795683-56-6	795683-57-7	795683-60-2	795683-61-3	795683-62-4
795683-63-5	795683-66-8	795683-67-9	795683-68-0	795683-69-1
795683-72-6	795683-73-7	795683-74-8	795683-76-0	795683-78-2
795683-79-3	795683-80-6	795683-82-8	795683-84-0	795683-85-1
795683-86-2	795683-89-5	795683-90-8	795683-91-9	795683-93-1
795683-95-3	795683-96-4	795683-97-5	795683-99-7	795684-01-4
795684-02-5	795684-03-6	795684-05-8	795684-07-0	795684-08-1
795684-09-2	795684-11-6	795684-13-8	795684-14-9	795684-16-1
795684-17-2	795684-19-4			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795684-20-7	795684-22-9	795684-24-1	795684-25-2	795684-26-3
	795684-28-5	795684-30-9	795684-31-0	795684-33-2	795684-34-3
	795684-36-5	795684-37-6	795684-39-8	795684-40-1	795684-42-3
	795684-43-4	795684-45-6	795684-46-7	795684-48-9	795684-49-0
	795684-51-4	795684-52-5	795684-54-7	795684-55-8	795684-57-0
	795684-58-1	795684-60-5	795684-61-6	795684-63-8	795684-64-9
	795684-66-1	795684-68-3	795684-69-4	795684-71-8	795684-73-0
	795684-74-1	795684-76-3	795684-77-4	795684-79-6	795684-80-9
	795684-82-1	795684-83-2	795684-85-4	795684-86-5	795684-88-7
	795684-89-8	795684-91-2	795684-92-3	795684-94-5	795684-95-6
	795684-97-8	795684-98-9	795685-00-6	795685-02-8	795685-03-9
	795685-04-0	795685-06-2	795685-08-4	795685-09-5	795685-10-8
	795685-12-0	795685-14-2	795685-15-3	795685-16-4	795685-18-6
	795685-19-7	795685-20-0	795685-21-1	795685-23-3	795685-24-4
	795685-25-5	795685-26-6	795685-28-8	795685-30-2	795685-31-3
	795685-33-5	795685-35-7	795685-36-8	795685-37-9	795685-39-1
	795685-41-5	795685-42-6	795685-43-7	795685-45-9	795685-47-1
	795685-48-2	795685-50-6	795685-51-7	795685-53-9	795685-54-0
	795685-56-2	795685-58-4	795685-59-5	795685-60-8	795685-62-0
	795685-64-2	795685-65-3	795685-66-4	795685-67-5	795685-69-7
	795685-70-0	795685-71-1	795685-73-3	795685-74-4	795685-75-5
	795685-76-6	795685-78-8	795685-79-9	795685-80-2	795685-82-4
	795685-83-5	795685-84-6	795685-86-8	795685-87-9	795685-89-1
	795685-90-4	795685-92-6	795685-93-7	795685-95-9	795685-96-0
	795685-98-2	795685-99-3	795686-01-0	795686-03-2	795686-04-3
	795686-06-5	795686-07-6	795686-09-8	795686-10-1	795686-12-3
	795686-13-4	795686-15-6	795686-16-7	795686-18-9	795686-20-3
	795686-21-4	795686-23-6	795686-24-7	795686-26-9	795686-27-0
	795686-29-2	795686-30-5	795686-32-7	795686-33-8	795686-35-0
	795686-36-1	795686-38-3	795686-40-7	795686-41-8	795686-43-0
	795686-44-1	795686-46-3	795686-47-4	795686-48-5	795686-49-6
	795686-51-0	795686-52-1	795686-53-2	795686-55-4	795686-57-6
	795686-58-7	795686-59-8	795686-62-3	795686-63-4	795686-64-5
	795686-65-6	795686-68-9	795686-69-0	795686-70-3	795686-73-6

795686-74-7	795686-75-8	795686-76-9	795686-79-2	795686-80-5
795686-81-6	795686-82-7	795686-85-0	795686-86-1	795686-87-2
795686-89-4	795686-91-8	795686-92-9	795686-93-0	795686-96-3
795686-97-4	795686-98-5	795687-01-3	795687-02-4	795687-03-5
795687-05-7	795687-07-9	795687-08-0	795687-10-4	795687-12-6
795687-13-7	795687-14-8	795687-17-1	795687-18-2	795687-19-3
795687-21-7	795687-23-9	795687-24-0	795687-25-1	795687-28-4
795687-29-5	795687-30-8	795687-32-0	795687-34-2	795687-35-3
795687-36-4	795687-39-7	795687-40-0	795687-41-1	795687-43-3
795687-44-4	795687-45-5	795687-46-6	795687-48-8	795687-49-9
795687-50-2	795687-53-5	795687-54-6	795687-55-7	795687-56-8
795687-59-1	795687-60-4	795687-61-5	795687-64-8	795687-65-9
795687-66-0	795687-67-1	795687-70-6	795687-71-7	795687-72-8
795687-73-9	795687-76-2			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795687-77-3	795687-78-4	795687-81-9	795687-82-0	795687-83-1
	795687-85-3	795687-87-5	795687-88-6	795687-89-7	
	795687-92-2	795687-93-3	795687-94-4	795687-96-6	795687-98-8
	795687-99-9	795688-00-5	795688-02-7	795688-03-8	795688-05-0
	795688-06-1	795688-07-2	795688-09-4	795688-10-7	795688-11-8
	795688-13-0	795688-14-1	795688-16-3	795688-18-5	795688-19-6
	795688-20-9	795688-22-1	795688-24-3	795688-25-4	795688-27-6
	795688-28-7	795688-31-2	795688-32-3	795688-33-4	795688-36-7
	795688-37-8	795688-38-9	795688-40-3	795688-42-5	795688-43-6
	795688-44-7	795688-47-0	795688-48-1	795688-49-2	795688-50-5
	795688-51-6	795688-52-7	795688-55-0	795688-56-1	795688-57-2
	795688-60-7	795688-61-8	795688-62-9	795688-63-0	795688-66-3
	795688-67-4	795688-68-5	795688-71-0	795688-72-1	795688-73-2
	795688-74-3	795688-77-6	795688-78-7	795688-81-2	795688-82-3
	795688-83-4	795688-86-7	795688-87-8	795688-88-9	795688-89-0
	795688-92-5	795688-93-6	795688-94-7	795688-97-0	795688-98-1
	795688-99-2	795689-01-9	795689-03-1	795689-04-2	795689-05-3
	795689-07-5	795689-08-6	795689-10-0	795689-12-2	795689-13-3
	795689-15-5	795689-16-6	795689-18-8	795689-20-2	795689-21-3
	795689-23-5	795689-25-7	795689-26-8	795689-29-1	795689-30-4
	795689-31-5	795689-32-6	795689-34-8	795689-35-9	795689-37-1
	795689-39-3	795689-40-6	795689-42-8	795689-43-9	795689-45-1
	795689-46-2	795689-48-4	795689-50-8	795689-51-9	795689-53-1
	795689-54-2	795689-56-4	795689-57-5	795689-59-7	795689-61-1
	795689-62-2	795689-64-4	795689-65-5	795689-67-7	795689-68-8
	795689-69-9	795689-71-3	795689-72-4	795689-74-6	795689-75-7
	795689-77-9	795689-79-1	795689-80-4	795689-81-5	795689-84-8
	795689-85-9	795689-86-0	795689-87-1	795689-90-6	795689-91-7
	795689-92-8	795689-94-0	795689-96-2	795689-97-3	795689-98-4
	795690-01-6	795690-02-7	795690-03-8	795690-06-1	795690-07-2
	795690-08-3	795690-10-7	795690-12-9	795690-13-0	795690-14-1
	795690-17-4	795690-18-5	795690-19-6	795690-22-1	795690-23-2
	795690-24-3	795690-27-6	795690-28-7	795690-29-8	795690-31-2
	795690-32-3	795690-34-5	795690-36-7	795690-37-8	795690-39-0
	795690-40-3	795690-42-5	795690-43-6	795690-45-8	795690-47-0
	795690-48-1	795690-50-5	795690-51-6	795690-53-8	795690-54-9
	795690-56-1	795690-58-3	795690-59-4	795690-60-7	795690-63-0
	795690-64-1	795690-65-2	795690-68-5	795690-69-6	795690-70-9
	795690-72-1	795690-74-3	795690-75-4	795690-77-6	795690-79-8
	795690-80-1	795690-81-2	795690-84-5	795690-85-6	795690-86-7
	795690-87-8	795690-90-3	795690-91-4	795690-92-5	795690-95-8
	795690-96-9	795690-97-0	795690-99-2	795691-00-8	795691-01-9
	795691-02-0	795691-04-2	795691-06-4	795691-07-5	795691-08-6
	795691-11-1	795691-12-2	795691-13-3	795691-15-5	795691-17-7
	795691-18-8	795691-20-2	795691-22-4	795691-23-5	795691-24-6
	795691-25-7	795691-27-9	795691-29-1	795691-30-4	795691-31-5
	795691-32-6	795691-34-8	795691-36-0	795691-37-1	795691-38-2
	795691-40-6	795691-42-8	795691-43-9		

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795691-44-0	795691-47-3	795691-48-4	795691-49-5	795691-50-8
	795691-52-0	795691-53-1	795691-54-2	795691-56-4	795691-58-6
	795691-59-7	795691-61-1	795691-63-3	795691-64-4	795691-66-6
	795691-68-8	795691-69-9	795691-71-3	795691-72-4	795691-74-6
	795691-76-8	795691-78-0	795691-80-4	795691-81-5	795691-83-7
	795691-84-8	795691-86-0	795691-88-2	795691-89-3	795691-91-7

795691-92-8	795691-94-0	795691-96-2	795691-97-3	795691-99-5
795692-00-1	795692-02-3	795692-03-4	795692-05-6	795692-07-8
795692-08-9	795692-10-3	795692-12-5	795692-13-6	795692-14-7
795692-16-9	795692-17-0	795692-18-1	795692-20-5	795692-21-6
795692-22-7	795692-24-9	795692-25-0	795692-26-1	795692-28-3
795692-29-4	795692-31-8	795692-32-9	795692-34-1	795692-36-3
795692-37-4	795692-39-6	795692-41-0	795692-42-1	795692-44-3
795692-46-5	795692-47-6	795692-49-8	795692-51-2	795692-52-3
795692-54-5	795692-55-6	795692-57-8	795692-58-9	795692-60-3
795692-62-5	795692-63-6	795692-65-8	795692-66-9	795692-67-0
795692-69-2	795692-71-6	795692-72-7	795692-74-9	795692-76-1
795692-78-3	795692-79-4	795692-81-8	795692-82-9	795692-84-1
795692-86-3	795692-87-4	795692-89-6	795692-91-0	795692-92-1
795692-94-3	795692-96-5	795692-97-6	795692-99-8	795693-01-5
795693-02-6	795693-04-8	795693-06-0	795693-07-1	795693-08-2
795693-11-7	795693-12-8	795693-13-9	795693-16-2	795693-17-3
795693-18-4	795693-20-8	795693-22-0	795693-23-1	795693-25-3
795693-27-5	795693-28-6	795693-30-0	795693-32-2	795693-33-3
795693-34-4	795693-37-7	795693-38-8	795693-41-3	795693-42-4
795693-43-5	795693-44-6	795693-47-9	795693-48-0	795693-49-1
795693-52-6	795693-53-7	795693-54-8	795693-57-1	795693-58-2
795693-59-3	795693-61-7	795693-63-9	795693-64-0	795693-65-1
795693-68-4	795693-69-5	795693-70-8	795693-73-1	795693-74-2
795693-75-3	795693-78-6	795693-79-7	795693-82-2	795693-83-3
795693-84-4	795693-87-7	795693-88-8	795693-89-9	795693-91-3
795693-93-5	795693-94-6	795693-96-8	795693-98-0	795693-99-1
795694-01-8	795694-03-0	795694-04-1	795694-06-3	795694-08-5
795694-09-6	795694-10-9	795694-13-2	795694-14-3	795694-15-4
795694-17-6	795694-19-8	795694-20-1	795694-21-2	795694-23-4
795694-25-6	795694-27-8	795694-29-0	795694-30-3	795694-31-4
795694-34-7	795694-35-8	795694-36-9	795694-39-2	795694-40-5
795694-42-7	795694-44-9	795694-45-0	795694-46-1	795694-49-4
795694-50-7	795694-51-8	795694-54-1	795694-55-2	795694-56-3
795694-59-6	795694-60-9	795694-61-0	795694-63-2	795694-65-4
795694-66-5	795694-68-7	795694-70-1	795694-71-2	795694-72-3
795694-75-6	795694-77-8	795694-79-0	795694-80-3	795694-82-5
795694-84-7	795694-85-8	795694-86-9	795694-89-2	795694-90-5
795694-91-6	795694-94-9	795694-95-0	795694-96-1	795694-98-3
795695-00-0	795695-01-1	795695-03-3	795695-05-5	795695-06-6
795695-09-9	795695-10-2	795695-12-4	795695-13-5	795695-15-7
795695-16-8	795695-18-0	795695-20-4	795695-21-5	795695-23-7
795695-25-9	795695-27-1			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795695-29-3	795695-31-7	795695-32-8	795695-34-0	795695-35-1
	795695-37-3	795695-39-5	795695-41-9	795695-42-0	795695-44-2
	795695-46-4	795695-47-5	795695-49-7	795695-51-1	795695-52-2
	795695-54-4	795695-56-6	795695-57-7	795695-59-9	795695-60-2
	795695-62-4	795695-64-6	795695-65-7	795695-67-9	795695-69-1
	795695-70-4	795695-72-6	795695-73-7	795695-75-9	795695-77-1
	795695-79-3	795695-81-7	795695-82-8	795695-84-0	795695-86-2
	795695-87-3	795695-89-5	795695-91-9	795695-92-0	795695-94-2
	795695-96-4	795695-97-5	795695-98-6	795696-00-3	795696-02-5
	795696-03-6	795696-05-8	795696-07-0	795696-08-1	795696-10-5
	795696-12-7	795696-13-8	795696-15-0	795696-17-2	795696-18-3
	795696-19-4	795696-22-9	795696-23-0	795696-24-1	795696-27-4
	795696-28-5	795696-29-6	795696-30-9	795696-31-0	795696-32-1
	795696-35-4	795696-36-5	795696-37-6	795696-39-8	795696-41-2
	795696-42-3	795696-44-5	795696-46-7	795696-47-8	795696-49-0
	795696-51-4	795696-52-5	795696-54-7	795696-56-9	795696-57-0
	795696-59-2	795696-61-6	795696-62-7	795696-64-9	795696-65-0
	795696-67-2	795696-69-4	795696-70-7	795696-72-9	795696-73-0
	795696-75-2	795696-78-5	795696-80-9	795696-81-0	795696-83-2
	795696-85-4	795696-86-5	795696-87-6	795696-90-1	795696-91-2
	795696-93-4	795696-95-6	795696-96-7	795696-98-9	795697-00-6
	795697-01-7	795697-03-9	795697-05-1	795697-06-2	795697-08-4
	795697-10-8	795697-11-9	795697-13-1	795697-15-3	795697-18-6
	795697-19-7	795697-21-1	795697-23-3	795697-24-4	795697-26-6
	795697-28-8	795697-29-9	795697-30-2	795697-33-5	795697-34-6
	795697-37-9	795697-38-0	795697-39-1	795697-42-6	795697-43-7
	795697-44-8	795697-47-1	795697-48-2	795697-49-3	795697-52-8
	795697-53-9	795697-54-0	795697-57-3	795697-58-4	795697-59-5
	795697-62-0	795697-63-1	795697-64-2	795697-67-5	795697-68-6
	795697-69-7	795697-71-1	795697-73-3	795697-74-4	795697-76-6

795697-78-8	795697-79-9	795697-80-2	795697-82-4	795697-84-6
795697-85-7	795697-87-9	795697-89-1	795697-90-4	795697-92-6
795697-94-8	795697-95-9	795697-97-1	795697-99-3	795698-00-9
795698-02-1	795698-04-3	795698-05-4	795698-07-6	795698-09-8
795698-10-1	795698-12-3	795698-14-5	795698-15-6	795698-17-8
795698-19-0	795698-20-3	795698-22-5	795698-24-7	795698-25-8
795698-28-1	795698-29-2	795698-31-6	795698-33-8	795698-34-9
795698-37-2	795698-38-3	795698-39-4	795698-42-9	795698-43-0
795698-44-1	795698-47-4	795698-48-5	795698-49-6	795698-51-0
795698-53-2	795698-54-3	795698-56-5	795698-58-7	795698-59-8
795698-61-2	795698-63-4	795698-64-5	795698-66-7	795698-68-9
795698-69-0	795698-71-4	795698-73-6	795698-74-7	795698-76-9
795698-78-1	795698-79-2	795698-80-5	795698-82-7	795698-84-9
795698-85-0	795698-86-1	795698-89-4	795698-90-7	795698-91-8
795698-94-1	795698-95-2	795698-96-3	795698-99-6	795699-00-2
795699-01-3	795699-04-6	795699-05-7	795699-06-8	795699-09-1
795699-10-4	795699-11-5	795699-13-7	795699-14-8	795699-17-1
795699-18-2	795699-19-3			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795699-21-7	795699-22-8	795699-23-9	795699-25-1	795699-26-2
	795699-29-5	795699-30-8	795699-31-9	795699-33-1	795699-34-2
	795699-35-3	795699-37-5	795699-38-6	795699-39-7	795699-41-1
	795699-42-2	795699-43-3	795699-46-6	795699-47-7	795699-48-8
	795699-51-3	795699-52-4	795699-53-5	795699-56-8	795699-57-9
	795699-58-0	795699-61-5	795699-62-6	795699-63-7	795699-66-0
	795699-67-1	795699-68-2	795699-71-7	795699-72-8	795699-73-9
	795699-76-2	795699-77-3	795699-80-8	795699-81-9	795699-82-0
	795699-85-3	795699-86-4	795699-87-5	795699-90-0	795699-91-1
	795699-92-2	795699-95-5	795699-96-6	795699-97-7	795700-00-4
	795700-01-5	795700-02-6	795700-05-9	795700-06-0	795700-07-1
	795700-09-3	795700-10-6	795700-11-7	795700-14-0	795700-15-1
	795700-16-2	795700-19-5	795700-20-8	795700-21-9	795700-24-2
	795700-25-3	795700-27-5	795700-28-6	795700-30-0	795700-32-2
	795700-33-3	795700-35-5	795700-37-7	795700-38-8	795700-40-2
	795700-42-4	795700-43-5	795700-45-7	795700-47-9	795700-48-0
	795700-50-4	795700-52-6	795700-53-7	795700-55-9	795700-57-1
	795700-58-2	795700-60-6	795700-62-8	795700-63-9	795700-65-1
	795700-67-3	795700-68-4	795700-70-8	795700-72-0	795700-73-1
	795700-76-4	795700-77-5	795700-79-7	795700-81-1	795700-82-2
	795700-84-4	795700-86-6	795700-87-7	795700-89-9	795700-91-3
	795700-92-4	795700-94-6	795700-96-8	795700-97-9	795700-99-1
	795701-01-8	795701-02-9	795701-04-1	795701-06-3	795701-07-4
	795701-09-6	795701-11-0	795701-12-1	795701-14-3	795701-16-5
	795701-17-6	795701-20-1	795701-21-2	795701-23-4	795701-25-6
	795701-27-8	795701-29-0	795701-30-3	795701-32-5	795701-34-7
	795701-35-8	795701-37-0	795701-39-2	795701-40-5	795701-42-7
	795701-44-9	795701-45-0	795701-47-2	795701-49-4	795701-51-8
	795701-52-9	795701-54-1	795701-55-2	795701-57-4	795701-59-6
	795701-61-0	795701-62-1	795701-64-3	795701-66-5	795701-67-6
	795701-69-8	795701-71-2	795701-72-3	795701-74-5	795701-76-7
	795701-77-8	795701-78-9	795701-80-3	795701-81-4	795701-82-5
	795701-84-7	795701-86-9	795701-87-0	795701-88-1	795701-89-2
	795701-91-6	795701-93-8	795701-94-9	795701-96-1	795701-98-3
	795701-99-4	795702-01-1	795702-03-3	795702-04-4	795702-07-7
	795702-08-8	795702-11-3	795702-12-4	795702-14-6	795702-16-8
	795702-17-9	795702-19-1	795702-21-5	795702-22-6	795702-24-8
	795702-26-0	795702-27-1	795702-28-2	795702-31-7	795702-32-8
	795702-33-9	795702-36-2	795702-37-3	795702-38-4	795702-41-9
	795702-42-0	795702-44-2	795702-46-4	795702-47-5	795702-49-7
	795702-51-1	795702-52-2	795702-55-5	795702-56-6	795702-57-7
	795702-60-2	795702-61-3	795702-62-4	795702-65-7	795702-66-8
	795702-67-9	795702-70-4	795702-71-5	795702-72-6	795702-75-9
	795702-76-0	795702-77-1	795702-80-6	795702-81-7	795702-82-8
	795702-85-1	795702-86-2	795702-87-3	795702-90-8	795702-91-9
	795702-92-0	795702-95-3	795702-96-4	795702-97-5	795703-00-3
	795703-01-4	795703-02-5	795703-05-8	795703-06-9	795703-09-2
	795703-10-5	795703-11-6			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795703-14-9	795703-15-0	795703-17-2	795703-19-4	795703-20-7
	795703-22-9	795703-24-1	795703-25-2	795703-27-4	795703-28-5

795703-31-0	795703-32-1	795703-34-3	795703-36-5	795703-38-7
795703-40-1	795703-41-2	795703-43-4	795703-45-6	795703-46-7
795703-48-9	795703-50-3	795703-51-4	795703-53-6	795703-55-8
795703-56-9	795703-58-1	795703-60-5	795703-61-6	795703-63-8
795703-65-0	795703-66-1	795703-69-4	795703-70-7	795703-71-8
795703-74-1	795703-75-2	795703-76-3	795703-78-5	795703-79-6
795703-81-0	795703-83-2	795703-84-3	795703-86-5	795703-88-7
795703-89-8	795703-91-2	795703-93-4	795703-94-5	795703-96-7
795703-98-9	795704-00-6	795704-02-8	795704-03-9	795704-05-1
795704-07-3	795704-08-4	795704-10-8	795704-12-0	795704-13-1
795704-15-3	795704-17-5	795704-18-6	795704-19-7	795704-22-2
795704-24-4	795704-26-6	795704-27-7	795704-30-2	795704-31-3
795704-32-4	795704-35-7	795704-36-8	795704-37-9	795704-39-1
795704-41-5	795704-42-6	795704-45-9	795704-46-0	795704-47-1
795704-50-6	795704-51-7	795704-52-8	795704-55-1	795704-56-2
795704-57-3	795704-60-8	795704-61-9	795704-63-1	795704-65-3
795704-66-4	795704-68-6	795704-70-0	795704-71-1	795704-73-3
795704-75-5	795704-76-6	795704-77-7	795704-80-2	795704-81-3
795704-82-4	795704-85-7	795704-86-8	795704-87-9	795704-90-4
795704-91-5	795704-94-8	795704-95-9	795704-96-0	795704-99-3
795705-00-9	795705-01-0	795705-04-3	795705-05-4	795705-08-7
795705-09-8	795705-10-1	795705-13-4	795705-14-5	795705-15-6
795705-18-9	795705-19-0	795705-20-3	795705-23-6	795705-24-7
795705-26-9	795705-27-0	795705-29-2	795705-31-6	795705-32-7
795705-34-9	795705-36-1	795705-37-2	795705-39-4	795705-41-8
795705-42-9	795705-44-1	795705-46-3	795705-47-4	795705-49-6
795705-51-0	795705-53-2	795705-55-4	795705-57-6	795705-58-7
795705-60-1	795705-62-3	795705-63-4	795705-65-6	795705-67-8
795705-68-9	795705-70-3	795705-72-5	795705-74-7	795705-76-9
795705-77-0	795705-79-2	795705-81-6	795705-83-8	795705-85-0
795705-86-1	795705-88-3	795705-89-4	795705-91-8	795705-93-0
795705-95-2	795705-96-3	795705-97-4	795705-99-6	795706-01-3
795706-02-4	795706-03-5	795706-05-7	795706-07-9	795706-09-1
795706-10-4	795706-12-6	795706-13-7	795706-15-9	795706-16-0
795706-17-1	795706-20-6	795706-21-7	795706-22-8	795706-25-1
795706-28-4	795706-29-5	795706-30-8	795706-33-1	795706-34-2
795706-35-3	795706-38-6	795706-39-7	795706-42-2	795706-43-3
795706-44-4	795706-47-7	795706-48-8	795706-49-9	795706-52-4
795706-53-5	795706-54-6	795706-57-9	795706-58-0	795706-59-1
795706-62-6	795706-64-8	795706-66-0	795706-67-1	795706-70-6
795706-71-7	795706-73-9	795706-75-1	795706-76-2	795706-77-3
795706-79-5	795706-81-9	795706-83-1	795706-85-3	795706-86-4
795706-88-6	795706-90-0	795706-91-1	795706-93-3	795706-95-5
795706-96-6	795706-98-8	795707-00-5	795707-01-6	795707-04-9
795707-05-0	795707-06-1	795707-09-4	795707-10-7	795707-12-9
795707-14-1	795707-15-2			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795707-17-4	795707-19-6	795707-20-9	795707-21-0	795707-23-2
	795707-24-3	795707-26-5	795707-27-6	795707-28-7	795707-30-1
	795707-31-2	795707-32-3	795707-34-5	795707-35-6	795707-37-8
	795707-39-0	795707-40-3	795707-42-5	795707-44-7	795707-46-9
	795707-48-1	795707-49-2	795707-51-6	795707-53-8	795707-54-9
	795707-57-2	795707-58-3	795707-60-7	795707-62-9	795707-63-0
	795707-65-2	795707-67-4	795707-68-5	795707-71-0	795707-73-2
	795707-75-4	795707-76-5	795707-79-8	795707-80-1	795707-82-3
	795707-84-5	795707-85-6	795707-86-7	795707-88-9	795707-90-3
	795707-91-4	795707-93-6	795707-95-8	795707-96-9	795707-99-2
	795708-00-8	795708-02-0	795708-04-2	795708-05-3	795708-07-5
	795708-09-7	795708-10-0	795708-12-2	795708-14-4	795708-15-5
	795708-17-7	795708-19-9	795708-20-2	795708-22-4	795708-24-6
	795708-25-7	795708-26-8	795708-28-0	795708-30-4	795708-32-6
	795708-34-8	795708-35-9	795708-37-1	795708-39-3	795708-41-7
	795708-43-9	795708-44-0	795708-46-2	795708-48-4	795708-49-5
	795708-51-9	795708-53-1	795708-54-2	795708-56-4	795708-58-6
	795708-60-0	795708-62-2	795708-63-3	795708-65-5	795708-67-7
	795708-68-8	795708-70-2	795708-72-4	795708-73-5	795708-75-7
	795708-77-9	795708-79-1	795708-80-4	795708-82-6	795708-84-8
	795708-86-0	795708-87-1	795708-89-3	795708-91-7	795708-92-8
	795708-94-0	795708-96-2	795708-98-4	795708-99-5	795709-01-2
	795709-03-4	795709-05-6	795709-06-7	795709-08-9	795709-10-3
	795709-11-4	795709-13-6	795709-15-8	795709-17-0	795709-18-1
	795709-20-5	795709-22-7	795709-23-8	795709-25-0	795709-27-2
	795709-29-4	795709-31-8	795709-32-9	795709-34-1	795709-36-3

795709-38-5	795709-39-6	795709-41-0	795709-43-2	795709-44-3
795709-46-5	795709-48-7	795709-50-1	795709-51-2	795709-53-4
795709-55-6	795709-56-7	795709-58-9	795709-60-3	795709-62-5
795709-63-6	795709-65-8	795709-67-0	795709-69-2	795709-70-5
795709-72-7	795709-74-9	795709-75-0	795709-77-2	795709-79-4
795709-80-7	795709-82-9	795709-84-1	795709-86-3	795709-88-5
795709-89-6	795709-91-0	795709-93-2	795709-94-3	795709-96-5
795709-98-7	795709-99-8	795710-02-0	795710-03-1	795710-05-3
795710-07-5	795710-08-6	795710-10-0	795710-12-2	795710-13-3
795710-15-5	795710-17-7	795710-19-9	795710-21-3	795710-23-5
795710-25-7	795710-26-8	795710-28-0	795710-30-4	795710-31-5
795710-33-7	795710-35-9	795710-36-0	795710-39-3	795710-40-6
795710-42-8	795710-44-0	795710-45-1	795710-47-3	795710-49-5
795710-50-8	795710-53-1	795710-54-2	795710-56-4	795710-58-6
795710-59-7	795710-61-1	795710-63-3	795710-64-4	795710-66-6
795710-68-8	795710-70-2	795710-72-4	795710-73-5	795710-75-7
795710-77-9	795710-78-0	795710-80-4	795710-82-6	795710-84-8
795710-86-0	795710-87-1	795710-89-3	795710-91-7	795710-93-9
795710-94-0	795710-96-2	795710-98-4	795711-02-3	795711-03-4
795711-05-6	795711-07-8	795711-09-0	795711-11-4	795711-12-5
795711-14-7	795711-16-9	795711-17-0	795711-19-2	795711-21-6
795711-23-8	795711-24-9			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT 795711-26-1	795711-28-3	795711-30-7	795711-32-9	795711-33-0
795711-35-2	795711-37-4	795711-38-5	795711-40-9	795711-42-1
795711-44-3	795711-46-5	795711-47-6	795711-49-8	795711-51-2
795711-52-3	795711-54-5	795711-56-7	795711-58-9	795711-60-3
795711-61-4	795711-63-6	795711-65-8	795711-66-9	795711-68-1
795711-70-5	795711-72-7	795711-73-8	795711-75-0	795711-77-2
795711-79-4	795711-80-7	795711-82-9	795711-84-1	795711-85-2
795711-87-4	795711-89-6	795711-90-9	795711-93-2	795711-94-3
795711-96-5	795711-98-7	795711-99-8	795712-01-5	795712-03-7
795712-05-9	795712-07-1	795712-08-2	795712-10-6	795712-12-8
795712-13-9	795712-15-1	795712-17-3	795712-19-5	795712-21-9
795712-22-0	795712-24-2	795712-26-4	795712-28-6	795712-30-0
795712-31-1	795712-33-3	795712-35-5	795712-36-6	795712-38-8
795712-40-2	795712-42-4	795712-44-6	795712-45-7	795712-47-9
795712-49-1	795712-50-4	795712-52-6	795712-53-7	795712-56-0
795712-57-1	795712-58-2	795712-61-7	795712-62-8	795712-63-9
795712-66-2	795712-67-3	795712-70-8	795712-71-9	795712-72-0
795712-75-3	795712-76-4	795712-79-7	795712-80-0	795712-83-3
795712-84-4	795712-85-5	795712-88-8	795712-89-9	795712-90-2
795712-93-5	795712-94-6	795712-97-9	795712-98-0	795712-99-1
795713-02-9	795713-03-0	795713-04-1	795713-07-4	795713-08-5
795713-11-0	795713-12-1	795713-13-2	795713-16-5	795713-17-6
795713-19-8	795713-21-2	795713-22-3	795713-25-6	795713-26-7
795713-27-8	795713-29-0	795713-30-3	795713-33-6	795713-34-7
795713-36-9	795713-38-1	795713-39-2	795713-40-5	795713-42-7
795713-43-8	795713-45-0	795713-47-2	795713-48-3	795713-50-7
795713-52-9	795713-53-0	795713-56-3	795713-57-4	795713-59-6
795713-61-0	795713-63-2	795713-65-4	795713-66-5	795713-68-7
795713-70-1	795713-71-2	795713-74-5	795713-75-6	795713-77-8
795713-79-0	795713-80-3	795713-83-6	795713-84-7	795713-86-9
795713-88-1	795713-89-2	795713-91-6	795713-93-8	795713-94-9
795713-97-2	795713-98-3	795714-00-0	795714-02-2	795714-03-3
795714-05-5	795714-07-7	795714-09-9	795714-10-2	795714-12-4
795714-14-6	795714-16-8	795714-17-9	795714-19-1	795714-21-5
795714-23-7	795714-25-9	795714-26-0	795714-28-2	795714-30-6
795714-32-8	795714-33-9	795714-35-1	795714-37-3	795714-39-5
795714-40-8	795714-42-0	795714-44-2	795714-46-4	795714-48-6
795714-50-0	795714-51-1	795714-53-3	795714-55-5	795714-57-7
795714-58-8	795714-60-2	795714-62-4	795714-64-6	795714-65-7
795714-67-9	795714-69-1	795714-71-5	795714-73-7	795714-74-8
795714-76-0	795714-78-2	795714-79-3	795714-81-7	795714-83-9
795714-85-1	795714-87-3	795714-88-4	795714-90-8	795714-92-0
795714-93-1	795714-95-3	795714-97-5	795714-99-7	795715-01-4
795715-02-5	795715-04-7	795715-06-9	795715-08-1	795715-10-5
795715-11-6	795715-14-9	795715-15-0	795715-17-2	795715-19-4
795715-20-7	795715-23-0	795715-24-1	795715-25-2	795715-28-5
795715-29-6	795715-32-1	795715-33-2	795715-35-4	795715-37-6
795715-38-7	795715-41-2			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795715-42-3	795715-43-4	795715-46-7	795715-47-8	795715-49-0
	795715-51-4	795715-52-5	795715-55-8	795715-56-9	795715-58-1
	795715-60-5	795715-61-6	795715-63-8	795715-65-0	795715-66-1
	795715-69-4	795715-70-7	795715-72-9	795715-74-1	795715-75-2
	795715-78-5	795715-79-6	795715-80-9	795715-83-2	795715-84-3
	795715-86-5	795715-88-7	795715-89-8	795715-92-3	795715-93-4
	795715-94-5	795715-97-8	795715-98-9	795716-00-6	795716-02-8
	795716-03-9	795716-06-2	795716-07-3	795716-09-5	795716-11-9
	795716-12-0	795716-15-3	795716-16-4	795716-18-6	795716-20-0
	795716-21-1	795716-24-4	795716-25-5	795716-27-7	795716-29-9
	795716-31-3	795716-33-5	795716-34-6	795716-37-9	795716-38-0
	795716-40-4	795716-42-6	795716-43-7	795716-45-9	795716-47-1
	795716-49-3	795716-51-7	795716-52-8	795716-54-0	795716-56-2
	795716-58-4	795716-60-8	795716-62-0	795716-64-2	795716-65-3
	795716-67-5	795716-69-7	795716-70-0	795716-72-2	795716-74-4
	795716-75-5	795716-78-8	795716-79-9	795716-81-3	795716-83-5
	795716-85-7	795716-87-9	795716-88-0	795716-91-5	795716-92-6
	795716-94-8	795716-96-0	795716-98-2	795717-00-9	795717-01-0
	795717-03-2	795717-05-4	795717-07-6	795717-09-8	795717-10-1
	795717-12-3	795717-14-5	795717-15-6	795717-18-9	795717-19-0
	795717-21-4	795717-23-6	795717-24-7	795717-26-9	795717-28-1
	795717-29-2	795717-31-6	795717-32-7	795717-34-9	795717-36-1
	795717-38-3	795717-40-7	795717-41-8	795717-43-0	795717-45-2
	795717-47-4	795717-48-5	795717-50-9	795717-52-1	795717-54-3
	795717-55-4	795717-57-6	795717-59-8	795717-61-2	795717-63-4
	795717-64-5	795717-66-7	795717-68-9	795717-70-3	795717-72-5
	795717-73-6	795717-75-8	795717-77-0	795717-79-2	795717-81-6
	795717-83-8	795717-84-9	795717-86-1	795717-88-3	795717-90-7
	795717-91-8	795717-93-0	795717-95-2	795717-97-4	795717-99-6
	795718-00-2	795718-02-4	795718-04-6	795718-06-8	795718-08-0
	795718-09-1	795718-11-5	795718-13-7	795718-15-9	795718-17-1
	795718-18-2	795718-20-6	795718-22-8	795718-24-0	795718-26-2
	795718-27-3	795718-29-5	795718-31-9	795718-33-1	795718-35-3
	795718-36-4	795718-38-6	795718-40-0	795718-42-2	795718-44-4
	795718-45-5	795718-47-7	795718-49-9	795718-51-3	795718-53-5
	795718-54-6	795718-56-8	795718-58-0	795718-60-4	795718-62-6
	795718-64-8	795718-66-0	795718-68-2	795718-69-3	795718-71-7
	795718-73-9	795718-74-0	795718-76-2	795718-78-4	795718-79-5
	795718-82-0	795718-83-1	795718-84-2	795718-87-5	795718-88-6
	795718-90-0	795718-92-2	795718-93-3	795718-94-4	795718-96-6
	795718-98-8	795719-00-5	795719-01-6	795719-03-8	795719-04-9
	795719-05-0	795719-07-2	795719-08-3	795719-10-7	795719-12-9
	795719-14-1	795719-16-3	795719-17-4	795719-19-6	795719-21-0
	795719-23-2	795719-25-4	795719-27-6	795719-28-7	795719-30-1
	795719-32-3	795719-34-5	795719-36-7	795719-38-9	795719-39-0
	795719-41-4	795719-43-6	795719-45-8	795719-47-0	795719-48-1
	795719-50-5	795719-52-7	795719-54-9	795719-55-0	795719-57-2
	795719-59-4	795719-61-8			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795719-62-9	795719-64-1	795719-66-3	795719-68-5	795719-70-9
	795719-71-0	795719-73-2	795719-75-4	795719-77-6	795719-79-8
	795719-80-1	795719-82-3	795719-84-5	795719-86-7	795719-88-9
	795719-89-0	795719-91-4	795719-93-6	795719-95-8	795719-97-0
	795719-98-1	795720-00-2	795720-02-4	795720-04-6	795720-06-8
	795720-07-9	795720-09-1	795720-11-5	795720-13-7	795720-15-9
	795720-16-0	795720-18-2	795720-20-6	795720-22-8	795720-24-0
	795720-26-2	795720-27-3	795720-29-5	795720-31-9	795720-33-1
	795720-34-2	795720-36-4	795720-38-6	795720-40-0	795720-42-2
	795720-43-3	795720-45-5	795720-47-7	795720-49-9	795720-51-3
	795720-52-4	795720-54-6	795720-56-8	795720-58-0	795720-60-4
	795720-61-5	795720-63-7	795720-65-9	795720-67-1	795720-68-2
	795720-69-3	795720-72-8	795720-73-9	795720-76-2	795720-77-3
	795720-78-4	795720-81-9	795720-82-0	795720-85-3	795720-86-4
	795720-88-6	795720-90-0	795720-91-1	795720-94-4	795720-95-5
	795720-98-8	795720-99-9	795721-00-5	795721-03-8	795721-04-9
	795721-07-2	795721-08-3	795721-09-4	795721-12-9	795721-13-0
	795721-16-3	795721-17-4	795721-18-5	795721-21-0	795721-22-1
	795721-25-4	795721-26-5	795721-27-6	795721-30-1	795721-31-2
	795721-33-4	795721-35-6	795721-36-7	795721-39-0	795721-40-3
	795721-41-4	795721-44-7	795721-45-8	795721-48-1	795721-49-2
	795721-51-6	795721-53-8	795721-54-9	795721-57-2	795721-58-3

795721-60-7	795721-62-9	795721-63-0	795721-66-3	795721-67-4
795721-69-6	795721-71-0	795721-72-1	795721-75-4	795721-76-5
795721-79-8	795721-80-1	795721-83-4	795721-84-5	795721-85-6
795721-88-9	795721-89-0	795721-92-5	795721-93-6	795721-94-7
795721-97-0	795721-98-1	795722-01-9	795722-02-0	795722-04-2
795722-06-4	795722-07-5	795722-10-0	795722-11-1	795722-13-3
795722-15-5	795722-16-6	795722-19-9	795722-20-2	795722-23-5
795722-24-6	795722-25-7	795722-28-0	795722-29-1	795722-31-5
795722-33-7	795722-35-9	795722-37-1	795722-38-2	795722-40-6
795722-42-8	795722-44-0	795722-46-2	795722-47-3	795722-50-8
795722-51-9	795722-53-1	795722-55-3	795722-57-5	795722-59-7
795722-60-0	795722-62-2	795722-64-4	795722-66-6	795722-68-8
795722-69-9	795722-71-3	795722-73-5	795722-74-6	795722-76-8
795722-78-0	795722-79-1	795722-82-6	795722-83-7	795722-85-9
795722-87-1	795722-88-2	795722-91-7	795722-92-8	795722-94-0
795722-96-2	795722-97-3	795723-00-1	795723-01-2	795723-03-4
795723-05-6	795723-06-7	795723-09-0	795723-10-3	795723-12-5
795723-14-7	795723-15-8	795723-18-1	795723-19-2	795723-22-7
795723-23-8	795723-26-1	795723-27-2	795723-30-7	795723-31-8
795723-33-0	795723-35-2	795723-36-3	795723-39-6	795723-40-9
795723-43-2	795723-44-3	795723-47-6	795723-48-7	795723-51-2
795723-52-3	795723-53-4	795723-56-7	795723-57-8	795723-60-3
795723-61-4	795723-62-5	795723-65-8	795723-66-9	795723-69-2
795723-70-5	795723-72-7	795723-74-9	795723-75-0	795723-78-3
795723-79-4	795723-81-8	795723-83-0	795723-84-1	795723-87-4
795723-88-5	795723-90-9			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795723-92-1	795723-93-2	795723-96-5	795723-97-6	795723-99-8
	795724-01-5	795724-03-7	795724-05-9	795724-06-0	795724-10-6
	795724-12-8	795724-14-0	795724-16-2	795724-20-8	795724-22-0
	795724-23-1	795724-26-4	795724-27-5	795724-29-7	795724-31-1
	795724-32-2	795724-35-5	795724-36-6	795724-38-8	795724-40-2
	795724-42-4	795724-43-5	795724-45-7	795724-47-9	795724-49-1
	795724-50-4	795724-52-6	795724-54-8	795724-55-9	795724-57-1
	795724-58-2	795724-59-3	795724-60-6	795724-62-8	795724-64-0
	795724-65-1	795724-66-2	795724-68-4	795724-69-5	795724-71-9
	795724-72-0	795724-73-1	795724-74-2	795724-77-5	795724-78-6
	795724-80-0	795724-82-2	795724-83-3	795724-86-6	795724-87-7
	795724-89-9	795724-91-3	795724-93-5	795724-95-7	795724-96-8
	795724-98-0	795725-00-7	795725-02-9	795725-04-1	795725-05-2
	795725-07-4	795725-09-6	795725-11-0	795725-13-2	795725-14-3
	795725-17-6	795725-18-7	795725-20-1	795725-22-3	795725-23-4
	795725-26-7	795725-27-8	795725-29-0	795725-31-4	795725-33-6
	795725-35-8	795725-36-9	795725-39-2	795725-40-5	795725-42-7
	795725-44-9	795725-45-0	795725-48-3	795725-49-4	795725-51-8
	795725-53-0	795725-55-2	795725-57-4	795725-58-5	795725-61-0
	795725-62-1	795725-64-3	795725-66-5	795725-67-6	795725-70-1
	795725-71-2	795725-74-5	795725-75-6	795725-77-8	795725-79-0
	795725-80-3	795725-83-6	795725-84-7	795725-85-8	795725-88-1
	795725-89-2	795725-92-7	795725-93-8	795725-94-9	795725-97-2
	795725-98-3	795726-01-1	795726-02-2	795726-04-4	795726-06-6
	795726-07-7	795726-10-2	795726-11-3	795726-13-5	795726-15-7
	795726-16-8	795726-19-1	795726-20-4	795726-22-6	795726-24-8
	795726-26-0	795726-28-2	795726-29-3	795726-32-8	795726-33-9
	795726-35-1	795726-37-3	795726-39-5	795726-41-9	795726-42-0
	795726-44-2	795726-46-4	795726-48-6	795726-50-0	795726-52-2
	795726-53-3	795726-55-5	795726-57-7	795726-59-9	795726-61-3
	795726-63-5	795726-64-6	795726-66-8	795726-68-0	795726-70-4
	795726-72-6	795726-74-8	795726-75-9	795726-77-1	795726-79-3
	795726-81-7	795726-83-9	795726-85-1	795726-86-2	795726-88-4
	795726-90-8	795726-92-0	795726-94-2	795726-96-4	795726-98-6
	795727-00-3	795727-01-4	795727-03-6	795727-05-8	795727-07-0
	795727-09-2	795727-10-5	795727-13-8	795727-14-9	795727-16-1
	795727-17-2	795727-19-4	795727-20-7	795727-22-9	795727-23-0
	795727-25-2	795727-26-3	795727-29-6	795727-30-9	795727-32-1
	795727-34-3	795727-36-5	795727-38-7	795727-39-8	795727-41-2
	795727-43-4	795727-44-5	795727-46-7	795727-47-8	795727-49-0
	795727-50-3	795727-52-5	795727-54-7	795727-56-9	795727-58-1
	795727-59-2	795727-61-6	795727-63-8	795727-65-0	795727-67-2
	795727-68-3	795727-70-7	795727-72-9	795727-74-1	795727-76-3
	795727-77-4	795727-79-6	795727-80-9	795727-82-1	795727-83-2
	795727-85-4	795727-87-6	795727-89-8	795727-91-2	795727-92-3
	795727-94-5	795727-96-7	795727-98-9	795728-00-6	795728-01-7

795728-03-9 795728-04-0 795728-06-2 795728-08-4 795728-09-5
795728-11-9 795728-13-1

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795728-15-3	795728-16-4	795728-18-6	795728-20-0	795728-22-2
	795728-24-4	795728-26-6	795728-28-8	795728-29-9	795728-31-3
	795728-33-5	795728-35-7	795728-37-9	795728-38-0	795728-40-4
	795728-42-6	795728-44-8	795728-46-0	795728-47-1	795728-49-3
	795728-50-6	795728-52-8	795728-53-9	795728-55-1	795728-57-3
	795728-59-5	795728-60-8	795728-62-0	795728-64-2	795728-65-3
	795728-68-6	795728-69-7	795728-70-0	795728-72-2	795728-73-3
	795728-75-5	795728-77-7	795728-78-8	795728-80-2	795728-82-4
	795728-84-6	795728-86-8	795728-88-0	795728-89-1	795728-91-5
	795728-93-7	795728-95-9	795728-97-1	795728-99-3	795729-00-9
	795729-02-1	795729-04-3	795729-06-5	795729-08-7	795729-10-1
	795729-11-2	795729-13-4	795729-15-6	795729-17-8	795729-19-0
	795729-21-4	795729-23-6	795729-25-8	795729-26-9	795729-28-1
	795729-30-5	795729-32-7	795729-34-9	795729-36-1	795729-37-2
	795729-39-4	795729-41-8	795729-43-0	795729-45-2	795729-47-4
	795729-48-5	795729-50-9	795729-52-1	795729-54-3	795729-56-5
	795729-58-7	795729-59-8	795729-61-2	795729-63-4	795729-65-6
	795729-67-8	795729-68-9	795729-70-3	795729-72-5	795729-74-7
	795729-76-9	795729-78-1	795729-80-5	795729-81-6	795729-83-8
	795729-85-0	795729-87-2	795729-89-4	795729-90-7	795729-93-0
	795729-94-1	795729-97-4	795729-98-5	795730-00-6	795730-02-8
	795730-04-0	795730-06-2	795730-07-3	795730-08-4	795730-10-8
	795730-11-9	795730-13-1	795730-14-2	795730-17-5	795730-18-6
	795730-19-7	795730-22-2	795730-23-3	795730-24-4	795730-27-7
	795730-28-8	795730-29-9	795730-31-3	795730-33-5	795730-34-6
	795730-36-8	795730-38-0	795730-39-1	795730-41-5	795730-42-6
	795730-44-8	795730-46-0	795730-47-1	795730-49-3	795730-51-7
	795730-52-8	795730-55-1	795730-56-2	795730-57-3	795730-60-8
	795730-62-0	795730-64-2	795730-65-3	795730-68-6	795730-69-7
	795730-72-2	795730-73-3	795730-74-4	795730-77-7	795730-78-8
	795730-81-3	795730-82-4	795730-84-6	795730-86-8	795730-87-9
	795730-90-4	795730-91-5	795730-94-8	795730-95-9	795730-97-1
	795730-99-3	795731-00-9	795731-03-2	795731-04-3	795731-06-5
	795731-08-7	795731-09-8	795731-12-3	795731-13-4	795731-16-7
	795731-17-8	795731-19-0	795731-21-4	795731-22-5	795731-25-8
	795731-26-9	795731-28-1	795731-30-5	795731-31-6	795731-34-9
	795731-35-0	795731-38-3	795731-39-4	795731-42-9	795731-43-0
	795731-45-2	795731-47-4	795731-48-5	795731-51-0	795731-52-1
	795731-55-4	795731-56-5	795731-58-7	795731-60-1	795731-61-2
	795731-64-5	795731-65-6	795731-67-8	795731-69-0	795731-71-4
	795731-73-6	795731-74-7	795731-76-9	795731-78-1	795731-79-2
	795731-82-7	795731-83-8	795731-85-0	795731-87-2	795731-88-3
	795731-91-8	795731-92-9	795731-95-2	795731-96-3	795731-99-6
	795732-00-2	795732-02-4	795732-04-6	795732-05-7	795732-08-0
	795732-09-1	795732-12-6	795732-13-7	795732-16-0	795732-17-1
	795732-19-3	795732-21-7	795732-22-8	795732-25-1	795732-26-2
	795732-29-5	795732-30-8	795732-32-0	795732-34-2	795732-35-3
	795732-38-6	795732-39-7			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795732-42-2	795732-43-3	795732-45-5	795732-47-7	795732-48-8
	795732-51-3	795732-52-4	795732-54-6	795732-56-8	795732-57-9
	795732-60-4	795732-61-5	795732-64-8	795732-65-9	795732-67-1
	795732-69-3	795732-70-6	795732-73-9	795732-74-0	795732-77-3
	795732-78-4	795732-80-8	795732-82-0	795732-84-2	795732-86-4
	795732-87-5	795732-90-0	795732-91-1	795732-94-4	795732-95-5
	795732-96-6	795732-99-9	795733-00-5	795733-03-8	795733-04-9
	795733-06-1	795733-08-3	795733-09-4	795733-12-9	795733-13-0
	795733-16-3	795733-17-4	795733-20-9	795733-21-0	795733-22-1
	795733-25-4	795733-26-5	795733-29-8	795733-30-1	795733-33-4
	795733-34-5	795733-35-6	795733-38-9	795733-39-0	795733-42-5
	795733-43-6	795733-46-9	795733-47-0	795733-48-1	795733-51-6
	795733-52-7	795733-55-0	795733-56-1	795733-59-4	795733-60-7
	795733-63-0	795733-64-1	795733-67-4	795733-68-5	795733-69-6
	795733-72-1	795733-73-2	795733-76-5	795733-77-6	795733-80-1
	795733-81-2	795733-82-3	795733-85-6	795733-86-7	795733-89-0
	795733-90-3	795733-92-5	795733-94-7	795733-95-8	795733-97-0
	795733-99-2	795734-01-9	795734-03-1	795734-05-3	795734-07-5

795734-09-7	795734-11-1	795734-13-3	795734-15-5	795734-17-7
795734-19-9	795734-21-3	795734-23-5	795734-24-6	795734-26-8
795734-28-0	795734-31-5	795734-32-6	795734-34-8	795734-36-0
795734-37-1	795734-39-3	795734-41-7	795734-43-9	795734-45-1
795734-47-3	795734-49-5	795734-51-9	795734-53-1	795734-54-2
795734-57-5	795734-58-6	795734-61-1	795734-62-2	795734-65-5
795734-66-6	795734-68-8	795734-70-2	795734-71-3	795734-74-6
795734-75-7	795734-78-0	795734-79-1	795734-81-5	795734-83-7
795734-84-8	795734-87-1	795734-88-2	795734-91-7	795734-92-8
795734-93-9	795734-96-2	795734-99-5	795735-00-1	795735-01-2
795735-04-5	795735-05-6	795735-08-9	795735-09-0	795735-11-4
795735-13-6	795735-14-7	795735-17-0	795735-18-1	795735-20-5
795735-22-7	795735-24-9	795735-26-1	795735-27-2	795735-29-4
795735-31-8	795735-32-9	795735-35-2	795735-36-3	795735-38-5
795735-40-9	795735-41-0	795735-44-3	795735-45-4	795735-48-7
795735-49-8	795735-51-2	795735-53-4	795735-54-5	795735-57-8
795735-58-9	795735-61-4	795735-62-5	795735-65-8	795735-66-9
795735-69-2	795735-70-5	795735-72-7	795735-74-9	795735-75-0
795735-78-3	795735-79-4	795735-82-9	795735-83-0	795735-86-3
795735-87-4	795735-88-5	795735-91-0	795735-92-1	795735-95-4
795735-96-5	795735-99-8	795736-00-4	795736-01-5	795736-04-8
795736-05-9	795736-08-2	795736-09-3	795736-12-8	795736-13-9
795736-16-2	795736-17-3	795736-18-4	795736-21-9	795736-22-0
795736-25-3	795736-26-4	795736-28-6	795736-30-0	795736-31-1
795736-34-4	795736-35-5	795736-38-8	795736-39-9	795736-42-4
795736-43-5	795736-46-8	795736-47-9	795736-49-1	795736-51-5
795736-52-6	795736-55-9	795736-56-0	795736-59-3	795736-60-6
795736-62-8	795736-64-0	795736-66-2	795736-68-4	795736-70-8
795736-72-0	795736-73-1	795736-76-4	795736-77-5	795736-80-0
795736-81-1	795736-83-3			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795736-85-5	795736-86-6	795736-89-9	795736-90-2	795736-92-4
	795736-94-6	795736-96-8	795736-98-0	795736-99-1	795737-02-9
	795737-03-0	795737-06-3	795737-07-4	795737-09-6	795737-11-0
	795737-13-2	795737-15-4	795737-16-5	795737-19-8	795737-20-1
	795737-23-4	795737-24-5	795737-26-7	795737-28-9	795737-30-3
	795737-32-5	795737-33-6	795737-36-9	795737-37-0	795737-39-2
	795737-41-6	795737-43-8	795737-45-0	795737-46-1	795737-48-3
	795737-50-7	795737-52-9	795737-54-1	795737-56-3	795737-58-5
	795737-60-9	795737-62-1	795737-64-3	795737-66-5	795737-67-6
	795737-69-8	795737-71-2	795737-73-4	795737-75-6	795737-77-8
	795737-79-0	795737-81-4	795737-83-6	795737-85-8	795737-87-0
	795737-88-1	795737-90-5	795737-92-7	795737-94-9	795737-96-1
	795737-98-3	795738-00-0	795738-02-2	795738-03-3	795738-05-5
	795738-07-7	795738-09-9	795738-11-3	795738-13-5	795738-15-7
	795738-16-8	795738-17-9	795738-19-1	795738-20-4	795738-21-5
	795738-23-7	795738-25-9	795738-26-0	795738-29-3	795738-30-6
	795738-33-9	795738-34-0	795738-37-3	795738-38-4	795738-39-5
	795738-42-0	795738-43-1	795738-46-4	795738-47-5	795738-50-0
	795738-51-1	795738-54-4	795738-55-5	795738-57-7	795738-59-9
	795738-60-2	795738-63-5	795738-64-6	795738-67-9	795738-68-0
	795738-70-4	795738-72-6	795738-73-7	795738-76-0	795738-77-1
	795738-80-6	795738-81-7	795738-82-8	795738-85-1	795738-86-2
	795738-88-4	795738-90-8	795738-92-0	795738-94-2	795738-96-4
	795738-98-6	795739-00-3	795739-02-5	795739-03-6	795739-06-9
	795739-08-1	795739-10-5	795739-12-7	795739-14-9	795739-15-0
	795739-18-3	795739-19-4	795739-21-8	795739-22-9	795739-24-1
	795739-26-3	795739-28-5	795739-30-9	795739-32-1	795739-34-3
	795739-35-4	795739-37-6	795739-39-8	795739-41-2	795739-43-4
	795739-45-6	795739-47-8	795739-48-9	795739-51-4	795739-52-5
	795739-54-7	795739-56-9	795739-58-1	795739-60-5	795739-61-6
	795739-64-9	795739-65-0	795739-68-3	795739-69-4	795739-70-7
	795739-73-0	795739-74-1	795739-77-4	795739-78-5	795739-81-0
	795739-82-1	795739-83-2	795739-86-5	795739-89-8	795739-90-1
	795739-91-2	795739-94-5	795739-95-6	795739-98-9	795739-99-0
	795740-02-2	795740-03-3	795740-06-6	795740-07-7	795740-08-8
	795740-11-3	795740-12-4	795740-15-7	795740-16-8	795740-19-1
	795740-20-4	795740-23-7	795740-24-8	795740-25-9	795740-28-2
	795740-29-3	795740-32-8	795740-33-9	795740-36-2	795740-37-3
	795740-39-5	795740-41-9	795740-42-0	795740-45-3	795740-46-4
	795740-49-7	795740-50-0	795740-52-2	795740-54-4	795740-56-6
	795740-58-8	795740-60-2	795740-62-4	795740-64-6	795740-66-8
	795740-67-9	795740-70-4	795740-71-5	795740-74-8	795740-75-9

795740-77-1 795740-79-3 795740-81-7 795740-83-9 795740-84-0
 795740-87-3 795740-88-4 795740-90-8 795740-92-0 795740-94-2
 795740-96-4 795740-97-5 795740-99-7 795741-01-4 795741-04-7
 795741-06-9 795741-07-0 795741-09-2 795741-11-6 795741-13-8
 795741-15-0 795741-16-1 795741-18-3 795741-19-4 795741-21-8
 795741-22-9 795741-25-2

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT 795741-26-3 795741-27-4 795741-29-6 795741-30-9 795741-31-0
 795741-32-1 795741-33-2 795741-34-3 795741-35-4 795741-36-5
 795741-39-8 795741-40-1 795741-42-3 795741-44-5 795741-45-6
 795741-47-8 795741-49-0

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT 795687-88-6
 RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

RN 795687-88-6 HCAPLUS

CN DNA, d(C-C-A-C-T-G-A-C-G-T-C-G-G-C-T-C-A-G-A-G-G-G-C-T) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 2 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:1022684 HCAPLUS

ED Entered STN: 29 Nov 2004

TI Oligonucleotide probes in nucleic acid arrays for genetic analysis of mouse

IN Mittman, Michael; Mack, David J.; Lockhart, David J.

PA Affymetrix, Inc., USA

SO U.S., 183 pp.

CODEN: USXXAM

DT Patent

LA English

IC C12Q001-68; C07H021-02; C07H021-04; G01N015-06; G01N033-00

NCL 435006000; 422068100; 536023100; 536024300; 536024310

CC 3-1 (Biochemical Genetics)

Section cross-reference(s): 13

FAN.CNT 26

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6821724	B1	20041123	US 1999-396196	19990915 <--
	US 6821724	B1	20041123	US 1999-396196	19990915 <--
PRAI	US 1998-100678P	P	19980917	<--	
	US 1999-396196	A	19990915	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6821724	IC	C12Q001-68IC C07H021-02IC C07H021-04IC G01N015-06IC G01N033-00
	NCL	435006000; 422068100; 536023100; 536024300; 536024310

AB This invention provides 127,806 unique oligonucleotide sequences which are complementary to .apprx.6500 specific known murine genes. The invention provides the sequences in such a way as to make them available for gene expression monitoring by hybridization to high d. oligonucleotide arrays, or for use as primers for PCR and other amplification protocols. As such, the invention related to diverse fields impacted by the nature of mol. interaction, including chemical, biol., medicine, and medical diagnostics. [This abstract record is one of 26 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

ST oligonucleotide probe microarray genetic analysis mouse; gene expression mouse oligonucleotide probe hybridization

IT DNA microarray technology
 DNA sequences
 Gene expression profiles, animal
 Genetic methods
 Mus musculus
 Nucleic acid amplification (method)
 Nucleic acid hybridization

PCR (polymerase chain reaction)
(oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT Primers (nucleic acid)
Probes (nucleic acid)
RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
(oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795526-79-3	795526-80-6	795526-81-7	795526-82-8	795526-83-9
	795526-84-0	795526-86-2	795526-87-3	795526-90-8	795526-91-9
	795526-92-0	795526-94-2	795526-95-3	795526-96-4	795526-97-5
	795526-98-6	795526-99-7	795527-00-3	795527-01-4	795527-02-5
	795527-03-6	795527-05-8	795527-06-9	795527-07-0	
	795527-08-1	795527-09-2	795527-10-5	795527-11-6	795527-12-7
	795527-14-9	795527-15-0	795527-16-1	795527-17-2	795527-18-3
	795527-19-4	795527-20-7	795527-25-2	795527-27-4	795527-28-5
	795527-29-6	795527-30-9	795527-32-1	795527-33-2	795527-34-3
	795527-35-4	795527-36-5	795527-37-6	795527-38-7	795527-39-8
	795527-41-2	795527-42-3	795527-43-4	795527-44-5	795527-45-6
	795527-46-7	795527-47-8	795527-49-0	795527-50-3	795527-51-4
	795527-52-5	795527-53-6	795527-55-8	795527-57-0	795527-59-2
	795527-61-6	795527-62-7	795527-63-8	795527-64-9	795527-65-0
	795527-67-2	795527-69-4	795527-71-8	795527-72-9	795527-73-0
	795527-74-1	795527-75-2	795527-76-3	795527-77-4	795527-78-5
	795527-79-6	795527-80-9	795527-81-0	795527-82-1	795527-84-3
	795527-85-4	795527-86-5	795527-87-6	795527-89-8	795527-91-2
	795527-93-4	795527-95-6	795527-97-8	795527-99-0	795528-01-7
	795528-03-9	795528-05-1	795528-06-2	795528-07-3	795528-08-4
	795528-09-5	795528-10-8	795528-11-9	795528-12-0	795528-13-1
	795528-37-9	795528-38-0	795528-39-1	795528-40-4	795528-41-5
	795528-42-6	795528-43-7	795528-45-9	795528-46-0	795528-47-1
	795528-48-2	795528-49-3	795528-50-6	795528-51-7	795528-52-8
	795528-53-9	795528-54-0	795528-56-2	795528-57-3	795528-58-4
	795528-59-5	795528-60-8	795528-62-0	795528-63-1	795528-64-2
	795528-65-3	795528-66-4	795528-67-5	795528-68-6	795528-69-7
	795528-70-0	795528-71-1	795528-72-2	795528-73-3	795528-74-4
	795528-75-5	795528-76-6	795528-77-7	795528-78-8	795528-79-9
	795528-80-2	795528-81-3	795528-82-4	795528-83-5	795528-84-6
	795528-85-7	795528-86-8	795528-87-9	795528-88-0	795528-89-1
	795528-90-4	795528-91-5	795528-93-7	795528-96-0	795528-97-1
	795528-98-2	795528-99-3	795529-00-9	795529-01-0	795529-02-1
	795529-04-3	795529-07-6	795529-09-8	795529-10-1	795529-11-2
	795529-12-3	795529-14-5	795529-15-6	795529-16-7	795529-18-9
	795529-23-6	795529-25-8	795529-26-9	795529-27-0	795529-28-1
	795529-29-2	795529-30-5	795529-31-6	795529-33-8	795529-34-9
	795529-35-0	795529-36-1	795529-37-2	795529-38-3	795529-39-4
	795529-43-0	795529-49-6	795529-54-3	795529-55-4	795529-56-5
	795529-57-6	795529-59-8	795529-61-2	795529-63-4	795529-65-6
	795529-67-8	795529-68-9	795529-69-0	795529-70-3	795529-71-4
	795529-72-5	795529-73-6	795529-76-9	795529-77-0	795529-78-1
	795529-79-2	795529-80-5	795529-81-6	795529-84-9	795529-86-1
	795529-88-3	795529-90-7	795529-92-9	795529-94-1	795529-96-3
	795529-97-4	795529-98-5	795529-99-6	795530-00-6	795530-01-7
	795530-02-8	795530-04-0	795530-05-1	795530-06-2	795530-07-3
	795530-08-4	795530-10-8	795530-12-0	795530-14-2	795530-16-4
	795530-18-6	795530-20-0	795530-22-2		

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795530-24-4	795530-26-6	795530-27-7	795530-28-8	795530-29-9
	795530-30-2	795530-31-3	795530-32-4	795530-33-5	795530-35-7
	795530-36-8	795530-37-9	795530-38-0	795530-40-4	795530-42-6
	795530-44-8	795530-46-0	795530-48-2	795530-50-6	795530-52-8
	795530-54-0	795530-56-2	795530-58-4	795530-60-8	795530-62-0
	795530-64-2	795530-66-4	795530-68-6	795530-69-7	795530-70-0
	795530-71-1	795530-72-2	795530-73-3	795530-75-5	795530-76-6
	795530-77-7	795530-78-8	795530-79-9	795530-80-2	795530-81-3
	795530-82-4	795530-83-5	795530-86-8	795530-88-0	795530-90-4
	795530-92-6	795530-94-8	795530-96-0	795530-98-2	795530-99-3
	795531-00-9	795531-01-0	795531-02-1	795531-04-3	795531-06-5
	795531-08-7	795531-10-1	795531-11-2	795531-12-3	795531-14-5
	795531-16-7	795531-18-9	795531-20-3	795531-22-5	795531-24-7
	795531-26-9	795531-28-1	795531-29-2	795531-30-5	795531-31-6
	795531-32-7	795531-34-9	795531-36-1	795531-38-3	795531-40-7

795531-42-9	795531-44-1	795531-46-3	795531-48-5	795531-50-9
795531-52-1	795531-54-3	795531-56-5	795531-57-6	795531-58-7
795531-59-8	795531-60-1	795531-62-3	795531-63-4	795531-65-6
795531-67-8	795531-69-0	795531-71-4	795531-73-6	795531-74-7
795531-76-9	795531-78-1	795531-80-5	795531-82-7	795531-84-9
795531-86-1	795531-88-3	795531-90-7	795531-92-9	795531-94-1
795531-95-2	795531-97-4	795531-99-6	795532-01-3	795532-03-5
795532-05-7	795532-07-9	795532-09-1	795532-11-5	795532-13-7
795532-16-0	795532-18-2	795532-20-6	795532-21-7	795532-22-8
795532-24-0	795532-25-1	795532-27-3	795532-29-5	795532-31-9
795532-32-0	795532-33-1	795532-35-3	795532-37-5	795532-39-7
795532-41-1	795532-43-3	795532-45-5	795532-47-7	795532-49-9
795532-50-2	795532-51-3	795532-52-4	795532-53-5	795532-55-7
795532-57-9	795532-59-1	795532-61-5	795532-63-7	795532-65-9
795532-67-1	795532-69-3	795532-71-7	795532-73-9	795532-74-0
795532-76-2	795532-77-3	795532-78-4	795532-80-8	795532-81-9
795532-82-0	795532-83-1	795532-84-2	795532-86-4	795532-88-6
795532-90-0	795532-92-2	795532-94-4	795532-96-6	795532-98-8
795533-00-5	795533-02-7	795533-04-9	795533-06-1	795533-08-3
795533-10-7	795533-12-9	795533-13-0	795533-15-2	795533-17-4
795533-19-6	795533-21-0	795533-23-2	795533-24-3	795533-26-5
795533-28-7	795533-30-1	795533-32-3	795533-34-5	795533-36-7
795533-38-9	795533-40-3	795533-42-5	795533-44-7	795533-45-8
795533-47-0	795533-49-2	795533-51-6	795533-53-8	795533-54-9
795533-56-1	795533-58-3	795533-60-7	795533-62-9	795533-64-1
795533-66-3	795533-68-5	795533-70-9	795533-71-0	795533-72-1
795533-73-2	795533-76-5	795533-78-7	795533-80-1	795533-82-3
795533-84-5	795533-86-7	795533-88-9	795533-90-3	795533-92-5
795533-94-7	795533-95-8	795533-96-9	795533-98-1	795533-99-2
795534-00-8	795534-01-9	795534-02-0	795534-03-1	795534-04-2
795534-06-4	795534-08-6	795534-10-0	795534-12-2	795534-14-4
795534-16-6	795534-18-8	795534-20-2	795534-22-4	795534-24-6
795534-26-8	795534-28-0			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795534-30-4	795534-31-5	795534-33-7	795534-35-9	795534-37-1
	795534-39-3	795534-41-7	795534-43-9	795534-45-1	795534-47-3
	795534-49-5	795534-50-8	795534-51-9	795534-52-0	795534-54-2
	795534-57-5	795534-60-0	795534-61-1	795534-62-2	795534-63-3
	795534-64-4	795534-68-8	795534-69-9	795534-70-2	795534-71-3
	795534-72-4	795534-74-6	795534-75-7	795534-76-8	795534-77-9
	795534-78-0	795534-79-1	795534-80-4	795534-87-1	795534-90-6
	795534-91-7	795534-92-8	795534-93-9	795534-94-0	795534-95-1
	795534-96-2	795534-97-3	795534-98-4	795535-00-1	795535-01-2
	795535-02-3	795535-03-4	795535-07-8	795535-14-7	795535-17-0
	795535-18-1	795535-19-2	795535-20-5	795535-21-6	795535-22-7
	795535-24-9	795535-25-0	795535-26-1	795535-27-2	795535-29-4
	795535-30-7	795535-31-8	795535-32-9	795535-33-0	795535-34-1
	795535-35-2	795535-36-3	795535-37-4	795535-38-5	795535-39-6
	795535-41-0	795535-42-1	795535-44-3	795535-46-5	795535-48-7
	795535-50-1	795535-52-3	795535-54-5	795535-56-7	795535-58-9
	795535-60-3	795535-62-5	795535-64-7	795535-66-9	795535-71-6
	795535-73-8	795535-74-9	795535-76-1	795535-79-4	795535-80-7
	795535-81-8	795535-82-9	795535-84-1	795535-85-2	795535-89-6
	795535-95-4	795535-96-5	795535-97-6	795535-98-7	795535-99-8
	795536-00-4	795536-01-5	795536-02-6	795536-04-8	795536-05-9
	795536-07-1	795536-13-9	795536-19-5	795536-21-9	795536-22-0
	795536-23-1	795536-24-2	795536-25-3	795536-26-4	795536-27-5
	795536-28-6	795536-30-0	795536-31-1	795536-32-2	795536-33-3
	795536-36-6	795536-45-7	795536-50-4	795536-52-6	795536-54-8
	795536-56-0	795536-58-2	795536-60-6	795536-62-8	795536-64-0
	795536-66-2	795536-68-4	795536-70-8	795536-72-0	795536-74-2
	795536-75-3	795536-76-4	795536-77-5	795536-78-6	795536-82-2
	795536-84-4	795536-85-5	795536-86-6	795536-87-7	795536-88-8
	795536-89-9	795536-93-5	795536-94-6	795536-95-7	795536-96-8
	795536-97-9	795536-98-0	795536-99-1	795537-00-7	795537-01-8
	795537-03-0	795537-04-1	795537-05-2	795537-09-6	795537-13-2
	795537-14-3	795537-15-4	795537-17-6	795537-18-7	795537-19-8
	795537-20-1	795537-21-2	795537-22-3	795537-23-4	795537-24-5
	795537-25-6	795537-27-8	795537-28-9	795537-31-4	795537-38-1
	795537-43-8	795537-44-9	795537-45-0	795537-46-1	795537-47-2
	795537-48-3	795537-49-4	795537-50-7	795537-52-9	795537-53-0
	795537-54-1	795537-55-2	795537-56-3	795537-57-4	795537-58-5
	795537-59-6	795537-60-9	795537-61-0	795537-64-3	795537-66-5

795537-68-7	795537-70-1	795537-72-3	795537-74-5	795537-76-7
795537-78-9	795537-80-3	795537-82-5	795537-84-7	795537-86-9
795537-87-0	795537-89-2	795537-91-6	795537-92-7	795537-94-9
795537-95-0	795537-97-2	795537-99-4	795538-01-1	795538-03-3
795538-04-4	795538-06-6	795538-08-8	795538-10-2	795538-12-4
795538-14-6	795538-16-8	795538-18-0	795538-19-1	795538-21-5
795538-23-7	795538-26-0	795538-29-3	795538-35-1	795538-36-2
795538-38-4	795538-40-8	795538-45-3	795538-47-5	795538-49-7
795538-51-1	795538-53-3			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795538-55-5	795538-57-7	795538-59-9	795538-61-3	795538-62-4
	795538-64-6	795538-66-8	795538-68-0	795538-70-4	795538-72-6
	795538-74-8	795538-76-0	795538-79-3	795538-81-7	795538-83-9
	795538-85-1	795538-87-3	795538-89-5	795538-91-9	795538-93-1
	795538-94-2	795538-96-4	795538-98-6	795539-00-3	795539-02-5
	795539-04-7	795539-06-9	795539-08-1	795539-10-5	795539-11-6
	795539-12-7	795539-14-9	795539-16-1	795539-18-3	795539-20-7
	795539-22-9	795539-24-1	795539-26-3	795539-28-5	795539-30-9
	795539-32-1	795539-34-3	795539-36-5	795539-37-6	795539-39-8
	795539-41-2	795539-43-4	795539-45-6	795539-47-8	795539-49-0
	795539-51-4	795539-53-6	795539-55-8	795539-57-0	795539-59-2
	795539-61-6	795539-63-8	795539-65-0	795539-66-1	795539-68-3
	795539-70-7	795539-71-8	795539-72-9	795539-73-0	795539-74-1
	795539-75-2	795539-76-3	795539-77-4	795539-79-6	795539-80-9
	795539-81-0	795539-82-1	795539-83-2	795539-87-6	795539-89-8
	795539-90-1	795539-91-2	795539-92-3	795539-93-4	795539-94-5
	795539-95-6	795539-96-7	795539-97-8	795540-03-3	795540-05-5
	795540-06-6	795540-07-7	795540-08-8	795540-09-9	795540-10-2
	795540-11-3	795540-12-4	795540-14-6	795540-15-7	795540-16-8
	795540-17-9	795540-18-0	795540-19-1	795540-20-4	795540-26-0
	795540-31-7	795540-32-8	795540-33-9	795540-34-0	795540-35-1
	795540-36-2	795540-38-4	795540-39-5	795540-40-8	795540-41-9
	795540-42-0	795540-43-1	795540-44-2	795540-45-3	795540-47-5
	795540-48-6	795540-50-0	795540-52-2	795540-54-4	795540-56-6
	795540-58-8	795540-60-2	795540-62-4	795540-64-6	795540-66-8
	795540-68-0	795540-70-4	795540-75-9	795540-76-0	795540-77-1
	795540-78-2	795540-80-6	795540-84-0	795540-85-1	795540-86-2
	795540-87-3	795540-88-4	795540-96-4	795540-97-5	795540-98-6
	795540-99-7	795541-00-3	795541-01-4	795541-02-5	795541-03-6
	795541-04-7	795541-06-9	795541-08-1	795541-15-0	795541-17-2
	795541-18-3	795541-19-4	795541-20-7	795541-21-8	795541-23-0
	795541-24-1	795541-25-2	795541-26-3	795541-27-4	795541-28-5
	795541-32-1	795541-41-2	795541-45-6	795541-47-8	795541-49-0
	795541-51-4	795541-53-6	795541-55-8	795541-57-0	795541-59-2
	795541-61-6	795541-63-8	795541-65-0	795541-67-2	795541-69-4
	795541-70-7	795541-71-8	795541-72-9	795541-73-0	795541-74-1
	795541-78-5	795541-79-6	795541-80-9	795541-82-1	795541-86-5
	795541-87-6	795541-88-7	795541-89-8	795541-91-2	795541-92-3
	795541-93-4	795541-95-6	795541-99-0	795542-01-7	795542-02-8
	795542-03-9	795542-04-0	795542-05-1	795542-06-2	795542-08-4
	795542-09-5	795542-10-8	795542-11-9	795542-12-0	795542-13-1
	795542-14-2	795542-15-3	795542-16-4	795542-23-3	795542-27-7
	795542-28-8	795542-30-2	795542-31-3	795542-32-4	795542-33-5
	795542-34-6	795542-35-7	795542-36-8	795542-37-9	795542-38-0
	795542-39-1	795542-41-5	795542-42-6	795542-43-7	795542-44-8
	795542-45-9	795542-46-0	795542-47-1	795542-48-2	795542-51-7
	795542-53-9	795542-55-1	795542-57-3	795542-59-5	795542-61-9
	795542-63-1	795542-64-2			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795542-66-4	795542-68-6	795542-70-0	795542-72-2	795542-74-4
	795542-76-6	795542-77-7	795542-78-8	795542-79-9	795542-80-2
	795542-82-4	795542-83-5	795542-84-6	795542-85-7	795542-86-8
	795542-88-0	795542-90-4	795542-92-6	795542-94-8	795542-96-0
	795542-98-2	795543-00-9	795543-01-0	795543-02-1	795543-04-3
	795543-06-5	795543-08-7	795543-10-1	795543-12-3	795543-14-5
	795543-16-7	795543-18-9	795543-20-3	795543-21-4	795543-23-6
	795543-24-7	795543-25-8	795543-26-9	795543-28-1	795543-30-5
	795543-32-7	795543-34-9	795543-36-1	795543-38-3	795543-40-7
	795543-42-9	795543-44-1	795543-46-3	795543-48-5	795543-50-9
	795543-51-0	795543-53-2	795543-55-4	795543-57-6	795543-59-8

795543-61-2	795543-64-5	795543-66-7	795543-68-9	795543-70-3
795543-72-5	795543-73-6	795543-75-8	795543-77-0	795543-79-2
795543-81-6	795543-83-8	795543-85-0	795543-87-2	795543-89-4
795543-91-8	795543-93-0	795543-94-1	795543-95-2	795543-96-3
795543-98-5	795544-00-2	795544-02-4	795544-04-6	795544-06-8
795544-08-0	795544-10-4	795544-12-6	795544-14-8	795544-16-0
795544-17-1	795544-18-2	795544-19-3	795544-20-6	795544-21-7
795544-22-8	795544-24-0	795544-26-2	795544-28-4	795544-30-8
795544-32-0	795544-34-2	795544-36-4	795544-38-6	795544-40-0
795544-41-1	795544-43-3	795544-45-5	795544-47-7	795544-49-9
795544-51-3	795544-53-5	795544-55-7	795544-57-9	795544-59-1
795544-60-4	795544-61-5	795544-62-6	795544-63-7	795544-64-8
795544-65-9	795544-66-0	795544-67-1	795544-68-2	795544-69-3
795544-70-6	795544-71-7	795544-72-8	795544-74-0	795544-76-2
795544-77-3	795544-78-4	795544-79-5	795544-80-8	795544-82-0
795544-83-1	795544-84-2	795544-85-3	795544-91-1	795544-92-2
795544-93-3	795544-94-4	795544-95-5	795544-97-7	795544-98-8
795544-99-9	795545-00-5	795545-01-6	795545-02-7	795545-03-8
795545-04-9	795545-05-0	795545-06-1	795545-07-2	795545-08-3
795545-10-7	795545-11-8	795545-12-9	795545-13-0	795545-14-1
795545-15-2	795545-16-3	795545-17-4	795545-18-5	795545-19-6
795545-20-9	795545-21-0	795545-22-1	795545-24-3	795545-25-4
795545-26-5	795545-27-6	795545-28-7	795545-29-8	795545-30-1
795545-31-2	795545-32-3	795545-33-4	795545-34-5	795545-36-7
795545-37-8	795545-38-9	795545-40-3	795545-42-5	795545-44-7
795545-46-9	795545-48-1	795545-50-5	795545-52-7	795545-53-8
795545-55-0	795545-57-2	795545-59-4	795545-60-7	795545-61-8
795545-62-9	795545-63-0	795545-64-1	795545-65-2	795545-66-3
795545-67-4	795545-68-5	795545-70-9	795545-71-0	795545-73-2
795545-75-4	795545-77-6	795545-79-8	795545-80-1	795545-81-2
795545-82-3	795545-83-4	795545-84-5	795545-85-6	795545-87-8
795545-89-0	795545-91-4	795545-93-6	795545-95-8	795545-97-0
795545-99-2	795546-00-8	795546-01-9	795546-02-0	795546-03-1
795546-04-2	795546-05-3	795546-07-5	795546-08-6	795546-10-0
795546-12-2	795546-14-4	795546-16-6	795546-18-8	795546-20-2
795546-22-4	795546-24-6	795546-26-8	795546-28-0	795546-30-4
795546-31-5	795546-33-7			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795546-35-9	795546-37-1	795546-39-3	795546-42-8	795546-44-0
	795546-46-2	795546-48-4	795546-50-8	795546-51-9	795546-52-0
	795546-54-2	795546-56-4	795546-57-5	795546-58-6	795546-59-7
	795546-60-0	795546-62-2	795546-64-4	795546-66-6	795546-68-8
	795546-70-2	795546-71-3	795546-72-4	795546-73-5	795546-74-6
	795546-76-8	795546-78-0	795546-80-4	795546-82-6	795546-84-8
	795546-86-0	795546-88-2	795546-90-6	795546-91-7	795546-92-8
	795546-93-9	795546-95-1	795546-96-2	795546-97-3	795546-98-4
	795546-99-5	795547-01-2	795547-03-4	795547-05-6	795547-07-8
	795547-09-0	795547-11-4	795547-13-6	795547-15-8	795547-17-0
	795547-18-1	795547-20-5	795547-22-7	795547-24-9	795547-26-1
	795547-28-3	795547-30-7	795547-32-9	795547-34-1	795547-35-2
	795547-36-3	795547-37-4	795547-41-0	795547-43-2	795547-44-3
	795547-49-8	795547-50-1	795547-51-2	795547-52-3	795547-53-4
	795547-54-5	795547-55-6	795547-60-3	795547-63-6	795547-65-8
	795547-66-9	795547-67-0	795547-68-1	795547-69-2	795547-70-5
	795547-71-6	795547-72-7	795547-73-8	795547-74-9	795547-75-0
	795547-84-1	795547-86-3	795547-87-4	795547-88-5	795547-89-6
	795547-90-9	795547-91-0	795547-93-2	795547-94-3	795547-95-4
	795547-96-5	795547-97-6	795547-98-7	795547-99-8	795548-00-4
	795548-01-5	795548-02-6	795548-05-9	795548-07-1	795548-09-3
	795548-11-7	795548-13-9	795548-15-1	795548-17-3	795548-19-5
	795548-21-9	795548-22-0	795548-24-2	795548-26-4	795548-28-6
	795548-29-7	795548-31-1	795548-33-3	795548-34-4	795548-35-5
	795548-36-6	795548-38-8	795548-40-2	795548-42-4	795548-44-6
	795548-46-8	795548-47-9	795548-48-0	795548-49-1	795548-51-5
	795548-53-7	795548-55-9	795548-57-1	795548-59-3	795548-61-7
	795548-63-9	795548-65-1	795548-67-3	795548-68-4	795548-69-5
	795548-70-8	795548-72-0	795548-74-2	795548-76-4	795548-78-6
	795548-80-0	795548-82-2	795548-84-4	795548-86-6	795548-88-8
	795548-90-2	795548-92-4	795548-94-6	795548-95-7	795548-97-9
	795549-99-1	795549-02-9	795549-04-1	795549-06-3	795549-08-5
	795549-10-9	795549-12-1	795549-13-2	795549-15-4	795549-17-6
	795549-18-7	795549-21-2	795549-23-4	795549-25-6	795549-27-8
	795549-29-0	795549-31-4	795549-32-5	795549-33-6	795549-35-8

795549-37-0	795549-39-2	795549-41-6	795549-43-8	795549-45-0
795549-47-2	795549-49-4	795549-50-7	795549-52-9	795549-53-0
795549-54-1	795549-56-3	795549-58-5	795549-60-9	795549-62-1
795549-64-3	795549-66-5	795549-68-7	795549-70-1	795549-72-3
795549-74-5	795549-76-7	795549-77-8	795549-79-0	795549-81-4
795549-83-6	795549-86-9	795549-87-0	795549-89-2	795549-90-5
795549-92-7	795549-94-9	795549-96-1	795549-98-3	795550-00-4
795550-01-5	795550-03-7	795550-05-9	795550-07-1	795550-09-3
795550-11-7	795550-13-9	795550-14-0	795550-15-1	795550-17-3
795550-19-5	795550-21-9	795550-23-1	795550-25-3	795550-27-5
795550-29-7	795550-31-1	795550-33-3	795550-34-4	795550-35-5
795550-37-7	795550-39-9	795550-41-3	795550-43-5	795550-45-7
795550-47-9	795550-49-1			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795550-51-5	795550-53-7	795550-55-9	795550-57-1	795550-59-3
	795550-60-6	795550-62-8	795550-65-1	795550-67-3	795550-69-5
	795550-71-9	795550-73-1	795550-75-3	795550-77-5	795550-79-7
	795550-81-1	795550-83-3	795550-85-5	795550-87-7	795550-89-9
	795550-91-3	795550-93-5	795550-95-7	795550-97-9	795550-99-1
	795551-01-8	795551-03-0	795551-05-2	795551-07-4	795551-09-6
	795551-11-0	795551-13-2	795551-14-3	795551-15-4	795551-17-6
	795551-19-8	795551-21-2	795551-23-4	795551-25-6	795551-27-8
	795551-29-0	795551-31-4	795551-33-6	795551-35-8	795551-37-0
	795551-38-1	795551-40-5	795551-42-7	795551-44-9	795551-46-1
	795551-49-4	795551-51-8	795551-53-0	795551-55-2	795551-56-3
	795551-58-5	795551-60-9	795551-62-1	795551-63-2	795551-65-4
	795551-67-6	795551-69-8	795551-71-2	795551-73-4	795551-75-6
	795551-76-7	795551-77-8	795551-79-0	795551-81-4	795551-83-6
	795551-85-8	795551-87-0	795551-89-2	795551-91-6	795551-93-8
	795551-94-9	795551-95-0	795551-96-1	795551-98-3	795552-00-0
	795552-02-2	795552-04-4	795552-06-6	795552-08-8	795552-10-2
	795552-12-4	795552-14-6	795552-16-8	795552-18-0	795552-20-4
	795552-22-6	795552-24-8	795552-26-0	795552-28-2	795552-30-6
	795552-32-8	795552-34-0	795552-35-1	795552-38-4	795552-40-8
	795552-41-9	795552-42-0	795552-44-2	795552-46-4	795552-48-6
	795552-50-0	795552-52-2	795552-54-4	795552-55-5	795552-57-7
	795552-59-9	795552-61-3	795552-63-5	795552-65-7	795552-67-9
	795552-69-1	795552-71-5	795552-72-6	795552-73-7	795552-74-8
	795552-76-0	795552-78-2	795552-80-6	795552-82-8	795552-84-0
	795552-86-2	795552-88-4	795552-90-8	795552-92-0	795552-94-2
	795552-95-3	795552-97-5	795552-99-7	795553-01-4	795553-04-7
	795553-06-9	795553-08-1	795553-10-5	795553-12-7	795553-14-9
	795553-16-1	795553-17-2	795553-19-4	795553-21-8	795553-23-0
	795553-25-2	795553-27-4	795553-29-6	795553-31-0	795553-33-2
	795553-35-4	795553-37-6	795553-39-8	795553-41-2	795553-43-4
	795553-45-6	795553-47-8	795553-48-9	795553-49-0	795553-51-4
	795553-53-6	795553-55-8	795553-57-0	795553-59-2	795553-61-6
	795553-63-8	795553-65-0	795553-67-2	795553-69-4	795553-71-8
	795553-72-9	795553-74-1	795553-77-4	795553-79-6	795553-81-0
	795553-83-2	795553-85-4	795553-86-5	795553-88-7	795553-90-1
	795553-92-3	795553-94-5	795553-96-7	795553-98-9	795554-00-6
	795554-02-8	795554-04-0	795554-05-1	795554-07-3	795554-09-5
	795554-11-9	795554-13-1	795554-15-3	795554-17-5	795554-19-7
	795554-21-1	795554-22-2	795554-23-3	795554-25-5	795554-27-7
	795554-29-9	795554-31-3	795554-33-5	795554-35-7	795554-37-9
	795554-39-1	795554-41-5	795554-43-7	795554-45-9	795554-46-0
	795554-48-2	795554-50-6	795554-53-9	795554-55-1	795554-57-3
	795554-60-8	795554-62-0	795554-64-2	795554-65-3	795554-67-5
	795554-69-7	795554-71-1	795554-73-3	795554-75-5	795554-77-7
	795554-78-8	795554-80-2	795554-82-4	795554-84-6	795554-86-8
	795554-88-0	795554-90-4	795554-92-6	795554-93-7	795554-94-8
	795554-95-9	795554-98-2			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795555-00-9	795555-02-1	795555-04-3	795555-06-5	795555-08-7
	795555-10-1	795555-12-3	795555-14-5	795555-16-7	795555-18-9
	795555-19-0	795555-21-4	795555-24-7	795555-26-9	795555-29-2
	795555-31-6	795555-32-7	795555-33-8	795555-35-0	795555-37-2
	795555-39-4	795555-41-8	795555-43-0	795555-45-2	795555-47-4
	795555-49-6	795555-51-0	795555-53-2	795555-55-4	795555-57-6
	795555-59-8	795555-61-2	795555-63-4	795555-65-6	795555-67-8

795555-68-9	795555-69-0	795555-71-4	795555-73-6	795555-75-8
795555-77-0	795555-79-2	795555-81-6	795555-83-8	795555-85-0
795555-87-2	795555-89-4	795555-91-8	795555-92-9	795555-95-2
795555-97-4	795555-99-6	795556-01-3	795556-02-4	795556-04-6
795556-06-8	795556-08-0	795556-10-4	795556-11-5	795556-13-7
795556-15-9	795556-17-1	795556-19-3	795556-21-7	795556-24-0
795556-26-2	795556-28-4	795556-30-8	795556-32-0	795556-34-2
795556-36-4	795556-38-6	795556-39-7	795556-40-0	795556-41-1
795556-43-3	795556-45-5	795556-47-7	795556-49-9	795556-51-3
795556-53-5	795556-55-7	795556-57-9	795556-59-1	795556-61-5
795556-63-7	795556-65-9	795556-66-0	795556-68-2	795556-70-6
795556-72-8	795556-74-0	795556-77-3	795556-78-4	795556-80-8
795556-82-0	795556-84-2	795556-86-4	795556-88-6	795556-90-0
795556-92-2	795556-94-4	795556-96-6	795556-98-8	795557-00-5
795557-02-7	795557-04-9	795557-06-1	795557-08-3	795557-10-7
795557-12-9	795557-13-0	795557-15-2	795557-17-4	795557-19-6
795557-21-0	795557-23-2	795557-25-4	795557-27-6	795557-29-8
795557-31-2	795557-33-4	795557-34-5	795557-36-7	795557-38-9
795557-41-4	795557-43-6	795557-44-7	795557-46-9	795557-47-0
795557-50-5	795557-51-6	795557-52-7	795557-55-0	795557-57-2
795557-59-4	795557-61-8	795557-63-0	795557-64-1	795557-65-2
795557-67-4	795557-69-6	795557-71-0	795557-73-2	795557-75-4
795557-77-6	795557-79-8	795557-81-2	795557-82-3	795557-84-5
795557-86-7	795557-88-9	795557-90-3	795557-92-5	795557-94-7
795557-96-9	795557-98-1	795558-00-8	795558-02-0	795558-04-2
795558-06-4	795558-08-6	795558-11-1	795558-14-4	795558-15-5
795558-16-6	795558-18-8	795558-20-2	795558-21-3	795558-23-5
795558-25-7	795558-27-9	795558-29-1	795558-31-5	795558-33-7
795558-34-8	795558-36-0	795558-38-2	795558-40-6	795558-42-8
795558-44-0	795558-46-2	795558-48-4	795558-50-8	795558-51-9
795558-53-1	795558-55-3	795558-57-5	795558-59-7	795558-61-1
795558-63-3	795558-65-5	795558-67-7	795558-69-9	795558-71-3
795558-72-4	795558-74-6	795558-76-8	795558-78-0	795558-80-4
795558-82-6	795558-84-8	795558-86-0	795558-87-1	795558-88-2
795558-90-6	795558-92-8	795558-93-9	795558-95-1	795558-97-3
795558-99-5	795559-01-2	795559-02-3	795559-03-4	795559-05-6
795559-06-7	795559-08-9	795559-10-3	795559-12-5	795559-14-7
795559-16-9	795559-18-1	795559-20-5	795559-21-6	795559-22-7
795559-24-9	795559-26-1	795559-28-3	795559-30-7	795559-32-9
795559-34-1	795559-36-3	795559-38-5	795559-40-9	795559-42-1
795559-44-3	795559-46-5			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795559-49-8	795559-51-2	795559-53-4	795559-55-6	795559-57-8
	795559-59-0	795559-61-4	795559-64-7	795559-66-9	795559-68-1
	795559-70-5	795559-72-7	795559-74-9	795559-76-1	795559-78-3
	795559-80-7	795559-82-9	795559-84-1	795559-86-3	795559-88-5
	795559-89-6	795559-91-0	795559-92-1	795559-94-3	795559-96-5
	795559-98-7	795560-00-8	795560-02-0	795560-04-2	795560-06-4
	795560-08-6	795560-09-7	795560-11-1	795560-13-3	795560-15-5
	795560-17-7	795560-19-9	795560-21-3	795560-23-5	795560-25-7
	795560-27-9	795560-29-1	795560-30-4	795560-31-5	795560-34-8
	795560-36-0	795560-38-2	795560-40-6	795560-41-7	795560-42-8
	795560-44-0	795560-46-2	795560-48-4	795560-50-8	795560-52-0
	795560-54-2	795560-55-3	795560-57-5	795560-58-6	795560-59-7
	795560-60-0	795560-62-2	795560-65-5	795560-67-7	795560-69-9
	795560-71-3	795560-73-5	795560-75-7	795560-77-9	795560-79-1
	795560-80-4	795560-82-6	795560-84-8	795560-87-1	795560-89-3
	795560-92-8	795560-94-0	795560-96-2	795560-98-4	795560-99-5
	795561-00-1	795561-02-3	795561-04-5	795561-06-7	795561-08-9
	795561-10-3	795561-11-4	795561-15-8	795561-17-0	795561-19-2
	795561-21-6	795561-22-7	795561-23-8	795561-25-0	795561-26-1
	795561-27-2	795561-29-4	795561-31-8	795561-33-0	795561-35-2
	795561-37-4	795561-39-6	795561-41-0	795561-43-2	795561-44-3
	795561-46-5	795561-48-7	795561-50-1	795561-52-3	795561-54-5
	795561-56-7	795561-58-9	795561-59-0	795561-60-3	795561-63-6
	795561-64-7	795561-65-8	795561-69-2	795561-70-5	795561-71-6
	795561-72-7	795561-73-8	795561-80-7	795561-81-8	795561-83-0
	795561-84-1	795561-85-2	795561-86-3	795561-87-4	795561-93-2
	795561-96-5	795561-98-7	795561-99-8	795562-00-4	795562-01-5
	795562-02-6	795562-03-7	795562-04-8	795562-05-9	795562-06-0
	795562-07-1	795562-09-3	795562-13-9	795562-15-1	795562-17-3
	795562-19-5	795562-21-9	795562-22-0	795562-24-2	795562-27-5
	795562-29-7	795562-30-0	795562-32-2	795562-33-3	795562-34-4

795562-36-6	795562-38-8	795562-40-2	795562-42-4	795562-43-5
795562-44-6	795562-45-7	795562-47-9	795562-49-1	795562-51-5
795562-53-7	795562-55-9	795562-57-1	795562-58-2	795562-59-3
795562-60-6	795562-62-8	795562-63-9	795562-65-1	795562-67-3
795562-69-5	795562-71-9	795562-73-1	795562-75-3	795562-77-5
795562-79-7	795562-80-0	795562-82-2	795562-84-4	795562-86-6
795562-88-8	795562-90-2	795562-92-4	795562-93-5	795562-94-6
795562-97-9	795562-98-0	795563-00-7	795563-02-9	795563-04-1
795563-05-2	795563-06-3	795563-07-4	795563-13-2	795563-14-3
795563-15-4	795563-16-5	795563-17-6	795563-18-7	795563-19-8
795563-20-1	795563-23-4	795563-30-3	795563-32-5	795563-33-6
795563-34-7	795563-35-8	795563-36-9	795563-37-0	795563-38-1
795563-39-2	795563-41-6	795563-43-8	795563-45-0	795563-47-2
795563-49-4	795563-54-1	795563-55-2	795563-57-4	795563-59-6
795563-60-9	795563-65-4	795563-67-6	795563-68-7	795563-69-8
795563-70-1	795563-73-4	795563-79-0	795563-80-3	795563-81-4
795563-83-6	795563-84-7			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795563-85-8	795563-86-9	795563-87-0	795563-95-0	795563-97-2
	795563-99-4	795564-01-1	795564-03-3	795564-05-5	795564-07-7
	795564-09-9	795564-11-3	795564-13-5	795564-15-7	795564-16-8
	795564-17-9	795564-20-4	795564-22-6	795564-25-9	795564-26-0
	795564-27-1	795564-28-2	795564-32-8	795564-34-0	795564-35-1
	795564-37-3	795564-38-4	795564-39-5	795564-40-8	795564-41-9
	795564-42-0	795564-50-0	795564-52-2	795564-53-3	795564-54-4
	795564-56-6	795564-57-7	795564-58-8	795564-59-9	795564-60-2
	795564-61-3	795564-63-5	795564-65-7	795564-67-9	795564-69-1
	795564-71-5	795564-73-7	795564-75-9	795564-76-0	795564-78-2
	795564-80-6	795564-81-7	795564-83-9	795564-85-1	795564-87-3
	795564-89-5	795564-91-9	795564-93-1	795564-95-3	795564-96-4
	795564-97-5	795564-98-6	795565-00-3	795565-02-5	795565-04-7
	795565-06-9	795565-08-1	795565-10-5	795565-11-6	795565-12-7
	795565-13-8	795565-15-0	795565-17-2	795565-19-4	795565-21-8
	795565-23-0	795565-25-2	795565-27-4	795565-29-6	795565-31-0
	795565-33-2	795565-35-4	795565-37-6	795565-39-8	795565-41-2
	795565-42-3	795565-44-5	795565-46-7	795565-48-9	795565-49-0
	795565-50-3	795565-54-7	795565-56-9	795565-58-1	795565-60-5
	795565-61-6	795565-63-8	795565-65-0	795565-67-2	795565-69-4
	795565-71-8	795565-73-0	795565-75-2	795565-77-4	795565-79-6
	795565-81-0	795565-83-2	795565-85-4	795565-87-6	795565-89-8
	795565-91-2	795565-93-4	795565-95-6	795565-97-8	795566-00-6
	795566-01-7	795566-02-8	795566-05-1	795566-07-3	795566-08-4
	795566-10-8	795566-12-0	795566-13-1	795566-15-3	795566-17-5
	795566-19-7	795566-21-1	795566-22-2	795566-23-3	795566-25-5
	795566-27-7	795566-29-9	795566-31-3	795566-33-5	795566-35-7
	795566-37-9	795566-38-0	795566-40-4	795566-42-6	795566-44-8
	795566-46-0	795566-48-2	795566-49-3	795566-50-6	795566-52-8
	795566-54-0	795566-56-2	795566-59-5	795566-61-9	795566-62-0
	795566-64-2	795566-66-4	795566-68-6	795566-70-0	795566-72-2
	795566-73-3	795566-74-4	795566-76-6	795566-78-8	795566-80-2
	795566-82-4	795566-84-6	795566-85-7	795566-87-9	795566-89-1
	795566-91-5	795566-93-7	795566-95-9	795566-97-1	795566-99-3
	795567-00-9	795567-02-1	795567-04-3	795567-06-5	795567-08-7
	795567-10-1	795567-12-3	795567-14-5	795567-16-7	795567-18-9
	795567-19-0	795567-22-5	795567-24-7	795567-26-9	795567-29-2
	795567-31-6	795567-32-7	795567-34-9	795567-36-1	795567-38-3
	795567-40-7	795567-42-9	795567-44-1	795567-45-2	795567-46-3
	795567-50-9	795567-52-1	795567-54-3	795567-56-5	795567-57-6
	795567-58-7	795567-59-8	795567-60-1	795567-62-3	795567-64-5
	795567-66-7	795567-68-9	795567-70-3	795567-72-5	795567-74-7
	795567-76-9	795567-78-1	795567-79-2	795567-82-7	795567-84-9
	795567-86-1	795567-87-2	795567-89-4	795567-92-9	795567-94-1
	795567-95-2	795567-97-4	795567-99-6	795568-01-3	795568-03-5
	795568-05-7	795568-07-9	795568-09-1	795568-11-5	795568-13-7
	795568-15-9	795568-17-1	795568-18-2	795568-19-3	795568-20-6
	795568-22-8	795568-24-0			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795568-26-2	795568-28-4	795568-30-8	795568-32-0	795568-34-2
	795568-36-4	795568-38-6	795568-39-7	795568-41-1	795568-43-3
	795568-45-5	795568-47-7	795568-49-9	795568-51-3	795568-53-5

795568-55-7	795568-56-8	795568-58-0	795568-60-4	795568-62-6
795568-64-8	795568-66-0	795568-68-2	795568-70-6	795568-72-8
795568-74-0	795568-76-2	795568-78-4	795568-79-5	795568-80-8
795568-82-0	795568-84-2	795568-86-4	795568-88-6	795568-90-0
795568-92-2	795568-94-4	795568-96-6	795568-98-8	795568-99-9
795569-01-6	795569-04-9	795569-06-1	795569-09-4	795569-11-8
795569-13-0	795569-15-2	795569-17-4	795569-19-6	795569-21-0
795569-23-2	795569-26-5	795569-28-7	795569-30-1	795569-32-3
795569-34-5	795569-36-7	795569-37-8	795569-38-9	795569-39-0
795569-44-7	795569-46-9	795569-47-0	795569-49-2	795569-51-6
795569-53-8	795569-55-0	795569-56-1	795569-58-3	795569-60-7
795569-63-0	795569-65-2	795569-66-3	795569-68-5	795569-69-6
795569-71-0	795569-73-2	795569-75-4	795569-77-6	795569-79-8
795569-81-2	795569-82-3	795569-83-4	795569-85-6	795569-87-8
795569-90-3	795569-92-5	795569-94-7	795569-96-9	795569-97-0
795569-98-1	795570-00-2	795570-02-4	795570-04-6	795570-06-8
795570-08-0	795570-10-4	795570-12-6	795570-14-8	795570-15-9
795570-17-1	795570-19-3	795570-22-8	795570-24-0	795570-26-2
795570-28-4	795570-30-8	795570-32-0	795570-34-2	795570-36-4
795570-39-7	795570-41-1	795570-42-2	795570-43-3	795570-45-5
795570-47-7	795570-49-9	795570-51-3	795570-53-5	795570-55-7
795570-58-0	795570-60-4	795570-62-6	795570-64-8	795570-66-0
795570-68-2	795570-70-6	795570-72-8	795570-74-0	795570-76-2
795570-78-4	795570-81-9	795570-83-1	795570-84-2	795570-88-6
795570-90-0	795570-92-2	795570-94-4	795570-96-6	795570-98-8
795571-00-5	795571-01-6	795571-03-8	795571-05-0	795571-07-2
795571-09-4	795571-11-8	795571-13-0	795571-15-2	795571-16-3
795571-18-5	795571-20-9	795571-22-1	795571-24-3	795571-26-5
795571-28-7	795571-30-1	795571-32-3	795571-35-6	795571-37-8
795571-39-0	795571-41-4	795571-43-6	795571-45-8	795571-47-0
795571-49-2	795571-50-5	795571-52-7	795571-54-9	795571-56-1
795571-57-2	795571-58-3	795571-61-8	795571-63-0	795571-65-2
795571-67-4	795571-69-6	795571-71-0	795571-72-1	795571-74-3
795571-76-5	795571-78-7	795571-80-1	795571-82-3	795571-83-4
795571-85-6	795571-87-8	795571-89-0	795571-91-4	795571-92-5
795571-95-8	795571-97-0	795572-00-8	795572-02-0	795572-03-1
795572-05-3	795572-07-5	795572-09-7	795572-11-1	795572-13-3
795572-15-5	795572-16-6	795572-18-8	795572-20-2	795572-22-4
795572-24-6	795572-26-8	795572-28-0	795572-30-4	795572-32-6
795572-34-8	795572-36-0	795572-38-2	795572-40-6	795572-42-8
795572-44-0	795572-46-2	795572-48-4	795572-50-8	795572-52-0
795572-54-2	795572-55-3	795572-57-5	795572-60-0	795572-62-2
795572-63-3	795572-66-6	795572-68-8	795572-71-3	795572-72-4
795572-74-6	795572-76-8	795572-78-0	795572-80-4	795572-82-6
795572-84-8	795572-85-9			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795572-87-1	795572-89-3	795572-91-7	795572-93-9	795572-95-1
	795572-97-3	795572-99-5	795573-01-2	795573-02-3	795573-04-5
	795573-06-7	795573-08-9	795573-11-4	795573-13-6	795573-15-8
	795573-17-0	795573-19-2	795573-20-5	795573-22-7	795573-24-9
	795573-26-1	795573-28-3	795573-30-7	795573-32-9	795573-34-1
	795573-36-3	795573-38-5	795573-40-9	795573-42-1	795573-44-3
	795573-46-5	795573-48-7	795573-50-1	795573-52-3	795573-54-5
	795573-56-7	795573-57-8	795573-59-0	795573-61-4	795573-64-7
	795573-66-9	795573-68-1	795573-69-2	795573-71-6	795573-73-8
	795573-74-9	795573-76-1	795573-78-3	795573-80-7	795573-82-9
	795573-83-0	795573-85-2	795573-87-4	795573-89-6	795573-91-0
	795573-93-2	795573-95-4	795573-98-7	795574-00-4	795574-02-6
	795574-04-8	795574-06-0	795574-08-2	795574-10-6	795574-12-8
	795574-14-0	795574-16-2	795574-18-4	795574-20-8	795574-22-0
	795574-24-2	795574-26-4	795574-28-6	795574-30-0	795574-31-1
	795574-33-3	795574-35-5	795574-37-7	795574-39-9	795574-41-3
	795574-43-5	795574-45-7	795574-47-9	795574-49-1	795574-51-5
	795574-53-7	795574-55-9	795574-57-1	795574-59-3	795574-61-7
	795574-63-9	795574-65-1	795574-67-3	795574-69-5	795574-74-2
	795574-77-5	795574-78-6	795574-83-3	795574-84-4	795574-85-5
	795574-86-6	795574-87-7	795574-91-3	795574-95-7	795574-96-8
	795574-97-9	795574-98-0	795574-99-1	795575-00-7	795575-01-8
	795575-08-5	795575-13-2	795575-14-3	795575-16-5	795575-18-7
	795575-20-1	795575-22-3	795575-24-5	795575-26-7	795575-27-8
	795575-30-3	795575-31-4	795575-32-5	795575-34-7	795575-35-8
	795575-36-9	795575-37-0	795575-39-2	795575-53-0	795575-54-1
	795575-56-3	795575-57-4	795575-58-5	795575-60-9	795575-62-1

795575-63-2	795575-65-4	795575-67-6	795575-69-8	795575-71-2
795575-73-4	795575-74-5	795575-76-7	795575-78-9	795575-80-3
795575-81-4	795575-83-6	795575-85-8	795575-87-0	795575-88-1
795575-90-5	795575-92-7	795575-94-9	795575-96-1	795575-98-3
795576-00-0	795576-02-2	795576-04-4	795576-06-6	795576-08-8
795576-10-2	795576-13-5	795576-15-7	795576-17-9	795576-19-1
795576-21-5	795576-23-7	795576-25-9	795576-27-1	795576-29-3
795576-32-8	795576-34-0	795576-37-3	795576-39-5	795576-41-9
795576-43-1	795576-45-3	795576-47-5	795576-51-1	795576-53-3
795576-55-5	795576-57-7	795576-59-9	795576-61-3	795576-62-4
795576-64-6	795576-66-8	795576-68-0	795576-70-4	795576-72-6
795576-74-8	795576-76-0	795576-78-2	795576-80-6	795576-82-8
795576-84-0	795576-86-2	795576-87-3	795576-89-5	795576-91-9
795576-93-1	795576-95-3	795576-97-5	795576-99-7	795577-01-4
795577-03-6	795577-05-8	795577-07-0	795577-09-2	795577-12-7
795577-14-9	795577-15-0	795577-16-1	795577-18-3	795577-20-7
795577-22-9	795577-24-1	795577-26-3	795577-28-5	795577-30-9
795577-32-1	795577-34-3	795577-36-5	795577-38-7	795577-40-1
795577-42-3	795577-44-5	795577-46-7	795577-48-9	795577-50-3
795577-52-5	795577-54-7	795577-56-9	795577-57-0	795577-61-6
795577-63-8	795577-65-0			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795577-67-2	795577-68-3	795577-69-4	795577-70-7	795577-72-9
	795577-74-1	795577-76-3	795577-78-5	795577-80-9	795577-82-1
	795577-84-3	795577-86-5	795577-87-6	795577-89-8	795577-92-3
	795577-94-5	795577-96-7	795577-97-8	795577-99-0	795578-01-7
	795578-03-9	795578-05-1	795578-08-4	795578-09-5	795578-10-8
	795578-12-0	795578-14-2	795578-16-4	795578-18-6	795578-20-0
	795578-22-2	795578-24-4	795578-26-6	795578-28-8	795578-30-2
	795578-32-4	795578-34-6	795578-36-8	795578-38-0	795578-40-4
	795578-42-6	795578-44-8	795578-46-0	795578-49-3	795578-50-6
	795578-53-9	795578-54-0	795578-55-1	795578-57-3	795578-59-5
	795578-61-9	795578-64-2	795578-66-4	795578-68-6	795578-70-0
	795578-72-2	795578-74-4	795578-76-6	795578-78-8	795578-80-2
	795578-82-4	795578-84-6	795578-86-8	795578-88-0	795578-90-4
	795578-92-6	795578-94-8	795578-97-1	795578-99-3	795579-02-1
	795579-03-2	795579-04-3	795579-06-5	795579-08-7	795579-10-1
	795579-12-3	795579-14-5	795579-16-7	795579-18-9	795579-20-3
	795579-22-5	795579-24-7	795579-26-9	795579-28-1	795579-29-2
	795579-31-6	795579-33-8	795579-35-0	795579-37-2	795579-39-4
	795579-41-8	795579-43-0	795579-45-2	795579-46-3	795579-49-6
	795579-51-0	795579-54-3	795579-55-4	795579-56-5	795579-59-8
	795579-60-1	795579-62-3	795579-64-5	795579-66-7	795579-68-9
	795579-70-3	795579-72-5	795579-74-7	795579-76-9	795579-78-1
	795579-80-5	795579-81-6	795579-83-8	795579-85-0	795579-87-2
	795579-89-4	795579-91-8	795579-93-0	795579-95-2	795579-97-4
	795579-98-5	795580-01-7	795580-03-9	795580-05-1	795580-07-3
	795580-09-5	795580-11-9	795580-13-1	795580-15-3	795580-17-5
	795580-19-7	795580-21-1	795580-23-3	795580-25-5	795580-27-7
	795580-29-9	795580-31-3	795580-33-5	795580-35-7	795580-37-9
	795580-39-1	795580-41-5	795580-43-7	795580-45-9	795580-47-1
	795580-49-3	795580-50-6	795580-52-8	795580-55-1	795580-57-3
	795580-58-4	795580-60-8	795580-62-0	795580-64-2	795580-66-4
	795580-68-6	795580-70-0	795580-72-2	795580-74-4	795580-76-6
	795580-78-8	795580-80-2	795580-82-4	795580-84-6	795580-86-8
	795580-88-0	795580-90-4	795580-92-6	795580-94-8	795580-96-0
	795581-00-9	795581-03-2	795581-04-3	795581-05-4	795581-07-6
	795581-09-8	795581-11-2	795581-13-4	795581-15-6	795581-17-8
	795581-19-0	795581-21-4	795581-23-6	795581-25-8	795581-27-0
	795581-29-2	795581-31-6	795581-33-8	795581-35-0	795581-37-2
	795581-39-4	795581-41-8	795581-43-0	795581-45-2	795581-49-6
	795581-52-1	795581-53-2	795581-54-3	795581-56-5	795581-58-7
	795581-59-8	795581-61-2	795581-63-4	795581-65-6	795581-67-8
	795581-69-0	795581-71-4	795581-73-6	795581-75-8	795581-77-0
	795581-79-2	795581-81-6	795581-83-8	795581-85-0	795581-87-2
	795581-89-4	795581-91-8	795581-93-0	795581-95-2	795581-98-5
	795582-00-2	795582-02-4	795582-04-6	795582-05-7	795582-07-9
	795582-09-1	795582-11-5	795582-13-7	795582-15-9	795582-17-1
	795582-19-3	795582-21-7	795582-23-9	795582-25-1	795582-27-3
	795582-29-5	795582-31-9			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for

genetic anal. of mouse)				
IT	795582-33-1	795582-35-3	795582-37-5	795582-39-7
	795582-43-3	795582-44-4	795582-46-6	795582-47-7
	795582-51-3	795582-53-5	795582-55-7	795582-57-9
	795582-61-5	795582-63-7	795582-65-9	795582-67-1
	795582-71-7	795582-73-9	795582-75-1	795582-77-3
	795582-81-9	795582-83-1	795582-85-3	795582-87-5
	795582-91-1	795582-93-3	795582-95-5	795583-00-5
	795583-02-7	795583-03-8	795583-05-0	795583-06-1
	795583-09-4	795583-11-8	795583-13-0	795583-14-1
	795583-18-5	795583-20-9	795583-22-1	795583-24-3
	795583-27-6	795583-29-8	795583-31-2	795583-33-4
	795583-37-8	795583-39-0	795583-41-4	795583-43-6
	795583-47-0	795583-49-2	795583-50-5	795583-52-7
	795583-56-1	795583-58-3	795583-60-7	795583-62-9
	795583-66-3	795583-68-5	795583-70-9	795583-72-1
	795583-76-5	795583-78-7	795583-80-1	795583-82-3
	795583-86-7	795583-88-9	795583-90-3	795583-91-4
	795583-95-8	795583-98-1	795583-99-2	795584-00-8
	795584-03-1	795584-04-2	795584-06-4	795584-08-6
	795584-12-2	795584-14-4	795584-16-6	795584-18-8
	795584-22-4	795584-24-6	795584-26-8	795584-28-0
	795584-32-6	795584-34-8	795584-36-0	795584-38-2
	795584-42-8	795584-44-0	795584-46-2	795584-48-4
	795584-52-0	795584-54-2	795584-56-4	795584-58-6
	795584-62-2	795584-64-4	795584-66-6	795584-68-8
	795584-72-4	795584-73-5	795584-75-7	795584-77-9
	795584-81-5	795584-83-7	795584-85-9	795584-87-1
	795584-92-8	795584-94-0	795584-95-1	795584-96-2
	795585-00-1	795585-02-3	795585-04-5	795585-06-7
	795585-10-3	795585-12-5	795585-14-7	795585-16-9
	795585-20-5	795585-22-7	795585-24-9	795585-26-1
	795585-30-7	795585-32-9	795585-34-1	795585-35-2
	795585-39-6	795585-41-0	795585-43-2	795585-45-4
	795585-49-8	795585-51-2	795585-53-4	795585-55-6
	795585-59-0	795585-61-4	795585-63-6	795585-65-8
	795585-69-2	795585-71-6	795585-73-8	795585-75-0
	795585-79-4	795585-81-8	795585-83-0	795585-85-2
	795585-89-6	795585-91-0	795585-94-3	795585-96-5
	795586-00-4	795586-02-6	795586-04-8	795586-06-0
	795586-09-3	795586-11-7	795586-13-9	795586-15-1
	795586-17-3	795586-19-5	795586-20-8	795586-21-9
	795586-25-3	795586-27-5	795586-29-7	795586-31-1
	795586-34-4	795586-36-6	795586-39-9	795586-41-3
	795586-45-7	795586-47-9	795586-49-1	795586-51-5
	795586-55-9	795586-56-0	795586-58-2	795586-60-6
	795586-64-0	795586-66-2	795586-67-3	795586-68-4
	795586-72-0	795586-74-2	795586-76-4	795586-78-6
	795586-82-2	795586-83-3		795586-80-0

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795586-86-6	795586-88-8	795586-91-3	795586-92-4
	795586-95-7	795586-96-8	795586-97-9	795586-99-1
	795587-03-0	795587-04-1	795587-05-2	795587-07-4
	795587-11-0	795587-13-2	795587-14-3	795587-15-4
	795587-19-8	795587-21-2	795587-23-4	795587-25-6
	795587-29-0	795587-30-3	795587-32-5	795587-34-7
	795587-38-1	795587-40-5	795587-42-7	795587-44-9
	795587-48-3	795587-50-7	795587-52-9	795587-54-1
	795587-58-5	795587-60-9	795587-62-1	795587-63-2
	795587-68-7	795587-70-1	795587-72-3	795587-74-5
	795587-77-8	795587-79-0	795587-81-4	795587-83-6
	795587-87-0	795587-88-1	795587-90-5	795587-92-7
	795587-96-1	795587-98-3	795587-99-4	795588-02-2
	795588-06-6	795588-08-8	795588-09-9	795588-10-2
	795588-13-5	795588-15-7	795588-17-9	795588-19-1
	795588-23-7	795588-25-9	795588-27-1	795588-29-3
	795588-34-0	795588-35-1	795588-36-2	795588-38-4
	795588-42-0	795588-44-2	795588-46-4	795588-47-5
	795588-50-0	795588-52-2	795588-54-4	795588-56-6
	795588-58-8	795588-61-3	795588-63-5	795588-65-7
	795588-69-1	795588-71-5	795588-72-6	795588-74-8
	795588-79-3	795588-80-6	795588-83-9	795588-85-1
	795588-89-5	795588-91-9	795588-93-1	795588-94-2
				795588-96-4

795588-98-6	795589-00-3	795589-02-5	795589-04-7	795589-05-8
795589-07-0	795589-09-2	795589-11-6	795589-13-8	795589-15-0
795589-17-2	795589-19-4	795589-21-8	795589-22-9	795589-25-2
795589-27-4	795589-29-6	795589-31-0	795589-33-2	795589-35-4
795589-37-6	795589-39-8	795589-40-1	795589-42-3	795589-44-5
795589-46-7	795589-48-9	795589-50-3	795589-51-4	795589-53-6
795589-55-8	795589-57-0	795589-59-2	795589-61-6	795589-63-8
795589-64-9	795589-66-1	795589-68-3	795589-70-7	795589-72-9
795589-74-1	795589-76-3	795589-78-5	795589-80-9	795589-82-1
795589-84-3	795589-86-5	795589-88-7	795589-90-1	795589-92-3
795589-94-5	795589-96-7	795589-98-9	795590-00-0	795590-02-2
795590-04-4	795590-06-6	795590-08-8	795590-10-2	795590-12-4
795590-14-6	795590-16-8	795590-18-0	795590-19-1	795590-22-6
795590-23-7	795590-26-0	795590-28-2	795590-34-0	795590-59-9
795590-62-4	795590-64-6	795590-66-8	795590-68-0	795590-70-4
795590-72-6	795590-74-8	795590-76-0	795590-78-2	795590-80-6
795590-83-9	795590-84-0	795590-86-2	795590-88-4	795590-90-8
795590-93-1	795590-94-2	795590-95-3	795590-97-5	795590-99-7
795591-01-4	795591-03-6	795591-05-8	795591-07-0	795591-09-2
795591-11-6	795591-13-8	795591-15-0	795591-17-2	795591-19-4
795591-22-9	795591-23-0	795591-25-2	795591-27-4	795591-29-6
795591-31-0	795591-33-2	795591-35-4	795591-37-6	795591-39-8
795591-40-1	795591-41-2	795591-43-4	795591-45-6	795591-47-8
795591-49-0	795591-51-4	795591-53-6	795591-55-8	795591-57-0
795591-59-2	795591-61-6			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795591-63-8	795591-65-0	795591-66-1	795591-70-7	795591-73-0
	795591-74-1	795591-76-3	795591-78-5	795591-79-6	795591-81-0
	795591-83-2	795591-85-4	795591-87-6	795591-89-8	795591-91-2
	795591-93-4	795591-95-6	795591-96-7	795591-98-9	795592-00-6
	795592-02-8	795592-04-0	795592-06-2	795592-08-4	795592-10-8
	795592-11-9	795592-14-2	795592-16-4	795592-18-6	795592-20-0
	795592-22-2	795592-24-4	795592-26-6	795592-28-8	795592-30-2
	795592-32-4	795592-34-6	795592-36-8	795592-38-0	795592-40-4
	795592-41-5	795592-42-6	795592-43-7	795592-44-8	795592-45-9
	795592-47-1	795592-49-3	795592-51-7	795592-53-9	795592-56-2
	795592-58-4	795592-60-8	795592-61-9	795592-64-2	795592-66-4
	795592-68-6	795592-70-0	795592-72-2	795592-74-4	795592-76-6
	795592-77-7	795592-79-9	795592-81-3	795592-83-5	795592-85-7
	795592-87-9	795592-89-1	795592-91-5	795592-93-7	795592-95-9
	795592-97-1	795592-99-3	795593-01-0	795593-02-1	795593-05-4
	795593-07-6	795593-10-1	795593-11-2	795593-13-4	795593-15-6
	795593-17-8	795593-19-0	795593-21-4	795593-22-5	795593-24-7
	795593-26-9	795593-28-1	795593-30-5	795593-32-7	795593-34-9
	795593-36-1	795593-38-3	795593-40-7	795593-42-9	795593-44-1
	795593-46-3	795593-47-4	795593-50-9	795593-52-1	795593-54-3
	795593-56-5	795593-58-7	795593-59-8	795593-62-3	795593-64-5
	795593-66-7	795593-67-8	795593-69-0	795593-71-4	795593-73-6
	795593-75-8	795593-77-0	795593-79-2	795593-81-6	795593-83-8
	795593-85-0	795593-87-2	795593-89-4	795593-91-8	795593-93-0
	795593-95-2	795593-97-4	795594-00-2	795594-01-3	795594-03-5
	795594-05-7	795594-07-9	795594-09-1	795594-11-5	795594-12-6
	795594-14-8	795594-16-0	795594-18-2	795594-20-6	795594-21-7
	795594-22-8	795594-24-0	795594-26-2	795594-28-4	795594-30-8
	795594-32-0	795594-34-2	795594-36-4	795594-37-5	795594-39-7
	795594-41-1	795594-43-3	795594-45-5	795594-47-7	795594-49-9
	795594-52-4	795594-54-6	795594-56-8	795594-58-0	795594-60-4
	795594-62-6	795594-66-0	795594-68-2	795594-70-6	795594-72-8
	795594-79-5	795594-81-9	795594-85-3	795594-87-5	795594-88-6
	795594-90-0	795594-92-2	795594-94-4	795594-97-7	795594-99-9
	795595-01-6	795595-03-8	795595-05-0	795595-07-2	795595-09-4
	795595-10-7	795595-13-0	795595-15-2	795595-17-4	795595-19-6
	795595-21-0	795595-23-2	795595-25-4	795595-27-6	795595-29-8
	795595-31-2	795595-33-4	795595-35-6	795595-37-8	795595-39-0
	795595-40-3	795595-42-5	795595-44-7	795595-46-9	795595-48-1
	795595-50-5	795595-52-7	795595-54-9	795595-56-1	795595-60-7
	795595-61-8	795595-63-0	795595-65-2	795595-67-4	795595-69-6
	795595-71-0	795595-73-2	795595-75-4	795595-77-6	795595-79-8
	795595-81-2	795595-82-3	795595-84-5	795595-86-7	795595-88-9
	795595-90-3	795595-92-5	795595-94-7	795595-96-9	795595-97-0
	795596-00-8	795596-02-0	795596-04-2	795596-06-4	795596-08-6
	795596-10-0	795596-12-2	795596-14-4	795596-16-6	795596-18-8
	795596-20-2	795596-22-4	795596-24-6	795596-26-8	795596-28-0

795596-30-4 795596-32-6
 RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
 (probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795596-34-8	795596-36-0	795596-38-2	795596-40-6	795596-42-8
	795596-44-0	795596-46-2	795596-48-4	795596-50-8	795596-52-0
	795596-54-2	795596-56-4	795596-58-6	795596-60-0	795596-62-2
	795596-64-4	795596-66-6	795596-68-8	795596-70-2	795596-72-4
	795596-74-6	795596-76-8	795596-78-0	795596-80-4	795596-82-6
	795596-84-8	795596-86-0	795596-88-2	795596-90-6	795596-92-8
	795596-94-0	795596-96-2	795596-98-4	795597-00-1	795597-01-2
	795597-03-4	795597-05-6	795597-07-8	795597-09-0	795597-10-3
	795597-11-4	795597-13-6	795597-15-8	795597-17-0	795597-19-2
	795597-21-6	795597-23-8	795597-25-0	795597-27-2	795597-29-4
	795597-31-8	795597-33-0	795597-35-2	795597-37-4	795597-39-6
	795597-41-0	795597-43-2	795597-44-3	795597-46-5	795597-48-7
	795597-50-1	795597-52-3	795597-54-5	795597-56-7	795597-58-9
	795597-60-3	795597-62-5	795597-64-7	795597-66-9	795597-68-1
	795597-70-5	795597-72-7	795597-73-8	795597-75-0	795597-77-2
	795597-79-4	795597-81-8	795597-83-0	795597-85-2	795597-87-4
	795597-89-6	795597-91-0	795597-93-2	795597-95-4	795597-97-6
	795597-99-8	795598-01-5	795598-03-7	795598-05-9	795598-07-1
	795598-09-3	795598-10-6	795598-13-9	795598-15-1	795598-17-3
	795598-19-5	795598-21-9	795598-23-1	795598-25-3	795598-27-5
	795598-28-6	795598-30-0	795598-32-2	795598-34-4	795598-36-6
	795598-38-8	795598-40-2	795598-42-4	795598-44-6	795598-46-8
	795598-48-0	795598-50-4	795598-52-6	795598-54-8	795598-56-0
	795598-58-2	795598-60-6	795598-62-8	795598-64-0	795598-66-2
	795598-68-4	795598-70-8	795598-72-0	795598-74-2	795598-76-4
	795598-78-6	795598-79-7	795598-80-0	795598-82-2	795598-83-3
	795598-85-5	795598-87-7	795598-89-9	795598-91-3	795598-93-5
	795598-94-6	795598-97-9	795598-99-1	795599-02-9	795599-04-1
	795599-06-3	795599-08-5	795599-10-9	795599-12-1	795599-14-3
	795599-16-5	795599-18-7	795599-20-1	795599-22-3	795599-23-4
	795599-25-6	795599-27-8	795599-29-0	795599-31-4	795599-33-6
	795599-35-8	795599-37-0	795599-39-2	795599-41-6	795599-43-8
	795599-45-0	795599-47-2	795599-49-4	795599-51-8	795599-53-0
	795599-55-2	795599-57-4	795599-59-6	795599-61-0	795599-63-2
	795599-65-4	795599-67-6	795599-69-8	795599-71-2	795599-73-4
	795599-75-6	795599-77-8	795599-79-0	795599-82-5	795599-84-7
	795599-86-9	795599-88-1	795599-90-5	795599-92-7	795599-94-9
	795599-96-1	795599-98-3	795600-00-9	795600-02-1	795600-04-3
	795600-06-5	795600-08-7	795600-10-1	795600-12-3	795600-14-5
	795600-16-7	795600-18-9	795600-20-3	795600-21-4	795600-24-7
	795600-26-9	795600-27-0	795600-30-5	795600-32-7	795600-34-9
	795600-36-1	795600-38-3	795600-39-4	795600-41-8	795600-43-0
	795600-45-2	795600-47-4	795600-49-6	795600-51-0	795600-53-2
	795600-55-4	795600-57-6	795600-59-8	795600-61-2	795600-63-4
	795600-66-7	795600-68-9	795600-70-3	795600-72-5	795600-74-7
	795600-76-9	795600-78-1	795600-80-5	795600-82-7	795600-84-9
	795600-86-1	795600-88-3	795600-90-7	795600-92-9	795600-94-1
	795600-96-3	795600-98-5			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
 (probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795601-00-2	795601-02-4	795601-04-6	795601-06-8	795601-08-0
	795601-10-4	795601-12-6	795601-14-8	795601-16-0	795601-18-2
	795601-20-6	795601-22-8	795601-24-0	795601-26-2	795601-28-4
	795601-30-8	795601-32-0	795601-34-2	795601-36-4	795601-38-6
	795601-40-0	795601-42-2	795601-44-4	795601-46-6	795601-49-9
	795601-51-3	795601-53-5	795601-55-7	795601-57-9	795601-59-1
	795601-61-5	795601-63-7	795601-64-8	795601-66-0	795601-68-2
	795601-70-6	795601-72-8	795601-74-0	795601-76-2	795601-78-4
	795601-80-8	795601-82-0	795601-84-2	795601-86-4	795601-88-6
	795601-90-0	795601-92-2	795601-94-4	795601-96-6	795601-98-8
	795602-00-5	795602-02-7	795602-04-9	795602-06-1	795602-08-3
	795602-10-7	795602-12-9	795602-13-0	795602-15-2	795602-17-4
	795602-19-6	795602-21-0	795602-23-2	795602-25-4	795602-27-6
	795602-29-8	795602-31-2	795602-34-5	795602-36-7	795602-38-9
	795602-40-3	795602-42-5	795602-44-7	795602-46-9	795602-48-1
	795602-50-5	795602-52-7	795602-54-9	795602-55-0	795602-57-2
	795602-59-4	795602-61-8	795602-63-0	795602-65-2	795602-67-4
	795602-70-9	795602-72-1	795602-73-2	795602-76-5	795602-78-7
	795602-80-1	795602-82-3	795602-84-5	795602-86-7	795602-88-9

795602-90-3	795602-92-5	795602-94-7	795602-96-9	795602-98-1
795603-00-8	795603-02-0	795603-04-2	795603-06-4	795603-08-6
795603-10-0	795603-12-2	795603-15-5	795603-16-6	795603-18-8
795603-20-2	795603-22-4	795603-24-6	795603-26-8	795603-28-0
795603-30-4	795603-32-6	795603-34-8	795603-36-0	795603-38-2
795603-40-6	795603-42-8	795603-44-0	795603-46-2	795603-48-4
795603-49-5	795603-52-0	795603-54-2	795603-55-3	795603-58-6
795603-60-0	795603-62-2	795603-64-4	795603-66-6	795603-68-8
795603-70-2	795603-72-4	795603-74-6	795603-76-8	795603-78-0
795603-80-4	795603-82-6	795603-84-8	795603-86-0	795603-88-2
795603-89-3	795603-91-7	795603-93-9	795603-95-1	795603-97-3
795603-99-5	795604-01-2	795604-03-4	795604-05-6	795604-06-7
795604-08-9	795604-10-3	795604-12-5	795604-14-7	795604-16-9
795604-18-1	795604-20-5	795604-22-7	795604-24-9	795604-26-1
795604-27-2	795604-29-4	795604-32-9	795604-34-1	795604-35-2
795604-37-4	795604-39-6	795604-41-0	795604-43-2	795604-45-4
795604-48-7	795604-50-1	795604-52-3	795604-54-5	795604-57-8
795604-59-0	795604-61-4	795604-63-6	795604-65-8	795604-67-0
795604-69-2	795604-70-5	795604-73-8	795604-76-1	795604-78-3
795604-79-4	795604-82-9	795604-84-1	795604-86-3	795604-88-5
795604-90-9	795604-92-1	795604-94-3	795604-97-6	795604-99-8
795605-01-5	795605-03-7	795605-05-9	795605-07-1	795605-10-6
795605-11-7	795605-13-9	795605-15-1	795605-17-3	795605-19-5
795605-20-8	795605-22-0	795605-24-2	795605-26-4	795605-27-5
795605-29-7	795605-31-1	795605-33-3	795605-35-5	795605-37-7
795605-39-9	795605-41-3	795605-43-5	795605-45-7	795605-47-9
795605-48-0	795605-51-5	795605-53-7	795605-56-0	795605-58-2
795605-60-6	795605-62-8	795605-64-0	795605-67-3	795605-69-5
795605-71-9	795605-73-1			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795605-75-3	795605-76-4	795605-78-6	795605-80-0	795605-82-2
	795605-84-4	795605-86-6	795605-95-7	795605-97-9	795605-98-0
	795606-00-7	795606-02-9	795606-04-1	795606-06-3	795606-07-4
	795606-09-6	795606-11-0	795606-13-2	795606-15-4	795606-17-6
	795606-20-1	795606-21-2	795606-23-4	795606-25-6	795606-27-8
	795606-29-0	795606-32-5	795606-34-7	795606-36-9	795606-37-0
	795606-39-2	795606-41-6	795606-43-8	795606-45-0	795606-48-3
	795606-50-7	795606-52-9	795606-54-1	795606-56-3	795606-58-5
	795606-60-9	795606-62-1	795606-65-4	795606-66-5	795606-68-7
	795606-71-2	795606-72-3	795606-74-5	795606-76-7	795606-78-9
	795606-82-5	795606-84-7	795606-86-9	795606-88-1	795606-90-5
	795606-92-7	795606-94-9	795606-96-1	795606-98-3	795607-00-0
	795607-02-2	795607-05-5	795607-07-7	795607-09-9	795607-10-2
	795607-12-4	795607-14-6	795607-16-8	795607-18-0	795607-21-5
	795607-23-7	795607-25-9	795607-27-1	795607-29-3	795607-31-7
	795607-32-8	795607-35-1	795607-37-3	795607-38-4	795607-41-9
	795607-44-2	795607-46-4	795607-48-6	795607-50-0	795607-52-2
	795607-54-4	795607-56-6	795607-58-8	795607-60-2	795607-62-4
	795607-65-7	795607-67-9	795607-69-1	795607-71-5	795607-72-6
	795607-75-9	795607-77-1	795607-79-3	795607-81-7	795607-83-9
	795607-85-1	795607-86-2	795607-87-3	795607-89-5	795607-91-9
	795607-93-1	795607-95-3	795607-96-4	795607-98-6	795608-00-3
	795608-02-5	795608-04-7	795608-06-9	795608-08-1	795608-09-2
	795608-12-7	795608-14-9	795608-15-0	795608-17-2	795608-20-7
	795608-22-9	795608-24-1	795608-26-3	795608-28-5	795608-30-9
	795608-32-1	795608-36-5	795608-38-7	795608-40-1	795608-42-3
	795608-45-6	795608-53-6	795608-55-8	795608-58-1	795608-60-5
	795608-62-7	795608-64-9	795608-66-1	795608-69-4	795608-71-8
	795608-73-0	795608-75-2	795608-77-4	795608-80-9	795608-81-0
	795608-83-2	795608-85-4	795608-87-6	795608-89-8	795608-90-1
	795608-92-3	795608-94-5	795608-96-7	795608-98-9	795609-00-6
	795609-02-8	795609-04-0	795609-05-1	795609-06-2	795609-08-4
	795609-10-8	795609-12-0	795609-14-2	795609-16-4	795609-18-6
	795609-20-0	795609-22-2	795609-25-5	795609-26-6	795609-28-8
	795609-30-2	795609-32-4	795609-34-6	795609-36-8	795609-38-0
	795609-40-4	795609-42-6	795609-44-8	795609-46-0	795609-48-2
	795609-50-6	795609-52-8	795609-54-0	795609-56-2	795609-58-4
	795609-59-5	795609-61-9	795609-62-0	795609-65-3	795609-68-6
	795609-70-0	795609-72-2	795609-73-3	795609-75-5	795609-77-7
	795609-79-9	795609-81-3	795609-82-4	795609-84-6	795609-86-8
	795609-88-0	795609-90-4	795609-92-6	795609-94-8	795609-95-9
	795609-99-3	795610-00-3	795610-02-5	795610-04-7	795610-06-9
	795610-08-1	795610-09-2	795610-11-6	795610-13-8	795610-15-0

795610-17-2	795610-19-4	795610-21-8	795610-23-0	795610-25-2
795610-27-4	795610-29-6	795610-32-1	795610-33-2	795610-35-4
795610-36-5	795610-39-8	795610-41-2	795610-43-4	795610-45-6
795610-47-8	795610-49-0	795610-51-4	795610-53-6	795610-55-8
795610-57-0	795610-59-2			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795610-61-6	795610-63-8	795610-65-0	795610-67-2	795610-69-4
	795610-71-8	795610-73-0	795610-76-3	795610-78-5	795610-80-9
	795610-82-1	795610-84-3	795610-86-5	795610-88-7	795610-90-1
	795610-92-3	795610-94-5	795610-96-7	795610-98-9	795611-00-6
	795611-02-8	795611-04-0	795611-06-2	795611-08-4	795611-10-8
	795611-12-0	795611-13-1	795611-15-3	795611-16-4	795611-17-5
	795611-18-6	795611-19-7	795611-20-0	795611-21-1	795611-22-2
	795611-23-3	795611-24-4	795611-25-5	795611-26-6	795611-27-7
	795611-28-8	795611-29-9	795611-30-2	795611-31-3	795611-32-4
	795611-33-5	795611-34-6	795611-35-7	795611-36-8	795611-37-9
	795611-38-0	795611-39-1	795611-40-4	795611-41-5	795611-42-6
	795611-43-7	795611-44-8	795611-45-9	795611-46-0	795611-47-1
	795611-48-2	795611-49-3	795611-50-6	795611-51-7	795611-52-8
	795611-53-9	795611-54-0	795611-55-1	795611-56-2	795611-57-3
	795611-58-4	795611-59-5	795611-60-8	795611-61-9	795611-62-0
	795611-63-1	795611-64-2	795611-65-3	795611-66-4	795611-67-5
	795611-68-6	795611-69-7	795611-70-0	795611-71-1	795611-72-2
	795611-73-3	795611-74-4	795611-75-5	795611-76-6	795611-77-7
	795611-78-8	795611-79-9	795611-80-2	795611-81-3	795611-82-4
	795611-83-5	795611-84-6	795611-85-7	795611-86-8	795611-87-9
	795611-88-0	795611-89-1	795611-90-4	795611-91-5	795611-92-6
	795611-93-7	795611-94-8	795611-95-9	795611-96-0	795611-97-1
	795611-98-2	795611-99-3	795612-00-9	795612-01-0	795612-02-1
	795612-03-2	795612-04-3	795612-05-4	795612-06-5	795612-07-6
	795612-08-7	795612-09-8	795612-10-1	795612-11-2	795612-12-3
	795612-13-4	795612-14-5	795612-15-6	795612-16-7	795612-17-8
	795612-18-9	795612-19-0	795612-20-3	795612-21-4	795612-22-5
	795612-23-6	795612-24-7	795612-25-8	795612-26-9	795612-27-0
	795612-28-1	795612-29-2	795612-30-5	795612-31-6	795612-32-7
	795612-33-8	795612-34-9	795612-35-0	795612-36-1	795612-37-2
	795612-38-3	795612-39-4	795612-40-7	795612-41-8	795612-42-9
	795612-43-0	795612-44-1	795612-45-2	795612-46-3	795612-47-4
	795612-48-5	795612-49-6	795612-50-9	795612-51-0	795612-52-1
	795612-53-2	795612-54-3	795612-55-4	795612-56-5	795612-57-6
	795612-58-7	795612-59-8	795612-60-1	795612-61-2	795612-62-3
	795612-63-4	795612-64-5	795612-65-6	795612-66-7	795612-67-8
	795612-68-9	795612-69-0	795612-70-3	795612-71-4	795612-72-5
	795612-73-6	795612-74-7	795612-75-8	795612-76-9	795612-77-0
	795612-78-1	795612-79-2	795612-80-5	795612-81-6	795612-82-7
	795612-83-8	795612-84-9	795612-85-0	795612-86-1	795612-87-2
	795612-88-3	795612-89-4	795612-90-7	795612-91-8	795612-92-9
	795612-93-0	795612-94-1	795612-95-2	795612-96-3	795612-97-4
	795612-98-5	795612-99-6	795613-00-2	795613-01-3	795613-02-4
	795613-03-5	795613-04-6	795613-05-7	795613-06-8	795613-07-9
	795613-08-0	795613-09-1	795613-10-4	795613-11-5	795613-12-6
	795613-13-7	795613-14-8	795613-15-9	795613-16-0	795613-17-1
	795613-18-2	795613-19-3	795613-20-6	795613-21-7	795613-22-8
	795613-23-9	795613-24-0			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795613-25-1	795613-26-2	795613-27-3	795613-28-4	795613-29-5
	795613-30-8	795613-31-9	795613-32-0	795613-33-1	795613-34-2
	795613-35-3	795613-36-4	795613-37-5	795613-38-6	795613-39-7
	795613-40-0	795613-41-1	795613-42-2	795613-43-3	795613-44-4
	795613-45-5	795613-46-6	795613-47-7	795613-48-8	795613-49-9
	795613-50-2	795613-51-3	795613-52-4	795613-53-5	795613-54-6
	795613-55-7	795613-56-8	795613-57-9	795613-58-0	795613-59-1
	795613-60-4	795613-61-5	795613-62-6	795613-63-7	795613-64-8
	795613-65-9	795613-66-0	795613-67-1	795613-68-2	795613-69-3
	795613-70-6	795613-71-7	795613-72-8	795613-73-9	795613-74-0
	795613-75-1	795613-76-2	795613-77-3	795613-78-4	795613-79-5
	795613-80-8	795613-81-9	795613-82-0	795613-83-1	795613-84-2
	795613-85-3	795613-86-4	795613-87-5	795613-88-6	795613-89-7
	795613-90-0	795613-91-1	795613-92-2	795613-93-3	795613-94-4
	795613-95-5	795613-96-6	795613-97-7	795613-98-8	795613-99-9

795614-00-5 795614-01-6 795614-02-7 795614-03-8 795614-04-9
 795614-05-0 795614-06-1 795614-07-2 795614-08-3 795614-09-4
 795614-10-7 795614-11-8 795614-12-9 795614-13-0 795614-14-1
 795614-15-2 795614-16-3 795614-17-4 795614-18-5 795614-19-6
 795614-20-9 795614-21-0 795614-22-1 795614-23-2 795614-24-3
 795614-25-4 795614-26-5 795614-27-6 795614-28-7 795614-29-8
 795614-30-1 795614-31-2 795614-32-3 795614-33-4 795614-34-5
 795614-35-6 795614-36-7 795614-37-8 795614-38-9 795614-39-0
 795614-40-3 795614-41-4 795614-42-5 795614-43-6 795614-44-7
 795614-45-8 795614-46-9 795614-47-0 795614-48-1 795614-49-2
 795614-50-5 795614-51-6 795614-52-7 795614-53-8 795614-54-9
 795614-55-0 795614-56-1 795614-57-2 795614-58-3 795614-59-4
 795614-60-7 795614-61-8 795614-62-9 795614-63-0 795614-64-1
 795614-65-2 795614-66-3 795614-67-4 795614-68-5 795614-69-6
 795614-70-9 795614-71-0 795614-72-1 795614-73-2 795614-74-3
 795614-75-4 795614-76-5 795614-77-6 795614-78-7 795614-79-8
 795614-80-1 795614-81-2 795614-82-3 795614-83-4 795614-84-5
 795614-85-6 795614-86-7 795614-87-8 795614-88-9 795614-89-0
 795614-90-3 795614-91-4 795614-92-5 795614-93-6 795614-94-7
 795614-95-8 795614-96-9 795614-97-0 795614-98-1 795614-99-2
 795615-00-8 795615-01-9 795615-02-0 795615-03-1 795615-04-2
 795615-05-3 795615-06-4 795615-07-5 795615-08-6 795615-09-7
 795615-10-0 795615-11-1 795615-12-2 795615-13-3 795615-14-4
 795615-15-5

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT 795527-07-0

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

RN 795527-07-0 HCAPLUS

CN DNA, d(T-A-A-C-A-C-T-G-A-C-C-G-G-C-C-A-G-C-T-T-G-G-G-A) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 3 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:1022683 HCAPLUS

ED Entered STN: 29 Nov 2004

TI Oligonucleotide probes in nucleic acid arrays for genetic analysis of mouse

IN Mittman, Michael; Mack, David J.; Lockhart, David J.

PA Affymetrix, Inc., USA

SO U.S., 183 pp.

CODEN: USXXAM

DT Patent

LA English

IC C12Q001-68; C07H021-02; C07H021-04; G01N015-06; G01N033-00

NCL 435006000; 422068100; 536023100; 536024300; 536024310

CC 3-1 (Biochemical Genetics)

Section cross-reference(s): 13

FAN.CNT 26

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6821724	B1	20041123	US 1999-396196	19990915 <--
	US 6821724	B1	20041123	US 1999-396196	19990915 <--
PRAI	US 1998-100678P	P	19980917	<--	
	US 1999-396196	A	19990915	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6821724	IC	C12Q001-68IC C07H021-02IC C07H021-04IC G01N015-06IC G01N033-00

NCL 435006000; 422068100; 536023100; 536024300; 536024310

AB This invention provides 127,806 unique oligonucleotide sequences which are complementary to .apprx.6500 specific known murine genes. The invention provides the sequences in such a way as to make them available for gene expression monitoring by hybridization to high d. oligonucleotide arrays, or for use as primers for PCR and other amplification protocols. As such, the invention related to diverse fields impacted by the nature of mol. interaction, including chemical, biol., medicine, and medical diagnostics. [This abstract record is one of 26 records for this document necessitated by the large number of index entries required to fully index the document and

publication system constraints.].

ST oligonucleotide probe microarray genetic analysis mouse; gene expression
mouse oligonucleotide probe hybridization

IT DNA microarray technology
DNA sequences
Gene expression profiles, animal
Genetic methods
Mus musculus
Nucleic acid amplification (method)
Nucleic acid hybridization
PCR (polymerase chain reaction)
(oligonucleotide probes in nucleic acid arrays for genetic anal. of
mouse)

IT Primers (nucleic acid)
Probes (nucleic acid)
RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical
study); USES (Uses)
(oligonucleotide probes in nucleic acid arrays for genetic anal. of
mouse)

IT 795466-62-5 795466-63-6 795466-64-7 795466-65-8 795466-66-9
795466-67-0 795466-68-1 795466-69-2 795466-70-5 795466-71-6
795466-72-7 795466-73-8 795466-74-9 795466-75-0 795466-76-1
795466-77-2 795466-78-3 795466-79-4 795466-80-7 795466-81-8
795466-82-9 795466-83-0 795466-84-1 795466-85-2 795466-86-3
795466-87-4 795466-88-5 795466-89-6 795466-90-9 795466-91-0
795466-92-1 795466-93-2 795466-94-3 795466-95-4 795466-96-5
795466-97-6 795466-98-7 795466-99-8 795467-00-4 795467-01-5
795467-02-6 795467-03-7 795467-04-8 795467-05-9 795467-06-0
795467-07-1 795467-08-2 795467-09-3 795467-10-6 795467-11-7
795467-12-8 795467-13-9 795467-14-0 795467-15-1 795467-16-2
795467-17-3 795467-18-4 795467-19-5 795467-20-8 795467-21-9
795467-22-0 795467-23-1 795467-24-2 795467-25-3 795467-26-4
795467-27-5 795467-28-6 795467-29-7 795467-30-0 795467-31-1
795467-32-2 795467-33-3 795467-34-4 795467-35-5 795467-36-6
795467-37-7 795467-38-8 795467-39-9 795467-40-2 795467-41-3
795467-42-4 795467-43-5 795467-44-6 795467-45-7 795467-46-8
795467-47-9 795467-48-0 795467-49-1 795467-50-4 795467-51-5
795467-52-6 795467-53-7 795467-54-8 795467-55-9 795467-56-0
795467-57-1 795467-58-2 795467-59-3 795467-60-6 795467-61-7
795467-62-8 795467-63-9 795467-64-0 795467-65-1 795467-66-2
795467-67-3 795467-68-4 795467-69-5 795467-70-8 795467-71-9
795467-72-0 795467-73-1 795467-74-2 795467-75-3 795467-76-4
795467-77-5 795467-78-6 795467-79-7 795467-80-0 795467-81-1
795467-82-2 795467-83-3 795467-84-4 795467-85-5 795467-86-6
795467-87-7 795467-88-8 795467-89-9 795467-90-2 795467-91-3
795467-92-4 795467-93-5 795467-94-6 795467-95-7 795467-96-8
795467-97-9 795467-98-0 795467-99-1 795468-00-7 795468-01-8
795468-02-9 795468-03-0 795468-04-1 795468-05-2 795468-06-3
795468-07-4 795468-08-5 795468-09-6 795468-10-9 795468-11-0
795468-12-1 795468-13-2 795468-14-3 795468-15-4 795468-16-5
795468-17-6 795468-18-7 795468-19-8 795468-20-1 795468-21-2
795468-22-3 795468-23-4 795468-24-5 795468-25-6 795468-26-7
795468-27-8 795468-28-9 795468-29-0 795468-30-3 795468-31-4
795468-32-5 795468-33-6 795468-34-7 795468-35-8 795468-36-9
795468-37-0 795468-38-1 795468-39-2 795468-40-5 795468-41-6
795468-42-7 795468-43-8 795468-44-9 795468-45-0 795468-46-1
795468-47-2 795468-48-3 795468-49-4 795468-50-7 795468-51-8
795468-52-9 795468-53-0 795468-54-1 795468-55-2 795468-56-3
795468-57-4 795468-58-5 795468-59-6 795468-60-9 795468-61-0
795468-62-1 795468-63-2 795468-64-3 795468-65-4 795468-66-5
795468-67-6 795468-68-7 795468-69-8 795468-70-1 795468-71-2
795468-72-3 795468-73-4 795468-74-5 795468-75-6 795468-76-7
795468-77-8 795468-78-9 795468-79-0 795468-80-3 795468-81-4
795468-82-5 795468-83-6 795468-84-7 795468-85-8 795468-86-9
795468-87-0 795468-88-1 795468-89-2 795468-90-5 795468-91-6
795468-92-7 795468-93-8 795468-94-9 795468-95-0 795468-96-1
795468-97-2 795468-98-3

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical
study); USES (Uses)
(probe and/or primer; oligonucleotide probes in nucleic acid arrays for
genetic anal. of mouse)

IT 795468-99-4 795469-00-0 795469-01-1 795469-02-2 795469-03-3
795469-04-4 795469-05-5 795469-06-6 795469-07-7 795469-08-8
795469-09-9 795469-10-2 795469-11-3 795469-12-4 795469-13-5
795469-14-6 795469-15-7 795469-16-8 795469-17-9 795469-18-0
795469-19-1 795469-20-4 795469-21-5 795469-22-6 795469-23-7

795469-24-8	795469-25-9	795469-26-0	795469-27-1	795469-28-2
795469-29-3	795469-30-6	795469-31-7	795469-32-8	795469-33-9
795469-34-0	795469-35-1	795469-36-2	795469-37-3	795469-38-4
795469-39-5	795469-40-8	795469-41-9	795469-42-0	795469-43-1
795469-44-2	795469-45-3	795469-46-4	795469-47-5	795469-48-6
795469-49-7	795469-50-0	795469-51-1	795469-52-2	795469-53-3
795469-54-4	795469-55-5	795469-56-6	795469-57-7	795469-58-8
795469-59-9	795469-60-2	795469-61-3	795469-62-4	795469-63-5
795469-64-6	795469-65-7	795469-66-8	795469-67-9	795469-68-0
795469-69-1	795469-70-4	795469-71-5	795469-72-6	795469-73-7
795469-74-8	795469-75-9	795469-76-0	795469-77-1	795469-78-2
795469-79-3	795469-80-6	795469-81-7	795469-82-8	795469-83-9
795469-84-0	795469-85-1	795469-86-2	795469-87-3	795469-88-4
795469-89-5	795469-90-8	795469-91-9	795469-92-0	795469-93-1
795469-94-2	795469-95-3	795469-96-4	795469-97-5	795469-98-6
795469-99-7	795470-00-7	795470-01-8	795470-02-9	795470-03-0
795470-04-1	795470-05-2	795470-06-3	795470-07-4	795470-08-5
795470-09-6	795470-10-9	795470-11-0	795470-12-1	795470-13-2
795470-14-3	795470-15-4	795470-16-5	795470-17-6	795470-18-7
795470-19-8	795470-20-1	795470-21-2	795470-22-3	795470-23-4
795470-24-5	795470-25-6	795470-26-7	795470-27-8	795470-28-9
795470-29-0	795470-30-3	795470-31-4	795470-32-5	795470-33-6
795470-34-7	795470-35-8	795470-36-9	795470-37-0	795470-38-1
795470-39-2	795470-40-5	795470-41-6	795470-42-7	795470-43-8
795470-44-9	795470-45-0	795470-46-1	795470-47-2	795470-48-3
795470-49-4	795470-50-7	795470-51-8	795470-52-9	795470-53-0
795470-54-1	795470-55-2	795470-56-3	795470-57-4	795470-58-5
795470-59-6	795470-60-9	795470-61-0	795470-62-1	795470-63-2
795470-64-3	795470-65-4	795470-66-5	795470-67-6	795470-68-7
795470-69-8	795470-70-1	795470-71-2	795470-72-3	795470-73-4
795470-74-5	795470-75-6	795470-76-7	795470-77-8	795470-78-9
795470-79-0	795470-80-3	795470-81-4	795470-82-5	795470-83-6
795470-84-7	795470-85-8	795470-86-9	795470-87-0	795470-88-1
795470-89-2	795470-90-5	795470-91-6	795470-92-7	795470-93-8
795470-94-9	795470-95-0	795470-96-1	795470-97-2	795470-98-3
795470-99-4	795471-00-0	795471-01-1	795471-02-2	795471-03-3
795471-04-4	795471-05-5	795471-06-6	795471-07-7	795471-08-8
795471-09-9	795471-10-2	795471-11-3	795471-12-4	795471-13-5
795471-14-6	795471-15-7	795471-16-8	795471-17-9	795471-18-0
795471-19-1	795471-20-4	795471-21-5	795471-22-6	795471-23-7
795471-24-8	795471-25-9	795471-26-0	795471-27-1	795471-28-2
795471-29-3	795471-30-6	795471-31-7	795471-32-8	795471-33-9
795471-34-0	795471-35-1			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795471-36-2	795471-37-3	795471-38-4	795471-39-5	795471-40-8
	795471-41-9	795471-42-0	795471-43-1	795471-44-2	795471-45-3
	795471-46-4	795471-47-5	795471-48-6	795471-49-7	795471-50-0
	795471-51-1	795471-52-2	795471-53-3	795471-54-4	795471-55-5
	795471-56-6	795471-57-7	795471-58-8	795471-59-9	795471-60-2
	795471-61-3	795471-62-4	795471-63-5	795471-64-6	795471-65-7
	795471-66-8	795471-67-9	795471-68-0	795471-69-1	795471-70-4
	795471-71-5	795471-72-6	795471-73-7	795471-74-8	795471-75-9
	795471-76-0	795471-77-1	795471-78-2	795471-79-3	795471-80-6
	795471-81-7	795471-82-8	795471-83-9	795471-84-0	795471-85-1
	795471-86-2	795471-87-3	795471-88-4	795471-89-5	795471-90-8
	795471-91-9	795471-92-0	795471-93-1	795471-94-2	795471-95-3
	795471-96-4	795471-97-5	795471-98-6	795471-99-7	795472-00-3
	795472-01-4	795472-02-5	795472-03-6	795472-04-7	795472-05-8
	795472-06-9	795472-07-0	795472-08-1	795472-09-2	795472-10-5
	795472-11-6	795472-12-7	795472-13-8	795472-14-9	795472-15-0
	795472-16-1	795472-17-2	795472-18-3	795472-19-4	795472-20-7
	795472-21-8	795472-22-9	795472-23-0	795472-24-1	795472-25-2
	795472-26-3	795472-27-4	795472-28-5	795472-29-6	795472-30-9
	795472-31-0	795472-32-1	795472-33-2	795472-34-3	795472-35-4
	795472-36-5	795472-37-6	795472-38-7	795472-39-8	795472-40-1
	795472-41-2	795472-42-3	795472-43-4	795472-44-5	795472-45-6
	795472-46-7	795472-47-8	795472-48-9	795472-49-0	795472-50-3
	795472-51-4	795472-52-5	795472-53-6	795472-54-7	795472-55-8
	795472-56-9	795472-57-0	795472-58-1	795472-59-2	795472-60-5
	795472-61-6	795472-62-7	795472-63-8	795472-64-9	795472-65-0
	795472-66-1	795472-67-2	795472-68-3	795472-69-4	795472-70-7
	795472-71-8	795472-72-9	795472-73-0	795472-74-1	795472-75-2
	795472-76-3	795472-77-4	795472-78-5	795472-79-6	795472-80-9

795472-81-0	795472-82-1	795472-83-2	795472-84-3	795472-85-4
795472-86-5	795472-87-6	795472-88-7	795472-89-8	795472-90-1
795472-91-2	795472-92-3	795472-93-4	795472-94-5	795472-95-6
795472-96-7	795472-97-8	795472-98-9	795472-99-0	795473-00-6
795473-01-7	795473-02-8	795473-03-9	795473-04-0	795473-05-1
795473-06-2	795473-07-3	795473-08-4	795473-09-5	795473-10-8
795473-11-9	795473-12-0	795473-13-1	795473-14-2	795473-15-3
795473-16-4	795473-17-5	795473-18-6	795473-19-7	795473-20-0
795473-21-1	795473-22-2	795473-23-3	795473-24-4	795473-25-5
795473-26-6	795473-27-7	795473-28-8	795473-29-9	795473-30-2
795473-31-3	795473-32-4	795473-33-5	795473-34-6	795473-35-7
795473-36-8	795473-37-9	795473-38-0	795473-39-1	795473-40-4
795473-41-5	795473-42-6	795473-43-7	795473-44-8	795473-45-9
795473-46-0	795473-47-1	795473-48-2	795473-49-3	795473-50-6
795473-51-7	795473-52-8	795473-53-9	795473-54-0	795473-55-1
795473-56-2	795473-57-3	795473-58-4	795473-59-5	795473-60-8
795473-61-9	795473-62-0	795473-63-1	795473-64-2	795473-65-3
795473-66-4	795473-67-5	795473-68-6	795473-69-7	795473-70-0
795473-71-1	795473-72-2			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795473-73-3	795473-74-4	795473-75-5	795473-76-6	795473-77-7
	795473-78-8	795473-79-9	795473-80-2	795473-81-3	795473-82-4
	795473-83-5	795473-84-6	795473-85-7	795473-86-8	795473-87-9
	795473-88-0	795473-89-1	795473-90-4	795473-91-5	795473-92-6
	795473-93-7	795473-94-8	795473-95-9	795473-96-0	795473-97-1
	795473-98-2	795473-99-3	795474-00-9	795474-01-0	795474-02-1
	795474-03-2	795474-04-3	795474-05-4	795474-06-5	795474-07-6
	795474-08-7	795474-09-8	795474-10-1	795474-11-2	795474-12-3
	795474-13-4	795474-14-5	795474-15-6	795474-16-7	795474-17-8
	795474-18-9	795474-19-0	795474-20-3	795474-21-4	795474-22-5
	795474-23-6	795474-24-7	795474-25-8	795474-26-9	795474-27-0
	795474-28-1	795474-29-2	795474-30-5	795474-31-6	795474-32-7
	795474-33-8	795474-34-9	795474-35-0	795474-36-1	795474-37-2
	795474-38-3	795474-39-4	795474-40-7	795474-41-8	795474-42-9
	795474-43-0	795474-44-1	795474-45-2	795474-46-3	795474-47-4
	795474-48-5	795474-49-6	795474-50-9	795474-51-0	795474-52-1
	795474-53-2	795474-54-3	795474-55-4	795474-56-5	795474-57-6
	795474-58-7	795474-59-8	795474-60-1	795474-61-2	795474-62-3
	795474-63-4	795474-64-5	795474-65-6	795474-66-7	795474-67-8
	795474-68-9	795474-69-0	795474-70-3	795474-71-4	795474-72-5
	795474-73-6	795474-74-7	795474-75-8	795474-76-9	795474-77-0
	795474-78-1	795474-79-2	795474-80-5	795474-81-6	795474-82-7
	795474-83-8	795474-84-9	795474-85-0	795474-86-1	795474-87-2
	795474-88-3	795474-89-4	795474-90-7	795474-91-8	795474-92-9
	795474-93-0	795474-94-1	795474-95-2	795474-96-3	795474-97-4
	795474-98-5	795474-99-6	795475-00-2	795475-01-3	795475-02-4
	795475-03-5	795475-04-6	795475-05-7	795475-06-8	795475-07-9
	795475-08-0	795475-09-1	795475-10-4	795475-11-5	795475-12-6
	795475-13-7	795475-14-8	795475-15-9	795475-16-0	795475-17-1
	795475-18-2	795475-19-3	795475-20-6	795475-21-7	795475-22-8
	795475-23-9	795475-24-0	795475-25-1	795475-26-2	795475-27-3
	795475-28-4	795475-29-5	795475-30-8	795475-31-9	795475-32-0
	795475-33-1	795475-34-2	795475-35-3	795475-36-4	795475-37-5
	795475-38-6	795475-39-7	795475-40-0	795475-41-1	795475-42-2
	795475-43-3	795475-44-4	795475-45-5	795475-46-6	795475-47-7
	795475-48-8	795475-49-9	795475-50-2	795475-51-3	795475-52-4
	795475-53-5	795475-54-6	795475-55-7	795475-56-8	795475-57-9
	795475-58-0	795475-59-1	795475-60-4	795475-61-5	795475-62-6
	795475-63-7	795475-64-8	795475-65-9	795475-66-0	795475-67-1
	795475-68-2	795475-69-3	795475-70-6	795475-71-7	795475-72-8
	795475-73-9	795475-74-0	795475-75-1	795475-76-2	795475-77-3
	795475-78-4	795475-79-5	795475-80-8	795475-81-9	795475-82-0
	795475-83-1	795475-84-2	795475-85-3	795475-86-4	795475-87-5
	795475-88-6	795475-89-7	795475-90-0	795475-91-1	795475-92-2
	795475-93-3	795475-94-4	795475-95-5	795475-96-6	795475-97-7
	795475-98-8	795475-99-9	795476-00-5	795476-01-6	795476-02-7
	795476-03-8	795476-04-9	795476-05-0	795476-06-1	795476-07-2
	795476-08-3	795476-09-4			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795476-10-7	795476-11-8	795476-12-9	795476-13-0	795476-14-1
----	-------------	-------------	-------------	-------------	-------------

795476-15-2	795476-16-3	795476-17-4	795476-18-5	795476-19-6
795476-20-9	795476-21-0	795476-22-1	795476-23-2	795476-24-3
795476-25-4	795476-26-5	795476-27-6	795476-28-7	795476-29-8
795476-30-1	795476-31-2	795476-32-3	795476-33-4	795476-34-5
795476-35-6	795476-36-7	795476-37-8	795476-38-9	795476-39-0
795476-40-3	795476-41-4	795476-42-5	795476-43-6	795476-44-7
795476-45-8	795476-46-9	795476-47-0	795476-48-1	795476-49-2
795476-50-5	795476-51-6	795476-52-7	795476-53-8	795476-54-9
795476-55-0	795476-56-1	795476-57-2	795476-58-3	795476-59-4
795476-60-7	795476-61-8	795476-62-9	795476-63-0	795476-64-1
795476-65-2	795476-66-3	795476-67-4	795476-68-5	795476-69-6
795476-70-9	795476-71-0	795476-72-1	795476-73-2	795476-74-3
795476-75-4	795476-76-5	795476-77-6	795476-78-7	795476-79-8
795476-80-1	795476-81-2	795476-82-3	795476-83-4	795476-84-5
795476-85-6	795476-86-7	795476-87-8	795476-88-9	795476-89-0
795476-90-3	795476-91-4	795476-92-5	795476-93-6	795476-94-7
795476-95-8	795476-96-9	795476-97-0	795476-98-1	795476-99-2
795477-00-8	795477-01-9	795477-02-0	795477-03-1	795477-04-2
795477-05-3	795477-06-4	795477-07-5	795477-08-6	795477-09-7
795477-10-0	795477-11-1	795477-12-2	795477-13-3	795477-14-4
795477-15-5	795477-16-6	795477-17-7	795477-18-8	795477-19-9
795477-20-2	795477-21-3	795477-22-4	795477-23-5	795477-24-6
795477-25-7	795477-26-8	795477-27-9	795477-28-0	795477-29-1
795477-30-4	795477-31-5	795477-32-6	795477-33-7	795477-34-8
795477-35-9	795477-36-0	795477-37-1	795477-38-2	795477-39-3
795477-40-6	795477-41-7	795477-42-8	795477-43-9	795477-44-0
795477-45-1	795477-46-2	795477-47-3	795477-48-4	795477-49-5
795477-50-8	795477-51-9	795477-52-0	795477-53-1	795477-54-2
795477-55-3	795477-56-4	795477-57-5	795477-58-6	795477-59-7
795477-60-0	795477-61-1	795477-62-2	795477-63-3	795477-64-4
795477-65-5	795477-66-6	795477-67-7	795477-68-8	795477-69-9
795477-70-2	795477-71-3	795477-72-4	795477-73-5	795477-74-6
795477-75-7	795477-76-8	795477-77-9	795477-78-0	795477-79-1
795477-80-4	795477-81-5	795477-82-6	795477-83-7	795477-84-8
795477-85-9	795477-86-0	795477-87-1	795477-88-2	795477-89-3
795477-90-6	795477-91-7	795477-92-8	795477-93-9	795477-94-0
795477-95-1	795477-96-2	795477-97-3	795477-98-4	795477-99-5
795478-00-1	795478-01-2	795478-02-3	795478-03-4	795478-04-5
795478-05-6	795478-06-7	795478-07-8	795478-08-9	795478-09-0
795478-10-3	795478-11-4	795478-12-5	795478-13-6	795478-14-7
795478-15-8	795478-16-9	795478-17-0	795478-18-1	795478-19-2
795478-20-5	795478-21-6	795478-22-7	795478-23-8	795478-24-9
795478-25-0	795478-26-1	795478-27-2	795478-28-3	795478-29-4
795478-30-7	795478-31-8	795478-32-9	795478-33-0	795478-34-1
795478-35-2	795478-36-3	795478-37-4	795478-38-5	795478-39-6
795478-40-9	795478-41-0	795478-42-1	795478-43-2	795478-44-3
795478-45-4	795478-46-5			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795478-47-6	795478-48-7	795478-49-8	795478-50-1	795478-51-2
	795478-52-3	795478-53-4	795478-54-5	795478-55-6	795478-56-7
	795478-57-8	795478-58-9	795478-59-0	795478-60-3	795478-61-4
	795478-62-5	795478-63-6	795478-64-7	795478-65-8	795478-66-9
	795478-67-0	795478-68-1	795478-69-2	795478-70-5	795478-71-6
	795478-72-7	795478-73-8	795478-74-9	795478-75-0	795478-76-1
	795478-77-2	795478-78-3	795478-79-4	795478-80-7	795478-81-8
	795478-82-9	795478-83-0	795478-84-1	795478-85-2	795478-86-3
	795478-87-4	795478-88-5	795478-89-6	795478-90-9	795478-91-0
	795478-92-1	795478-93-2	795478-94-3	795478-95-4	795478-96-5
	795478-97-6	795478-98-7	795478-99-8	795479-00-4	795479-01-5
	795479-02-6	795479-03-7	795479-04-8	795479-05-9	795479-06-0
	795479-07-1	795479-08-2	795479-09-3	795479-10-6	795479-11-7
	795479-12-8	795479-13-9	795479-14-0	795479-15-1	795479-16-2
	795479-17-3	795479-18-4	795479-19-5	795479-20-8	795479-21-9
	795479-22-0	795479-23-1	795479-24-2	795479-25-3	795479-26-4
	795479-27-5	795479-28-6	795479-29-7	795479-30-0	795479-31-1
	795479-32-2	795479-33-3	795479-34-4	795479-35-5	795479-36-6
	795479-37-7	795479-38-8	795479-39-9	795479-40-2	795479-41-3
	795479-42-4	795479-43-5	795479-44-6	795479-45-7	795479-46-8
	795479-47-9	795479-48-0	795479-49-1	795479-50-4	795479-51-5
	795479-52-6	795479-53-7	795479-54-8	795479-55-9	795479-56-0
	795479-57-1	795479-58-2	795479-59-3	795479-60-6	795479-61-7
	795479-62-8	795479-63-9	795479-64-0	795479-65-1	795479-66-2
	795479-67-3	795479-68-4	795479-69-5	795479-70-8	795479-71-9

795479-72-0	795479-73-1	795479-74-2	795479-75-3	795479-76-4
795479-77-5	795479-78-6	795479-79-7	795479-80-0	795479-81-1
795479-82-2	795479-83-3	795479-84-4	795479-85-5	795479-86-6
795479-87-7	795479-88-8	795479-89-9	795479-90-2	795479-91-3
795479-92-4	795479-93-5	795479-94-6	795479-95-7	795479-96-8
795479-97-9	795479-98-0	795479-99-1	795480-00-1	795480-01-2
795480-02-3	795480-03-4	795480-04-5	795480-05-6	795480-06-7
795480-07-8	795480-08-9	795480-09-0	795480-10-3	795480-11-4
795480-12-5	795480-13-6	795480-14-7	795480-15-8	795480-16-9
795480-17-0	795480-18-1	795480-19-2	795480-20-5	795480-21-6
795480-22-7	795480-23-8	795480-24-9	795480-25-0	795480-26-1
795480-27-2	795480-28-3	795480-29-4	795480-30-7	795480-31-8
795480-32-9	795480-33-0	795480-34-1	795480-35-2	795480-36-3
795480-37-4	795480-38-5	795480-39-6	795480-40-9	795480-41-0
795480-42-1	795480-43-2	795480-44-3	795480-45-4	795480-46-5
795480-47-6	795480-48-7	795480-49-8	795480-50-1	795480-51-2
795480-52-3	795480-53-4	795480-54-5	795480-55-6	795480-56-7
795480-57-8	795480-58-9	795480-59-0	795480-60-3	795480-61-4
795480-62-5	795480-63-6	795480-64-7	795480-65-8	795480-66-9
795480-67-0	795480-68-1	795480-69-2	795480-70-5	795480-71-6
795480-72-7	795480-73-8	795480-74-9	795480-75-0	795480-76-1
795480-77-2	795480-78-3	795480-79-4	795480-80-7	795480-81-8
795480-82-9	795480-83-0			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795480-84-1	795480-85-2	795480-86-3	795480-87-4	795480-88-5
	795480-89-6	795480-90-9	795480-91-0	795480-92-1	795480-93-2
	795480-94-3	795480-95-4	795480-96-5	795480-97-6	795480-98-7
	795480-99-8	795481-00-4	795481-01-5	795481-02-6	795481-03-7
	795481-04-8	795481-05-9	795481-06-0	795481-07-1	795481-08-2
	795481-09-3	795481-10-6	795481-11-7	795481-12-8	795481-13-9
	795481-14-0	795481-15-1	795481-16-2	795481-17-3	795481-18-4
	795481-19-5	795481-20-8	795481-21-9	795481-22-0	795481-23-1
	795481-24-2	795481-25-3	795481-26-4	795481-27-5	795481-28-6
	795481-29-7	795481-30-0	795481-31-1	795481-32-2	795481-33-3
	795481-34-4	795481-35-5	795481-36-6	795481-37-7	795481-38-8
	795481-39-9	795481-40-2	795481-41-3	795481-42-4	795481-43-5
	795481-44-6	795481-45-7	795481-46-8	795481-47-9	795481-48-0
	795481-49-1	795481-50-4	795481-51-5	795481-52-6	795481-53-7
	795481-54-8	795481-55-9	795481-56-0	795481-57-1	795481-58-2
	795481-59-3	795481-60-6	795481-61-7	795481-62-8	795481-63-9
	795481-64-0	795481-65-1	795481-66-2	795481-67-3	795481-68-4
	795481-69-5	795481-70-8	795481-71-9	795481-72-0	795481-73-1
	795481-74-2	795481-75-3	795481-76-4	795481-77-5	795481-78-6
	795481-79-7	795481-80-0	795481-81-1	795481-82-2	795481-83-3
	795481-84-4	795481-85-5	795481-86-6	795481-87-7	795481-88-8
	795481-89-9	795481-90-2	795481-91-3	795481-92-4	795481-93-5
	795481-94-6	795481-95-7	795481-96-8	795481-97-9	795481-98-0
	795481-99-1	795482-00-7	795482-01-8	795482-02-9	795482-03-0
	795482-04-1	795482-05-2	795482-06-3	795482-07-4	795482-08-5
	795482-09-6	795482-10-9	795482-11-0	795482-12-1	795482-13-2
	795482-14-3	795482-15-4	795482-16-5	795482-17-6	795482-18-7
	795482-19-8	795482-20-1	795482-21-2	795482-22-3	795482-23-4
	795482-24-5	795482-25-6	795482-26-7	795482-27-8	795482-28-9
	795482-29-0	795482-30-3	795482-31-4	795482-32-5	795482-33-6
	795482-34-7	795482-35-8	795482-36-9	795482-37-0	795482-38-1
	795482-39-2	795482-40-5	795482-41-6	795482-42-7	795482-43-8
	795482-44-9	795482-45-0	795482-46-1	795482-47-2	
	795482-48-3	795482-49-4	795482-50-7	795482-51-8	795482-52-9
	795482-53-0	795482-54-1	795482-55-2	795482-56-3	795482-57-4
	795482-58-5	795482-59-6	795482-60-9	795482-61-0	795482-62-1
	795482-63-2	795482-64-3	795482-65-4	795482-66-5	795482-67-6
	795482-68-7	795482-69-8	795482-70-1	795482-71-2	795482-72-3
	795482-73-4	795482-74-5	795482-75-6	795482-76-7	795482-77-8
	795482-78-9	795482-79-0	795482-80-3	795482-81-4	795482-82-5
	795482-83-6	795482-84-7	795482-85-8	795482-86-9	795482-87-0
	795482-88-1	795482-89-2	795482-90-5	795482-91-6	795482-92-7
	795482-93-8	795482-94-9	795482-95-0	795482-96-1	795482-97-2
	795482-98-3	795482-99-4	795483-00-0	795483-01-1	795483-02-2
	795483-03-3	795483-04-4	795483-05-5	795483-06-6	795483-07-7
	795483-08-8	795483-09-9	795483-10-2	795483-11-3	795483-12-4
	795483-13-5	795483-14-6	795483-15-7	795483-16-8	795483-17-9
	795483-18-0	795483-19-1	795483-20-4		

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

study); USES (Uses)
(probe and/or primer; oligonucleotide probes in nucleic acid arrays for
genetic anal. of mouse)

IT	795483-21-5	795483-22-6	795483-23-7	795483-24-8	795483-25-9
	795483-26-0	795483-27-1	795483-28-2	795483-29-3	795483-30-6
	795483-31-7	795483-32-8	795483-33-9	795483-34-0	795483-35-1
	795483-36-2	795483-37-3	795483-38-4	795483-39-5	795483-40-8
	795483-41-9	795483-42-0	795483-43-1	795483-44-2	795483-45-3
	795483-46-4	795483-47-5	795483-48-6	795483-49-7	795483-50-0
	795483-51-1	795483-52-2	795483-53-3	795483-54-4	795483-55-5
	795483-56-6	795483-57-7	795483-58-8	795483-59-9	795483-60-2
	795483-61-3	795483-62-4	795483-63-5	795483-64-6	795483-65-7
	795483-66-8	795483-67-9	795483-68-0	795483-69-1	795483-70-4
	795483-71-5	795483-72-6	795483-73-7	795483-74-8	795483-75-9
	795483-76-0	795483-77-1	795483-78-2	795483-79-3	795483-80-6
	795483-81-7	795483-82-8	795483-83-9	795483-84-0	795483-85-1
	795483-86-2	795483-87-3	795483-88-4	795483-89-5	795483-90-8
	795483-91-9	795483-92-0	795483-93-1	795483-94-2	795483-95-3
	795483-96-4	795483-97-5	795483-98-6	795483-99-7	795484-00-3
	795484-01-4	795484-02-5	795484-03-6	795484-04-7	795484-05-8
	795484-06-9	795484-07-0	795484-08-1	795484-09-2	795484-10-5
	795484-11-6	795484-12-7	795484-13-8	795484-14-9	795484-15-0
	795484-16-1	795484-17-2	795484-18-3	795484-19-4	795484-20-7
	795484-21-8	795484-22-9	795484-23-0	795484-24-1	795484-25-2
	795484-26-3	795484-27-4	795484-28-5	795484-29-6	795484-30-9
	795484-31-0	795484-32-1	795484-33-2	795484-34-3	795484-35-4
	795484-36-5	795484-37-6	795484-38-7	795484-39-8	795484-40-1
	795484-41-2	795484-42-3	795484-43-4	795484-44-5	795484-45-6
	795484-46-7	795484-47-8	795484-48-9	795484-49-0	795484-50-3
	795484-51-4	795484-52-5	795484-53-6	795484-54-7	795484-55-8
	795484-56-9	795484-57-0	795484-58-1	795484-59-2	795484-60-5
	795484-61-6	795484-62-7	795484-63-8	795484-64-9	795484-65-0
	795484-66-1	795484-67-2	795484-68-3	795484-69-4	795484-70-7
	795484-71-8	795484-72-9	795484-73-0	795484-74-1	795484-75-2
	795484-76-3	795484-77-4	795484-78-5	795484-79-6	795484-80-9
	795484-81-0	795484-82-1	795484-83-2	795484-84-3	795484-85-4
	795484-86-5	795484-87-6	795484-88-7	795484-89-8	795484-90-1
	795484-91-2	795484-92-3	795484-93-4	795484-94-5	795484-95-6
	795484-96-7	795484-97-8	795484-98-9	795484-99-0	795485-00-6
	795485-01-7	795485-02-8	795485-03-9	795485-04-0	795485-05-1
	795485-06-2	795485-07-3	795485-08-4	795485-09-5	795485-10-8
	795485-11-9	795485-12-0	795485-13-1	795485-14-2	795485-15-3
	795485-16-4	795485-17-5	795485-18-6	795485-19-7	795485-20-0
	795485-21-1	795485-22-2	795485-23-3	795485-24-4	795485-25-5
	795485-26-6	795485-27-7	795485-28-8	795485-29-9	795485-30-2
	795485-31-3	795485-32-4	795485-33-5	795485-34-6	795485-35-7
	795485-36-8	795485-37-9	795485-38-0	795485-39-1	795485-40-4
	795485-41-5	795485-42-6	795485-43-7	795485-44-8	795485-45-9
	795485-46-0	795485-47-1	795485-48-2	795485-49-3	795485-50-6
	795485-51-7	795485-52-8	795485-53-9	795485-54-0	795485-55-1
	795485-56-2	795485-57-3			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical
study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for
genetic anal. of mouse)

IT	795485-58-4	795485-59-5	795485-60-8	795485-61-9	795485-62-0
	795485-63-1	795485-64-2	795485-65-3	795485-66-4	795485-67-5
	795485-68-6	795485-69-7	795485-70-0	795485-71-1	795485-72-2
	795485-73-3	795485-74-4	795485-75-5	795485-76-6	795485-77-7
	795485-78-8	795485-79-9	795485-80-2	795485-81-3	795485-82-4
	795485-83-5	795485-84-6	795485-85-7	795485-86-8	795485-87-9
	795485-88-0	795485-89-1	795485-90-4	795485-91-5	795485-92-6
	795485-93-7	795485-94-8	795485-95-9	795485-96-0	795485-97-1
	795485-98-2	795485-99-3	795486-00-9	795486-01-0	795486-02-1
	795486-03-2	795486-04-3	795486-05-4	795486-06-5	795486-07-6
	795486-08-7	795486-09-8	795486-10-1	795486-11-2	795486-12-3
	795486-13-4	795486-14-5	795486-15-6	795486-16-7	795486-17-8
	795486-18-9	795486-19-0	795486-20-3	795486-21-4	795486-22-5
	795486-23-6	795486-24-7	795486-25-8	795486-26-9	795486-27-0
	795486-28-1	795486-29-2	795486-30-5	795486-31-6	795486-32-7
	795486-33-8	795486-34-9	795486-35-0	795486-36-1	795486-37-2
	795486-38-3	795486-39-4	795486-40-7	795486-41-8	795486-42-9
	795486-43-0	795486-44-1	795486-45-2	795486-46-3	795486-47-4
	795486-48-5	795486-49-6	795486-50-9	795486-51-0	795486-52-1
	795486-53-2	795486-54-3	795486-55-4	795486-56-5	795486-57-6
	795486-58-7	795486-59-8	795486-60-1	795486-61-2	795486-62-3

795486-63-4	795486-64-5	795486-65-6	795486-66-7	795486-67-8
795486-68-9	795486-69-0	795486-70-3	795486-71-4	795486-72-5
795486-73-6	795486-74-7	795486-75-8	795486-76-9	795486-77-0
795486-78-1	795486-79-2	795486-80-5	795486-81-6	795486-82-7
795486-83-8	795486-84-9	795486-85-0	795486-86-1	795486-87-2
795486-88-3	795486-89-4	795486-90-7	795486-91-8	795486-92-9
795486-93-0	795486-94-1	795486-95-2	795486-96-3	795486-97-4
795486-98-5	795486-99-6	795487-00-2	795487-01-3	795487-02-4
795487-03-5	795487-04-6	795487-05-7	795487-06-8	795487-07-9
795487-08-0	795487-09-1	795487-10-4	795487-11-5	795487-12-6
795487-13-7	795487-14-8	795487-15-9	795487-16-0	795487-17-1
795487-18-2	795487-19-3	795487-20-6	795487-21-7	795487-22-8
795487-23-9	795487-24-0	795487-25-1	795487-26-2	795487-27-3
795487-28-4	795487-29-5	795487-30-8	795487-31-9	795487-32-0
795487-33-1	795487-34-2	795487-35-3	795487-36-4	795487-37-5
795487-38-6	795487-39-7	795487-40-0	795487-41-1	795487-42-2
795487-43-3	795487-44-4	795487-45-5	795487-46-6	795487-47-7
795487-48-8	795487-49-9	795487-50-2	795487-51-3	795487-52-4
795487-53-5	795487-54-6	795487-55-7	795487-56-8	795487-57-9
795487-58-0	795487-59-1	795487-60-4	795487-61-5	795487-62-6
795487-63-7	795487-64-8	795487-65-9	795487-66-0	795487-67-1
795487-68-2	795487-69-3	795487-70-6	795487-71-7	795487-72-8
795487-73-9	795487-74-0	795487-75-1	795487-76-2	795487-77-3
795487-78-4	795487-79-5	795487-80-8	795487-81-9	795487-82-0
795487-83-1	795487-84-2	795487-85-3	795487-86-4	795487-87-5
795487-88-6	795487-89-7	795487-90-0	795487-91-1	795487-92-2
795487-93-3	795487-94-4			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795487-95-5	795487-96-6	795487-97-7	795487-98-8	795487-99-9
	795488-00-5	795488-01-6	795488-02-7	795488-03-8	795488-04-9
	795488-05-0	795488-06-1	795488-07-2	795488-08-3	795488-09-4
	795488-10-7	795488-11-8	795488-12-9	795488-13-0	795488-14-1
	795488-15-2	795488-16-3	795488-17-4	795488-18-5	795488-19-6
	795488-20-9	795488-21-0	795488-22-1	795488-23-2	795488-24-3
	795488-25-4	795488-26-5	795488-27-6	795488-28-7	795488-29-8
	795488-30-1	795488-31-2	795488-32-3	795488-33-4	795488-34-5
	795488-35-6	795488-36-7	795488-37-8	795488-38-9	795488-39-0
	795488-40-3	795488-41-4	795488-42-5	795488-43-6	795488-44-7
	795488-45-8	795488-46-9	795488-47-0	795488-48-1	795488-49-2
	795488-50-5	795488-51-6	795488-52-7	795488-53-8	795488-54-9
	795488-55-0	795488-56-1	795488-57-2	795488-58-3	795488-59-4
	795488-60-7	795488-61-8	795488-62-9	795488-63-0	795488-64-1
	795488-65-2	795488-66-3	795488-67-4	795488-68-5	795488-69-6
	795488-70-9	795488-71-0	795488-72-1	795488-73-2	795488-74-3
	795488-75-4	795488-76-5	795488-77-6	795488-78-7	795488-79-8
	795488-80-1	795488-81-2	795488-82-3	795488-83-4	795488-84-5
	795488-85-6	795488-86-7	795488-87-8	795488-88-9	795488-89-0
	795488-90-3	795488-91-4	795488-92-5	795488-93-6	795488-94-7
	795488-95-8	795488-96-9	795488-97-0	795488-98-1	795488-99-2
	795489-00-8	795489-01-9	795489-02-0	795489-03-1	795489-04-2
	795489-05-3	795489-06-4	795489-07-5	795489-08-6	795489-09-7
	795489-10-0	795489-11-1	795489-12-2	795489-13-3	795489-14-4
	795489-15-5	795489-16-6	795489-17-7	795489-18-8	795489-19-9
	795489-20-2	795489-21-3	795489-22-4	795489-23-5	795489-24-6
	795489-25-7	795489-26-8	795489-27-9	795489-28-0	795489-29-1
	795489-30-4	795489-31-5	795489-32-6	795489-33-7	795489-34-8
	795489-35-9	795489-36-0	795489-37-1	795489-38-2	795489-39-3
	795489-40-6	795489-41-7	795489-42-8	795489-43-9	795489-44-0
	795489-45-1	795489-46-2	795489-47-3	795489-48-4	795489-49-5
	795489-50-8	795489-51-9	795489-52-0	795489-53-1	795489-54-2
	795489-55-3	795489-56-4	795489-57-5	795489-58-6	795489-59-7
	795489-60-0	795489-61-1	795489-62-2	795489-63-3	795489-64-4
	795489-65-5	795489-66-6	795489-67-7	795489-68-8	795489-69-9
	795489-70-2	795489-71-3	795489-72-4	795489-73-5	795489-74-6
	795489-75-7	795489-76-8	795489-77-9	795489-78-0	795489-79-1
	795489-80-4	795489-81-5	795489-82-6	795489-83-7	795489-84-8
	795489-85-9	795489-86-0	795489-87-1	795489-88-2	795489-89-3
	795489-90-6	795489-91-7	795489-92-8	795489-93-9	795489-94-0
	795489-95-1	795489-96-2	795489-97-3	795489-98-4	795489-99-5
	795490-00-5	795490-01-6	795490-02-7	795490-03-8	795490-04-9
	795490-05-0	795490-06-1	795490-07-2	795490-08-3	795490-09-4
	795490-10-7	795490-11-8	795490-12-9	795490-13-0	795490-14-1
	795490-15-2	795490-16-3	795490-17-4	795490-18-5	795490-19-6

795490-20-9 795490-21-0 795490-22-1 795490-23-2 795490-24-3
795490-25-4 795490-26-5 795490-27-6 795490-28-7 795490-29-8
795490-30-1 795490-31-2

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795490-32-3	795490-33-4	795490-34-5	795490-35-6	795490-36-7
	795490-37-8	795490-38-9	795490-39-0	795490-40-3	795490-41-4
	795490-42-5	795490-43-6	795490-44-7	795490-45-8	795490-46-9
	795490-47-0	795490-48-1	795490-49-2	795490-50-5	795490-51-6
	795490-52-7	795490-53-8	795490-54-9	795490-55-0	795490-56-1
	795490-57-2	795490-58-3	795490-59-4	795490-60-7	795490-61-8
	795490-62-9	795490-63-0	795490-64-1	795490-65-2	795490-66-3
	795490-67-4	795490-68-5	795490-69-6	795490-70-9	795490-71-0
	795490-72-1	795490-73-2	795490-74-3	795490-75-4	795490-76-5
	795490-77-6	795490-78-7	795490-79-8	795490-80-1	795490-81-2
	795490-82-3	795490-83-4	795490-84-5	795490-85-6	795490-86-7
	795490-87-8	795490-88-9	795490-89-0	795490-90-3	795490-91-4
	795490-92-5	795490-93-6	795490-94-7	795490-95-8	795490-96-9
	795490-97-0	795490-98-1	795490-99-2	795491-00-8	795491-01-9
	795491-02-0	795491-03-1	795491-04-2	795491-05-3	795491-06-4
	795491-07-5	795491-08-6	795491-09-7	795491-10-0	795491-11-1
	795491-12-2	795491-13-3	795491-14-4	795491-15-5	795491-16-6
	795491-17-7	795491-18-8	795491-19-9	795491-20-2	795491-21-3
	795491-22-4	795491-23-5	795491-24-6	795491-25-7	795491-26-8
	795491-27-9	795491-28-0	795491-29-1	795491-30-4	795491-31-5
	795491-32-6	795491-33-7	795491-34-8	795491-35-9	795491-36-0
	795491-37-1	795491-38-2	795491-39-3	795491-40-6	795491-41-7
	795491-42-8	795491-43-9	795491-44-0	795491-45-1	795491-46-2
	795491-47-3	795491-48-4	795491-49-5	795491-50-8	795491-51-9
	795491-52-0	795491-53-1	795491-54-2	795491-55-3	795491-56-4
	795491-57-5	795491-58-6	795491-59-7	795491-60-0	795491-61-1
	795491-62-2	795491-63-3	795491-64-4	795491-65-5	795491-66-6
	795491-67-7	795491-68-8	795491-69-9	795491-70-2	795491-71-3
	795491-72-4	795491-73-5	795491-74-6	795491-75-7	795491-76-8
	795491-77-9	795491-78-0	795491-79-1	795491-80-4	795491-81-5
	795491-82-6	795491-83-7	795491-84-8	795491-85-9	795491-86-0
	795491-87-1	795491-88-2	795491-89-3	795491-90-6	795491-91-7
	795491-92-8	795491-93-9	795491-94-0	795491-95-1	795491-96-2
	795491-97-3	795491-98-4	795491-99-5	795492-00-1	795492-01-2
	795492-02-3	795492-03-4	795492-04-5	795492-05-6	795492-06-7
	795492-07-8	795492-08-9	795492-09-0	795492-10-3	795492-11-4
	795492-12-5	795492-13-6	795492-14-7	795492-15-8	795492-16-9
	795492-17-0	795492-18-1	795492-19-2	795492-20-5	795492-21-6
	795492-22-7	795492-23-8	795492-24-9	795492-25-0	795492-26-1
	795492-27-2	795492-28-3	795492-29-4	795492-30-7	795492-31-8
	795492-32-9	795492-33-0	795492-34-1	795492-35-2	795492-36-3
	795492-37-4	795492-38-5	795492-39-6	795492-40-9	795492-41-0
	795492-42-1	795492-43-2	795492-44-3	795492-45-4	795492-46-5
	795492-47-6	795492-48-7	795492-49-8	795492-50-1	795492-51-2
	795492-52-3	795492-53-4	795492-54-5	795492-55-6	795492-56-7
	795492-57-8	795492-58-9	795492-59-0	795492-60-3	795492-61-4
	795492-62-5	795492-63-6	795492-64-7	795492-65-8	795492-66-9
	795492-67-0	795492-68-1			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795492-69-2	795492-70-5	795492-71-6	795492-72-7	795492-73-8
	795492-74-9	795492-75-0	795492-76-1	795492-77-2	795492-78-3
	795492-79-4	795492-80-7	795492-81-8	795492-82-9	795492-83-0
	795492-84-1	795492-85-2	795492-86-3	795492-87-4	795492-88-5
	795492-89-6	795492-90-9	795492-91-0	795492-92-1	795492-93-2
	795492-94-3	795492-95-4	795492-96-5	795492-97-6	795492-98-7
	795492-99-8	795493-00-4	795493-01-5	795493-02-6	795493-03-7
	795493-04-8	795493-05-9	795493-06-0	795493-07-1	795493-08-2
	795493-09-3	795493-10-6	795493-11-7	795493-12-8	795493-13-9
	795493-14-0	795493-15-1	795493-16-2	795493-17-3	795493-18-4
	795493-19-5	795493-20-8	795493-21-9	795493-22-0	795493-23-1
	795493-24-2	795493-25-3	795493-26-4	795493-27-5	795493-28-6
	795493-29-7	795493-30-0	795493-31-1	795493-32-2	795493-33-3
	795493-34-4	795493-35-5	795493-36-6	795493-37-7	795493-38-8
	795493-39-9	795493-40-2	795493-41-3	795493-42-4	795493-43-5
	795493-44-6	795493-45-7	795493-46-8	795493-47-9	795493-48-0
	795493-49-1	795493-50-4	795493-51-5	795493-52-6	795493-53-7

795493-54-8	795493-55-9	795493-56-0	795493-57-1	795493-58-2
795493-59-3	795493-60-6	795493-61-7	795493-62-8	795493-63-9
795493-64-0	795493-65-1	795493-66-2	795493-67-3	795493-68-4
795493-69-5	795493-70-8	795493-71-9	795493-72-0	795493-73-1
795493-74-2	795493-75-3	795493-76-4	795493-77-5	795493-78-6
795493-79-7	795493-80-0	795493-81-1	795493-82-2	795493-83-3
795493-84-4	795493-85-5	795493-86-6	795493-87-7	795493-88-8
795493-89-9	795493-90-2	795493-91-3	795493-92-4	795493-93-5
795493-94-6	795493-95-7	795493-96-8	795493-97-9	795493-98-0
795493-99-1	795494-00-7	795494-01-8	795494-02-9	795494-03-0
795494-04-1	795494-05-2	795494-06-3	795494-07-4	795494-08-5
795494-09-6	795494-10-9	795494-11-0	795494-12-1	795494-13-2
795494-14-3	795494-15-4	795494-16-5	795494-17-6	795494-18-7
795494-19-8	795494-20-1	795494-21-2	795494-22-3	795494-23-4
795494-24-5	795494-25-6	795494-26-7	795494-27-8	795494-28-9
795494-29-0	795494-30-3	795494-31-4	795494-32-5	795494-33-6
795494-34-7	795494-35-8	795494-36-9	795494-37-0	795494-38-1
795494-39-2	795494-40-5	795494-41-6	795494-42-7	795494-43-8
795494-44-9	795494-45-0	795494-46-1	795494-47-2	795494-48-3
795494-49-4	795494-50-7	795494-51-8	795494-52-9	795494-53-0
795494-54-1	795494-55-2	795494-56-3	795494-57-4	795494-58-5
795494-59-6	795494-60-9	795494-61-0	795494-62-1	795494-63-2
795494-64-3	795494-65-4	795494-66-5	795494-67-6	795494-68-7
795494-69-8	795494-70-1	795494-71-2	795494-72-3	795494-73-4
795494-74-5	795494-75-6	795494-76-7	795494-77-8	795494-78-9
795494-79-0	795494-80-3	795494-81-4	795494-82-5	795494-83-6
795494-84-7	795494-85-8	795494-86-9	795494-87-0	795494-88-1
795494-89-2	795494-90-5	795494-91-6	795494-92-7	795494-93-8
795494-94-9	795494-95-0	795494-96-1	795494-97-2	795494-98-3
795494-99-4	795495-00-0	795495-01-1	795495-02-2	795495-03-3
795495-04-4	795495-05-5			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795495-06-6	795495-07-7	795495-08-8	795495-09-9	795495-10-2
	795495-11-3	795495-12-4	795495-13-5	795495-14-6	795495-15-7
	795495-16-8	795495-17-9	795495-18-0	795495-19-1	795495-20-4
	795495-21-5	795495-22-6	795495-23-7	795495-24-8	795495-25-9
	795495-26-0	795495-27-1	795495-28-2	795495-29-3	795495-30-6
	795495-31-7	795495-32-8	795495-33-9	795495-34-0	795495-35-1
	795495-36-2	795495-37-3	795495-38-4	795495-39-5	795495-40-8
	795495-41-9	795495-42-0	795495-43-1	795495-44-2	795495-45-3
	795495-46-4	795495-47-5	795495-48-6	795495-49-7	795495-50-0
	795495-51-1	795495-52-2	795495-53-3	795495-54-4	795495-55-5
	795495-56-6	795495-57-7	795495-58-8	795495-59-9	795495-60-2
	795495-61-3	795495-62-4	795495-63-5	795495-64-6	795495-65-7
	795495-66-8	795495-67-9	795495-68-0	795495-69-1	795495-70-4
	795495-71-5	795495-72-6	795495-73-7	795495-74-8	795495-75-9
	795495-76-0	795495-77-1	795495-78-2	795495-79-3	795495-80-6
	795495-81-7	795495-82-8	795495-83-9	795495-84-0	795495-85-1
	795495-86-2	795495-87-3	795495-88-4	795495-89-5	795495-90-8
	795495-91-9	795495-92-0	795495-93-1	795495-94-2	795495-95-3
	795495-96-4	795495-97-5	795495-98-6	795495-99-7	795496-00-3
	795496-01-4	795496-02-5	795496-03-6	795496-04-7	795496-05-8
	795496-06-9	795496-07-0	795496-08-1	795496-09-2	795496-10-5
	795496-11-6	795496-12-7	795496-13-8	795496-14-9	795496-15-0
	795496-16-1	795496-17-2	795496-18-3	795496-19-4	795496-20-7
	795496-21-8	795496-22-9	795496-23-0	795496-24-1	795496-25-2
	795496-26-3	795496-27-4	795496-28-5	795496-29-6	795496-30-9
	795496-31-0	795496-32-1	795496-33-2	795496-34-3	795496-35-4
	795496-36-5	795496-37-6	795496-38-7	795496-39-8	795496-40-1
	795496-41-2	795496-42-3	795496-43-4	795496-44-5	795496-45-6
	795496-46-7	795496-47-8	795496-48-9	795496-49-0	795496-50-3
	795496-51-4	795496-52-5	795496-53-6	795496-54-7	795496-55-8
	795496-56-9	795496-57-0	795496-58-1	795496-59-2	795496-60-5
	795496-61-6	795496-62-7	795496-63-8	795496-64-9	795496-65-0
	795496-66-1	795496-67-2	795496-68-3	795496-69-4	795496-70-7
	795496-71-8	795496-72-9	795496-73-0	795496-74-1	795496-75-2
	795496-76-3	795496-77-4	795496-78-5	795496-79-6	795496-80-9
	795496-81-0	795496-82-1	795496-83-2	795496-84-3	795496-85-4
	795496-86-5	795496-87-6	795496-88-7	795496-89-8	795496-90-1
	795496-91-2	795496-92-3	795496-93-4	795496-94-5	795496-95-6
	795496-96-7	795496-97-8	795496-98-9	795496-99-0	795497-00-6
	795497-01-7	795497-02-8	795497-03-9	795497-04-0	795497-05-1
	795497-06-2	795497-07-3	795497-08-4	795497-09-5	795497-10-8

795497-11-9	795497-12-0	795497-13-1	795497-14-2	795497-15-3
795497-16-4	795497-17-5	795497-18-6	795497-19-7	795497-20-0
795497-21-1	795497-22-2	795497-23-3	795497-24-4	795497-25-5
795497-26-6	795497-27-7	795497-28-8	795497-29-9	795497-30-2
795497-31-3	795497-32-4	795497-33-5	795497-34-6	795497-35-7
795497-36-8	795497-37-9	795497-38-0	795497-39-1	795497-40-4
795497-41-5	795497-42-6			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795497-43-7	795497-44-8	795497-45-9	795497-46-0	795497-47-1
	795497-48-2	795497-49-3	795497-50-6	795497-51-7	795497-52-8
	795497-53-9	795497-54-0	795497-55-1	795497-56-2	795497-57-3
	795497-58-4	795497-59-5	795497-60-8	795497-61-9	795497-62-0
	795497-63-1	795497-64-2	795497-65-3	795497-66-4	795497-67-5
	795497-68-6	795497-69-7	795497-70-0	795497-71-1	795497-72-2
	795497-73-3	795497-74-4	795497-75-5	795497-76-6	795497-77-7
	795497-78-8	795497-79-9	795497-80-2	795497-81-3	795497-82-4
	795497-83-5	795497-84-6	795497-85-7	795497-86-8	795497-87-9
	795497-88-0	795497-89-1	795497-90-4	795497-91-5	795497-92-6
	795497-93-7	795497-94-8	795497-95-9	795497-96-0	795497-97-1
	795497-98-2	795497-99-3	795498-00-9	795498-01-0	795498-02-1
	795498-03-2	795498-04-3	795498-05-4	795498-06-5	795498-07-6
	795498-08-7	795498-09-8	795498-10-1	795498-11-2	795498-12-3
	795498-13-4	795498-14-5	795498-15-6	795498-16-7	795498-17-8
	795498-18-9	795498-19-0	795498-20-3	795498-21-4	795498-22-5
	795498-23-6	795498-24-7	795498-25-8	795498-26-9	795498-27-0
	795498-28-1	795498-29-2	795498-30-5	795498-31-6	795498-32-7
	795498-33-8	795498-34-9	795498-35-0	795498-36-1	795498-37-2
	795498-38-3	795498-39-4	795498-40-7	795498-41-8	795498-42-9
	795498-43-0	795498-44-1	795498-45-2	795498-46-3	795498-47-4
	795498-48-5	795498-49-6	795498-50-9	795498-51-0	795498-52-1
	795498-53-2	795498-54-3	795498-55-4	795498-56-5	795498-57-6
	795498-58-7	795498-59-8	795498-60-1	795498-61-2	795498-62-3
	795498-63-4	795498-64-5	795498-65-6	795498-66-7	795498-67-8
	795498-68-9	795498-69-0	795498-70-3	795498-71-4	795498-72-5
	795498-73-6	795498-74-7	795498-75-8	795498-76-9	795498-77-0
	795498-78-1	795498-79-2	795498-80-5	795498-81-6	795498-82-7
	795498-83-8	795498-84-9	795498-85-0	795498-86-1	795498-87-2
	795498-88-3	795498-89-4	795498-90-7	795498-91-8	795498-92-9
	795498-93-0	795498-94-1	795498-95-2	795498-96-3	795498-97-4
	795498-98-5	795498-99-6	795499-00-2	795499-01-3	795499-02-4
	795499-03-5	795499-04-6	795499-05-7	795499-06-8	795499-07-9
	795499-08-0	795499-09-1	795499-10-4	795499-11-5	795499-12-6
	795499-13-7	795499-14-8	795499-15-9	795499-16-0	795499-17-1
	795499-18-2	795499-19-3	795499-20-6	795499-21-7	795499-22-8
	795499-23-9	795499-24-0	795499-25-1	795499-26-2	795499-27-3
	795499-28-4	795499-29-5	795499-30-8	795499-31-9	795499-32-0
	795499-33-1	795499-34-2	795499-35-3	795499-36-4	795499-37-5
	795499-38-6	795499-39-7	795499-40-0	795499-41-1	795499-42-2
	795499-43-3	795499-44-4	795499-45-5	795499-46-6	795499-47-7
	795499-48-8	795499-49-9	795499-50-2	795499-51-3	795499-52-4
	795499-53-5	795499-54-6	795499-55-7	795499-56-8	795499-57-9
	795499-58-0	795499-59-1	795499-60-4	795499-61-5	795499-62-6
	795499-63-7	795499-64-8	795499-65-9	795499-66-0	795499-67-1
	795499-68-2	795499-69-3	795499-70-6	795499-71-7	795499-72-8
	795499-73-9	795499-74-0	795499-75-1	795499-76-2	795499-77-3
	795499-78-4	795499-79-5			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795499-80-8	795499-81-9	795499-82-0	795499-83-1	795499-84-2
	795499-85-3	795499-86-4	795499-87-5	795499-88-6	795499-89-7
	795499-90-0	795499-91-1	795499-92-2	795499-93-3	795499-94-4
	795499-95-5	795499-96-6	795499-97-7	795499-98-8	795499-99-9
	795500-00-4	795500-01-5	795500-02-6	795500-03-7	795500-04-8
	795500-05-9	795500-06-0	795500-07-1	795500-08-2	795500-09-3
	795500-10-6	795500-11-7	795500-12-8	795500-13-9	795500-14-0
	795500-15-1	795500-16-2	795500-17-3	795500-18-4	795500-19-5
	795500-20-8	795500-21-9	795500-22-0	795500-23-1	795500-24-2
	795500-25-3	795500-26-4	795500-27-5	795500-28-6	795500-29-7
	795500-30-0	795500-31-1	795500-32-2	795500-33-3	795500-34-4
	795500-35-5	795500-36-6	795500-37-7	795500-38-8	795500-39-9
	795500-40-2	795500-41-3	795500-42-4	795500-43-5	795500-44-6

795500-45-7	795500-46-8	795500-47-9	795500-48-0	795500-49-1
795500-50-4	795500-51-5	795500-52-6	795500-53-7	795500-54-8
795500-55-9	795500-56-0	795500-57-1	795500-58-2	795500-59-3
795500-60-6	795500-61-7	795500-62-8	795500-63-9	795500-64-0
795500-65-1	795500-66-2	795500-67-3	795500-68-4	795500-69-5
795500-70-8	795500-71-9	795500-72-0	795500-73-1	795500-74-2
795500-75-3	795500-76-4	795500-77-5	795500-78-6	795500-79-7
795500-80-0	795500-81-1	795500-82-2	795500-83-3	795500-84-4
795500-85-5	795500-86-6	795500-87-7	795500-88-8	795500-89-9
795500-90-2	795500-91-3	795500-92-4	795500-93-5	795500-94-6
795500-95-7	795500-96-8	795500-97-9	795500-98-0	795500-99-1
795501-00-7	795501-01-8	795501-02-9	795501-03-0	795501-04-1
795501-05-2	795501-06-3	795501-07-4	795501-08-5	795501-09-6
795501-10-9	795501-11-0	795501-12-1	795501-13-2	795501-14-3
795501-15-4	795501-16-5	795501-17-6	795501-18-7	795501-19-8
795501-20-1	795501-21-2	795501-22-3	795501-23-4	795501-24-5
795501-25-6	795501-26-7	795501-27-8	795501-28-9	795501-29-0
795501-30-3	795501-31-4	795501-32-5	795501-33-6	795501-34-7
795501-35-8	795501-36-9	795501-37-0	795501-38-1	795501-39-2
795501-40-5	795501-41-6	795501-42-7	795501-43-8	795501-44-9
795501-45-0	795501-46-1	795501-47-2	795501-48-3	795501-49-4
795501-50-7	795501-51-8	795501-52-9	795501-53-0	795501-54-1
795501-55-2	795501-56-3	795501-57-4	795501-58-5	795501-59-6
795501-60-9	795501-61-0	795501-62-1	795501-63-2	795501-64-3
795501-65-4	795501-66-5	795501-67-6	795501-68-7	795501-69-8
795501-70-1	795501-71-2	795501-72-3	795501-73-4	795501-74-5
795501-75-6	795501-76-7	795501-77-8	795501-78-9	795501-79-0
795501-80-3	795501-81-4	795501-82-5	795501-83-6	795501-84-7
795501-85-8	795501-86-9	795501-87-0	795501-88-1	795501-89-2
795501-90-5	795501-91-6	795501-92-7	795501-93-8	795501-94-9
795501-95-0	795501-96-1	795501-97-2	795501-98-3	795501-99-4
795502-00-0	795502-01-1	795502-02-2	795502-03-3	795502-04-4
795502-05-5	795502-06-6	795502-07-7	795502-08-8	795502-09-9
795502-10-2	795502-11-3	795502-12-4	795502-13-5	795502-14-6
795502-15-7	795502-16-8			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795502-17-9	795502-18-0	795502-19-1	795502-20-4	795502-21-5
	795502-22-6	795502-23-7	795502-24-8	795502-25-9	795502-26-0
	795502-27-1	795502-28-2	795502-29-3	795502-30-6	795502-31-7
	795502-32-8	795502-33-9	795502-34-0	795502-35-1	795502-36-2
	795502-37-3	795502-38-4	795502-39-5	795502-40-8	795502-41-9
	795502-42-0	795502-43-1	795502-44-2	795502-45-3	795502-46-4
	795502-47-5	795502-48-6	795502-49-7	795502-50-0	795502-51-1
	795502-52-2	795502-53-3	795502-54-4	795502-55-5	795502-56-6
	795502-57-7	795502-58-8	795502-59-9	795502-60-2	795502-61-3
	795502-62-4	795502-63-5	795502-64-6	795502-65-7	795502-66-8
	795502-67-9	795502-68-0	795502-69-1	795502-70-4	795502-71-5
	795502-72-6	795502-73-7	795502-74-8	795502-75-9	795502-76-0
	795502-77-1	795502-78-2	795502-79-3	795502-80-6	795502-81-7
	795502-82-8	795502-83-9	795502-84-0	795502-85-1	795502-86-2
	795502-87-3	795502-88-4	795502-89-5	795502-90-8	795502-91-9
	795502-92-0	795502-93-1	795502-94-2	795502-95-3	795502-96-4
	795502-97-5	795502-98-6	795502-99-7	795503-00-3	795503-01-4
	795503-02-5	795503-03-6	795503-04-7	795503-05-8	795503-06-9
	795503-07-0	795503-08-1	795503-09-2	795503-10-5	795503-11-6
	795503-12-7	795503-13-8	795503-14-9	795503-15-0	795503-16-1
	795503-17-2	795503-18-3	795503-19-4	795503-20-7	795503-21-8
	795503-22-9	795503-23-0	795503-24-1	795503-25-2	795503-26-3
	795503-27-4	795503-28-5	795503-29-6	795503-30-9	795503-31-0
	795503-32-1	795503-33-2	795503-34-3	795503-35-4	795503-36-5
	795503-37-6	795503-38-7	795503-39-8	795503-40-1	795503-41-2
	795503-42-3	795503-43-4	795503-44-5	795503-45-6	795503-46-7
	795503-47-8	795503-48-9	795503-49-0	795503-50-3	795503-51-4
	795503-52-5	795503-53-6	795503-54-7	795503-55-8	795503-56-9
	795503-57-0	795503-58-1	795503-59-2	795503-60-5	795503-61-6
	795503-62-7	795503-63-8	795503-64-9	795503-65-0	795503-66-1
	795503-67-2	795503-68-3	795503-69-4	795503-70-7	795503-71-8
	795503-72-9	795503-73-0	795503-74-1	795503-75-2	795503-76-3
	795503-77-4	795503-78-5	795503-79-6	795503-80-9	795503-81-0
	795503-82-1	795503-83-2	795503-84-3	795503-85-4	795503-86-5
	795503-87-6	795503-88-7	795503-89-8	795503-90-1	795503-91-2
	795503-92-3	795503-93-4	795503-94-5	795503-95-6	795503-96-7
	795503-97-8	795503-98-9	795503-99-0	795504-00-6	795504-01-7

795504-02-8	795504-03-9	795504-04-0	795504-05-1	795504-06-2
795504-07-3	795504-08-4	795504-09-5	795504-10-8	795504-11-9
795504-12-0	795504-13-1	795504-14-2	795504-15-3	795504-16-4
795504-17-5	795504-18-6	795504-19-7	795504-20-0	795504-21-1
795504-22-2	795504-23-3	795504-24-4	795504-25-5	795504-26-6
795504-27-7	795504-28-8	795504-29-9	795504-30-2	795504-31-3
795504-32-4	795504-33-5	795504-34-6	795504-35-7	795504-36-8
795504-37-9	795504-38-0	795504-39-1	795504-40-4	795504-41-5
795504-42-6	795504-43-7	795504-44-8	795504-45-9	795504-46-0
795504-47-1	795504-48-2	795504-49-3	795504-50-6	795504-51-7
795504-52-8	795504-53-9			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795504-54-0	795504-55-1	795504-56-2	795504-57-3	795504-58-4
	795504-59-5	795504-60-8	795504-61-9	795504-62-0	795504-63-1
	795504-64-2	795504-65-3	795504-66-4	795504-67-5	795504-68-6
	795504-69-7	795504-70-0	795504-71-1	795504-72-2	795504-73-3
	795504-74-4	795504-75-5	795504-76-6	795504-77-7	795504-78-8
	795504-79-9	795504-80-2	795504-81-3	795504-82-4	795504-83-5
	795504-84-6	795504-85-7	795504-86-8	795504-87-9	795504-88-0
	795504-89-1	795504-90-4	795504-91-5	795504-92-6	795504-93-7
	795504-94-8	795504-95-9	795504-96-0	795504-97-1	795504-98-2
	795504-99-3	795505-00-9	795505-01-0	795505-02-1	795505-03-2
	795505-04-3	795505-05-4	795505-06-5	795505-07-6	795505-08-7
	795505-09-8	795505-10-1	795505-11-2	795505-12-3	795505-13-4
	795505-14-5	795505-15-6	795505-16-7	795505-17-8	795505-18-9
	795505-19-0	795505-20-3	795505-21-4	795505-22-5	795505-23-6
	795505-24-7	795505-25-8	795505-26-9	795505-27-0	795505-28-1
	795505-29-2	795505-30-5	795505-31-6	795505-32-7	795505-33-8
	795505-34-9	795505-35-0	795505-36-1	795505-37-2	795505-38-3
	795505-39-4	795505-40-7	795505-41-8	795505-42-9	795505-43-0
	795505-44-1	795505-45-2	795505-46-3	795505-47-4	795505-48-5
	795505-49-6	795505-50-9	795505-51-0	795505-52-1	795505-53-2
	795505-54-3	795505-55-4	795505-56-5	795505-57-6	795505-58-7
	795505-59-8	795505-60-1	795505-61-2	795505-62-3	795505-63-4
	795505-64-5	795505-65-6	795505-66-7	795505-67-8	795505-68-9
	795505-69-0	795505-70-3	795505-71-4	795505-72-5	795505-73-6
	795505-74-7	795505-75-8	795505-76-9	795505-77-0	795505-78-1
	795505-79-2	795505-80-5	795505-81-6	795505-82-7	795505-83-8
	795505-84-9	795505-85-0	795505-86-1	795505-87-2	795505-88-3
	795505-89-4	795505-90-7	795505-91-8	795505-92-9	795505-93-0
	795505-94-1	795505-95-2	795505-96-3	795505-97-4	795505-98-5
	795505-99-6	795506-00-2	795506-01-3	795506-02-4	795506-03-5
	795506-04-6	795506-05-7	795506-06-8	795506-07-9	795506-08-0
	795506-09-1	795506-10-4	795506-11-5	795506-12-6	795506-13-7
	795506-14-8	795506-15-9	795506-16-0	795506-17-1	795506-18-2
	795506-19-3	795506-20-6	795506-21-7	795506-22-8	795506-23-9
	795506-24-0	795506-25-1	795506-26-2	795506-27-3	795506-28-4
	795506-29-5	795506-30-8	795506-31-9	795506-32-0	795506-33-1
	795506-34-2	795506-35-3	795506-36-4	795506-37-5	795506-38-6
	795506-39-7	795506-40-0	795506-41-1	795506-42-2	795506-43-3
	795506-44-4	795506-45-5	795506-46-6	795506-47-7	795506-48-8
	795506-49-9	795506-50-2	795506-51-3	795506-52-4	795506-53-5
	795506-54-6	795506-55-7	795506-56-8	795506-57-9	795506-58-0
	795506-59-1	795506-60-4	795506-61-5	795506-62-6	795506-63-7
	795506-64-8	795506-65-9	795506-66-0	795506-67-1	795506-68-2
	795506-69-3	795506-70-6	795506-71-7	795506-72-8	795506-73-9
	795506-74-0	795506-75-1	795506-76-2	795506-77-3	795506-78-4
	795506-79-5	795506-80-8	795506-81-9	795506-82-0	795506-83-1
	795506-84-2	795506-85-3	795506-86-4	795506-87-5	795506-88-6
	795506-89-7	795506-90-0			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795506-91-1	795506-92-2	795506-93-3	795506-94-4	795506-95-5
	795506-96-6	795506-97-7	795506-98-8	795506-99-9	795507-00-5
	795507-01-6	795507-02-7	795507-03-8	795507-04-9	795507-05-0
	795507-06-1	795507-07-2	795507-08-3	795507-09-4	795507-10-7
	795507-11-8	795507-12-9	795507-13-0	795507-14-1	795507-15-2
	795507-16-3	795507-17-4	795507-18-5	795507-19-6	795507-20-9
	795507-21-0	795507-22-1	795507-23-2	795507-24-3	795507-25-4
	795507-26-5	795507-27-6	795507-28-7	795507-29-8	795507-30-1
	795507-31-2	795507-32-3	795507-33-4	795507-34-5	795507-35-6

795507-36-7	795507-37-8	795507-38-9	795507-39-0	795507-40-3
795507-41-4	795507-42-5	795507-43-6	795507-44-7	795507-45-8
795507-46-9	795507-47-0	795507-48-1	795507-49-2	795507-50-5
795507-51-6	795507-52-7	795507-53-8	795507-54-9	795507-55-0
795507-56-1	795507-57-2	795507-58-3	795507-59-4	795507-60-7
795507-61-8	795507-62-9	795507-63-0	795507-64-1	795507-65-2
795507-66-3	795507-67-4	795507-68-5	795507-69-6	795507-70-9
795507-71-0	795507-72-1	795507-73-2	795507-74-3	795507-75-4
795507-76-5	795507-77-6	795507-78-7	795507-79-8	795507-80-1
795507-81-2	795507-82-3	795507-83-4	795507-84-5	795507-85-6
795507-86-7	795507-87-8	795507-88-9	795507-89-0	795507-90-3
795507-91-4	795507-92-5	795507-93-6	795507-94-7	795507-95-8
795507-96-9	795507-97-0	795507-98-1	795507-99-2	795508-00-8
795508-01-9	795508-02-0	795508-03-1	795508-04-2	795508-05-3
795508-06-4	795508-07-5	795508-08-6	795508-09-7	795508-10-0
795508-11-1	795508-12-2	795508-13-3	795508-14-4	795508-15-5
795508-16-6	795508-17-7	795508-18-8	795508-19-9	795508-20-2
795508-21-3	795508-22-4	795508-23-5	795508-24-6	795508-25-7
795508-26-8	795508-27-9	795508-28-0	795508-29-1	795508-30-4
795508-31-5	795508-32-6	795508-33-7	795508-34-8	795508-35-9
795508-36-0	795508-37-1	795508-38-2	795508-39-3	795508-40-6
795508-41-7	795508-42-8	795508-43-9	795508-44-0	795508-45-1
795508-46-2	795508-47-3	795508-48-4	795508-49-5	795508-50-8
795508-51-9	795508-52-0	795508-53-1	795508-54-2	795508-55-3
795508-56-4	795508-57-5	795508-58-6	795508-59-7	795508-60-0
795508-61-1	795508-62-2	795508-63-3	795508-64-4	795508-65-5
795508-66-6	795508-67-7	795508-68-8	795508-69-9	795508-70-2
795508-71-3	795508-72-4	795508-73-5	795508-74-6	795508-75-7
795508-76-8	795508-77-9	795508-78-0	795508-79-1	795508-80-4
795508-81-5	795508-82-6	795508-83-7	795508-84-8	795508-85-9
795508-86-0	795508-87-1	795508-88-2	795508-89-3	795508-90-6
795508-91-7	795508-92-8	795508-93-9	795508-94-0	795508-95-1
795508-96-2	795508-97-3	795508-98-4	795508-99-5	795509-00-1
795509-01-2	795509-02-3	795509-03-4	795509-04-5	795509-05-6
795509-06-7	795509-07-8	795509-08-9	795509-09-0	795509-10-3
795509-11-4	795509-12-5	795509-13-6	795509-14-7	795509-15-8
795509-16-9	795509-17-0	795509-18-1	795509-19-2	795509-20-5
795509-21-6	795509-22-7	795509-23-8	795509-24-9	795509-25-0
795509-26-1	795509-27-2			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795509-28-3	795509-29-4	795509-30-7	795509-31-8	795509-32-9
	795509-33-0	795509-34-1	795509-35-2	795509-36-3	795509-37-4
	795509-38-5	795509-39-6	795509-40-9	795509-41-0	795509-42-1
	795509-43-2	795509-44-3	795509-45-4	795509-46-5	795509-47-6
	795509-48-7	795509-49-8	795509-50-1	795509-51-2	795509-52-3
	795509-53-4	795509-54-5	795509-55-6	795509-56-7	795509-57-8
	795509-58-9	795509-59-0	795509-60-3	795509-61-4	795509-62-5
	795509-63-6	795509-64-7	795509-65-8	795509-66-9	795509-67-0
	795509-68-1	795509-69-2	795509-70-5	795509-71-6	795509-72-7
	795509-73-8	795509-74-9	795509-75-0	795509-76-1	795509-77-2
	795509-78-3	795509-79-4	795509-80-7	795509-81-8	795509-82-9
	795509-83-0	795509-84-1	795509-85-2	795509-86-3	795509-87-4
	795509-88-5	795509-89-6	795509-90-9	795509-91-0	795509-92-1
	795509-93-2	795509-94-3	795509-95-4	795509-96-5	795509-97-6
	795509-98-7	795509-99-8	795510-00-8	795510-01-9	795510-02-0
	795510-03-1	795510-04-2	795510-05-3	795510-06-4	795510-07-5
	795510-08-6	795510-09-7	795510-10-0	795510-11-1	795510-12-2
	795510-13-3	795510-14-4	795510-15-5	795510-16-6	795510-17-7
	795510-18-8	795510-19-9	795510-20-2	795510-21-3	795510-22-4
	795510-23-5	795510-24-6	795510-25-7	795510-26-8	795510-27-9
	795510-28-0	795510-29-1	795510-30-4	795510-31-5	795510-32-6
	795510-33-7	795510-34-8	795510-35-9	795510-36-0	795510-37-1
	795510-38-2	795510-39-3	795510-40-6	795510-41-7	795510-42-8
	795510-43-9	795510-44-0	795510-45-1	795510-46-2	795510-47-3
	795510-48-4	795510-49-5	795510-50-8	795510-51-9	795510-52-0
	795510-53-1	795510-54-2	795510-55-3	795510-56-4	795510-57-5
	795510-58-6	795510-59-7	795510-60-0	795510-61-1	795510-62-2
	795510-63-3	795510-64-4	795510-65-5	795510-66-6	795510-67-7
	795510-68-8	795510-69-9	795510-70-2	795510-71-3	795510-72-4
	795510-73-5	795510-74-6	795510-75-7	795510-76-8	795510-77-9
	795510-78-0	795510-79-1	795510-80-4	795510-81-5	795510-82-6
	795510-83-7	795510-84-8	795510-85-9	795510-86-0	795510-87-1
	795510-88-2	795510-89-3	795510-90-6	795510-91-7	795510-92-8

795510-93-9	795510-94-0	795510-95-1	795510-96-2	795510-97-3
795510-98-4	795510-99-5	795511-00-1	795511-01-2	795511-02-3
795511-03-4	795511-04-5	795511-05-6	795511-06-7	795511-07-8
795511-08-9	795511-09-0	795511-10-3	795511-11-4	795511-12-5
795511-13-6	795511-14-7	795511-15-8	795511-16-9	795511-17-0
795511-18-1	795511-19-2	795511-20-5	795511-21-6	795511-22-7
795511-23-8	795511-24-9	795511-25-0	795511-26-1	795511-27-2
795511-28-3	795511-29-4	795511-30-7	795511-31-8	795511-32-9
795511-33-0	795511-34-1	795511-35-2	795511-36-3	795511-37-4
795511-38-5	795511-39-6	795511-40-9	795511-41-0	795511-42-1
795511-43-2	795511-44-3	795511-45-4	795511-46-5	795511-47-6
795511-48-7	795511-49-8	795511-50-1	795511-51-2	795511-52-3
795511-53-4	795511-54-5	795511-55-6	795511-56-7	795511-57-8
795511-58-9	795511-59-0	795511-60-3	795511-61-4	795511-62-5
795511-63-6	795511-64-7			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795511-65-8	795511-66-9	795511-67-0	795511-68-1	795511-69-2
	795511-70-5	795511-71-6	795511-72-7	795511-73-8	795511-74-9
	795511-75-0	795511-76-1	795511-77-2	795511-78-3	795511-79-4
	795511-80-7	795511-81-8	795511-82-9	795511-83-0	795511-84-1
	795511-85-2	795511-86-3	795511-87-4	795511-88-5	795511-89-6
	795511-90-9	795511-91-0	795511-92-1	795511-93-2	795511-94-3
	795511-95-4	795511-96-5	795511-97-6	795511-98-7	795511-99-8
	795512-00-4	795512-01-5	795512-02-6	795512-03-7	795512-04-8
	795512-05-9	795512-06-0	795512-07-1	795512-08-2	795512-09-3
	795512-10-6	795512-11-7	795512-12-8	795512-13-9	795512-14-0
	795512-15-1	795512-16-2	795512-17-3	795512-18-4	795512-19-5
	795512-20-8	795512-21-9	795512-22-0	795512-23-1	795512-24-2
	795512-25-3	795512-26-4	795512-27-5	795512-28-6	795512-29-7
	795512-30-0	795512-31-1	795512-32-2	795512-33-3	795512-34-4
	795512-35-5	795512-36-6	795512-37-7	795512-38-8	795512-39-9
	795512-40-2	795512-41-3	795512-42-4	795512-43-5	795512-44-6
	795512-45-7	795512-46-8	795512-47-9	795512-48-0	795512-49-1
	795512-50-4	795512-51-5	795512-52-6	795512-53-7	795512-54-8
	795512-55-9	795512-56-0	795512-57-1	795512-58-2	795512-59-3
	795512-60-6	795512-61-7	795512-62-8	795512-63-9	795512-64-0
	795512-65-1	795512-66-2	795512-67-3	795512-68-4	795512-69-5
	795512-70-8	795512-71-9	795512-72-0	795512-73-1	795512-74-2
	795512-75-3	795512-76-4	795512-77-5	795512-78-6	795512-79-7
	795512-80-0	795512-81-1	795512-82-2	795512-83-3	795512-84-4
	795512-85-5	795512-86-6	795512-87-7	795512-88-8	795512-89-9
	795512-90-2	795512-91-3	795512-92-4	795512-93-5	795512-94-6
	795512-95-7	795512-96-8	795512-97-9	795512-98-0	795512-99-1
	795513-00-7	795513-01-8	795513-02-9	795513-03-0	795513-04-1
	795513-05-2	795513-06-3	795513-07-4	795513-08-5	795513-09-6
	795513-10-9	795513-11-0	795513-12-1	795513-13-2	795513-14-3
	795513-15-4	795513-16-5	795513-17-6	795513-18-7	795513-19-8
	795513-20-1	795513-21-2	795513-22-3	795513-23-4	795513-24-5
	795513-25-6	795513-26-7	795513-27-8	795513-28-9	795513-29-0
	795513-30-3	795513-31-4	795513-32-5	795513-33-6	795513-34-7
	795513-35-8	795513-36-9	795513-37-0	795513-38-1	795513-39-2
	795513-40-5	795513-41-6	795513-42-7	795513-43-8	795513-44-9
	795513-45-0	795513-46-1	795513-47-2	795513-48-3	795513-49-4
	795513-50-7	795513-51-8	795513-52-9	795513-53-0	795513-54-1
	795513-55-2	795513-56-3	795513-57-4	795513-58-5	795513-59-6
	795513-60-9	795513-61-0	795513-62-1	795513-63-2	795513-64-3
	795513-65-4	795513-66-5	795513-67-6	795513-68-7	795513-69-8
	795513-70-1	795513-71-2	795513-72-3	795513-73-4	795513-74-5
	795513-75-6	795513-76-7	795513-77-8	795513-78-9	795513-79-0
	795513-80-3	795513-81-4	795513-82-5	795513-83-6	795513-84-7
	795513-85-8	795513-86-9	795513-87-0	795513-88-1	795513-89-2
	795513-90-5	795513-91-6	795513-92-7	795513-93-8	795513-94-9
	795513-95-0	795513-96-1	795513-97-2	795513-98-3	795513-99-4
	795514-00-0	795514-01-1			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795514-02-2	795514-03-3	795514-04-4	795514-05-5	795514-06-6
	795514-07-7	795514-08-8	795514-09-9	795514-10-2	795514-11-3
	795514-12-4	795514-13-5	795514-14-6	795514-15-7	795514-16-8
	795514-17-9	795514-18-0	795514-19-1	795514-20-4	795514-21-5
	795514-22-6	795514-23-7	795514-24-8	795514-25-9	795514-26-0

795514-27-1 795514-28-2 795514-29-3 795514-30-6 795514-31-7
 795514-32-8 795514-33-9 795514-34-0 795514-35-1 795514-36-2
 795514-37-3 795514-38-4 795514-39-5 795514-40-8 795514-41-9
 795514-42-0 795514-43-1 795514-44-2 795514-45-3 795514-46-4
 795514-47-5 795514-48-6 795514-49-7 795514-50-0 795514-51-1
 795514-52-2 795514-53-3 795514-54-4 795514-55-5 795514-56-6
 795514-57-7 795514-58-8 795514-59-9 795514-60-2 795514-61-3
 795514-62-4 795514-63-5 795514-64-6 795514-65-7 795514-66-8
 795514-67-9 795514-68-0 795514-69-1 795514-70-4 795514-71-5
 795514-72-6 795514-73-7 795514-74-8 795514-75-9 795514-76-0
 795514-77-1 795514-78-2 795514-79-3 795514-80-6 795514-81-7
 795514-82-8 795514-83-9 795514-84-0 795514-85-1 795514-86-2
 795514-87-3 795514-88-4 795514-89-5 795514-90-8 795514-91-9
 795514-92-0 795514-93-1 795514-94-2 795514-95-3 795514-96-4
 795514-97-5 795514-98-6 795514-99-7 795515-00-3 795515-01-4
 795515-02-5 795515-03-6 795515-04-7 795515-05-8 795515-06-9
 795515-07-0 795515-08-1 795515-09-2 795515-10-5 795515-11-6
 795515-12-7 795515-13-8 795515-14-9 795515-15-0 795515-16-1
 795515-17-2 795515-18-3 795515-19-4 795515-20-7 795515-21-8
 795515-22-9 795515-23-0 795515-24-1 795515-25-2 795515-26-3
 795515-27-4 795515-28-5 795515-29-6 795515-30-9 795515-31-0
 795515-32-1 795515-33-2 795515-34-3 795515-35-4 795515-36-5
 795515-37-6 795515-38-7 795515-39-8 795515-40-1 795515-41-2
 795515-42-3 795515-43-4 795515-44-5 795515-45-6 795515-46-7
 795515-47-8 795515-48-9 795515-49-0 795515-50-3 795515-51-4
 795515-52-5 795515-53-6 795515-54-7 795515-55-8 795515-56-9
 795515-57-0 795515-58-1 795515-59-2 795515-60-5 795515-61-6
 795515-62-7 795515-63-8 795515-64-9 795515-65-0 795515-66-1
 795515-67-2 795515-68-3 795515-69-4 795515-70-7 795515-71-8
 795515-72-9 795515-73-0 795515-74-1 795515-75-2 795515-76-3
 795515-77-4 795515-78-5 795515-79-6 795515-80-9 795515-81-0
 795515-82-1 795515-83-2 795515-84-3 795515-85-4 795515-86-5
 795515-87-6 795515-88-7 795515-89-8 795515-90-1 795515-91-2
 795515-92-3 795515-93-4 795515-94-5 795515-95-6 795515-96-7
 795515-97-8 795515-98-9

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT 795482-46-1

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

RN 795482-46-1 HCAPLUS

CN DNA, d(A-C-A-G-A-A-A-C-C-G-G-C-G-A-T-G-A-G-G-G-C-A-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 4 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:1012103 HCAPLUS

ED Entered STN: 24 Nov 2004

TI Oligonucleotide probes in nucleic acid arrays for genetic analysis of mouse

IN Mittman, Michael; Mack, David J.; Lockhart, David J.

PA Affymetrix, Inc., USA

SO U.S., 183 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM C12Q001-68

ICS C07H021-02; C07H021-04; G01N015-06; G01N033-00

NCL 435006000; 422068100; 536023100; 536024300; 536024310

CC 3-1 (Biochemical Genetics)

Section cross-reference(s): 13

FAN.CNT 26

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6821724	B1	20041123	US 1999-396196	19990915 <--
	US 6821724	B1	20041123	US 1999-396196	19990915 <--
	US 6821724	B1	20041123	US 1999-396196	19990915 <--
	US 6821724	B1	20041123	US 1999-396196	19990915 <--
	US 6821724	B1	20041123	US 1999-396196	19990915 <--
	US 6821724	B1	20041123	US 1999-396196	19990915 <--
	US 6821724	B1	20041123	US 1999-396196	19990915 <--

US 6821724	B1	20041123	US 1999-396196	19990915 <--
US 6821724	B1	20041123	US 1999-396196	19990915 <--
US 6821724	B1	20041123	US 1999-396196	19990915 <--
US 6821724	B1	20041123	US 1999-396196	19990915 <--
US 6821724	B1	20041123	US 1999-396196	19990915 <--
US 6821724	B1	20041123	US 1999-396196	19990915 <--
US 6821724	B1	20041123	US 1999-396196	19990915 <--
US 6821724	B1	20041123	US 1999-396196	19990915 <--
US 6821724	B1	20041123	US 1999-396196	19990915 <--
US 6821724	B1	20041123	US 1999-396196	19990915 <--
US 6821724	B1	20041123	US 1999-396196	19990915 <--
US 6821724	B1	20041123	US 1999-396196	19990915 <--
US 6821724	B1	20041123	US 1999-396196	19990915 <--
US 6821724	B1	20041123	US 1999-396196	19990915 <--
US 6821724	B1	20041123	US 1999-396196	19990915 <--
US 6821724	B1	20041123	US 1999-396196	19990915 <--
US 6821724	B1	20041123	US 1999-396196	19990915 <--
US 6821724	B1	20041123	US 1999-396196	19990915 <--
PRAI US 1998-100678P	P	19980917	<--	
US 1999-396196	A	19990915	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

US 6821724	ICM	C12Q001-68
------------	-----	------------

ICS	C07H021-02; C07H021-04; G01N015-06; G01N033-00
-----	--

NCL	435006000; 422068100; 536023100; 536024300; 536024310
-----	---

AB This invention provides 127,806 unique oligonucleotide sequences which are complementary to approx.6500 specific known murine genes. The invention provides the sequences in such a way as to make them available for gene expression monitoring by hybridization to high d. oligonucleotide arrays, or for use as primers for PCR and other amplification protocols. As such, the invention related to diverse fields impacted by the nature of mol. interaction, including chemical, biol., medicine, and medical diagnostics. [This abstract record is one of 26 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

ST oligonucleotide probe microarray genetic analysis mouse; gene expression mouse oligonucleotide probe hybridization

IT DNA microarray technology

DNA sequences

Gene expression profiles, animal

Genetic methods

Mus musculus

Nucleic acid amplification (method)

Nucleic acid hybridization

PCR (polymerase chain reaction)

(oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT Primers (nucleic acid)

Probes (nucleic acid)

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795416-62-5	795416-63-6	795416-64-7	795416-65-8	795416-66-9
	795416-67-0	795416-68-1	795416-69-2	795416-70-5	795416-71-6
	795416-72-7	795416-73-8	795416-74-9	795416-75-0	795416-76-1
	795416-77-2	795416-78-3	795416-79-4	795416-80-7	795416-81-8
	795416-82-9	795416-83-0	795416-84-1	795416-85-2	795416-86-3
	795416-87-4	795416-88-5	795416-89-6	795416-90-9	795416-91-0
	795416-92-1	795416-93-2	795416-94-3	795416-95-4	795416-96-5
	795416-97-6	795416-98-7	795416-99-8	795417-00-4	795417-01-5
	795417-02-6	795417-03-7	795417-04-8	795417-05-9	795417-06-0
	795417-07-1	795417-08-2	795417-09-3	795417-10-6	795417-11-7
	795417-12-8	795417-13-9	795417-14-0	795417-15-1	795417-16-2
	795417-17-3	795417-18-4	795417-19-5	795417-20-8	795417-21-9
	795417-22-0	795417-23-1	795417-24-2	795417-25-3	795417-26-4
	795417-27-5	795417-28-6	795417-29-7	795417-30-0	795417-31-1
	795417-32-2	795417-33-3	795417-34-4	795417-35-5	795417-36-6
	795417-37-7	795417-38-8	795417-39-9	795417-40-2	795417-41-3
	795417-42-4	795417-43-5	795417-44-6	795417-45-7	795417-46-8
	795417-47-9	795417-48-0	795417-49-1	795417-50-4	795417-51-5
	795417-52-6	795417-53-7	795417-54-8	795417-55-9	795417-56-0
	795417-57-1	795417-58-2	795417-59-3	795417-60-6	795417-61-7
	795417-62-8	795417-63-9	795417-64-0	795417-65-1	795417-66-2

795417-67-3	795417-68-4	795417-69-5	795417-70-8	795417-71-9
795417-72-0	795417-73-1	795417-74-2	795417-75-3	795417-76-4
795417-77-5	795417-78-6	795417-79-7	795417-80-0	795417-81-1
795417-82-2	795417-83-3	795417-84-4	795417-85-5	795417-86-6
795417-87-7	795417-88-8	795417-89-9	795417-90-2	795417-91-3
795417-92-4	795417-93-5	795417-94-6	795417-95-7	795417-96-8
795417-97-9	795417-98-0	795417-99-1	795418-00-7	795418-01-8
795418-02-9	795418-03-0	795418-04-1	795418-05-2	795418-06-3
795418-07-4	795418-08-5	795418-09-6	795418-10-9	795418-11-0
795418-12-1	795418-13-2	795418-14-3	795418-15-4	795418-16-5
795418-17-6	795418-18-7	795418-19-8	795418-20-1	795418-21-2
795418-22-3	795418-23-4	795418-24-5	795418-25-6	795418-26-7
795418-27-8	795418-28-9	795418-29-0	795418-30-3	795418-31-4
795418-32-5	795418-33-6	795418-34-7	795418-35-8	795418-36-9
795418-37-0	795418-38-1	795418-39-2	795418-40-5	795418-41-6
795418-42-7	795418-43-8	795418-44-9	795418-45-0	795418-46-1
795418-47-2	795418-48-3	795418-49-4	795418-50-7	795418-51-8
795418-52-9	795418-53-0	795418-54-1	795418-55-2	795418-56-3
795418-57-4	795418-58-5	795418-59-6	795418-60-9	795418-61-0
795418-62-1	795418-63-2	795418-64-3	795418-65-4	795418-66-5
795418-67-6	795418-68-7	795418-69-8	795418-70-1	795418-71-2
795418-72-3	795418-73-4	795418-74-5	795418-75-6	795418-76-7
795418-77-8	795418-78-9	795418-79-0	795418-80-3	795418-81-4
795418-82-5	795418-83-6	795418-84-7	795418-85-8	795418-86-9
795418-87-0	795418-88-1	795418-89-2	795418-90-5	795418-91-6
795418-92-7	795418-93-8	795418-94-9	795418-95-0	795418-96-1
795418-97-2	795418-98-3			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795418-99-4	795419-00-0	795419-01-1	795419-02-2	795419-03-3
	795419-04-4	795419-05-5	795419-06-6	795419-07-7	795419-08-8
	795419-09-9	795419-10-2	795419-11-3	795419-12-4	795419-13-5
	795419-14-6	795419-15-7	795419-16-8	795419-17-9	795419-18-0
	795419-19-1	795419-20-4	795419-21-5	795419-22-6	795419-23-7
	795419-24-8	795419-25-9	795419-26-0	795419-27-1	795419-28-2
	795419-29-3	795419-30-6	795419-31-7	795419-32-8	795419-33-9
	795419-34-0	795419-35-1	795419-36-2	795419-37-3	795419-38-4
	795419-39-5	795419-40-8	795419-41-9	795419-42-0	795419-43-1
	795419-44-2	795419-45-3	795419-46-4	795419-47-5	795419-48-6
	795419-49-7	795419-50-0	795419-51-1	795419-52-2	795419-53-3
	795419-54-4	795419-55-5	795419-56-6	795419-57-7	795419-58-8
	795419-59-9	795419-60-2	795419-61-3	795419-62-4	795419-63-5
	795419-64-6	795419-65-7	795419-66-8	795419-67-9	795419-68-0
	795419-69-1	795419-70-4	795419-71-5	795419-72-6	795419-73-7
	795419-74-8	795419-75-9	795419-76-0	795419-77-1	795419-78-2
	795419-79-3	795419-80-6	795419-81-7	795419-82-8	795419-83-9
	795419-84-0	795419-85-1	795419-86-2	795419-87-3	795419-88-4
	795419-89-5	795419-90-8	795419-91-9	795419-92-0	795419-93-1
	795419-94-2	795419-95-3	795419-96-4	795419-97-5	795419-98-6
	795419-99-7	795420-00-7	795420-01-8	795420-02-9	795420-03-0
	795420-04-1	795420-05-2	795420-06-3	795420-07-4	795420-08-5
	795420-09-6	795420-10-9	795420-11-0	795420-12-1	795420-13-2
	795420-14-3	795420-15-4	795420-16-5	795420-17-6	795420-18-7
	795420-19-8	795420-20-1	795420-21-2	795420-22-3	795420-23-4
	795420-24-5	795420-25-6	795420-26-7	795420-27-8	795420-28-9
	795420-29-0	795420-30-3	795420-31-4	795420-32-5	795420-33-6
	795420-34-7	795420-35-8	795420-36-9	795420-37-0	795420-38-1
	795420-39-2	795420-40-5	795420-41-6	795420-42-7	795420-43-8
	795420-44-9	795420-45-0	795420-46-1	795420-47-2	795420-48-3
	795420-49-4	795420-50-7	795420-51-8	795420-52-9	795420-53-0
	795420-54-1	795420-55-2	795420-56-3	795420-57-4	795420-58-5
	795420-59-6	795420-60-9	795420-61-0	795420-62-1	795420-63-2
	795420-64-3	795420-65-4	795420-66-5	795420-67-6	795420-68-7
	795420-69-8	795420-70-1	795420-71-2	795420-72-3	795420-73-4
	795420-74-5	795420-75-6	795420-76-7	795420-77-8	795420-78-9
	795420-79-0	795420-80-3	795420-81-4	795420-82-5	795420-83-6
	795420-84-7	795420-85-8	795420-86-9	795420-87-0	795420-88-1
	795420-89-2	795420-90-5	795420-91-6	795420-92-7	795420-93-8
	795420-94-9	795420-95-0	795420-96-1	795420-97-2	795420-98-3
	795420-99-4	795421-00-0	795421-01-1	795421-02-2	795421-03-3
	795421-04-4	795421-05-5	795421-06-6	795421-07-7	795421-08-8
	795421-09-9	795421-10-2	795421-11-3	795421-12-4	795421-13-5
	795421-14-6	795421-15-7	795421-16-8	795421-17-9	795421-18-0
	795421-19-1	795421-20-4	795421-21-5	795421-22-6	795421-23-7

795421-24-8 795421-25-9 795421-26-0 795421-27-1 795421-28-2
795421-29-3 795421-30-6 795421-31-7 795421-32-8 795421-33-9
795421-34-0 795421-35-1

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795421-36-2	795421-37-3	795421-38-4	795421-39-5	795421-40-8
	795421-41-9	795421-42-0	795421-43-1	795421-44-2	795421-45-3
	795421-46-4	795421-47-5	795421-48-6	795421-49-7	795421-50-0
	795421-51-1	795421-52-2	795421-53-3	795421-54-4	795421-55-5
	795421-56-6	795421-57-7	795421-58-8	795421-59-9	795421-60-2
	795421-61-3	795421-62-4	795421-63-5	795421-64-6	795421-65-7
	795421-66-8	795421-67-9	795421-68-0	795421-69-1	795421-70-4
	795421-71-5	795421-72-6	795421-73-7	795421-74-8	795421-75-9
	795421-76-0	795421-77-1	795421-78-2	795421-79-3	795421-80-6
	795421-81-7	795421-82-8	795421-83-9	795421-84-0	795421-85-1
	795421-86-2	795421-87-3	795421-88-4	795421-89-5	795421-90-8
	795421-91-9	795421-92-0	795421-93-1	795421-94-2	795421-95-3
	795421-96-4	795421-97-5	795421-98-6	795421-99-7	795422-00-3
	795422-01-4	795422-02-5	795422-03-6	795422-04-7	795422-05-8
	795422-06-9	795422-07-0	795422-08-1	795422-09-2	795422-10-5
	795422-11-6	795422-12-7	795422-13-8	795422-14-9	795422-15-0
	795422-16-1	795422-17-2	795422-18-3	795422-19-4	795422-20-7
	795422-21-8	795422-22-9	795422-23-0	795422-24-1	795422-25-2
	795422-26-3	795422-27-4	795422-28-5	795422-29-6	795422-30-9
	795422-31-0	795422-32-1	795422-33-2	795422-34-3	795422-35-4
	795422-36-5	795422-37-6	795422-38-7	795422-39-8	795422-40-1
	795422-41-2	795422-42-3	795422-43-4	795422-44-5	795422-45-6
	795422-46-7	795422-47-8	795422-48-9	795422-49-0	795422-50-3
	795422-51-4	795422-52-5	795422-53-6	795422-54-7	795422-55-8
	795422-56-9	795422-57-0	795422-58-1	795422-59-2	795422-60-5
	795422-61-6	795422-62-7	795422-63-8	795422-64-9	795422-65-0
	795422-66-1	795422-67-2	795422-68-3	795422-69-4	795422-70-7
	795422-71-8	795422-72-9	795422-73-0	795422-74-1	795422-75-2
	795422-76-3	795422-77-4	795422-78-5	795422-79-6	795422-80-9
	795422-81-0	795422-82-1	795422-83-2	795422-84-3	795422-85-4
	795422-86-5	795422-87-6	795422-88-7	795422-89-8	795422-90-1
	795422-91-2	795422-92-3	795422-93-4	795422-94-5	795422-95-6
	795422-96-7	795422-97-8	795422-98-9	795422-99-0	795423-00-6
	795423-01-7	795423-02-8	795423-03-9	795423-04-0	795423-05-1
	795423-06-2	795423-07-3	795423-08-4	795423-09-5	795423-10-8
	795423-11-9	795423-12-0	795423-13-1	795423-14-2	795423-15-3
	795423-16-4	795423-17-5	795423-18-6	795423-19-7	795423-20-0
	795423-21-1	795423-22-2	795423-23-3	795423-24-4	795423-25-5
	795423-26-6	795423-27-7	795423-28-8	795423-29-9	795423-30-2
	795423-31-3	795423-32-4	795423-33-5	795423-34-6	795423-35-7
	795423-36-8	795423-37-9	795423-38-0	795423-39-1	795423-40-4
	795423-41-5	795423-42-6	795423-43-7	795423-44-8	795423-45-9
	795423-46-0	795423-47-1	795423-48-2	795423-49-3	795423-50-6
	795423-51-7	795423-52-8	795423-53-9	795423-54-0	795423-55-1
	795423-56-2	795423-57-3	795423-58-4	795423-59-5	795423-60-8
	795423-61-9	795423-62-0	795423-63-1	795423-64-2	795423-65-3
	795423-66-4	795423-67-5	795423-68-6	795423-69-7	795423-70-0
	795423-71-1	795423-72-2			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795423-73-3	795423-74-4	795423-75-5	795423-76-6	795423-77-7
	795423-78-8	795423-79-9	795423-80-2	795423-81-3	795423-82-4
	795423-83-5	795423-84-6	795423-85-7	795423-86-8	795423-87-9
	795423-88-0	795423-89-1	795423-90-4	795423-91-5	795423-92-6
	795423-93-7	795423-94-8	795423-95-9	795423-96-0	795423-97-1
	795423-98-2	795423-99-3	795424-00-9	795424-01-0	795424-02-1
	795424-03-2	795424-04-3	795424-05-4	795424-06-5	795424-07-6
	795424-08-7	795424-09-8	795424-10-1	795424-11-2	795424-12-3
	795424-13-4	795424-14-5	795424-15-6	795424-16-7	795424-17-8
	795424-18-9	795424-19-0	795424-20-3	795424-21-4	795424-22-5
	795424-23-6	795424-24-7	795424-25-8	795424-26-9	795424-27-0
	795424-28-1	795424-29-2	795424-30-5	795424-31-6	795424-32-7
	795424-33-8	795424-34-9	795424-35-0	795424-36-1	795424-37-2
	795424-38-3	795424-39-4	795424-40-7	795424-41-8	795424-42-9
	795424-43-0	795424-44-1	795424-45-2	795424-46-3	795424-47-4
	795424-48-5	795424-49-6	795424-50-9	795424-51-0	795424-52-1
	795424-53-2	795424-54-3	795424-55-4	795424-56-5	795424-57-6

795424-58-7	795424-59-8	795424-60-1	795424-61-2	795424-62-3
795424-63-4	795424-64-5	795424-65-6	795424-66-7	795424-67-8
795424-68-9	795424-69-0	795424-70-3	795424-71-4	795424-72-5
795424-73-6	795424-74-7	795424-75-8	795424-76-9	795424-77-0
795424-78-1	795424-79-2	795424-80-5	795424-81-6	795424-82-7
795424-83-8	795424-84-9	795424-85-0	795424-86-1	795424-87-2
795424-88-3	795424-89-4	795424-90-7	795424-91-8	795424-92-9
795424-93-0	795424-94-1	795424-95-2	795424-96-3	795424-97-4
795424-98-5	795424-99-6	795425-00-2	795425-01-3	795425-02-4
795425-03-5	795425-04-6	795425-05-7	795425-06-8	795425-07-9
795425-08-0	795425-09-1	795425-10-4	795425-11-5	795425-12-6
795425-13-7	795425-14-8	795425-15-9	795425-16-0	795425-17-1
795425-18-2	795425-19-3	795425-20-6	795425-21-7	795425-22-8
795425-23-9	795425-24-0	795425-25-1	795425-26-2	795425-27-3
795425-28-4	795425-29-5	795425-30-8	795425-31-9	795425-32-0
795425-33-1	795425-34-2	795425-35-3	795425-36-4	795425-37-5
795425-38-6	795425-39-7	795425-40-0	795425-41-1	795425-42-2
795425-43-3	795425-44-4	795425-45-5	795425-46-6	795425-47-7
795425-48-8	795425-49-9	795425-50-2	795425-51-3	795425-52-4
795425-53-5	795425-54-6	795425-55-7	795425-56-8	795425-57-9
795425-58-0	795425-59-1	795425-60-4	795425-61-5	795425-62-6
795425-63-7	795425-64-8	795425-65-9	795425-66-0	795425-67-1
795425-68-2	795425-69-3	795425-70-6	795425-71-7	795425-72-8
795425-73-9	795425-74-0	795425-75-1	795425-76-2	795425-77-3
795425-78-4	795425-79-5	795425-80-8	795425-81-9	795425-82-0
795425-83-1	795425-84-2	795425-85-3	795425-86-4	795425-87-5
795425-88-6	795425-89-7	795425-90-0	795425-91-1	795425-92-2
795425-93-3	795425-94-4	795425-95-5	795425-96-6	795425-97-7
795425-98-8	795425-99-9	795426-00-5	795426-01-6	795426-02-7
795426-03-8	795426-04-9	795426-05-0	795426-06-1	795426-07-2
795426-08-3	795426-09-4			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795426-10-7	795426-11-8	795426-12-9	795426-13-0	795426-14-1
	795426-15-2	795426-16-3	795426-17-4	795426-18-5	795426-19-6
	795426-20-9	795426-21-0	795426-22-1	795426-23-2	795426-24-3
	795426-25-4	795426-26-5	795426-27-6	795426-28-7	795426-29-8
	795426-30-1	795426-31-2	795426-32-3	795426-33-4	795426-34-5
	795426-35-6	795426-36-7	795426-37-8	795426-38-9	795426-39-0
	795426-40-3	795426-41-4	795426-42-5	795426-43-6	795426-44-7
	795426-45-8	795426-46-9	795426-47-0	795426-48-1	795426-49-2
	795426-50-5	795426-51-6	795426-52-7	795426-53-8	795426-54-9
	795426-55-0	795426-56-1	795426-57-2	795426-58-3	795426-59-4
	795426-60-7	795426-61-8	795426-62-9	795426-63-0	795426-64-1
	795426-65-2	795426-66-3	795426-67-4	795426-68-5	795426-69-6
	795426-70-9	795426-71-0	795426-72-1	795426-73-2	795426-74-3
	795426-75-4	795426-76-5	795426-77-6	795426-78-7	795426-79-8
	795426-80-1	795426-81-2	795426-82-3	795426-83-4	795426-84-5
	795426-85-6	795426-86-7	795426-87-8	795426-88-9	795426-89-0
	795426-90-3	795426-91-4	795426-92-5	795426-93-6	795426-94-7
	795426-95-8	795426-96-9	795426-97-0	795426-98-1	795426-99-2
	795427-00-8	795427-01-9	795427-02-0	795427-03-1	795427-04-2
	795427-05-3	795427-06-4	795427-07-5	795427-08-6	795427-09-7
	795427-10-0	795427-11-1	795427-12-2	795427-13-3	795427-14-4
	795427-15-5	795427-16-6	795427-17-7	795427-18-8	795427-19-9
	795427-20-2	795427-21-3	795427-22-4	795427-23-5	795427-24-6
	795427-25-7	795427-26-8	795427-27-9	795427-28-0	795427-29-1
	795427-30-4	795427-31-5	795427-32-6	795427-33-7	795427-34-8
	795427-35-9	795427-36-0	795427-37-1	795427-38-2	795427-39-3
	795427-40-6	795427-41-7	795427-42-8	795427-43-9	795427-44-0
	795427-45-1	795427-46-2	795427-47-3	795427-48-4	795427-49-5
	795427-50-8	795427-51-9	795427-52-0	795427-53-1	795427-54-2
	795427-55-3	795427-56-4	795427-57-5	795427-58-6	795427-59-7
	795427-60-0	795427-61-1	795427-62-2	795427-63-3	795427-64-4
	795427-65-5	795427-66-6	795427-67-7	795427-68-8	795427-69-9
	795427-70-2	795427-71-3	795427-72-4	795427-73-5	795427-74-6
	795427-75-7	795427-76-8	795427-77-9	795427-78-0	795427-79-1
	795427-80-4	795427-81-5	795427-82-6	795427-83-7	795427-84-8
	795427-85-9	795427-86-0	795427-87-1	795427-88-2	795427-89-3
	795427-90-6	795427-91-7	795427-92-8	795427-93-9	795427-94-0
	795427-95-1	795427-96-2	795427-97-3	795427-98-4	795427-99-5
	795428-00-1	795428-01-2	795428-02-3	795428-03-4	795428-04-5
	795428-05-6	795428-06-7	795428-07-8	795428-08-9	795428-09-0
	795428-10-3	795428-11-4	795428-12-5	795428-13-6	795428-14-7

795428-15-8	795428-16-9	795428-17-0	795428-18-1	795428-19-2
795428-20-5	795428-21-6	795428-22-7	795428-23-8	795428-24-9
795428-25-0	795428-26-1	795428-27-2	795428-28-3	795428-29-4
795428-30-7	795428-31-8	795428-32-9	795428-33-0	795428-34-1
795428-35-2	795428-36-3	795428-37-4	795428-38-5	795428-39-6
795428-40-9	795428-41-0	795428-42-1	795428-43-2	795428-44-3
795428-45-4	795428-46-5			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795428-47-6	795428-48-7	795428-49-8	795428-50-1	795428-51-2
	795428-52-3	795428-53-4	795428-54-5	795428-55-6	795428-56-7
	795428-57-8	795428-58-9	795428-59-0	795428-60-3	795428-61-4
	795428-62-5	795428-63-6	795428-64-7	795428-65-8	795428-66-9
	795428-67-0	795428-68-1	795428-69-2	795428-70-5	795428-71-6
	795428-72-7	795428-73-8	795428-74-9	795428-75-0	795428-76-1
	795428-77-2	795428-78-3	795428-79-4	795428-80-7	795428-81-8
	795428-82-9	795428-83-0	795428-84-1	795428-85-2	795428-86-3
	795428-87-4	795428-88-5	795428-89-6	795428-90-9	795428-91-0
	795428-92-1	795428-93-2	795428-94-3	795428-95-4	795428-96-5
	795428-97-6	795428-98-7	795428-99-8	795429-00-4	795429-01-5
	795429-02-6	795429-03-7	795429-04-8	795429-05-9	795429-06-0
	795429-07-1	795429-08-2	795429-09-3	795429-10-6	795429-11-7
	795429-12-8	795429-13-9	795429-14-0	795429-15-1	795429-16-2
	795429-17-3	795429-18-4	795429-19-5	795429-20-8	795429-21-9
	795429-22-0	795429-23-1	795429-24-2	795429-25-3	795429-26-4
	795429-27-5	795429-28-6	795429-29-7	795429-30-0	795429-31-1
	795429-32-2	795429-33-3	795429-34-4	795429-35-5	795429-36-6
	795429-37-7	795429-38-8	795429-39-9	795429-40-2	795429-41-3
	795429-42-4	795429-43-5	795429-44-6	795429-45-7	795429-46-8
	795429-47-9	795429-48-0	795429-49-1	795429-50-4	795429-51-5
	795429-52-6	795429-53-7	795429-54-8	795429-55-9	795429-56-0
	795429-57-1	795429-58-2	795429-59-3	795429-60-6	795429-61-7
	795429-62-8	795429-63-9	795429-64-0	795429-65-1	795429-66-2
	795429-67-3	795429-68-4	795429-69-5	795429-70-8	795429-71-9
	795429-72-0	795429-73-1	795429-74-2	795429-75-3	795429-76-4
	795429-77-5	795429-78-6	795429-79-7	795429-80-0	795429-81-1
	795429-82-2	795429-83-3	795429-84-4	795429-85-5	795429-86-6
	795429-87-7	795429-88-8	795429-89-9	795429-90-2	795429-91-3
	795429-92-4	795429-93-5	795429-94-6	795429-95-7	795429-96-8
	795429-97-9	795429-98-0	795429-99-1	795430-00-1	795430-01-2
	795430-02-3	795430-03-4	795430-04-5	795430-05-6	795430-06-7
	795430-07-8	795430-08-9	795430-09-0	795430-10-3	795430-11-4
	795430-12-5	795430-13-6	795430-14-7	795430-15-8	795430-16-9
	795430-17-0	795430-18-1	795430-19-2	795430-20-5	795430-21-6
	795430-22-7	795430-23-8	795430-24-9	795430-25-0	795430-26-1
	795430-27-2	795430-28-3	795430-29-4	795430-30-7	795430-31-8
	795430-32-9	795430-33-0	795430-34-1	795430-35-2	795430-36-3
	795430-37-4	795430-38-5	795430-39-6	795430-40-9	795430-41-0
	795430-42-1	795430-43-2	795430-44-3	795430-45-4	795430-46-5
	795430-47-6	795430-48-7	795430-49-8	795430-50-1	795430-51-2
	795430-52-3	795430-53-4	795430-54-5	795430-55-6	795430-56-7
	795430-57-8	795430-58-9	795430-59-0	795430-60-3	795430-61-4
	795430-62-5	795430-63-6	795430-64-7	795430-65-8	795430-66-9
	795430-67-0	795430-68-1	795430-69-2	795430-70-5	795430-71-6
	795430-72-7	795430-73-8	795430-74-9	795430-75-0	795430-76-1
	795430-77-2	795430-78-3	795430-79-4	795430-80-7	795430-81-8
	795430-82-9	795430-83-0			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795430-84-1	795430-85-2	795430-86-3	795430-87-4	795430-88-5
	795430-89-6	795430-90-9	795430-91-0	795430-92-1	795430-93-2
	795430-94-3	795430-95-4	795430-96-5	795430-97-6	795430-98-7
	795430-99-8	795431-00-4	795431-01-5	795431-02-6	795431-03-7
	795431-04-8	795431-05-9	795431-06-0	795431-07-1	795431-08-2
	795431-09-3	795431-10-6	795431-11-7	795431-12-8	795431-13-9
	795431-14-0	795431-15-1	795431-16-2	795431-17-3	795431-18-4
	795431-19-5	795431-20-8	795431-21-9	795431-22-0	795431-23-1
	795431-24-2	795431-25-3	795431-26-4	795431-27-5	795431-28-6
	795431-29-7	795431-30-0	795431-31-1	795431-32-2	795431-33-3
	795431-34-4	795431-35-5	795431-36-6	795431-37-7	795431-38-8
	795431-39-9	795431-40-2	795431-41-3	795431-42-4	795431-43-5
	795431-44-6	795431-45-7	795431-46-8	795431-47-9	795431-48-0

795431-49-1	795431-50-4	795431-51-5	795431-52-6	795431-53-7
795431-54-8	795431-55-9	795431-56-0	795431-57-1	795431-58-2
795431-59-3	795431-60-6	795431-61-7	795431-62-8	795431-63-9
795431-64-0	795431-65-1	795431-66-2	795431-67-3	795431-68-4
795431-69-5	795431-70-8	795431-71-9	795431-72-0	795431-73-1
795431-74-2	795431-75-3	795431-76-4	795431-77-5	795431-78-6
795431-79-7	795431-80-0	795431-81-1	795431-82-2	795431-83-3
795431-84-4	795431-85-5	795431-86-6	795431-87-7	795431-88-8
795431-89-9	795431-90-2	795431-91-3	795431-92-4	795431-93-5
795431-94-6	795431-95-7	795431-96-8	795431-97-9	795431-98-0
795431-99-1	795432-00-7	795432-01-8	795432-02-9	795432-03-0
795432-04-1	795432-05-2	795432-06-3	795432-07-4	795432-08-5
795432-09-6	795432-10-9	795432-11-0	795432-12-1	795432-13-2
795432-14-3	795432-15-4	795432-16-5	795432-17-6	795432-18-7
795432-19-8	795432-20-1	795432-21-2	795432-22-3	795432-23-4
795432-24-5	795432-25-6	795432-26-7	795432-27-8	795432-28-9
795432-29-0	795432-30-3	795432-31-4	795432-32-5	795432-33-6
795432-34-7	795432-35-8	795432-36-9	795432-37-0	795432-38-1
795432-39-2	795432-40-5	795432-41-6	795432-42-7	795432-43-8
795432-44-9	795432-45-0	795432-46-1	795432-47-2	795432-48-3
795432-49-4	795432-50-7	795432-51-8	795432-52-9	795432-53-0
795432-54-1	795432-55-2	795432-56-3	795432-57-4	795432-58-5
795432-59-6	795432-60-9	795432-61-0	795432-62-1	795432-63-2
795432-64-3	795432-65-4	795432-66-5	795432-67-6	795432-68-7
795432-69-8	795432-70-1	795432-71-2	795432-72-3	795432-73-4
795432-74-5	795432-75-6	795432-76-7	795432-77-8	795432-78-9
795432-79-0	795432-80-3	795432-81-4	795432-82-5	795432-83-6
795432-84-7	795432-85-8	795432-86-9	795432-87-0	795432-88-1
795432-89-2	795432-90-5	795432-91-6	795432-92-7	795432-93-8
795432-94-9	795432-95-0	795432-96-1	795432-97-2	795432-98-3
795432-99-4	795433-00-0	795433-01-1	795433-02-2	795433-03-3
795433-04-4	795433-05-5	795433-06-6	795433-07-7	795433-08-8
795433-09-9	795433-10-2	795433-11-3	795433-12-4	795433-13-5
795433-14-6	795433-15-7	795433-16-8	795433-17-9	795433-18-0
795433-19-1	795433-20-4			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795433-21-5	795433-22-6	795433-23-7	795433-24-8	795433-25-9
	795433-26-0	795433-27-1	795433-28-2	795433-29-3	795433-30-6
	795433-31-7	795433-32-8	795433-33-9	795433-34-0	795433-35-1
	795433-36-2	795433-37-3	795433-38-4	795433-39-5	795433-40-8
	795433-41-9	795433-42-0	795433-43-1	795433-44-2	795433-45-3
	795433-46-4	795433-47-5	795433-48-6	795433-49-7	795433-50-0
	795433-51-1	795433-52-2	795433-53-3	795433-54-4	795433-55-5
	795433-56-6	795433-57-7	795433-58-8	795433-59-9	795433-60-2
	795433-61-3	795433-62-4	795433-63-5	795433-64-6	795433-65-7
	795433-66-8	795433-67-9	795433-68-0	795433-69-1	795433-70-4
	795433-71-5	795433-72-6	795433-73-7	795433-74-8	795433-75-9
	795433-76-0	795433-77-1	795433-78-2	795433-79-3	795433-80-6
	795433-81-7	795433-82-8	795433-83-9	795433-84-0	795433-85-1
	795433-86-2	795433-87-3	795433-88-4	795433-89-5	795433-90-8
	795433-91-9	795433-92-0	795433-93-1	795433-94-2	795433-95-3
	795433-96-4	795433-97-5	795433-98-6	795433-99-7	795434-00-3
	795434-01-4	795434-02-5	795434-03-6	795434-04-7	795434-05-8
	795434-06-9	795434-07-0	795434-08-1	795434-09-2	795434-10-5
	795434-11-6	795434-12-7	795434-13-8	795434-14-9	795434-15-0
	795434-16-1	795434-17-2	795434-18-3	795434-19-4	795434-20-7
	795434-21-8	795434-22-9	795434-23-0	795434-24-1	795434-25-2
	795434-26-3	795434-27-4	795434-28-5	795434-29-6	795434-30-9
	795434-31-0	795434-32-1	795434-33-2	795434-34-3	795434-35-4
	795434-36-5	795434-37-6	795434-38-7	795434-39-8	795434-40-1
	795434-41-2	795434-42-3	795434-43-4	795434-44-5	795434-45-6
	795434-46-7	795434-47-8	795434-48-9	795434-49-0	795434-50-3
	795434-51-4	795434-52-5	795434-53-6	795434-54-7	795434-55-8
	795434-56-9	795434-57-0	795434-58-1	795434-59-2	795434-60-5
	795434-61-6	795434-62-7	795434-63-8	795434-64-9	795434-65-0
	795434-66-1	795434-67-2	795434-68-3	795434-69-4	795434-70-7
	795434-71-8	795434-72-9	795434-73-0	795434-74-1	795434-75-2
	795434-76-3	795434-77-4	795434-78-5	795434-79-6	795434-80-9
	795434-81-0	795434-82-1	795434-83-2	795434-84-3	795434-85-4
	795434-86-5	795434-87-6	795434-88-7	795434-89-8	795434-90-1
	795434-91-2	795434-92-3	795434-93-4	795434-94-5	795434-95-6
	795434-96-7	795434-97-8	795434-98-9	795434-99-0	795435-00-6
	795435-01-7	795435-02-8	795435-03-9	795435-04-0	795435-05-1

795435-06-2	795435-07-3	795435-08-4	795435-09-5	795435-10-8
795435-11-9	795435-12-0	795435-13-1	795435-14-2	795435-15-3
795435-16-4	795435-17-5	795435-18-6	795435-19-7	795435-20-0
795435-21-1	795435-22-2	795435-23-3	795435-24-4	795435-25-5
795435-26-6	795435-27-7	795435-28-8	795435-29-9	795435-30-2
795435-31-3	795435-32-4	795435-33-5	795435-34-6	795435-35-7
795435-36-8	795435-37-9	795435-38-0	795435-39-1	795435-40-4
795435-41-5	795435-42-6	795435-43-7	795435-44-8	795435-45-9
795435-46-0	795435-47-1	795435-48-2	795435-49-3	795435-50-6
795435-51-7	795435-52-8	795435-53-9	795435-54-0	795435-55-1
795435-56-2	795435-57-3			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795435-58-4	795435-59-5	795435-60-8	795435-61-9	795435-62-0
	795435-63-1	795435-64-2	795435-65-3	795435-66-4	795435-67-5
	795435-68-6	795435-69-7	795435-70-0	795435-71-1	795435-72-2
	795435-73-3	795435-74-4	795435-75-5	795435-76-6	795435-77-7
	795435-78-8	795435-79-9	795435-80-2	795435-81-3	795435-82-4
	795435-83-5	795435-84-6	795435-85-7	795435-86-8	795435-87-9
	795435-88-0	795435-89-1	795435-90-4	795435-91-5	795435-92-6
	795435-93-7	795435-94-8	795435-95-9	795435-96-0	795435-97-1
	795435-98-2	795435-99-3	795436-00-9	795436-01-0	795436-02-1
	795436-03-2	795436-04-3	795436-05-4	795436-06-5	795436-07-6
	795436-08-7	795436-09-8	795436-10-1	795436-11-2	795436-12-3
	795436-13-4	795436-14-5	795436-15-6	795436-16-7	795436-17-8
	795436-18-9	795436-19-0	795436-20-3	795436-21-4	795436-22-5
	795436-23-6	795436-24-7	795436-25-8	795436-26-9	795436-27-0
	795436-28-1	795436-29-2	795436-30-5	795436-31-6	795436-32-7
	795436-33-8	795436-34-9	795436-35-0	795436-36-1	795436-37-2
	795436-38-3	795436-39-4	795436-40-7	795436-41-8	795436-42-9
	795436-43-0	795436-44-1	795436-45-2	795436-46-3	795436-47-4
	795436-48-5	795436-49-6	795436-50-9	795436-51-0	795436-52-1
	795436-53-2	795436-54-3	795436-55-4	795436-56-5	795436-57-6
	795436-58-7	795436-59-8	795436-60-1	795436-61-2	795436-62-3
	795436-63-4	795436-64-5	795436-65-6	795436-66-7	795436-67-8
	795436-68-9	795436-69-0	795436-70-3	795436-71-4	795436-72-5
	795436-73-6	795436-74-7	795436-75-8	795436-76-9	795436-77-0
	795436-78-1	795436-79-2	795436-80-5	795436-81-6	795436-82-7
	795436-83-8	795436-84-9	795436-85-0	795436-86-1	795436-87-2
	795436-88-3	795436-89-4	795436-90-7	795436-91-8	795436-92-9
	795436-93-0	795436-94-1	795436-95-2	795436-96-3	795436-97-4
	795436-98-5	795436-99-6	795437-00-2	795437-01-3	795437-02-4
	795437-03-5	795437-04-6	795437-05-7	795437-06-8	795437-07-9
	795437-08-0	795437-09-1	795437-10-4	795437-11-5	795437-12-6
	795437-13-7	795437-14-8	795437-15-9	795437-16-0	795437-17-1
	795437-18-2	795437-19-3	795437-20-6	795437-21-7	795437-22-8
	795437-23-9	795437-24-0	795437-25-1	795437-26-2	795437-27-3
	795437-28-4	795437-29-5	795437-30-8	795437-31-9	795437-32-0
	795437-33-1	795437-34-2	795437-35-3	795437-36-4	795437-37-5
	795437-38-6	795437-39-7	795437-40-0	795437-41-1	795437-42-2
	795437-43-3	795437-44-4	795437-45-5	795437-46-6	795437-47-7
	795437-48-8	795437-49-9	795437-50-2	795437-51-3	795437-52-4
	795437-53-5	795437-54-6	795437-55-7	795437-56-8	795437-57-9
	795437-58-0	795437-59-1	795437-60-4	795437-61-5	795437-62-6
	795437-63-7	795437-64-8	795437-65-9	795437-66-0	795437-67-1
	795437-68-2	795437-69-3	795437-70-6	795437-71-7	795437-72-8
	795437-73-9	795437-74-0	795437-75-1	795437-76-2	795437-77-3
	795437-78-4	795437-79-5	795437-80-8	795437-81-9	795437-82-0
	795437-83-1	795437-84-2	795437-85-3	795437-86-4	795437-87-5
	795437-88-6	795437-89-7	795437-90-0	795437-91-1	795437-92-2
	795437-93-3	795437-94-4			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795437-95-5	795437-96-6	795437-97-7	795437-98-8	795437-99-9
	795438-00-5	795438-01-6	795438-02-7	795438-03-8	795438-04-9
	795438-05-0	795438-06-1	795438-07-2	795438-08-3	795438-09-4
	795438-10-7	795438-11-8	795438-12-9	795438-13-0	795438-14-1
	795438-15-2	795438-16-3	795438-17-4	795438-18-5	795438-19-6
	795438-20-9	795438-21-0	795438-22-1	795438-23-2	795438-24-3
	795438-25-4	795438-26-5	795438-27-6	795438-28-7	795438-29-8
	795438-30-1	795438-31-2	795438-32-3	795438-33-4	795438-34-5
	795438-35-6	795438-36-7	795438-37-8	795438-38-9	795438-39-0

795438-40-3	795438-41-4	795438-42-5	795438-43-6	795438-44-7
795438-45-8	795438-46-9	795438-47-0	795438-48-1	795438-49-2
795438-50-5	795438-51-6	795438-52-7	795438-53-8	795438-54-9
795438-55-0	795438-56-1	795438-57-2	795438-58-3	795438-59-4
795438-60-7	795438-61-8	795438-62-9	795438-63-0	795438-64-1
795438-65-2	795438-66-3	795438-67-4	795438-68-5	795438-69-6
795438-70-9	795438-71-0	795438-72-1	795438-73-2	795438-74-3
795438-75-4	795438-76-5	795438-77-6	795438-78-7	795438-79-8
795438-80-1	795438-81-2	795438-82-3	795438-83-4	795438-84-5
795438-85-6	795438-86-7	795438-87-8	795438-88-9	795438-89-0
795438-90-3	795438-91-4	795438-92-5	795438-93-6	795438-94-7
795438-95-8	795438-96-9	795438-97-0	795438-98-1	795438-99-2
795439-00-8	795439-01-9	795439-02-0	795439-03-1	795439-04-2
795439-05-3	795439-06-4	795439-07-5	795439-08-6	795439-09-7
795439-10-0	795439-11-1	795439-12-2	795439-13-3	795439-14-4
795439-15-5	795439-16-6	795439-17-7	795439-18-8	795439-19-9
795439-20-2	795439-21-3	795439-22-4	795439-23-5	795439-24-6
795439-25-7	795439-26-8	795439-27-9	795439-28-0	795439-29-1
795439-30-4	795439-31-5	795439-32-6	795439-33-7	795439-34-8
795439-35-9	795439-36-0	795439-37-1	795439-38-2	795439-39-3
795439-40-6	795439-41-7	795439-42-8	795439-43-9	795439-44-0
795439-45-1	795439-46-2	795439-47-3	795439-48-4	795439-49-5
795439-50-8	795439-51-9	795439-52-0	795439-53-1	795439-54-2
795439-55-3	795439-56-4	795439-57-5	795439-58-6	795439-59-7
795439-60-0	795439-61-1	795439-62-2	795439-63-3	795439-64-4
795439-65-5	795439-66-6	795439-67-7	795439-68-8	795439-69-9
795439-70-2	795439-71-3	795439-72-4	795439-73-5	795439-74-6
795439-75-7	795439-76-8	795439-77-9	795439-78-0	795439-79-1
795439-80-4	795439-81-5	795439-82-6	795439-83-7	795439-84-8
795439-85-9	795439-86-0	795439-87-1	795439-88-2	795439-89-3
795439-90-6	795439-91-7	795439-92-8	795439-93-9	795439-94-0
795439-95-1	795439-96-2	795439-97-3	795439-98-4	795439-99-5
795440-00-5	795440-01-6	795440-02-7	795440-03-8	795440-04-9
795440-05-0	795440-06-1	795440-07-2	795440-08-3	795440-09-4
795440-10-7	795440-11-8	795440-12-9	795440-13-0	795440-14-1
795440-15-2	795440-16-3	795440-17-4	795440-18-5	795440-19-6
795440-20-9	795440-21-0	795440-22-1	795440-23-2	795440-24-3
795440-25-4	795440-26-5	795440-27-6	795440-28-7	795440-29-8
795440-30-1	795440-31-2			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795440-32-3	795440-33-4	795440-34-5	795440-35-6	795440-36-7
	795440-37-8	795440-38-9	795440-39-0	795440-40-3	795440-41-4
	795440-42-5	795440-43-6	795440-44-7	795440-45-8	795440-46-9
	795440-47-0	795440-48-1	795440-49-2	795440-50-5	795440-51-6
	795440-52-7	795440-53-8	795440-54-9	795440-55-0	795440-56-1
	795440-57-2	795440-58-3	795440-59-4	795440-60-7	795440-61-8
	795440-62-9	795440-63-0	795440-64-1	795440-65-2	795440-66-3
	795440-67-4	795440-68-5	795440-69-6	795440-70-9	795440-71-0
	795440-72-1	795440-73-2	795440-74-3	795440-75-4	795440-76-5
	795440-77-6	795440-78-7	795440-79-8	795440-80-1	795440-81-2
	795440-82-3	795440-83-4	795440-84-5	795440-85-6	795440-86-7
	795440-87-8	795440-88-9	795440-89-0	795440-90-3	795440-91-4
	795440-92-5	795440-93-6	795440-94-7	795440-95-8	795440-96-9
	795440-97-0	795440-98-1	795440-99-2	795441-00-8	795441-01-9
	795441-02-0	795441-03-1	795441-04-2	795441-05-3	795441-06-4
	795441-07-5	795441-08-6	795441-09-7	795441-10-0	795441-11-1
	795441-12-2	795441-13-3	795441-14-4	795441-15-5	795441-16-6
	795441-17-7	795441-18-8	795441-19-9	795441-20-2	795441-21-3
	795441-22-4	795441-23-5	795441-24-6	795441-25-7	795441-26-8
	795441-27-9	795441-28-0	795441-29-1	795441-30-4	795441-31-5
	795441-32-6	795441-33-7	795441-34-8	795441-35-9	795441-36-0
	795441-37-1	795441-38-2	795441-39-3	795441-40-6	795441-41-7
	795441-42-8	795441-43-9	795441-44-0	795441-45-1	795441-46-2
	795441-47-3	795441-48-4	795441-49-5	795441-50-8	795441-51-9
	795441-52-0	795441-53-1	795441-54-2	795441-55-3	795441-56-4
	795441-57-5	795441-58-6	795441-59-7	795441-60-0	795441-61-1
	795441-62-2	795441-63-3	795441-64-4	795441-65-5	795441-66-6
	795441-67-7	795441-68-8	795441-69-9	795441-70-2	795441-71-3
	795441-72-4	795441-73-5	795441-74-6	795441-75-7	795441-76-8
	795441-77-9	795441-78-0	795441-79-1	795441-80-4	795441-81-5
	795441-82-6	795441-83-7	795441-84-8	795441-85-9	795441-86-0
	795441-87-1	795441-88-2	795441-89-3	795441-90-6	795441-91-7
	795441-92-8	795441-93-9	795441-94-0	795441-95-1	795441-96-2

795441-97-3	795441-98-4	795441-99-5	795442-00-1	795442-01-2
795442-02-3	795442-03-4	795442-04-5	795442-05-6	795442-06-7
795442-07-8	795442-08-9	795442-09-0	795442-10-3	795442-11-4
795442-12-5	795442-13-6	795442-14-7	795442-15-8	795442-16-9
795442-17-0	795442-18-1	795442-19-2	795442-20-5	795442-21-6
795442-22-7	795442-23-8	795442-24-9	795442-25-0	795442-26-1
795442-27-2	795442-28-3	795442-29-4	795442-30-7	795442-31-8
795442-32-9	795442-33-0	795442-34-1	795442-35-2	795442-36-3
795442-37-4	795442-38-5	795442-39-6	795442-40-9	795442-41-0
795442-42-1	795442-43-2	795442-44-3	795442-45-4	795442-46-5
795442-47-6	795442-48-7	795442-49-8	795442-50-1	795442-51-2
795442-52-3	795442-53-4	795442-54-5	795442-55-6	795442-56-7
795442-57-8	795442-58-9	795442-59-0	795442-60-3	795442-61-4
795442-62-5	795442-63-6	795442-64-7	795442-65-8	795442-66-9
795442-67-0	795442-68-1			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795442-69-2	795442-70-5	795442-71-6	795442-72-7	795442-73-8
	795442-74-9	795442-75-0	795442-76-1	795442-77-2	795442-78-3
	795442-79-4	795442-80-7	795442-81-8	795442-82-9	795442-83-0
	795442-84-1	795442-85-2	795442-86-3	795442-87-4	795442-88-5
	795442-89-6	795442-90-9	795442-91-0	795442-92-1	795442-93-2
	795442-94-3	795442-95-4	795442-96-5	795442-97-6	795442-98-7
	795442-99-8	795443-00-4	795443-01-5	795443-02-6	795443-03-7
	795443-04-8	795443-05-9	795443-06-0	795443-07-1	795443-08-2
	795443-09-3	795443-10-6	795443-11-7	795443-12-8	795443-13-9
	795443-14-0	795443-15-1	795443-16-2	795443-17-3	795443-18-4
	795443-19-5	795443-20-8	795443-21-9	795443-22-0	795443-23-1
	795443-24-2	795443-25-3	795443-26-4	795443-27-5	795443-28-6
	795443-29-7	795443-30-0	795443-31-1	795443-32-2	795443-33-3
	795443-34-4	795443-35-5	795443-36-6	795443-37-7	795443-38-8
	795443-39-9	795443-40-2	795443-41-3	795443-42-4	795443-43-5
	795443-44-6	795443-45-7	795443-46-8	795443-47-9	795443-48-0
	795443-49-1	795443-50-4	795443-51-5	795443-52-6	795443-53-7
	795443-54-8	795443-55-9	795443-56-0	795443-57-1	795443-58-2
	795443-59-3	795443-60-6	795443-61-7	795443-62-8	795443-63-9
	795443-64-0	795443-65-1	795443-66-2	795443-67-3	795443-68-4
	795443-69-5	795443-70-8	795443-71-9	795443-72-0	795443-73-1
	795443-74-2	795443-75-3	795443-76-4	795443-77-5	795443-78-6
	795443-79-7	795443-80-0	795443-81-1	795443-82-2	795443-83-3
	795443-84-4	795443-85-5	795443-86-6	795443-87-7	795443-88-8
	795443-89-9	795443-90-2	795443-91-3	795443-92-4	795443-93-5
	795443-94-6	795443-95-7	795443-96-8	795443-97-9	795443-98-0
	795443-99-1	795444-00-7	795444-01-8	795444-02-9	795444-03-0
	795444-04-1	795444-05-2	795444-06-3	795444-07-4	795444-08-5
	795444-09-6	795444-10-9	795444-11-0	795444-12-1	795444-13-2
	795444-14-3	795444-15-4	795444-16-5	795444-17-6	795444-18-7
	795444-19-8	795444-20-1	795444-21-2	795444-22-3	795444-23-4
	795444-24-5	795444-25-6	795444-26-7	795444-27-8	795444-28-9
	795444-29-0	795444-30-3	795444-31-4	795444-32-5	795444-33-6
	795444-34-7	795444-35-8	795444-36-9	795444-37-0	795444-38-1
	795444-39-2	795444-40-5	795444-41-6	795444-42-7	795444-43-8
	795444-44-9	795444-45-0	795444-46-1	795444-47-2	795444-48-3
	795444-49-4	795444-50-7	795444-51-8	795444-52-9	795444-53-0
	795444-54-1	795444-55-2	795444-56-3	795444-57-4	795444-58-5
	795444-59-6	795444-60-9	795444-61-0	795444-62-1	795444-63-2
	795444-64-3	795444-65-4	795444-66-5	795444-67-6	795444-68-7
	795444-69-8	795444-70-1	795444-71-2	795444-72-3	795444-73-4
	795444-74-5	795444-75-6	795444-76-7	795444-77-8	795444-78-9
	795444-79-0	795444-80-3	795444-81-4	795444-82-5	795444-83-6
	795444-84-7	795444-85-8	795444-86-9	795444-87-0	795444-88-1
	795444-89-2	795444-90-5	795444-91-6	795444-92-7	795444-93-8
	795444-94-9	795444-95-0	795444-96-1	795444-97-2	795444-98-3
	795444-99-4	795445-00-0	795445-01-1	795445-02-2	795445-03-3
	795445-04-4	795445-05-5			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795445-06-6	795445-07-7	795445-08-8	795445-09-9	795445-10-2
	795445-11-3	795445-12-4	795445-13-5	795445-14-6	795445-15-7
	795445-16-8	795445-17-9	795445-18-0	795445-19-1	795445-20-4
	795445-21-5	795445-22-6	795445-23-7	795445-24-8	795445-25-9
	795445-26-0	795445-27-1	795445-28-2	795445-29-3	795445-30-6

795445-31-7	795445-32-8	795445-33-9	795445-34-0	795445-35-1
795445-36-2	795445-37-3	795445-38-4	795445-39-5	795445-40-8
795445-41-9	795445-42-0	795445-43-1	795445-44-2	795445-45-3
795445-46-4	795445-47-5	795445-48-6	795445-49-7	795445-50-0
795445-51-1	795445-52-2	795445-53-3	795445-54-4	795445-55-5
795445-56-6	795445-57-7	795445-58-8	795445-59-9	795445-60-2
795445-61-3	795445-62-4	795445-63-5	795445-64-6	795445-65-7
795445-66-8	795445-67-9	795445-68-0	795445-69-1	795445-70-4
795445-71-5	795445-72-6	795445-73-7	795445-74-8	795445-75-9
795445-76-0	795445-77-1	795445-78-2	795445-79-3	795445-80-6
795445-81-7	795445-82-8	795445-83-9	795445-84-0	795445-85-1
795445-86-2	795445-87-3	795445-88-4	795445-89-5	795445-90-8
795445-91-9	795445-92-0	795445-93-1	795445-94-2	795445-95-3
795445-96-4	795445-97-5	795445-98-6	795445-99-7	795446-00-3
795446-01-4	795446-02-5	795446-03-6	795446-04-7	795446-05-8
795446-06-9	795446-07-0	795446-08-1	795446-09-2	795446-10-5
795446-11-6	795446-12-7	795446-13-8	795446-14-9	795446-15-0
795446-16-1	795446-17-2	795446-18-3	795446-19-4	795446-20-7
795446-21-8	795446-22-9	795446-23-0	795446-24-1	795446-25-2
795446-26-3	795446-27-4	795446-28-5	795446-29-6	795446-30-9
795446-31-0	795446-32-1	795446-33-2	795446-34-3	795446-35-4
795446-36-5	795446-37-6	795446-38-7	795446-39-8	795446-40-1
795446-41-2	795446-42-3	795446-43-4	795446-44-5	795446-45-6
795446-46-7	795446-47-8	795446-48-9	795446-49-0	795446-50-3
795446-51-4	795446-52-5	795446-53-6	795446-54-7	795446-55-8
795446-56-9	795446-57-0	795446-58-1	795446-59-2	795446-60-5
795446-61-6	795446-62-7	795446-63-8	795446-64-9	795446-65-0
795446-66-1	795446-67-2	795446-68-3	795446-69-4	795446-70-7
795446-71-8	795446-72-9	795446-73-0	795446-74-1	795446-75-2
795446-76-3	795446-77-4	795446-78-5	795446-79-6	795446-80-9
795446-81-0	795446-82-1	795446-83-2	795446-84-3	795446-85-4
795446-86-5	795446-87-6	795446-88-7	795446-89-8	795446-90-1
795446-91-2	795446-92-3	795446-93-4	795446-94-5	795446-95-6
795446-96-7	795446-97-8	795446-98-9	795446-99-0	795447-00-6
795447-01-7	795447-02-8	795447-03-9	795447-04-0	795447-05-1
795447-06-2	795447-07-3	795447-08-4	795447-09-5	795447-10-8
795447-11-9	795447-12-0	795447-13-1	795447-14-2	795447-15-3
795447-16-4	795447-17-5	795447-18-6	795447-19-7	795447-20-0
795447-21-1	795447-22-2	795447-23-3	795447-24-4	795447-25-5
795447-26-6	795447-27-7	795447-28-8	795447-29-9	795447-30-2
795447-31-3	795447-32-4	795447-33-5	795447-34-6	795447-35-7
795447-36-8	795447-37-9	795447-38-0	795447-39-1	795447-40-4
795447-41-5	795447-42-6			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795447-43-7	795447-44-8	795447-45-9	795447-46-0	795447-47-1
	795447-48-2	795447-49-3	795447-50-6	795447-51-7	795447-52-8
	795447-53-9	795447-54-0	795447-55-1	795447-56-2	795447-57-3
	795447-58-4	795447-59-5	795447-60-8	795447-61-9	795447-62-0
	795447-63-1	795447-64-2	795447-65-3	795447-66-4	795447-67-5
	795447-68-6	795447-69-7	795447-70-0	795447-71-1	795447-72-2
	795447-73-3	795447-74-4	795447-75-5	795447-76-6	795447-77-7
	795447-78-8	795447-79-9	795447-80-2	795447-81-3	795447-82-4
	795447-83-5	795447-84-6	795447-85-7	795447-86-8	795447-87-9
	795447-88-0	795447-89-1	795447-90-4	795447-91-5	795447-92-6
	795447-93-7	795447-94-8	795447-95-9	795447-96-0	795447-97-1
	795447-98-2	795447-99-3	795448-00-9	795448-01-0	795448-02-1
	795448-03-2	795448-04-3	795448-05-4	795448-06-5	795448-07-6
	795448-08-7	795448-09-8	795448-10-1	795448-11-2	795448-12-3
	795448-13-4	795448-14-5	795448-15-6	795448-16-7	795448-17-8
	795448-18-9	795448-19-0	795448-20-3	795448-21-4	795448-22-5
	795448-23-6	795448-24-7	795448-25-8	795448-26-9	795448-27-0
	795448-28-1	795448-29-2	795448-30-5	795448-31-6	795448-32-7
	795448-33-8	795448-34-9	795448-35-0	795448-36-1	795448-37-2
	795448-38-3	795448-39-4	795448-40-7	795448-41-8	795448-42-9
	795448-43-0	795448-44-1	795448-45-2	795448-46-3	795448-47-4
	795448-48-5	795448-49-6	795448-50-9	795448-51-0	795448-52-1
	795448-53-2	795448-54-3	795448-55-4	795448-56-5	795448-57-6
	795448-58-7	795448-59-8	795448-60-1	795448-61-2	795448-62-3
	795448-63-4	795448-64-5	795448-65-6	795448-66-7	795448-67-8
	795448-68-9	795448-69-0	795448-70-3	795448-71-4	795448-72-5
	795448-73-6	795448-74-7	795448-75-8	795448-76-9	795448-77-0
	795448-78-1	795448-79-2	795448-80-5	795448-81-6	795448-82-7
	795448-83-8	795448-84-9	795448-85-0	795448-86-1	795448-87-2

795448-88-3	795448-89-4	795448-90-7	795448-91-8	795448-92-9
795448-93-0	795448-94-1	795448-95-2	795448-96-3	795448-97-4
795448-98-5	795448-99-6	795449-00-2	795449-01-3	795449-02-4
795449-03-5	795449-04-6	795449-05-7	795449-06-8	795449-07-9
795449-08-0	795449-09-1	795449-10-4	795449-11-5	795449-12-6
795449-13-7	795449-14-8	795449-15-9	795449-16-0	795449-17-1
795449-18-2	795449-19-3	795449-20-6	795449-21-7	795449-22-8
795449-23-9	795449-24-0	795449-25-1	795449-26-2	795449-27-3
795449-28-4	795449-29-5	795449-30-8	795449-31-9	795449-32-0
795449-33-1	795449-34-2	795449-35-3	795449-36-4	795449-37-5
795449-38-6	795449-39-7	795449-40-0	795449-41-1	795449-42-2
795449-43-3	795449-44-4	795449-45-5	795449-46-6	795449-47-7
795449-48-8	795449-49-9	795449-50-2	795449-51-3	795449-52-4
795449-53-5	795449-54-6	795449-55-7	795449-56-8	795449-57-9
795449-58-0	795449-59-1	795449-60-4	795449-61-5	795449-62-6
795449-63-7	795449-64-8	795449-65-9	795449-66-0	795449-67-1
795449-68-2	795449-69-3	795449-70-6	795449-71-7	795449-72-8
795449-73-9	795449-74-0	795449-75-1	795449-76-2	795449-77-3
795449-78-4	795449-79-5			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795449-80-8	795449-81-9	795449-82-0	795449-83-1	795449-84-2
	795449-85-3	795449-86-4	795449-87-5	795449-88-6	795449-89-7
	795449-90-0	795449-91-1	795449-92-2	795449-93-3	795449-94-4
	795449-95-5	795449-96-6	795449-97-7	795449-98-8	795449-99-9
	795450-00-9	795450-01-0	795450-02-1	795450-03-2	795450-04-3
	795450-05-4	795450-06-5	795450-07-6	795450-08-7	795450-09-8
	795450-10-1	795450-11-2	795450-12-3	795450-13-4	795450-14-5
	795450-15-6	795450-16-7	795450-17-8	795450-18-9	795450-19-0
	795450-20-3	795450-21-4	795450-22-5	795450-23-6	795450-24-7
	795450-25-8	795450-26-9	795450-27-0	795450-28-1	795450-29-2
	795450-30-5	795450-31-6	795450-32-7	795450-33-8	795450-34-9
	795450-35-0	795450-36-1	795450-37-2	795450-38-3	795450-39-4
	795450-40-7	795450-41-8	795450-42-9	795450-43-0	795450-44-1
	795450-45-2	795450-46-3	795450-47-4	795450-48-5	795450-49-6
	795450-50-9	795450-51-0	795450-52-1	795450-53-2	795450-54-3
	795450-55-4	795450-56-5	795450-57-6	795450-58-7	795450-59-8
	795450-60-1	795450-61-2	795450-62-3	795450-63-4	795450-64-5
	795450-65-6	795450-66-7	795450-67-8	795450-68-9	795450-69-0
	795450-70-3	795450-71-4	795450-72-5	795450-73-6	795450-74-7
	795450-75-8	795450-76-9	795450-77-0	795450-78-1	795450-79-2
	795450-80-5	795450-81-6	795450-82-7	795450-83-8	795450-84-9
	795450-85-0	795450-86-1	795450-87-2	795450-88-3	795450-89-4
	795450-90-7	795450-91-8	795450-92-9	795450-93-0	795450-94-1
	795450-95-2	795450-96-3	795450-97-4	795450-98-5	795450-99-6
	795451-00-2	795451-01-3	795451-02-4	795451-03-5	795451-04-6
	795451-05-7	795451-06-8	795451-07-9	795451-08-0	795451-09-1
	795451-10-4	795451-11-5	795451-12-6	795451-13-7	795451-14-8
	795451-15-9	795451-16-0	795451-17-1	795451-18-2	795451-19-3
	795451-20-6	795451-21-7	795451-22-8	795451-23-9	795451-24-0
	795451-25-1	795451-26-2	795451-27-3	795451-28-4	795451-29-5
	795451-30-8	795451-31-9	795451-32-0	795451-33-1	795451-34-2
	795451-35-3	795451-36-4	795451-37-5	795451-38-6	795451-39-7
	795451-40-0	795451-41-1	795451-42-2	795451-43-3	795451-44-4
	795451-45-5	795451-46-6	795451-47-7	795451-48-8	795451-49-9
	795451-50-2	795451-51-3	795451-52-4	795451-53-5	795451-54-6
	795451-55-7	795451-56-8	795451-57-9	795451-58-0	795451-59-1
	795451-60-4	795451-61-5	795451-62-6	795451-63-7	795451-64-8
	795451-65-9	795451-66-0	795451-67-1	795451-68-2	795451-69-3
	795451-70-6	795451-71-7	795451-72-8	795451-73-9	795451-74-0
	795451-75-1	795451-76-2	795451-77-3	795451-78-4	795451-79-5
	795451-80-8	795451-81-9	795451-82-0	795451-83-1	795451-84-2
	795451-85-3	795451-86-4	795451-87-5	795451-88-6	795451-89-7
	795451-90-0	795451-91-1	795451-92-2	795451-93-3	795451-94-4
	795451-95-5	795451-96-6	795451-97-7	795451-98-8	795451-99-9
	795452-00-5	795452-01-6	795452-02-7	795452-03-8	795452-04-9
	795452-05-0	795452-06-1	795452-07-2	795452-08-3	795452-09-4
	795452-10-7	795452-11-8	795452-12-9	795452-13-0	795452-14-1
	795452-15-2	795452-16-3			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795452-17-4	795452-18-5	795452-19-6	795452-20-9	795452-21-0
----	-------------	-------------	-------------	-------------	-------------

795452-22-1	795452-23-2	795452-24-3	795452-25-4	795452-26-5
795452-27-6	795452-28-7	795452-29-8	795452-30-1	795452-31-2
795452-32-3	795452-33-4	795452-34-5	795452-35-6	795452-36-7
795452-37-8	795452-38-9	795452-39-0	795452-40-3	795452-41-4
795452-42-5	795452-43-6	795452-44-7	795452-45-8	795452-46-9
795452-47-0	795452-48-1	795452-49-2	795452-50-5	795452-51-6
795452-52-7	795452-53-8	795452-54-9	795452-55-0	795452-56-1
795452-57-2	795452-58-3	795452-59-4	795452-60-7	795452-61-8
795452-62-9	795452-63-0	795452-64-1	795452-65-2	795452-66-3
795452-67-4	795452-68-5	795452-69-6	795452-70-9	795452-71-0
795452-72-1	795452-73-2	795452-74-3	795452-75-4	795452-76-5
795452-77-6	795452-78-7	795452-79-8	795452-80-1	795452-81-2
795452-82-3	795452-83-4	795452-84-5	795452-85-6	795452-86-7
795452-87-8	795452-88-9	795452-89-0	795452-90-3	795452-91-4
795452-92-5	795452-93-6	795452-94-7	795452-95-8	795452-96-9
795452-97-0	795452-98-1	795452-99-2	795453-00-8	795453-01-9
795453-02-0	795453-03-1	795453-04-2	795453-05-3	795453-06-4
795453-07-5	795453-08-6	795453-09-7	795453-10-0	795453-11-1
795453-12-2	795453-13-3	795453-14-4	795453-15-5	795453-16-6
795453-17-7	795453-18-8	795453-19-9	795453-20-2	795453-21-3
795453-22-4	795453-23-5	795453-24-6	795453-25-7	795453-26-8
795453-27-9	795453-28-0	795453-29-1	795453-30-4	795453-31-5
795453-32-6	795453-33-7	795453-34-8	795453-35-9	795453-36-0
795453-37-1	795453-38-2	795453-39-3	795453-40-6	795453-41-7
795453-42-8	795453-43-9	795453-44-0	795453-45-1	795453-46-2
795453-47-3	795453-48-4	795453-49-5	795453-50-8	795453-51-9
795453-52-0	795453-53-1	795453-54-2	795453-55-3	795453-56-4
795453-57-5	795453-58-6	795453-59-7	795453-60-0	795453-61-1
795453-62-2	795453-63-3	795453-64-4	795453-65-5	795453-66-6
795453-67-7	795453-68-8	795453-69-9	795453-70-2	795453-71-3
795453-72-4	795453-73-5	795453-74-6	795453-75-7	795453-76-8
795453-77-9	795453-78-0	795453-79-1	795453-80-4	795453-81-5
795453-82-6	795453-83-7	795453-84-8	795453-85-9	795453-86-0
795453-87-1	795453-88-2	795453-89-3	795453-90-6	795453-91-7
795453-92-8	795453-93-9	795453-94-0	795453-95-1	795453-96-2
795453-97-3	795453-98-4	795453-99-5	795454-00-1	795454-01-2
795454-02-3	795454-03-4	795454-04-5	795454-05-6	795454-06-7
795454-07-8	795454-08-9	795454-09-0	795454-10-3	795454-11-4
795454-12-5	795454-13-6	795454-14-7	795454-15-8	795454-16-9
795454-17-0	795454-18-1	795454-19-2	795454-20-5	795454-21-6
795454-22-7	795454-23-8	795454-24-9	795454-25-0	795454-26-1
795454-27-2	795454-28-3	795454-29-4	795454-30-7	795454-31-8
795454-32-9	795454-33-0	795454-34-1	795454-35-2	795454-36-3
795454-37-4	795454-38-5	795454-39-6	795454-40-9	795454-41-0
795454-42-1	795454-43-2	795454-44-3	795454-45-4	795454-46-5
795454-47-6	795454-48-7	795454-49-8	795454-50-1	795454-51-2
795454-52-3	795454-53-4			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795454-54-5	795454-55-6	795454-56-7	795454-57-8	795454-58-9
	795454-59-0	795454-60-3	795454-61-4	795454-62-5	795454-63-6
	795454-64-7	795454-65-8	795454-66-9	795454-67-0	795454-68-1
	795454-69-2	795454-70-5	795454-71-6	795454-72-7	795454-73-8
	795454-74-9	795454-75-0	795454-76-1	795454-77-2	795454-78-3
	795454-79-4	795454-80-7	795454-81-8	795454-82-9	795454-83-0
	795454-84-1	795454-85-2	795454-86-3	795454-87-4	795454-88-5
	795454-89-6	795454-90-9	795454-91-0	795454-92-1	795454-93-2
	795454-94-3	795454-95-4	795454-96-5	795454-97-6	795454-98-7
	795454-99-8	795455-00-4	795455-01-5	795455-02-6	795455-03-7
	795455-04-8	795455-05-9	795455-06-0	795455-07-1	795455-08-2
	795455-09-3	795455-10-6	795455-11-7	795455-12-8	795455-13-9
	795455-14-0	795455-15-1	795455-16-2	795455-17-3	795455-18-4
	795455-19-5	795455-20-8	795455-21-9	795455-22-0	795455-23-1
	795455-24-2	795455-25-3	795455-26-4	795455-27-5	795455-28-6
	795455-29-7	795455-30-0	795455-31-1	795455-32-2	795455-33-3
	795455-34-4	795455-35-5	795455-36-6	795455-37-7	795455-38-8
	795455-39-9	795455-40-2	795455-41-3	795455-42-4	795455-43-5
	795455-44-6	795455-45-7	795455-46-8	795455-47-9	795455-48-0
	795455-49-1	795455-50-4	795455-51-5	795455-52-6	795455-53-7
	795455-54-8	795455-55-9	795455-56-0	795455-57-1	795455-58-2
	795455-59-3	795455-60-6	795455-61-7	795455-62-8	795455-63-9
	795455-64-0	795455-65-1	795455-66-2	795455-67-3	795455-68-4
	795455-69-5	795455-70-8	795455-71-9	795455-72-0	795455-73-1
	795455-74-2	795455-75-3	795455-76-4	795455-77-5	795455-78-6

795455-79-7	795455-80-0	795455-81-1	795455-82-2	795455-83-3
795455-84-4	795455-85-5	795455-86-6	795455-87-7	795455-88-8
795455-89-9	795455-90-2	795455-91-3	795455-92-4	795455-93-5
795455-94-6	795455-95-7	795455-96-8	795455-97-9	795455-98-0
795455-99-1	795456-00-7	795456-01-8	795456-02-9	795456-03-0
795456-04-1	795456-05-2	795456-06-3	795456-07-4	795456-08-5
795456-09-6	795456-10-9	795456-11-0	795456-12-1	795456-13-2
795456-14-3	795456-15-4	795456-16-5	795456-17-6	795456-18-7
795456-19-8	795456-20-1	795456-21-2	795456-22-3	795456-23-4
795456-24-5	795456-25-6	795456-26-7	795456-27-8	795456-28-9
795456-29-0	795456-30-3	795456-31-4	795456-32-5	795456-33-6
795456-34-7	795456-35-8	795456-36-9	795456-37-0	795456-38-1
795456-39-2	795456-40-5	795456-41-6	795456-42-7	795456-43-8
795456-44-9	795456-45-0	795456-46-1	795456-47-2	795456-48-3
795456-49-4	795456-50-7	795456-51-8	795456-52-9	795456-53-0
795456-54-1	795456-55-2	795456-56-3	795456-57-4	795456-58-5
795456-59-6	795456-60-9	795456-61-0	795456-62-1	795456-63-2
795456-64-3	795456-65-4	795456-66-5	795456-67-6	795456-68-7
795456-69-8	795456-70-1	795456-71-2	795456-72-3	795456-73-4
795456-74-5	795456-75-6	795456-76-7	795456-77-8	795456-78-9
795456-79-0	795456-80-3	795456-81-4	795456-82-5	795456-83-6
795456-84-7	795456-85-8	795456-86-9	795456-87-0	795456-88-1
795456-89-2	795456-90-5			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795456-91-6	795456-92-7	795456-93-8	795456-94-9	795456-95-0
	795456-96-1	795456-97-2	795456-98-3	795456-99-4	795457-00-0
	795457-01-1	795457-02-2	795457-03-3	795457-04-4	795457-05-5
	795457-06-6	795457-07-7	795457-08-8	795457-09-9	795457-10-2
	795457-11-3	795457-12-4	795457-13-5	795457-14-6	795457-15-7
	795457-16-8	795457-17-9	795457-18-0	795457-19-1	795457-20-4
	795457-21-5	795457-22-6	795457-23-7	795457-24-8	795457-25-9
	795457-26-0	795457-27-1	795457-28-2	795457-29-3	795457-30-6
	795457-31-7	795457-32-8	795457-33-9	795457-34-0	795457-35-1
	795457-36-2	795457-37-3	795457-38-4	795457-39-5	795457-40-8
	795457-41-9	795457-42-0	795457-43-1	795457-44-2	795457-45-3
	795457-46-4	795457-47-5	795457-48-6	795457-49-7	795457-50-0
	795457-51-1	795457-52-2	795457-53-3	795457-54-4	795457-55-5
	795457-56-6	795457-57-7	795457-58-8	795457-59-9	795457-60-2
	795457-61-3	795457-62-4	795457-63-5	795457-64-6	795457-65-7
	795457-66-8	795457-67-9	795457-68-0	795457-69-1	795457-70-4
	795457-71-5	795457-72-6	795457-73-7	795457-74-8	795457-75-9
	795457-76-0	795457-77-1	795457-78-2	795457-79-3	795457-80-6
	795457-81-7	795457-82-8	795457-83-9	795457-84-0	795457-85-1
	795457-86-2	795457-87-3	795457-88-4	795457-89-5	795457-90-8
	795457-91-9	795457-92-0	795457-93-1	795457-94-2	795457-95-3
	795457-96-4	795457-97-5	795457-98-6	795457-99-7	795458-00-3
	795458-01-4	795458-02-5	795458-03-6	795458-04-7	795458-05-8
	795458-06-9	795458-07-0	795458-08-1	795458-09-2	795458-10-5
	795458-11-6	795458-12-7	795458-13-8	795458-14-9	795458-15-0
	795458-16-1	795458-17-2	795458-18-3	795458-19-4	795458-20-7
	795458-21-8	795458-22-9	795458-23-0	795458-24-1	795458-25-2
	795458-26-3	795458-27-4	795458-28-5	795458-29-6	795458-30-9
	795458-31-0	795458-32-1	795458-33-2	795458-34-3	795458-35-4
	795458-36-5	795458-37-6	795458-38-7	795458-39-8	795458-40-1
	795458-41-2	795458-42-3	795458-43-4	795458-44-5	795458-45-6
	795458-46-7	795458-47-8	795458-48-9	795458-49-0	795458-50-3
	795458-51-4	795458-52-5	795458-53-6	795458-54-7	795458-55-8
	795458-56-9	795458-57-0	795458-58-1	795458-59-2	795458-60-5
	795458-61-6	795458-62-7	795458-63-8	795458-64-9	795458-65-0
	795458-66-1	795458-67-2	795458-68-3	795458-69-4	795458-70-7
	795458-71-8	795458-72-9	795458-73-0	795458-74-1	795458-75-2
	795458-76-3	795458-77-4	795458-78-5	795458-79-6	795458-80-9
	795458-81-0	795458-82-1	795458-83-2	795458-84-3	795458-85-4
	795458-86-5	795458-87-6	795458-88-7	795458-89-8	795458-90-1
	795458-91-2	795458-92-3	795458-93-4	795458-94-5	795458-95-6
	795458-96-7	795458-97-8	795458-98-9	795458-99-0	795459-00-6
	795459-01-7	795459-02-8	795459-03-9	795459-04-0	795459-05-1
	795459-06-2	795459-07-3	795459-08-4	795459-09-5	795459-10-8
	795459-11-9	795459-12-0	795459-13-1	795459-14-2	795459-15-3
	795459-16-4	795459-17-5	795459-18-6	795459-19-7	795459-20-0
	795459-21-1	795459-22-2	795459-23-3	795459-24-4	
	795459-25-5	795459-26-6	795459-27-7		

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical

study); USES (Uses)
(probe and/or primer; oligonucleotide probes in nucleic acid arrays for
genetic anal. of mouse)

IT	795459-28-8	795459-29-9	795459-30-2	795459-31-3	795459-32-4
	795459-33-5	795459-34-6	795459-35-7	795459-36-8	795459-37-9
	795459-38-0	795459-39-1	795459-40-4	795459-41-5	795459-42-6
	795459-43-7	795459-44-8	795459-45-9	795459-46-0	795459-47-1
	795459-48-2	795459-49-3	795459-50-6	795459-51-7	795459-52-8
	795459-53-9	795459-54-0	795459-55-1	795459-56-2	795459-57-3
	795459-58-4	795459-59-5	795459-60-8	795459-61-9	795459-62-0
	795459-63-1	795459-64-2	795459-65-3	795459-66-4	795459-67-5
	795459-68-6	795459-69-7	795459-70-0	795459-71-1	795459-72-2
	795459-73-3	795459-74-4	795459-75-5	795459-76-6	795459-77-7
	795459-78-8	795459-79-9	795459-80-2	795459-81-3	795459-82-4
	795459-83-5	795459-84-6	795459-85-7	795459-86-8	795459-87-9
	795459-88-0	795459-89-1	795459-90-4	795459-91-5	795459-92-6
	795459-93-7	795459-94-8	795459-95-9	795459-96-0	795459-97-1
	795459-98-2	795459-99-3	795460-00-3	795460-01-4	795460-02-5
	795460-03-6	795460-04-7	795460-05-8	795460-06-9	795460-07-0
	795460-08-1	795460-09-2	795460-10-5	795460-11-6	795460-12-7
	795460-13-8	795460-14-9	795460-15-0	795460-16-1	795460-17-2
	795460-18-3	795460-19-4	795460-20-7	795460-21-8	795460-22-9
	795460-23-0	795460-24-1	795460-25-2	795460-26-3	795460-27-4
	795460-28-5	795460-29-6	795460-30-9	795460-31-0	795460-32-1
	795460-33-2	795460-34-3	795460-35-4	795460-36-5	795460-37-6
	795460-38-7	795460-39-8	795460-40-1	795460-41-2	795460-42-3
	795460-43-4	795460-44-5	795460-45-6	795460-46-7	795460-47-8
	795460-48-9	795460-49-0	795460-50-3	795460-51-4	795460-52-5
	795460-53-6	795460-54-7	795460-55-8	795460-56-9	795460-57-0
	795460-58-1	795460-59-2	795460-60-5	795460-61-6	795460-62-7
	795460-63-8	795460-64-9	795460-65-0	795460-66-1	795460-67-2
	795460-68-3	795460-69-4	795460-70-7	795460-71-8	795460-72-9
	795460-73-0	795460-74-1	795460-75-2	795460-76-3	795460-77-4
	795460-78-5	795460-79-6	795460-80-9	795460-81-0	795460-82-1
	795460-83-2	795460-84-3	795460-85-4	795460-86-5	795460-87-6
	795460-88-7	795460-89-8	795460-90-1	795460-91-2	795460-92-3
	795460-93-4	795460-94-5	795460-95-6	795460-96-7	795460-97-8
	795460-98-9	795461-00-0	795461-00-6	795461-01-7	795461-02-8
	795461-03-9	795461-04-0	795461-05-1	795461-06-2	795461-07-3
	795461-08-4	795461-09-5	795461-10-8	795461-11-9	795461-12-0
	795461-13-1	795461-14-2	795461-15-3	795461-16-4	795461-17-5
	795461-18-6	795461-19-7	795461-20-0	795461-21-1	795461-22-2
	795461-23-3	795461-24-4	795461-25-5	795461-26-6	795461-27-7
	795461-28-8	795461-29-9	795461-30-2	795461-31-3	795461-32-4
	795461-33-5	795461-34-6	795461-35-7	795461-36-8	795461-37-9
	795461-38-0	795461-39-1	795461-40-4	795461-41-5	795461-42-6
	795461-43-7	795461-44-8	795461-45-9	795461-46-0	795461-47-1
	795461-48-2	795461-49-3	795461-50-6	795461-51-7	795461-52-8
	795461-53-9	795461-54-0	795461-55-1	795461-56-2	795461-57-3
	795461-58-4	795461-59-5	795461-60-8	795461-61-9	795461-62-0
	795461-63-1	795461-64-2			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical
study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for
genetic anal. of mouse)

IT	795461-65-3	795461-66-4	795461-67-5	795461-68-6	795461-69-7
	795461-70-0	795461-71-1	795461-72-2	795461-73-3	795461-74-4
	795461-75-5	795461-76-6	795461-77-7	795461-78-8	795461-79-9
	795461-80-2	795461-81-3	795461-82-4	795461-83-5	795461-84-6
	795461-85-7	795461-86-8	795461-87-9	795461-88-0	795461-89-1
	795461-90-4	795461-91-5	795461-92-6	795461-93-7	795461-94-8
	795461-95-9	795461-96-0	795461-97-1	795461-98-2	795461-99-3
	795462-00-9	795462-01-0	795462-02-1	795462-03-2	795462-04-3
	795462-05-4	795462-06-5	795462-07-6	795462-08-7	795462-09-8
	795462-10-1	795462-11-2	795462-12-3	795462-13-4	795462-14-5
	795462-15-6	795462-16-7	795462-17-8	795462-18-9	795462-19-0
	795462-20-3	795462-21-4	795462-22-5	795462-23-6	795462-24-7
	795462-25-8	795462-26-9	795462-27-0	795462-28-1	795462-29-2
	795462-30-5	795462-31-6	795462-32-7	795462-33-8	795462-34-9
	795462-35-0	795462-36-1	795462-37-2	795462-38-3	795462-39-4
	795462-40-7	795462-41-8	795462-42-9	795462-43-0	795462-44-1
	795462-45-2	795462-46-3	795462-47-4	795462-48-5	795462-49-6
	795462-50-9	795462-51-0	795462-52-1	795462-53-2	795462-54-3
	795462-55-4	795462-56-5	795462-57-6	795462-58-7	795462-59-8
	795462-60-1	795462-61-2	795462-62-3	795462-63-4	795462-64-5
	795462-65-6	795462-66-7	795462-67-8	795462-68-9	795462-69-0

795462-70-3	795462-71-4	795462-72-5	795462-73-6	795462-74-7
795462-75-8	795462-76-9	795462-77-0	795462-78-1	795462-79-2
795462-80-5	795462-81-6	795462-82-7	795462-83-8	795462-84-9
795462-85-0	795462-86-1	795462-87-2	795462-88-3	795462-89-4
795462-90-7	795462-91-8	795462-92-9	795462-93-0	795462-94-1
795462-95-2	795462-96-3	795462-97-4	795462-98-5	795462-99-6
795463-00-2	795463-01-3	795463-02-4	795463-03-5	795463-04-6
795463-05-7	795463-06-8	795463-07-9	795463-08-0	795463-09-1
795463-10-4	795463-11-5	795463-12-6	795463-13-7	795463-14-8
795463-15-9	795463-16-0	795463-17-1	795463-18-2	795463-19-3
795463-20-6	795463-21-7	795463-22-8	795463-23-9	795463-24-0
795463-25-1	795463-26-2	795463-27-3	795463-28-4	795463-29-5
795463-30-8	795463-31-9	795463-32-0	795463-33-1	795463-34-2
795463-35-3	795463-36-4	795463-37-5	795463-38-6	795463-39-7
795463-40-0	795463-41-1	795463-42-2	795463-43-3	795463-44-4
795463-45-5	795463-46-6	795463-47-7	795463-48-8	795463-49-9
795463-50-2	795463-51-3	795463-52-4	795463-53-5	795463-54-6
795463-55-7	795463-56-8	795463-57-9	795463-58-0	795463-59-1
795463-60-4	795463-61-5	795463-62-6	795463-63-7	795463-64-8
795463-65-9	795463-66-0	795463-67-1	795463-68-2	795463-69-3
795463-70-6	795463-71-7	795463-72-8	795463-73-9	795463-74-0
795463-75-1	795463-76-2	795463-77-3	795463-78-4	795463-79-5
795463-80-8	795463-81-9	795463-82-0	795463-83-1	795463-84-2
795463-85-3	795463-86-4	795463-87-5	795463-88-6	795463-89-7
795463-90-0	795463-91-1	795463-92-2	795463-93-3	795463-94-4
795463-95-5	795463-96-6	795463-97-7	795463-98-8	795463-99-9
795464-00-5	795464-01-6			

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT	795464-02-7	795464-03-8	795464-04-9	795464-05-0	795464-06-1
	795464-07-2	795464-08-3	795464-09-4	795464-10-7	795464-11-8
	795464-12-9	795464-13-0	795464-14-1	795464-15-2	795464-16-3
	795464-17-4	795464-18-5	795464-19-6	795464-20-9	795464-21-0
	795464-22-1	795464-23-2	795464-24-3	795464-25-4	795464-26-5
	795464-27-6	795464-28-7	795464-29-8	795464-30-1	795464-31-2
	795464-32-3	795464-33-4	795464-34-5	795464-35-6	795464-36-7
	795464-37-8	795464-38-9	795464-39-0	795464-40-3	795464-41-4
	795464-42-5	795464-43-6	795464-44-7	795464-45-8	795464-46-9
	795464-47-0	795464-48-1	795464-49-2	795464-50-5	795464-51-6
	795464-52-7	795464-53-8	795464-54-9	795464-55-0	795464-56-1
	795464-57-2	795464-58-3	795464-59-4	795464-60-7	795464-61-8
	795464-62-9	795464-63-0	795464-64-1	795464-65-2	795464-66-3
	795464-67-4	795464-68-5	795464-69-6	795464-70-9	795464-71-0
	795464-72-1	795464-73-2	795464-74-3	795464-75-4	795464-76-5
	795464-77-6	795464-78-7	795464-79-8	795464-80-1	795464-81-2
	795464-82-3	795464-83-4	795464-84-5	795464-85-6	795464-86-7
	795464-87-8	795464-88-9	795464-89-0	795464-90-3	795464-91-4
	795464-92-5	795464-93-6	795464-94-7	795464-95-8	795464-96-9
	795464-97-0	795464-98-1	795464-99-2	795465-00-8	795465-01-9
	795465-02-0	795465-03-1	795465-04-2	795465-05-3	795465-06-4
	795465-07-5	795465-08-6	795465-09-7	795465-10-0	795465-11-1
	795465-12-2	795465-13-3	795465-14-4	795465-15-5	795465-16-6
	795465-17-7	795465-18-8	795465-19-9	795465-20-2	795465-21-3
	795465-22-4	795465-23-5	795465-24-6	795465-25-7	795465-26-8
	795465-27-9	795465-28-0	795465-29-1	795465-30-4	795465-31-5
	795465-32-6	795465-33-7	795465-34-8	795465-35-9	795465-36-0
	795465-37-1	795465-38-2	795465-39-3	795465-40-6	795465-41-7
	795465-42-8	795465-43-9	795465-44-0	795465-45-1	795465-46-2
	795465-47-3	795465-48-4	795465-49-5	795465-50-8	795465-51-9
	795465-52-0	795465-53-1	795465-54-2	795465-55-3	795465-56-4
	795465-57-5	795465-58-6	795465-59-7	795465-60-0	795465-61-1
	795465-62-2	795465-63-3	795465-64-4	795465-65-5	795465-66-6
	795465-67-7	795465-68-8	795465-69-9	795465-70-2	795465-71-3
	795465-72-4	795465-73-5	795465-74-6	795465-75-7	795465-76-8
	795465-77-9	795465-78-0	795465-79-1	795465-80-4	795465-81-5
	795465-82-6	795465-83-7	795465-84-8	795465-85-9	795465-86-0
	795465-87-1	795465-88-2	795465-89-3	795465-90-6	795465-91-7
	795465-92-8	795465-93-9	795465-94-0	795465-95-1	795465-96-2
	795465-97-3	795465-98-4	795465-99-5	795466-00-1	795466-01-2
	795466-02-3	795466-03-4	795466-04-5	795466-05-6	795466-06-7
	795466-07-8	795466-08-9	795466-09-0	795466-10-3	795466-11-4
	795466-12-5	795466-13-6	795466-14-7	795466-15-8	795466-16-9
	795466-17-0	795466-18-1	795466-19-2	795466-20-5	795466-21-6
	795466-22-7	795466-23-8	795466-24-9	795466-25-0	795466-26-1

795466-27-2 795466-28-3 795466-29-4 795466-30-7 795466-31-8
795466-32-9 795466-33-0 795466-34-1 795466-35-2 795466-36-3
795466-37-4 795466-38-5

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

IT 795466-39-6 795466-40-9 795466-41-0 795466-42-1 795466-43-2
795466-44-3 795466-45-4 795466-46-5 795466-47-6 795466-48-7
795466-49-8 795466-50-1 795466-51-2 795466-52-3 795466-53-4
795466-54-5 795466-55-6 795466-56-7 795466-57-8 795466-58-9
795466-59-0 795466-60-3 795466-61-4

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)

RE.CNT 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Affymetrix Inc; <http://www.sec.gov/Archives/edgar/data/913077/0001047469-97-001100.txt> 1997
- (2) Anon; AFFYMETRIC GeneChipArrays and Assays Product List 1998
- (3) Anon; AFFYMETRIC GeneChipAssays and Controls Price List 1997
- (4) Anon; AFFYMETRIX: Addendum (U S and Canada) GeneChipArrays and Reagents 1999
- (5) Anon; AFFYMETRIX: Affymetrix Price Catalog Addendum GeneChip Arrays and Reagents (U S and Canada) 2000
- (6) Anon; AFFYMETRIX: Affymetrix Product Catalog (Global) 2000
- (7) Anon; AFFYMETRIX: Affymetrix Product Catalog (Global) 2001
- (8) Anon; AFFYMETRIX: Affymetrix Product Catalog (Global) 2002
- (9) Anon; AFFYMETRIX: Affymetrix Product Catalog Global 2002
- (10) Anon; AFFYMETRIX: GenChip Price Catalog (U S and Canada) 2000
- (11) Anon; AFFYMETRIX: GeneChip Arrays and Reagents 1999
- (12) Anon; AFFYMETRIX: GeneChip Price Catalog (U S and Canada) 1999
- (13) Anon; AFFYMETRIX: GeneChipArrays and Assays Product List 1998
- (14) Anon; AFFYMETRIX: Product Information GeneChip Test 3 Array 2001
- (15) Anon; AFFYMETRIX: Product Information GeneChip Yeast GENOME S96 Array 1999
- (16) Anon; AFFYMETRIX: Product Information GeneChip CYP450 Assay 1997
- (17) Anon; AFFYMETRIX: Product Information GeneChip CYP450 Probe Array and Reagents 1998
- (18) Anon; AFFYMETRIX: Product Information GeneChip GenFlex TM Tag Array 2000
- (19) Anon; AFFYMETRIX: Product Information GeneChip HIV PRT Assay 1997
- (20) Anon; AFFYMETRIX: Product Information GeneChip HIV PRT Plus 1998
- (21) Anon; AFFYMETRIX: Product Information GeneChip HU6800 Array 1998
- (22) Anon; AFFYMETRIX: Product Information GeneChip HuSNP Managing Assay 1999
- (23) Anon; AFFYMETRIX: Product Information GeneChip Human Cancer G110 Array 1999
- (24) Anon; AFFYMETRIX: Product Information GeneChip Human Genome Focus Array 2002
- (25) Anon; AFFYMETRIX: Product Information GeneChip Human Genome U133 Set 2000
- (26) Anon; AFFYMETRIX: Product Information GeneChip Rat Genome U34 Array Set 1999
- (27) Anon; AFFYMETRIX: Product Information GeneChip Test 1 1998
- (28) Anon; AFFYMETRIX: Product Information GeneChip Test 2 Array 1999
- (29) Anon; AFFYMETRIX: Product Information GeneChip Yeast Genome S98 Array 2000
- (30) Anon; AFFYMETRIX: Product Information GeneChip p53 Assay 1997
- (31) Anon; AFFYMETRIX: Product Information GeneChip p53 Probe Array and Reagents 1998
- (32) Anon; AFFYMETRIX: Product Information Human Genome U95 Set 2000
- (33) Anon; AFFYMETRIX: Product Information Rat Neurobiology U34 Array 2000
- (34) Anon; Affymetrix:Product Information Arabidopsis Genome Array 2000
- (35) Anon; Affymetrix:Product Information Drosophila Genome Array 2000
- (36) Anon; Affymetrix:Product Information E coli Genome Array 2000
- (37) Anon; Affymetrix:Product Information GeneChip Arabidopsis ATH1 Genome Array 2002
- (38) Anon; Affymetrix:Product Information GeneChip B subtilis Genome Array 2002
- (39) Anon; Affymetrix:Product Information GeneChip C elegans Genome Array 2002
- (40) Anon; Affymetrix:Product Information GeneChip Custom Arrays 1998
- (41) Anon; Affymetrix:Product Information GeneChip Custom Arrays 2002
- (42) Anon; Affymetrix:Product Information GeneChip Human 35K Set 1998
- (43) Anon; Affymetrix:Product Information GeneChip Mu6500 Set 1998
- (44) Anon; Affymetrix:Product Information GeneChip Murine 11K Set 1998
- (45) Anon; Affymetrix:Product Information GeneChip Murine 11K Set 2001
- (46) Anon; Affymetrix:Product Information GeneChip Murine 19K Set 1998
- (47) Anon; Affymetrix:Product Information GeneChip Murine Genome U74 Set 2001
- (48) Anon; Affymetrix:Product Information GeneChip P aeruginosa Genome Array 2001

(49) Anon; Affymetrix:Product Information GeneChip Ye6100 Set 1998
 (50) Anon; Affymetrix:Product Information P aeruginosa Genome Array 2001
 (51) Bakay; Sources of variability and effect of experimental approach on expression profiling data interpretation 2002, V3, P4
 (52) Carmel; Pyphysiol Genomics 2001, V7, P201 HCAPLUS
 (53) Chee, M; Science 1996, V274(5287), P610 HCAPLUS
 (54) Cho; PNAS 1998, V95, P3752 HCAPLUS
 (55) Cho, R; Proceedings of the National Academy of Sciences of the United States of America 1998, V95(7), P3752 HCAPLUS
 (56) Cronin, M; Human Mutation 1996, V7(3), P244 HCAPLUS
 (57) de Saizieu, A; Nature Biotechnology 1998, V16(1), P45 HCAPLUS
 (58) Fan, J; Genome Research 2000, V10(6), P853 HCAPLUS
 (59) Fodor; US 5800992 A 1998 HCAPLUS
 (60) Goodfellow; US 5994075 A 1999 HCAPLUS
 (61) Hacia, J; Nature Genetics 1996, V14(4), P441 HCAPLUS
 (62) Hakak, Y; Proceedings of the National Academy of Sciences, USA 2001, V98(8), P4746 HCAPLUS
 (63) Harmer, S; Science 2000, V290(5499), P2110 HCAPLUS
 (64) Kozal, M; Nature Medicine 1996, V2(7), P753 HCAPLUS
 (65) Lipschultz, R; Letter from Lipschutz to Dr Carrano 1994
 (66) Lockhart, D; Nature Biotechnology 1996, V14(13), P1675 HCAPLUS
 (67) Lu, S; Proceedings of the National Academy of Sciences, USA 2001, V98(10), P5560 HCAPLUS
 (68) Macdonald, T; Nature Genetics 2001, V2, P143
 (69) Niculescu, A; American Journal of Psychiatry 2001, V158(10), P1587
 (70) Pirrung; US 5143854 A 1992 HCAPLUS
 (71) Rieneck, K; Apmis 2000, V108(12), P855 HCAPLUS
 (72) Roberts; PNAS 1997, V94, P12297 HCAPLUS
 (73) Rudd, K; Nature Biotechnology 2000, V18(12), P1241 HCAPLUS
 (74) Selinger, D; Nature Biotechnology 2000, V18(12), P1262 HCAPLUS
 (75) Shoemaker, D; Nature Genetics 1996, V14(4), P450 HCAPLUS
 (76) Stamey, T; Journal of Urology 2001, V166(6), P2171 HCAPLUS
 (77) Travers, K; Cell 2000, V101(3), P249 HCAPLUS
 (78) Welsh, J; Proceedings of the National Academy of Sciences, USA 2001, V96(3), P1176
 (79) Wodicka, L; Nature Biotechnology 1997, V15(13), P1359 HCAPLUS
 IT 795459-21-1
 RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
 (probe and/or primer; oligonucleotide probes in nucleic acid arrays for genetic anal. of mouse)
 RN 795459-21-1 HCAPLUS
 CN DNA, d(T-C-T-G-C-T-G-A-G-C-A-T-C-G-A-T-A-C-G-A-G-G-G-A) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 5 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:878139 HCAPLUS
 DN 141:370508
 ED Entered STN: 22 Oct 2004
 TI RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (sina)
 IN McSwiggen, James; Beigelman, Leonid; Macejak, Dennis
 PA USA
 SO U.S. Pat. Appl. Publ., 111 pp., Cont.-in-part of U.S. Ser. No. 444,853.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K048-00
 ICS C07H021-02
 NCL 514044000; 536023100
 CC 63-3 (Pharmaceuticals)
 Section cross-reference(s): 3, 13
 FAN.CNT 130

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004209831	A1	20041021	US 2003-667271	20030916
AU 9851819	A1	19980611	AU 1998-51819	19980112 <--
AU 729657	B2	20010208		
AU 9939188	A1	19990916	AU 1999-39188	19990713 <--
AU 769175	B2	20040115	AU 2000-56616	20000911 <--
WO 2002081494	A1	20021017	WO 2002-US9187	20020326

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 WO 2003070750 A2 20030828 WO 2003-US5043 20030220
 WO 2003070750 A3 20040318
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2004192626 A1 20040930 US 2003-444853 20030523
 PRAI US 2002-358580P P 20020220
 US 2002-363124P P 20020311
 WO 2002-US9187 A2 20020326
 US 2002-386782P P 20020606
 US 2002-401104P P 20020805
 US 2002-406784P P 20020829
 US 2002-408378P P 20020905
 US 2002-409293P P 20020909
 US 2003-440129P P 20030115
 WO 2003-US5043 A2 20030220
 US 2003-444853 A2 20030523
 AU 1995-26422 A3 19950518 <--
 US 1996-623891 A 19960325 <--
 AU 1996-76662 A3 19961025 <--
 US 2001-817879 A 20010326
 US 2001-296876P P 20010608
 US 2001-877478 A 20010608
 US 2001-335059P P 20011024
 US 2001-337055P P 20011205
 WO 2002-US15876 A2 20020520
 WO 2003-US5028 A2 20030220
 WO 2003-US5346 A2 20030220
 US 2003-417012 A1 20030416
 US 2003-422704 A2 20030424
 US 2003-427160 A2 20030430

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

US 2004209831 ICM A61K048-00
 ICS C07H021-02
 NCL 514044000; 536023100
 US 2004209831 ECLA C12N015/11B1A; C12N015/11D; C12N015/11H

AB The present invention concerns methods and reagents useful in modulating hepatitis C virus (HCV) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid mols., such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) mols. capable of mediating RNA interference (RNAi) against hepatitis C virus (HCV) gene expression and/or activity. The small nucleic acid mols. are useful in the treatment and diagnosis of HCV infection, liver failure, hepatocellular carcinoma, cirrhosis and any other disease or condition that responds to modulation of HCV expression or activity.

ST RNA interference inhibition gene hepatitis virus HCV

IT Pyrimidine nucleotides

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (2'-O-Me, 2'-deoxy-2'-fluoro; RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (sina))

IT Purine nucleotides

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (2'-deoxy, 2'-O-Me; RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (sina))

IT Gene, microbial

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HCV, expression; RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (sina))

IT Antiviral agents
Hepatitis C virus
Human
(RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (sina))

IT Antisense nucleic acids
Oligonucleotides
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (sina))

IT Post-transcriptional processing
(interference; RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (sina))

IT Nucleic acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(short interfering; RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (sina))

IT Double stranded RNA
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(small interfering; RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (sina))

IT 50-89-5, 2'-Deoxy-thymidine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (sina))

IT 777969-54-7 777969-55-8 777969-56-9 777969-57-0 777969-58-1
777969-59-2 777969-60-5
RL: PRP (Properties)
(unclaimed nucleotide sequence; rRNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (sina))

IT 777954-29-7 777954-30-0 777954-31-1 777954-32-2 777954-33-3
777954-34-4 777954-35-5 777954-36-6 777954-37-7 777954-38-8
777954-39-9 777954-40-2 777954-41-3 777954-42-4 777954-43-5
777954-44-6 777954-45-7 777954-46-8 777954-47-9 777954-48-0
777954-49-1 777954-50-4 777954-51-5 777954-52-6 777954-53-7
777954-54-8 777954-55-9 777954-56-0 777954-57-1 777954-58-2
777954-59-3 777954-60-6 777954-61-7 777954-62-8 777954-63-9
777954-64-0 777954-65-1 777954-66-2 777954-67-3 777954-68-4
777954-69-5 777954-70-8 777954-71-9 777954-72-0 777954-73-1
777954-74-2 777954-75-3 777954-76-4 777954-77-5 777954-78-6
777954-79-7 777954-80-0 777954-81-1 777954-82-2 777954-83-3
777954-84-4 777954-85-5 777954-86-6 777954-87-7 777954-88-8
777954-89-9 777954-90-2 777954-91-3 777954-92-4 777954-93-5
777954-94-6 777954-95-7 777954-96-8 777954-97-9 777954-98-0
777954-99-1 777955-00-7 777955-01-8 777955-02-9 777955-03-0
777955-04-1 777955-05-2 777955-06-3 777955-07-4 777955-08-5
777955-09-6 777955-10-9 777955-11-0 777955-12-1 777955-13-2
777955-14-3 777955-15-4 777955-16-5 777955-17-6 777955-18-7
777955-19-8 777955-20-1 777955-21-2 777955-22-3 777955-23-4
777955-24-5 777955-25-6 777955-26-7 777955-27-8 777955-28-9
777955-29-0 777955-30-3 777955-31-4 777955-32-5 777955-33-6
777955-34-7 777955-35-8 777955-36-9 777955-37-0 777955-38-1
777955-39-2 777955-40-5 777955-41-6 777955-42-7 777955-43-8
777955-44-9 777955-45-0 777955-46-1 777955-47-2 777955-48-3
777955-49-4 777955-50-7 777955-51-8 777955-52-9 777955-53-0
777955-54-1 777955-55-2 777955-56-3 777955-57-4 777955-58-5
777955-59-6 777955-60-9 777955-61-0 777955-62-1 777955-63-2
777955-64-3 777955-65-4 777955-66-5 777955-67-6 777955-68-7
777955-69-8 777955-70-1 777955-71-2 777955-72-3 777955-73-4
777955-74-5 777955-75-6 777955-76-7 777955-77-8 777955-78-9
777955-79-0 777955-80-3 777955-81-4 777955-82-5 777955-83-6
777955-84-7 777955-85-8 777955-86-9 777955-87-0 777955-88-1
777955-89-2 777955-90-5 777955-91-6 777955-92-7 777955-93-8
777955-94-9 777955-95-0 777955-96-1 777955-97-2 777955-98-3
777955-99-4 777956-00-0 777956-01-1 777956-02-2 777956-03-3
777956-04-4 777956-05-5 777956-06-6 777956-07-7 777956-08-8
777956-09-9 777956-10-2 777956-11-3 777956-12-4 777956-13-5

777956-14-6	777956-15-7	777956-16-8	777956-17-9	777956-18-0
777956-19-1	777956-20-4	777956-21-5	777956-22-6	777956-23-7
777956-24-8	777956-25-9	777956-26-0	777956-27-1	777956-28-2
777956-29-3	777956-30-6	777956-31-7	777956-32-8	777956-33-9
777956-34-0	777956-35-1	777956-36-2	777956-37-3	777956-38-4
777956-39-5	777956-40-8	777956-41-9	777956-42-0	777956-43-1
777956-44-2	777956-45-3	777956-46-4	777956-47-5	777956-48-6
777956-49-7	777956-50-0	777956-51-1	777956-52-2	777956-53-3
777956-54-4	777956-55-5	777956-56-6	777956-57-7	777956-58-8
777956-59-9	777956-60-2	777956-61-3	777956-62-4	777956-63-5
777956-64-6	777956-65-7	777956-66-8	777956-67-9	777956-68-0

RL: PRP (Properties)

(unclaimed sequence; rNA interference mediated inhibition of hepatitis
C virus (HCV) gene expression using short interfering nucleic acid
(sina))

IT	777956-69-1	777956-70-4	777956-71-5	777956-72-6	777956-73-7
	777956-74-8	777956-75-9	777956-76-0	777956-77-1	777956-78-2
	777956-79-3	777956-80-6	777956-81-7	777956-82-8	777956-83-9
	777956-84-0	777956-85-1	777956-86-2	777956-87-3	777956-88-4
	777956-89-5	777956-90-8	777956-91-9	777956-92-0	777956-93-1
	777956-94-2	777956-95-3	777956-96-4	777956-97-5	777956-98-6
	777956-99-7	777957-00-3	777957-01-4	777957-02-5	777957-03-6
	777957-04-7	777957-05-8	777957-06-9	777957-07-0	777957-08-1
	777957-09-2	777957-10-5	777957-11-6	777957-12-7	777957-13-8
	777957-14-9	777957-15-0	777957-16-1	777957-17-2	777957-18-3
	777957-19-4	777957-20-7	777957-21-8	777957-22-9	777957-23-0
	777957-24-1	777957-25-2	777957-26-3	777957-27-4	777957-28-5
	777957-29-6	777957-30-9	777957-31-0	777957-32-1	777957-33-2
	777957-34-3	777957-35-4	777957-36-5	777957-37-6	777957-38-7
	777957-39-8	777957-40-1	777957-41-2	777957-42-3	777957-43-4
	777957-44-5	777957-45-6	777957-46-7	777957-47-8	777957-48-9
	777957-49-0	777957-50-3	777957-51-4	777957-52-5	777957-53-6
	777957-54-7	777957-55-8	777957-56-9	777957-57-0	777957-58-1
	777957-59-2	777957-60-5	777957-61-6	777957-62-7	
	777957-63-8	777957-64-9	777957-65-0	777957-66-1	777957-67-2
	777957-68-3	777957-69-4	777957-70-7	777957-71-8	777957-72-9
	777957-73-0	777957-74-1	777957-75-2	777957-76-3	777957-77-4
	777957-78-5	777957-79-6	777957-80-9	777957-81-0	777957-82-1
	777957-83-2	777957-84-3	777957-85-4	777957-86-5	777957-87-6
	777957-88-7	777957-89-8	777957-90-1	777957-91-2	777957-92-3
	777957-93-4	777957-94-5	777957-95-6	777957-96-7	777957-97-8
	777957-98-9	777957-99-0	777958-00-6	777958-01-7	777958-02-8
	777958-03-9	777958-04-0	777958-05-1	777958-06-2	777958-07-3
	777958-08-4	777958-09-5	777958-10-8	777958-11-9	777958-12-0
	777958-13-1	777958-14-2	777958-15-3	777958-16-4	777958-17-5
	777958-18-6	777958-19-7	777958-20-0	777958-21-1	777958-22-2
	777958-23-3	777958-24-4	777958-25-5	777958-26-6	777958-27-7
	777958-28-8	777958-29-9	777958-30-2	777958-31-3	777958-32-4
	777958-33-5	777958-34-6	777958-35-7	777958-36-8	777958-37-9
	777958-38-0	777958-39-1	777958-40-4	777958-41-5	777958-42-6
	777958-43-7	777958-44-8	777958-45-9	777958-46-0	777958-47-1
	777958-48-2	777958-49-3	777958-50-6	777958-51-7	777958-52-8
	777958-53-9	777958-54-0	777958-55-1	777958-56-2	777958-57-3
	777958-58-4	777958-59-5	777958-60-8	777958-61-9	777958-62-0
	777958-63-1	777958-64-2	777958-65-3	777958-66-4	777958-67-5
	777958-68-6	777958-69-7	777958-70-0	777958-71-1	777958-72-2
	777958-73-3	777958-74-4	777958-75-5	777958-76-6	
	777958-77-7	777958-78-8	777958-79-9	777958-80-2	777958-81-3
	777958-82-4	777958-83-5	777958-84-6	777958-85-7	777958-86-8
	777958-87-9	777958-88-0	777958-89-1	777958-90-4	777958-91-5
	777958-92-6	777958-93-7	777958-94-8	777958-95-9	777958-96-0
	777958-97-1	777958-98-2	777958-99-3	777959-00-9	777959-01-0
	777959-02-1	777959-03-2	777959-04-3	777959-05-4	777959-06-5
	777959-07-6	777959-08-7			

RL: PRP (Properties)

(unclaimed sequence; rNA interference mediated inhibition of hepatitis
C virus (HCV) gene expression using short interfering nucleic acid
(sina))

IT	777959-09-8	777959-10-1	777959-11-2	777959-12-3	777959-13-4
	777959-14-5	777959-15-6	777959-16-7	777959-17-8	777959-18-9
	777959-19-0	777959-20-3	777959-21-4	777959-22-5	777959-23-6
	777959-24-7	777959-25-8	777959-26-9	777959-27-0	777959-28-1
	777959-29-2	777959-30-5	777959-31-6	777959-32-7	777959-33-8
	777959-34-9	777959-35-0	777959-36-1	777959-37-2	777959-38-3
	777959-39-4	777959-40-7	777959-41-8	777959-42-9	777959-43-0
	777959-44-1	777959-45-2	777959-46-3	777959-47-4	777959-48-5

777959-49-6	777959-50-9	777959-51-0	777959-52-1	777959-53-2
777959-54-3	777959-55-4	777959-56-5	777959-57-6	777959-58-7
777959-59-8	777959-60-1	777959-61-2	777959-62-3	777959-63-4
777959-64-5	777959-65-6	777959-66-7	777959-67-8	777959-68-9
777959-69-0	777959-70-3	777959-71-4	777959-72-5	777959-73-6
777959-74-7	777959-75-8	777959-76-9	777959-77-0	777959-78-1
777959-79-2	777959-80-5	777959-81-6	777959-82-7	777959-83-8
777959-84-9	777959-85-0	777959-86-1	777959-87-2	777959-88-3
777959-89-4	777959-90-7	777959-91-8	777959-92-9	777959-93-0
777959-94-1	777959-95-2	777959-96-3	777959-97-4	777959-98-5
777959-99-6	777960-00-6	777960-01-7	777960-02-8	777960-03-9
777960-04-0	777960-05-1	777960-06-2	777960-07-3	777960-08-4
777960-09-5	777960-10-8	777960-11-9	777960-12-0	777960-13-1
777960-14-2	777960-15-3	777960-16-4	777960-17-5	777960-18-6
777960-19-7	777960-20-0	777960-21-1	777960-22-2	777960-23-3
777960-24-4	777960-25-5	777960-26-6	777960-27-7	777960-28-8
777960-29-9	777960-30-2	777960-31-3	777960-32-4	777960-33-5
777960-34-6	777960-35-7	777960-36-8	777960-37-9	777960-38-0
777960-39-1	777960-40-4	777960-41-5	777960-42-6	777960-43-7
777960-44-8	777960-45-9	777960-46-0	777960-47-1	777960-48-2
777960-49-3	777960-50-6	777960-51-7	777960-52-8	777960-53-9
777960-54-0	777960-55-1	777960-56-2	777960-57-3	777960-58-4
777960-59-5	777960-60-8	777960-61-9	777960-62-0	777960-63-1
777960-64-2	777960-65-3	777960-66-4	777960-67-5	777960-68-6
777960-69-7	777960-70-0	777960-71-1	777960-72-2	777960-73-3
777960-74-4	777960-75-5	777960-76-6	777960-77-7	777960-78-8
777960-79-9	777960-80-2	777960-81-3	777960-82-4	777960-83-5
777960-84-6	777960-85-7	777960-86-8	777960-87-9	777960-88-0
777960-89-1	777960-90-4	777960-91-5	777960-92-6	777960-93-7
777960-94-8	777960-95-9	777960-96-0	777960-97-1	777960-98-2
777961-00-3	777961-01-0	777961-02-1	777961-03-2	777961-04-3
777961-04-3	777961-05-4	777961-06-5	777961-07-6	777961-08-7
777961-09-8	777961-10-1	777961-11-2	777961-12-3	777961-13-4
777961-14-5	777961-15-6	777961-16-7	777961-17-8	777961-18-9
777961-19-0	777961-20-3	777961-21-4	777961-22-5	777961-23-6
777961-24-7	777961-25-8	777961-26-9	777961-27-0	777961-28-1
777961-29-2	777961-30-5	777961-31-6	777961-32-7	777961-33-8
777961-34-9	777961-35-0	777961-36-1	777961-37-2	777961-38-3
777961-39-4	777961-40-7	777961-41-8	777961-42-9	777961-43-0
777961-44-1	777961-45-2	777961-46-3	777961-47-4	777961-48-5

RL: PRP (Properties)

(unclaimed sequence; rNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (sina))

IT	777961-49-6	777961-50-9	777961-51-0	777961-52-1	777961-53-2
	777961-54-3	777961-55-4	777961-56-5	777961-57-6	777961-58-7
	777961-59-8	777961-60-1	777961-61-2	777961-62-3	777961-63-4
	777961-64-5	777961-65-6	777961-66-7	777961-67-8	777961-68-9
	777961-69-0	777961-70-3	777961-71-4	777961-72-5	777961-73-6
	777961-74-7	777961-75-8	777961-76-9	777961-77-0	777961-78-1
	777961-79-2	777961-80-5	777961-81-6	777961-82-7	777961-83-8
	777961-84-9	777961-85-0	777961-86-1	777961-87-2	777961-88-3
	777961-89-4	777961-90-7	777961-91-8	777961-92-9	777961-93-0
	777961-94-1	777961-95-2	777961-96-3	777961-97-4	777961-98-5
	777961-99-6	777962-00-2	777962-01-3	777962-02-4	777962-03-5
	777962-04-6	777962-05-7	777962-06-8	777962-07-9	777962-08-0
	777962-09-1	777962-10-4	777962-11-5	777962-12-6	777962-13-7
	777962-14-8	777962-15-9	777962-16-0	777962-17-1	777962-18-2
	777962-19-3	777962-20-6	777962-21-7	777962-22-8	777962-23-9
	777962-24-0	777962-25-1	777962-26-2	777962-27-3	777962-28-4
	777962-29-5	777962-30-8	777962-31-9	777962-32-0	777962-33-1
	777962-34-2	777962-35-3	777962-36-4	777962-37-5	777962-38-6
	777962-39-7	777962-40-0	777962-41-1	777962-42-2	777962-43-3
	777962-44-4	777962-45-5	777962-46-6	777962-47-7	777962-48-8
	777962-49-9	777962-50-2	777962-51-3	777962-52-4	777962-53-5
	777962-54-6	777962-55-7	777962-56-8	777962-57-9	777962-58-0
	777962-59-1	777962-60-4	777962-61-5	777962-62-6	777962-63-7
	777962-64-8	777962-65-9	777962-66-0	777962-67-1	777962-68-2
	777962-69-3	777962-70-6	777962-71-7	777962-72-8	777962-73-9
	777962-74-0	777962-75-1	777962-76-2	777962-77-3	777962-78-4
	777962-79-5	777962-80-8	777962-81-9	777962-82-0	777962-83-1
	777962-84-2	777962-85-3	777962-86-4	777962-87-5	777962-88-6
	777962-89-7	777962-90-0	777962-91-1	777962-92-2	777962-93-3
	777962-94-4	777962-95-5	777962-96-6	777962-97-7	777962-98-8
	777962-99-9	777963-00-5	777963-01-6	777963-02-7	777963-03-8
	777963-04-9	777963-05-0	777963-06-1	777963-07-2	777963-08-3

777963-09-4	777963-10-7	777963-11-8	777963-12-9	777963-13-0
777963-14-1	777963-15-2	777963-16-3	777963-17-4	777963-18-5
777963-19-6	777963-20-9	777963-21-0	777963-22-1	777963-23-2
777963-24-3	777963-25-4	777963-26-5	777963-27-6	777963-28-7
777963-29-8	777963-30-1	777963-31-2	777963-32-3	777963-33-4
777963-34-5	777963-35-6	777963-36-7	777963-37-8	777963-38-9
777963-39-0	777963-40-3	777963-41-4	777963-42-5	777963-43-6
777963-44-7	777963-45-8	777963-46-9	777963-47-0	777963-48-1
777963-49-2	777963-50-5	777963-51-6	777963-52-7	777963-53-8
777963-54-9	777963-55-0	777963-56-1	777963-57-2	777963-58-3
777963-59-4	777963-60-7	777963-61-8	777963-62-9	777963-63-0
777963-64-1	777963-65-2	777963-66-3	777963-67-4	777963-68-5
777963-69-6	777963-70-9	777963-71-0	777963-72-1	777963-73-2
777963-74-3	777963-75-4	777963-76-5	777963-77-6	777963-78-7
777963-79-8	777963-80-1	777963-81-2	777963-82-3	777963-83-4
777963-84-5	777963-85-6	777963-86-7	777963-87-8	777963-88-9

RL: PRP (Properties)

(unclaimed sequence; rRNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (sina))

IT	777963-89-0	777963-90-3	777963-91-4	777963-92-5	777963-93-6
	777963-94-7	777963-95-8	777963-96-9	777963-97-0	777963-98-1
	777963-99-2	777964-00-8	777964-01-9	777964-02-0	777964-03-1
	777964-04-2	777964-05-3	777964-06-4	777964-07-5	777964-08-6
	777964-09-7	777964-10-0	777964-11-1	777964-12-2	777964-13-3
	777964-14-4	777964-15-5	777964-16-6	777964-17-7	777964-18-8
	777964-19-9	777964-20-2	777964-21-3	777964-22-4	777964-23-5
	777964-24-6	777964-25-7	777964-26-8	777964-27-9	777964-28-0
	777964-29-1	777964-30-4	777964-31-5	777964-32-6	777964-33-7
	777964-34-8	777964-35-9	777964-36-0	777964-37-1	777964-38-2
	777964-39-3	777964-40-6	777964-41-7	777964-42-8	777964-43-9
	777964-44-0	777964-45-1	777964-46-2	777964-47-3	777964-48-4
	777964-49-5	777964-50-8	777964-51-9	777964-52-0	777964-53-1
	777964-54-2	777964-55-3	777964-56-4	777964-57-5	777964-58-6
	777964-59-7	777964-60-0	777964-61-1	777964-62-2	777964-63-3
	777964-64-4	777964-65-5	777964-66-6	777964-67-7	777964-68-8
	777964-69-9	777964-70-2	777964-71-3	777964-72-4	777964-73-5
	777964-74-6	777964-75-7	777964-76-8	777964-77-9	777964-78-0
	777964-79-1	777964-80-4	777964-81-5	777964-82-6	777964-83-7
	777964-84-8	777964-85-9	777964-86-0	777964-87-1	777964-88-2
	777964-89-3	777964-90-6	777964-91-7	777964-92-8	777964-93-9
	777964-94-0	777964-95-1	777964-96-2	777964-97-3	777964-98-4
	777964-99-5	777965-00-1	777965-01-2	777965-02-3	777965-03-4
	777965-04-5	777965-05-6	777965-06-7	777965-07-8	777965-08-9
	777965-09-0	777965-10-3	777965-11-4	777965-12-5	777965-13-6
	777965-14-7	777965-15-8	777965-16-9	777965-17-0	777965-18-1
	777965-19-2	777965-20-5	777965-21-6	777965-22-7	777965-23-8
	777965-24-9	777965-25-0	777965-26-1	777965-27-2	777965-28-3
	777965-29-4	777965-30-7	777965-31-8	777965-32-9	777965-33-0
	777965-34-1	777965-35-2	777965-36-3	777965-37-4	777965-38-5
	777965-39-6	777965-40-9	777965-41-0	777965-42-1	777965-43-2
	777965-44-3	777965-45-4	777965-46-5	777965-47-6	777965-48-7
	777965-49-8	777965-50-1	777965-51-2	777965-52-3	777965-53-4
	777965-54-5	777965-55-6	777965-56-7	777965-57-8	777965-58-9
	777965-59-0	777965-60-3	777965-61-4	777965-62-5	777965-63-6
	777965-64-7	777965-65-8	777965-66-9	777965-67-0	777965-68-1
	777965-69-2	777965-70-5	777965-71-6	777965-72-7	777965-73-8
	777965-74-9	777965-75-0	777965-76-1	777965-77-2	777965-78-3
	777965-79-4	777965-80-7	777965-81-8	777965-82-9	777965-83-0
	777965-84-1	777965-85-2	777965-86-3	777965-87-4	777965-88-5
	777965-89-6	777965-90-9	777965-91-0	777965-92-1	777965-93-2
	777965-94-3	777965-95-4	777965-96-5	777965-97-6	777965-98-7
	777965-99-8	777966-00-4	777966-01-5	777966-02-6	777966-03-7
	777966-04-8	777966-05-9	777966-06-0	777966-07-1	777966-08-2
	777966-09-3	777966-10-6	777966-11-7	777966-12-8	777966-13-9
	777966-14-0	777966-15-1	777966-16-2	777966-17-3	777966-18-4
	777966-19-5	777966-20-8	777966-21-9	777966-22-0	777966-23-1
	777966-24-2	777966-25-3	777966-26-4	777966-27-5	777966-28-6

RL: PRP (Properties)

(unclaimed sequence; rRNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (sina))

IT	777966-29-7	777966-30-0	777966-31-1	777966-32-2	777966-33-3
	777966-34-4	777966-35-5	777966-36-6	777966-37-7	777966-38-8
	777966-39-9	777966-40-2	777966-41-3	777966-42-4	777966-43-5
	777966-44-6	777966-45-7	777966-46-8	777966-47-9	777966-48-0

777966-49-1	777966-50-4	777966-51-5	777966-52-6	777966-53-7
777966-54-8	777966-55-9	777966-56-0	777966-57-1	777966-58-2
777966-59-3	777966-60-6	777966-61-7	777966-62-8	777966-63-9
777966-64-0	777966-65-1	777966-66-2	777966-67-3	777966-68-4
777966-69-5	777966-70-8	777966-71-9	777966-72-0	777966-73-1
777966-74-2	777966-75-3	777966-76-4	777966-77-5	777966-78-6
777966-79-7	777966-80-0	777966-81-1	777966-82-2	777966-83-3
777966-84-4	777966-85-5	777966-86-6	777966-87-7	777966-88-8
777966-89-9	777966-90-2	777966-91-3	777966-92-4	777966-93-5
777966-94-6	777966-95-7	777966-96-8	777966-97-9	777966-98-0
777966-99-1	777967-00-7	777967-01-8	777967-02-9	777967-03-0
777967-04-1	777967-05-2	777967-06-3	777967-07-4	777967-08-5
777967-09-6	777967-10-9	777967-11-0	777967-12-1	777967-13-2
777967-14-3	777967-15-4	777967-16-5	777967-17-6	777967-18-7
777967-19-8	777967-20-1	777967-21-2	777967-22-3	777967-23-4
777967-24-5	777967-25-6	777967-26-7	777967-27-8	777967-28-9
777967-29-0	777967-30-3	777967-31-4	777967-32-5	777967-33-6
777967-34-7	777967-35-8	777967-36-9	777967-37-0	777967-38-1
777967-39-2	777967-40-5	777967-41-6	777967-42-7	777967-43-8
777967-44-9	777967-45-0	777967-46-1	777967-47-2	777967-48-3
777967-49-4	777967-50-7	777967-51-8	777967-52-9	777967-53-0
777967-54-1	777967-55-2	777967-56-3	777967-57-4	777967-58-5
777967-59-6	777967-60-9	777967-61-0	777967-62-1	777967-63-2
777967-64-3	777967-65-4	777967-66-5	777967-67-6	777967-68-7
777967-69-8	777967-70-1	777967-71-2	777967-72-3	777967-73-4
777967-74-5	777967-75-6	777967-76-7	777967-77-8	777967-78-9
777967-79-0	777967-80-3	777967-81-4	777967-82-5	777967-83-6
777967-84-7	777967-85-8	777967-86-9	777967-87-0	777967-88-1
777967-89-2	777967-90-5	777967-91-6	777967-92-7	777967-93-8
777967-94-9	777967-95-0	777967-96-1	777967-97-2	777967-98-3
777967-99-4	777968-00-0	777968-01-1	777968-02-2	777968-03-3
777968-04-4	777968-05-5	777968-06-6	777968-07-7	777968-08-8
777968-09-9	777968-10-2	777968-11-3	777968-12-4	777968-13-5
777968-14-6	777968-15-7	777968-16-8	777968-17-9	777968-18-0
777968-19-1	777968-20-4	777968-21-5	777968-22-6	777968-23-7
777968-24-8	777968-25-9	777968-26-0	777968-27-1	777968-28-2
777968-29-3	777968-30-6	777968-31-7	777968-32-8	777968-33-9
777968-34-0	777968-35-1	777968-36-2	777968-37-3	777968-38-4
777968-39-5	777968-40-8	777968-41-9	777968-42-0	777968-43-1
777968-44-2	777968-45-3	777968-46-4	777968-47-5	777968-48-6
777968-49-7	777968-50-0	777968-51-1	777968-52-2	777968-53-3
777968-54-4	777968-55-5	777968-56-6	777968-57-7	777968-58-8
777968-59-9	777968-60-2	777968-61-3	777968-62-4	777968-63-5
777968-64-6	777968-65-7	777968-66-8	777968-67-9	777968-68-0

RL: PRP (Properties)

(unclaimed sequence; rNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (sina))

IT	777968-69-1	777968-70-4	777968-71-5	777968-72-6	777968-73-7
	777968-74-8	777968-75-9	777968-76-0	777968-77-1	777968-78-2
	777968-79-3	777968-80-6	777968-81-7	777968-82-8	777968-83-9
	777968-84-0	777968-85-1	777968-86-2	777968-87-3	777968-88-4
	777968-89-5	777968-90-8	777968-91-9	777968-92-0	777968-93-1
	777968-94-2	777968-95-3	777968-96-4	777968-97-5	777968-98-6
	777968-99-7	777969-00-3	777969-01-4	777969-02-5	777969-03-6
	777969-04-7	777969-05-8	777969-06-9	777969-07-0	777969-08-1
	777969-09-2	777969-10-5	777969-11-6	777969-12-7	777969-13-8
	777969-14-9	777969-15-0	777969-16-1	777969-17-2	777969-18-3
	777969-19-4	777969-20-7	777969-21-8	777969-22-9	777969-23-0
	777969-24-1	777969-25-2	777969-26-3	777969-27-4	777969-28-5
	777969-29-6	777969-30-9	777969-31-0	777969-32-1	777969-33-2
	777969-34-3	777969-35-4	777969-36-5	777969-37-6	777969-38-7
	777969-39-8	777969-40-1	777969-41-2	777969-42-3	777969-43-4
	777969-44-5	777969-45-6	777969-46-7	777969-47-8	777969-48-9
	777969-49-0	777969-50-3	777969-51-4	777969-52-5	777969-53-6
	777969-61-6	777969-62-7	777969-63-8	777969-64-9	777969-65-0
	777969-66-1	777969-67-2	777969-68-3	777969-69-4	777969-70-7
	777969-71-8	777969-72-9	777969-73-0	777969-74-1	777969-75-2
	777969-76-3	777969-77-4	777969-78-5	777969-79-6	777969-80-9
	777969-81-0	777969-82-1	777969-83-2	777969-84-3	777969-85-4
	777969-86-5	777969-87-6	777969-88-7	777969-89-8	777969-90-1
	777969-91-2	777969-92-3	777969-93-4	777969-94-5	777969-95-6
	777969-96-7	777969-97-8	777969-98-9	777969-99-0	777970-00-0
	777970-01-1	777970-02-2	777970-03-3	777970-04-4	777970-05-5
	777970-06-6	777970-07-7	777970-08-8	777970-09-9	777970-10-2
	777970-11-3	777970-12-4	777970-13-5	777970-14-6	777970-15-7

777970-16-8 777970-17-9 777970-18-0 777970-19-1 777970-20-4
777970-21-5 777970-22-6 777970-23-7 777970-24-8 777970-25-9
777970-26-0 777970-27-1 777970-28-2 777970-29-3 777970-30-6
777970-31-7 777970-32-8 777970-33-9 777970-34-0 777970-35-1
777970-36-2 777970-37-3 777970-38-4

RL: PRP (Properties)
(unclaimed sequence; rRNA interference mediated inhibition of hepatitis
C virus (HCV) gene expression using short interfering nucleic acid
(sina))

IT 777957-59-2 777958-74-4

RL: PRP (Properties)
(unclaimed sequence; rRNA interference mediated inhibition of hepatitis
C virus (HCV) gene expression using short interfering nucleic acid
(sina))

RN 777957-59-2 HCAPLUS

CN RNA, (U-U-C-G-C-C-G-A-C-C-U-C-A-U-G-G-G-G-U) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 777958-74-4 HCAPLUS

CN RNA, (C-U-U-C-G-C-C-G-A-C-C-U-C-A-U-G-G-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 6 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:817415 HCAPLUS

DN 141:309637

ED Entered STN: 07 Oct 2004

TI Transgenic plants expressing chymotrypsin inhibitor mutant proteins with
increased levels of essential amino acids for food or feed use

IN Rao, Aragula Gururaj; Roesler, Keith R.

PA Pioneer Hi-Bred International, Inc., USA

SO U.S., 47 pp., Cont.-in-part of U.S. Ser. No. 297,418, abandoned.

CODEN: USXXAM

DT Patent

LA English

IC ICM C07K014-00

NCL 530300000; 530350000; 530370000; 426044000

CC 7-3 (Enzymes)

Section cross-reference(s): 3, 11, 17

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6800726	B1	20041005	US 1999-311689	19990513 <--
PRAI	US 1996-740682	B2	19961101	<--	
	US 1999-297418	B2	19990420	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6800726	ICM	C07K014-00
	NCL	530300000; 530350000; 530370000; 426044000
US 6800726	ECLA	A23K001/16G; A23L001/305C; C07K014/81; C07K014/81B1; C12N015/82C4; C12N015/82C4B10; C12N015/82C4B10A; C12N015/82C4B10B <--

AB The present invention provides methods for increasing essential amino acid content of plants using modified polypeptides derived from a protease inhibitor, and more specifically, a chymotrypsin inhibitor. The invention based on the discovery that chymotrypsin inhibitor-2 (CI-2) can be modified to enhance its essential amino acid content. Protease inhibitor proteins can be modified from the proteins of barley or maize by substitution mutation to increase the essential amino acid content and decrease protease inhibitor activities. Sequences for wild-type CI-2 protein from barley, as well as truncated and mutated variants, are provided. Other plant species that may be used as a source for chymotrypsin inhibitor include Zea mays, Vicia faba, Cucurbita maxima, Canavalia lineata, Vigna angularis, Nicotiana tabacum, Nicotiana sylvestris, Sambucus nigra, Momordica charantia, Solanum tuberosum, Lycopersicon peruvianum, Lycopersicon esculentum, Amaranthus caudatus and Arabidopsis thaliana. The invention further provides recombinant expression cassettes, host cells, transgenic plants, and antibody compns. The compds. of the invention are thus excellent candidates for transformation of feed grain and food to enhance nutrition.

ST plant protease inhibitor mutant feed essential amino acid; chymotrypsin inhibitor essential amino acid feed transgenic plant; barley chymotrypsin inhibitor essential amino acid mutant; proteinase inhibitor CI2 sequence homolog cDNA Hordeum

IT Fusion proteins (chimeric proteins)

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
 BIOL (Biological study); PREP (Preparation)
 (BHL3N dimer; transgenic plants expressing chymotrypsin inhibitor
 mutant proteins with increased levels of essential amino acids for food
 or feed use)

IT Sequence homology analysis
 (BLAST, use of; transgenic plants expressing chymotrypsin inhibitor
 mutant proteins with increased levels of essential amino acids for food
 or feed use)

IT *Amaranthus caudatus*
Arabidopsis thaliana
Canavalia lineata
Cucurbita maxima
Hordeum vulgare
Lycopersicon esculentum
Lycopersicon peruvianum
Momordica charantia
Nicotiana sylvestris
Nicotiana tabacum
Sambucus nigra
Solanum tuberosum
Vicia faba
Vigna angularis
Zea mays
 (chymotrypsin inhibitor from; transgenic plants expressing chymotrypsin
 inhibitor mutant proteins with increased levels of essential amino
 acids for food or feed use)

IT Amino acids, biological studies
 RL: BPN (Biosynthetic preparation); FFD (Food or feed use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)
 (essential; transgenic plants expressing chymotrypsin inhibitor mutant
 proteins with increased levels of essential amino acids for food or
 feed use)

IT Digestion, biological
 (improved digestibility of engineered proteins; transgenic plants
 expressing chymotrypsin inhibitor mutant proteins with increased levels
 of essential amino acids for food or feed use)

IT Disulfide group
 (increased stability achieved by addition of; transgenic plants expressing
 chymotrypsin inhibitor mutant proteins with increased levels of
 essential amino acids for food or feed use)

IT Mutagenesis
 (site-directed, substitution; transgenic plants expressing chymotrypsin
 inhibitor mutant proteins with increased levels of essential amino
 acids for food or feed use)

IT Antibodies and Immunoglobulins
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
 (Uses)
 (to epitopes of protease inhibitors; transgenic plants expressing
 chymotrypsin inhibitor mutant proteins with increased levels of
 essential amino acids for food or feed use)

IT Feed
 Food
 Genetic engineering
 Molecular cloning
 Protein engineering
 Protein sequences
 cDNA sequences
 (transgenic plants expressing chymotrypsin inhibitor mutant proteins
 with increased levels of essential amino acids for food or feed use)

IT Embryophyta
 (transgenic; transgenic plants expressing chymotrypsin inhibitor mutant
 proteins with increased levels of essential amino acids for food or
 feed use)

IT 56-87-1P, Lysine, biological studies
 RL: BPN (Biosynthetic preparation); FFD (Food or feed use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)
 (-high content variants; transgenic plants expressing chymotrypsin
 inhibitor mutant proteins with increased levels of essential amino
 acids for food or feed use)

IT 765830-30-6DP, mutated variants 765830-32-8P 765830-34-0P
 765830-36-2P 765830-38-4P 765830-40-8P 765830-42-0P 765830-44-2P
 765830-46-4P 765830-48-6P
 RL: AGR (Agricultural use); BPN (Biosynthetic preparation); BSU
 (Biological study, unclassified); FFD (Food or feed use); PRP
 (Properties); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; transgenic plants expressing chymotrypsin inhibitor mutant proteins with increased levels of essential amino acids for food or feed use)

IT 12063-98-8, Gallium phosphide, analysis
 RL: ARU (Analytical role, unclassified); ANST (Analytical study)
 (anal.; transgenic plants expressing chymotrypsin inhibitor mutant proteins with increased levels of essential amino acids for food or feed use)

IT 765830-29-3D, mutated variants 765830-31-7 765830-33-9 765830-35-1
 765830-37-3 765830-39-5 765830-41-9 765830-43-1 765830-45-3
 765830-47-5
 RL: AGR (Agricultural use); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
 (nucleotide sequence; transgenic plants expressing chymotrypsin inhibitor mutant proteins with increased levels of essential amino acids for food or feed use)

IT 139466-47-ODP, Chymotrypsin inhibitor 2, derivs.
 RL: AGR (Agricultural use); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); FFD (Food or feed use); PRP (Properties); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (transgenic plants expressing chymotrypsin inhibitor mutant proteins with increased levels of essential amino acids for food or feed use)

IT 37205-61-1D, Protease inhibitor, derivs. 141256-43-1D, Chymotrypsin inhibitor, derivs.
 RL: AGR (Agricultural use); BSU (Biological study, unclassified); FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (transgenic plants expressing chymotrypsin inhibitor mutant proteins with increased levels of essential amino acids for food or feed use)

IT 63-68-3P, Methionine, biological studies 72-19-5P, Threonine, biological studies 73-22-3P, Tryptophan, biological studies
 RL: BPN (Biosynthetic preparation); FFD (Food or feed use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (transgenic plants expressing chymotrypsin inhibitor mutant proteins with increased levels of essential amino acids for food or feed use)

IT 765830-49-7 765830-50-0 765830-52-2 765830-54-4 765830-56-6
 765830-58-8 765830-81-7 765830-82-8 765830-83-9 765830-84-0
 765830-85-1 765830-86-2 765830-87-3 765830-88-4
 765830-89-5 765830-90-8 765830-91-9 765830-92-0 765830-93-1
 765830-94-2 765830-95-3 765830-96-4 765830-97-5 765830-98-6
 765830-99-7 765831-00-3 765831-01-4 765831-02-5
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; transgenic plants expressing chymotrypsin inhibitor mutant proteins with increased levels of essential amino acids for food or feed use)

IT 765830-51-1 765830-53-3 765830-55-5 765830-57-7 765830-59-9
 765830-60-2 765830-61-3 765830-62-4 765830-63-5 765830-64-6
 765830-65-7 765830-66-8 765830-67-9 765830-68-0 765830-69-1
 765830-70-4 765830-71-5 765830-72-6 765830-73-7 765830-74-8
 765830-75-9 765830-76-0 765830-77-1 765830-78-2 765830-79-3
 765830-80-6
 RL: PRP (Properties)
 (unclaimed protein sequence; transgenic plants expressing chymotrypsin inhibitor mutant proteins with increased levels of essential amino acids for food or feed use)

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; WO 9007862 1990
- (2) Anon; EP 0485970 WO 1992 HCAPLUS
- (3) Anon; WO 9205239 1992 HCAPLUS
- (4) Anon; WO 9320175 1993 HCAPLUS
- (5) Anon; WO 9410315 1994 HCAPLUS
- (6) Anon; WO 9416078 1994 HCAPLUS
- (7) Anon; WO 9527068 1995 HCAPLUS
- (8) Burow; Mol Gen Genet 1993, V241, P431 HCAPLUS
- (9) Campbell, A; Plant Protein Engineering 1992, P257 HCAPLUS
- (10) Clore; Protein Eng 1987, V1, P313 HCAPLUS
- (11) Glassman; US 5258300 A 1993 HCAPLUS
- (12) Hey; US 6169232 B1 2001 HCAPLUS
- (13) Hirabayashi; J Biol Chem 1991, V266, P23648 HCAPLUS
- (14) Jaynes; US 5597945 A 1997 HCAPLUS
- (15) Jaynes; US 5811654 A 1998 HCAPLUS
- (16) Jonassen, I; Carlsberg Res Commun 1980, V45, P47 HCAPLUS
- (17) Karchi; The Plant J 1993, V3, P721 HCAPLUS
- (18) Lundquist; US 6160208 A 2000
- (19) McPhalen; Biochemistry 1987, V26, P261 HCAPLUS

CLASS			
PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
-----	-----	-----	
US 2004186071	ICM	A61K048-00	
	ICS	C07H021-04	
	NCL	514044000; 536023500	
US 2002028923	ECLA	C12N015/10C4; C12Q001/68A8; G06F019/00A	
AB	<p>Antisense compds., compns. and methods are provided for inhibiting the expression of CD40. The compns. comprise antisense compds., particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40. Methods of using these compds. for modulation of CD40 expression and for treatment of diseases associated with expression of CD40 are provided. Antisense oligonucleotides were designed targeting different regions of the CD40 mRNA sequence and may be modified to contain phosphorothioate linkages, 2'-O-methoxyethyl sugar moiety, and 5-methylcytosine bases. The</p>		

antisense oligonucleotides demonstrated at least 50% inhibition of human CD40 expression. The invention provides methods for synthesis of the antisense oligonucleotides. The antisense oligonucleotides could be used for treatments of hyperproliferative disease, cancer, immune-associated disorder, and inflammatory condition.

- ST antisense oligonucleotide human CD40 inhibition; immunomodulator inflammation tumor therapy antisense PNA
- IT Human
 - Mus
 - (CD40 from; antisense modulation of CD40 expression for treatment of diseases)
- IT Interleukin 2
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (CD40-dependent production of, antisense reducing; antisense modulation of CD40 expression for treatment of diseases)
- IT Disease, animal
 - (CD40-related, treatment of; antisense modulation of CD40 expression for treatment of diseases)
- IT Transplant rejection
 - (allotransplant, treatment of; antisense modulation of CD40 expression for treatment of diseases)
- IT Antiarteriosclerotics
 - (antiatherosclerotics; antisense modulation of CD40 expression for treatment of diseases)
- IT Immunomodulators
 - (antisense as; antisense modulation of CD40 expression for treatment of diseases)
- IT Anti-inflammatory agents
 - Antiasthmatics
 - Antirheumatic agents
 - Antitumor agents
 - Drug screening
 - Test kits
 - (antisense modulation of CD40 expression for treatment of diseases)
- IT CD40 (antigen)
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (antisense modulation of CD40 expression for treatment of diseases)
- IT Antisense oligonucleotides
 - Phosphorothioate oligonucleotides
 - RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (antisense modulation of CD40 expression for treatment of diseases)
- IT Peptide nucleic acids
 - RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (antisense; antisense peptide nucleic acid modulation of CD40 expression for treatment of diseases)
- IT Immunity
 - (disorder, treatment of; antisense modulation of CD40 expression for treatment of diseases)
- IT Transplant and Transplantation
 - (graft-vs.-host reaction, treatment of; antisense modulation of CD40 expression for treatment of diseases)
- IT Intestine, disease
 - (inflammatory, treatment of; antisense modulation of CD40 expression for treatment of diseases)
- IT B cell (lymphocyte)
 - Macrophage
 - (inhibiting CD 40 in; antisense modulation of CD40 expression for treatment of diseases)
- IT RNA splicing
 - (of CD40, antisense redirection of; antisense modulation of CD40 expression for treatment of diseases)
- IT Signal transduction, biological
 - (of CD40, antisense reducing; antisense modulation of CD40 expression for treatment of diseases)
- IT Diagnosis
 - (of CD40-related disease; antisense modulation of CD40 expression for treatment of diseases)
- IT Disease, animal
 - (proliferative, hyper-, treatment of; antisense modulation of CD40 expression for treatment of diseases)
- IT Asthma
- Atherosclerosis

Autoimmune disease

Inflammation

Neoplasm

Psoriasis

Rheumatoid arthritis

(treatment of; antisense modulation of CD40 expression for treatment of diseases)

IT Primers (nucleic acid)

Probes (nucleic acid)

RL: ARG (Analytical reagent use); DGN (Diagnostic use); PRP (Properties);

ANST (Analytical study); BIOL (Biological study); USES (Uses)

(used for diagnosis of CD 40-related disease; antisense modulation of CD40 expression for treatment of diseases)

IT 247211-92-3P, ISIS 19212 247211-94-5P, ISIS 19216 247212-29-9P, ISIS 19251 247212-33-5P, ISIS 19262 247212-36-8P, ISIS 19267 250225-18-4P, ISIS 19218 634220-95-4P, ISIS 19211 634220-96-5P, ISIS 19213 634220-97-6P, ISIS 19217 634220-98-7P, ISIS 19219 634220-99-8P, ISIS 19220 634221-00-4P, ISIS 19221 634221-01-5P, ISIS 19222 634221-02-6P, ISIS 19223 634221-03-7P, ISIS 19225 634221-04-8P, ISIS 19230 634221-05-9P, ISIS 19233 634221-06-0P, ISIS 19235 634221-07-1P, ISIS 19236 634221-08-2P, ISIS 19237 634221-09-3P, ISIS 19241 634221-10-6P, ISIS 19242 634221-11-7P, ISIS 19243 634221-12-8P, ISIS 19245 634221-13-9P, ISIS 19247 634221-15-1P, ISIS 19256 634221-16-2P, ISIS 19257 634221-17-3P, ISIS 19263 634221-18-4P, ISIS 19264 634221-19-5P, ISIS 19268 634221-20-8P, ISIS 19269 634221-21-9P, ISIS 19270 634221-22-0P, ISIS 19275 634221-23-1P, ISIS 19281 634221-24-2P, ISIS 19283 634221-25-3P, ISIS 19284 634221-26-4P, ISIS 19287 634221-27-5P, ISIS 19291 634221-28-6P, ISIS 19259 634221-29-7P, ISIS 19292 733812-50-5P, ISIS 208529 733812-51-6P, ISIS 256634 733812-52-7P, ISIS 256635 733812-55-0P, ISIS 256638 733812-56-1P, ISIS 256639 733812-57-2P, ISIS 256640 733812-58-3P, ISIS 256641 733812-59-4P, ISIS 256642 733812-60-7P, ISIS 256643 733812-67-4P, ISIS 286247 733812-68-5P, ISIS 286248 733812-69-6P, ISIS 286249 733812-70-9P, ISIS 298841 733812-71-0P, ISIS 298842 733812-72-1P, ISIS 298843 733812-73-2P, ISIS 298844 733812-74-3P, ISIS 298845 761467-07-6P, ISIS 19215 761467-08-7P, ISIS 19250 761467-09-8P, ISIS 19253 761467-10-1P, ISIS 19274 761467-12-3P, ISIS 208345 761467-13-4P, ISIS 208346 761467-14-5P, ISIS 208347 761467-15-6P, ISIS 208352 761467-16-7P, ISIS 208353 761467-17-8P, ISIS 208354 761467-18-9P, ISIS 208356 761467-19-0P, ISIS 208357 761467-20-3P, ISIS 208359 761467-21-4P, ISIS 208360 761467-22-5P, ISIS 117886 761569-24-8P, ISIS 208521 761569-25-9P, ISIS 208522 761569-26-0P, ISIS 208523 761569-27-1P, ISIS 208524 761569-28-2P, ISIS 208525 761569-29-3P, ISIS 208528 761569-30-6P, ISIS 208530 761569-31-7P, ISIS 208532 761569-32-8P, ISIS 208533 761569-33-9P, ISIS 208535 761569-34-0P, ISIS 208536 761569-35-1P, ISIS 278646-1 761569-36-2P, ISIS 278086-1 762312-05-0P, ISIS 208348 762312-06-1P, ISIS 208349 762413-93-4P, ISIS 278647-1 762413-94-5P, ISIS 303357-1 762413-95-6P, ISIS 330890-1 762413-96-7P, ISIS 315570-1 762413-97-8P, ISIS 309860-1 762413-98-9P, ISIS 309883-1 762413-99-0P, ISIS 309861-1 762414-00-6P, ISIS 309864-1 762414-01-7P, ISIS 309862-1 762414-02-8P, ISIS 309884-1 762414-03-9P, ISIS 309885-1 762414-04-0P, ISIS 326744-1

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(antisense modulation of CD40 expression for treatment of diseases)

IT 56-87-1, L-Lysine, biological studies 70-26-8, L-Ornithine 71-00-1, L-Histidine, biological studies 74-79-3, L-Arginine, biological studies 156-86-5, L-Homoarginine 305-62-4, 2,4-Diamino butyric acid 348-66-3, D-Ornithine 351-50-8, D-Histidine 498-56-6, Homolysine 923-27-3, D-Lysine 2259-86-1 4299-56-3, .beta.-Lysine 14191-90-3, L-Norarginine 110798-13-5, D-Homoarginine 760975-35-7 760975-36-8

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(in antisense PNA; antisense peptide nucleic acid modulation of CD40 expression for treatment of diseases)

IT 554-01-8, 5-Methylcytosine

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(in antisense oligo; antisense modulation of CD40 expression for treatment of diseases)

IT 762312-02-7 762312-03-8

RL: ARG (Analytical reagent use); DGN (Diagnostic use); PRP (Properties);

ANST (Analytical study); BIOL (Biological study); USES (Uses)

(primer used for diagnosis of CD 40-related disease; antisense

modulation of CD40 expression for treatment of diseases)

IT 762312-04-9
 RL: ARG (Analytical reagent use); DGN (Diagnostic use); PRP (Properties);
 ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (probe used for diagnosis of CD 40-related disease; antisense
 modulation of CD40 expression for treatment of diseases)

IT 762416-84-2 762416-85-3 762416-86-4 762416-87-5 762416-88-6
 762416-89-7 762416-90-0 762416-91-1 762416-92-2 762416-93-3
 762416-94-4 762416-95-5 762416-96-6 762416-97-7 762416-98-8
 762416-99-9 762417-00-5 762417-01-6 762417-02-7 762417-03-8
 762417-04-9 762417-05-0 762417-06-1 762417-07-2 762417-08-3
 762417-09-4 762417-10-7 762417-11-8 762417-12-9
 762417-13-0 762417-14-1 762417-15-2 762417-16-3 762417-17-4
 762417-18-5 762417-19-6 762417-20-9 762417-21-0 762417-22-1
 762417-23-2 762417-24-3 762417-25-4 762417-26-5 762417-27-6
 762417-28-7 762417-29-8 762417-30-1 762417-31-2 762417-32-3
 762417-33-4 762417-34-5 762417-35-6 762417-36-7 762417-37-8
 762417-38-9 762417-39-0 762417-40-3 762417-41-4 762417-42-5
 762417-43-6 762417-44-7 762417-45-8 762417-46-9 762417-47-0
 762417-48-1 762417-49-2 762417-50-5 762417-51-6 762417-52-7
 762417-53-8 762417-54-9 762417-55-0 762417-57-2 762417-58-3
 762417-59-4 762417-60-7 762417-61-8 762417-62-9 762417-63-0
 762417-64-1 762417-65-2 762417-66-3 762417-67-4 762417-68-5
 762417-69-6 762417-70-9 762417-71-0 762417-72-1 762417-73-2
 762417-74-3 762417-75-4 762417-76-5 762417-77-6 762417-78-7
 762417-79-8 762417-80-1 762417-81-2 762417-82-3 762417-83-4
 762417-84-5 762417-85-6 762417-86-7 762417-87-8 762417-88-9
 762417-89-0 762417-90-3 762417-91-4 762417-92-5 762417-93-6
 762417-94-7 762417-95-8 762417-96-9 762417-97-0 762417-98-1
 762417-99-2 762418-00-8 762418-01-9 762418-02-0 762418-03-1
 762418-04-2 762418-05-3 762418-06-4 762418-07-5 762418-08-6
 762418-09-7 762418-10-0 762418-11-1 762418-12-2 762418-13-3
 762418-14-4 762418-15-5 762418-16-6 762418-17-7 762418-18-8
 762418-19-9 762418-20-2 762418-21-3 762418-22-4 762418-23-5
 762418-24-6 762418-25-7 762418-26-8 762418-27-9 762418-28-0
 762418-29-1 762418-30-4 762418-31-5 762418-32-6 762418-33-7
 762418-34-8 762418-35-9 762418-36-0 762418-37-1 762418-38-2
 762418-39-3 762418-40-6 762418-41-7 762418-42-8 762418-43-9
 762418-44-0 762418-45-1 762418-46-2 762418-47-3 762418-48-4
 762418-49-5 762418-50-8 762418-51-9
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; antisense modulation of CD40 expression
 for treatment of diseases)

IT 762294-11-1 762294-12-2
 RL: PRP (Properties)
 (unclaimed sequence; antisense modulation of CD40 expression for
 treatment of diseases)

IT 762417-10-7
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; antisense modulation of CD40 expression
 for treatment of diseases)

RN 762417-10-7 HCAPLUS
 CN DNA, d(T-C-A-G-C-C-G-A-T-C-C-T-G-G-G-A-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 8 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:971393 HCAPLUS
 DN 140:35886
 ED Entered STN: 12 Dec 2003
 TI Identification of genetic targets for modulation by antisense
 oligonucleotides and generation of oligonucleotides for gene modulation
 IN Cowser, Lex M.; Baker, Brenda F.; McNeil, John; Freier, Susan M.; Sasmor,
 Henri M.; Brooks, Douglas G.; Ohashi, Cara; Wyatt, Jacqueline R.;
 Borchers, Alexander H.; Vickers, Timothy A.
 PA USA
 SO U.S. Pat. Appl. Publ., 344 pp., Cont.-in-part of U.S. Ser. No. 295,463.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM C12Q001-68
 NCL 435006000
 CC 1-1 (Pharmacology)
 Section cross-reference(s): 3
 FAN.CNT 4
 PATENT NO. KIND DATE APPLICATION NO. DATE

Search done by Noble Jarrell

```

-----
PI    US 2003228597    A1    20031211    US 2003-388263    20030312 <--
      US 2002028923    A1    20020307    US 1998-67638    19980428 <--
PRAI US 1998-81483P    P      19980413    <--
      US 1998-67638    A2      19980428    <--
      US 1999-295463    A2      19990413    <--
CLASS
PATENT NO.    CLASS    PATENT FAMILY CLASSIFICATION CODES
-----
US 2003228597    ICM      C12Q001-68
                        NCL      435006000
US 2003228597    ECLA     C12N015/10C4; C12Q001/68A8; G06F019/00A    <--
US 2002028923    ECLA     C12N015/10C4; C12Q001/68A8; G06F019/00A    <--
AB    Iterative, preferably computer based iterative processes for generating
      synthetic compds. capable of modulation of target expression are provided.
      During iterations of the processes, a target nucleic acid sequence is
      provided or selected, and a library of candidate nucleobase sequences is
      generated in silico according to defined criteria. A "virtual"
      oligonucleotide chemical is chosen and a library of virtual oligonucleotide
      compds. having the selected nucleobase sequences is generated. These
      virtual compds. are reviewed and compds. predicted to have particular
      properties are selected. The selected compds. are robotically synthesized
      and are preferably robotically assayed for a desired phys., chemical or biol.
      activity. Compds. exhibiting the ability to modulate target expression
      are identified as target modulators. Target modulators thus generated are
      used in assays of parameters indicative of biol. processes to effect gene
      function anal. and in assays of parameters indicative of diseases or
      disorders to effect target valid. The methods are exemplified by
      generation of antisense oligonucleotides targeted to CD40, RhoC, cellular
      inhibitor of apoptosis 2 (c-IAP-2), Gi protein .alpha.-subunit, ELK-1,
      Akt-1, Jagged 2, transforming growth factor .beta.3, apolipoprotein B, BH3
      interacting domain death agonist, and PTEN in the treatment of diseases of
      angiogenesis, breast cancer, and melanoma.
ST    antisense oligonucleotide generation gene modulation
IT    Apolipoproteins
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
          (B, target gene encoding; identification of genetic targets for
          modulation by antisense oligonucleotides and generation of
          oligonucleotides for gene modulation)
IT    Proteins
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
          (BH3 interacting domain death agonist, target gene encoding;
          identification of genetic targets for modulation by antisense
          oligonucleotides and generation of oligonucleotides for gene
          modulation)
IT    G proteins (guanine nucleotide-binding proteins)
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
          (Gi (adenylate cyclase-inhibiting), target gene encoding
          .alpha.-subunit of; identification of genetic targets for modulation by
          antisense oligonucleotides and generation of oligonucleotides for gene
          modulation)
IT    Proteins
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
          (Jagged 2, target gene encoding; identification of genetic targets for
          modulation by antisense oligonucleotides and generation of
          oligonucleotides for gene modulation)
IT    Rho protein (G protein)
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
          (RhoC, target gene encoding; identification of genetic targets for
          modulation by antisense oligonucleotides and generation of
          oligonucleotides for gene modulation)
IT    Angiogenesis
      Apoptosis
      Cell cycle
      Inflammation
          (assay system; identification of genetic targets for modulation by
          antisense oligonucleotides and generation of oligonucleotides for gene
          modulation)
IT    Glycerides, analysis
      Lipoproteins
      RL: ARU (Analytical role, unclassified); ANST (Analytical study)
          (assay system; identification of genetic targets for modulation by
          antisense oligonucleotides and generation of oligonucleotides for gene
          modulation)
IT    Proteins
      RL: BSU (Biological study, unclassified); BIOL (Biological study)

```

(cIAP-2 (cellular inhibitor of apoptosis protein 2), target gene encoding; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)

- IT DNA
 - RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (double-stranded; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)
- IT Immunoassay
 - (enzyme-linked immunosorbent assay; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)
- IT Hepatitis
 - (fulminant; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)
- IT Disease, animal
 - (genes related to; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)
- IT Angiogenesis inhibitors
 - Antitumor agents
 - Computer application
 - Mammary gland, neoplasm
 - Melanoma
 - (identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)
- IT Antisense oligonucleotides
 - RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)
- IT Gene, animal
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)
- IT Liver, disease
 - (injury; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)
- IT Rodentia
 - (model test system; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)
- IT DNA sequences
 - (of antisense oligonucleotides targeted for gene modulation)
- IT PCR (polymerase chain reaction)
 - (real-time; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)
- IT Double stranded RNA
 - RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (small interfering; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)
- IT CD40 (antigen)
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (target gene encoding; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)
- IT Free energy
 - Thermodynamics
 - (virtual compound selection by evaluation of; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)
- IT Transforming growth factors
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)

(.beta.3-, target gene encoding; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)

IT 404880-85-9, ISIS 119902 404880-86-0, ISIS 120000 404880-87-1, ISIS 120001 404880-88-2, ISIS 120002 404880-89-3, ISIS 119845 404880-90-6, ISIS 119846 404880-91-7, ISIS 119847 404880-92-8, ISIS 119848 404880-93-9, ISIS 119849 404880-94-0, ISIS 119850 404880-95-1, ISIS 119851 404880-96-2, ISIS 119852 404880-97-3, ISIS 119853 404880-98-4, ISIS 119854 404880-99-5, ISIS 119855 404881-00-1, ISIS 119856 404881-01-2, ISIS 119857 404881-02-3, ISIS 119858 404881-03-4, ISIS 119859 404881-04-5, ISIS 119860 404881-05-6, ISIS 119861 404881-06-7, ISIS 119862 404881-07-8, ISIS 119863 404881-08-9, ISIS 119864 404881-09-0, ISIS 119865 404881-10-3, ISIS 119866 404881-11-4, ISIS 119867 404881-12-5, ISIS 119868 404881-13-6, ISIS 119869 404881-14-7, ISIS 119870 404881-15-8, ISIS 119871 404881-16-9, ISIS 119872 404881-17-0, ISIS 119873 404881-18-1, ISIS 119874 404881-19-2, ISIS 119875 404881-20-5, ISIS 119876 404881-21-6, ISIS 119877 404881-23-8, ISIS 119879 404881-24-9, ISIS 119880 404881-25-0, ISIS 119881 404881-26-1, ISIS 119882 404881-27-2, ISIS 119883 404881-28-3, ISIS 119884 404881-29-4, ISIS 119885 404881-30-7, ISIS 119886 404881-31-8, ISIS 119887 404881-32-9, ISIS 119888 404881-33-0, ISIS 119889 404881-34-1, ISIS 119890 404881-35-2, ISIS 119891 404881-36-3, ISIS 119892 404881-37-4, ISIS 119893 404881-38-5, ISIS 119894 404881-39-6, ISIS 119895 404881-40-9, ISIS 119896 404881-41-0, ISIS 119897 404881-42-1, ISIS 119898 404881-43-2, ISIS 119899 404881-44-3, ISIS 119900 404881-45-4, ISIS 119901 404881-46-5, ISIS 119903 404881-47-6, ISIS 119904 404881-48-7, ISIS 119905 404881-49-8, ISIS 119906 404881-50-1, ISIS 119907 404881-51-2, ISIS 119908 404881-52-3, ISIS 119909 404881-53-4, ISIS 119910 404881-54-5, ISIS 119911 404881-55-6, ISIS 119912 404881-57-8, ISIS 119914 404881-58-9, ISIS 119915 404881-59-0, ISIS 119916 404881-60-3, ISIS 119917 404997-71-3, ISIS 119992 404997-73-5, ISIS 119919 404997-75-7, ISIS 119921 404997-76-8, ISIS 119922 404997-77-9, ISIS 119925 404997-78-0, ISIS 119926 404997-79-1, ISIS 119927 404997-80-4, ISIS 119928 404997-81-5, ISIS 119929 404997-82-6, ISIS 119930 404997-83-7, ISIS 119931 404997-84-8, ISIS 119932 404997-85-9, ISIS 119933 404997-86-0, ISIS 119934 404997-87-1, ISIS 119935 404997-88-2, ISIS 119936 404997-89-3, ISIS 119937 404997-90-6, ISIS 119938 404997-91-7, ISIS 119939 404997-92-8, ISIS 119940 404997-93-9, ISIS 119941 404997-94-0, ISIS 119942 404997-95-1, ISIS 119943 404997-96-2, ISIS 119944 404997-97-3, ISIS 119945 404997-98-4, ISIS 119946 404997-99-5, ISIS 119947 404998-00-1, ISIS 119948 404998-01-2, ISIS 119949 404998-03-4, ISIS 119951 404998-04-5, ISIS 119952 404998-05-6, ISIS 119953 404998-06-7, ISIS 119954 404998-08-9, ISIS 119956 404998-09-0, ISIS 119957 404998-10-3, ISIS 119958 404998-11-4, ISIS 119959 404998-12-5, ISIS 119960 404998-13-6, ISIS 119961 404998-15-8, ISIS 119963 404998-16-9, ISIS 119964 404998-17-0, ISIS 119965 404998-18-1, ISIS 119966 404998-19-2, ISIS 119967 404998-20-5, ISIS 119968 404998-21-6, ISIS 119969 404998-22-7, ISIS 119970 404998-23-8, ISIS 119971 404998-24-9, ISIS 119972 404998-25-0, ISIS 119973 404998-26-1, ISIS 119974 404998-27-2, ISIS 119975 404998-28-3, ISIS 119976 404998-29-4, ISIS 119977 404998-30-7, ISIS 119978 404998-31-8, ISIS 119979 404998-32-9, ISIS 119980 404998-33-0, ISIS 119981 404998-34-1, ISIS 119982 404998-35-2, ISIS 119983 404998-36-3, ISIS 119984 404998-37-4, ISIS 119985 404998-39-6, ISIS 119987 404998-40-9, ISIS 119988 404998-41-0, ISIS 119989 404998-42-1, ISIS 119990 404998-43-2, ISIS 119991 404998-44-3, ISIS 119993 404998-45-4, ISIS 119994 404998-46-5, ISIS 119995 404998-47-6, ISIS 119996 404998-48-7, ISIS 119997 404998-49-8, ISIS 119998 404998-50-1, ISIS 119999

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(BH3 interacting domain death agonist-targeted; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)

IT 247116-73-0 247162-49-8 247162-51-2 247211-92-3 247211-94-5 247212-29-9 247212-33-5 247212-36-8 250225-18-4 634220-94-3, ISIS 18624 634220-95-4, ISIS 19211 634220-96-5, ISIS 19213 634220-97-6, ISIS 19217 634220-98-7, ISIS 19219 634220-99-8, ISIS 19220 634221-00-4, ISIS 19221 634221-01-5, ISIS 19222 634221-02-6, ISIS 19223 634221-03-7, ISIS 19225 634221-04-8, ISIS 19230 634221-05-9, ISIS 19233 634221-06-0, ISIS 19235 634221-07-1, ISIS 19236 634221-08-2, ISIS 19237 634221-09-3, ISIS 19241 634221-10-6, ISIS

19242 634221-11-7, ISIS 19243 634221-12-8, ISIS 19245 634221-13-9, .
 ISIS 19247 634221-14-0, ISIS 19450 634221-15-1, ISIS 19256
 634221-16-2, ISIS 19257 634221-17-3, ISIS 19263 634221-18-4, ISIS
 19264 634221-19-5, ISIS 19268 634221-20-8, ISIS 19269 634221-21-9,
 ISIS 19270 634221-22-0, ISIS 19275 634221-23-1, ISIS 19281
 634221-24-2, ISIS 19283 634221-25-3, ISIS 19284 634221-26-4, ISIS
 19287 634221-27-5, ISIS 19291 634221-28-6, ISIS 19259 634221-29-7,
 ISIS 19292

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(CD40-targeted; identification of genetic targets for modulation by
 antisense oligonucleotides and generation of oligonucleotides for gene
 modulation)

IT 597585-34-7, ISIS 148702 597585-37-0, ISIS 148705 597585-38-1, ISIS
 148706 597585-39-2, ISIS 148707 597585-41-6, ISIS 148709
 597585-42-7, ISIS 148710 597585-43-8, ISIS 148711 597585-44-9, ISIS
 148712 597585-45-0, ISIS 148713 597585-46-1, ISIS 148714
 597585-47-2, ISIS 148716 597585-48-3, ISIS 148717 597585-49-4, ISIS
 148718 597585-51-8, ISIS 148720 597585-52-9, ISIS 148721
 597585-53-0, ISIS 148722 597585-54-1, ISIS 148723 597585-55-2, ISIS
 148724 597585-56-3, ISIS 148725 597585-57-4, ISIS 148726
 597585-58-5, ISIS 148727 597585-60-9, ISIS 148729 597585-61-0, ISIS
 148730 597585-62-1, ISIS 148731 597585-63-2, ISIS 148732
 597585-64-3, ISIS 148733 597585-65-4, ISIS 148734 597585-66-5, ISIS
 148735 597585-67-6, ISIS 148736 597585-68-7, ISIS 148737
 597585-69-8, ISIS 148738 597585-70-1, ISIS 148739 597585-71-2, ISIS
 148740 597585-72-3, ISIS 148741 597585-73-4, ISIS 148742
 597585-74-5, ISIS 148743 597585-75-6, ISIS 148744 597585-76-7, ISIS
 148745 597585-77-8, ISIS 148746 597585-78-9, ISIS 148747
 597585-79-0, ISIS 148748 597585-80-3, ISIS 148749 597585-81-4, ISIS
 148750 597585-82-5, ISIS 148751 597585-83-6, ISIS 148752
 597585-84-7, ISIS 148753 597585-85-8, ISIS 148754 597585-86-9, ISIS
 148755 597585-87-0, ISIS 148756 597585-88-1, ISIS 148757
 597585-89-2, ISIS 148758 597585-91-6, ISIS 148760 597585-92-7, ISIS
 148761 597585-93-8, ISIS 148762 597585-94-9, ISIS 148763
 597585-95-0, ISIS 148764 597585-96-1, ISIS 148765 597585-97-2, ISIS
 148766 597585-98-3, ISIS 148767 597586-00-0, ISIS 148769
 597586-01-1, ISIS 148770 597586-02-2, ISIS 148771 597586-03-3, ISIS
 148772 597586-04-4, ISIS 148773 597586-06-6, ISIS 148775
 597586-08-8, ISIS 148777 597586-09-9, ISIS 148778 597586-10-2, ISIS
 148779 599224-87-0, ISIS 148715

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(Jagged 2-targeted; identification of genetic targets for modulation by
 antisense oligonucleotides and generation of oligonucleotides for gene
 modulation)

IT 256631-53-5, ISIS 29576 256631-54-6, ISIS 29577 256631-55-7, ISIS
 29578 256631-56-8, ISIS 29579 256631-59-1, ISIS 29582 256631-60-4,
 ISIS 29583 256631-61-5, ISIS 29584 256631-62-6, ISIS 29585
 256631-63-7, ISIS 29586 256631-65-9, ISIS 29588 256631-66-0, ISIS
 29589 256631-68-2, ISIS 29591 256631-69-3, ISIS 29592 256631-74-0,
 ISIS 29597 256631-76-2, ISIS 29599 256631-77-3, ISIS 29600
 256631-78-4, ISIS 29601 256631-79-5, ISIS 29602 256631-80-8, ISIS
 29603 256631-81-9, ISIS 29604 256631-83-1, ISIS 29606 256631-87-5,
 ISIS 29610 256631-90-0, ISIS 29613 634221-35-5, ISIS 29581
 634221-36-6, ISIS 29590 634221-37-7, ISIS 29595 634221-38-8, ISIS
 29596 634221-39-9, ISIS 29612

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(PTEN phosphatase-targeted; identification of genetic targets for
 modulation by antisense oligonucleotides and generation of
 oligonucleotides for gene modulation)

IT 497213-28-2, ISIS 147780 497213-29-3, ISIS 147781 497213-30-6, ISIS
 147782 497213-34-0, ISIS 147786 497213-35-1, ISIS 147788
 497213-37-3, ISIS 147790 497213-41-9, ISIS 147794 497213-48-6, ISIS
 147801 497213-53-3, ISIS 147806 497213-56-6, ISIS 147809
 497213-61-3, ISIS 147814 497213-62-4, ISIS 147815 497213-63-5, ISIS
 147816 497213-65-7, ISIS 147818 497213-67-9, ISIS 147820
 497213-72-6, ISIS 147825 497213-73-7, ISIS 147826 497213-76-0, ISIS
 147829 497213-81-7, ISIS 147475 497213-84-0, ISIS 147478
 497213-86-2, ISIS 147480 497213-88-4, ISIS 147482 497213-91-9, ISIS
 147485 497213-93-1, ISIS 147487 497213-94-2, ISIS 147488
 497213-97-5, ISIS 147491 497213-98-6, ISIS 147492 497214-00-3, ISIS
 147494 497214-11-6, ISIS 147505 497214-12-7, ISIS 147506
 497214-13-8, ISIS 147507 497214-19-4, ISIS 147764 497214-20-7, ISIS
 147765 497214-21-8, ISIS 147766 497214-24-1, ISIS 147769

497214-25-2, ISIS 147770 497214-26-3, ISIS 147771 497214-27-4, ISIS 147772 497214-28-5, ISIS 147773 497214-29-6, ISIS 147774 497214-30-9, ISIS 147775 497214-31-0, ISIS 147776

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(apolipoprotein B-targeted; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)

IT 50-99-7, D-Glucose, analysis 57-88-5, Cholesterol, analysis 9004-10-8, Insulin, analysis 9013-08-5, Phosphoenolpyruvate carboxykinase 141907-41-7, Matrix metalloproteinase 186322-81-6, Caspase

RL: ARU (Analytical role, unclassified); ANST (Analytical study)

(assay system; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)

IT 148640-14-6, Protein kinase Akt-1 260402-76-4, Protein kinase ELK1 301166-54-1, Gene PTEN phosphatase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(target gene encoding; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)

IT 493666-87-8, ISIS 155638 493666-88-9, ISIS 155639 493666-89-0, ISIS 155640 493666-90-3, ISIS 155642 493666-91-4, ISIS 155643 493666-92-5, ISIS 155644 493666-93-6, ISIS 155645 493666-94-7, ISIS 155646 493666-95-8, ISIS 155647 493666-96-9, ISIS 155648 493666-97-0, ISIS 155649 493666-98-1, ISIS 155650 493666-99-2, ISIS 155651 493667-00-8, ISIS 155652 493667-01-9, ISIS 155653 493667-02-0, ISIS 155654 493667-03-1, ISIS 155655 493667-04-2, ISIS 155656 493667-05-3, ISIS 155657 493667-06-4, ISIS 155658 493667-07-5, ISIS 155659 493667-08-6, ISIS 155660 493667-09-7, ISIS 155661 493667-10-0, ISIS 155662 493667-11-1, ISIS 155663 493667-12-2, ISIS 155664 493667-13-3, ISIS 155665 493667-14-4, ISIS 155666 493667-15-5, ISIS 155669 493667-16-6, ISIS 155670 493667-17-7, ISIS 155672 493667-18-8, ISIS 155673 493667-19-9, ISIS 155674 493667-20-2, ISIS 155675 493667-21-3, ISIS 155676 493667-22-4, ISIS 155677 493667-23-5, ISIS 155678 493667-24-6, ISIS 155679 493667-25-7, ISIS 155680 493667-26-8, ISIS 155682 493667-27-9, ISIS 155683 493667-28-0, ISIS 155684 493667-29-1, ISIS 155685 493667-30-4, ISIS 155686 493667-31-5, ISIS 155687 493667-32-6, ISIS 155688 493667-33-7, ISIS 155689 493667-34-8, ISIS 155691 493667-35-9, ISIS 155692 493667-36-0, ISIS 155695 493667-37-1, ISIS 155697 493667-38-2, ISIS 155699 493667-39-3, ISIS 155700 493667-40-6, ISIS 155701 493667-41-7, ISIS 155702 494231-55-9, ISIS 155703 494231-56-0, ISIS 155704 494231-57-1, ISIS 155709 494231-58-2, ISIS 155714

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(transforming growth factor .beta.3-targeted; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)

IT 634241-31-9 634241-32-0 634241-33-1 634241-34-2 634241-35-3 634241-36-4 634241-37-5 634241-38-6 634241-39-7 634241-40-0 634241-41-1 634241-42-2 634241-43-3 634241-44-4 634241-45-5 634241-46-6 634241-47-7 634241-48-8 634241-49-9 634241-50-2 634241-51-3 634241-52-4 634241-53-5 634241-54-6 634241-55-7 634241-56-8 634241-57-9 634241-58-0 634241-59-1 634241-60-4 634241-61-5 634241-62-6 634241-63-7 634241-64-8 634241-65-9 634241-66-0 634241-67-1 634241-68-2 634241-69-3 634241-70-6 634241-71-7 634241-72-8 634241-73-9 634241-74-0 634241-75-1 634241-76-2 634241-77-3 634241-78-4 634241-79-5 634241-80-8 634241-81-9 634241-82-0 634241-83-1 634241-84-2 634241-85-3 634241-86-4 634241-87-5 634241-88-6 634241-89-7 634241-90-0 634241-91-1 634241-92-2 634241-93-3 634241-94-4 634241-95-5 634241-96-6 634241-97-7 634241-98-8 634241-99-9 634242-00-5 634242-01-6 634242-02-7 634242-03-8 634242-04-9 634242-05-0 634242-06-1 634242-07-2 634242-08-3 634242-09-4 634242-10-7 634242-11-8 634242-12-9 634242-13-0 634242-14-1 634242-15-2 634242-16-3 634242-17-4 634242-18-5 634242-19-6 634242-20-9 634242-21-0 634242-22-1 634242-23-2 634242-24-3 634242-25-4 634242-26-5 634242-27-6 634242-28-7 634242-29-8 634242-30-1 634242-31-2 634242-32-3 634242-33-4 634242-34-5 634242-35-6 634242-36-7 634242-37-8 634242-38-9 634242-39-0 634242-40-3 634242-41-4 634242-42-5 634242-43-6 634242-44-7 634242-45-8 634242-46-9 634242-47-0 634242-48-1 634242-49-2 634242-50-5 634242-51-6 634242-52-7 634242-53-8 634242-54-9 634242-55-0 634242-56-1 634242-57-2 634242-58-3 634242-59-4

634242-60-7	634242-61-8	634242-62-9	634242-63-0	634242-64-1
634242-65-2	634242-66-3	634242-67-4	634242-68-5	634242-69-6
634242-70-9	634242-71-0	634242-72-1	634242-73-2	634242-74-3
634242-75-4	634242-76-5	634242-77-6	634242-78-7	634242-79-8
634242-80-1	634242-81-2	634242-82-3	634242-83-4	634242-84-5
634242-85-6	634242-86-7	634242-87-8	634242-88-9	634242-89-0
634242-90-3	634242-91-4	634242-92-5	634242-93-6	634242-94-7
634242-95-8	634242-96-9	634242-97-0	634242-98-1	634242-99-2
634243-00-8	634243-01-9	634243-02-0	634243-03-1	634243-04-2
634243-05-3	634243-06-4	634243-07-5	634243-08-6	634243-09-7
634243-10-0	634243-11-1	634243-12-2	634243-13-3	634243-14-4
634243-15-5	634243-16-6	634243-17-7	634243-18-8	634243-19-9
634243-20-2	634243-21-3	634243-22-4	634243-23-5	634243-24-6
634243-25-7	634243-26-8	634243-27-9	634243-28-0	634243-29-1
634243-30-4	634243-31-5	634243-32-6	634243-33-7	634243-34-8
634243-35-9	634243-36-0	634243-37-1	634243-38-2	634243-39-3
634243-40-6	634243-41-7	634243-42-8	634243-43-9	634243-44-0
634243-45-1	634243-46-2	634243-47-3	634243-48-4	634243-49-5
634243-50-8	634243-51-9	634243-52-0	634243-53-1	634243-54-2
634243-55-3	634243-56-4	634243-57-5	634243-58-6	634243-59-7
634243-60-0	634243-61-1	634243-62-2	634243-63-3	634243-64-4
634243-65-5	634243-66-6	634243-67-7	634243-68-8	634243-69-9
634243-70-2				

RL: PRP (Properties)

(unclaimed nucleotide sequence; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)

IT	634243-71-3	634243-72-4	634243-73-5	634243-74-6	634243-75-7
	634243-76-8	634243-77-9	634243-78-0	634243-79-1	634243-80-4
	634243-81-5	634243-82-6	634243-83-7	634243-84-8	634243-85-9
	634243-86-0	634243-87-1	634243-88-2	634243-89-3	634243-90-6
	634243-91-7	634243-92-8	634243-93-9	634243-94-0	634243-95-1
	634243-96-2	634243-97-3	634243-98-4	634243-99-5	634244-00-1
	634244-01-2	634244-02-3	634244-03-4	634244-04-5	634244-05-6
	634244-06-7	634244-07-8	634244-08-9	634244-09-0	634244-10-3
	634244-11-4	634244-12-5	634244-13-6	634244-14-7	634244-15-8
	634244-16-9	634244-17-0	634244-18-1	634244-19-2	634244-20-5
	634244-21-6	634244-22-7	634244-23-8	634244-24-9	634244-25-0
	634244-26-1	634244-27-2	634244-28-3	634244-29-4	634244-30-7
	634244-31-8	634244-32-9	634244-33-0	634244-34-1	634244-35-2
	634244-36-3	634244-37-4	634244-38-5	634244-39-6	634244-40-9
	634244-41-0	634244-42-1	634244-43-2	634244-44-3	634244-45-4
	634244-46-5	634244-47-6	634244-48-7	634244-49-8	634244-50-1
	634244-51-2	634244-52-3	634244-53-4	634244-54-5	634244-55-6
	634244-56-7	634244-57-8	634244-58-9	634244-59-0	634244-60-3
	634244-61-4	634244-62-5	634244-63-6	634244-64-7	634244-65-8
	634244-66-9	634244-67-0	634244-68-1	634244-69-2	634244-70-5
	634244-71-6	634244-72-7	634244-73-8	634244-74-9	634244-75-0
	634244-76-1	634244-77-2	634244-78-3	634244-79-4	634244-80-7
	634244-81-8	634244-82-9	634244-83-0	634244-84-1	634244-85-2
	634244-86-3	634244-87-4	634244-88-5	634244-89-6	634244-90-9
	634244-91-0	634244-92-1	634244-93-2	634244-94-3	634244-95-4
	634244-96-5	634244-97-6	634244-98-7	634244-99-8	634245-00-4
	634245-01-5	634245-02-6	634245-03-7	634245-04-8	634245-05-9
	634245-06-0	634245-07-1	634245-08-2	634245-09-3	634245-10-6
	634245-11-7	634245-12-8	634245-13-9	634245-14-0	634245-15-1
	634245-16-2	634245-17-3	634245-18-4	634245-19-5	634245-20-8
	634245-21-9	634245-22-0	634245-23-1	634245-24-2	634245-25-3
	634245-26-4	634245-27-5	634245-28-6	634245-29-7	634245-30-0
	634245-31-1	634245-32-2	634245-33-3	634245-34-4	634245-35-5
	634245-36-6	634245-37-7	634245-38-8	634245-39-9	634245-40-2
	634245-41-3	634245-42-4	634245-43-5	634245-44-6	634245-45-7
	634245-46-8	634245-47-9	634245-48-0	634245-49-1	634245-50-4
	634245-51-5	634245-52-6	634245-53-7	634245-54-8	634245-55-9
	634245-56-0	634245-57-1	634245-58-2	634245-59-3	634245-60-6
	634245-61-7	634245-62-8	634245-63-9	634245-64-0	634245-65-1
	634245-66-2	634245-67-3	634245-68-4	634245-69-5	634245-70-8
	634245-71-9	634245-72-0	634245-73-1	634245-74-2	634245-75-3
	634245-76-4	634245-77-5	634245-78-6	634245-79-7	634245-80-0
	634245-81-1	634245-82-2	634245-84-4	634245-85-5	634245-86-6
	634245-87-7	634245-88-8	634245-89-9	634245-90-2	634245-91-3
	634245-92-4	634245-93-5	634245-94-6	634245-95-7	634245-96-8
	634245-97-9	634245-98-0	634245-99-1	634246-00-7	634246-01-8
	634246-02-9	634246-03-0	634246-04-1	634246-05-2	634246-06-3
	634246-07-4	634246-08-5	634246-09-6	634246-10-9	634246-11-0

RL: PRP (Properties)

(unclaimed nucleotide sequence; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)

IT	634246-12-1	634246-13-2	634246-14-3	634246-15-4	634246-16-5
	634246-17-6	634246-18-7	634246-19-8	634246-20-1	634246-21-2
	634246-22-3	634246-23-4	634246-24-5	634246-25-6	634246-26-7
	634246-27-8	634246-28-9	634246-29-0	634246-30-3	634246-31-4
	634246-32-5	634246-33-6	634246-34-7	634246-35-8	634246-36-9
	634246-37-0	634246-38-1	634246-39-2	634246-40-5	634246-41-6
	634246-42-7	634246-43-8	634246-44-9	634246-45-0	634246-46-1
	634246-47-2	634246-48-3	634246-49-4	634246-50-7	634246-51-8
	634246-52-9	634246-53-0	634246-54-1	634246-55-2	634246-56-3
	634246-57-4	634246-58-5	634246-59-6	634246-60-9	634246-61-0
	634246-62-1	634246-63-2	634246-64-3	634246-65-4	634246-66-5
	634246-67-6	634246-68-7	634246-69-8	634246-70-1	634246-71-2
	634246-72-3	634246-73-4	634246-74-5	634246-75-6	634246-76-7
	634246-77-8	634246-78-9	634246-79-0	634246-80-3	634246-81-4
	634246-82-5	634246-83-6	634246-84-7	634246-85-8	634246-86-9
	634246-87-0	634246-88-1	634246-89-2	634246-90-5	634246-91-6
	634246-92-7	634246-93-8	634246-94-9	634246-95-0	634246-96-1
	634246-97-2	634246-98-3	634246-99-4	634247-00-0	634247-01-1
	634247-02-2	634247-03-3	634247-04-4	634247-05-5	634247-06-6
	634247-07-7	634247-08-8	634247-09-9	634247-10-2	634247-11-3
	634247-12-4	634247-13-5	634247-14-6	634247-15-7	634247-16-8
	634247-17-9	634247-18-0	634247-19-1	634247-20-4	634247-21-5
	634247-22-6	634247-23-7	634247-24-8	634247-25-9	634247-26-0
	634247-27-1	634247-28-2	634247-29-3	634247-30-6	634247-31-7
	634247-32-8	634247-33-9	634247-34-0	634247-35-1	634247-36-2
	634247-37-3	634247-38-4	634247-39-5	634247-40-8	634247-41-9
	634247-42-0	634247-43-1	634247-44-2	634247-45-3	634247-46-4
	634247-47-5	634247-48-6	634247-49-7	634247-50-0	634247-51-1
	634247-52-2	634247-53-3	634247-54-4	634247-55-5	634247-56-6
	634247-57-7	634247-58-8	634247-59-9	634247-60-2	634247-61-3
	634247-62-4	634247-63-5	634247-64-6	634247-65-7	634247-66-8
	634247-67-9	634247-68-0	634247-69-1	634247-70-4	634247-71-5
	634247-72-6	634247-73-7	634247-74-8	634247-75-9	634247-76-0
	634247-77-1	634247-78-2	634247-79-3	634247-80-6	634247-81-7
	634247-82-8	634247-83-9	634247-84-0	634247-85-1	634247-86-2
	634247-87-3	634247-88-4	634247-89-5	634247-90-8	634247-91-9
	634247-92-0	634247-93-1	634247-94-2	634247-95-3	634247-96-4
	634247-97-5	634247-98-6	634247-99-7	634248-00-3	634248-01-4
	634248-02-5	634248-03-6	634248-04-7	634248-05-8	634248-06-9
	634248-07-0	634248-08-1	634248-09-2	634248-10-5	634248-11-6
	634248-12-7	634248-13-8	634248-14-9	634248-15-0	634248-16-1
	634248-17-2	634248-18-3	634248-19-4	634248-20-7	634248-21-8
	634248-22-9	634248-23-0	634248-24-1	634248-25-2	634248-26-3
	634248-27-4	634248-28-5	634248-29-6	634248-30-9	634248-31-0
	634248-32-1	634248-33-2	634248-34-3	634248-35-4	634248-36-5
	634248-37-6	634248-38-7	634248-39-8	634248-40-1	634248-41-2
	634248-42-3	634248-43-4	634248-44-5	634248-45-6	634248-46-7
	634248-47-8	634248-48-9	634248-49-0	634248-50-3	634248-51-4

RL: PRP (Properties)

(unclaimed nucleotide sequence; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)

IT	634248-52-5	634248-53-6	634248-54-7	634248-55-8	634248-56-9
	634248-57-0	634248-58-1	634248-59-2	634248-60-5	634248-61-6
	634248-62-7	634248-63-8	634248-64-9	634248-65-0	634248-66-1
	634248-67-2	634248-68-3	634248-69-4	634248-70-7	634248-71-8
	634248-72-9	634248-73-0	634248-74-1	634248-75-2	634248-76-3
	634248-77-4	634248-78-5	634248-79-6	634248-80-9	634248-81-0
	634248-82-1	634248-83-2	634248-84-3	634248-85-4	634248-86-5
	634248-87-6	634248-88-7	634248-89-8	634248-90-1	634248-91-2
	634248-92-3	634248-93-4	634248-94-5	634248-95-6	634248-96-7
	634248-97-8	634248-98-9	634248-99-0	634249-00-6	634249-01-7
	634249-02-8	634249-03-9	634249-04-0	634249-05-1	634249-06-2
	634249-07-3	634249-08-4	634249-09-5	634249-10-8	634249-11-9
	634249-12-0	634249-13-1	634249-14-2	634249-15-3	634249-16-4
	634249-17-5	634249-18-6	634249-19-7	634249-20-0	634249-21-1
	634249-22-2	634249-23-3	634249-24-4	634249-25-5	634249-26-6
	634249-27-7	634249-28-8	634249-29-9	634249-30-2	634249-31-3
	634249-32-4	634249-33-5	634249-34-6	634249-35-7	634249-36-8
	634249-37-9	634249-38-0	634249-39-1	634249-40-4	634249-41-5
	634249-42-6	634249-43-7	634249-44-8	634249-45-9	634249-46-0
	634249-47-1	634249-48-2	634249-49-3	634249-50-6	634249-51-7
	634249-52-8	634249-53-9	634249-54-0	634249-55-1	634249-56-2

634249-57-3 634249-58-4 634249-59-5 634249-60-8 634249-61-9
 634249-62-0 634249-63-1 634249-64-2 634249-65-3 634249-66-4
 634249-67-5 634249-68-6 634249-69-7 634249-70-0 634249-71-1
 634249-72-2 634249-73-3 634249-74-4 634249-75-5 634249-76-6
 634249-77-7 634249-78-8 634249-79-9 634249-80-2 634249-81-3
 634249-82-4 634249-83-5 634249-84-6 634249-85-7 634249-86-8
 634249-87-9 634249-88-0 634249-89-1 634249-90-4 634249-91-5
 634249-92-6 634249-93-7 634249-94-8 634249-95-9 634249-96-0
 634249-97-1 634249-98-2 634249-99-3 634250-00-3 634250-01-4
 634250-02-5 634250-03-6 634250-04-7 634250-05-8 634250-06-9
 634250-07-0 634250-08-1 634250-09-2 634250-10-5 634250-11-6
 634250-12-7 634250-13-8 634250-14-9 634250-15-0 634250-16-1
 634250-17-2 634250-18-3 634250-19-4 634250-20-7 634250-21-8
 634250-22-9 634250-23-0 634250-24-1 634250-25-2 634250-26-3
 634250-27-4 634250-28-5 634250-29-6 634250-30-9 634250-31-0
 634250-32-1 634250-33-2 634250-34-3 634250-35-4 634250-36-5
 634250-37-6 634250-38-7 634250-39-8 634250-40-1 634250-41-2
 634250-42-3 634250-43-4 634250-44-5 634250-45-6 634250-46-7
 634250-47-8 634250-48-9 634250-49-0 634250-50-3 634250-51-4
 634250-52-5 634250-53-6 634250-54-7 634250-55-8 634250-56-9
 634250-57-0 634250-58-1 634250-59-2 634250-60-5 634250-61-6
 634250-62-7 634250-63-8 634250-64-9 634250-65-0 634250-66-1
 634250-67-2 634250-68-3 634250-69-4 634250-70-7 634250-71-8
 634250-72-9 634250-73-0 634251-04-0

RL: PRP (Properties)

(unclaimed nucleotide sequence; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)

IT 634241-88-6

RL: PRP (Properties)

(unclaimed nucleotide sequence; identification of genetic targets for modulation by antisense oligonucleotides and generation of oligonucleotides for gene modulation)

RN 634241-88-6 HCAPLUS

CN DNA, d(T-C-A-G-C-C-G-A-T-C-C-T-G-G-G-G-A-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 9 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:633032 HCAPLUS

DN 139:185625

ED Entered STN: 15 Aug 2003

TI Compositions comprising tissue specific replication competent adenoviral vectors

IN Little, Andrew S.; Lamparski, Henry G.; Henderson, Daniel R.; Schuur, Eric R.

PA USA

SO U.S. Pat. Appl. Publ., 115 pp., Cont.-in-part of U.S. Ser. No. 509,591.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K048-00

ICS C12N007-00; C12N015-861

NCL 424093200; 435456000; 435235100

CC 63-5 (Pharmaceuticals)

FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003152553	A1	20030814	US 2002-139089	20020502 <--
	US 5698443	A	19971216	US 1995-495034	19950627 <--
	US 5871726	A	19990216	US 1996-669753	19960626 <--
	US 6197293	B1	20010306	US 1998-33333	19980302 <--
	US 6254862	B1	20010703	US 1998-33428	19980302 <--
	US 6432700	B1	20020813	US 1998-33556	19980302 <--
	US 2003044383	A1	20030306	US 1998-151376	19980910 <--
	US 6676935	B2	20040113		
	US 2002164799	A1	20021107	US 2001-898883	20010702 <--
	US 6585968	B2	20030701		
	US 2003026792	A1	20030206	US 2001-45116	20011023 <--
	US 2003091538	A1	20030515	US 2002-222479	20020816 <--
PRAI	US 1995-495034	A2	19950627	<--	
	US 1996-669753	A2	19960626	<--	
	US 1997-39597P	P	19970303	<--	
	US 1997-39762P	P	19970303	<--	
	US 1997-39763P	P	19970303	<--	
	US 1998-33333	A2	19980302	<--	

US 1998-33428	A2	19980302	<--
US 1998-33555	B2	19980302	<--
US 1998-151376	A2	19980910	<--
US 2000-509591	A2	20000602	
US 1997-39599P	P	19970303	<--
US 1997-54523P	P	19970804	<--
US 2000-593308	B1	20000613	
US 2000-614495	A1	20000711	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

US 2003152553	ICM	A61K048-00	
	ICS	C12N007-00; C12N015-861	
	NCL	424093200; 435456000; 435235100	
US 5698443	ECLA	C12N015/86F	<--
US 5871726	ECLA	C12N009/64F2C21M34; C12N015/86F	<--
US 6254862	ECLA	C07K014/075; C07K014/47A6; C12N015/63; C12N015/86F8	<--
US 2002164799	ECLA	C07K014/075; C07K014/47A6; C12N015/63; C12N015/86F; C12N015/86F8	<--

AB The present invention provides compns. comprising host cell specific adenovirus vehicles for transfecting target host cells. The compns. comprise replication competent adenovirus having an adenovirus gene essential for replication under transcriptional control of a cell type specific transcriptional response element (TRE) and polyethylene glycol (PEG) as a masking agent.

ST tissue specific replication competent adenovirus vector drug carrier

IT Gene, microbial
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (E1A; compns. comprising tissue specific replication competent adenoviral vectors)

IT Gene, microbial
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (E1B; compns. comprising tissue specific replication competent adenoviral vectors)

IT Gene, microbial
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (E4; compns. comprising tissue specific replication competent adenoviral vectors)

IT Gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK2, transcriptional regulatory element; compns. comprising tissue specific replication competent adenoviral vectors)

IT Mucins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (MUC1, gene, transcriptional regulatory element of; compns. comprising tissue specific replication competent adenoviral vectors)

IT Genetic element
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (TRE (transcriptional response element); compns. comprising tissue specific replication competent adenoviral vectors)

IT Drug delivery systems
 (carriers; compns. comprising tissue specific replication competent adenoviral vectors)

IT Prostate gland
 (cell specific TRE; compns. comprising tissue specific replication competent adenoviral vectors)

IT Adenoviral vectors
 DNA sequences
 Gene therapy
 Human
 (compns. comprising tissue specific replication competent adenoviral vectors)

IT Transgene
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (compns. comprising tissue specific replication competent adenoviral vectors)

IT Polyoxyalkylenes, biological studies
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. comprising tissue specific replication competent adenoviral vectors)

IT Gene, microbial
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (early; compns. comprising tissue specific replication competent adenoviral vectors)

IT Carcinoembryonic antigen

.alpha.-Fetoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene, transcriptional regulatory element of; compns. comprising tissue
 specific replication competent adenoviral vectors)

IT Prostate-specific antigen
 RL: BSU (Biological study, unclassified); PRP (Properties); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (gene; compns. comprising tissue specific replication competent
 adenoviral vectors)

IT Animal cell
 (mammalian; compns. comprising tissue specific replication competent
 adenoviral vectors)

IT Enhancer (genetic element)
 Promoter (genetic element)
 RL: BSU (Biological study, unclassified); PRP (Properties); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (of prostate specific antigen gene; compns. comprising tissue specific
 replication competent adenoviral vectors)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (probasins, gene, transcriptional regulatory element of; compns.
 comprising tissue specific replication competent adenoviral vectors)

IT Adenoviridae
 (vector; compns. comprising tissue specific replication competent
 adenoviral vectors)

IT 9001-01-8, Kallikrein
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (2 gene, human, transcriptional regulatory element of; compns.
 comprising tissue specific replication competent adenoviral vectors)

IT 79-09-4D, Propanoic acid, succinimidyl, biological studies 110-14-5D,
 Succinamide, succinimidyl 102696-21-9, Succinimidyl succinate
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (compns. comprising tissue specific replication competent adenoviral
 vectors)

IT 25322-68-3, Polyethylene glycol
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (compns. comprising tissue specific replication competent adenoviral
 vectors)

IT 6066-82-6D, N-Hydroxysuccinimide, active esters
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (compns. comprising tissue specific replication competent adenoviral
 vectors)

IT 579529-72-9
 RL: BSU (Biological study, unclassified); PRP (Properties); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nucleotide sequence; compns. comprising tissue specific replication
 competent adenoviral vectors)

IT 579542-25-9 579542-26-0 579542-27-1 579542-28-2 579542-29-3
 579542-30-6 579542-31-7 579542-33-9 579542-34-0 579542-35-1
 579542-36-2 579542-37-3 579542-38-4 579542-39-5 579542-40-8
 579542-41-9 579542-42-0 579542-43-1 579542-44-2 579542-45-3
 579542-46-4 579542-47-5 579542-48-6 579542-49-7 579542-50-0
 579542-51-1 579542-52-2 579542-53-3 579542-54-4 579542-55-5
 579542-56-6 579542-57-7 579542-58-8 579542-59-9 579542-60-2
 579542-61-3 579542-62-4 579542-63-5 579542-64-6 579542-65-7
 579542-66-8 579542-67-9 579542-68-0 579542-69-1 579542-70-4
 579542-71-5 579542-72-6 579542-73-7 579542-74-8 579542-75-9
 579542-76-0 579542-77-1 579542-78-2 579542-79-3 579542-80-6
 579542-81-7 579542-82-8 579542-83-9 579542-84-0 579542-85-1
 579542-86-2 579542-87-3
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; compns. comprising tissue specific
 replication competent adenoviral vectors)

IT 579542-25-9 579542-26-0 579542-27-1 579542-28-2 579542-29-3
 579542-30-6 579542-31-7 579542-33-9 579542-34-0 579542-35-1
 579542-36-2 579542-37-3 579542-38-4 579542-39-5 579542-40-8
 579542-41-9 579542-42-0 579542-43-1 579542-44-2 579542-45-3
 579542-46-4 579542-47-5 579542-48-6 579542-49-7 579542-50-0
 579542-51-1 579542-52-2 579542-53-3 579542-54-4 579542-55-5
 579542-56-6 579542-57-7 579542-58-8 579542-59-9 579542-60-2
 579542-61-3 579542-62-4 579542-63-5 579542-64-6 579542-65-7
 579542-66-8 579542-67-9 579542-68-0 579542-69-1 579542-70-4
 579542-71-5 579542-72-6 579542-73-7 579542-74-8 579542-75-9
 579542-76-0 579542-77-1 579542-78-2 579542-79-3 579542-80-6
 579542-81-7 579542-82-8 579542-83-9 579542-84-0 579542-85-1

579542-86-2 579542-87-3
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; compns. comprising tissue specific
 replication competent adenoviral vectors)
 IT 579542-40-8
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; compns. comprising tissue specific
 replication competent adenoviral vectors)
 RN 579542-40-8 HCAPLUS
 CN DNA, d(C-A-T-T-A-A-C-C-G-G-T-A-A-G-C-T-T-G-G-G-G-C-T-G-G-G-G) (9CI) (CA
 INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 10 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:590814 HCAPLUS
 DN 139:112801
 ED Entered STN: 01 Aug 2003
 TI Protein and cDNA sequences of a human cytokine CD40-ligand lacking
 native-pattern glycosylation
 IN Armitage, Richard J.; Fanslow, William C.; Spriggs, Melanie K.
 PA USA
 SO U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 392,618,
 abandoned.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K038-17
 ICS C07K014-705; C12P021-02; C12N005-06; C07H021-04
 NCL 514008000; 530350000; 536023500; 435069100; 435320100; 435325000
 CC 3-3 (Biochemical Genetics)
 Section cross-reference(s): 13, 15

FAN.CNT 8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003144182	A1	20030731	US 2002-200242	20020719 <--
US 2004006006	A9	20040108		
JP 10150994	A2	19980609	JP 1997-318110	19921023 <--
EP 897983	A2	19990224	EP 1998-113461	19921023 <--
EP 897983	A3	19990317		
EP 897983	B1	20030507		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
CA 2312667	C	20021119	CA 1992-2312667	19921023 <--
US 5961974	A	19991005	US 1994-249189	19940524 <--
WO 2004009615	A2	20040129	WO 2003-US22641	20030718
WO 2004009615	A3	20040805		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI US 1991-783707	B2	19911025		<--
US 1991-805723	B2	19911205		<--
US 1992-969703	B2	19921023		<--
US 1994-249189	A2	19940524		<--
US 1999-392618	B2	19990909		<--
CA 1992-2121798	A3	19921023		<--
EP 1992-925017	A3	19921023		<--
JP 1993-507897	A3	19921023		<--
US 2002-200242	A	20020719		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003144182	ICM	A61K038-17
	ICS	C07K014-705; C12P021-02; C12N005-06; C07H021-04
	NCL	514008000; 530350000; 536023500; 435069100; 435320100; 435325000
US 2003144182	ECLA	C07K014/705Q; C12N015/62 <--
EP 897983	ECLA	C07K016/28Q <--
US 5961974	ECLA	C07K014/705Q; C12N015/62 <--

AB The invention provides protein and cDNA sequences of a human cytokine

CD40-ligand lacking native-pattern glycosylation. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor and lack native-pattern glycosylation.

ST sequence human cytokine CD40 ligand glycosylation
IT Cytokines
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation)
(CD40-ligand; protein and cDNA sequences of human cytokine CD40-ligand lacking native-pattern glycosylation)
IT Gene, animal
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(for CD40-ligand; protein and cDNA sequences of human cytokine CD40-ligand lacking native-pattern glycosylation)
IT Protein motifs
(leucine zipper; protein and cDNA sequences of human cytokine CD40-ligand lacking native-pattern glycosylation)
IT Glycosylation
Human
Molecular cloning
Mutation
Protein sequences
cDNA sequences
(protein and cDNA sequences of human cytokine CD40-ligand lacking native-pattern glycosylation)
IT CD40 (antigen)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(protein and cDNA sequences of human cytokine CD40-ligand lacking native-pattern glycosylation)
IT 562120-99-4P, Cytokine CD40-ligand (human)
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation)
(amino acid sequence; protein and cDNA sequences of human cytokine CD40-ligand lacking native-pattern glycosylation)
IT 562121-48-6
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(leucine zipper domain sequence; protein and cDNA sequences of human cytokine CD40-ligand lacking native-pattern glycosylation)
IT 562120-98-3
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence; protein and cDNA sequences of human cytokine CD40-ligand lacking native-pattern glycosylation)
IT 562122-83-2 562122-85-4 562122-86-5 562122-87-6 562122-88-7
562122-89-8 562122-90-1 562122-91-2 562122-92-3 562122-93-4
562122-94-5 562122-96-7 562122-97-8 562122-98-9 562123-00-6
RL: PRP (Properties)
(unclaimed nucleotide sequence; protein and cDNA sequences of a human cytokine CD40-ligand lacking native-pattern glycosylation)
IT 562122-84-3 562122-95-6 562122-99-0 562123-01-7
RL: PRP (Properties)
(unclaimed protein sequence; protein and cDNA sequences of a human cytokine CD40-ligand lacking native-pattern glycosylation)
IT 98849-88-8 203244-38-6 245427-08-1
RL: PRP (Properties)
(unclaimed sequence; protein and cDNA sequences of a human cytokine CD40-ligand lacking native-pattern glycosylation)
IT 562122-88-7
RL: PRP (Properties)
(unclaimed nucleotide sequence; protein and cDNA sequences of a human cytokine CD40-ligand lacking native-pattern glycosylation)
RN 562122-88-7 HCAPLUS
CN DNA, d(C-C-G-T-C-G-A-C-G-T-C-T-A-G-A-G-C-C-G-A-T-C-C-T-G-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 11 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:545709 HCAPLUS
DN 139:79122
ED Entered STN: 17 Jul 2003
TI A new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans

Search done by Noble Jarrell

IN Smith, Alvin W.
 PA The State of Oregon Acting by and Through the State Board of Higher
 Education On Behalf of Oregon State University, USA
 SO U.S., 48 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM C12Q001-70
 ICS G01N033-53; C07K017-00
 NCL 435005000; 435007100; 530350000
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 10

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6593080	B1	20030715	US 2000-496320	20000201 <--
	US 2003180323	A1	20030925	US 2003-352393	20030127 <--
PRAI	US 1999-118209P	P	19990201	<--	
	US 2000-496320	A1	20000201		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6593080	ICM	C12Q001-70
	ICS	G01N033-53; C07K017-00
	NCL	435005000; 435007100; 530350000

AB Caliciviruses are herein recognized as potentially important human pathogens, infecting a large percentage (18%) of a sampled human population. A new calicivirus isolate called "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1) is also disclosed. Compns. and methods are disclosed that allow diagnosis, prevention and treatment of calicivirus (including SMSV-5 Hom-1) infection in humans.

ST calicivirus SMSV5Hom1 human infection diagnosis

IT Calicivirus
 (SMSV-5 Hom-1; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT Thymus gland, disease
 (atrophy, detecting calicivirus in samples from; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT Epitopes
 (calicivirus; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT Fatigue, biological
 (chronic fatigue syndrome, detecting calicivirus in samples from; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT Blister
 Diarrhea
 Encephalitis
 Hemorrhage
 Hepatitis
 Pneumonia
 (detecting calicivirus in samples from; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT Mucous membrane
 (disease, erosion, detecting calicivirus in samples from; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT Proteins
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation)
 (encoded by p5RT73 genomic segment; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT Diagnosis
 (mol.; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT Heart, disease
 (myocarditis, detecting calicivirus in samples from; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and

diagnosis, prevention and treatment of calicivirus infection in humans)

IT Muscle, disease
(myositis, detecting calicivirus in samples from; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT Antiviral agents
Human
Immunostimulants
Molecular cloning
Protein sequences
(new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT Antigens
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT Gene, microbial
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(pSRT73 genomic segment; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT Abortion
(spontaneous, detecting calicivirus in samples from; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT Antibodies and Immunoglobulins
RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(to calicivirus; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT Organelle
(vesicle, detecting calicivirus in samples from; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT Infection
(viral, diagnosis and treatment of; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT 556161-83-2P, Antigen (calicivirus) 556162-56-2P 556162-57-3P 556162-58-4P
RL: ARG (Analytical reagent use); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT 556164-55-7, 1: PN: US6593080 SEQID: 1 unclaimed DNA 556164-57-9, 3: PN: US6593080 SEQID: 3 unclaimed DNA 556164-58-0, 4: PN: US6593080 SEQID: 4 unclaimed DNA 556164-59-1 556164-60-4 556164-61-5 556164-62-6 556165-87-8
RL: PRP (Properties)
(unclaimed nucleotide sequence; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT 556164-56-8 556165-88-9 556165-89-0 556165-90-3 556165-91-4 556165-92-5 556172-58-8 556172-64-6 556172-65-7
RL: PRP (Properties)
(unclaimed protein sequence; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

IT 556065-03-3 556065-04-4 556065-05-5 556065-06-6 556065-07-7 556065-08-8 556065-09-9 556065-10-2 556065-11-3 556065-12-4 556065-13-5 556065-14-6
RL: PRP (Properties)
(unclaimed sequence; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE
(1) Berry; ASM Annual Meeting 1987

- (2) Berry; Abstract, 1987 ASM Annual Meeting 1987
- (3) Bradley; Journal of Hepatology 1995, V22(Suppl 1), P140
- (4) Nakata; Journal of Clinical Microbiology 1983, V17, P198 MEDLINE
- (5) Neill; Genbank Accession No P89669 1997
- (6) Neill; Virus Research 1992, V24, P211 HCAPLUS
- (7) Neill; Virus Research 1992, V24, P211 HCAPLUS
- (8) Poet, S; Thesis presented 1994
- (9) Smith; Amer J Vet Res 1977, V38(1), P101 MEDLINE
- (10) Smith; Amer J Vet Res 1978, V39(2), P287 MEDLINE
- (11) Smith; Calicivirus Isolation and Persistence in a Pygmy Chimpanzee (Pan paniscus), 1983, V221, P79 MEDLINE
- (12) Smith; Clinical Infectious Diseases 1998, V26, P424
- (13) Smith; Emerging Infectious Diseases 1998, V4(1), P13 MEDLINE
- (14) Soergel; Archives of Virology 1978, V57(3) HCAPLUS

IT 556164-59-1

RL: PRP (Properties)

(unclaimed nucleotide sequence; new calicivirus "San Miguel sea lion virus 5 serotype Homosapien-1" (SMSV-5 Hom-1), and diagnosis, prevention and treatment of calicivirus infection in humans)

RN 556164-59-1 HCAPLUS

CN DNA, d(G-T-G-G-T-C-G-G-C-C-G-G-G-G-C-T-C-G-T-T-G-G-G-A-G-G-T-G) (9CI)
(CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 12 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:260540 HCAPLUS

DN 138:249945

ED Entered STN: 04 Apr 2003

TI Biallelic markers for use in constructing a high density disequilibrium map of the human genome and for diagnosis of the risk for developing Alzheimer's disease

IN Cohen, Daniel; Chumakov, Ilya; Blumenfeld, Marta

PA Genset, Fr.

SO U.S., 134 pp., Cont.-in-part of U.S. Ser. No. 298,850, abandoned.

CODEN: USXXAM

DT Patent

LA English

IC C07H021-04; C07Q001-68

NCL 435006000; 435091200; 536023100; 536024300; 536023400

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 13, 14

FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6537751	B1	20030325	US 1999-422978	19991020 <--
	WO 9954500	A2	19991028	WO 1999-1B822	19990421 <--
	WO 9954500	A3	20000316		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1998-82614P	P	19980421		<--
	US 1998-109732P	P	19981123		<--
	US 1999-298850	B2	19990421		<--
	WO 1999-1B822	A2	19990421		<--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6537751	IC	C07H021-04IC C07Q001-68
	NCL	435006000; 435091200; 536023100; 536024300; 536023400
WO 9954500	ECLA	C12Q001/68B6; C12Q001/68B10A; C12Q001/68M <--

AB The present invention relates to genomic maps comprising biallelic markers, new biallelic markers, and methods of using biallelic markers. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides a number of methods utilizing the biallelic markers of the invention including methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.

The compns. and methods of the invention also find use in the identification of targets for the development of pharmaceutical agents and diagnostic methods, as well as the characterization of differential efficacious responses to and side effects from pharmaceutical agents acting on a disease (e.g., Alzheimer's disease, prostate cancer, or asthma) as well as other treatments. The invention provides 3934 biallelic marker sequences, as well as the primer pairs for amplification and detection of each marker. In particular, an allele at position 24 of biallelic marker 99-365-344 is associated with an increased risk for developing Alzheimer's disease. [This abstract record is one of three records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

- ST biallelic marker human genome mapping; sequence biallelic marker DNA human genome; PCR primer biallelic marker human genome; drug Alzheimers asthma gene biallelic marker
- IT Gene, animal
 - RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 - (APOE, determination of haplotype frequency; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)
- IT Computer application
 - DNA sequences
 - Drug design
 - Drug screening
 - Genetic mapping
 - Genetic markers
 - Genome
 - Genotyping (method)
 - Human
 - Nucleic acid amplification (method)
 - Nucleic acid hybridization
 - PCR (polymerase chain reaction)
 - (biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)
- IT Primers (nucleic acid)
 - RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 - (biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)
- IT Anti-Alzheimer's agents
 - Antiasthmatics
 - (design and screening of; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)
- IT Allele frequency
 - (determination in a population; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)
- IT Haplotypes
 - (determination of frequency of; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)
- IT Test kits
 - (diagnostic; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)
- IT Genetic linkage
 - (disequil.; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)
- IT Genetic methods
 - (enzyme-based mismatch detection assay; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)
- IT Diagnosis
 - (genetic; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)
- IT Prostate gland, neoplasm
 - (inhibitors, design and screening of; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)
- IT Antitumor agents

(prostate gland, design and screening of; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)

IT Alzheimer's disease

(screening for; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)

IT Genomic library

cDNA library

(screening of; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)

IT Genetic polymorphism

(single nucleotide; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)

IT	502238-04-2	502238-05-3	502238-06-4	502238-07-5	502238-08-6
	502238-09-7	502238-10-0	502238-11-1	502238-12-2	502238-13-3
	502238-14-4	502238-15-5	502238-16-6	502238-17-7	502238-18-8
	502238-19-9	502238-20-2	502238-21-3	502238-22-4	502238-23-5
	502238-24-6	502238-25-7	502238-26-8	502238-27-9	502238-28-0
	502238-29-1	502238-30-4	502238-31-5	502238-32-6	502238-33-7
	502238-34-8	502238-35-9	502238-36-0	502238-37-1	502238-38-2
	502238-39-3	502238-40-6	502238-41-7	502238-42-8	502238-43-9
	502238-44-0	502238-45-1	502238-46-2	502238-47-3	502238-48-4
	502238-49-5	502238-50-8	502238-51-9	502238-52-0	502238-53-1
	502238-54-2	502238-55-3	502238-56-4	502238-57-5	502238-58-6
	502238-59-7	502238-60-0	502238-61-1	502238-62-2	502238-63-3
	502238-64-4	502238-65-5	502238-66-6	502238-67-7	502238-68-8
	502238-69-9	502238-70-2	502238-71-3	502238-72-4	502238-73-5
	502238-74-6	502238-75-7	502238-76-8	502238-77-9	502238-78-0
	502238-79-1	502238-80-4	502238-81-5	502238-82-6	502238-83-7
	502238-84-8	502238-85-9	502238-86-0	502238-87-1	502238-88-2
	502238-89-3	502238-90-6	502238-91-7	502238-92-8	502238-93-9
	502238-94-0	502238-95-1	502238-96-2	502238-97-3	502238-98-4
	502238-99-5	502239-00-1	502239-01-2	502239-02-3	502239-03-4
	502239-04-5	502239-05-6	502239-06-7	502239-07-8	502239-08-9
	502239-09-0	502239-10-3	502239-11-4	502239-12-5	502239-13-6
	502239-14-7	502239-15-8	502239-16-9	502239-17-0	502239-18-1
	502239-19-2	502239-20-5	502239-21-6	502239-22-7	502239-23-8
	502239-24-9	502239-25-0	502239-26-1	502239-27-2	502239-28-3
	502239-29-4	502239-30-7	502239-31-8	502239-32-9	502239-33-0
	502239-34-1	502239-35-2	502239-36-3	502239-37-4	502239-38-5
	502239-39-6	502239-40-9	502239-41-0	502239-42-1	502239-43-2
	502239-44-3	502239-45-4	502239-46-5	502239-47-6	502239-48-7
	502239-49-8	502239-50-1	502239-51-2	502239-52-3	502239-53-4
	502239-54-5	502239-55-6	502239-56-7	502239-57-8	502239-58-9
	502239-59-0	502239-60-3	502239-61-4	502239-62-5	502239-63-6
	502239-64-7	502239-65-8	502239-66-9	502239-67-0	502239-68-1
	502239-69-2	502239-70-5	502239-71-6	502239-72-7	502239-73-8
	502239-74-9	502239-75-0	502239-76-1	502239-77-2	502239-78-3
	502239-79-4	502239-80-7	502239-81-8	502239-82-9	502239-83-0
	502239-84-1	502239-85-2	502239-86-3	502239-87-4	502239-88-5
	502239-89-6	502239-90-9	502239-91-0	502239-92-1	502239-93-2
	502239-94-3	502239-95-4	502239-96-5	502239-97-6	502239-98-7
	502239-99-8	502240-00-8	502240-01-9	502240-02-0	502240-03-1
	502240-04-2	502240-05-3	502240-06-4	502240-07-5	502240-08-6
	502240-09-7	502240-10-0	502240-11-1	502240-12-2	502240-13-3
	502240-14-4	502240-15-5	502240-16-6	502240-17-7	502240-18-8
	502240-19-9	502240-20-2	502240-21-3	502240-22-4	502240-23-5
	502240-24-6	502240-25-7	502240-26-8	502240-27-9	502240-28-0
	502240-29-1	502240-30-4	502240-31-5	502240-32-6	502240-33-7
	502240-34-8	502240-35-9	502240-36-0	502240-37-1	502240-38-2

RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST

(Analytical study); BIOL (Biological study); USES (Uses)

(downstream amplification primer for biallelic marker; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)

IT	502240-39-3	502240-40-6	502240-41-7	502240-42-8	502240-43-9
	502240-44-0	502240-45-1	502240-46-2	502240-47-3	502240-48-4
	502240-49-5	502240-50-8	502240-51-9	502240-52-0	502240-53-1
	502240-54-2	502240-55-3	502240-56-4	502240-57-5	502240-58-6
	502240-59-7	502240-60-0	502240-61-1	502240-62-2	502240-63-3
	502240-64-4	502240-65-5	502240-66-6	502240-67-7	502240-68-8
	502240-69-9	502240-70-2	502240-71-3	502240-72-4	502240-73-5

502240-74-6	502240-75-7	502240-76-8	502240-77-9	502240-78-0
502240-79-1	502240-80-4	502240-81-5	502240-82-6	502240-83-7
502240-84-8	502240-85-9	502240-86-0	502240-87-1	502240-88-2
502240-89-3	502240-90-6	502240-91-7	502240-92-8	502240-93-9
502240-94-0	502240-95-1	502240-96-2	502240-97-3	502240-98-4
502240-99-5	502241-00-1	502241-01-2	502241-02-3	502241-03-4
502241-04-5	502241-05-6	502241-06-7	502241-07-8	502241-08-9
502241-09-0	502241-10-3	502241-11-4	502241-12-5	502241-13-6
502241-14-7	502241-15-8	502241-16-9	502241-17-0	502241-18-1
502241-19-2	502241-20-5	502241-21-6	502241-22-7	502241-23-8
502241-24-9	502241-25-0	502241-26-1	502241-27-2	502241-28-3
502241-29-4	502241-30-7	502241-31-8	502241-32-9	502241-33-0
502241-34-1	502241-35-2	502241-36-3	502241-37-4	502241-38-5
502241-39-6	502241-40-9	502241-41-0	502241-42-1	502241-43-2
502241-44-3	502241-45-4	502241-46-5	502241-47-6	502241-48-7
502241-49-8	502241-50-1	502241-51-2	502241-52-3	502241-53-4
502241-54-5	502241-55-6	502241-56-7	502241-57-8	502241-58-9
502241-59-0	502241-60-3	502241-61-4	502241-62-5	502241-63-6
502241-64-7	502241-65-8	502241-66-9	502241-67-0	502241-68-1
502241-69-2	502241-70-5	502241-71-6	502241-72-7	502241-73-8
502241-74-9	502241-75-0	502241-76-1	502241-77-2	502241-78-3
502241-79-4	502241-80-7	502241-81-8	502241-82-9	502241-83-0
502241-84-1	502241-85-2	502241-86-3	502241-87-4	502241-88-5
502241-89-6	502241-90-9	502241-91-0	502241-92-1	502241-93-2
502241-94-3	502241-95-4	502241-96-5	502241-97-6	502241-98-7
502241-99-8	502242-00-4	502242-01-5	502242-02-6	502242-03-7
502242-04-8	502242-05-9	502242-06-0	502242-07-1	502242-08-2
502242-09-3	502242-10-6	502242-11-7	502242-12-8	502242-13-9
502242-14-0	502242-15-1	502242-16-2	502242-17-3	502242-18-4
502242-19-5	502242-20-8	502242-21-9	502242-22-0	502242-23-1
502242-24-2	502242-25-3	502242-26-4	502242-27-5	502242-28-6
502242-29-7	502242-30-0	502242-31-1	502242-32-2	502242-33-3
502242-34-4	502242-35-5	502242-36-6	502242-37-7	502242-38-8
502242-39-9	502242-40-2	502242-41-3	502242-42-4	502242-43-5
502242-44-6	502242-45-7	502242-46-8	502242-47-9	502242-48-0
502242-49-1	502242-50-4	502242-51-5	502242-52-6	502242-53-7
502242-54-8	502242-55-9	502242-56-0	502242-57-1	502242-58-2
502242-59-3	502242-60-6	502242-61-7	502242-62-8	502242-63-9
502242-64-0	502242-65-1	502242-66-2	502242-67-3	502242-68-4
502242-69-5	502242-70-8	502242-71-9	502242-72-0	502242-73-1

RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST
(Analytical study); BIOL (Biological study); USES (Uses)
(downstream amplification primer for biallelic marker; biallelic
markers for use in constructing a high d. disequil. map of the human
genome and for diagnosis of the risk for developing Alzheimer's
disease)

IT	502242-74-2	502242-75-3	502242-76-4	502242-77-5	502242-78-6
	502242-79-7	502242-80-0	502242-81-1	502242-82-2	502242-83-3
	502242-84-4	502242-85-5	502242-86-6	502242-87-7	502242-88-8
	502242-89-9	502242-90-2	502242-91-3	502242-92-4	502242-93-5
	502242-94-6	502242-95-7	502242-96-8	502242-97-9	502242-98-0
	502242-99-1	502243-00-7	502243-01-8	502243-02-9	502243-03-0
	502243-04-1	502243-05-2	502243-06-3	502243-07-4	502243-08-5
	502243-09-6	502243-10-9	502243-11-0	502243-12-1	502243-13-2
	502243-14-3	502243-15-4	502243-16-5	502243-17-6	502243-18-7
	502243-19-8	502243-20-1	502243-21-2	502243-22-3	502243-23-4
	502243-24-5	502243-25-6	502243-26-7	502243-27-8	502243-28-9
	502243-29-0	502243-30-3	502243-31-4	502243-32-5	502243-33-6
	502243-34-7	502243-35-8	502243-36-9	502243-37-0	502243-38-1
	502243-39-2	502243-40-5	502243-41-6	502243-42-7	502243-43-8
	502243-44-9	502243-45-0	502243-46-1	502243-47-2	502243-48-3
	502243-49-4	502243-50-7	502243-51-8	502243-52-9	502243-53-0
	502243-54-1	502243-55-2	502243-56-3	502243-57-4	502243-58-5
	502243-59-6	502243-60-9	502243-61-0	502243-62-1	502243-63-2
	502243-64-3	502243-65-4	502243-66-5	502243-67-6	502243-68-7
	502243-69-8	502243-70-1	502243-71-2	502243-72-3	502243-73-4
	502243-74-5	502243-75-6	502243-76-7	502243-77-8	502243-78-9
	502243-79-0	502243-80-3	502243-81-4	502243-82-5	502243-83-6
	502243-84-7	502243-85-8	502243-86-9	502243-87-0	502243-88-1
	502243-89-2	502243-90-5	502243-91-6	502243-92-7	502243-93-8
	502243-94-9	502243-95-0	502243-96-1	502243-97-2	502243-98-3
	502243-99-4	502244-00-0	502244-01-1	502244-02-2	502244-03-3
	502244-04-4	502244-05-5	502244-06-6	502244-07-7	502244-08-8
	502244-09-9	502244-10-2	502244-11-3	502244-12-4	502244-13-5
	502244-14-6	502244-15-7	502244-16-8	502244-17-9	502244-18-0
	502244-19-1	502244-20-4	502244-21-5	502244-22-6	502244-23-7

502244-24-8	502244-25-9	502244-26-0	502244-27-1	502244-28-2
502244-29-3	502244-30-6	502244-31-7	502244-32-8	502244-33-9
502244-34-0	502244-35-1	502244-36-2	502244-37-3	502244-38-4
502244-39-5	502244-40-8	502244-41-9	502244-42-0	502244-43-1
502244-44-2	502244-45-3	502244-46-4	502244-47-5	502244-48-6
502244-49-7	502244-50-0	502244-51-1	502244-52-2	502244-53-3
502244-54-4	502244-55-5	502244-56-6	502244-57-7	502244-58-8
502244-59-9	502244-60-2	502244-61-3	502244-62-4	502244-63-5
502244-64-6	502244-65-7	502244-66-8	502244-67-9	502244-68-0
502244-69-1	502244-70-4	502244-71-5	502244-72-6	502244-73-7
502244-74-8	502244-75-9	502244-76-0	502244-77-1	502244-78-2
502244-79-3	502244-80-6	502244-81-7	502244-82-8	502244-83-9
502244-84-0	502244-85-1	502244-86-2	502244-87-3	502244-88-4
502244-89-5	502244-90-8	502244-91-9	502244-92-0	502244-93-1
502244-94-2	502244-95-3	502244-96-4	502244-97-5	502244-98-6
502244-99-7	502245-00-3	502245-01-4	502245-02-5	502245-03-6
502245-04-7	502245-05-8	502245-06-9	502245-07-0	502245-08-1

RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST

(Analytical study); BIOL (Biological study); USES (Uses)

(downstream amplification primer for biallelic marker; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)

IT	502245-09-2	502245-10-5	502245-11-6	502245-12-7	502245-13-8
	502245-14-9	502245-15-0	502245-16-1	502245-17-2	502245-18-3
	502245-19-4	502245-20-7	502245-21-8	502245-22-9	502245-23-0
	502245-24-1	502245-25-2	502245-26-3	502245-27-4	502245-28-5
	502245-29-6	502245-30-9	502245-31-0	502245-32-1	502245-33-2
	502245-34-3	502245-35-4	502245-36-5	502245-37-6	502245-38-7
	502245-39-8	502245-40-1	502245-41-2	502245-42-3	502245-43-4
	502245-44-5	502245-45-6	502245-46-7	502245-47-8	502245-48-9
	502245-49-0	502245-50-3	502245-51-4	502245-52-5	502245-53-6
	502245-54-7	502245-55-8	502245-56-9	502245-57-0	502245-58-1
	502245-59-2	502245-60-5	502245-61-6	502245-62-7	502245-63-8
	502245-64-9	502245-65-0	502245-66-1	502245-67-2	502245-68-3
	502245-69-4	502245-70-7	502245-71-8	502245-72-9	502245-73-0
	502245-74-1	502245-75-2	502245-76-3	502245-77-4	502245-78-5
	502245-79-6	502245-80-9	502245-81-0	502245-82-1	502245-83-2
	502245-84-3	502245-85-4	502245-86-5	502245-87-6	502245-88-7
	502245-89-8	502245-90-1	502245-91-2	502245-92-3	502245-93-4
	502245-94-5	502245-95-6	502245-96-7	502245-97-8	502245-98-9
	502246-00-0	502246-01-7	502246-02-8	502246-03-9	502246-04-0
	502246-04-0	502246-05-1	502246-06-2	502246-07-3	502246-08-4
	502246-09-5	502246-10-8	502246-11-9	502246-12-0	502246-13-1
	502246-14-2	502246-15-3	502246-16-4	502246-17-5	502246-18-6
	502246-19-7	502246-20-0	502246-21-1	502246-22-2	502246-23-3
	502246-24-4	502246-25-5	502246-26-6	502246-27-7	502246-28-8
	502246-29-9	502246-30-2	502246-31-3	502246-32-4	502246-33-5
	502246-34-6	502246-35-7	502246-36-8	502246-37-9	502246-38-0
	502246-39-1	502246-40-4	502246-41-5	502246-42-6	502246-43-7
	502246-44-8	502246-45-9	502246-46-0	502246-47-1	502246-48-2
	502246-49-3	502246-50-6	502246-51-7	502246-52-8	502246-53-9
	502246-54-0	502246-55-1	502246-56-2	502246-57-3	502246-58-4
	502246-59-5	502246-60-8	502246-61-9	502246-62-0	502246-63-1
	502246-64-2	502246-65-3	502246-66-4	502246-67-5	502246-68-6
	502246-69-7	502246-70-0	502246-71-1	502246-72-2	502246-73-3
	502246-74-4	502246-75-5	502246-76-6	502246-77-7	502246-78-8
	502246-79-9	502246-80-2	502246-81-3	502246-82-4	502246-83-5
	502246-84-6	502246-85-7	502246-86-8	502246-87-9	502246-88-0
	502246-89-1	502246-90-4	502246-91-5	502246-92-6	502246-93-7
	502246-94-8	502246-95-9	502246-96-0	502246-97-1	502246-98-2
	502247-00-3	502247-01-0	502247-02-1	502247-03-2	502247-04-3
	502247-05-4	502247-06-5	502247-07-6	502247-08-7	502247-09-8
	502247-10-1	502247-11-2	502247-12-3	502247-13-4	502247-14-5
	502247-15-6	502247-16-7	502247-17-8	502247-18-9	502247-19-0
	502247-20-3	502247-21-4	502247-22-5	502247-23-6	502247-24-7
	502247-25-8	502247-26-9	502247-27-0	502247-28-1	502247-29-2
	502247-30-5	502247-31-6	502247-32-7	502247-33-8	502247-34-9
	502247-35-0	502247-36-1	502247-37-2	502247-38-3	502247-39-4
	502247-40-7	502247-41-8	502247-42-9	502247-43-0	

RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST

(Analytical study); BIOL (Biological study); USES (Uses)

(downstream amplification primer for biallelic marker; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)

IT	502247-44-1	502247-45-2	502247-46-3	502247-47-4	502247-48-5
	502247-49-6	502247-50-9	502247-51-0	502247-52-1	502247-53-2
	502247-54-3	502247-55-4	502247-56-5	502247-57-6	502247-58-7
	502247-59-8	502247-60-1	502247-61-2	502247-62-3	502247-63-4
	502247-64-5	502247-65-6	502247-66-7	502247-67-8	502247-68-9
	502247-69-0	502247-70-3	502247-71-4	502247-72-5	502247-73-6
	502247-74-7	502247-75-8	502247-76-9	502247-77-0	502247-78-1
	502247-79-2	502247-80-5	502247-81-6	502247-82-7	502247-83-8
	502247-84-9	502247-85-0	502247-86-1	502247-87-2	502247-88-3
	502247-89-4	502247-90-7	502247-91-8	502247-92-9	502247-93-0
	502247-94-1	502247-95-2	502247-96-3	502247-97-4	502247-98-5
	502247-99-6	502248-00-2	502248-01-3	502248-02-4	502248-03-5
	502248-04-6	502248-05-7	502248-06-8	502248-07-9	502248-08-0
	502248-09-1	502248-10-4	502248-11-5	502248-12-6	502248-13-7
	502248-14-8	502248-15-9	502248-16-0	502248-17-1	502248-18-2
	502248-19-3	502248-20-6	502248-21-7	502248-23-9	502248-24-0
	502248-25-1	502248-26-2	502248-27-3	502248-28-4	502248-29-5
	502248-30-8	502248-31-9	502248-32-0	502248-33-1	502248-34-2
	502248-35-3	502248-36-4	502248-37-5	502248-38-6	502248-39-7
	502248-40-0	502248-41-1	502248-42-2	502248-43-3	502248-44-4
	502248-45-5	502248-47-7	502248-48-8	502248-49-9	502248-50-2
	502248-51-3	502248-52-4	502248-53-5	502248-54-6	502248-55-7
	502248-56-8	502248-57-9	502248-58-0	502248-59-1	502248-60-4
	502248-61-5	502248-62-6	502248-63-7	502248-64-8	502248-65-9
	502248-66-0	502248-67-1	502248-68-2	502248-69-3	502248-70-6
	502248-71-7	502248-72-8	502248-73-9	502248-74-0	502248-75-1
	502248-76-2	502248-78-4	502248-79-5	502248-80-8	502248-81-9
	502248-82-0	502248-83-1	502248-84-2	502248-85-3	502248-86-4
	502248-87-5	502248-88-6	502248-89-7	502248-90-0	502248-91-1
	502248-92-2	502248-93-3	502248-94-4	502248-95-5	502248-96-6
	502248-97-7	502248-98-8	502248-99-9	502249-00-5	502249-01-6
	502249-02-7	502249-03-8	502249-04-9	502249-05-0	502249-06-1
	502249-07-2	502249-08-3	502249-09-4	502249-10-7	502249-11-8
	502249-12-9	502249-13-0	502249-14-1	502249-15-2	502249-16-3
	502249-17-4	502249-18-5	502249-19-6	502249-20-9	502249-21-0
	502249-22-1	502249-23-2	502249-24-3	502249-25-4	502249-26-5
	502249-27-6	502249-28-7	502249-29-8	502249-30-1	502249-31-2
	502249-32-3	502249-33-4	502249-34-5	502249-35-6	502249-36-7
	502249-37-8	502249-38-9	502249-39-0	502249-40-3	502249-41-4
	502249-42-5	502249-43-6	502249-44-7	502249-45-8	502249-46-9
	502249-48-1	502249-50-5	502249-51-6	502249-52-7	502249-53-8
	502249-54-9	502249-55-0	502249-56-1	502249-57-2	502249-58-3
	502249-59-4	502249-60-7	502249-61-8	502249-62-9	502249-63-0
	502249-64-1	502249-65-2	502249-66-3	502249-67-4	502249-68-5
	502249-69-6	502249-70-9	502249-71-0	502249-72-1	502249-73-2
	502249-74-3	502249-75-4	502249-76-5	502249-77-6	502249-78-7
	502249-79-8	502249-80-1	502249-81-2	502249-82-3	502249-83-4

RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses) (downstream amplification primer for biallelic marker; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)

IT	502249-84-5	502249-85-6	502249-86-7	502249-87-8	502249-88-9
	502249-89-0	502249-90-3	502249-91-4	502249-92-5	502249-93-6
	502249-94-7	502249-95-8	502249-96-9	502249-97-0	502249-98-1
	502249-99-2	502250-00-2	502250-01-3	502250-02-4	502250-03-5
	502250-04-6	502250-05-7	502250-06-8	502250-07-9	502250-08-0
	502250-09-1	502250-10-4	502250-11-5	502250-12-6	502250-13-7
	502250-14-8	502250-15-9	502250-16-0	502250-17-1	502250-18-2
	502250-19-3	502250-20-6	502250-21-7	502250-22-8	502250-23-9
	502250-24-0	502250-25-1	502250-26-2	502250-27-3	502250-28-4
	502250-29-5	502250-30-8	502250-31-9	502250-32-0	502250-33-1
	502250-34-2	502250-35-3	502250-36-4	502250-37-5	502250-38-6
	502250-39-7	502250-40-0	502250-41-1	502250-42-2	502250-43-3
	502250-44-4	502250-45-5	502250-46-6	502250-47-7	502250-48-8
	502250-49-9	502250-50-2	502250-51-3	502250-52-4	502250-53-5
	502250-54-6	502250-55-7	502250-56-8	502250-57-9	502250-58-0
	502250-59-1	502250-60-4	502250-61-5	502250-62-6	502250-63-7
	502250-64-8	502250-65-9	502250-66-0	502250-67-1	502250-68-2
	502250-69-3	502250-70-6	502250-71-7	502250-72-8	502250-73-9
	502250-74-0	502250-75-1	502250-76-2	502250-77-3	502250-78-4
	502250-79-5	502250-80-8	502250-81-9	502250-82-0	502250-83-1
	502250-84-2	502250-85-3	502250-86-4	502250-87-5	502250-88-6
	502250-89-7	502250-90-0	502250-91-1	502250-92-2	502250-93-3
	502250-94-4	502250-95-5	502250-96-6	502250-97-7	502250-98-8

502250-99-9	502251-00-5	502251-01-6	502251-02-7	502251-03-8
502251-04-9	502251-05-0	502251-06-1	502251-07-2	502251-08-3
502251-09-4	502251-10-7	502251-11-8	502251-12-9	502251-13-0
502251-14-1	502251-15-2	502251-16-3	502251-17-4	502251-18-5
502251-19-6	502251-20-9	502251-21-0	502251-22-1	502251-23-2
502251-24-3	502251-25-4	502251-26-5	502251-27-6	502251-28-7
502251-29-8	502251-30-1	502251-31-2	502251-32-3	502251-33-4
502251-34-5	502251-35-6	502251-36-7	502251-37-8	502251-38-9
502251-39-0	502251-40-3	502251-41-4	502251-42-5	502251-43-6
502251-44-7	502251-45-8	502251-46-9	502251-47-0	502251-48-1
502251-49-2	502251-50-5	502251-51-6	502251-52-7	502251-53-8
502251-54-9	502251-55-0	502251-56-1	502251-57-2	502251-58-3
502251-59-4	502251-60-7	502251-61-8	502251-62-9	502251-63-0
502251-64-1	502251-65-2	502251-66-3	502251-67-4	502251-68-5
502251-69-6	502251-70-9	502251-71-0	502251-72-1	502251-73-2
502251-74-3	502251-75-4	502251-76-5	502251-77-6	502251-78-7
502251-79-8	502251-80-1	502251-81-2	502251-82-3	502251-83-4
502251-84-5	502251-85-6	502251-86-7	502251-87-8	502251-88-9
502251-89-0	502251-90-3	502251-91-4	502251-92-5	502251-93-6
502251-94-7	502251-95-8	502251-96-9	502251-97-0	502251-98-1
502251-99-2	502252-00-8	502252-01-9	502252-02-0	502252-03-1
502252-04-2	502252-05-3	502252-06-4	502252-07-5	502252-08-6
502252-09-7	502252-10-0	502252-11-1	502252-12-2	502252-13-3
502252-14-4	502252-15-5	502252-16-6	502252-17-7	502252-18-8

RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST
(Analytical study); BIOL (Biological study); USES (Uses)

(downstream amplification primer for biallelic marker; biallelic
markers for use in constructing a high d. disequil. map of the human
genome and for diagnosis of the risk for developing Alzheimer's
disease)

IT	502252-19-9	502252-20-2	502252-21-3	502252-22-4	502252-23-5
	502252-24-6	502252-25-7	502252-26-8	502252-27-9	502252-28-0
	502252-29-1	502252-30-4	502252-31-5	502252-32-6	502252-33-7
	502252-34-8	502252-35-9	502252-36-0	502252-37-1	502252-38-2
	502252-39-3	502252-40-6	502252-41-7	502252-42-8	502252-43-9
	502252-44-0	502252-45-1	502252-46-2	502252-47-3	502252-48-4
	502252-49-5	502252-50-8	502252-51-9	502252-52-0	502252-53-1
	502252-54-2	502252-55-3	502252-56-4	502252-57-5	502252-58-6
	502252-59-7	502252-60-0	502252-61-1	502252-62-2	502252-63-3
	502252-64-4	502252-65-5	502252-66-6	502252-67-7	502252-68-8
	502252-69-9	502252-70-2	502252-71-3	502252-72-4	502252-73-5
	502252-74-6	502252-75-7	502252-76-8	502252-77-9	502252-78-0
	502252-79-1	502252-80-4	502252-81-5	502252-82-6	502252-83-7
	502252-84-8	502252-85-9	502252-86-0	502252-87-1	502252-88-2
	502252-89-3	502252-90-6	502252-91-7	502252-92-8	502252-93-9
	502252-94-0	502252-95-1	502252-96-2	502252-97-3	502252-98-4
	502252-99-5	502253-00-1	502253-01-2	502253-02-3	502253-03-4
	502253-04-5	502253-05-6	502253-06-7	502253-07-8	502253-08-9
	502253-09-0	502253-10-3	502253-11-4	502253-12-5	502253-13-6
	502253-14-7	502253-15-8	502253-16-9	502253-17-0	502253-18-1
	502253-19-2	502253-20-5	502253-21-6	502253-22-7	502253-23-8
	502253-24-9	502253-25-0	502253-26-1	502253-27-2	502253-28-3
	502253-29-4	502253-30-7	502253-31-8	502253-32-9	502253-33-0
	502253-34-1	502253-35-2	502253-36-3	502253-37-4	502253-38-5
	502253-39-6	502253-40-9	502253-41-0	502253-42-1	502253-43-2
	502253-44-3	502253-45-4	502253-46-5	502253-47-6	502253-48-7
	502253-49-8	502253-50-1	502253-51-2	502253-52-3	502253-53-4
	502253-54-5	502253-55-6	502253-56-7	502253-57-8	502253-58-9
	502253-59-0	502253-60-3	502253-61-4	502253-62-5	502253-63-6
	502253-64-7	502253-65-8	502253-66-9	502253-67-0	502253-68-1
	502253-69-2	502253-70-5	502253-71-6	502253-72-7	502253-73-8
	502253-74-9	502253-75-0	502253-76-1	502253-77-2	502253-78-3
	502253-79-4	502253-80-7	502253-81-8	502253-82-9	502253-83-0
	502253-84-1	502253-85-2	502253-86-3	502253-87-4	502253-88-5
	502253-89-6	502253-90-9	502253-91-0	502253-92-1	502253-93-2
	502253-94-3	502253-95-4	502253-96-5	502253-97-6	502253-98-7
	502253-99-8	502254-00-4	502254-01-5	502254-02-6	502254-03-7
	502254-04-8	502254-05-9	502254-06-0	502254-07-1	502254-08-2
	502254-09-3	502254-10-6	502254-11-7	502254-12-8	502254-13-9
	502254-14-0	502254-15-1	502254-16-2	502254-17-3	502254-18-4
	502254-19-5	502254-20-8	502254-21-9	502254-22-0	502254-23-1
	502254-24-2	502254-25-3	502254-26-4	502254-27-5	502254-28-6
	502254-29-7	502254-30-0	502254-31-1	502254-32-2	502254-33-3
	502254-34-4	502254-35-5	502254-36-6	502254-37-7	502254-38-8
	502254-39-9	502254-40-2	502254-41-3	502254-42-4	502254-43-5
	502254-44-6	502254-45-7	502254-46-8	502254-47-9	502254-48-0

502254-49-1 502254-50-4 502254-51-5 502254-52-6 502254-53-7
 RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST
 (Analytical study); BIOL (Biological study); USES (Uses)
 (downstream amplification primer for biallelic marker; biallelic
 markers for use in constructing a high d. disequil. map of the human
 genome and for diagnosis of the risk for developing Alzheimer's
 disease)

IT	502254-54-8	502254-55-9	502254-56-0	502254-57-1	502254-58-2
	502254-59-3	502254-60-6	502254-61-7	502254-62-8	502254-63-9
	502254-64-0	502254-65-1	502254-66-2	502254-67-3	502254-68-4
	502254-69-5	502254-70-8	502254-71-9	502254-72-0	502254-73-1
	502254-74-2	502254-75-3	502254-76-4	502254-77-5	502254-78-6
	502254-79-7	502254-80-0	502254-81-1	502254-82-2	502254-83-3
	502254-84-4	502254-85-5	502254-86-6	502254-87-7	502254-88-8
	502254-89-9	502254-90-2	502254-91-3	502254-92-4	502254-93-5
	502254-94-6	502254-95-7	502254-96-8	502254-97-9	502254-98-0
	502254-99-1	502255-00-7	502255-01-8	502255-02-9	502255-03-0
	502255-04-1	502255-05-2	502255-06-3	502255-07-4	502255-08-5
	502255-09-6	502255-10-9	502255-11-0	502255-12-1	502255-13-2
	502255-14-3	502255-15-4	502255-16-5	502255-17-6	502255-18-7
	502255-19-8	502255-20-1	502255-21-2	502255-22-3	502255-23-4
	502255-24-5	502255-25-6	502255-26-7	502255-27-8	502255-28-9
	502255-29-0	502255-30-3	502255-31-4	502255-32-5	502255-33-6
	502255-34-7	502255-35-8	502255-36-9	502255-37-0	502255-38-1
	502255-39-2	502255-40-5	502255-41-6	502255-42-7	502255-43-8
	502255-44-9	502255-45-0	502255-46-1	502255-47-2	502255-48-3
	502255-49-4	502255-50-7	502255-51-8	502255-52-9	502255-53-0
	502255-54-1	502255-55-2	502255-56-3	502255-57-4	502255-58-5
	502255-59-6	502255-60-9	502255-61-0	502255-62-1	502255-63-2
	502255-64-3	502255-65-4	502255-66-5	502255-67-6	502255-68-7
	502255-69-8	502255-70-1	502255-71-2	502255-72-3	502255-73-4
	502255-74-5	502255-75-6	502255-76-7	502255-77-8	502255-78-9
	502255-79-0	502255-80-3	502255-81-4	502255-82-5	502255-83-6
	502255-84-7	502255-85-8	502255-86-9	502255-87-0	502255-88-1
	502255-89-2	502255-90-5	502255-91-6	502255-92-7	502255-93-8
	502255-94-9	502255-95-0	502255-96-1	502255-97-2	502255-98-3
	502255-99-4	502256-00-0	502256-01-1	502256-02-2	502256-03-3
	502256-04-4	502256-05-5	502256-06-6	502256-07-7	502256-08-8
	502256-09-9	502256-10-2	502256-11-3	502256-12-4	502256-13-5
	502256-14-6	502256-15-7	502256-16-8	502256-17-9	502256-18-0
	502256-19-1	502256-20-4	502256-21-5	502256-22-6	502256-23-7
	502256-24-8	502256-25-9	502256-26-0	502256-27-1	502256-28-2
	502256-29-3	502256-30-6	502256-31-7	502256-32-8	502256-33-9
	502256-34-0	502256-35-1	502256-36-2	502256-37-3	502256-38-4
	502256-39-5	502256-40-8	502256-41-9	502256-42-0	502256-43-1
	502256-44-2	502256-45-3	502256-46-4	502256-47-5	502256-48-6
	502256-49-7	502256-50-0	502256-51-1	502256-52-2	502256-53-3
	502256-54-4	502256-55-5	502256-56-6	502256-57-7	502256-58-8
	502256-59-9	502256-60-2	502256-61-3	502256-62-4	502256-63-5
	502256-64-6	502256-65-7	502256-66-8	502256-67-9	502256-68-0
	502256-69-1	502256-70-4	502256-71-5	502256-72-6	502256-73-7
	502256-74-8	502256-75-9	502256-76-0	502256-77-1	502256-78-2
	502256-79-3	502256-80-6	502256-81-7	502256-82-8	502256-83-9
	502256-84-0	502256-85-1	502256-86-2	502256-87-3	502256-88-4

RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST
 (Analytical study); BIOL (Biological study); USES (Uses)
 (downstream amplification primer for biallelic marker; biallelic
 markers for use in constructing a high d. disequil. map of the human
 genome and for diagnosis of the risk for developing Alzheimer's
 disease)

IT	502256-89-5	502256-90-8	502256-91-9	502256-92-0	502256-93-1
	502256-94-2	502256-95-3	502256-96-4	502256-97-5	502256-98-6
	502256-99-7	502257-00-3	502257-01-4	502257-02-5	502257-03-6
	502257-04-7	502257-05-8	502257-06-9	502257-07-0	502257-08-1
	502257-09-2	502257-10-5	502257-11-6	502257-12-7	502257-13-8
	502257-14-9	502257-15-0	502257-16-1	502257-17-2	502257-18-3
	502257-19-4	502257-20-7	502257-21-8	502257-22-9	502257-23-0
	502257-24-1	502257-25-2	502257-26-3	502257-27-4	502257-28-5
	502257-29-6	502257-30-9	502257-31-0	502257-32-1	502257-33-2
	502257-34-3	502257-35-4	502257-36-5	502257-37-6	502257-38-7
	502257-39-8	502257-40-1	502257-41-2	502257-42-3	502257-43-4
	502257-44-5	502257-45-6	502257-46-7	502257-47-8	502257-48-9
	502257-49-0	502257-50-3	502257-51-4	502257-52-5	502257-53-6
	502257-54-7	502257-55-8	502257-56-9	502257-57-0	502257-58-1
	502257-59-2	502257-60-5	502257-61-6	502257-62-7	502257-63-8
	502257-64-9	502257-65-0	502257-66-1	502257-67-2	502257-68-3

502257-69-4	502257-70-7	502257-71-8	502257-72-9	502257-73-0
502257-74-1	502257-75-2	502257-76-3	502257-77-4	502257-78-5
502257-79-6	502257-80-9	502257-81-0	502257-82-1	502257-83-2
502257-84-3	502257-85-4	502257-86-5	502257-87-6	502257-88-7
502257-89-8	502257-90-1	502257-91-2	502257-92-3	502257-93-4
502257-94-5	502257-95-6	502257-96-7	502257-97-8	502257-98-9
502257-99-0	502258-00-6	502258-01-7	502258-02-8	502258-03-9
502258-04-0	502258-05-1	502258-06-2	502258-07-3	502258-08-4
502258-09-5	502258-10-8	502258-11-9	502258-12-0	502258-13-1
502258-14-2	502258-15-3	502258-16-4	502258-17-5	502258-18-6
502258-19-7	502258-20-0	502258-21-1	502258-22-2	502258-23-3
502258-24-4	502258-25-5	502258-26-6	502258-27-7	502258-28-8
502258-29-9	502258-30-2	502258-31-3	502258-32-4	502258-33-5
502258-34-6	502258-35-7	502258-36-8	502258-37-9	502258-38-0
502258-39-1	502258-40-4	502258-41-5	502258-42-6	502258-43-7
502258-44-8	502258-45-9	502258-46-0	502258-47-1	502258-48-2
502258-49-3	502258-50-6	502258-51-7	502258-52-8	502258-53-9
502258-54-0	502258-55-1	502258-56-2	502258-57-3	502258-58-4
502258-59-5	502258-60-8	502258-61-9	502258-62-0	502258-63-1
502258-64-2	502258-65-3	502258-66-4	502258-67-5	502258-68-6
502258-69-7	502258-70-0	502258-71-1	502258-72-2	502258-73-3
502258-74-4	502258-75-5	502258-76-6	502258-77-7	502258-78-8
502258-79-9	502258-80-2	502258-81-3	502258-82-4	502258-83-5
502258-84-6	502258-85-7	502258-86-8	502258-87-9	502258-88-0
502258-89-1	502258-90-4	502258-91-5	502258-92-6	502258-93-7
502258-94-8	502258-95-9	502258-96-0	502258-97-1	502258-98-2
502258-99-3	502259-00-9	502259-01-0	502259-02-1	502259-03-2
502259-04-3	502259-05-4	502259-06-5	502259-07-6	502259-08-7
502259-09-8	502259-10-1	502259-11-2	502259-12-3	502259-13-4
502259-14-5	502259-15-6	502259-16-7	502259-17-8	502259-18-9
502259-19-0	502259-20-3	502259-21-4	502259-22-5	502259-23-6

RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST
(Analytical study); BIOL (Biological study); USES (Uses)

(downstream amplification primer for biallelic
markers for use in constructing a high d. disequil. map of the human
genome and for diagnosis of the risk for developing Alzheimer's
disease)

IT	502259-24-7	502259-25-8	502259-26-9	502259-27-0	502259-28-1
	502259-29-2	502259-30-5	502259-31-6	502259-32-7	502259-33-8
	502259-34-9	502259-35-0	502259-36-1	502259-37-2	502259-38-3
	502259-39-4	502259-40-7	502259-41-8	502259-42-9	502259-43-0
	502259-44-1	502259-45-2	502259-46-3	502259-47-4	502259-48-5
	502259-49-6	502259-50-9	502259-51-0	502259-52-1	502259-53-2
	502259-54-3	502259-55-4	502259-56-5	502259-57-6	502259-58-7
	502259-59-8	502259-60-1	502259-61-2	502259-62-3	502259-63-4
	502259-64-5	502259-65-6	502259-66-7	502259-67-8	502259-68-9
	502259-69-0	502259-70-3	502259-71-4	502259-72-5	502259-73-6
	502259-74-7	502259-75-8	502259-76-9	502259-77-0	502259-78-1
	502259-79-2	502259-80-5	502259-81-6	502259-82-7	502259-83-8
	502259-84-9	502259-85-0	502259-86-1	502259-87-2	502259-88-3
	502259-89-4	502259-90-7	502259-91-8	502259-92-9	502259-93-0
	502259-94-1	502259-95-2	502259-96-3	502259-97-4	502259-98-5
	502259-99-6	502260-00-6	502260-01-7	502260-02-8	502260-03-9
	502260-04-0	502260-05-1	502260-06-2	502260-07-3	502260-08-4
	502260-09-5	502260-10-8	502260-11-9	502260-12-0	502260-13-1
	502260-14-2	502260-15-3	502260-16-4	502260-17-5	502260-18-6
	502260-19-7	502260-20-0	502260-21-1	502260-22-2	502260-23-3
	502260-24-4	502260-25-5	502260-26-6	502260-27-7	502260-28-8
	502260-29-9	502260-30-2	502260-31-3	502260-32-4	502260-33-5
	502260-34-6	502260-35-7	502260-36-8	502260-37-9	502260-38-0
	502260-39-1	502260-40-4	502260-41-5	502260-42-6	502260-43-7
	502260-44-8	502260-45-9	502260-46-0	502260-47-1	502260-48-2
	502260-49-3	502260-50-6	502260-51-7	502260-52-8	502260-53-9
	502260-54-0	502260-55-1	502260-56-2	502260-57-3	502260-58-4
	502260-59-5	502260-60-8	502260-61-9	502260-62-0	502260-63-1
	502260-64-2	502260-65-3	502260-66-4	502260-67-5	502260-68-6
	502260-69-7	502260-70-0	502260-71-1	502260-72-2	502260-73-3
	502260-74-4	502260-75-5	502260-76-6	502260-77-7	502260-78-8
	502260-79-9	502260-80-2	502260-81-3	502260-82-4	502260-83-5
	502260-84-6	502260-85-7	502260-86-8	502260-87-9	502260-88-0
	502260-89-1	502260-90-4	502260-91-5	502260-92-6	502260-93-7
	502260-94-8	502260-95-9	502260-96-0	502260-97-1	502260-98-2
	502260-99-3	502261-00-9	502261-01-0	502261-02-1	502261-03-2
	502261-04-3	502261-05-4	502261-06-5	502261-07-6	502261-08-7
	502261-09-8	502261-10-1	502261-11-2	502261-12-3	502261-13-4
	502261-14-5	502261-15-6	502261-16-7	502261-17-8	502261-18-9

502261-19-0	502261-20-3	502261-21-4	502261-22-5	502261-23-6
502261-24-7	502261-25-8	502261-26-9	502261-27-0	502261-28-1
502261-29-2	502261-30-5	502261-31-6	502261-32-7	502261-33-8
502261-34-9	502261-35-0	502261-36-1	502261-37-2	502261-38-3
502261-39-4	502261-40-7	502261-41-8	502261-42-9	502261-43-0
502261-44-1	502261-45-2	502261-46-3	502261-47-4	502261-48-5
502261-49-6	502261-50-9	502261-51-0	502261-52-1	502261-53-2
502261-54-3	502261-55-4	502261-56-5	502261-57-6	502261-58-7

RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST
(Analytical study); BIOL (Biological study); USES (Uses)
(downstream amplification primer for biallelic marker; biallelic
markers for use in constructing a high d. disequil. map of the human
genome and for diagnosis of the risk for developing Alzheimer's
disease)

IT	502261-59-8	502261-60-1	502261-61-2	502261-62-3	502261-63-4
	502261-64-5	502261-65-6	502261-66-7	502261-67-8	502261-68-9
	502261-69-0	502261-70-3	502261-71-4	502261-72-5	502261-73-6
	502261-74-7	502261-75-8	502261-76-9	502261-77-0	502261-78-1
	502261-79-2	502261-80-5	502261-81-6	502261-82-7	502261-83-8
	502261-84-9	502261-85-0	502261-86-1	502261-87-2	502261-88-3
	502261-89-4	502261-90-7	502261-91-8	502261-92-9	502261-93-0
	502261-94-1	502261-95-2	502261-96-3	502261-97-4	502261-98-5
	502261-99-6	502262-00-2	502262-01-3	502262-02-4	502262-03-5
	502262-04-6	502262-05-7	502262-06-8	502262-07-9	502262-08-0
	502262-09-1	502262-10-4	502262-11-5	502262-12-6	502262-13-7
	502262-14-8	502262-15-9	502262-16-0	502262-17-1	502262-18-2
	502262-19-3	502262-20-6	502262-21-7	502262-22-8	502262-23-9
	502262-24-0	502262-25-1	502262-26-2	502262-27-3	502262-28-4
	502262-29-5	502262-30-8	502262-31-9	502262-32-0	502262-33-1
	502262-34-2	502262-35-3	502262-36-4	502262-37-5	502262-38-6
	502262-39-7	502262-40-0	502262-41-1	502262-42-2	502262-43-3
	502262-44-4	502262-45-5	502262-46-6	502262-47-7	502262-48-8
	502262-49-9	502262-50-2	502262-51-3	502262-52-4	502262-53-5
	502262-54-6	502262-55-7	502262-56-8	502262-57-9	502262-58-0
	502262-59-1	502262-60-4	502262-61-5	502262-62-6	502262-63-7
	502262-64-8	502262-65-9	502262-66-0	502262-67-1	502262-68-2
	502262-69-3	502262-70-6	502262-71-7	502262-72-8	502262-73-9
	502262-74-0	502262-75-1	502262-76-2	502262-77-3	502262-78-4
	502262-79-5	502262-80-8	502262-81-9	502262-82-0	502262-83-1
	502262-84-2	502262-85-3	502262-86-4	502262-87-5	502262-88-6
	502262-89-7	502262-90-0	502262-91-1	502262-92-2	502262-93-3
	502262-94-4	502262-95-5	502262-96-6	502262-97-7	502262-98-8
	502262-99-9	502263-00-5	502263-01-6	502263-02-7	502263-03-8
	502263-04-9	502263-05-0	502263-06-1	502263-07-2	502263-08-3
	502263-09-4	502263-10-7	502263-11-8	502263-12-9	502263-13-0
	502263-14-1	502263-15-2	502263-16-3	502263-17-4	502263-18-5
	502263-19-6	502263-20-9	502263-21-0	502263-22-1	502263-23-2
	502263-24-3	502263-25-4	502263-26-5	502263-27-6	502263-28-7
	502263-29-8	502263-30-1	502263-31-2	502263-32-3	502263-33-4
	502263-34-5	502263-35-6	502263-36-7	502263-37-8	502263-38-9
	502263-39-0	502263-40-3	502263-41-4	502263-42-5	502263-43-6
	502263-44-7	502263-45-8	502263-46-9	502263-47-0	502263-48-1
	502263-49-2	502263-50-5	502263-51-6	502263-52-7	502263-53-8
	502263-54-9	502263-55-0	502263-56-1	502263-57-2	502263-58-3
	502263-59-4	502263-60-7	502263-61-8	502263-62-9	502263-63-0
	502263-64-1	502263-65-2	502263-66-3	502263-67-4	502263-68-5
	502263-69-6	502263-70-9	502263-71-0	502263-72-1	502263-73-2
	502263-74-3	502263-75-4	502263-76-5	502263-77-6	502263-78-7
	502263-79-8	502263-80-1	502263-81-2	502263-82-3	502263-83-4
	502263-84-5	502263-85-6	502263-86-7	502263-87-8	502263-88-9
	502263-89-0	502263-90-3	502263-91-4	502263-92-5	502263-93-6

RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST
(Analytical study); BIOL (Biological study); USES (Uses)
(downstream amplification primer for biallelic marker; biallelic
markers for use in constructing a high d. disequil. map of the human
genome and for diagnosis of the risk for developing Alzheimer's
disease)

IT	502263-94-7	502263-95-8	502263-96-9	502263-97-0	502263-98-1
	502263-99-2	502264-00-8	502264-01-9	502264-02-0	502264-03-1
	502264-04-2	502264-05-3	502264-06-4	502264-07-5	502264-08-6
	502264-09-7	502264-10-0	502264-11-1	502264-12-2	502264-13-3
	502264-14-4	502264-15-5	502264-16-6	502264-17-7	502264-18-8
	502264-19-9	502264-20-2	502264-21-3	502264-22-4	502264-23-5
	502264-24-6	502264-25-7	502264-26-8	502264-27-9	502264-28-0
	502264-29-1	502264-30-4	502264-31-5	502264-32-6	502264-33-7
	502264-34-8	502264-35-9	502264-36-0	502264-37-1	502264-38-2

502264-39-3	502264-40-6	502264-41-7	502264-42-8	502264-43-9
502264-44-0	502264-45-1	502264-46-2	502264-47-3	502264-48-4
502264-49-5	502264-50-8	502264-51-9	502264-52-0	502264-53-1
502264-54-2	502264-55-3	502264-56-4	502264-57-5	502264-58-6
502264-59-7	502264-60-0	502264-61-1	502264-62-2	502264-63-3
502264-64-4	502264-65-5	502264-66-6	502264-67-7	502264-68-8
502264-69-9	502264-70-2	502264-71-3	502264-72-4	502264-73-5
502264-74-6	502264-75-7	502264-76-8	502264-77-9	502264-78-0
502264-79-1	502264-80-4	502264-81-5	502264-82-6	502264-83-7
502264-84-8	502264-85-9	502264-86-0	502264-87-1	502264-88-2
502264-89-3	502264-90-6	502264-91-7	502264-92-8	502264-93-9
502264-94-0	502264-95-1	502264-96-2	502264-97-3	502264-98-4
502264-99-5	502265-00-1	502265-01-2	502265-02-3	502265-03-4
502265-04-5	502265-05-6	502265-06-7	502265-07-8	502265-08-9
502265-09-0	502265-10-3	502265-11-4	502265-12-5	502265-13-6
502265-14-7	502265-15-8	502265-16-9	502265-17-0	502265-18-1
502265-19-2	502265-20-5	502265-21-6	502265-22-7	502265-23-8
502265-24-9	502265-25-0	502265-26-1	502265-27-2	502265-28-3
502265-29-4	502265-30-7	502265-31-8	502265-32-9	502265-33-0
502265-34-1	502265-35-2	502265-36-3	502265-37-4	502265-38-5
502265-39-6	502265-40-9	502265-41-0	502265-42-1	502265-43-2
502265-44-3	502265-45-4	502265-46-5	502265-47-6	502265-48-7
502265-49-8	502265-50-1	502265-51-2	502265-52-3	502265-53-4
502265-54-5	502265-55-6	502265-56-7	502265-57-8	502265-58-9
502265-59-0	502265-60-3	502265-61-4	502265-62-5	502265-63-6
502265-64-7	502265-65-8	502265-66-9	502265-67-0	502265-68-1
502265-69-2	502265-70-5	502265-71-6	502265-72-7	502265-73-8
502265-74-9	502265-75-0	502265-76-1	502265-77-2	502265-78-3
502265-79-4	502265-80-7	502265-81-8	502265-82-9	502265-83-0
502265-84-1	502265-85-2	502265-86-3	502265-87-4	502265-88-5
502265-89-6	502265-90-9	502265-91-0	502265-92-1	502265-93-2
502265-94-3	502265-95-4	502265-96-5	502265-97-6	502265-98-7
502265-99-8	502266-00-4	502266-01-5	502266-02-6	502266-03-7
502266-04-8	502266-05-9	502266-06-0	502266-07-1	502266-08-2
502266-09-3	502266-10-6	502266-11-7	502266-12-8	502266-13-9
502266-14-0	502266-15-1	502266-16-2	502266-17-3	502266-18-4
502266-19-5	502266-20-8	502266-21-9	502266-22-0	502266-23-1
502266-24-2	502266-25-3	502266-26-4	502266-27-5	502266-28-6

RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST

(Analytical study); BIOL (Biological study); USES (Uses)

(downstream amplification primer for biallelic marker; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)

IT	502266-29-7	502266-30-0	502266-31-1	502266-32-2	502266-33-3
	502266-34-4	502266-35-5	502266-36-6	502266-37-7	502266-38-8
	502266-39-9	502266-40-2	502266-41-3	502266-42-4	502266-43-5
	502266-44-6	502266-45-7	502266-46-8	502266-47-9	502266-48-0
	502266-49-1	502266-50-4	502266-51-5	502266-52-6	502266-53-7
	502266-54-8	502266-55-9	502266-56-0	502266-57-1	502266-58-2
	502266-59-3	502266-60-6	502266-61-7	502266-62-8	502266-63-9
	502266-64-0	502266-65-1	502266-66-2	502266-67-3	502266-68-4
	502266-69-5	502266-70-8	502266-71-9	502266-72-0	502266-73-1
	502266-74-2	502266-75-3	502266-76-4	502266-77-5	502266-78-6
	502266-79-7	502266-80-0	502266-81-1	502266-82-2	502266-83-3
	502266-84-4	502266-85-5	502266-86-6	502266-87-7	502266-88-8
	502266-89-9	502266-90-2	502266-91-3	502266-92-4	502266-93-5
	502266-94-6	502266-95-7	502266-96-8	502266-97-9	502266-98-0
	502266-99-1	502267-00-7	502267-01-8	502267-02-9	502267-03-0
	502267-04-1	502267-05-2	502267-06-3	502267-07-4	502267-08-5
	502267-09-6	502267-10-9	502267-11-0	502267-12-1	502267-13-2
	502267-14-3	502267-15-4	502267-16-5	502267-17-6	502267-18-7
	502267-19-8	502267-20-1	502267-21-2	502267-22-3	502267-23-4
	502267-24-5	502267-25-6	502267-26-7	502267-27-8	502267-28-9
	502267-29-0	502267-30-3	502267-31-4	502267-32-5	502267-33-6
	502267-34-7	502267-35-8	502267-36-9	502267-37-0	502267-38-1
	502267-39-2	502267-40-5	502267-41-6	502267-42-7	502267-43-8
	502267-44-9	502267-45-0	502267-46-1	502267-47-2	502267-48-3
	502267-49-4	502267-50-7	502267-51-8	502267-52-9	502267-53-0
	502267-54-1	502267-55-2	502267-56-3	502267-57-4	502267-58-5
	502267-59-6	502267-60-9	502267-61-0	502267-62-1	502267-63-2
	502267-64-3	502267-65-4	502267-66-5	502267-67-6	502267-68-7
	502267-69-8	502267-70-1	502267-71-2	502267-72-3	502267-73-4
	502267-74-5	502267-75-6	502267-76-7	502267-77-8	502267-78-9
	502267-79-0	502267-80-3	502267-81-4	502267-82-5	502267-83-6
	502267-84-7	502267-85-8	502267-86-9	502267-87-0	502267-88-1

502267-89-2	502267-90-5	502267-91-6	502267-92-7	502267-93-8
502267-94-9	502267-95-0	502267-96-1	502267-97-2	502267-98-3
502267-99-4	502268-00-0	502268-01-1	502268-02-2	502268-03-3
502268-04-4	502268-05-5	502268-06-6	502268-07-7	502268-08-8
502268-09-9	502268-10-2	502268-11-3	502268-12-4	502268-13-5
502268-14-6	502268-15-7	502268-16-8	502268-17-9	502268-18-0
502268-19-1	502268-20-4	502268-21-5	502268-22-6	502268-23-7
502268-24-8	502268-25-9	502268-26-0	502268-27-1	502268-28-2
502268-29-3	502268-30-6	502268-31-7	502268-32-8	502268-33-9
502268-34-0	502268-35-1	502268-36-2	502268-37-3	502268-38-4
502268-39-5	502268-40-8	502268-41-9	502268-42-0	502268-43-1
502268-44-2	502268-45-3	502268-46-4	502268-47-5	502268-48-6
502268-49-7	502268-50-0	502268-51-1	502268-52-2	502268-53-3
502268-54-4	502268-55-5	502268-56-6	502268-57-7	502268-58-8
502268-59-9	502268-60-2	502268-61-3	502268-62-4	502268-63-5

RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST

(Analytical study); BIOL (Biological study); USES (Uses)

(downstream amplification primer for biallelic marker; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)

IT	502268-64-6	502268-65-7	502268-66-8	502268-67-9	502268-68-0
	502268-69-1	502268-70-4	502268-71-5	502268-72-6	502268-73-7
	502268-74-8	502268-75-9	502268-76-0	502268-77-1	502268-78-2
	502268-79-3	502268-80-6	502268-81-7	502268-82-8	502268-83-9
	502268-84-0	502268-85-1	502268-86-2	502268-87-3	502268-88-4
	502268-89-5	502268-90-8	502268-91-9	502268-92-0	502268-93-1
	502268-94-2	502268-95-3	502268-96-4	502268-97-5	502268-98-6
	502268-99-7	502269-00-3	502269-01-4	502269-02-5	502269-03-6
	502269-04-7	502269-05-8	502269-06-9	502269-07-0	502269-08-1
	502269-09-2	502269-10-5	502269-11-6	502269-12-7	502269-13-8
	502269-14-9	502269-15-0	502269-16-1	502269-17-2	502269-18-3
	502269-19-4	502269-20-7	502269-21-8	502269-22-9	502269-23-0
	502269-24-1	502269-25-2	502269-26-3	502269-27-4	502269-28-5
	502269-29-6	502269-30-9	502269-31-0	502269-32-1	502269-33-2
	502269-34-3	502269-35-4	502269-36-5	502269-37-6	502269-38-7
	502269-39-8	502269-40-1	502269-41-2	502269-42-3	502269-43-4
	502269-44-5	502269-45-6	502269-46-7	502269-47-8	502269-48-9
	502269-49-0	502269-50-3	502269-51-4	502269-52-5	502269-53-6
	502269-54-7	502269-55-8	502269-56-9	502269-57-0	502269-58-1
	502269-59-2	502269-60-5	502269-61-6	502269-62-7	502269-63-8
	502269-64-9	502269-65-0	502269-66-1	502269-67-2	502269-68-3
	502269-69-4	502269-70-7	502269-71-8	502269-72-9	502269-73-0
	502269-74-1	502269-75-2	502269-76-3	502269-77-4	502269-78-5
	502269-79-6	502269-80-9	502269-81-0	502269-82-1	502269-83-2
	502269-84-3	502269-85-4	502269-86-5	502269-87-6	502269-88-7
	502269-89-8	502269-90-1	502269-91-2	502269-92-3	502269-93-4
	502269-94-5	502269-95-6	502269-96-7	502269-97-8	502269-98-9
	502269-99-0	502270-00-0	502270-01-1	502270-02-2	502270-03-3
	502270-04-4	502270-05-5	502270-06-6	502270-07-7	502270-08-8
	502270-09-9	502270-10-2	502270-11-3	502270-12-4	502270-13-5
	502270-14-6	502270-15-7	502270-16-8	502270-17-9	502270-18-0
	502270-19-1	502270-20-4	502270-21-5	502270-22-6	502270-23-7
	502270-24-8	502270-25-9	502270-26-0	502270-27-1	502270-28-2
	502270-29-3	502270-30-6	502270-31-7	502270-32-8	502270-33-9
	502270-34-0	502270-35-1	502270-36-2	502270-37-3	502270-38-4
	502270-39-5	502270-40-8	502270-41-9	502270-42-0	502270-43-1
	502270-44-2	502270-45-3	502270-46-4	502270-47-5	502270-48-6
	502270-49-7	502270-50-0	502270-51-1	502270-52-2	502270-53-3
	502270-54-4	502270-55-5	502270-56-6	502270-57-7	502270-58-8
	502270-59-9	502270-60-2	502270-61-3	502270-62-4	502270-63-5
	502270-64-6	502270-65-7	502270-66-8	502270-67-9	502270-68-0
	502270-69-1	502270-70-4	502270-71-5	502270-72-6	502270-73-7
	502270-74-8	502270-75-9	502270-76-0	502270-77-1	502270-78-2
	502270-79-3	502270-80-6	502270-81-7	502270-82-8	502270-83-9
	502270-84-0	502270-85-1	502270-86-2	502270-87-3	502270-88-4
	502270-89-5	502270-90-8	502270-91-9	502270-92-0	502270-93-1
	502270-94-2	502270-95-3	502270-96-4	502270-97-5	502270-98-6

RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST

(Analytical study); BIOL (Biological study); USES (Uses)

(downstream amplification primer for biallelic marker; biallelic markers for use in constructing a high d. disequil. map of the human genome and for diagnosis of the risk for developing Alzheimer's disease)

IT	502270-99-7	502271-00-3	502271-01-4	502271-02-5	502271-03-6
	502271-04-7	502271-05-8	502271-06-9	502271-07-0	502271-08-1

502271-09-2	502271-10-5	502271-11-6	502271-12-7	502271-13-8
502271-14-9	502271-15-0	502271-16-1	502271-17-2	502271-18-3
502271-19-4	502271-20-7	502271-21-8	502271-22-9	502271-23-0
502271-24-1	502271-25-2	502271-26-3	502271-27-4	502271-28-5
502271-29-6	502271-30-9	502271-31-0	502271-32-1	502271-33-2
502271-34-3	502271-35-4	502271-36-5	502271-37-6	502271-38-7
502271-39-8	502271-40-1	502271-41-2	502271-42-3	502271-43-4
502271-44-5	502271-45-6	502271-46-7	502271-47-8	502271-48-9
502271-49-0	502271-50-3	502271-51-4	502271-52-5	502271-53-6
502271-54-7	502271-55-8	502271-56-9	502271-57-0	502271-58-1
502271-59-2	502271-60-5	502271-61-6	502271-62-7	502271-63-8
502271-64-9	502271-65-0	502271-66-1	502271-67-2	502271-68-3
502271-69-4	502271-70-7	502271-71-8	502271-72-9	502271-73-0
502271-74-1	502271-75-2	502271-76-3	502271-77-4	502271-78-5
502271-79-6	502271-80-9	502271-81-0	502271-82-1	502271-83-2
502271-84-3	502271-85-4	502271-86-5	502271-87-6	502271-88-7
502271-89-8	502271-90-1	502271-91-2	502271-92-3	502271-93-4
502271-94-5	502271-95-6	502271-96-7	502271-97-8	502271-98-9
502271-99-0	502272-00-6	502272-01-7	502272-02-8	502272-03-9
502272-04-0	502272-05-1	502272-06-2	502272-07-3	502272-08-4
502272-09-5	502272-10-8	502272-11-9	502272-12-0	502272-13-1
502272-14-2	502272-15-3	502272-16-4	502272-17-5	502272-18-6
502272-19-7	502272-20-0	502272-21-1	502272-22-2	502272-23-3
502272-24-4	502272-25-5	502272-26-6	502272-27-7	502272-28-8
502272-29-9	502272-30-2	502272-31-3	502272-32-4	502272-33-5
502272-34-6	502272-35-7	502272-36-8	502272-37-9	502272-38-0
502272-39-1	502272-40-4	502272-41-5	502272-42-6	502272-43-7
502272-44-8	502272-45-9	502272-46-0	502272-47-1	502272-48-2
502272-49-3	502272-50-6	502272-51-7	502272-52-8	502272-53-9
502272-54-0	502272-55-1	502272-56-2	502272-57-3	502272-58-4
502272-59-5	502272-60-8	502272-61-9	502272-62-0	502272-63-1
502272-64-2	502272-65-3	502272-66-4	502272-67-5	502272-68-6
502272-69-7	502272-70-0	502272-71-1	502272-72-2	502272-73-3
502272-74-4	502272-75-5	502272-76-6	502272-77-7	502272-78-8
502272-79-9	502272-80-2	502272-81-3	502272-82-4	502272-83-5
502272-84-6	502272-85-7	502272-86-8	502272-87-9	502272-88-0
502272-89-1	502272-90-4	502272-91-5	502272-92-6	502272-93-7
502272-94-8	502272-95-9	502272-96-0	502272-97-1	502272-98-2
502272-99-3	502273-00-9	502273-01-0	502273-02-1	502273-03-2
502273-04-3	502273-05-4	502273-06-5	502273-07-6	502273-08-7
502273-09-8	502273-10-1	502273-11-2	502273-12-3	502273-13-4
502273-14-5	502273-15-6	502273-16-7	502273-17-8	502273-18-9
502273-19-0	502273-20-3	502273-21-4	502273-22-5	502273-23-6
502273-24-7	502273-25-8	502273-26-9	502273-27-0	502273-28-1
502273-29-2	502273-30-5	502273-31-6	502273-32-7	502273-33-8

RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST
(Analytical study); BIOL (Biological study); USES (Uses)

(downstream amplification primer for biallelic
markers for use in constructing a high d. disequil. map of the human
genome and for diagnosis of the risk for developing Alzheimer's
disease)

IT	502273-34-9	502273-35-0	502273-36-1	502273-37-2	502273-38-3
	502273-39-4	502273-40-7	502273-41-8	502273-42-9	502273-43-0
	502273-44-1	502273-45-2	502273-46-3	502273-47-4	502273-48-5
	502273-49-6	502273-50-9	502273-51-0	502273-52-1	502273-53-2
	502273-54-3	502273-55-4	502273-56-5	502273-57-6	502273-58-7
	502273-59-8	502273-60-1	502273-61-2	502273-62-3	502273-63-4
	502273-64-5	502273-65-6	502273-66-7	502273-67-8	502273-68-9
	502273-69-0	502273-70-3	502273-71-4	502273-72-5	502273-73-6
	502273-74-7	502273-75-8	502273-76-9	502273-77-0	502273-78-1
	502273-79-2	502273-80-5	502273-81-6	502273-82-7	502273-83-8
	502273-84-9	502273-85-0	502273-86-1	502273-87-2	502273-88-3
	502273-89-4	502273-90-7	502273-91-8	502273-92-9	502273-93-0
	502273-94-1	502273-95-2	502273-96-3	502273-97-4	502273-98-5
	502273-99-6	502274-00-2	502274-01-3	502274-02-4	502274-03-5
	502274-04-6	502274-05-7	502274-06-8	502274-07-9	502274-08-0
	502274-09-1	502274-10-4	502274-11-5	502274-12-6	502274-13-7
	502274-14-8	502274-15-9	502274-16-0	502274-17-1	502274-18-2
	502274-19-3	502274-20-6	502274-21-7	502274-22-8	502274-23-9
	502274-24-0	502274-25-1	502274-26-2	502274-27-3	502274-28-4
	502274-29-5	502274-30-8	502274-31-9	502274-32-0	502274-33-1
	502274-34-2	502274-35-3	502274-36-4	502274-37-5	502274-38-6
	502274-39-7	502274-40-0	502274-41-1	502274-42-2	502274-43-3
	502274-44-4	502274-45-5	502274-46-6	502274-47-7	502274-48-8
	502274-49-9	502274-50-2	502274-51-3	502274-52-4	502274-53-5
	502274-54-6	502274-55-7	502274-56-8	502274-57-9	502274-58-0

502274-59-1	502274-60-4	502274-61-5	502274-62-6	502274-63-7
502274-64-8	502274-65-9	502274-66-0	502274-67-1	502274-68-2
502274-69-3	502274-70-6	502274-71-7	502274-72-8	502274-73-9
502274-74-0	502274-75-1	502274-76-2	502274-77-3	502274-78-4
502274-79-5	502274-80-8	502274-81-9	502274-82-0	502274-83-1
502274-84-2	502274-85-3	502274-86-4	502274-87-5	502274-88-6
502274-89-7	502274-90-0	502274-91-1	502274-92-2	502274-93-3
502274-94-4	502274-95-5	502274-96-6	502274-97-7	502274-98-8
502274-99-9	502275-00-5	502275-01-6	502275-02-7	502275-03-8
502275-04-9	502275-05-0	502275-06-1	502275-07-2	502275-08-3
502275-09-4	502275-10-7	502275-11-8	502275-12-9	502275-13-0
502275-14-1	502275-15-2	502275-16-3	502275-17-4	502275-18-5
502275-19-6	502275-20-9	502275-21-0	502275-22-1	502275-23-2
502275-24-3	502275-25-4	502275-26-5	502275-27-6	502275-28-7
502275-29-8	502275-30-1	502275-31-2	502275-32-3	502275-33-4
502275-34-5	502275-35-6	502275-36-7	502275-37-8	502275-38-9
502275-39-0	502275-40-3	502275-41-4	502275-42-5	502275-43-6
502275-44-7	502275-45-8	502275-46-9	502275-47-0	502275-48-1
502275-49-2	502275-50-5	502275-51-6	502275-52-7	502275-53-8
502275-54-9	502275-55-0	502275-56-1	502275-57-2	502275-58-3
502275-59-4	502275-60-7	502275-61-8	502275-62-9	502275-63-0
502275-64-1	502275-65-2	502275-66-3	502275-67-4	502275-68-5

RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST
(Analytical study); BIOL (Biological study); USES (Uses)
(downstream amplification primer for biallelic marker; biallelic
markers for use in constructing a high d. disequil. map of the human
genome and for diagnosis of the risk for developing Alzheimer's
disease)

IT	502275-69-6	502275-70-9	502275-71-0	502275-72-1	502275-73-2
	502275-74-3	502275-75-4	502275-76-5	502275-77-6	502275-78-7
	502275-79-8	502275-80-1	502275-81-2	502275-82-3	502275-83-4
	502275-84-5	502275-85-6	502275-86-7	502275-87-8	502275-88-9
	502275-89-0	502275-90-3	502275-91-4	502275-92-5	502275-93-6
	502275-94-7	502275-96-9	502275-97-0	502275-98-1	502276-00-8
	502276-01-9	502276-02-0	502276-03-1	502276-04-2	502276-05-3
	502276-06-4	502276-07-5	502276-08-6	502276-09-7	502276-10-0
	502276-11-1	502276-12-2	502276-13-3	502276-14-4	502276-15-5
	502276-16-6	502276-17-7	502276-18-8	502276-19-9	502276-20-2
	502276-21-3	502276-22-4	502276-23-5	502276-24-6	502276-25-7
	502276-26-8	502276-27-9	502276-28-0	502276-29-1	502276-30-4
	502276-31-5	502276-32-6	502276-33-7	502276-34-8	502276-35-9
	502276-36-0	502276-37-1	502276-38-2	502276-39-3	502276-40-6
	502276-41-7	502276-42-8	502276-43-9	502276-44-0	502276-45-1
	502276-46-2	502276-47-3	502276-48-4	502276-49-5	502276-50-8
	502276-51-9	502276-52-0	502276-53-1	502276-54-2	502276-55-3
	502276-56-4	502276-57-5	502276-58-6	502276-59-7	502276-60-0
	502276-61-1	502276-62-2	502276-63-3	502276-64-4	502276-65-5
	502276-66-6	502276-67-7	502276-68-8	502276-69-9	502276-70-2
	502276-71-3	502276-72-4	502276-73-5	502276-74-6	502276-75-7
	502276-76-8	502276-77-9	502276-78-0	502276-79-1	502276-80-4
	502276-81-5	502276-82-6	502276-83-7	502276-84-8	502276-85-9
	502276-86-0	502276-87-1	502276-88-2	502276-89-3	502276-90-6
	502276-91-7	502276-92-8	502276-93-9	502276-94-0	502276-95-1
	502276-96-2	502276-97-3	502276-98-4	502276-99-5	502277-00-1
	502277-01-2	502277-02-3	502277-03-4	502277-04-5	502277-05-6
	502277-06-7	502277-07-8	502277-08-9	502277-09-0	502277-10-3
	502277-11-4	502277-12-5	502277-13-6	502277-14-7	502277-15-8
	502277-16-9	502277-17-0	502277-18-1	502277-19-2	502277-20-5
	502277-21-6	502277-22-7	502277-23-8	502277-24-9	

RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST
(Analytical study); BIOL (Biological study); USES (Uses)
(downstream amplification primer for biallelic marker; biallelic
markers for use in constructing a high d. disequil. map of the human
genome and for diagnosis of the risk for developing Alzheimer's
disease)

IT 502270-98-6
RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); ANST
(Analytical study); BIOL (Biological study); USES (Uses)
(downstream amplification primer for biallelic marker; biallelic
markers for use in constructing a high d. disequil. map of the human
genome and for diagnosis of the risk for developing Alzheimer's
disease)

RN 502270-98-6 HCAPLUS

CN DNA, d(T-T-C-A-T-G-T-C-G-A-T-G-A-G-C-A-G-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 13 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:174220 HCAPLUS
 DN 138:216496
 ED Entered STN: 07 Mar 2003
 TI Tissue specific adenoviral vectors
 IN Henderson, Daniel R.; Schuur, Eric R.
 PA Cell Genesys, Inc., USA
 SO U.S. Pat. Appl. Publ., 83 pp., Cont.-in-part of U.S. Ser. No. 33,555,
 abandoned.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K048-00
 ICS C12P021-02; C12N005-06; C12N015-87
 NCL 424093200; 514044000; 435320100; 435325000; 435440000; 435455000
 CC 3-2 (Biochemical Genetics)
 Section cross-reference(s): 1, 63

FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003044383	A1	20030306	US 1998-151376	19980910 <--
	US 6676935	B2	20040113		
	US 5698443	A	19971216	US 1995-495034	19950627 <--
	US 5871726	A	19990216	US 1996-669753	19960626 <--
	US 6197293	B1	20010306	US 1998-33333	19980302 <--
	US 6254862	B1	20010703	US 1998-33428	19980302 <--
	US 6432700	B1	20020813	US 1998-33556	19980302 <--
	US 2002068049	A1	20020606	US 2000-732169	20001206 <--
	US 2002164799	A1	20021107	US 2001-898883	20010702 <--
	US 6585968	B2	20030701		
	US 2003026792	A1	20030206	US 2001-45116	20011023 <--
	US 2003152553	A1	20030814	US 2002-139089	20020502 <--
	US 2003091538	A1	20030515	US 2002-222479	20020816 <--
	US 2004241857	A1	20041202	US 2004-822873	20040413 <--
PRAI	US 1995-495034	A2	19950627	<--	
	US 1996-669753	A2	19960626	<--	
	US 1997-39597P	P	19970303	<--	
	US 1997-39599P	P	19970303	<--	
	US 1997-39762P	P	19970303	<--	
	US 1997-39763P	P	19970303	<--	
	US 1998-33333	A2	19980302	<--	
	US 1998-33428	A2	19980302	<--	
	US 1998-33555	B2	19980302	<--	
	US 1997-54523P	P	19970804	<--	
	US 1998-151376	A1	19980910	<--	
	US 2000-509591	A2	20000602		
	US 2000-593308	B1	20000613		
	US 2000-614495	A1	20000711		
	US 2000-732169	A1	20001206		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003044383	ICM	A61K048-00
	ICS	C12P021-02; C12N005-06; C12N015-87
	NCL	424093200; 514044000; 435320100; 435325000; 435440000; 435455000
US 5698443	ECLA	C12N015/86F <--
US 5871726	ECLA	C12N009/64F2C21M34; C12N015/86F <--
US 6254862	ECLA	C07K014/075; C07K014/47A6; C12N015/63; C12N015/86F8 <--
US 2002164799	ECLA	C07K014/075; C07K014/47A6; C12N015/63; C12N015/86F; C12N015/86F8 <--

AB Host cell specific adenovirus vehicles are provided for transfecting target host cells. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication will be restricted to the target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity for treating neoplasia.

ST genetic engineering gene therapy adenoviral vector tissue targeting

IT Liver

Mammary gland, neoplasm

Prostate gland

(-specific transcriptional response element; tissue-specific adenoviral vectors)

IT Carcinoembryonic antigen

.alpha.-Fetoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (-specific transcriptional response element; tissue-specific adenoviral
 vectors)

IT Genetic element
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (AgeI; tissue-specific adenoviral vectors)

IT Gene, microbial
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (E1A; tissue-specific adenoviral vectors)

IT Gene, microbial
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (E1B; tissue-specific adenoviral vectors)

IT Gene, microbial
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (E4; tissue-specific adenoviral vectors)

IT Genetic element
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TRE (transcriptional response element); tissue-specific adenoviral
 vectors)

IT Intestine, neoplasm
 (colon, -specific transcriptional response element; tissue-specific
 adenoviral vectors)

IT Protein motifs
 (death domain; tissue-specific adenoviral vectors)

IT Gene, microbial
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (early; tissue-specific adenoviral vectors)

IT Gene, microbial
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (late; tissue-specific adenoviral vectors)

IT Adenoviral vectors
 Antitumor agents
 Gene targeting
 Gene therapy
 Genetic engineering
 Human
 Transformation, genetic
 (tissue-specific adenoviral vectors)

IT Enhancer (genetic element)
 Transgene
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (tissue-specific adenoviral vectors)

IT 500747-84-2 500747-85-3 500747-86-4 500747-87-5 500747-88-6
 500747-89-7 500747-90-0 500747-92-2 500747-93-3 500747-94-4
 500747-95-5 500747-96-6 500747-97-7 500747-98-8 500747-99-9
 500748-00-5 500748-01-6 500748-02-7 500748-03-8 500748-04-9
 500748-05-0 500748-06-1 500748-07-2 500748-08-3 500748-09-4
 500748-10-7 500748-11-8 500748-12-9 500748-13-0 500748-14-1
 500748-15-2 500748-16-3 500748-17-4 500748-18-5 500748-19-6
 500748-20-9 500748-21-0 500748-22-1 500748-23-2 500748-24-3
 500748-25-4 500748-26-5 500748-27-6 500748-28-7 500748-29-8
 500748-30-1 500748-31-2 500748-32-3 500748-33-4 500748-34-5
 500748-35-6 500748-36-7 500748-37-8 500748-38-9 500748-39-0
 500748-40-3 500748-41-4 500748-42-5 500748-43-6 500748-44-7
 500748-45-8
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; tissue specific adenoviral vectors)

IT 500747-84-2 500747-85-3 500747-86-4 500747-87-5 500747-88-6
 500747-89-7 500747-90-0 500747-92-2 500747-93-3 500747-94-4
 500747-95-5 500747-96-6 500747-97-7 500747-98-8 500747-99-9
 500748-00-5 500748-01-6 500748-02-7 500748-03-8 500748-04-9
 500748-05-0 500748-06-1 500748-07-2 500748-08-3 500748-09-4
 500748-10-7 500748-11-8 500748-12-9 500748-13-0 500748-14-1
 500748-15-2 500748-16-3 500748-17-4 500748-18-5 500748-19-6
 500748-20-9 500748-21-0 500748-22-1 500748-23-2 500748-24-3
 500748-25-4 500748-26-5 500748-27-6 500748-28-7 500748-29-8
 500748-30-1 500748-31-2 500748-32-3 500748-33-4 500748-34-5
 500748-35-6 500748-36-7 500748-37-8 500748-38-9 500748-39-0
 500748-40-3 500748-41-4 500748-42-5 500748-43-6 500748-44-7
 500748-45-8
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; tissue specific adenoviral vectors)

IT 500747-99-9
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; tissue specific adenoviral vectors)

RN 500747-99-9 HCAPLUS
CN DNA, d(C-A-T-T-A-A-C-C-G-G-T-A-A-G-C-T-T-G-G-G-C-T-G-G-G-G) (9CI) (CA
INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 14 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:118636 HCAPLUS
DN 138:164699
ED Entered STN: 14 Feb 2003
TI Antisense oligonucleotides inhibiting aldehyde dehydrogenase gene
expression for use in treatment of alcohol abuse
IN Garver, Eric; Tu, Guang-chou; Israel, Yedy
PA Thomas Jefferson University, USA
SO U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of U. S. 6,277,981.
CODEN: USXXCO

DT Patent
LA English
IC ICM C07H021-04
ICS A61K048-00
NCL 536023200; 514044000
CC 3-1 (Biochemical Genetics)
Section cross-reference(s): 1, 4
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003032788	A1	20030213	US 2001-932300	20010817 <--
	US 6277981	B1	20010821	US 1998-109663	19980702 <--
PRAI	US 1997-51705P	P	19970703	<--	
	US 1998-109663	A2	19980702	<--	

CLASS
PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

US 2003032788 ICM C07H021-04
ICS A61K048-00
NCL 536023200; 514044000
US 2003032788 ECLA C12N015/11B; C12N015/11B3 <--

AB The invention includes methods for reducing alc. consumption in mammals by inhibiting expression of an aldehyde dehydrogenase (e.g., liver mitochondrial aldehyde dehydrogenase) in cells of the mammal. Expression of the aldehyde dehydrogenase can be inhibited by administering (locally or systemically) an antisense oligonucleotide (e.g., one 12-2000 residues in length) to the mammal, whereby expression of a relatively active allele of an aldehyde dehydrogenase gene can be inhibited. Aldehyde dehydrogenase activity can also be inhibited in the cells of a mammal, for the same purposes, by administering to the cells an expression vector encoding an inactive allele dominant of the aldehyde dehydrogenase. Upon expression, subunits of the protein encoded by the inactive allele can coalesce with one another or with subunits of the cells normally-expressed aldehyde dehydrogenase to lower the level of aldehyde dehydrogenase activity in the cell. The invention also relates to methods for predicting whether an antisense oligonucleotide (ASO) will be efficacious for inhibiting expression of a gene. Thus, oligonucleotides targeting GGGG motifs seem to be particularly effective.

ST antisense oligonucleotide efficacy; alc abuse aldehyde dehydrogenase ALDH2 gene antisense oligonucleotide

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ALDH2-1; antisense oligonucleotides inhibiting aldehyde dehydrogenase gene expression for use in treatment of alc. abuse)

IT Gene, animal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ALDH2-2, enzyme inhibition by expression of; antisense oligonucleotides inhibiting aldehyde dehydrogenase gene expression for use in treatment of alc. abuse)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ALDH2; antisense oligonucleotides inhibiting aldehyde dehydrogenase gene expression for use in treatment of alc. abuse)

IT Alcoholism
Human
(antisense oligonucleotides inhibiting aldehyde dehydrogenase gene expression for use in treatment of alc. abuse)

IT Antisense oligonucleotides
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antisense oligonucleotides inhibiting aldehyde dehydrogenase gene expression for use in treatment of alc. abuse)

IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antisense oligonucleotides inhibiting tumor necrosis factor .alpha. gene expression)

IT Gene
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(expression; method for producing effective antisense oligonucleotides for inhibition of gene expression)

IT Pre-mRNA
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(oligonucleotides complementary to; method for producing effective antisense oligonucleotides for inhibition of gene expression)

IT 9028-86-8, Aldehyde dehydrogenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antisense oligonucleotides inhibiting aldehyde dehydrogenase gene expression for use in treatment of alc. abuse)

IT 497279-53-5 497279-57-9
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antisense oligonucleotides inhibiting aldehyde dehydrogenase gene expression for use in treatment of alc. abuse)

IT 497279-58-0 497279-59-1 497279-60-4 497279-61-5 497279-62-6
497279-63-7 497279-64-8 497279-65-9 497279-66-0 497279-67-1
497279-68-2 497279-69-3 497279-70-6 497279-71-7 497279-72-8
497279-73-9 497279-74-0 497279-75-1 497279-76-2 497279-77-3
497279-78-4 497279-79-5 497279-80-8 497279-81-9 497279-82-0
497279-83-1 497279-84-2 497279-85-3
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antisense oligonucleotides inhibiting tumor necrosis factor .alpha. gene expression)

IT 252769-48-5
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mRNA containing; method for producing effective antisense oligonucleotides for inhibition of gene expression)

IT 497279-54-6 497279-55-7
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence; antisense oligonucleotides inhibiting aldehyde dehydrogenase gene expression for use in treatment of alc. abuse)

IT 497279-56-8
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; antisense oligonucleotides inhibiting aldehyde dehydrogenase gene expression for use in treatment of alc. abuse)

IT 497279-86-4 497279-87-5 497279-88-6 497279-89-7 497279-90-0
497279-91-1 497279-92-2 497279-93-3 497279-94-4
497279-95-5 497279-96-6 497279-97-7 497279-98-8 497279-99-9
497280-00-9 497280-01-0 497280-02-1 497280-03-2 497280-04-3
497280-05-4 497280-06-5 497280-07-6 497280-08-7 497280-09-8
497280-10-1 497280-11-2 497280-12-3 497280-13-4 497280-14-5
497280-15-6 497280-16-7 497280-17-8 497280-18-9 497280-19-0
497280-20-3 497280-21-4 497280-22-5 497280-23-6 497280-24-7
497280-25-8 497280-26-9 497280-27-0 497280-28-1 497280-29-2
497280-30-5 497280-31-6 497280-32-7 497280-33-8 497280-34-9
497280-35-0 497280-36-1 497280-37-2 497280-39-4 497280-40-7
497280-41-8 497280-42-9 497280-43-0
RL: PRP (Properties)
(unclaimed nucleotide sequence; antisense oligonucleotides inhibiting aldehyde dehydrogenase gene expression for use in treatment of alc. abuse)

IT 32956-89-1 70081-31-1 112755-78-9 382590-36-5 382590-37-6
497280-38-3
RL: PRP (Properties)
(unclaimed sequence; antisense oligonucleotides inhibiting aldehyde dehydrogenase gene expression for use in treatment of alc. abuse)

IT 497279-93-3
RL: PRP (Properties)
(unclaimed nucleotide sequence; antisense oligonucleotides inhibiting aldehyde dehydrogenase gene expression for use in treatment of alc. abuse)

RN 497279-93-3 HCAPLUS
CN DNA, d(G-G-C-A-T-C-G-A-C-A-T-T-C-G-G-G-A-T-C-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 15 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:830210 HCAPLUS
DN 137:334622

ED Entered STN: 31 Oct 2002

TI Engineering of cyclodextrin glycosyltransferase deletion mutants for improved production of gamma cyclodextrin

IN Schulz, Georg E.; Parsiegla, Goetz

PA Consortium Fuer Elektrochemische Industrie G.m.b.H., Germany

SO U.S., 24 pp., Cont.-in-part of U.S. Ser. No. 816,317.

CODEN: USXXAM

DT Patent

LA English

IC ICM C12N009-10

ICS C12N001-00; C12P021-04; C08H001-00; C07H021-04

NCL 435193000

CC 7-2 (Enzymes)

Section cross-reference(s): 3, 10

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6472192	B1	20021029	US 1999-430702	19991029 <--
	DE 19615336	A1	19971023	DE 1996-19615336	19960418 <--
PRAI	DE 1996-19615336	A	19960418	<--	
	US 1997-816317	A2	19970313	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6472192	ICM	C12N009-10
	ICS	C12N001-00; C12P021-04; C08H001-00; C07H021-04
	NCL	435193000
US 6472192	ECLA	C12N009/10D1A19 <--
DE 19615336	ECLA	C12N009/10D1A19 <--

AB CGTases, which, when converting starch or starch-like substrates to CD, produce gamma-CD to an increased extent and still exhibit at least 60% of the specific total CGTase activity of the starting CGTase which was used for preparing the enzyme concerned. The amino acid sequences differ from the amino acid sequences of known CGTases by the deletion of from 3 to 8 amino acids from the region from amino acid position 155 up to and including amino acid position 195, where position 1 of the protein sequence is the beginning of the signal peptide of the CGTase and the deletion brings about the increase in the gamma-CGTase activity of the protein. In particular, cyclodextrin glycosyltransferase deletion variants of Bacillus sp.1-1, Bacillus circulans, Bacillus ohbensis, Paenibacillus macerans and Thermanerobacter are described.

ST glycosyltransferase cyclodextrin deletion mutant recombinant; cyclodextrin gamma starch recombinant glycosyltransferase mutant; sequence cyclodextrin glycosyltransferase Bacillus Thermoanerobacter Paenibacillus

IT Bacillus circulans
Bacillus ohbensis
Paenibacillus macerans
Thermoanaerobacter
(CGTase of; engineering of cyclodextrin glycosyltransferase deletion mutants for improved production of gamma cyclodextrin)

IT Microorganism
(CGTase; engineering of cyclodextrin glycosyltransferase deletion mutants for improved production of gamma cyclodextrin)

IT Peptides, biological studies
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(cyclodextrin glycosyltransferase; engineering of cyclodextrin glycosyltransferase deletion mutants for improved production of gamma cyclodextrin)

IT Mutation
(deletion; engineering of cyclodextrin glycosyltransferase deletion mutants for improved production of gamma cyclodextrin)

IT Molecular cloning
(engineering of cyclodextrin glycosyltransferase deletion mutants for improved production of gamma cyclodextrin)

IT Gene, microbial
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(for cyclodextrin glycosyltransferase; engineering of cyclodextrin glycosyltransferase deletion mutants for improved production of gamma cyclodextrin)

IT Protein engineering
(of cyclodextrin glycosyltransferase deletion variants; engineering of cyclodextrin glycosyltransferase deletion mutants for improved production of gamma cyclodextrin)

IT Protein sequences
(of cyclodextrin glycosyltransferase variants of Bacillus, Thermoanaerobacter and Paenibacillus macerans; engineering of cyclodextrin glycosyltransferase deletion mutants for improved production of gamma cyclodextrin)

IT Mutagenesis
(of cyclodextrin glycosyltransferase; engineering of cyclodextrin glycosyltransferase deletion mutants for improved production of gamma cyclodextrin)

IT Bacillus (bacterium genus)
(sp. 1-1, CGTase of; engineering of cyclodextrin glycosyltransferase deletion mutants for improved production of gamma cyclodextrin)

IT 474035-93-3P 474035-94-4P 474035-95-5P 474035-96-6P 474035-97-7P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); CAT (Catalyst use); PRP (Properties); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; engineering of cyclodextrin glycosyltransferase deletion mutants for improved production of gamma cyclodextrin)

IT 9005-25-8, Starch, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(as substrate for cyclodextrin glycosyltransferase; engineering of cyclodextrin glycosyltransferase deletion mutants for improved production of gamma cyclodextrin)

IT 7585-39-9P, .beta.-Cyclodextrin 10016-20-3P, .alpha.-Cyclodextrin 12619-70-4P, Cyclodextrin 17465-86-0P, .gamma.-Cyclodextrin
RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)
(engineering of cyclodextrin glycosyltransferase deletion mutants for improved production of gamma cyclodextrin)

IT 9030-09-SDP, Cyclodextrin glycosyltransferase, deletion mutants
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); CAT (Catalyst use); PRP (Properties); BIOL (Biological study); PREP (Preparation); USES (Uses)
(engineering of cyclodextrin glycosyltransferase deletion mutants for improved production of gamma cyclodextrin)

IT 473999-14-3 473999-15-4 473999-16-5 473999-17-6 473999-19-8
473999-21-2 473999-23-4 473999-25-6 473999-26-7 473999-28-9
473999-30-3 473999-42-7
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(peptide sequence; engineering of cyclodextrin glycosyltransferase deletion mutants for improved production of gamma cyclodextrin)

IT 474038-50-1 474038-51-2 474038-52-3 474038-53-4 474038-54-5
474038-55-6 474038-56-7 474038-57-8 474038-58-9
474038-59-0 474038-60-3 474038-61-4
RL: PRP (Properties)
(unclaimed nucleotide sequence; engineering of cyclodextrin glycosyltransferase deletion mutants for improved production of gamma cyclodextrin)

IT 473999-32-5 473999-34-7 473999-36-9 473999-37-0 473999-39-2
473999-40-5 473999-44-9 473999-46-1 473999-48-3
RL: PRP (Properties)
(unclaimed sequence; engineering of cyclodextrin glycosyltransferase deletion mutants for improved production of gamma cyclodextrin)

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; EP 0291067 1988 HCAPLUS
- (2) Anon; DE 4009822 1991 HCAPLUS
- (3) Anon; WO 9114770 1991 HCAPLUS
- (4) Anon; EP 0481513 1992
- (5) Anon; EP 0614571 1994
- (6) Anon; EP 0630567 1994
- (7) Anon; DE 4324650 1995 HCAPLUS
- (8) Anon; WO 9633267 1996 HCAPLUS
- (9) Anon; Promega 1992-93 Catalog 150, "Revolutions in Science", Molecular Biology/Reagent System P138
- (10) Ausubel; Current Protocols In Molecular Biology P2.4.1
- (11) Ausubel; Current Protocols in Molecular Biology P8.1.1
- (12) Beesley; US 4808232 A 1989 HCAPLUS
- (13) Cami; US 5376537 A 1994 HCAPLUS
- (14) Fujita; J Ferm Bioeng 1990, V70(3), P150 HCAPLUS
- (15) Horikoshi; 1987 HCAPLUS

(16) Leung; Technique 1989, V1(1), P11
 (17) Maniatis, T; Molecular Cloning "Large Scale Isolation of Plasmid DNA" P86
 (18) Michael, S; Ann Rev Genet 1985, V19, P423
 (19) Miller, J; Experiments in Molecular Genetics P121
 (20) Nakamaye; Nucl Acids Res 1986, V14, P9679 HCAPLUS
 (21) Nakamura; Biochemistry 1994, V33(33), P9929 HCAPLUS
 (22) Nitschke; Appl Microbiol Biotechnol 1990, V33, P542 HCAPLUS
 (23) Penninga; Biochemistry 1995, V34(10), P3368 HCAPLUS
 (24) Sanger; Proc Natl Acad Sci USA P5463
 (25) Schmid; US 4822874 A 1989 HCAPLUS
 (26) Schmid; US 5409824 A 1995 HCAPLUS
 (27) Schulz; US 5474917 A 1995 HCAPLUS
 (28) Tomita; Journal of Fermentation and Bioengineering 1990, V70(3), P190 HCAPLUS

IT 474038-56-7 474038-58-9
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; engineering of cyclodextrin
 glycosyltransferase deletion mutants for improved production of gamma
 cyclodextrin)
 RN 474038-56-7 HCAPLUS
 CN DNA, d(C-A-T-T-C-A-T-C-A-C-C-G-G-C-A-G-T-T-G-A-A-A-T-G-G-G-G-C-G) (9CI)
 (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 474038-58-9 HCAPLUS
 CN DNA, d(A-A-T-C-A-T-T-C-A-T-C-A-C-C-G-G-T-T-G-A-A-A-T-G-G-G-G-C-G) (9CI)
 (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 16 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:669668 HCAPLUS
 DN 137:210920
 ED Entered STN: 05 Sep 2002
 TI Antisense oligonucleotides inhibiting human telomerase reverse
 transcriptase in diagnosis and treatment of cancer
 IN Cech, Thomas R.; Lingner, Joachim; Nakamura, Toru; Chapman, Karen B.;
 Morin, Gregg B.; Harley, Calvin B.; Andrews, William H.
 PA Geron Corporation, USA
 SO U.S., 34 pp., Cont.-in-part of U.S. 6,166,178.
 CODEN: USXXAM
 DT Patent
 LA English
 IC A01N043-04; A61K031-70; C02H021-04
 NCL 514044000
 CC 1-6 (Pharmacology)
 Section cross-reference(s): 3, 7, 14, 63

FAN.CNT 15

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6444650	B1	20020903	US 1998-52919	19980331 <--
US 6093809	A	20000725	US 1997-851843	19970506 <--
US 6261836	B1	20010717	US 1997-854050	19970509 <--
US 6475789	B1	20021105	US 1997-912951	19970814 <--
WO 9814592	A2	19980409	WO 1997-US17618	19971001 <--
WO 9814592	A3	19990401		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, US, US, US, US, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
WO 9814593	A2	19980409	WO 1997-US17885	19971001 <--
WO 9814593	A3	19990218		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 6166178	A	20001226	US 1997-974549	19971119 <--

WO 9950279 A1 19991007 WO 1999-US7160 19990331 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9934612 A1 19991018 AU 1999-34612 19990331 <--
AU 763956 B2 20030807 AU 2001-47992 20010523 <--
US 2002173476 A1 20021121 US 2001-953052 20010914 <--
US 6627619 B2 20030930
PRAI US 1996-724643 B2 19961001 <--
US 1997-844419 B2 19970418 <--
US 1997-846017 B2 19970425 <--
US 1997-851843 A2 19970506 <--
US 1997-854050 A2 19970509 <--
US 1997-911312 B2 19970814 <--
US 1997-912951 A2 19970814 <--
US 1997-915503 A2 19970814 <--
WO 1997-US17618 W 19971001 <--
WO 1997-US17885 W 19971001 <--
US 1997-974549 A2 19971119 <--
US 1997-974584 A2 19971119 <--
US 1997-845050 A2 19970509 <--
AU 1997-48073 A 19971001 <--
US 1998-52919 A 19980331 <--
WO 1999-US7160 W 19990331 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6444650	IC	A01N043-04IC A61K031-70IC C02H021-04
	NCL	514044000
US 6444650	ECLA	C12N009/12B7; C12N009/12B7B49; C12N015/11B5 <--
US 6093809	ECLA	C12N009/12B7; C12N009/12B7B49; C12N015/11B5 <--
US 6261836	ECLA	C12N009/12B7; C12N009/12B7B49; C12N015/11B5 <--
US 6475789	ECLA	C12N009/12B7; C12N009/12B7B49; C12N015/11B5 <--
WO 9814592	ECLA	C12N009/12B7B49; C12N009/12B7; C12N015/11B5 <--
WO 9814593	ECLA	C12N009/12B7B49; C12N009/12B7; C12N015/11B5 <--
US 6166178	ECLA	C12N009/12B7B49 <--
WO 9950279	ECLA	C12N015/11B5 <--
AB		The present invention provides TRT antisense oligonucleotides, methods of detecting TRT, methods of diagnosing telomerase-related conditions, methods of diagnosing and providing a prognosis for cancer, and methods of treating telomerase-related conditions, including cancer.
ST		telomerase reverse transcriptase antisense oligonucleotide diagnosis treatment cancer; human telomerase reverse transcriptase cDNA sequence
IT		Antitumor agents Human Neoplasm Nucleic acid hybridization (antisense oligonucleotides inhibiting human telomerase reverse transcriptase in diagnosis and treatment of cancer)
IT		DNA RNA RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study) (antisense oligonucleotides inhibiting human telomerase reverse transcriptase in diagnosis and treatment of cancer)
IT		Antisense oligonucleotides RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antisense oligonucleotides inhibiting human telomerase reverse transcriptase in diagnosis and treatment of cancer)
IT		Phosphorothioate oligonucleotides RL: BSU (Biological study, unclassified); BIOL (Biological study) (antisense oligonucleotides; antisense oligonucleotides inhibiting human telomerase reverse transcriptase in diagnosis and treatment of cancer)
IT		Diagnosis (cancer; antisense oligonucleotides inhibiting human telomerase reverse transcriptase in diagnosis and treatment of cancer)
IT		cDNA sequences (for telomerase reverse transcriptase of human; antisense

oligonucleotides inhibiting human telomerase reverse transcriptase in diagnosis and treatment of cancer)

- IT cDNA
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (for telomerase reverse transcriptase; antisense oligonucleotides inhibiting human telomerase reverse transcriptase in diagnosis and treatment of cancer)
- IT DNA sequences
(of antisense oligonucleotides; antisense oligonucleotides inhibiting human telomerase reverse transcriptase in diagnosis and treatment of cancer)
- IT Prognosis
(of cancer, TRT antisense DNA in; antisense oligonucleotides inhibiting human telomerase reverse transcriptase in diagnosis and treatment of cancer)
- IT Protein sequences
(of telomerase reverse transcriptase of human; antisense oligonucleotides inhibiting human telomerase reverse transcriptase in diagnosis and treatment of cancer)
- IT mRNA
RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (telomerase reverse transcriptase; antisense oligonucleotides inhibiting human telomerase reverse transcriptase in diagnosis and treatment of cancer)
- IT 454491-87-3
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; antisense oligonucleotides inhibiting human telomerase reverse transcriptase in diagnosis and treatment of cancer)
- IT 454491-89-5 454491-90-8 454491-91-9 454491-92-0 454491-93-1
454491-94-2 454491-95-3 454491-96-4 454491-97-5 454491-98-6
454491-99-7 454492-00-3 454492-01-4 454492-02-5 454492-03-6
454492-04-7 454492-05-8 454492-06-9 454492-07-0 454492-08-1
454492-09-2 454492-10-5 454492-11-6 454492-12-7 454492-13-8
454492-14-9 454492-15-0 454492-16-1 454492-17-2 454492-18-3
454492-19-4 454492-20-7 454492-21-8 454492-22-9 454492-23-0
454492-24-1 454492-25-2 454492-26-3 454492-27-4 454492-28-5
454492-29-6 454492-30-9 454492-31-0 454492-32-1 454492-33-2
454492-34-3 454492-35-4 454492-36-5 454492-37-6
454492-38-7 454492-39-8 454492-40-1 454492-41-2 454492-42-3
454492-43-4 454492-44-5 454492-45-6 454492-46-7 454492-47-8
454492-48-9 454492-49-0 454492-50-3 454492-51-4 454492-52-5
454492-53-6 454492-54-7 454492-55-8 454492-56-9 454492-57-0
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antisense oligonucleotide sequence; antisense oligonucleotides inhibiting human telomerase reverse transcriptase in diagnosis and treatment of cancer)
- IT 120178-12-3, Telomerase reverse transcriptase
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antisense oligonucleotides inhibiting human telomerase reverse transcriptase in diagnosis and treatment of cancer)
- IT 454491-88-4
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nucleotide sequence; antisense oligonucleotides inhibiting human telomerase reverse transcriptase in diagnosis and treatment of cancer)
- IT 454491-88-4
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nucleotide sequence; antisense oligonucleotides inhibiting human telomerase reverse transcriptase in diagnosis and treatment of cancer)

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; WO 9738013 1997 HCAPLUS
- (2) Collins, K; Cell 1995, V81, P677 HCAPLUS
- (3) Greider, C; Current Biology 1998, V8(5), PR178 HCAPLUS
- (4) Gura; Science 1995, V270, P575 HCAPLUS
- (5) Harrington, L; Science 1997, V275, P973 HCAPLUS
- (6) Harrington, L; The Journal of Biological Chemistry 1995, V270(15), P8893 HCAPLUS
- (7) Kilian, A; Human Molecular Genetics 1997, V6(12), P2011 HCAPLUS
- (8) Langford, L; Human Pathology 1997, V28(4), P416 HCAPLUS

Search done by Noble Jarrell

(9) Meyerson, M; Cell 1970, V90, P785
 (10) Morin, G; European Journal of Cancer 1997, V33(5), P750 HCAPLUS
 (11) Nakamura, T; Science 1997, V277, P955 HCAPLUS
 (12) Shay; US 5639613 A 1997
 (13) Villeponteau; US 5583016 A 1996 HCAPLUS
 IT 454492-34-3
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antisense oligonucleotide sequence; antisense oligonucleotides inhibiting human telomerase reverse transcriptase in diagnosis and treatment of cancer)
 RN 454492-34-3 HCAPLUS
 CN DNA, d(G-C-A-C-A-G-A-C-A-C-C-G-G-C-T-G-C-T-G-G-G-T-G-A-C-C-G-C-A) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 17 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:257978 HCAPLUS
 DN 134:261854
 ED Entered STN: 12 Apr 2001
 TI Coupled amplification and sequencing method for detection of disease causing microorganism
 IN Leushner, James; Hui, May; Dunn, James M.; Lacroix, Jean-Michel
 PA Visible Genetics Inc., Can.
 SO U.S., 62 pp., Cont.-in-part of U.S. Ser. No. 9,483.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM C12Q001-68
 ICS C07K013-00
 NCL 435006000
 CC 3-1 (Biochemical Genetics)
 Section cross-reference(s): 10
 FAN.CNT 29

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6214555	B1	20010410	US 1999-311260	19990513 <--
	US 5789168	A	19980804	US 1996-640672	19960501 <--
	US 5830657	A	19981103	US 1996-684498	19960719 <--
	CA 2240831	AA	19970717	CA 1997-2240831	19970106 <--
	WO 9724974	A2	19970717	WO 1997-CA6	19970106 <--
	WO 9724974	A3	19971127		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF			
	AU 9711875	A1	19970801	AU 1997-11875	19970106 <--
	EP 871779	A2	19981021	EP 1997-900057	19970106 <--
	R:	CH, DE, FR, GB, LI, SE			
	US 5888736	A	19990330	US 1997-807138	19970227 <--
	US 6083699	A	20000704	US 1998-9483	19980120 <--
	US 2003082535	A1	20030501	US 2001-802110	20010307 <--
PRAI	US 1996-640672	A2	19960501		<--
	US 1996-684498	A2	19960719		<--
	US 1997-807138	A2	19970227		<--
	US 1998-9483	A2	19980120		<--
	US 1995-577858	A2	19951222		<--
	US 1996-583289	A	19960105		<--
	US 1996-699628	A	19960819		<--
	WO 1997-CA6	W	19970106		<--
	WO 1997-US7134	A2	19970429		<--
	US 1999-311260	A1	19990513		<--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6214555	ICM	C12Q001-68
	ICS	C07K013-00
	NCL	435006000
US 6214555	ECLA	B01L007/00D; C12Q001/68B14; C12Q001/68E; C12Q001/68M4; C12Q001/68M10B; C12Q001/70B2B <--
US 5789168	ECLA	B01L007/00D; C12Q001/68B14; C12Q001/68M4; C12Q001/68M10B; C12Q001/70B2B <--

US 5830657 ECLA B01L007/00D; C12Q001/68B14; C12Q001/68M4;
C12Q001/68M10B; C12Q001/70B2B <--
WO 9724974 ECLA C07K014/47A1A; C07K016/18; C12Q001/68M6B <--
US 5888736 ECLA B01L007/00D; C12Q001/68B14; C12Q001/68D2G; C12Q001/68E;
C12Q001/68M4; C12Q001/68M10B; C12Q001/70B2B <--
US 6083699 ECLA C12Q001/68E <--
US 2003082535 ECLA B01L007/00D; C12Q001/68B14; C12Q001/68E; C12Q001/68M4;
C12Q001/68M10B; C12Q001/70B2B <--

AB Evaluation of a sample for the presence and qual. nature of a
microorganism can be performed in a single vessel by combining a natural
abundance DNA sample with a sequencing mixture containing a primer pair, a
thermally stable polymerase such as ThermoSequenaseTM which incorporates
dideoxynucleotides into an extending nucleic acid polymer at a rate which
is no less than about 0.4 times the rate of incorporation of
deoxynucleotides, nucleotide triphosphate feedstocks, and a chain
terminating nucleotide triphosphate. The mixture is processed through
multiple thermal cycles for annealing, extension and denaturation to
produce a product mixture which is analyzed by electrophoresis. The present
invention also provides a composition comprising a mixture of four
deoxynucleotide triphosphates and at least one dideoxynucleotide
triphosphate corresponding to one of the four deoxynucleotide
triphosphates in a mole ratio from 1:50 to 1:500. Also provided is a kit
for detection of a target microorganism comprising, in packaged
combination, the above composition, thermostable polymerase enzyme and a pair
of primers.

ST PCR microorganism diagnosis kit primer sequence

IT Nucleotides, biological studies
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified);
ANST (Analytical study); BIOL (Biological study); USES (Uses)
(2',3'-dideoxyribo-, triphosphates, in the kit; coupled amplification
and sequencing method for detection of disease causing microorganism)

IT Primers (nucleic acid)
RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic use);
ANST (Analytical study); BIOL (Biological study); USES (Uses)
(DNA, fluorescent labeled; coupled amplification and sequencing method
for detection of disease causing microorganism)

IT Chlamydia trachomatis
Human immunodeficiency virus 1
Human papillomavirus
Test kits
(coupled amplification and sequencing method for detection of disease
causing microorganism)

IT Nucleic acid amplification (method)
(coupled amplification and sequencing; coupled amplification and
sequencing method for detection of disease causing microorganism)

IT Human immunodeficiency virus
(detection; coupled amplification and sequencing method for detection
of disease causing microorganism)

IT Deoxyribonucleoside triphosphates
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified);
ANST (Analytical study); BIOL (Biological study); USES (Uses)
(in the kit; coupled amplification and sequencing method for detection
of disease causing microorganism)

IT Diagnosis
(mol., of disease causing microorganism; coupled amplification and
sequencing method for detection of disease causing microorganism)

IT DNA
RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic use);
ANST (Analytical study); BIOL (Biological study); USES (Uses)
(primer, fluorescent labeled; coupled amplification and sequencing
method for detection of disease causing microorganism)

IT 198087-52-4 199301-62-7 199301-63-8 199301-64-9 199301-65-0
199301-66-1 199301-67-2 199301-68-3 199301-69-4 199301-70-7
199301-71-8 199301-72-9 199301-73-0 199301-74-1 199301-75-2
199301-76-3 199301-77-4
RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic use);
ANST (Analytical study); BIOL (Biological study); USES (Uses)
(primer for detection of Chlamydia trachomatis; coupled amplification
and sequencing method for detection of disease causing microorganism)

IT 138360-16-4 199301-78-5 199301-79-6
RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic use);
ANST (Analytical study); BIOL (Biological study); USES (Uses)
(primer for detection of human immunodeficiency virus; coupled
amplification and sequencing method for detection of disease causing
microorganism)

IT 182031-33-0, GenBank I22779 199301-81-0

RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic use);
ANST (Analytical study); BIOL (Biological study); USES (Uses)
(primer for detection of human papillomavirus; coupled amplification
and sequencing method for detection of disease causing microorganism)

IT 9012-90-2, DNA polymerase

RL: ARG (Analytical reagent use); BAC (Biological activity or effector,
except adverse); BSU (Biological study, unclassified); ANST (Analytical
study); BIOL (Biological study); USES (Uses)

(thermostable; coupled amplification and sequencing method for
detection of disease causing microorganism)

IT	124630-87-1	125052-04-2	125052-05-3	125052-15-5	126699-02-3
	126729-13-3	133923-94-1	135116-05-1	135116-08-4	136360-90-2
	136361-16-5	136857-17-5	137367-78-3	137367-94-3	138159-24-7
	139736-42-8	139736-43-9	139916-37-3	139947-95-8	140207-42-7
	140229-58-9	140229-59-0	141442-82-2	141615-04-5	142443-33-2
	143475-75-6	143475-76-7	143475-84-7	143492-81-3	144199-94-0
	144199-95-1	146318-26-5	146416-09-3	146416-10-6	146592-72-5
	146592-73-6	147178-83-4	147479-41-2	147479-83-2	147479-84-3
	147483-18-9	147483-19-0	147550-32-1	150068-37-4	150068-38-5
	150068-52-3	151639-83-7	152416-90-5	152790-42-6	155001-42-6
	156622-49-0	157011-69-3	157011-70-6	158913-66-7	158913-68-9
	158913-70-3	159205-88-6	159995-72-9	160967-29-3	160967-30-6
	165527-11-7	165726-24-9	167977-75-5	173455-78-2	173455-79-3
	180395-03-3	183973-19-5	184111-91-9	185262-80-0	185262-81-1
	185262-86-6	185262-87-7	185404-60-8	194945-85-2	194945-86-3
	199619-91-5	202758-37-0	204020-93-9	204784-88-3	
	204784-89-4	206011-15-6	207928-12-9	214772-97-1	216969-79-8
	234436-47-6	260959-89-5	277762-77-3	282122-37-6	282122-38-7
	321930-28-3	331483-02-4	332001-71-5	332001-72-6	332001-73-7
	332001-74-8	332001-75-9	332001-76-0	332001-77-1	332001-78-2
	332001-79-3	332001-80-6	332001-81-7	332001-82-8	332001-83-9
	332001-84-0	332001-85-1	332001-86-2	332001-87-3	332001-88-4
	332001-89-5	332001-90-8	332001-91-9	332001-92-0	332001-93-1
	332001-94-2	332001-95-3	332001-96-4	332001-97-5	332001-98-6
	332001-99-7	332002-00-3	332002-01-4	332002-02-5	332002-03-6
	332002-04-7	332002-05-8	332002-06-9	332002-07-0	332002-08-1
	332002-09-2	332002-10-5	332002-11-6	332002-12-7	332002-13-8
	332002-14-9	332002-15-0	332002-16-1	332002-17-2	332002-18-3
	332002-19-4	332002-20-7	332002-21-8	332002-22-9	332002-23-0
	332002-24-1	332002-25-2	332002-26-3	332002-27-4	332002-28-5
	332002-29-6	332002-30-9	332002-31-0	332002-32-1	332002-33-2
	332002-34-3	332002-35-4	332002-36-5	332002-37-6	332002-38-7
	332002-39-8	332002-40-1	332002-41-2	332003-24-4	

RL: PRP (Properties)

(unclaimed nucleotide sequence; coupled amplification and sequencing
method for detection of disease causing microorganism)

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; EP 0265293 1988 HCAPLUS
- (2) Anon; WO 8907149 1989 HCAPLUS
- (3) Anon; EP 0386859 1990 HCAPLUS
- (4) Anon; WO 9302212 1993 HCAPLUS
- (5) Anon; WO 9308305 1993 HCAPLUS
- (6) Anon; WO 9426894 1994 HCAPLUS
- (7) Anon; EP 0655506 1995 HCAPLUS
- (8) Anon; WO 9601909 1996 HCAPLUS
- (9) Carothers; Bio-Techniques V7, P494 HCAPLUS
- (10) Creasey; Biotechniques 1991, V11, P102 HCAPLUS
- (11) Deng; J Microbiol Methods 1993, V17, P103 HCAPLUS
- (12) Gelfand; US 4889818 1989 HCAPLUS
- (13) Gelfand; US 5079352 1992 HCAPLUS
- (14) Gelfand; US 5352600 1994 HCAPLUS
- (15) Gyllenstein; Proc Nat'l Acad Sci USA 1988, V85, P7652
- (16) Kambara; Biotechnology 1991, V9, P648 HCAPLUS
- (17) Kretz; PCR Methods and Applications 1994, V3, PS107 HCAPLUS
- (18) Middendorf; US 4729947 1988 HCAPLUS
- (19) Miller; General Atomics Pre-Print 1991
- (20) Mullis; US 4683195 1987 HCAPLUS
- (21) Mullis; US 4965188 1990 HCAPLUS
- (22) Mullis; Meth Enzymol 1987, V155, P335 HCAPLUS
- (23) Murakawa; DNA 1988, V7, P287 HCAPLUS
- (24) Murray, V; Nucl Acids Res 1989, V17, P8889 HCAPLUS
- (25) Nuovo, G; PCR Primer: A Laboratory Manual 1995, P235
- (26) Olesen; Biotechniques 1993, V15, P480 HCAPLUS
- (27) Rao, V; Anal Biochem 1994, V216, P1 HCAPLUS
- (28) Reeve; Nature 1995, V376, P796 HCAPLUS

(29) Roemer; Poster presented at 9th International Genome Sequencing and Analysis Conference 1997
 (30) Ruano; US 5427911 1995 HCAPLUS
 (31) Ruano; Nucl Acids Res 1991, V19, P6877 HCAPLUS
 (32) Ruano; Proc Nat'l Acad Sci (USA) 1991, V88, P2815 HCAPLUS
 (33) Saiki; US 4683194 1987 HCAPLUS
 (34) Sanger; Proc Nat'l Acad Sci 1977, V74, P5463 HCAPLUS
 (35) Sarkar; Genomics 1992, V13, P441 HCAPLUS
 (36) Tabor; US 4795699 1989 HCAPLUS
 (37) Tabor; Proc Nat'l Acad Sci USA 1995, V92, P6339 HCAPLUS
 (38) Wiemann; Anal Biochem 1995, V224, P117 HCAPLUS
 (39) Wiemann; Anal Biochem 1995, V224, P117 HCAPLUS
 (40) Wiemann; Anal Biochem 1996, V234, P166 HCAPLUS
 IT 199619-91-5
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; coupled amplification and sequencing method for detection of disease causing microorganism)
 RN 199619-91-5 HCAPLUS
 CN DNA, d(T-A-C-A-T-C-G-C-G-T-C-A-T-C-T-G-C-G-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 18 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:163434 HCAPLUS
 DN 134:203399
 ED Entered STN: 08 Mar 2001
 TI Nucleic acid amplification using modular branched primers
 IN Ulanovsky, Levy; Raja, Mugasimangalam C.
 PA The University of Chicago, USA
 SO U.S., 33 pp., Cont.-in-part of U.S. 5,627,037.
 CODEN: USXXAM

DT Patent
 LA English
 IC ICM C12P019-34
 ICS C12Q001-68; C07H021-02; C07H021-04
 NCL 435091200

CC 3-1 (Biochemical Genetics)

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6197556	B1	20010306	US 1997-852001	19970506 <--
	US 5627032	A	19970506	US 1995-384699	19950206 <--
	US 6235889	B1	20010522	US 1999-264466	19990308 <--
PRAI	US 1991-810898	B1	19911220	<--	
	US 1995-384699	A2	19950206	<--	
	IL 1990-98775	A	19901224	<--	
	US 1997-852001	A1	19970506	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6197556	ICM	C12P019-34
	ICS	C12Q001-68; C07H021-02; C07H021-04
	NCL	435091200
US 6197556	ECLA	C12Q001/68D4+525/155 <--
US 6235889	ECLA	C12Q001/68D2E; C12Q001/68D4+525/155; C12Q001/68E <--

AB Methods and compns. which expand the options for making primers for use in amplifying nucleic acid segments are disclosed. The invention eliminates the step of custom synthesis of primers for Polymerase Chain Reactions (PCR). Instead of being custom-synthesized, a primer is replaced by a combination of two or more oligonucleotide modules selected from a pre-synthesized library. A modular combination of just two oligonucleotides can mimic the performance of a conventional, custom-made primer by matching the sequence of the priming site in the template. Each oligonucleotide has a segment (I) that matches one of the stretches within the priming site as well as another segment (II) which is complementary to a segment of another oligonucleotide. A primer may be formed by two oligonucleotides with complementary II segments, while the I segments of the two oligonucleotides combine to form the target-complementary primer. The resulting branched primers comprise a double-stranded stem portion and a single-stranded, target complementary portion. The branched primer forms a three-way junction when annealed to the target. Two branched primers, or a branched and a traditional primer, may be used for the amplification.

ST PCR modular branched primer
 IT Nucleic acid amplification (method)
 PCR (polymerase chain reaction)

(nucleic acid amplification using modular branched primers)
 IT Primers (nucleic acid)
 RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
 (nucleic acid amplification using modular branched primers)
 IT 328603-22-1 328603-23-2 328603-24-3 328603-25-4 328603-26-5
 328603-27-6 328603-28-7 328603-29-8 328603-30-1 328603-31-2
 328603-32-3 328603-33-4 328603-34-5 328603-35-6 328603-36-7
 328603-37-8 328603-38-9 328603-39-0 328603-40-3 328603-41-4
 328603-42-5 328603-43-6 328603-44-7 328603-45-8 328603-46-9
 328603-47-0 328603-48-1 328603-49-2 328603-50-5
 328603-51-6 328603-52-7 328603-53-8 328603-54-9 328603-55-0
 328603-56-1 328603-57-2 328603-58-3 328603-59-4
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; nucleic acid amplification using modular branched primers)

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Azhikina; Proc Natl Acad Sci USA 1993, V90, P11460 HCAPLUS
- (2) Beskin; Nucleic Acids Research 1995, V23(15), P2881 HCAPLUS
- (3) Blocker; US 5114839 1992 HCAPLUS
- (4) Blocker; Cabios 1994, V10(2), P193 MEDLINE
- (5) Egholm; Nature 1993, V365, P566 HCAPLUS
- (6) Guo; Nature Biotechnology 1997, V15, P331 HCAPLUS
- (7) Kieleczawa; Science 1992, V258, P1787 HCAPLUS
- (8) Kotler; BioTechniques 1994, V17(3), P554 HCAPLUS
- (9) Kotler; Proc Natl Acad Sci USA 1993, V90, P4241 HCAPLUS
- (10) Leontis; Nucleic Acids Research 1991, V19(4), P759 HCAPLUS
- (11) Lerner; US 5573905 1996 HCAPLUS
- (12) McCombie; BioTechniques 1994, V17(3), P574 HCAPLUS
- (13) Mullis; US 4965188 1990 HCAPLUS
- (14) Nielsen; Science 1991, V254, P1497 HCAPLUS
- (15) Ohtsuka; Journal of Biological Chemistry 1985, V260(5), P2605 HCAPLUS
- (16) Ohtsuka; The Journal of Biological Chemistry 1985, V260(5), P2605 HCAPLUS
- (17) Raja; Nucleic Acids Research 1997, V25(4), P800 HCAPLUS
- (18) Sorge; US 5663062 1997 HCAPLUS
- (19) Studier, E; Proc Natl Acad Sci USA 1989, V86, P6917
- (20) Szybalski, W; Gene 1990, V90, P177 HCAPLUS
- (21) Ulanovsky; US 5627032 1997 HCAPLUS
- (22) Ulanovsky; Nature 1987, V326, P720 HCAPLUS
- (23) Ulanovsky; Nature 1990, V343, P190 HCAPLUS
- (24) Ulanovsky; Proc Natl Acad Sci USA 1986, V83, P862 HCAPLUS
- (25) Walker; Nucleic Acids Research 1992, V20(7), P1691 HCAPLUS
- (26) Walker; PCR Methods and Applications 1993, V3, P1 HCAPLUS
- (27) Yamamoto; US 5624798 1997 HCAPLUS

IT 328603-49-2 328603-50-5

RL: PRP (Properties)

(unclaimed nucleotide sequence; nucleic acid amplification using modular branched primers)

RN 328603-49-2 HCAPLUS

CN DNA, d(C-C-A-T-G-C-C-G-A-T-G-T-C-G-G-G-G-N-N-T-N-T-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 328603-50-5 HCAPLUS

CN DNA, d(C-C-A-T-G-C-C-G-A-T-G-T-C-G-G-G-G-G-T-G-G-N-N-G-G-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 19 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:736280 HCAPLUS

DN 133:291951

ED Entered STN: 18 Oct 2000

TI Cloning and expression of rat and human purinergic receptor P2X7 cDNA

IN Buell, Gary Nutter; Surprenant, Annmarie; Kawashima, Eric

PA Glaxo Group Limited, UK

SO U.S., 40 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM C07H021-00

ICS C07K014-475

NCL 536023500

CC 3-2 (Biochemical Genetics)

Section cross-reference(s): 13, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6133434	A	20001017	US 1997-842079	19970428 <--
US 6509163	B1	20030121	US 2000-638857	20000815 <--
PRAI US 1997-842079	A1	19970428	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6133434	ICM	C07H021-00
	ICS	C07K014-475
	NCL	536023500
US 6509163	ECLA	C07K014/705 <--

AB The present invention relates, in general, to a purinergic receptor and, in particular, to a P2X7 (also designated P2Z) receptor. Rat and human purinergic receptor P2X7 cDNA are cloned and expressed, and their tissue distribution and pharmacol. profiles are demonstrated. The invention also relates to a method of screening compds. for their ability to inhibit P2X7 activity and thereby for their usefulness in treating a variety of diseases/disorders, including arthritic and respiratory disorders and neurodegenerative diseases.

ST rat human purinoceptor P2X cDNA sequence therapy; ATP receptor P2X7 cDNA sequence human rat

IT Purinoceptors
 RL: BOC (Biological occurrence); BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); USES (Uses)
 (P2Z, of human and rat; cloning and expression of rat and human purinergic receptor P2X7 cDNA)

IT Arthritis
 Drug screening
 Gene therapy
 Genetic vectors
 Molecular cloning
 (cloning and expression of rat and human purinergic receptor P2X7 cDNA)

IT Antibodies
 RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (cloning and expression of rat and human purinergic receptor P2X7 cDNA)

IT Nervous system
 (degeneration; cloning and expression of rat and human purinergic receptor P2X7 cDNA)

IT Nucleic acid hybridization
 (detection by; cloning and expression of rat and human purinergic receptor P2X7 cDNA)

IT Respiratory tract
 (disease; cloning and expression of rat and human purinergic receptor P2X7 cDNA)

IT Gene, animal
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (for P2X7, of human and rat; cloning and expression of rat and human purinergic receptor P2X7 cDNA)

IT cDNA sequences
 (for human and rat purinoceptors P2X7; cloning and expression of rat and human purinergic receptor P2X7 cDNA)

IT Diagnosis
 (mol.; cloning and expression of rat and human purinergic receptor P2X7 cDNA)

IT Protein sequences
 (of human and rat purinoceptors P2X7; cloning and expression of rat and human purinergic receptor P2X7 cDNA)

IT 159521-88-7
 RL: PRP (Properties)
 (Unclaimed; cloning and expression of rat and human purinergic receptor P2X7 cDNA)

IT 176521-57-6P, Receptor, purinergic P2x7 (rat brain) 301456-99-5P, Purinoceptor P2X7 (human) 301457-00-1P, Purinoceptor P2X7 (human)
 RL: BOC (Biological occurrence); BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); USES (Uses)
 (amino acid sequence; cloning and expression of rat and human purinergic receptor P2X7 cDNA)

IT 301456-98-4 301457-01-2
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (nucleotide sequence; cloning and expression of rat and human
 purinergic receptor P2X7 cDNA)
 IT 301457-02-3, 1: PN: US6133434 SEQID: 1 unclaimed DNA
 301457-03-4, 2: PN: US6133434 SEQID: 2 unclaimed DNA 301457-04-5, 3: PN:
 US6133434 SEQID: 3 unclaimed DNA 301457-05-6, 4: PN: US6133434 SEQID: 4
 unclaimed DNA
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; cloning and expression of rat and human
 purinergic receptor P2X7 cDNA)
 IT 301335-88-6 301335-89-7 301335-90-0 301335-91-1 301335-92-2
 301335-93-3 301335-94-4 301335-95-5 301335-96-6
 RL: PRP (Properties)
 (unclaimed sequence; cloning and expression of rat and human purinergic
 receptor P2X7 cDNA)

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; EP 0506032 1992 HCAPLUS
- (2) Anon; WO 9533048 1995 HCAPLUS
- (3) Anon; GenBank Accession No. X95882 1998
- (4) Anon; GenBank Accession No. Y09561 1998
- (5) Anon; J Physiol 1997, V498(Pt 2), P427
- (6) Bo; The Journal of Biological Chemistry 1992, V267(25), P17581 HCAPLUS
- (7) Buell; Eur J Neurosci 1996, V8(10), P2221 MEDLINE
- (8) Buell; European Journal of Neuroscience 1996, V8, P2221 MEDLINE
- (9) Di Virgilio; Ital J Biochem 1996, V45(4), P195 HCAPLUS
- (10) Dubyak; Drug Dev Res 1996, V39, P269 HCAPLUS
- (11) Humphreys; J Immunol 1996, V157(12), P5627 HCAPLUS
- (12) Murgia; J Biol Chem 1993, V268(11), P8199 HCAPLUS
- (13) Owens; US 5360893 1994 HCAPLUS
- (14) Owens; Molecular and Cellular Biology 1991, V11(8), P4177 HCAPLUS
- (15) Rassendren; J Biol Chem 1997, V272(9), P5482 HCAPLUS
- (16) Simon; Biochemical Society Transactions 1993, V21(2), P200S HCAPLUS
- (17) Surprenant; Science 1996, V272, P735 HCAPLUS
- (18) Valera; Nature 1994, V371, P516 HCAPLUS
- (19) Valera; Receptors and Channels 1995, V3(4), P283 HCAPLUS
- (20) Wiley; Br J Pharmacol 1994, V112, P946 HCAPLUS

IT 301457-02-3, 1: PN: US6133434 SEQID: 1 unclaimed DNA
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; cloning and expression of rat and human
 purinergic receptor P2X7 cDNA)

RN 301457-02-3 HCAPLUS

CN 1: PN: US6133434 SEQID: 1 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 20 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:316649 HCAPLUS
 DN 132:333387
 ED Entered STN: 16 May 2000
 TI Recombinant multivalent M protein vaccine against Streptococcus
 IN Dale, James B.; Lederer, James W.
 PA University of Tennessee Research Corporation, USA
 SO U.S., 62 pp., Cont.-in-part of U.S. Ser. No. 945,954, abandoned.
 CODEN: USXXAM

DT Patent
 LA English
 IC ICM A61K039-09

NCL 424244100
 CC 15-2 (Immunochimistry)

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6063386	A	20000516	US 1997-937271	19970915 <--
ES 2170075	T3	20020801	ES 1993-922201	19930915 <--
PRAI US 1992-945954	B2	19920916	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6063386	ICM	A61K039-09
	NCL	424244100
US 6063386	ECLA	C07K014/315

AB The authors disclose the preparation of chimeric matrix proteins derived from multiple serotypes of group A streptococci. The chimeric proteins are

immunogenic and provoke opsonic antibodies in rabbits.

ST Streptococcus multivalent M protein vaccine

IT Proteins, specific or class
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (M12; of chimeric multivalent matrix protein construct as vaccine
 against group A streptococci)

IT Proteins, specific or class
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (M18; of chimeric multivalent matrix protein construct as vaccine
 against group A streptococci)

IT Proteins, specific or class
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (M19; of chimeric multivalent matrix protein construct as vaccine
 against group A streptococci)

IT Proteins, specific or class
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (M1; of chimeric multivalent matrix protein construct as vaccine
 against group A streptococci)

IT Proteins, specific or class
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (M24; of chimeric multivalent matrix protein construct as vaccine
 against group A streptococci)

IT Proteins, specific or class
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (M2; of chimeric multivalent matrix protein construct as vaccine
 against group A streptococci)

IT Proteins, specific or class
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (M3; of chimeric multivalent matrix protein construct as vaccine
 against group A streptococci)

IT Proteins, specific or class
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (M4; of chimeric multivalent matrix protein construct as vaccine
 against group A streptococci)

IT Proteins, specific or class
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (M5; of chimeric multivalent matrix protein construct as vaccine
 against group A streptococci)

IT Proteins, specific or class
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (M6; of chimeric multivalent matrix protein construct as vaccine
 against group A streptococci)

IT Peptides, biological studies
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
 BIOL (Biological study); OCCU (Occurrence)
 (as linkers in chimeric multivalent matrix protein construct as vaccine
 against group A streptococci)

IT Streptococcus group A
 (chimeric multivalent M proteins as vaccine against)

IT Rheumatic fever
 (chimeric multivalent M proteins of group A streptococci as vaccine
 against)

IT Fusion proteins (chimeric proteins)
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (chimeric multivalent matrix protein construct as vaccine against group
 A streptococci)

IT Antibodies
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
 BIOL (Biological study); OCCU (Occurrence)
 (crossreacting; with heart tissue in relation to chimeric multivalent M
 protein vaccine against group A streptococci)

IT DNA sequences
 Protein sequences
 (for chimeric multivalent matrix proteins from group A streptococci)

IT Synthetic gene
 Synthetic gene
 RL: PRP (Properties)
 (microbial; for chimeric multivalent matrix proteins from group A
 streptococci)

IT Pharynx
 (pharyngitis, streptococcal; chimeric multivalent M proteins of group A
 streptococci as vaccine against)

IT Heart, disease
 (rheumatic; chimeric multivalent M proteins of group A streptococci as

vaccine against)

IT Vaccines
(synthetic; against group A streptococci using chimeric multivalent M proteins)

IT Gene, microbial
Gene, microbial
RL: PRP (Properties)
(synthetic; for chimeric multivalent matrix proteins from group A streptococci)

IT Opsonins
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(to M proteins of group A streptococci induced by chimeric multivalent constructs)

IT 153-94-6, D-Tryptophan 157-06-2, D-Arginine 312-84-5, D-Serine 344-25-2, D-Proline 640-68-6, D-Valine 1783-96-6, D-Aspartic acid
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(of peptide linkers in chimeric multivalent matrix protein construct as vaccine against group A streptococci)

IT 151873-14-2 156066-98-7 156067-02-6 156067-04-8 156067-08-2
156067-14-0 267640-93-7, 3: PN: US6063386 SEQID: 9 unclaimed DNA
267640-95-9, 8: PN: US6063386 SEQID: 14 unclaimed DNA 267640-96-0
267640-98-2 267641-00-9 267641-01-0 267641-02-1 267641-03-2
267641-04-3 267641-05-4 267641-06-5 267641-07-6 267641-08-7
267641-09-8 267641-10-1 267641-11-2 267641-12-3
267641-13-4 267641-14-5 267641-15-6
RL: PRP (Properties)
(unclaimed nucleotide sequence; recombinant multivalent M protein vaccine against Streptococcus)

IT 153550-77-7 156067-03-7 156067-05-9 156067-07-1 156067-09-3
156067-11-7 156067-13-9 267640-94-8 267640-97-1 267640-99-3
267641-16-7 267658-81-1
RL: PRP (Properties)
(unclaimed protein sequence; recombinant multivalent M protein vaccine against Streptococcus)

IT 153550-77-7 156067-03-7 156067-05-9 156067-07-1 156067-09-3
156067-11-7 156067-13-9 267640-94-8 267640-97-1 267640-99-3
267641-16-7 267658-81-1
RL: PRP (Properties)
(unclaimed protein sequence; recombinant multivalent M protein vaccine against Streptococcus)

RE.CNT 85 THERE ARE 85 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Ada; Fundamental Immunology, 2nd Edition 1989, P1010
- (2) Anon; Biological Abstracts 50 1936, 4
- (3) Baird; The Journal Of Immunology 1991, V146(9), P3132 HCAPLUS
- (4) Beachey; US 4284537 1981 HCAPLUS
- (5) Beachey; US 4454121 1984 HCAPLUS
- (6) Beachey; US 4521334 1985 HCAPLUS
- (7) Beachey; US 4597967 1986 HCAPLUS
- (8) Beachey; US 4705684 1987 HCAPLUS
- (9) Beachey; US 4919930 1990 HCAPLUS
- (10) Beachey; US 5124153 1992 HCAPLUS
- (11) Beachey; Infection And Immunity 1974, V9(5), P891 HCAPLUS
- (12) Beachey; J Exp Med 1979, V150, P862 HCAPLUS
- (13) Beachey; J Exp Med 1986, V163, P1451 HCAPLUS
- (14) Beachey; J Exp Med 1987, V166, P647 HCAPLUS
- (15) Beachey; J Immunol 1986, V135(6), P2287
- (16) Beachey; Nature (London) 1981, V292, P457 HCAPLUS
- (17) Beachey; Proc Natl Acad Sci USA 1978, V75(7), P3163 HCAPLUS
- (18) Beachey; Seminars in Infectious Disease 1982, VIV, P401
- (19) Beachey; The Journal Of Biological Chemistry 1980, V255(13), P6284 HCAPLUS
- (20) Beachey; The Journal Of Biological Chemistry 1983, V258(21), P13250 HCAPLUS
- (21) Beachey; The Journal Of Experimental Medicine 1971, V134, P351 HCAPLUS
- (22) Beachey; The Journal Of Experimental Medicine 1976, V143, P759 MEDLINE
- (23) Beachey; The Journal Of Experimental Medicine 1977, V145, P1469 HCAPLUS
- (24) Beachey; The Journal Of Immunology 1986, V136(6), P2287 HCAPLUS
- (25) Beachey; The Journal Of Clinical Investigation 1973, V52, P2563 HCAPLUS
- (26) Beachey; Transactions Of The Association Of American Physicians 1977, VXC, P390
- (27) Beachey; Transactions Of The Association Of American Physicians 1979, VXCII, P346
- (28) Beall; Journal Of Clinical Microbiology 1996, V34(4), P953 HCAPLUS
- (29) Blenden; American Journal Of Veterinary Research 1968, V29(11), P2237 MEDLINE

Search done by Noble Jarrell

- (30) Bricas; Peptides Proceedings of the Eight European Peptide Symposium Sep 1966 1967, P286
 - (31) Bronze; J Exp Med 1988, V167, P1849 HCAPLUS
 - (32) Chou; Biochemistry 1974, V13(2), P222 HCAPLUS
 - (33) Cunningham; Infection And Immunity 1974, V9(2), P244 HCAPLUS
 - (34) Cunningham; The Journal Of Immunology 1989, V143(8), P2677 HCAPLUS
 - (35) Dale; Infection And Immunity 1996, V64(5), P1495 HCAPLUS
 - (36) Dale; J Clin Invest 1999, V103, P1261 HCAPLUS
 - (37) Dale; J Exp Med 1986, V163, P113
 - (38) Dale; J Immunol 1993, V151(4), P2188 HCAPLUS
 - (39) Dale; Journal Of Experimental Medicine 1985, V161, P113 HCAPLUS
 - (40) Dale; Journal Of Experimental Medicine 1986, V164, P1785 HCAPLUS
 - (41) Dale; New Vaccines And New Vaccine Technology 1999, V13(1), P227 MEDLINE
 - (42) Dale; Pediatric Annals 1998, V27, P301 MEDLINE
 - (43) Dale; The Journal Of Experimental Medicine 1980, V151, P1026 HCAPLUS
 - (44) Dale; The Journal Of Experimental Medicine 1983, V158, P1727 HCAPLUS
 - (45) Dale; The Journal Of Experimental Medicine 1985, V167, P583
 - (46) Dale; The Journal Of Experimental Medicine 1986, V163, P1191 HCAPLUS
 - (47) Dale; The Journal Of Immunology 1981, V126(4), P1499 MEDLINE
 - (48) Dale; Vaccine 1996, V14(10), P944 HCAPLUS
 - (49) Dale; Vaccine 1999, V17, P193 HCAPLUS
 - (50) Dixit; Biochemistry 1975, V14(9), P1933 HCAPLUS
 - (51) Edman; European J Biochem 1967, V1, P80 HCAPLUS
 - (52) Fischetti; New Perspectives on Streptococci and Streptococcal Infections Proceedings of the XI Lancefield International Symposium on Streptococci and Streptococcal Diseases 1992, P165 HCAPLUS
 - (53) Fischetti; Scientific American 1991, P58 HCAPLUS
 - (54) Freimer; Scientific American 1965, V213(6), P67
 - (55) Gibbons; Biochemistry 1975, V14(2), P420 HCAPLUS
 - (56) Goldsberg; Nature 1971, V232, P478
 - (57) Hollingshead; The Journal Of Biological Chemistry 1986, V261(4), P1677 HCAPLUS
 - (58) Hopp; Proc Natl Acad Sci USA 1981, V78(6), P3824 HCAPLUS
 - (59) Jones; The Journal Of Immunology 1987, V139(2), P380 MEDLINE
 - (60) Kang; Biochemistry 1970, V9(4), P796 HCAPLUS
 - (61) Kang; Biochemistry 1972, V11(10), P1828 HCAPLUS
 - (62) Kaplan; The Journal Of Infectious Diseases 1989, V159(1), P101 MEDLINE
 - (63) Koch; Federation Proceedings 1983, V42(7), P1810
 - (64) Kraus; The Journal Of Immunology 1987, V139(9), P3084 HCAPLUS
 - (65) Kraus; The Journal Of Immunology 1990, V145(12), P4089 HCAPLUS
 - (66) Lancefield; J Exp Med 1959, V110, P271 MEDLINE
 - (67) Laver; Proc Natl Acad Sci USA 1979, V76(3), P1425 HCAPLUS
 - (68) Lockey; Hospital Practice 1979, P49 MEDLINE
 - (69) Manjula; J Exp Med 1980, V151, P695 HCAPLUS
 - (70) Miller; Infection And Immunity 1988, V56(8), P2198 HCAPLUS
 - (71) Miller; J Biol Chem 1988, V263(12), PS668
 - (72) Mouw; Journal Of Bacteriology 1988, V170(2), P676 HCAPLUS
 - (73) Phillips; Proc Natl Acad Sci USA 1981, V78(8), P4689 HCAPLUS
 - (74) Podbielski; Med Microbiol Immunol 1991, V180, P213 HCAPLUS
 - (75) Rijn; The Journal Of Experimental Medicine 1977, V146, P579
 - (76) Robbins; Journal Of Bacteriology 1987, V169(12), P5633 HCAPLUS
 - (77) Sargent; The Journal Of Immunology 1987, V139(4), P1285 HCAPLUS
 - (78) Scott; US 4784948 1988 HCAPLUS
 - (79) Seyer; Biochemical And Biophysical Research Communications 1980, V92(2), P546 HCAPLUS
 - (80) Seyer; Biochemistry 1977, V10(6), P1158
 - (81) Smithies; Biochemistry 1971, V10(26), P4912 HCAPLUS
 - (82) Vashishtha; Abstracts Of The 91st General Meeting of the Society for Microbiology 1991, P129
 - (83) Weigent; Infection And Immunity 1984, V43(1), P122 HCAPLUS
 - (84) Wistedt; Molecular Microbiology 1995, V18(3), P569 HCAPLUS
 - (85) Wittner; Infection And Immunity 1977, V15(1), P104 MEDLINE
- IT 267641-09-8
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; recombinant multivalent M protein vaccine against Streptococcus)
- RN 267641-09-8 HCAPLUS
- CN 27: PN: US6063386 SEQID: 34 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 21 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1999:731773 HCAPLUS
 DN 131:346558
 ED Entered STN: 17 Nov 1999
 TI Recombinant adenovirus particles (Addys.beta.gal) containing sequences

Search done by Noble Jarrell

encoding full length dystrophin used to treat patients with muscular dystrophy

IN Kochanek, Stefan; Caskey, C. Thomas; Mitani, Kohnosuke; Clemens, Paula R.
PA Baylor College of Medicine, USA; Howard Hughes Medical Institute
SO U.S., 22 pp.
CODEN: USXXAM

DT Patent
LA English
IC ICM A01N043-04
ICS C12N015-00

NCL 514044000
CC 1-12 (Pharmacology)

Section cross-reference(s): 3, 10, 14

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5985846	A	19991116	US 1995-488014	19950607 <--
PRAI	US 1995-488014		19950607 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5985846	ICM	A01N043-04
	ICS	C12N015-00
	NCL	514044000
US 5985846	ECLA	C07K014/47A2A; C12N015/86F <--

AB The invention provides a method for treatment of muscular dystrophy using mol. genetics. The method involves infecting muscle cells of muscular dystrophy patients with a recombinant adenovirus particle (AddYS.beta.gal) which has encapsidated a gene transfer vector (pAddYS.beta.gal). The gene transfer vector pAddYS.beta.gal contains (5' to 3' orientation): (a) an adenovirus inverted terminal repeat (ITR); (b) an adenovirus packaging signal; (c) cDNA sequence encoding dystrophin operably linked to a mouse muscle creatine kinase gene (MCK) promoter; (d) a second adenovirus packaging signal and (e) a second adenovirus ITR. The infection of the recombinant adenovirus particle AddYS.beta.gal results in recombinant expression of dystrophin which corrects the cytoskeletal defects found in the muscular dystrophy patient. The invention also presented: (a) construction of gene transfer vector pAddYS.beta.gal; (b) production of recombinant adenovirus AddYS.beta.gal using the gene transfer vector; (c) expression of dystrophin in myoblasts transformed with AddYS.beta.gal virus particles and (d) in vivo expression of dystrophin in mdx mice injected with AddYS.beta.gal virus particles. The invention postulated that it may be possible to accommodate up to 37-kb of foreign DNA into the defective adenovirus, making it possible to deliver multiple or large genes containing tissue-specific or inducible promoters.

ST gene therapy muscular dystrophy recombinant adenovirus AddYSbetagal; dystrophin gene therapy muscular dystrophy recombinant adenovirus AddYSbetagal; signal packaging ITR adenovirus AddYSbetagal muscular dystrophy gene therapy; inverted terminal repeat adenovirus AddYSbetagal muscular dystrophy gene therapy

IT Cytoskeleton
(correction of cytoskeletal defects; recombinant adenovirus particles (AddYS.beta.gal) containing sequences encoding full length dystrophin, adenovirus ITRs and packaging signals used to treat patients with muscular dystrophy)

IT Gene, animal
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(for dystrophin; recombinant adenovirus particles (AddYS.beta.gal) containing sequences encoding full length dystrophin used to treat patients with muscular dystrophy)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(for muscle creatine kinase, promoter of; recombinant adenovirus particles (AddYS.beta.gal) containing sequences encoding full length dystrophin linked to a mouse muscle creatine kinase promoter used to treat patients with muscular dystrophy)

IT Repetitive DNA
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(inverted, terminal; recombinant adenovirus particles (AddYS.beta.gal) containing sequences encoding full length dystrophin and adenovirus internal terminal repeats used to treat patients with muscular dystrophy)

IT Promoter (genetic element)
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES

(Uses)
 (of mouse muscle creatine kinase gene; recombinant adenovirus particles (AdDYS.beta.gal) containing sequences encoding full length dystrophin linked to a mouse muscle creatine kinase promoter used to treat patients with muscular dystrophy)

IT Virus vectors
 (pAdDYS.beta.gal; recombinant adenovirus particles (AdDYS.beta.gal) containing sequences encoding full length dystrophin used to treat patients with muscular dystrophy)

IT Genetic element
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (packaging signal; recombinant adenovirus particles (AdDYS.beta.gal) containing sequences encoding full length dystrophin, adenovirus ITRs and packaging signals used to treat patients with muscular dystrophy)

IT Human adenovirus 5
 Mouse
 Muscular dystrophy
 Myoblast
 (recombinant adenovirus particles (AdDYS.beta.gal) containing sequences encoding full length dystrophin used to treat patients with muscular dystrophy)

IT Dystrophin
 RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (recombinant adenovirus particles (AdDYS.beta.gal) containing sequences encoding full length dystrophin used to treat patients with muscular dystrophy)

IT Molecular cloning
 (recombinant adenovirus particles (AdDYS.beta.gal) containing sequences encoding full length dystrophin, adenovirus ITRs and packaging signals used to treat patients with muscular dystrophy)

IT Gene therapy
 (recombinant adenovirus particles (AdDYS.beta.gal) used in gene therapy for muscular dystrophy)

IT Human adenovirus
 (recombinant, AdDYS.beta.gal; recombinant adenovirus particles (AdDYS.beta.gal) containing sequences encoding full length dystrophin used to treat patients with muscular dystrophy)

IT 9001-15-4, Creatine kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (muscle, promoter of; recombinant adenovirus particles (AdDYS.beta.gal) containing sequences encoding full length dystrophin linked to a mouse muscle creatine kinase promoter used to treat patients with muscular dystrophy)

IT 247214-45-5 250262-38-5, 1: PN: US5985846 SEQID: 2 unclaimed DNA
 250262-39-6, 2: PN: US5985846 SEQID: 3 unclaimed DNA 250262-40-9, 3: PN: US5985846 SEQID: 4 unclaimed DNA 250262-47-6, 4: PN: US5985846 SEQID: 5 unclaimed DNA 250262-49-8, 5: PN: US5985846 SEQID: 6 unclaimed DNA 250262-50-1, 6: PN: US5985846 SEQID: 7 unclaimed DNA
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; recombinant adenovirus particles (AdDYS.beta.gal) containing sequences encoding full length dystrophin used to treat patients with muscular dystrophy)

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE
 (1) Amalfitano; Am J Human Genetics 1995, V57(4 supp), PA234
 (2) Anon; WO 9428152 1994 HCAPLUS
 (3) Anon; WO 9613597 1996 HCAPLUS
 (4) Berkner, K; Biotechniques 1988, V6(7), P616 HCAPLUS
 (5) Culver; TIG 1994, V10(5), P174 MEDLINE
 (6) Deuring; Proc Natl Acad Sci USA 1981, V78(5), P3142 HCAPLUS
 (7) Gilardi; FEBS Letters 1990, V267(1), P60 HCAPLUS
 (8) Gregory; US 5670488 1997 HCAPLUS
 (9) Hodgson; Exp Op Ther Pat 1995, V5(5), P459 HCAPLUS
 (10) Karpati; Clin Invest Med 1994, V17(5), P499 MEDLINE
 (11) Marshall; Science 1995, V269, P1050 HCAPLUS
 (12) Miller; FASEB J 1995, V9, P190 HCAPLUS
 (13) Mitani; Proc Natl Acad Sci USA 1995, V92, P3854 HCAPLUS

IT 250262-49-8, 5: PN: US5985846 SEQID: 6 unclaimed DNA
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; recombinant adenovirus particles (AdDYS.beta.gal) containing sequences encoding full length dystrophin used to treat patients with muscular dystrophy)

RN 250262-49-8 HCAPLUS

CN 5: PN: US5985846 SEQID: 6 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 22 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1999:719024 HCAPLUS
 DN 131:350272
 ED Entered STN: 11 Nov 1999
 TI Human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use
 IN Armitage, Richard J.; Fanslow, William C.; Spriggs, Melanie K.; Srinivasan, Subhashini; Gibson, Marylou G.; Morris, Arvia E.; McGrew, Jeffrey T.
 PA Immunex Corporation, USA
 SO U.S., 65 pp., Cont.-in-part of U.S. Ser. No. 249,189.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM C12N015-12
 ICS C12N015-63
 NCL 536023500
 CC 15-5 (Immunochemistry)
 FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5981724	A	19991109	US 1995-477733	19950607 <--
	JP 10150994	A2	19980609	JP 1997-318110	19921023 <--
	EP 897983	A2	19990224	EP 1998-113461	19921023 <--
	EP 897983	A3	19990317		
	EP 897983	B1	20030507		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	CA 2312667	C	20021119	CA 1992-2312667	19921023 <--
	US 5961974	A	19991005	US 1994-249189	19940524 <--
	CA 2222914	AA	19961219	CA 1996-2222914	19960606 <--
	CA 2222914	C	20020402		
	WO 9640918	A2	19961219	WO 1996-US9632	19960606 <--
	WO 9640918	A3	19970123		
	W: AU, CA, IL, JP, KR, MX, NO, NZ				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9662638	A1	19961230	AU 1996-62638	19960606 <--
	AU 693713	B2	19980702		
	EP 832229	A2	19980401	EP 1996-921405	19960606 <--
	EP 832229	B1	20040114		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 11504819	T2	19990511	JP 1997-501911	19960606 <--
	JP 3279573	B2	20020430		
	AT 257858	E	20040115	AT 1996-921405	19960606 <--
	PT 832229	T	20040630	PT 1996-921405	19960606 <--
	ES 2214541	T3	20040916	ES 1996-921405	19960606 <--
	US 6290972	B1	20010918	US 1996-770974	19961219 <--
	US 6391637	B1	20020521	US 1996-770981	19961219 <--
	NO 9705437	A	19980206	NO 1997-5437	19971126 <--
	US 6410711	B1	20020625	US 1999-399106	19990920 <--
PRAI	US 1991-783707	B2	19911025	<--	
	US 1991-805723	B2	19911205	<--	
	US 1992-969703	B2	19921023	<--	
	US 1994-249189	A2	19940524	<--	
	CA 1992-2121798	A3	19921023	<--	
	EP 1992-925017	A3	19921023	<--	
	JP 1993-507897	A3	19921023	<--	
	US 1995-477733	A	19950607	<--	
	US 1995-484624	A	19950607	<--	
	WO 1996-US9632	W	19960606	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 5981724	ICM	C12N015-12	
	ICS	C12N015-63	
	NCL	536023500	
US 5981724	ECLA	C07K014/705Q; C12N015/62	<--
EP 897983	ECLA	C07K016/28Q	<--
US 5961974	ECLA	C07K014/705Q; C12N015/62	<--
WO 9640918	ECLA	C07K014/705Q	<--
US 6290972	ECLA	C07K014/705Q; C12N015/62	<--
US 6391637	ECLA	C07K014/705Q; C12N015/62	<--

US 6410711 ECLA C07K014/705Q; C12N015/62 <--

AB Membrane-bound and soluble forms of the cytokine CD40 ligand (CD40-L) of mouse and human are described and cDNAs encoding them are cloned and expressed. Expression constructs and host cells for manufacture of the protein are described. Deletion and substitution analogs of the ligand that retain specific binding to the extracellular binding region of a CD40 receptor are described. Antisense nucleic acids and antibodies to the protein that can be used to modulate its action are described. Cell lines with high levels of CD40-L were screened for using a CD40 fusion protein with Ig/Fc as an affinity label and the mouse thymoma line EL-4 identified as high in the ligand. An expression cDNA library in the mammalian expression vector pDC406 was screened using the fusion protein upon expression in CV1-EBNA cells. The mouse clone was used as a probe to obtain a clone from a human peripheral blood lymphocyte cDNA library in .lambda.gt10. CD40-L stimulates B cell proliferation, the synthesis of polyclonal Igs and the shedding of Fc.epsilon.RII (CD23 antigen) from B cells.

ST CD40 ligand cDNA cloning expression; B cell proliferation CD40 ligand; cytotoxic T cell CD40 ligand

IT Immunoglobulins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (A, CD40 ligand stimulation of production of; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT Cell proliferation
 (B cell, CD40 ligand stimulation of; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT Allergy inhibitors
 (CD40 derivs. as; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT Immunoglobulins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (CD40 ligand stimulation of production of; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT Glycoproteins, specific or class
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (CD40-L (antigen CD40 ligand); human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT Immunoglobulins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (E, CD40 ligand stimulation of production of; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT Immunoglobulins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (G1, CD40 ligand stimulation of production of; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT Immunoglobulins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (G2b, CD40 ligand stimulation of production of; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT Immunoglobulins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (G3, CD40 ligand stimulation of production of; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT Immunoglobulin receptors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (IgE type II, CD40 ligand stimulation of shedding of; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT Immunoglobulins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (M, CD40 ligand stimulation of production of; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT Gene, animal
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (cDNA, for CD40 ligand of mouse and human; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT Immunity
(cell-mediated, CD40-L and stimulation of; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT T cell (lymphocyte)
(cytotoxic, CD40-L stimulation of proliferation of; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT cDNA sequences
(for CD40 ligand of human and mouse; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT Immunoglobulins
RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)
(fusion products, with CD40 ligand, preparation of; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT Mouse
(human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT Antibodies
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(monoclonal, to CD40 ligand; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT Protein sequences
(of CD40 ligand of human and mouse; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT Antibodies
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(to CD40 ligand; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT 149119-84-6D, analogs, conjugates, fusion proteins 149119-85-7D, analogs, conjugates, fusion proteins 149119-86-8D, analogs, conjugates, fusion proteins 149119-89-1 186361-68-2D, 120-261-CD40 ligand (human), analogs, conjugates, fusion proteins 245524-07-6, 47-260-CD40 ligand (mouse) 245524-52-1, 119-260-CD40 ligand (mouse) 249604-61-3D, analogs, conjugates, fusion proteins 249604-62-4D, analogs, conjugates, fusion proteins 249604-63-5D, analogs, conjugates, fusion proteins 249604-64-6D, analogs, conjugates, fusion proteins 249604-65-7D, analogs, conjugates, fusion proteins 249604-66-8D, analogs, conjugates, fusion proteins
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(amino acid sequence; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT 157214-04-5DP, fusion products with CD40 ligand
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation)
(amino acid sequence; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT 149119-87-9, DNA (human CD40 ligand cDNA plus flanks) 186434-07-1, DNA (human CD40 ligand cDNA) 212581-01-6, DNA (mouse CD40 ligand cDNA) 245524-43-0, DNA (mouse 47-260-CD40 ligand cDNA) 245524-47-4 245524-54-3 245524-60-1 249604-67-9 249604-68-0 249604-69-1 249604-70-4 249604-71-5 249604-72-6 250159-26-3
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT 149119-90-4 149119-91-5 182083-56-3, PN: US5962406 SEQID: 25 unclaimed DNA 182083-57-4, PN: US5962406 SEQID: 26 unclaimed DNA 203341-34-8 245524-01-0 245524-04-3 245525-95-5, PN: US5962406 SEQID: 13 unclaimed DNA 245525-96-6, PN: US5962406 SEQID: 14 unclaimed DNA 245525-99-9, PN: US5962406 SEQID: 18 unclaimed DNA 245526-01-6, PN: US5962406 SEQID: 19 unclaimed DNA 250160-85-1, 5: PN: US5981724 SEQID: 5 unclaimed DNA 250160-86-2, 6: PN: US5981724 SEQID: 6 unclaimed DNA 250160-88-4, 7: PN: US5981724 SEQID: 7 unclaimed DNA 250160-90-8, 9: PN: US5981724 SEQID: 9 unclaimed DNA 250160-91-9
RL: PRP (Properties)
(unclaimed nucleotide sequence; human and mouse CD40 ligands and analogs and cDNAs encoding them and their preparation and use)

IT 148814-08-8, Glycoprotein gp 39 (human clone 19 reduced) 186361-47-7 203244-38-6 245427-08-1 245524-02-1 245524-10-1

RL: PRP (Properties)
 (unclaimed protein sequence; human and mouse CD40 ligands and analogs
 and cDNAs encoding them and their preparation and use)
 IT 148814-08-8, Glycoprotein gp 39 (human clone 19 reduced) 186361-47-7
 203244-38-6 245427-08-1 245524-02-1 245524-10-1

RL: PRP (Properties)
 (unclaimed protein sequence; human and mouse CD40 ligands and analogs
 and cDNAs encoding them and their preparation and use)

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; EP 0315062 1989 HCAPLUS
- (2) Anon; EP 0330191 1989 HCAPLUS
- (3) Anon; EP 0555880 1993 HCAPLUS
- (4) Anon; WO 9309812 1993 HCAPLUS
- (5) Anon; WO 9323550 1993 HCAPLUS
- (6) Anon; EP 0585943 1994 HCAPLUS
- (7) Armitage; Nature 1992, V357, P80 HCAPLUS
- (8) Aruffo; US 5540926 1996 HCAPLUS
- (9) Aruffo; Proc Natl Acad Sci 1987, V84, P8573 HCAPLUS
- (10) Banchereau; Clinical Immunology Spectrum 1991, V3, P9
- (11) Banchereau; Science 1991, V251, P70 HCAPLUS
- (12) Clark; Proc Natl Acad Sci 1986, V83, P4494 HCAPLUS
- (13) Durie; Science 1993, V261, P1328 HCAPLUS
- (14) Fanslow; J Immunol 1992, V149, P655 HCAPLUS
- (15) Farrah; Nature 1992, V358, P26 MEDLINE
- (16) Gascan; J Immunol 1991, V147, P8 HCAPLUS
- (17) Ghaderi; Immunology 1991, V73, P510 HCAPLUS
- (18) Gordon; Eur J Immunol 1987, V17, P1535 HCAPLUS
- (19) Gordon; J Immunol 1988, V140, P1425 HCAPLUS
- (20) Hollenbaugh; EMBO J 1992, V11, P4313 HCAPLUS
- (21) Jabara; J Exp Med 1990, V172, P1861 HCAPLUS
- (22) Kikutani; Cell 1986, V47, P657 HCAPLUS
- (23) Lauzon; Mol Immunol 1988, V25, P829 HCAPLUS
- (24) Ledbetter; US 5182368 1993 HCAPLUS
- (25) Ledbetter; US 5247069 1993 HCAPLUS
- (26) Lederman; US 5474771 1995 HCAPLUS
- (27) Liu; Nature 1989, V342, P929 MEDLINE
- (28) Noelle; Proc Natl Acad Sci 1992, V89, P6550 HCAPLUS
- (29) Paulie; J Immunol 1989, V142, P590 HCAPLUS
- (30) Potocnik; Scan J Immunol 1990, V31, P213 MEDLINE
- (31) Rousset; J Exp Med 1991, V173, P705 HCAPLUS
- (32) Spriggs; J Exp Med 1992, V176, P1543 HCAPLUS
- (33) Srinivasan; US 5716805 1998 HCAPLUS
- (34) Stamenkovic; EMBO J 1989, V8, P1403 HCAPLUS
- (35) Valle; Eur J Immunol 1989, V19, P1463 HCAPLUS
- (36) Wang; J Virol 1991, V65, P4101 HCAPLUS
- (37) Zettlmeissl; DNA Cell Biol 1990, V9, P347 HCAPLUS
- (38) Zhang; J Immunol 1991, V146, P1836 HCAPLUS

IT 250160-86-2, 6: PN: US5981724 SEQID: 6 unclaimed DNA

RL: PRP (Properties)
 (unclaimed nucleotide sequence; human and mouse CD40 ligands and
 analogs and cDNAs encoding them and their preparation and use)

RN 250160-86-2 HCAPLUS

CN 6: PN: US5981724 SEQID: 6 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 23 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:635456 HCAPLUS

DN 131:270947

ED Entered STN: 07 Oct 1999

TI Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition
 containing the same

IN Armitage, Richard J.; Fanslow, William C.; Spriggs, Melanie K.;
 Srinivasan, Subhashini; Gibson, Marylou G.; Morris, Arvia E.; McGrew,
 Jeffrey T.

PA Immunex Corporation, USA

SO U.S., 64 pp., Cont.-in-part of U.S. Ser. No. 249,189.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K038-18

ICS C07K014-435

NCL 514008000

CC 15-2 (Immunochemistry)

Section cross-reference(s): 3

FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5962406	A	19991005	US 1995-484624	19950607 <--
	JP 10150994	A2	19980609	JP 1997-318110	19921023 <--
	EP 897983	A2	19990224	EP 1998-113461	19921023 <--
	EP 897983	A3	19990317		
	EP 897983	B1	20030507		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	CA 2312667	C	20021119	CA 1992-2312667	19921023 <--
	US 5961974	A	19991005	US 1994-249189	19940524 <--
	CA 2222914	AA	19961219	CA 1996-2222914	19960606 <--
	CA 2222914	C	20020402		
	WO 9640918	A2	19961219	WO 1996-US9632	19960606 <--
	WO 9640918	A3	19970123		
	W: AU, CA, IL, JP, KR, MX, NO, NZ				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9662638	A1	19961230	AU 1996-62638	19960606 <--
	AU 693713	B2	19980702		
	EP 832229	A2	19980401	EP 1996-921405	19960606 <--
	EP 832229	B1	20040114		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 11504819	T2	19990511	JP 1997-501911	19960606 <--
	JP 3279573	B2	20020430		
	AT 257858	E	20040115	AT 1996-921405	19960606 <--
	PT 832229	T	20040630	PT 1996-921405	19960606 <--
	ES 2214541	T3	20040916	ES 1996-921405	19960606 <--
	US 6264951	B1	20010724	US 1996-769819	19961219 <--
	NO 9705437	A	19980206	NO 1997-5437	19971126 <--
	US 6087329	A	20000711	US 1998-88913	19980602 <--
	US 2003091564	A1	20030515	US 1999-365940	19990802 <--
PRAI	US 1991-783707	B2	19911025	<--	
	US 1991-805723	B2	19911205	<--	
	US 1992-969703	B2	19921023	<--	
	US 1994-249189	A2	19940524	<--	
	CA 1992-2121798	A3	19921023	<--	
	EP 1992-925017	A3	19921023	<--	
	JP 1993-507897	A3	19921023	<--	
	US 1995-477733	A	19950607	<--	
	US 1995-484624	A	19950607	<--	
	WO 1996-US9632	W	19960606	<--	
	US 1996-769819	A1	19961219	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 5962406	ICM	A61K038-18	
	ICS	C07K014-435	
	NCL	514008000	
US 5962406	ECLA	C07K014/705Q	<--
EP 897983	ECLA	C07K016/28Q	<--
US 5961974	ECLA	C07K014/705Q; C12N015/62	<--
WO 9640918	ECLA	C07K014/705Q	<--
US 6264951	ECLA	C07K014/705Q; C12N015/62	<--
US 6087329	ECLA	C07K014/705Q; C12N015/62	<--
US 2003091564	ECLA	C07K014/705Q; C12N015/62	<--

AB Disclosed are polypeptides (e.g. membrane bound CD40-L, monomeric and oligomeric CD40-L, soluble CD40-L, and fusion protein of CD40-L) and antisense and sense DNA and RNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor. Also, provided are soluble CD40 comprising extracellular region of human CD40 and CD40/Fc fusion proteins, and antibodies. CD40 agonists, i.e. membrane-bound CD40-L and oligomeric CD40-L, are useful as vaccine adjuvant and for stimulating B cell proliferation and monoclonal antibody production from hybridoma cells. CD40 antagonists, i.e. CD40 receptor, CD40/Fc fusion protein, soluble CD40/Fc, monomeric CD40-L, are useful for treating autoimmune diseases characterized by presence of high levels of antigen-antibody complexes, such as allergy, insulin dependent diabetes mellitus, graft vs. host disease and others.

ST CD40 ligand oligomer fusion protein; soluble CD40 ligand antisense DNA RNA; monoclonal antibody CD40 ligand adjuvant; autoimmune disease B cell proliferation antiallergic

IT Cell proliferation
(B cell; recombinant soluble CD40 ligand polypeptide as CD40 agonist and

- antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Glycoproteins, specific or class
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(CD40-L (antigen CD40 ligand); recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CD40; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Immunoglobulins
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(E, secretion induction; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Animal cell line
(EL4; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(G1, fragment fusion protein; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Immunoglobulins
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(G; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Immunoglobulin receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(IgE type II; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Immunoglobulins
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(M; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Antigens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(T-cell-dependent antigens; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Immunostimulants
(adjuvants; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Drug delivery systems
(carriers; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT T cell (lymphocyte)
(cytotoxic, induction; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Immunoassay
(enzyme-linked immunosorbent assay; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)

- diseases)
- IT Transplant and Transplantation
(graft-vs.-host reaction; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT T cell (lymphocyte)
(helper cell; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Immunoassay
(immunoblotting, dot; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Diabetes mellitus
(insulin-dependent; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Antibodies
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Mononuclear cell (leukocyte)
(peripheral blood; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Blood
(peripheral; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Immunoglobulins
RL: BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
(polyclonal; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Allergy
Allergy inhibitors
Autoimmune disease
Hybridoma
Molecular cloning
Protein sequences
Vaccines
cDNA library
cDNA sequences
(recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Interleukin 4
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Antibodies
RL: BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
(recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT CD40 (antigen)
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)
- IT Fusion proteins (chimeric proteins)
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)
 (recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)

IT Antisense DNA
 Antisense RNA
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)

IT DNA
 RNA
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (sense; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)

IT 148814-08-8, CD40 ligand (human) 149119-89-1 155979-32-1
 186361-42-2, CD40 ligand [194-tryptophan] (human) 186361-47-7
 186361-66-0, 113-261-CD40 ligand (human) 186361-68-2, 120-261-CD40 ligand (human) 245524-02-1 245524-07-6, 47-260-CD40 ligand (mouse) 245524-10-1 245524-52-1, 119-260-CD40 ligand (mouse) 245524-56-5, 51-261-CD40 ligand (human clone CD40-L)
 RL: PRP (Properties)
 (amino acid sequence; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)

IT 149119-87-9, DNA (human clone CD40-L CD40 ligand cDNA plus flanks)
 203341-34-8 212581-01-6, DNA (mouse CD40 ligand cDNA) 245524-01-0
 245524-04-3 245524-43-0, DNA (mouse 47-260-CD40 ligand cDNA)
 245524-47-4 245524-51-0, DNA (mouse 119-260-CD40 ligand cDNA)
 245524-54-3 245524-57-6 245524-60-1 245524-81-6
 RL: PRP (Properties)
 (nucleotide sequence; recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)

IT 157214-04-5P 245670-70-6P 245670-71-7P 245677-02-5P 245677-29-6P
 245677-43-4P 245677-46-7P 245677-63-8P 245677-64-9P
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (recombinant soluble CD40 ligand polypeptide as CD40 agonist and antagonist as adjuvant, stimulant of B cell proliferation and antibody production, and for treating autoimmune diseases)

IT 149119-90-4 149119-91-5 182083-56-3, PN: US5962406 SEQID: 25 unclaimed DNA 182083-57-4, PN: US5962406 SEQID: 26 unclaimed DNA 245525-83-1, PN: US5962406 SEQID: 5 unclaimed DNA 245525-84-2, PN: US5962406 SEQID: 6 unclaimed DNA 245525-85-3, PN: US5962406 SEQID: 7 unclaimed DNA 245525-93-3, PN: US5962406 SEQID: 9 unclaimed DNA 245525-94-4, PN: US5962406 SEQID: 10 unclaimed DNA 245525-95-5, PN: US5962406 SEQID: 13 unclaimed DNA 245525-96-6, PN: US5962406 SEQID: 14 unclaimed DNA 245525-99-9, PN: US5962406 SEQID: 18 unclaimed DNA 245526-01-6, PN: US5962406 SEQID: 19 unclaimed DNA
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same)

IT 203244-38-6 245427-08-1
 RL: PRP (Properties)
 (unclaimed sequence; recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same)

RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; EP 0315062 1989 HCAPLUS
- (2) Anon; EP 0330191 1989 HCAPLUS
- (3) Anon; EP 0555880 1993 HCAPLUS
- (4) Anon; WO 9309812 1993 HCAPLUS
- (5) Anon; WO 9323550 1993 HCAPLUS
- (6) Anon; EP 0585943 1994 HCAPLUS
- (7) Armitage; Nature 1992, V357, P80 HCAPLUS
- (8) Aruffo; US 5540926 1996 HCAPLUS
- (9) Aruffo And Seed; Proc Natl Acad Sci USA 1987, V84, P8573
- (10) Banachereau; Science 1991, V251, P70 HCAPLUS
- (11) Banachereau And Rousset; Clinical Immunology Spectrum 1991, V3, P9

(12) Clark; Proc Natl Acad Sci USA 1986, V83, P4494 HCAPLUS
 (13) Conney; Mol Immunol 1994, V31, P471
 (14) Durie; Science 1993, V261, P1328 HCAPLUS
 (15) Fanslow; J Immunol 1992, V149, P655 HCAPLUS
 (16) Farrah And Smith; Nature 1992, V358, P26
 (17) Gascan; J Immunol 1991, V147, P8 HCAPLUS
 (18) Ghaderi; Immunology 1991, V73, P510 HCAPLUS
 (19) Gordon; Eur J Immunol 1987, V17, P1535 HCAPLUS
 (20) Gordon; J Immunol 1988, V140, P1425 HCAPLUS
 (21) Graf; Eur J Immunol 1992, V22, P3191 HCAPLUS
 (22) Hollenbaugh; EMBO J 1992, V11, P4313 HCAPLUS
 (23) Jabara; J Exp Med 1990, V172, P1861 HCAPLUS
 (24) Kehry; US 5817516 1998 HCAPLUS
 (25) Kikutani; Cell 1986, V47, P657 HCAPLUS
 (26) Lauzon; Mol Immunol 1988, V25, P829 HCAPLUS
 (27) Ledbetter; US 5182368 1993 HCAPLUS
 (28) Ledbetter; US 5247069 1993 HCAPLUS
 (29) Lederman; US 5474771 1995 HCAPLUS
 (30) Lederman; J Exp Med 1992, V175, P1091 HCAPLUS
 (31) Liu; Nature 1989, V342, P929 MEDLINE
 (32) Noelle; Immunology Today 1992, V13, P431 HCAPLUS
 (33) Noelle; Proc Natl Acad Sci USA 1992, V89, P6550 HCAPLUS
 (34) Ostlund; Encyclopedia of Immunology 1992, P776
 (35) Paulie; J Immunol 1989, V142, P590 HCAPLUS
 (36) Potocnik; Scan J Immunol 1990, V31, P213 MEDLINE
 (37) Rousset; J Exp Med 1991, V173, P705 HCAPLUS
 (38) Spriggs; US 5565321 1996 HCAPLUS
 (39) Spriggs; J Exp Med 1992, V176, P1543 HCAPLUS
 (40) Srinivasan; US 5716805 1998 HCAPLUS
 (41) Stamenkovic; EMBO J 1989, V8, P1403 HCAPLUS
 (42) Valle; Eur J Immunol 1989, V19, P1463 HCAPLUS
 (43) Wang; J Virol 1991, V65, P4101 HCAPLUS
 (44) Zettlmeissl; DNA Cell Biol 1990, V9, P347 HCAPLUS
 (45) Zhang; J Immunol 1991, V146, P1836 HCAPLUS
 IT 245525-84-2, PN: US5962406 SEQID: 6 unclaimed DNA
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; recombinant soluble CD40 ligand
 polypeptide and pharmaceutical composition containing the same)
 RN 245525-84-2 HCAPLUS
 CN PN: US5962406 SEQID: 6 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 24 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1999:633252 HCAPLUS
 DN 131:270955
 ED Entered STN: 06 Oct 1999
 TI Monoclonal antibodies to CD40 ligand, pharmaceutical composition
 comprising the same and hybridomas producing the same
 IN Armitage, Richard J.; Fanslow, William C.; Spriggs, Melanie K.
 PA Immunex Corporation, USA
 SO U.S., 59 pp., Cont.-in-part of U.S. Ser. No. 969,703, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM C07K016-28
 ICS A61K039-395; C12N005-12
 NCL 424154100
 CC 15-3 (Immunochemistry)
 Section cross-reference(s): 3
 FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5961974	A	19991005	US 1994-249189	19940524 <--
	JP 10150994	A2	19980609	JP 1997-318110	19921023 <--
	EP 897983	A2	19990224	EP 1998-113461	19921023 <--
	EP 897983	A3	19990317		
	EP 897983	B1	20030507		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	CA 2312667	C	20021119	CA 1992-2312667	19921023 <--
	US 5962406	A	19991005	US 1995-484624	19950607 <--
	US 5981724	A	19991109	US 1995-477733	19950607 <--
	US 6264951	B1	20010724	US 1996-769819	19961219 <--
	US 6290972	B1	20010918	US 1996-770974	19961219 <--
	US 6391637	B1	20020521	US 1996-770981	19961219 <--
	US 6087329	A	20000711	US 1998-88913	19980602 <--

Search done by Noble Jarrell

	US 2003091564	A1	20030515	US 1999-365940	19990802 <--
	US 6410711	B1	20020625	US 1999-399106	19990920 <--
	US 2003144182	A1	20030731	US 2002-200242	20020719 <--
	US 2004006006	A9	20040108		
PRAI	US 1991-783707	B2	19911025	<--	
	US 1991-805723	B2	19911205	<--	
	US 1992-969703	B2	19921023	<--	
	CA 1992-2121798	A3	19921023	<--	
	EP 1992-925017	A3	19921023	<--	
	JP 1993-507897	A3	19921023	<--	
	US 1994-249189	A2	19940524	<--	
	US 1995-477733	A3	19950607	<--	
	US 1995-484624	A3	19950607	<--	
	US 1996-769819	A1	19961219	<--	
	US 1999-392618	B2	19990909	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 5961974	ICM	C07K016-28	
	ICS	A61K039-395; C12N005-12	
	NCL	424154100	
US 5961974	ECLA	C07K014/705Q; C12N015/62	<--
EP 897983	ECLA	C07K016/28Q	<--
US 5962406	ECLA	C07K014/705Q	<--
US 5981724	ECLA	C07K014/705Q; C12N015/62	<--
US 6264951	ECLA	C07K014/705Q; C12N015/62	<--
US 6290972	ECLA	C07K014/705Q; C12N015/62	<--
US 6391637	ECLA	C07K014/705Q; C12N015/62	<--
US 6087329	ECLA	C07K014/705Q; C12N015/62	<--
US 2003091564	ECLA	C07K014/705Q; C12N015/62	<--
US 6410711	ECLA	C07K014/705Q; C12N015/62	<--
US 2003144182	ECLA	C07K014/705Q; C12N015/62	<--

AB Disclosed is a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor. The invention further provides CD40-L fragment for production of monoclonal antibodies specific for CD40-L. Also, soluble CD40 protein and CD40 fusion proteins are prepared for inducing B cell proliferation and antibody (e.g. IgE) secretion, and for anti-allergic treatment. Also, fusion proteins comprising soluble human or murine CD40-L and Fc or trimeric CD40-L are constructed. In summary, CD40 agonists (i.e. membrane-bound CD40-L and oligomeric CD40-L) are provided for use as vaccine adjuvant and antibody production stimulant, and CD40 antagonists (i.e. CD40 receptor, CD40/Fc, and soluble monomeric CD40-L) are provided for treating autoimmune diseases.

ST CD40 ligand fusion protein monoclonal antibody

IT Cell proliferation
(B cell; monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

IT Mouse
(CD40 ligand fragments of mouse and human in production of monoclonal antibodies to CD40 ligand and preparation of CD40 agonist and antagonists and their therapeutical applications)

IT Glycoproteins, specific or class
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)
(CD40-L (antigen CD40 ligand); monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

IT Receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CD40; monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

IT Immunoglobulins
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(E, secretion; monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

IT Animal cell line
(EL4; monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

IT Immunoglobulins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(G1; monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

IT Secretion (process)
(Ig; monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

IT Immunoglobulin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgE type II; monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

IT Immunostimulants
(adjuvants; monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

IT Drug delivery systems
(carriers; monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

IT Allergy inhibitors
Autoimmune disease
Drug delivery systems
Hybridoma
Immunostimulants
Molecular cloning
Protein sequences
Vaccines
cDNA sequences
(monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

IT Interleukin 4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

IT Fusion proteins (chimeric proteins)
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

IT Antibodies
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

IT Antisense DNA
Antisense RNA
DNA
RNA
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

IT CD40 (antigen)
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

IT Antibodies
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal; monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

IT Immunoglobulins
RL: BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(polyclonal; monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

IT 148814-08-8, CD40 ligand (human) 149119-89-1 155979-32-1 186361-47-7 245524-02-1 245524-07-6, 47-260-CD40 ligand (mouse) 245524-10-1
RL: PRP (Properties)
(amino acid sequence; CD40 ligand fragments of mouse and human in production of monoclonal antibodies to CD40 ligand and preparation of CD40 agonist and antagonists and their therapeutic applications)

IT 149119-87-9, DNA (human CD40 ligand cDNA plus flanks) 203341-34-8 212581-01-6, DNA (mouse CD40 ligand cDNA) 245524-01-0 245524-04-3
RL: PRP (Properties)
(nucleotide sequence; CD40 ligand fragments of mouse and human in

production of monoclonal antibodies to CD40 ligand and preparation of CD40 agonist and antagonists and their therapeutical applications)

- IT 149119-90-4 149119-91-5 245525-83-1, PN: US5962406 SEQID: 5 unclaimed DNA 245525-84-2, PN: US5962406 SEQID: 6 unclaimed DNA 245525-85-3, PN: US5962406 SEQID: 7 unclaimed DNA 245525-93-3, PN: US5962406 SEQID: 9 unclaimed DNA 245525-94-4, PN: US5962406 SEQID: 10 unclaimed DNA 245525-95-5, PN: US5962406 SEQID: 13 unclaimed DNA 245525-96-6, PN: US5962406 SEQID: 14 unclaimed DNA 245525-99-9, PN: US5962406 SEQID: 18 unclaimed DNA 245526-07-2, PN: US5961974 SEQID: 19 unclaimed DNA
- RL: PRP (Properties)
(unclaimed nucleotide sequence; monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)
- IT 157214-04-5
- RL: PRP (Properties)
(unclaimed protein sequence; monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)
- IT 157214-04-5
- RL: PRP (Properties)
(unclaimed protein sequence; monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; EP 0315062 1989 HCAPLUS
- (2) Anon; EP 0330191 1989 HCAPLUS
- (3) Anon; WO 0555880 1993
- (4) Anon; WO 9309812 1993 HCAPLUS
- (5) Anon; WO 9323550 1993 HCAPLUS
- (6) Anon; WO 0585943 1994
- (7) Anon; 6th International Workshop and Conference on Human Leukocyte Differentiation Antigens, Kobe Japan, Abstracts 1996, V48(4-Part II), P477
- (8) Anon; HLDA Antibody Database-Antibodies Assigned to CD154 1998
- (9) Armitage; 6th International Workshop and Conference on Human Leukocyte Differentiation Antigens, Kobe Japan, Abstract #381, Program TC-3-01 1996
- (10) Armitage; Nature 1992, V357, P80 HCAPLUS
- (11) Aruffo And Seed; Proc Natl Acad Sci USA 1987, V84, P8573
- (12) Banchemreau; Science 1991, V251, P70 HCAPLUS
- (13) Banchemreau And Rousset; Clinical Immunology Spectrum 1991, V3, P9
- (14) Casamayor-Palleja; J Exp Med 1995, V181, P1293 MEDLINE
- (15) Clark; Proc Natl Acad Sci USA 1986, V83, P4494 HCAPLUS
- (16) Durie; Science 1993, V261, P1328 HCAPLUS
- (17) Fanslow; 6th International Workshop and Conference on Human Leukocyte Differentiation Antigens (Nov 10-14, 1996) Kobe Japan, Proceedings P101
- (18) Fanslow; J Immunol 1992, V149, P655 HCAPLUS
- (19) Farrah And Smith; Nature 1992, V358, P26
- (20) Gascan; J Immunol 1991, V147, P8 HCAPLUS
- (21) Ghaderi; Immunology 1991, V73, P510 HCAPLUS
- (22) Gordon; Eur J Immunol 1987, V17, P1535 HCAPLUS
- (23) Gordon; J Immunol 1988, V140, P1425 HCAPLUS
- (24) Hollenbaugh; EMBO J 1992, V11, P4313 HCAPLUS
- (25) Jabara; J Exp Med 1990, V172, P1861 HCAPLUS
- (26) Kikutani; Cell 1986, V47, P657 HCAPLUS
- (27) Lauzon; Mol Immunol 1988, V25, P829 HCAPLUS
- (28) Ledbetter; US 5182368 1993 HCAPLUS
- (29) Ledbetter; US 5247069 1993 HCAPLUS
- (30) Lederman; US 5474771 1995 HCAPLUS
- (31) Lederman; J Exp Med 1992, V175, P1091 HCAPLUS
- (32) Liu; Nature 1989, V342, P929 MEDLINE
- (33) Noelle; Proc Natl Acad Sci USA 1992, V89, P6550 HCAPLUS
- (34) Paulie; J Immunol 1989, V142, P590 HCAPLUS
- (35) Rousset; J Exp Med 1991, V173, P705 HCAPLUS
- (36) Siadak; US 5876950 1999 HCAPLUS
- (37) Spriggs; J Exp Med 1992, V176, P1543 HCAPLUS
- (38) Stamenkovic; EMBO J 1989, V8, P1403 HCAPLUS
- (39) Valle; Eur J Immunol 1989, V19, P1463 HCAPLUS
- (40) Wang; J Virol 1991, V65, P4101 HCAPLUS
- (41) Zettlmeissl; DNA Cell Biol 1990, V9, P347 HCAPLUS
- (42) Zhang; J Immunol 1991, V146, P1836 HCAPLUS

- IT 245525-84-2, PN: US5962406 SEQID: 6 unclaimed DNA
- RL: PRP (Properties)
(unclaimed nucleotide sequence; monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same)

RN 245525-84-2 HCAPLUS
CN PN: US5962406 SEQID: 6 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L27 ANSWER 25 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:585381 HCAPLUS
DN 129:201670
ED Entered STN: 15 Sep 1998
TI Somatic mutations in the multiple tumor suppressor gene MTS1 and their use in the diagnosis and prognosis of cancers
IN Kamb, Alexander
PA Myriad Genetics, Inc., USA
SO U.S., 73 pp., Cont.-in-part of U. S. Ser. No. 251,938, abandoned.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07H021-04
ICS C12N015-63
NCL 536024310
CC 14-1 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 3, 9

FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5801236	A	19980901	US 1995-480810	19950607 <--
	CA 2162150	AA	19950928	CA 1995-2162150	19950317 <--
	CN 1128049	A	19960731	CN 1995-190374	19950317 <--
	US 6090578	A	20000718	US 1997-986515	19971208 <--
	US 6030301	A	20000509	US 1998-115252	19980714 <--
	US 6037462	A	20000314	US 1998-120130	19980722 <--
PRAI	US 1994-214582	B2	19940318	<--	
	US 1994-215086	B2	19940318	<--	
	US 1994-215087	B2	19940318	<--	
	US 1994-227369	B2	19940414	<--	
	US 1994-251938	B2	19940601	<--	
	WO 1995-US3316	A2	19950317	<--	
	US 1995-480810	A3	19950607	<--	
	US 1997-986147	A1	19971208	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5801236	ICM	C07H021-04
	ICS	C12N015-63
	NCL	536024310

AB The present invention relates to somatic mutations in the Multiple Tumor Suppressor (MTS) gene in human cancers and their use in the diagnosis and prognosis of human cancer. The invention further relates to germ line mutations in the MTS gene and their use in the diagnosis of predisposition to melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, CLL, and cancers of the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and rectum. The invention also relates to the therapy of human cancers which have a mutation in the MTS gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy. Map-based cloning of the gene is described.

ST multiple tumor suppressor gene MTS1 human; somatic mutation MTS1 gene cancer

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(MTS2; somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)

IT Astrocyte
(astrocytoma, susceptibility, diagnosis, and prognosis; somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)

IT Leukemia
(chronic lymphocytic, susceptibility, diagnosis, and prognosis; somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)

IT Intestine, neoplasm
(colorectal, susceptibility, diagnosis, and prognosis; somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)

- IT Primers (nucleic acid)
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(for detection of somatic mutation in MTS1 gene; somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)
- IT Neuroglia
(glioblastoma, susceptibility, diagnosis, and prognosis; somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)
- IT Neuroglia
(glioma, susceptibility, diagnosis, and prognosis; somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)
- IT Chromosome
(human 9, 9p-ter, MTS1 and MTS2 genes mapping to; somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)
- IT Diagnosis
(mol.; somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(mts1; somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)
- IT Mammary gland
(neoplasm, susceptibility, diagnosis, and prognosis; somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)
- IT DNA sequences
(of MTS1 and MTS2 genes of human; somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)
- IT Protein sequences
(of MTS1 gene product of human; somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)
- IT Genetic mapping
(of MTS1 gene; somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)
- IT Gene therapy
(of MTS1-dependent tumors; somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)
- IT Susceptibility (genetic)
(somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)
- IT Hodgkin's disease
Kidney, neoplasm
Leukemia
Lymphoma
Melanoma
Ovary, neoplasm
Pancreas, neoplasm
Stomach, neoplasm
Testis, neoplasm
Thyroid gland, neoplasm
Uterus, neoplasm
(susceptibility, diagnosis, and prognosis; somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)
- IT 153520-02-6
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)
- IT 211994-88-6
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence; somatic mutations in multiple tumor suppressor gene MTS1 and their use in diagnosis and prognosis of cancers)
- IT 189642-31-7 211993-71-4 211994-61-5 211994-62-6 211994-63-7
211994-64-8 211994-65-9 211994-66-0 211994-67-1 211994-68-2
211994-69-3 211994-70-6 211994-71-7 211994-72-8 211994-87-5

RL: BSU (Biological study, unclassified); PRP (Properties); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; somatic mutations in multiple tumor suppressor
gene MTS1 and their use in diagnosis and prognosis of cancers)

IT 189642-31-7 211993-71-4 211994-61-5 211994-62-6 211994-63-7
211994-64-8 211994-65-9 211994-66-0 211994-67-1 211994-68-2
211994-69-3 211994-70-6 211994-71-7 211994-72-8 211994-87-5

RL: BSU (Biological study, unclassified); PRP (Properties); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; somatic mutations in multiple tumor suppressor
gene MTS1 and their use in diagnosis and prognosis of cancers)

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Aaronson, S; Science 1991, V254, P1146 HCAPLUS
- (2) Anon; WO 9409135 1994 HCAPLUS
- (3) Anon; WO 9528483 1995 HCAPLUS
- (4) Cairns, P; Cancer Research 1994, V54, P1422 HCAPLUS
- (5) Cannon-Albright, L; Genomics 1994, V23, P265 HCAPLUS
- (6) Cannon-Albright, L; Science 1992, V258, P1148 HCAPLUS
- (7) Cheng, J; Cancer Research 1993, V53, P4761 HCAPLUS
- (8) Ebralidze, A; Genes & Development 1989, V3, P1086 HCAPLUS
- (9) Fountain, J; Proc Natl Acad Sci USA 1992, V89, P10557 HCAPLUS
- (10) Goldstein, A; Am J Hum Genet 1994, V54, P489 MEDLINE
- (11) Gruis, N; Am J Pathology 1995, V146, P1199 HCAPLUS
- (12) Gu, Y; Nature 1993, V366, P707 HCAPLUS
- (13) Hannon, G; Nature 1994, V371, P257 HCAPLUS
- (14) Harris, C; Science 1993, V262, P1980 HCAPLUS
- (15) Hinds, P; Proc Natl Acad Sci USA 1994, V91, P709 HCAPLUS
- (16) Hunter, T; Cell 1993, V75, P839 HCAPLUS
- (17) Kamb, A; Nature Genetics 1994, V8, P22 HCAPLUS
- (18) Kamb, A; Science 1994, V264, P436 HCAPLUS
- (19) Marx, J; Science 1994, V263, P319 MEDLINE
- (20) Marx, J; Science 1994, V264, P344 MEDLINE
- (21) Matsushime, H; Cell 1992, V71, P323 HCAPLUS
- (22) Motokura, T; Nature 1991, V350, P512 HCAPLUS
- (23) Nancarrow, D; Am J Hum Genet 1993, V53, P936 MEDLINE
- (24) Nasmyth, K; Nature 1993, V366, P634 MEDLINE
- (25) Nobori, T; Nature 1994, V368, P753 MEDLINE
- (26) Pardee, A; Science 1989, V246, P603 HCAPLUS
- (27) Parker, C; Melanoma Research 1992, V2, P337 HCAPLUS
- (28) Parry, D; EMBO J 1995, V14, P503 HCAPLUS
- (29) Ruppert, J; Cancer Research 1993, V53, P5093 HCAPLUS
- (30) Serrano, M; Nature 1993, V366, P704 HCAPLUS
- (31) Sherr, C; Cell 1993, V73, P1059 HCAPLUS
- (32) Tulchinsky, E; Proc Natl Acad Sci USA 1992, V89, P9146 HCAPLUS
- (33) van der Riet, P; Cancer Research 1994, V54, P1156 HCAPLUS
- (34) Walker, G; Oncogene 1994, V9, P819 HCAPLUS
- (35) Weaver-Feldhaus, J; Proc Natl Acad Sci 1994, V91, P7563 HCAPLUS
- (36) Xiong, Y; Nature 1993, V366, P701 HCAPLUS

=> b home

FILE 'HOME' ENTERED AT 09:42:39 ON 13 DEC 2004

=>